
<html lang="en"     class="pb-page"  data-request-id="30261261-2fc6-4d50-95f9-78fce19fe548"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm300682j;issue:issue:10.1021/jmcmar.2012.55.issue-22;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Chemokine Receptor Antagonists" /></meta><meta name="dc.Creator" content="James  Pease" /></meta><meta name="dc.Creator" content="Richard  Horuk" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 24, 2012" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300682j" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300682j" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300682j" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300682j" /></link>
        
    
    

<title>Chemokine Receptor Antagonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300682j" /></meta><meta property="og:title" content="Chemokine Receptor Antagonists" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="" /></meta><meta name="twitter:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta name="twitter:title" content="Chemokine Receptor Antagonists" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300682j"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300682j">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300682j&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300682j&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300682j&amp;href=/doi/10.1021/jm300682j" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 9363-9392</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm300915b" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Chemokine Receptor Antagonists</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Pease">James Pease</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Horuk">Richard Horuk</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Leukocyte Biology Section, National Heart and Lung Institute, Faculty of Medicine, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London SW7 2AZ, U.K.</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Department of Pharmacology, University of CaliforniaâDavis, 451 Health Sciences Drive, Davis, California 95616, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 925-708-0358. E-mail: <a href="/cdn-cgi/l/email-protection#470f2835322c0737262425222b2b69292233"><span class="__cf_email__" data-cfemail="1a5275686f715a6a7b79787f767634747f6e">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300682j&amp;href=/doi/10.1021%2Fjm300682j" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 9363â9392</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 29, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 May 2012</li><li><span class="item_label"><b>Published</b> online</span>24 September 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 November 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300682j" title="DOI URL">https://doi.org/10.1021/jm300682j</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9363%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BPease%252C%2BRichard%2BHoruk%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D22%26contentID%3Djm300682j%26title%3DChemokine%2BReceptor%2BAntagonists%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9392%26publicationDate%3DNovember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300682j"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4385</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">73</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300682j" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Chemokine Receptor Antagonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Pease&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Horuk&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;9363-9392&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300682j&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300682j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300682j" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300682j&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300682j" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300682j&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300682j" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300682j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300682j&amp;href=/doi/10.1021/jm300682j" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300682j" /></input><a href="/doi/pdf/10.1021/jm300682j" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300682j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300682j%26sid%3Dliteratum%253Aachs%26pmid%3D22931505%26genre%3Darticle%26aulast%3DPease%26date%3D2012%26atitle%3DChemokine%2BReceptor%2BAntagonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D22%26spage%3D9363%26epage%3D9392%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=292043" title="Pharmaceutics">Pharmaceutics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/22" title="Go to Volume 55, Issue 22"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jmcmar.2012.55.issue-22/production/jmcmar.2012.55.issue-22.largecover.jpg" alt="Go to Volume 55, Issue 22"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chemokines are small basic proteins that are defined by the number and position of the invariant cysteines in their protein sequence.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> At the time this review was written more than 40 different chemokines clustered into two major (CC and CXC) and two minor (CX3C and C) classes have been identified.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Chemokines are potent chemoattractants and play an important role in host defense by mobilizing immune cells to combat invading microorganisms such as bacteria and viruses.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Under certain circumstances the immune system can turn rogue and destroy its own cells, leading to autoimmunity. Because of their role in the immune response, chemokines participate in this process; thus, they are important targets for treating autoimmune diseases.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Chemokines initiate immune cell activation by binding to cell surface receptors of the G-protein-coupled receptor (GPCR) superfamily.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> At the last count, 19 functional chemokine receptors and two nonfunctional decoy receptors, Duffy antigen receptor for chemokines (DARC) and the protein D6, have been cloned.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> There are several reviews that describe the biology of the chemokines and their receptors, and we refer the reader to these excellent monographs for more background than we can comfortably cover here.<a onclick="showRef(event, 'ref2 ref3 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref5 ref6">(2, 3, 5, 6)</a></div><div class="NLM_p">It is estimated that around 50 million Americans, especially women, suffer from autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, asthma, etc.;<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> therefore, the market for therapeutic approaches to treat these and other illnesses is huge<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and could exceed $77 billion by the year 2017 according to a recent report by global industry analysts.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Consequently most of the major pharmaceutical companies have poured billions of dollars into research and development to identify safe and effective drugs to treat these diseases. Because of their important role in host defense, chemokine receptors have been closely scrutinized as drug targets by a number of companies, and a Pub Med search in 2012 with the term âchemokine receptor antagonistsâ lists over 4500 hits. However, despite the fact that numerous chemokine receptor antagonists have progressed from discovery into the clinic (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), so far only two, the CCR5 inhibitor from Pfizer<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and the CXCR4 antagonist from Anormed,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> are registered drugs. These successes and failures will be discussed further below.</div><div class="NLM_table-wrap" id="tbl1">Table 1<div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">receptor</th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">generic name</th><th class="colsep0 rowsep0" align="center">affinity (nM)</th><th class="colsep0 rowsep0" align="center">MW</th><th class="colsep0 rowsep0" align="center">logÂ <i>P</i></th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">status</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">Schering AG (Berlex)</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">BX471</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">434</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">MS, psoriasis, endometriosis</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">Millennium</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">MLN 3701</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MS, multiple myeloma</td><td class="colsep0 rowsep0" align="left">no longer reported</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">Millennium</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">MLN 3897</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">518</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">RA, multiple myeloma</td><td class="colsep0 rowsep0" align="left">no efficacy in RA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">CP-481,715</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">482</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">RA</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">AZD4818</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">461</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">COPD</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">Chemocentryx</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">CCX354</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">RA</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">C-4462</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">RA</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR1</td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">C-6448</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MS</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">Millennium</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">MLN 1202<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">RA</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">atherosclerosis, MS</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">Incyte</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">INCB8696</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MS, lupus</td><td class="colsep0 rowsep0" align="left">no longer reported</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">Incyte</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">INCB32S4</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">520</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">RA, type II diabetes</td><td class="colsep0 rowsep0" align="left">no longer reported</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">Chemocentryx</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">CCX915</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MS</td><td class="colsep0 rowsep0" align="left">terminated</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">Chemocentryx</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">CCX140</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">diabetic nephropathy</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">MK-0518</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">469</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">RA, MS</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">PF-4136309</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">pain</td><td class="colsep0 rowsep0" align="left">no longer reported</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">BMS</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">BMS-741672</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">diabetic neuropathy</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="left">JÂ &Â J</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">JNJ-17166864</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">20.0</td><td class="colsep0 rowsep0" align="left">443</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">allergic rhinitis</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR3</td><td class="colsep0 rowsep0" align="left">Pharmaxis</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">ASM8<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">asthma</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR3</td><td class="colsep0 rowsep0" align="left">GSK</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">GSK766994</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">10.0</td><td class="colsep0 rowsep0" align="left">450</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">asthma and allergic rhinitis</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR3</td><td class="colsep0 rowsep0" align="left">Dupont</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">DPC168</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">475</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">asthma</td><td class="colsep0 rowsep0" align="left">development halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR3</td><td class="colsep0 rowsep0" align="left">BMS</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">BMS-639623</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">481</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">asthma</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR3</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">QAP-642</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">allergic rhinits</td><td class="colsep0 rowsep0" align="left">development halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR3</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">AZD3778</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">526</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">allergic rhinitis</td><td class="colsep0 rowsep0" align="left">no longer reported</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR4</td><td class="colsep0 rowsep0" align="left">Amgen</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">KW-0761<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR4</td><td class="colsep0 rowsep0" align="left">GSK</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">GSK2239633</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">10.0</td><td class="colsep0 rowsep0" align="left">506</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">asthma</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">UK-127,857</td><td class="colsep0 rowsep0" align="left">maraviroc</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">513</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">RA</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">registered drug</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Schering-Plough</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">SCH-C</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">557</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">RA</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">development halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Schering-Plough</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">SCH-D</td><td class="colsep0 rowsep0" align="left">vicriviroc</td><td class="colsep0 rowsep0" align="left">0.45</td><td class="colsep0 rowsep0" align="left">533</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">development halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">GSK</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">GW2239633</td><td class="colsep0 rowsep0" align="left">aplaviroc</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">577</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">development halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Incyte</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">INCB9471</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">559</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">development halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Progenies</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Pro 140<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Tobira</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">TAK652</td><td class="colsep0 rowsep0" align="left">cenicriviroc</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">696</td><td class="colsep0 rowsep0" align="left">10.2</td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">AZD5672</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.26</td><td class="colsep0 rowsep0" align="left">672</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">RA</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">NIBR-6465</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">Sangamo</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">SB-728<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="left">HGS</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">HGS004<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">AIDS</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR9</td><td class="colsep0 rowsep0" align="left">Chemocentryx</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">CCX-282</td><td class="colsep0 rowsep0" align="left">vercimon</td><td class="colsep0 rowsep0" align="left">6.0</td><td class="colsep0 rowsep0" align="left">444</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">IBD, Crohnâs</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR1/</td><td class="colsep0 rowsep0" align="left">Schering-Plough</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">SCH 527123</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">415</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">COPD</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR2</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR1/</td><td class="colsep0 rowsep0" align="left">Damps</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Repertaxin</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">283</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">pancreatic islet</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR2</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">transplantation</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR2</td><td class="colsep0 rowsep0" align="left">GSK</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">SB-656933</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">463</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">COPD, cystic fibrosis</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR3</td><td class="colsep0 rowsep0" align="left">Amgen</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">AMG487</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="left">603</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">psoriasis</td><td class="colsep0 rowsep0" align="left">no efficacy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR4</td><td class="colsep0 rowsep0" align="left">Genzyme</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="left">AMD3100</td><td class="colsep0 rowsep0" align="left">plerixafor</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">502</td><td class="colsep0 rowsep0" align="left">â0.4</td><td class="colsep0 rowsep0" align="left">MM, non-Hodgkins lymphoma</td><td class="colsep0 rowsep0" align="left">registered drug</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR4</td><td class="colsep0 rowsep0" align="left">TaiGen</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">Burixafor</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">stem cell transplant</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR4</td><td class="colsep0 rowsep0" align="left">Polyphor</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">POL6326</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">stem cell transplant</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR4</td><td class="colsep0 rowsep0" align="left">Medarex</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">MDX-1338<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">multiple myeloma</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR4</td><td class="colsep0 rowsep0" align="left">Biokine</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">BKT140<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">stem cell transplant</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Neutralizing monoclonal antibodies.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Antisense oligonucletide.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Zinc finger nuclease.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Peptide.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Protein Structure and Regulation of Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58342" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58342" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chemokine receptors belong to the class A grouping of the GPCR superfamily, and technological breakthroughs in crystallization techniques over the past decade have led to a wealth of information regarding class A GPCR structure<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> exemplified by the recent structure of the chemokine receptor CXCR4 (a target recently reviewed in this journal<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>). GPCRs contain seven Î±-helices that span the membrane and are linked through three intracellular and three extracellular loops (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The receptors are normally found in the inactive or ground state and, upon binding of ligand, adopt alternative active conformations that recruit signaling molecules to the intracellular face of the receptor and ultimately transduce a signal to the cytoplasm of the cell.</div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Agonist and antagonist binding pockets in GPCRs. Model of the crystal structure of the inactive state of CXCR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ODU">3ODU</a>) as viewed from the extracellular face. TM helices are numbered (Roman numerals) and the extracellular loops (ECLs) marked. Major and minor binding pockets are denoted by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first GPCR crystal structure obtained was that of ground state bovine rhodopsin<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and showed that the highly conserved âDRYâ (Asp-Arg-Tyr) motif at the extracellular end of transmembrane III (TM III) acts as an ionic lock, holding the receptor in the inactive state by means of salt bridges between the arginine residue and the aspartate and a neighboring glutamate residue in TM VI. Ionic locks were subsequently incorporated into several homology models based upon the rhodopsin structure. However, subsequent elucidation of crystal structures of other class A GPCRs in inactive conformations, notably the human Î²<sub>2</sub>AR<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and CXCR4,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> indicated that despite the existence of the DRY motif, no ionic lock was evident. This may explain why some GPCRs are more prone to constitutive activity (signaling in the absence of ligand) and may account for the considerable technical difficulties that had to be overcome to obtain these crystal structures, typically by the introduction of stabilizing mutations.</div><div class="NLM_p">Within class A GPCRs a major binding pocket (comprising TM helices IV, V, VI, and VII) and a minor binding pocket (TM helices II, III, and VII) form crevices into which small ligands such as peptides and amines can bind (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). This binding event triggers movement of the helices, resulting in coupling to heterotrimeric G proteins, although other effectors such as the arrestins can be activated independently.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Movement of TMVI is thought to be critical in the activation process, with the pivoting of the helix around a conserved proline residue, Pro 6.50.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This ârotomer toggle switchâ involves a conserved tryptophan residue Trp 6.48.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Both residues play a role in the opening up of intracellular loop III, thereby providing access for G proteins and their subsequent activation. This results in the parting of the G protein Î± and Î²Î³ subunits, leaving them free to activate a variety of effector molecules including phosphatidylinositide 3-kinase (PI3K), phospholipase CÎ², and Src family kinases.</div><div class="NLM_p">The activation of chemokine receptors by their much larger protein ligands is, broadly speaking, a two-step process in which the typically basic chemokine is first tethered by interactions with the acidic amino-terminal domain of the receptor<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> with additional charge contributions from sulfated tyrosine residues<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and O-linked carbohydrate<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> within this region. This serves to orientate the chemokine, allowing the N-terminus of the chemokine to insert into the helical bundle (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A) and interact with residues in either the major or minor binding pockets.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemokine receptor activation and inactivation. Panels AâD show cartoons of receptor activated by chemokines (red) or small molecule agonists (yellow) or inactivated by intrahelical small molecule antagonists (green) or intracellular antagonists (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Truncation of the N-termini of many chemokines by the enzyme CD26/dipetidylpeptidase IV (DPP-IV) typically ablates a chemokineâs agonist activity while leaving its capacity to bind to the chemokine receptor untouched. This leads to the generation of endogenous antagonists<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and underscores the importance of access of this part of the chemokine to the binding pocket for effective agonism. These findings have been exploited to create chemokine analogues with potent antagonist activity and efficacy in vivo.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The requirements for the receptor N-terminus can be bypassed by synthetic small molecule agonists that insert themselves into the major or minor binding pockets of the chemokine receptor to directly induce receptor activation, independently of the extracellular domains (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In the case of a recently described CXCR3 agonist, this small molecule successfully mimicked a region of a natural chemokine agonist to induce receptor activation.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Similarly, the tripeptide <i>N-</i>acetyl Pro-Gly-Pro (PGP), derived from the proteolysis of extracellular matrix, mimics a portion of CXCL8 and can activate CXCR2 in vivo and in vitro.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p last">A vast majority of small molecule antagonists described to date are allosteric modulators and interact with either the minor or minor intrahelical binding pockets distinct from the main chemokine binding sites found in the extracellular domains. In doing so, they stabilize inactive receptor conformations, which in many cases can still bind ligand but are unable to transduce a signal (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C). More recently a second class of allosteric modulator has been described<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> that requires access to the intracellular C-tail of the chemokine receptors CCR4 and CCR5 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>D). The binding site of these compounds is thought to include helix VIII, found within the C-tail of several class A GPCR crystal structures, which may play a key role in receptor conformation and signaling.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Notably this motif is absent from the CXCR4 crystal structure,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> suggesting that this class of intracellular antagonist may have limited activity among the chemokine receptor family.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Selected Biology and Pathophysiology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In a review of this size we can only hope to scratch at the surface of the role that chemokines and their receptors play in health and disease. Thus, we have restricted ourselves here to discussing the evidence that links chemokine receptors to the pathophysiology of multiple sclerosis, rheumatoid arthritis, and asthma. Indeed these autoimmune diseases represent those that have been the most targeted in the clinic by chemokine receptor antagonists (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Multiple Sclerosis</h3><div class="NLM_p">Multiple sclerosis is the most common neurological disorder in young adults in the developed world. It is a chronic autoimmune disease that involves the central nervous system (CNS) and affects upward of 400â000 individuals in the U.S. alone. The total annual cost for patients with multiple sclerosis in Europe has recently been estimated at around 12.5 billion euros,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and this has attracted massive investment from the pharmaceutical industry in the development of new therapeutic approaches. A variety of approaches have been aimed at inhibiting chemokine receptors with the major rationale for targeting these proteins based on the pathophysiology of the disease and mainly provided by animal models. Multiple sclerosis appears to be induced when T helper 1 (Th1) cells  recognize components of the myelin sheath. Activated, autoreactive T cells within the lesions are believed to drive the chronic inflammatory process and activate local or hematogenous macrophages that destroy myelin. This inflammatory cascade leads to large focal lesions of primary demyelination with relative axonal preservation. Recent research suggests that the pathogenetic scheme described above is oversimplified and cannot explain lesion formation. It is known that T-cell populations other than classical Th1 cells contribute to inflammation in multiple sclerosis and that amplification of demyelination in a chronic inflammatory reaction in the brain requires additional factors. Furthermore, the patterns of demyelination are different between different subgroups of multiple sclerosis patients, which suggests that the disease is heterogeneous.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a></div><div class="NLM_p">Demyelinating plaques from the brains of multiple sclerosis patients express a variety of inflammatory chemokines and their receptors<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and notably contain macrophages and microglia that express CCR1 and its ligand CCL3.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> In acute and chronic-active multiple sclerosis lesions, immunoreactivity for CCL7 (a CCR1 ligand) and CCL8 has also been described, with staining prominent throughout the lesion center.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> CXCR3 is expressed by almost all the T cells recovered from the CSF of multiple sclerosis patients with active disease and is expressed at significantly higher levels on CD4+ T cells from the cerebrospinal fluid (CSF) compared with circulating cells.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Likewise, the CXCR3 ligands CXCL9 and CXCL10 are elevated in the CSF of patients with active multiple sclerosis.</div><div class="NLM_p last">The major driving force for therapeutic approaches that target chemokines in multiple sclerosis has mostly been provided by animal models of disease, particularly the experimental autoimmune encephalomyelitis (EAE) models carried out in rodents. Although these models have been extremely valuable in leading to an understanding of the pathogenesis of the human disease, they need to be interpreted with some caution particularly because they do not recapitulate the entire complex spectrum of the human disease. For example, animal studies revealed that blocking the TNF receptor was effective in ameliorating disease in an EAE model. However, when this approach was translated to human clinical trials in patients suffering from multiple sclerosis, the trials had to be halted because the TNF receptor blockers actually made the disease worse. Also it is clear that many aspects of the human disease, in particular the contributions of B-lymphocytes and autoantibodies in disease pathology, are not captured by these models. Finally, as we shall see later in this review, selection of the appropriate EAE model is important in determining the validity of a disease target. For example, the acute EAE model in rats is driven by a cell type, neutrophils, that does not really figure in the human disease. An excellent monograph on the role of translational animal studies for multiple sclerosis, particularly the EAE model, discusses this important issue further.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Rheumatoid Arthritis</h3><div class="NLM_p">A hallmark of rheumatoid arthritis is an accumulation of leukocytes from the vasculature into the synovial tissue, notably monocytes and Th1 cells, where they initiate an autoimmune reaction leading to destruction of the cartilage. Consequently there has been much interest in the chemokines and receptors responsible for leukocyte trafficking to the synovium.</div><div class="NLM_p">Among the CC chemokines, CCL3 and CCL5 are readily detectable in synovial fluid of rheumatoid arthritis patients with increased levels correlating with disease severity.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> These clinical data have been supported by studies in murine models of rheumatoid arthritis. For example, in the collagen induced arthritis (CIA) model<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and in a rat adjuvant-induced arthritis (AIA) model CCL3 levels are elevated.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Moreover, disease severity was significantly reduced by neutralizing anti-CCL3 and anti-CCL5 antibodies, establishing a proof of principle for antagonism of CCR1 signaling in rheumatoid arthritis.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">Several lines of evidence implicate CCR1 in the pathophysiology of rheumatoid arthritis. First, CCR1 is expressed in macrophages in rodent models of rheumatoid arthritis.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Second, CCR1 and its ligands showed significant expression in peripheral mononuclear cells obtained from biopsied synovial tissue from patients with rheumatoid arthritis.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Third, a non-peptide antagonist of murine CCR1 was efficacious in a collagen induced arthritis model in the mouse.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Finally, synovial biopsy specimens obtained in a small study of 16 patients with rheumatoid arthritis revealed a significant reduction in the number of macrophages in patients treated with a CCR1 antagonist compared with the placebo group<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (see later).</div><div class="NLM_p">The CCR2-speciifc chemokine CCL2 has also been reported to be up-regulated in the synovial tissue of rheumatoid arthritis patients<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and to be produced by articular chondrocytes cultured ex vivo.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Studies of material from rheumatoid arthritis patients suggest that CD68+ macrophages that express CCR1, CCR2, and CCR5 are recruited to the synovium by these chemokines.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p last">Among CXC chemokines, the CXCR1/2 specific chemokines CXCL8 and CXCL1 are also abundantly expressed in the synovial tissues of rheumatoid arthritis patients<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50, 51)</a> as are the CXCR3 specific chemokines CXCL9 and CXCL10.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Since most of the T cells within the synovium of rheumatoid arthritis patients express CXCR3, this axis may be worthy of targeting. Similarly, elevated CXCL16 levels are found in the synovial tissue of rheumatoid arthritis patients, which correlates with the recruitment of CXCR6+Th1/Tc1 effector cells<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and suggests that CXCR6 might be a potential target.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Allergic Asthma</h3><div class="NLM_p">The allergic response results from an inappropriate immune response to an otherwise innocuous antigen and can be broken down into the early phase and late phase reactions. The early phase reaction peaks at around 15 min following allergen challenge and is mediated by the cross-linking of IgE by allergen. This activates mast cell degranulation and the release of preformed mediators, such as histamine, which is present in granules and rapidly synthesized mediators such as leukotriene C<sub>4</sub> (LTC<sub>4</sub>) and prostaglandin D<sub>2</sub> (PGD<sub>2</sub>). These mediators act in a paracrine fashion on other cells to induce airway smooth muscle contraction, increased microvascular permeability, and mucus production. The late phase asthmatic reaction follows the early phase reaction several hours later and is notable for an influx of eosinophils and lymphocytes to the inflamed tissue.</div><div class="NLM_p">Eosinophils, in addition to being a source of leukotrienes (therefore promoting bronchoconstriction and mucus hypersecretion), are also a source of profibrotic cytokines such as transforming growth factor Î²1 (TGF-Î²1), which may promote an excessive repair process. This may result in increased airway smooth-muscle mass, collagen deposition, angiogenesis, and subsequent thickening of the airway wall, a process known as remodeling.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The recruitment of leukocytes in the late phase reaction is chiefly coordinated by chemokines that are released following the interaction of dendritic cells, T-lymphocytes, and structural cells. Consequently, blocking chemokine-mediated activation and trafficking of these cells is a potential therapeutic avenue for asthma treatment.</div><div class="NLM_p">Co-stimulation of CCR1 and the high affinity IgE receptor FcÎµRI has been reported to enhance mast cell degranulation and conversely to decrease chemotaxis to CCL3,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> which is thought to maintain mast cell numbers at sites of allergic inflammation. In keeping with this, antagonism of the CCR1/CCL3 axis results in a reduction in disease score following co-stimulation of CCR1 and FcÎµRI.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Several chemokine receptors have been reported to recruit immature dendritic cells (DCs) to allergen sensitized tissues, notably CCR6, CCR2, CCR5, and CXCR4.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Dendritic cell maturation is accompanied by the production of the CCR4 ligands CCL17 and CCL22. These two chemokines recruit Th2 cells which following polarization either in vitro or in vivo, express CCR3, CCR4, and CCR8 on their cell surface.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> CCL22 and CCL17 are also up-regulated in the lung following allergen challenge<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> with CCR4 and CCR8 coexpressed on a significant number of T lymphocytes found following bronchioalveolar lavage (BAL) of asthmatics.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Similarly, increased numbers of CCR8+ cells have been reported in bronchial biopsies from asthmatics compared with controls which also correlated with 3-fold-higher levels of the CCR8 ligand CCL1 in the BAL fluid.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p last">The recruitment of eosinophils is characteristic of the late-phase allergic reaction and is predominantly mediated by the âeotaxinsâ CCL11, CCL24, and CCL26, which are selective agonists for CCR3, the principal chemokine receptor expressed by eosinophils.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> CCL11 plasma levels are raised in acute compared with stable asthmatic humans, and increased expression of CCL11 and CCL24 is observed in the allergic lungs of asthmatics<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61, 62)</a> and in their sputum.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> CCR3 is also expressed on other cell types involved in the allergic response, notably Th2 lymphocytes;<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> therefore, targeting CCR3 may provide additional benefit, and several clinical trials have been carried out with CCR3 antagonists (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Lessons from Animal Knockouts</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the murine genome has orthologues for most of the human chemokines and receptors, the targeted deletion of these molecules in the mouse has been undertaken with the view of providing a greater understanding of the role of chemokine and receptor in vivo, allowing the role of each receptor/ligand axis to be probed in the disease setting. For the purposes of this review, we will focus upon a select group of murine chemokine receptors for which the human orthologue has been targeted in clinical studies. In the vast majority of cases, mice heterozygous for deletion of a particular chemokine receptor are viable, suggesting that there is apparent redundancy in the system.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> However, closer scrutiny often reveals specific defects in some aspects of immune defense, suggesting a nonredundant role in vivo.</div><div class="NLM_p">For example, deletion of CCR1 results not only in the predicted loss of neutrophil chemotaxis to the ligand CCL3 but also in a skewing of the Th1/Th2 cytokine balance.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In murine models of EAE, CCR1-deficent mice show significantly less severe disease scores in terms of both incidence and severity but maintain intact cutaneous hypersensitivity responses, suggesting that antagonism of CCR1 may be of therapeutic benefit in multiple sclerosis without the potential for immunosuppression.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Likewise, in models of cardiac transplant rejection, CCR1-deficent mice show a reduced risk of transplant rejection.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In stark contrast, adoptive transfer of CCR1-deficent bone marrow to atherosclerosis-prone ApoE-deficent mice results in enhanced plaque development, suggesting that in atherosclerosis, signaling via this receptor is anti-inflammatory.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">Deletion of CCR2 results in mice with impaired responses to intracellular pathogens,<a onclick="showRef(event, 'ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref71">(69-71)</a> suggesting that CCR2 is critical for an effective Th1 response and that its deletion results in defective trafficking of monocytes with Th1-polarizing potential. As might be expected with the reciprocal nature of Th1/Th2 responses, CCR2-deficient mice also exhibit enhanced Th2 responses in allergen challenge models.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> However, all is not straightforward. Deletion of CCL2, the principal CCR2 ligand, results in a defect in Th2 polarization supported by data from studies in which depletion of CCL2 reduced airways hyper-responsivess (AHR) allergen challenge models.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> There also appears to be a role for the CCR2/CCL2 axis in mast cell recruitment to allergic airways. Mast cell progenitor recruitment to the aiways following allergen challenge is reduced in both CCR2- and CCL2-deficient mice.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Deletion of CCR2 on the ApoE-deficient background results in reduced development of atherosclerotic lesions, implicating the receptor in the trafficking of monocytes to the plaque.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p">Deletion of CCR3 results in mice with reduced numbers of eosinophils in the gut, suggesting an important role for this receptor in directing eosinophils to the gut where they can protect the host from helminth infection.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Likewise, the same CCR3-deficient mice reveal a role for CCR3 in mediating eosinophil recruitment to the allergic lung with decreased numbers of eosinophils observed following allergen challenge. Interestingly, in the same allergen challenge models, the eosinophils of CCR3-deficient mice are able to traffic from the circulation to the subendothelial space of the lung parenchyma but not beyond, suggesting that other chemoattractants cooperate in eosinophil recruitment.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In contrast, mast cell numbers in the skin are normal in CCR3-deficient mice following epicutaneous sensitization, suggesting that CCR3 does not play a role in mast cell homing to the sites of allergic inflammation in skin.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Intraperitoneal sensitization of CCR3-deficient mice results in increased numbers of intraepithelial mast cells in the trachea compared with that of wild type mice which is accompanied by increased AHR,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> suggesting that CCR3 does not play a major role in mast cell homing to the lung. This is supported by an ex vivo study in which bone marrow derived mast cells were unresponsive to CCR3 ligands in chemotaxis assays.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Interestingly, intraperitoneal sensitization in the same CCR3-deficient background results in an absence of AHR development.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">The original description of CCR4-deficient mice found an unexpected role for the receptor in endotoxic shock, with CCR4-null mice significantly protected from the endotoxic effects of LPS.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In contrast and unexpectedly, CCR4-deficient mice showed no protection from airway inflammation following allergen challenge, despite CCR4 being a key receptor expressed by Th2 cells<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> and several earlier studies supporting a role for CCR4 ligands in T-cell trafficking to the allergic murine lung.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> One complicating factor might be that CCR4 is also expressed by T regulatory cells (Tregs).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> These cells have an anti-inflammatory phenotype; hence, CCR4 blockade may be detrimental. CCR4 is also expressed by innate natural killer cells, and the trafficking of these cells to the allergic lung is impaired in CCR4-null mice. In a model of inflammatory bowel disease (IBD), adoptively transferred CCR4-deficient Tregs failed to traffic to the mesenteric lymph nodes in the early stages of disease, resulting in a failure to suppress the generation of pathogenic T lymphocytes and the development of colitis.</div><div class="NLM_p">CXCR1 and CXCR2 coordinate the trafficking of neutrophils to a variety of ELR+ CXC chemokines in humans, notably CXCL8 and related chemokines such as CXCL1, CXCL6, CXCL7 and also non-chemokine ligands such as macrophage inhibitory factor (MIF).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Curiously, there is no orthologue of human CXCL8 in the mouse. Initial studies of the murine genome by Southern blotting suggested that the mouse only harbored an orthologue of CXCR2,<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> although subsequent whole genome sequence revealed a CXCR1 orthologue in proximity on mouse chromosome 1, which responds to CXCL6 but not other murine CXC chemokines.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Deletion of CXCR2 results in outwardly healthy mice, although on closer examination, the mice exhibited lymphadenopathy and splenomegaly resulting from an increase in B lymphocyte and neutrophil numbers, suggesting that CXCR2 regulates both neutrophils and B lymphoyte development. CXCR2-null mice also display decreased numbers of mucosal mast cell progenitors within the intestine and the allergic lung, suggesting that CXCR2 is important for mast cell localization.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Neutrophils lacking CXCR2 have been reported to be preferentially retained in the bone marrow of mice, suggesting an additional role for CXCR2 in neutrophil retention.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p last">Unsurprisingly, mice deficient in CXCR2 display innate immune defects including increased susceptibility to <i>Toxoplasma gondii</i> infection.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Perhaps, more surprisingly, CXCR2 appears to play a role in the migration of oligodendrocyte precursors during the development of the spinal cord, with CXCR2 deficiency associated with reduced numbers of oligodendrocytes and abnormal distribution.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> In a murine model of multiple sclerosis using cuprizone-induced demyelination, CXCR2 deficiency was associated with reduced oligodendrocyte loss, suggesting a role for CXCR2+ neutrophils in the disease process.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Similarly, a role for CXCR2-mediated macrophage recruitment to atherosclerotic plaques was supported by the finding that CXCR2-null mice on the LDL-deficient background have reduced plaque development when fed a high-fat diet.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Chemokine Receptor Antagonists</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The past decade has seen literally hundreds of chemokine receptor antagonist programs initiated against a broad range of the receptors by many of the major pharmaceutical and biotechnology companies. There have been a plethora of reviews that have discussed many of these programs, and thus, we will concentrate here only on those inhibitors, around 40 or so, that have at one time or another progressed into human clinical trials (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Most of these antagonists are small molecule allosteric receptor inhibitors, although neutralizing antibodies, peptides, and even nucleic acid approaches have also been described (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> CCR1 Antagonists</h3><div class="NLM_p">As far as we are aware, eight CCR1 antagonists have been in human clinical trials (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). One of the first was a compound from Berlex, BX 471 (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), which is a potent diacylpiperazine that is more than 1000-fold selective for CCR1.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The antagonist has a reported <i>K</i><sub>D</sub> of 1.0 nM for human CCR1 calculated from radiolabeled binding studies and was poorly cross-reactive with rat and mouse, CCR1 (<i>K</i><sub>D</sub> of 121, and 200 nM respectively). Nevertheless, the antagonist <b>1</b> had sufficient affinity that it could be tested in animal models and it was efficacious in an acute rat EAE model of multiple sclerosis, a rat heart transplant model, a mouse model of renal fibrosis, and a mouse model of multiple myeloma.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> On the basis of these data, the antagonist entered phase I clinical trials. Although the safety profile of compound <b>1</b> was excellent, it had a relatively short biological half-life in humans (<i>t</i><sub>1/2</sub> â 2.3 h) and an extended release tablet had to be formulated that allowed three times a day dosing.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The CCR1 antagonist entered phase II clinical trials for multiple sclerosis in early 2004. Although the drug was well tolerated and showed no safety concerns, its development was stopped after the clinical phase II study failed to show a reduction in the number of new inflammatory CNS lesions (detected by magnetic resonance imaging).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In addition the CCR1 antagonist <b>1</b> was tested in phase II clinical trials for psoriasis and endometriosis but was not efficacious in either.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. CCR1 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Millennium has reported a number of CCR1 antagonists including MLN3701 (structure not disclosed) which was co-developed with Sanofi-Aventis (AVE9897) for multiple sclerosis, but no structures or data were ever published.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The most advanced CCR1 program from the company is MLN3897 (<b>2</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> This antagonist is a substituted pyridylbenzoxepine of a series previously described by this group and optimized from a tricyclic nonspecific CCR1 antagonist originally described by Berlex researchers.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> It demonstrated high affinity binding for CCR1 (<i>K</i><sub>i</sub> = 2.3 nM) and had an IC<sub>50</sub> of 3.4 nM for the inhibition of chemotaxis induced by CCL3. Compound <b>2</b> was effective in vivo and demonstrated an EC<sub>50</sub> of 0.03 mg/kg in inhibiting CCL3 induced immune cell recruitment in a guinea pig skin sensitization model (pharmacokinetic studies revealed that it had a half-life of 3 h in rat and oral bioavailability of 35% in rat and 100% in dog). Recently compound <b>2</b> was shown to be able to impair osteoclastogenesis and to inhibit the interaction of multiple myeloma cells with osteoclasts, thus demonstrating a potential utility in treating multiple myeloma.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> In 2004 Millennium announced that they were in phase I clinical trials with compound <b>2</b> and the major indications appeared to be rheumatoid arthritis and multiple myeloma. However, in November 2007 Millennium announced that they were terminating the development of compound <b>2</b> for rheumatoid arthritis because it had failed to reach its clinical end point in a phase II trial.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">Pfizer scientists discovered that a quinoline carboxamide containing a hydroxyethylene peptide isostere was a weak 2.3 Î¼M CCR1 inhibitor.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Optimization of this weak hit included replacing the cyclohexyl ring with a phenyl ring and adding an extra nitrogen to the quinoline ring that yielded a 34-fold improvement in potency to 64 nM.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> This template underwent further optimization to increase its metabolic stability and pharmacokinetic properties finally yielding CP-481715, a quinoxaline-2-carboxylic acid derivative (<b>3</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The CCR1 inhibitor is a competitive and reversible antagonist and is more than 100-fold selective for CCR1 as compared to a panel of G-protein-coupled receptors.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Unfortunately, compound <b>3</b> is species specific for human CCR1, precluding its evaluation in classical animal models of disease. To circumvent this problem, Pfizer researchers generated transgenic mice expressing human CCR1 and demonstrated efficacy in models of inflammation in these animals.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Compound <b>3</b> successfully completed phase I safety studies and demonstrated efficacy in a 16-patient phase Ib clinical trial.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> On the basis of these data, compound <b>3</b> entered phase II studies, but the trial was stopped after 6 weeks because the compound did not demonstrate any efficacy.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p">Chemocentryx has disclosed a number of CCR1 inhibitors in patent applications including a series of azaindazole compounds.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Presumably CCX354 <b>4A</b> (structure not disclosed), which is their lead compound and is currently in phase II clinical trials,<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> is a member of this class of compounds, and a generalized structure is shown (<b>4B</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Compound <b>4A</b> blocked radiolabeled binding of CCL15 to human monocytes with a <i>K</i><sub>i</sub> of 1.5 nM and was a fully functional antagonist inhibiting CCL15 mediated chemotaxis in THP-1 cells (IC<sub>50</sub> of 1.4 nM), even in the presence of 100% human serum.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> In addition, compound <b>4A</b> also blocked the chemotaxis of THP-1 cells that were induced with synovial fluid from rheumatoid arthritis patients. The antagonist was specific for CCR1 and had no effect on the induction of chemotaxis through 13 other chemokine receptors at concentrations of up to 10 Î¼M. The antagonist was active in vivo, since it was able to block leukocyte trafficking in two animal models (thioglycollate-induced peritonitis in rats and LPS-induced synovitis in rabbits). On the basis of these favorable animal data, compound <b>4A</b> was evaluated in a human phase I clinical trial for safety. The antagonist appeared to be well tolerated, and no serious adverse events were reported. It displayed linear doseâresponse kinetics at all doses up to 300 mg (<i>t</i><sub>1/2</sub> = 7 h), and steady state plasma levels fluctuated from 0.5 to 1.3 uM. Phase II clinical trial data for compound <b>4A</b> reported at the recent American College of Rheumatology meetings showed that at a once daily dose of 200 mg the antagonist was safe and well tolerated by patients with rheumatoid arthritis. Furthermore the compound reached its clinical end points in the study (reduction in disease score and in the levels of proinflammatory markers).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p">Merck entered phase II studies with two CCR1 antagonists, C-6448 (structure not disclosed) for multiple sclerosis and C-4462 (structure not disclosed) for rheumatoid arthritis.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Although little has been reported about these programs, it is possible the compounds are xanthene carboxamides from the CCR1 antagonist program developed by Banyu (Merckâs subsidiary in Japan),<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> and a prototypical structure is shown (<b>5</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Both programs were listed in the Merck annual report for 2004 as being in phase II clinical trials;<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> however, neither compound was listed in the Merck annual report for 2005 and no further mention of these compounds has since appeared.</div><div class="NLM_p last">AstraZeneca identified CCR1 antagonists from its screening of an in-house library, and optimization yielded the clinical candidate AZD4818 a spirocyclic piperidine derivative (<b>6</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The drug inhibited CCL3 binding to human mouse and rat CCR1 receptors (no affinity reported) and blocked chemotaxis of human monocytes.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> On the basis of these and other nonreported data, the CCR1 antagonist entered clinical trials for the treatment of chronic obstructive pulmonary disease (COPD).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The CCR1 antagonist was given by inhalation at a dose of 300 Î¼g twice daily for 4 weeks to patients with COPD. Although the drug was well tolerated, it failed to meet its clinical end points and there was no benefit to COPD patients treated with the antagonist compared to patients that were given placebo.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> CCR2 Antagonists</h3><div class="NLM_p">Seven CCR2 inhibitors including small molecule receptor antagonists and neutralizing antibodies to the receptor have been evaluated in clinical trials (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><figure id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CCR2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Merck has disclosed a variety of CCR2 antagonists<a onclick="showRef(event, 'ref106 ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref106 ref107 ref108">(106-108)</a> including the structure of MK-0812, a potent CCR2 antagonist (IC<sub>50</sub> of 5.0 nM) with four chiral centers featuring a tetrahydro-3-trifluoromethyl-1,6-naphthyridine nucleus (<b>7</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The molecule was their clinical candidate in phase II clinical trials for both rheumatoid arthritis and multiple sclerosis.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The CCR2 antagonist failed to show any significant improvement compared to placebo for any of the end points studied.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The multiple sclerosis trial was a randomized, double-blind placebo controlled study with a 12-week protocol and 120 patients. The primary end point was new GD-enhancing lesions by MRI.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Merck has so far not reported any data for this study, and all reference to the program has been removed from the company's Web site and from its pipeline. However, it is possible that there is still some interest in the program, perhaps in the area of pain relief. In support of this are the findings that CCR2 knockout mice show a marked attenuation of pain responses<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> and that compounds belonging to this series of antagonists are effective in rat models of pain.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">Incyte has disclosed a number of CCR2 antagonists,<a onclick="showRef(event, 'ref112 ref113 ref114 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref112 ref113 ref114 ref115 ref116">(112-116)</a> some of which have been developed jointly with Pfizer.<a onclick="showRef(event, 'ref114 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref114 ref115 ref116">(114-116)</a> The lead series are 3-aminopyrrolidine derivatives exemplified by INCB3284 (<b>8</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), which was one of their clinical compounds in phase II clinical studies for multiple sclerosis and lupus.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Previously Incyte had reported that INCB3344 (<i>N</i>-[2-[[(3<i>S</i>,4<i>S</i>)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide), another potent 3-aminopyrrolidine derivative, was efficacious in an EAE model of multiple sclerosis in mice and reduced inflammation in a rat adjuvant induced model of arthritis.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Neither compound <b>8</b> nor INCB8696<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> (structure not disclosed), another clinical CCR2 antagonist, is currently reported in the companyâs pipeline, suggesting either that the clinical trials were not successful or that the company is no longer pursuing these projects for business reasons.</div><div class="NLM_p">In addition to these compounds Incyte reported the joint development of CCR2 antagonists with Pfizer. One of the lead candidates PF-4136309 (structure not disclosed) has been reported to be in phase II clinical trials for neurophathic pain;<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> however, no structure was ever revealed and the compound is no longer reported in Pfizerâs pipeline. Incyte also recently disclosed INCB10820/PF-4178903, which was jointly developed with Pfizer and is a dual CCR2/CCR5 antagonist with an IC<sub>50</sub> for inhibition of CCR2 and CCR5 binding of 3.0 and 5.3 nM, respectively (<b>9</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> This compound is structurally identical to the Merck compound <b>7</b> except that it has a trifluoromethylpyridinepiperazine ring that replaces the trifluoromethylnaphthyridine group in <b>7</b> (<b>7</b> and <b>9</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Compound <b>9</b> was initially selected as a clinical candidate based on its potency and favorable pharmacokinetic properties; however, it had some cardiovascular liabilities, an affinity of 1.7 Î¼M for hERG (an ion channel associated with cardiovascular adverse events) that precluded further clinical development.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Further optimization of this template by replacement of the pyridine ring on the right-hand side of the compound (<b>9</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) with a pyradizine ring resulted in PF-4254196, which had no cardiovascular liabilities (IC<sub>50</sub> = 31.3 Î¼M for hERG) and was potent for CCR2 (IC<sub>50</sub> for inhibition of CCR2 binding of 8.1 nM) (<b>10</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><div class="NLM_p">Millennium has long had an interest in chemokines and chemokine receptors as drug targets and has developed blocking antibodies to these proteins as potential therapeutics. CCR2 neutralizing antibodies as a therapeutic to treat autoimmune diseases such as rheumatoid arthritis represent one of the companyâs most advanced programs in its portfolio. This approach has had mixed success with positive results in phase II trials for atherosclerosis<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> and multiple sclerosis<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> but negative results in a phase II trial for rheumatoid arthritis.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> In a double-blind placebo controlled study in patients at risk for atherosclerotic cardiovascular disease, subjects were given a single infusion of 10 mg/kg MLN1202. The drug was well tolerated and fully met its primary end point of a significant reduction in C-reactive protein levels, an inflammatory biomarker associated with atherosclerosis, after a single dose of MLN1202. These results were statistically and clinically significant relative to the placebo control arm. No serious adverse events were observed in patients exposed to MLN1202. These data indicate that blockade of CCR2 could be of potential benefit in atherosclerosis. At the American Neurological Association meeting in 2007 Millennium announced that their CCR2 neutralizing antibody, MLN1202, reduced gadolinium-enhancing lesions on magnetic resonance images of the brain in a multicenter phase II clinical trial involving 50 patients with relapsing-remitting multiple sclerosis.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> These two positive clinical trials have been somewhat tempered by results from a phase IIa trial with MLN1202 in patients with active rheumatoid arthritis.<a onclick="showRef(event, 'ref97 ref121'); return false;" href="javascript:void(0);" class="ref ref97 ref121">(97, 121)</a> Thirty-two patients received three infusions over a period of 6 weeks with either placebo or MLN1202 at three doses. Treatment with MLN1202 reduced the levels of free CCR2 on CD14 monocytes, demonstrating the biologic activity of the compound. However, there was no reduction in the levels or expression of any of the synovial biomarkers and no clinical improvement was observed.</div><div class="NLM_p">Chemocentryx has reported an interest in CCR2 antagonists in several patent applications,<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122, 123)</a> and two candidate molecules have progressed to clinical trials (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The development of their first clinical candidate CCX915 (structure not disclosed) was terminated because of its poor pharmacokinetic properties in phase I clinical trials.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Their current clinical candidate is CCX140 (<b>11 A</b>, structure not disclosed). Although the structure of <b>11A</b> has not been reported, it is likely that it belongs to the triazolylpyridylbenzenesulfonamide class of compounds exemplified by <b>11B</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), which is reported to have a potency of 5 nM in an inhibition of chemotaxis assay, excellent pharmacokinetic properties, and no cytochrome p450 issues.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Recently the pharmacological characterization of <b>11A</b> was reported.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> It has an affinity of 1.5 nM measured by direct binding of radiolabeled compound to human monocytes, inhibited CCL-2 induced chemotaxis to human monocytes with an IC<sub>50</sub> of 17 nM, and had no activity against a selected panel of 142 other receptors tested. <b>11A</b> was also tested at 10 Î¼M against the major CYP isoforms and was found to lack any inhibitory activity in enzymatic assays. Assessment of inhibition of the hERG potassium channel activity by patch clamp technique showed that <b>11A</b> lacked inhibition of hERG at concentrations up to 100 Î¼M. The compound had favorable pharmacokinetics in rodents and in dogs with <i>t</i><sub>1/2</sub> of 2.8 and 8.7 h, respectively, and was highly bioavailable. Although the compound had poor crossreactivity in rodents, it was effective in reducing hyperglycemia and insulin sensitivity in obese human CCR2 knock-in mice. The compound is currently being evaluated in clinical trials for the treatment of type II diabetes, and favorable results from a phase II trial were recently reported.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In this trial a total of 159 subjects, on stable doses of the antidiabetes drug metformin, were randomized to receive placebo, 5 mg or 10 mg of <b>11A</b>, or 30 mg of pioglitazone hydrochloride once daily for 4 weeks. Fasting plasma glucose decreased dose-dependently with <b>11A</b> treatment, and hemoglobin A1c (a marker of diabetes) was significantly reduced by the higher dose of <b>11A</b>. Plasma CCL2 and circulating monocyte levels were unchanged by <b>11A</b> treatment, and the compound was generally well tolerated and safe in this study.</div><div class="NLM_p">Bristol-Myers Squibb has been very active in the CCR2 antagonist field and has disclosed capped diaminopropionamideglycine dipeptides, di- and trisubstituted cyclohexanes, spiroindenes, and piperidines as potent CCR2 inhibitors.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The company reported clinical trials for BMS-741672 (structure not disclosed), which presumably belongs to one of the class of compounds reported above. A prototypical CCR2 antagonist from this group is shown as <b>12</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Two phase II clinical trials have been described for BMS-741672; one was a double blind study for the treatment of neuropathic pain associated with type II diabetes, and the clinical end points were a reduction in pain score.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The second trial was a 12-week randomized double blind study for the treatment of type II diabetes in which patients were treated with placebo or with 50 mg of CCR2 antagonist given once a day.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The clinical end point was the reduction of glycated hemoglobins (a marker of diabetes). Both clinical studies ended in 2009; however, no reports were ever issued.</div><div class="NLM_p last">A number of CCR2 antagonists have been disclosed by Johnson & Johnson including indole substituted dipiperidines and azetidinylcyclohexanes.<a onclick="showRef(event, 'ref131 ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref131 ref132 ref133">(131-133)</a> But perhaps their most interesting approach was the extensive SAR carried out around the Takeda dual CCR2/CCR5 antagonist to eliminate the CCR5 activity and discover a specific CCR2 antagonist.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> This led to the identification of JNJ-17166864, which was highly selective for CCR2 and had a binding affinity of affinity of 20 nM (<b>13</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> The compound had a 100-fold reduced affinity for rodent CCR2 (IC<sub>50</sub> for mouse of 2 Î¼M) but was still able to demonstrate efficacy in two mouse models of inflammation.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> In line with its structure as a quaternary, compound <b>13</b> demonstrated poor oral bioavailability but dosing by nasal spray allowed it to enter human clinical trials for allergic rhinitis.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> No clinical data from this trial have ever been revealed, but it is clear from the recent flurry of activity describing CCR2 antagonists that the company is still interested in this receptor as a drug target.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> CCR3 Antagonists</h3><div class="NLM_p">Several pharmaceutical companies have disclosed CCR3 antagonists, and six have been described in human clinical trials (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. CCR3 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dupont Merck described a series of 4-benzylpiperidine analogues with good potency for CCR3 but with limited selectivity. Subsequent SAR resulted in several compounds with midpicomolar to high picomolar range antagonism in both calcium mobilization and chemotaxis assays.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Replacement of the 4-benzylpiperidine with a 3-benzylpiperidine and the phenyl linker with a cyclohexyl linker resulted in the discovery of DPC168 with inhibition of CCR3 binding of 2.0 nM and picomolar activity in CCL11-induced chemotaxis assays (<b>14</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Compound <b>14</b> was found to have limited oral bioavailability in mice and reduced eosinophil recruitment into the lungs in a dose-dependent manner following allergen challenge. Further development of compound <b>14</b> was discontinued however because of potent cytochrome P450 2D6 and hERG activity (IC<sub>50</sub> of 40 and 400 nM, respectively).</div><div class="NLM_p">Dupont sold its pharmaceutical business in 2004, and the CCR3 program was acquired by BMS who took over development of this project. They made substantial progress in overcoming the p450 and hERG channel activity by replacing the cyclohexyl central ring of <b>14</b> with saturated heterocycles, which maintained potency for CCR3 with improved selectivity against CYP2D6 and hERG activities. BMS-570520 emerged as the analogue with the best overall balance of selectivity and predicted pharmacokinetic characteristics (<b>15</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Further development of <b>15</b> led to the subnanomolar compound BMS-639623 (<b>16</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) that is in phase I clinical development for asthma.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><div class="NLM_p">GlaxoSmithKline reported that it was in clinical trials with GSK766994, a potent CCR3 antagonist (<b>17</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). In preclinical studies this compound had good pharmacokinetics in dogs with a reported 89% bioavailability and a half-life of 2.8 h. This compound was also orally active in a Brown Norway rat model of asthma and had a potency of 10 nM for CCR3. The drug has been reported as failing to show efficacy in a phase III clinical trial for the treatment of allergic rhinitis.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> However, development still appears to be active, since the company reported that it was conducting phase II studies in patients with asthma in early 2011, but no data have been reported as yet.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><div class="NLM_p">AZD3778 is a novel low molecular weight dual CCR3 and histamine H<sub>1</sub> receptor antagonist developed by AstraZeneca. The compound has an IC<sub>50</sub> of 8.1 nM for the inhibition of eotaxin binding to CCR3 and an IC<sub>50</sub> of 40 nM for the inhibition of binding to the H<sub>1</sub> histamine receptor (<b>18</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> A phase II clinical trial in patients with allergic rhinitis revealed that <b>18</b> exerted moderate antieosinophilic and symptom-reducing effects thought to be through inhibition of CCR3 rather than through its effects on the histaminergic receptor.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Since the effects of <b>18</b> were only modest, no further development of the compound has been reported (see also the section <a class="ref internalNav" href="#sec10" aria-label="Promiscuous Chemokine Receptor Antagonists">Promiscuous Chemokine Receptor Antagonists</a> later).</div><div class="NLM_p">Novartis had a CCR3 antagonist program and identified the compound QAP 642 (structure not disclosed) as the clinical lead<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> but has not disclosed any structural or potency data. A human clinical pharmacodynamic study reporting the effects of QAP642 on cutaneous eosinophil migration in the skin following subcutaneous injection of eotaxin in human volunteers has been reported.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> At the highest dose the compound caused a modest increase in the QTc prolongation. The compound was able to inhibit eosinophil migration in this human pharmacodynamic study; however, it subsequently failed in clinical trials for asthma and its development was discontinued.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><div class="NLM_p last">A novel approach to inhibiting CCR3, ASM8, has been recently described by scientists at Pharmaxis.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common Î² chain of the IL-3, IL-5, and GMCSF receptors. In a small clinical study with patients with mild asthma the drug was safe and well tolerated. It attenuated the allergen-induced increase in target gene mRNA, allergen-induced sputum eosinophils, and the early and late asthmatic responses.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144, 145)</a> It also reduced the number of CD34(+) CCR3(+) cells and CD34(+) IL-5RÎ±(+) cells and the proportion of CD34(+) cells expressing IL-5RÎ±. Currently ASM8 is being evaluated in larger phase II clinical trials for asthma.</div></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> CCR4 Antagonists</h3><div class="NLM_p">In addition to its role in allergic inflammation, CCR4 is expressed on tumor cells from patients with adult T-cell leukemia (ATL),<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> an aggressive peripheral T-cell cancer caused by the human T-cell lymphotropic virus type I (HTLV-1). The disease does not respond well to conventional chemotherapeutics and thus has a poor prognosis. A number of small molecule CCR4 antagonists have been described, several of which are still in preclinical development.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Two CCR4 antagonists have been described in clinical studies: an antibody to the receptor and a small molecule inhibitor (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div><div class="NLM_p">A humanized monoclonal antibody, KW-0761, directed against CCR4 with potential anti-inflammatory and antineoplastic activities is being developed by Amgen (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). KW-0761 selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and therefore chemokine-mediated cellular migration and proliferation of T cells and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity against CCR4-positive T cells. Initial phase I studies were carried out in relapsed patients with CCR4 positive adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. KW-0761 was tolerated at all of the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> On the basis of the positive phase I study, a phase II study of KW-0761 in CCR4-positive ATL patients was carried out to evaluate the efficacy of the drug. Twenty-eight patients were enrolled in a multicenter study and received intravenous infusions of KW-0761 once per week for 8 weeks at a dose of 1.0 mg/kg. KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The most common adverse events were infusion reactions and skin rashes, which were manageable and reversible in all cases.</div><div class="NLM_p">A number of companies have described CCR4 antagonists, and these have been recently reviewed.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> All of these molecules are still preclinical, but GSK recently disclosed a series of indazolesulfonamides<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> and identified a clinical development compound, (GSK2239633) (<b>19</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) that has entered phase I clinical trials presumably for allergy and asthma.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The pharmacokinetics of the compound were tested in rats and in beagle dogs with a half-life of 2.5 and 2.6 h, respectively, and oral bioavailability of 85% and 97%, respectively. The authors in the study pointed out that they did not generate any in vivo pharmacodynamic data for compound <b>19</b> in animals, citing differences in immunology between animals and humans and the complexity of chemokine systems across species. They did not reveal whether the antagonist cross-reacted with rodent CCR4 receptors. In addition they noted that in their opinion the lack of convincing evidence that CCR4 can drive inflammation in animal models of asthma rendered such studies moot. Instead the authors regarded data from in vitro studies using target human CD4+ CCR4+ and CD45RO+ T cells and biopsies taken from atopic asthmatics, supernatants from which were used to induce chemotaxis of autologous memory T-lymphocytes, as more relevant to confirm the role of CCR4 in asthma.</div><figure id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. CCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> CCR5 Antagonists</h3><div class="NLM_p">Although CCR5 was initially viewed as a target for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis (discussed earlier), it quickly attracted attention from the pharmaceutical industry because of its role as an entry factor for macrophage-tropic strains of HIV-1.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Indeed all of the CCR5 small molecule antagonists currently in the clinic are antiviral inhibitors of CCR5 (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).</div><figure id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. CCR5 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To date, only one small molecule antagonist of CCR5, maraviroc, originally known as UK-427,857 (<b>20</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), has made it as an approved drug.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The discovery of the drug came at the end of a long screening and optimization process. This initially involved high throughput screening of the Pfizer compound library with a chemokine radioligand binding assay. Initial hits from this screen included compounds such as the imidazopyridine UK107,543; however, these compounds were not ideal because although they inhibited CCL4 binding to CCR5, they had no measurable antiviral activity.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Subsequent work was directed at optimizing these compounds to produce novel, selective ligands with enhanced ligand efficiency.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> This necessitated the replacement of the imidazopyridine moiety to avoid inhibition of cytochrome p450 2D6. Further optimization was focused upon reducing the lipophilicity of the series by introducing a variety of amide substituents. Among the resulting series of analogues, benzamide, isopropylamide, and cyclobutylamide were identified with potency in ligand binding assays; however, this did not necessarily correlate with antiviral activity.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> After SAR analysis of over 1000 compounds, compound <b>20</b> was discovered.</div><div class="NLM_p">Compound <b>20</b> is potent against all known CCR5-trophic HIV-1 strain, with a mean IC<sub>90</sub> of 2 nM in antiviral assays.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> It was also active against 200 clinically derived HIV-1 envelope pseudoviruses, many of which were from viruses that were resistant to other HIV treatments. Unlike the earlier analogues in the series, compound <b>20</b> had no detectable in vitro issues, notably a lack of activity for the hERG ion channel. Subsequent phase IIb/III studies found the antagonist to be efficacious in reducing the viral load at 48 weeks in CCR5-trophic HIV-1 infected patients.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Once bound to CCR5, compound <b>20</b> appears to have a long dissociation time because in monotherapy studies over 60% of receptors remained occupied 5 days after the discontinuation of treatment.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> The CCR5 antagonist is currently approved by the U.S. Food and Drug Administration for use in combination with other antiretroviral agents in patients infected with multidrug-resistant, CCR5-tropic HIV- 1.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><div class="NLM_p">To search for CCR5 antagonists, scientists at Schering-Plough screened for hits with high-throughput CCL5 competition binding assays and then tested interesting compounds in viral entry assays. Screening of the compound library led to the identification of a CCR5 antagonist, compound <b>2</b>, which had modest affinity for the receptor (<i>K</i><sub>i</sub> = 1.0 Î¼M) but was also a potent muscarinic M<sub>2</sub> receptor antagonist (M<sub>2</sub><i>K</i><sub>i</sub> = 1.3 nM).<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Extensive SAR that involved replacing the unsymmetrical nicotinamide <i>N</i>-oxide moiety with a 4,6-dimethylpyrimidine-5-carboxamide gave a molecule that had improved potency for CCR5 and reduced affinity for the muscarinic receptors.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Subsequent SAR investigations using the knowledge gained from this approach yielded a low molecular weight early lead, compound <b>3</b> (CCR5 <i>K</i><sub>i</sub> = 66 nM; M2 <i>K</i><sub>i</sub> = 1323 nM). Further SAR development of oximinopiperidinopiperidineamides derived from this series led to the discovery of the clinical candidate SCH 351125 also known as SCH-C (<b>21</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). This compound had potent activity in CCL5 displacement assays (<i>K</i><sub>i</sub> of 2 nM), subnanomolar activity in the blockade of viral entry (IC<sub>50</sub> of 0.6 nM against the HIV-1 reporter virus ADA), and good oral bioavailability in rats, dogs, and monkeys.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Unfortunately phase I studies were suspended in part because of the affinity of the antagonist for the hERG ion channel. Inhibition of this channel in human phase I studies led to QTc prolongation in patients, increasing their risk of developing ventricular arrhythmias and potentially resulting in sudden death.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p">Parallel SAR studies of an earlier lead compound resulted in the discovery of SCH-417690, also known as SCH-D (vicriviroc), a methoxymethyl analogue, which had improved receptor selectivity and notably a reduced affinity for hERG (<b>22</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> On the basis of these favorable data, compound <b>22</b> entered clinical trials for treatment of AIDS. Unfortunately the development of the drug experienced multiple problems; initially a phase II study in treatment-naive individuals was halted in 2005 because individuals who first experienced viral suppression when taking the drug quickly experienced viral rebound.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Although a recent study indicated that the antagonist demonstrated potent virologic suppression in HIV-1-infected, treatment-experienced patients, increased liver malignancies were observed in the drug treated group.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Subsequent to these data Merck acquired Schering-Plough in 2009 and a recent communication from the company stated that all further development of compound <b>22</b> had ceased and the program was terminated.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div><div class="NLM_p">In common with other major pharmaceutical companies GSK also had an interest in CCR5 antagonists. Their most advanced compound GW873410 (aplaviroc) is a spiroketopiperazine obtained from collaboration with Ono and originally designated as ONO-4128 (<b>23</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) discovered from their spiroketopiperazine program.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> The compound was a potent CCR5 inhibitor and blocked the binding of CCL3 and CCL4 to CCR5 (<i>K</i><sub>D</sub> of 3.0 nM) but interestingly had almost no effect on inhibiting the binding of the CCR5 ligand CCL5.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> In addition compound <b>23</b> potently blocked the binding of a wide spectrum of laboratory and primary R5 HIV isolates (50% inhibitory concentration values of 0.1â0.6 nM). Compound <b>23</b> demonstrates a slow receptor off rate with a half-life of receptor dissociation exceeding 150 h in vitro.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Pharmacokinetic studies revealed favorable oral bioavailability in monkeys of 30%.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> On the basis of these and other favorable preclinical data, it entered clinical trials as a viral entry inhibitor.</div><div class="NLM_p">Compound <b>23</b> completed phase I safety studies, and single and repeat doses of 50â800 mg were well tolerated, with no serious adverse events. No specific trends in laboratory parameters or clinically significant ECG changes were noted. The pharmacokinetic and safety profile supported the continued investigation of 873140 with HIV-infected subjects. Unfortunately, however, phase II trials for the antagonist were halted in 2005 because of serious liver toxicity.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> GSK tried to salvage the drug by continuing phase III trials with treatment-experienced patients and monitoring for liver toxicity; however, these trials were recently terminated because of poor efficacy and GSK stopped the further development of compound <b>23</b> and abandoned the program.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p">Takeda has disclosed a number of CCR5 antagonists obtained from HTS screening of an inhibition of CCL5 binding assay of the Takeda compound library. One of these compounds, TAK-779, an anilide derivative with a quaternary ammonium group, had good in vitro activity in an inhibition of HIV entry assay and displayed nanomolar affinity for CCR5 as well as CCR2 in binding assays (<b>24</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref169 ref170">(169, 170)</a> Unfortunately <b>24</b> had poor oral bioavailability in part due to the quaternary ammonium moiety.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Extensive chemical optimization included replacing the quaternary ammonium group of the compound with a polar sulfoxide moiety, replacement of the [6,7]-fused 1-benzazepine nucleus to a (6,8)-fused nuclei, and substitution of a 4-(2-butoxyethoxy) group for the methyl group.<a onclick="showRef(event, 'ref171 ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref171 ref172 ref173">(171-173)</a> These changes led to the identification of the clinical candidate TAK-652 (cencriviroc) (<b>25</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), which was a potent, metabolically stable, and orally bioavailable CCR5 antagonist.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Compound <b>25</b> blocked the binding of CCR5 chemokines with an IC<sub>50</sub> of 3.0 nM for CCL3. It also inhibited CCL2 binding to CCR2 with an IC<sub>50</sub> of 5.9 nM, demonstrating that it was a dual CCR2/CCR5 antagonist.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> The compound was active against HIV-1 clinical isolates with an EC<sub>50</sub> of 61 pM.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><div class="NLM_p">Phase I clinical studies in healthy volunteers have shown the drug to be safe, with a mean half-life of 35â40 h, supporting once a day dosing.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Currently compound <b>25</b> is in phase II clinical trials to treat AIDS and Tobira Therapeutics has obtained the exclusive worldwide rights to develop, manufacture, and commercialize this anti-HIV drug.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> A dose-escalating study to assess the antiviral activity, pharmacokinetics, safety, and tolerability of an oral once-daily monotherapy of the drug in HIV-1-infected, antiretroviral-treatment-experienced, CCR5-antagonist-naive subjects has just been reported.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> The study found that compound <b>25</b> caused significant reductions in HIV-1 RNA at all doses tested. The drug was well tolerated with no dose-limiting adverse events and demonstrated potential as a once-daily oral CCR5 antagonist. Interestingly <b>25</b> also appears to have clinical potential as a CCR2 receptor antagonist, since it demonstrated strong CCR2 antagonism manifested as significant CCL2 increases in all subjects tested. The increases in CCL2 would have the effect of down-regulating CCR2 by inducing receptor internalization.</div><div class="NLM_p">Incyte has disclosed CCR5 antagonists for the treatment of AIDS.<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176, 177)</a> Its approach included rational drug design around existing CCR5 literature compounds especially the inhibitors designed by Schering-Plough, which are potent antiviral CCR5 inhibitors with good pharmacokinetic properties (see <b>21</b> and <b>22</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). On the basis of the idea that the phenyl ring on the left-hand side of compound <b>22</b> is a critical component of its activity, they carried out extensive SAR on this region of the molecule and discovered that a benzene-fused bicyclic system such as an indane could be beneficial to the molecular properties of the antagonist if it was connected to the piperazine nitrogen. This molecule constituted the starting point of further optimization that resulted in the discovery of INCB9471 (<b>26</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> The antagonist demonstrated fast on rates and slow off rates for CCR5 with an overall <i>K</i><sub>D</sub> of 3.1 nM in human peripheral blood mononuclear cells. It was a potent CCR5 antagonist and inhibited calcium transients induced by CCR5 agonists with an IC<sub>50</sub> of 16 nM. Compound <b>26</b> was highly selective for CCR5 and did not cross-react with any other chemokine receptors or GPCRs tested. Kinetic studies indicated that <b>26</b> is an allosteric noncompetitive CCR5 inhibitor and has highly potent anti-HIV-1 activity with an IC<sub>90</sub> of 9.0 nM for all M5 viruses, whereas it is inactive against cells infected with X4 HIV-1 strains. Furthermore <b>26</b> was found to be a potent inhibitor of mutant HIV-1 variants that are resistant to other drugs. The antagonist inhibited hERG with an IC<sub>50</sub> of 4.5 Î¼M, which is 500 times above its mean antiviral IC<sub>90</sub> value. The compound is not a cytochrome p450 inhibitor, with IC<sub>50</sub> values greater than 25 Î¼M against the five major cytochrome p450 isozymes tested. In vivo, the antagonist exhibited good oral bioavailability in rats (<i>F</i> = 100%) and in dogs (<i>F</i> = 95%), and this coupled with its excellent half-life suggested the possibility of once a day dosing in humans. On the basis of these studies together with its safety in toxicology studies in rodents and primates, the compound was advanced into human clinical trials.</div><div class="NLM_p">Results from a 14-day placebo-controlled phase IIa study, which involved a total of 23 HIV-infected patients, demonstrated that compound <b>26</b> was safe and well tolerated with no clinically significant chemistry, hematology, or ECG changes compared to placebo patients. Once a day oral dosing with 200 mg of compound <b>26</b> had prolonged antiviral effects in HIV patients infected with R5-tropic virus. Consistent with the long half-life of the molecule (<i>T</i><sub>1/2</sub> = 58â60 h), treated patients continued to show evidence of viral suppression 2 weeks after their last dose of drug.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Despite these promising data, Incyte announced its decision to halt all further internal development of its CCR5 antagonist to allow for focus on their JAK kinase inhibitors for the treatment of cancer.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></div><div class="NLM_p">AstraZeneca has disclosed a number of CCR5 antagonists including a series of substituted 1-(3,3-diphenylpropyl)piperidinephenylacetamides.<a onclick="showRef(event, 'ref180 ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref180 ref181 ref182">(180-182)</a> Optimization of this series yielded compound <b>1</b> (<b>27</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) that had excellent CCR5 potency (binding IC<sub>50</sub> = 0.32 nM) and selectivity together with good oral pharmacokinetic profiles in rat and dog. However, <b>27</b> showed moderate activity against the hERG ion channel, an indicator of cardiotoxicity risk, and its cardiac safety margin (250-fold) was judged to be insufficient for further development. However, further optimization of compound <b>27</b> revealed that replacing the upper phenyl ring in the diphenylpropyl group with a C-linked piperidine reduced hERG activity and gave a much improved cardiac safety margin (6400-fold).<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> The resulting compound AZD5672 (<b>28</b> Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) had excellent CCR5 potency (binding <i>K</i><sub>i</sub> = 0.17 nM) and excellent pharmacokinetic properties that merited its further development as a clinical compound. Compound <b>28</b> was subsequently tested in a phase IIb study in patients with rheumatoid arthritis.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Although the compound had excellent, once daily oral pharmacokinetic properties and exhibited high levels of receptor occupancy and maximal inhibition of CCR5 as confirmed by an ex vivo pharmacodynamic assay (% CCR5 internalized following ex vivo stimulation with 100 nM CCL4), it had no efficacy.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></div><div class="NLM_p">Two companies, Progenics and Human Genome Sciences, have described monoclonal antibodies as inhibitors of CCR5 function. Progenics is developing a humanized monoclonal antibody to CCR5 (PRO 140) as a potent inhibitor of viral entry for the treatment of X5 HIV-1 infected individuals. A small phase IIa clinical trial evaluated the pharmacokinetics, antiviral activity, and tolerability of PRO 140 in 31 HIV positive adults randomly assigned to receive single 5 or 10 mg/kg iv doses or placebo. A single intravenous dose of PRO 140 reduced virus by nearly 100-fold for up to 10 days, and the drug was found to be safe and generally well tolerated with no serious drug-related adverse events or dose-limiting toxicities.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> In further studies, the investigators demonstrated that 10 mg/kg iv and 324 mg subcutaneous forms of PRO 140 had similar efficacy. Given its antiviral equivalence, Progenics has chosen the subcutaneous formulation of PRO 140 for further development because it can potentially be self-administered by patients. The drug is continuing its development in further clinical trials.</div><div class="NLM_p">Human Genome Sciences has described a human IgG4 monoclonal antibody against CCR5, HGS004, that is a potent inhibitor of all three of the CCR5 ligands CCL3, CCL4, and CCL5, and in addition the antibody has potent HIV co-receptor activity<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Phase 1 clinical studies demonstrated that HGS004 was safe and well tolerated by patients.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> However, the nonlinear pharmacokinetics exhibited by HGS004 indicated that its anti-HIV potency as a single agent might be suboptimal. Of further concern was the finding that some patients treated with high doses of HGS004 showed a switch from CCR5- to CXCR4-trophism. This change in chemokine coreceptor usage by the virus could be deleterious in the treatment of HIV patients because when it occurs during the natural course of HIV infection, it usually correlates with subsequent disease progression and a poorer prognosis.</div><div class="NLM_p">Novartis is in phase I clinical trials with a CCR5 antagonist (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> This inhibitor is a dual CCR2/CCR5 antagonist and will be covered later in the section under promiscuous antagonists.</div><div class="NLM_p last">A novel approach to target CCR5 is that taken by Sangamo Science which uses zinc finger nuclease technology to cut DNA sequences.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> They are in phase II clinical trials to treat AIDS with SB-728 a zinc finger nuclease that modifies the gene encoding CCR5, thus knocking out the chemokine receptor and recapitulating the HIV resistance manifested by individuals that express the naturally occurring CCR5-Î32 mutation.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> CCR9 Antagonists</h3><div class="NLM_p">CCR9 is selectively expressed by thymocytes, small intestinal lamina propria lymphocytes, and intraepithelial lymphocytes and binds the ligand CCL25/TECK.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> CCR9+ peripheral blood T lymphocytes have been reported to be markedly elevated in patients with diseases of the small bowel that correlates with increased expression of CCL25, suggestive of a role for the CCR9/CCL25 axis in Crohnâs disease.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> These data prompted Chemocentryx to develop CCR9 antagonists for the treatment of Crohnâs disease, and Chemocentryx has filed a number of patents claiming CCR9 antagonists including arylsulfonamides.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> The clinical candidate CCX282 from this program (<b>29</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>)<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> has been reported to have an IC<sub>50</sub> of 6 nM in direct binding experiments with radiolabeled compound.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> The compound inhibits CCL25 induced chemotaxis in cells expressing CCR9 with an IC<sub>50</sub> of 2.8 nM and has clear selectivity against a panel of 25 other GPCRs tested. Oral administration of <b>29</b> was efficacious in murine models of ileal Crohnâs disease and ulcerative colitis.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> In a 4-week phase II clinical trial of patients with moderate-to-severe Crohnâs disease, a single daily dose of 250 mg of compound <b>29</b> was well tolerated and displayed clear signs of clinical activity as recorded by a reduction in blood levels of C-reactive protein.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> In 2006, a phase II/III clinical trial to further assess the safety and efficacy of the antagonist in patients with moderate to severe Crohnâs disease was initiated. The study revealed that the 500 mg once daily dose of <b>29</b> in patients with small bowel and/or colonic Crohnâs disease was consistently superior to placebo across multiple efficacy end points. Recently GlaxoSmithKline exercised its option to obtain an exclusive license to compound <b>29</b> and is now solely responsible for all further clinical development of the drug (renamed vercirnon) that is currently in four pivotal phase III clinical trials.</div><figure id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. CCR9 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> CXCR1 and CXCR2 Antagonists</h3><div class="NLM_p">The pathophysiological role played by CXCL8 receptors has generated considerable interest by pharmaceutical companies, and several small molecule inhibitors of the receptors have been described (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).</div><figure id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. CXCR1 and CXCR2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A phenol containing diarylurea SB 225002 was the first small molecule chemokine receptor antagonist to be described in the literature (<b>30</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> It is an antagonist of CXCL8 binding to CXCR2 with an IC<sub>50</sub> of 22 nM and showed >150-fold selectivity over other GPCRs tested. In vitro, <b>30</b> potently inhibited human and rabbit neutrophil chemotaxis induced by both CXCL8 and CXCL1. In vivo, SB 225002 selectively blocked CXCL8-induced neutrophil migration in rabbits. Early SAR evaluation indicated that substitution at both the 3 and 4 positions on the phenol ring was well tolerated.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> However, this compound and some others from this series were not developed further because of undesirable pharmacokinetics.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> Extensive SAR around this issue revealed that insertion of a sulfonamide group on the phenol ring greatly reduced metabolic clearance.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Substitution of a 3-piperidinesulfonamide moiety on the phenol ring yielded the compound SB 656933 (<b>31</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>) with an IC<sub>50</sub> of 22 nM for binding to CXCR2. Compound <b>31</b> was found to inhibit neutrophil CD11b up-regulation (IC<sub>50</sub> of 260.7 nM) and shape change (IC<sub>50</sub> of 310.5 nM) in patients with chronic obstructive pulmonary disease and entered clinical trials for cystic fibrosis and chronic obstructive pulmonary disease.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></div><div class="NLM_p">Phase I clinical studies assessed the safety, pharmacokinetics, and pharmacodynamics of single escalating doses of <b>31</b> in healthy subjects, as well as the effect of CXCR2-selective antagonism on airway inflammation in healthy humans using an inhalation challenge model of ozone-induced airway inflammation. These two studies demonstrated that the antagonist was safe and well tolerated at all doses (2â100 mg). In addition single doses of <b>31</b> reduced ozone-induced airway inflammation in a dose-dependent manner.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></div><div class="NLM_p">The observation that 2-arylpropionic acids such as ibuprofen were able to potently inhibit CXCL8-induced chemotaxis in neutrophils prompted scientists at DompÃ© to screen for novel potent inhibitors of CXCL8-induced chemotaxis.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> A class of derivatives of 2-arylphenylpropionic acids was extensively investigated leading to the selection of an acylmethanesulfonamide derivative, repertaxin (<b>32</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), as the lead compound.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Compound <b>32</b> was able to inhibit CXCL8-induced neutrophil chemotaxis with an IC<sub>50</sub> of 1 nM but interestingly did not inhibit chemokine binding;<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> thus, its mechanism of action is unclear. Compound <b>32</b> is reported to be in phase II clinical trials for ischemia and reperfusion injury that is responsible for poor graft function after organ transplantation, but no published data have been forthcoming so far. In addition a recent report suggests that it may have some utility in certain forms of breast cancer.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Apparently the drug targets breast cancer stem cells in an NOD/SCID mouse model by inhibiting tumor growth and metastasis formation. The same group has recently begun a clinical trial combining repertaxin with chemotherapy in women with advanced breast cancer.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a></div><div class="NLM_p">Structureâactivity studies of a lead cyclobutenedione compound enabled scientists at Schering-Plough to identify SCH-527123 (<b>33</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>) as a potent, orally bioavailable dual CXCR1/CXCR2 receptor antagonist.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> The compound had good pharmacokinetic properties and oral bioavailability in the rat. The antagonist inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on irrelevant ligands. The antagonist displayed saturable and reversible binding kinetics to both CXCR1 (<i>K</i><sub>D</sub> of 3.9 nM) and CXCR2 (<i>K</i><sub>D</sub> of 40 pM).<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> In a lipopolysaccharide-induced model of pulmonary inflammation in the mouse, oral treatment with <b>33</b> blocked both pulmonary neutrophilia and goblet cell hyperplasia.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> In a similar model in the rat, <b>33</b> was equally as efficacious and suppressed both pulmonary neutrophilia and the increase in BAL induced by intratracheal administration of lipopolysaccharide.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> In cynomolgus monkeys, <b>33</b> reduced the pulmonary neutrophilia induced by repeat bronchoscopy and lavage.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a></div><div class="NLM_p last">On the basis of these data, compound <b>33</b> was recently tested in an ozone-induced airway neutrophilia clinical study in healthy subjects.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> The drug significantly lowered sputum neutrophil counts compared with prednisolone or placebo. Comparable results were obtained for total cell count, percentage of sputum neutrophils, and interleukin-8 and myeloperoxidase in sputum supernatant. All treatments were safe and well tolerated. Further evaluation in a large trial of patients with pulmonary disorders is planned.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> CXCR3 Antagonists</h3><div class="NLM_p">As mentioned earlier, the chemokine receptor CXCR3 is highly expressed in activated T cells of the Th1 phenotype and is implicated in autoimmune diseases such as RA. In line with these data, a CXCR3 antagonist SCH 546738 (<b>34</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) has shown utility in a mouse collagen induced arthritis model of arthritis as well as in rat and mouse experimental autoimmune encephalomyelitis models of multiple sclerosis.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a></div><figure id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. CXCR3 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Chemocentryx has disclosed a number of CXCR3 antagonists including a series of dihydroquinazoline analogues.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> Amgen exercised its option to obtain an exclusive license to the lead compound from this series and renamed it AMG 487 (<b>35</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). In preclinical studies, <b>35</b> blocked immune cell migration and demonstrated excellent potency, high selectivity, and good oral bioavailability.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> The drug dose-dependently inhibited cellular infiltration of immune cells into the lungs in a bleomycin-induced model of inflammation in mice. A twice daily dose of 3 mg/kg of compound <b>35</b> (given subcutaneously) was as effective in inhibiting immune cell migration into the lungs as that observed for CXCR3 deficient mice. The evaluation of <b>35</b> in the clinic was complicated by the discovery of significant circulating levels of a pyridine <i>N</i>-oxide active metabolite.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Nevertheless the compound entered phase II clinical trials for the treatment of psoriasis but failed to demonstrate any signs of efficacy, and the trial was terminated.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div></div><div id="sec8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> CXCR4 Antagonists</h3><div class="NLM_p">CXCR4 is expressed by most of the leukocyte subsets, including naive T lymphocytes, B lymphocytes, monocytes, and neutrophils<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and binds the chemokine CXCL12/SDF-1.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Notably, CXCR4 is used as a portal for the entry of T-tropic HIV-1 strains,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> a finding that has greatly accelerated research in this area. CXCR4 has recently been the subject of an excellent review in this journal,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> so our treatment here will be brief.</div><div class="NLM_p">The first CXCR4 antagonist to be described was the bicyclam-containing small molecule AMD3100 (plerixafor) (<b>36</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The antagonist was initially selected for clinical trials for the treatment of AIDS, but although effective in vitro, it suffered from a lack of oral bioavailability.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Interestingly, however, the development of <b>36</b> took on an entirely different direction based on the finding that the CXCR4/CXCL12 axis plays a major role in the retention of hematopoetic stem cells and their progenitors in the bone marrow.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> By inhibiting CXCR4, the antagonist was shown to be able to rapidly mobilize stem cells from the bone marrow, increasing their numbers in the circulation. These cells can then be harvested and given back to patients suffering from white blood cell cancers such as non-Hodgkin lymphoma.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> Because <b>36</b> also mobilizes cancer cells in the bone marrow and these cells are a major cause of relapse in multiple myeloma, the drug could be a useful treatment of this cancer. The drug entered the clinic for both diseases and, based on strong positive data for the drug in phase III,<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> was approved by the FDA in 2008 to treat non-Hodgkin lymphoma and multiple myeloma.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. CXCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The success of <b>36</b> has paved the way for a number of companies to target CXCR4 for the indications above (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Foremost among these is TaiGen with their CXCR4 antagonist TG-0054 (Burixafor). Although the structure of the drug has not yet been disclosed, TaiGen has disclosed polyamine and pyrimidines as CXCR4 antagonists in patent applications.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Receptor binding studies revealed potencies for CXCR4 ranging from 4 to 100 nM, and a prototypical structure is shown (<b>37</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>). Phase I clinical trials revealed that single-dose administration of the antagonist more than increased the number of circulating stem cells to the numbers required for a successful transplant.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> Phase 1 results also indicated that TG-0054 may be given as a monotherapy in contrast to <b>36</b> that is given with granulocyte macrophage colony stimulating factor (GM-CSF). Currently the antagonist is undergoing several phase II clinical trials for the treatment of multiple myeloma and non-Hodgkinâs lymphoma.</div><div class="NLM_p">The CXCR4 antagonist described by Polyphor, POL6326, is derived from their proprietary technology, known as Protein Epitope Mimetics. These molecules are peptidomimetics of 0.7â2 kDa that are potent CXCR4 antagonists.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> According to the company, POL6326 has successfully completed phase I clinical trials in the U.K. with 74 healthy volunteers. The drug was safe and well tolerated and is currently being investigated in a phase II clinical trial for safety and efficacy in transplantation of autologous hematopoetic stem cells in multiple myeloma patients after chemotherapy.</div><div class="NLM_p last">Two other CXCR4 approaches in the clinic are worth mentioning. The first is a neutralizing antibody to the receptor (MDX-1338) that shows promise in treating multiple myeloma.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> This is currently being evaluated in phase I clinical trials as a monotherapy with chemotherapy to treat patients with relapsed or refractory acute myelogenous leukemia. Also in phase I clinical trials is a peptide (BKT140) that is reported to block CXCR4<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div></div><div id="sec9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Potential Reasons for the Failures of Chemokine Receptor Antagonists in the Clinic</h3><div class="NLM_p">Clinical trials of chemokine receptor antagonists for the treatment of autoimmune diseases have been disappointingly unsuccessful. Out of the more than 40 development candidates for which clinical trials have been reported, only two have become registered drugs and those are in indications that are totally unrelated to inflammation (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). There are numerous explanations to account for these clinical failures, including chemokine and chemokine receptor promiscuity, disease heterogeneity, insufficient receptor occupancy or blockade, incorrect clinical indications, misleading data from animal models, etc., and they have been discussed in several recent reviews.<a onclick="showRef(event, 'ref91 ref98 ref217'); return false;" href="javascript:void(0);" class="ref ref91 ref98 ref217">(91, 98, 217)</a> The first two of these options, chemokine and chemokine receptor redundancy and disease heterogeneity, could well account for some of these clinical failures. For example, more than 40 chemokines and 19 chemokine receptors have been identified and the complexity of this vast system of immunological molecules might make it extremely difficult to demonstrate clinical efficacy with a specific antagonist to a single receptor. Consider CCR1 antagonists for the treatment of multiple sclerosis, for example; three separate clinical trials have failed to demonstrate efficacy (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The evidence for a role of CCR1 in the pathophysiology of multiple sclerosis is based on a number of studies. First, neutralizing antibodies to one of the CCR1 ligands, CCL3, prevented the development of both acute and relapsing paralytic disease as well as infiltration of mononuclear cells into the CNS initiated by the transfer of activated T cells.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> Second, deletion of CCR1 was protective in a myelin oligodendrocyte glycoprotein (MOG) model of multiple sclerosis in mice decreasing the disease score by around half compared to their wild type littermates.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Third, CCR1 is expressed in human multiple sclerosis lesions associated with hematogenous macrophages usually coexpressed with CCR5.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Finally, a non-peptide antagonist of CCR1, <b>1</b>, was efficacious in a dose responsive manner in an acute rat EAE model of multiple sclerosis.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a></div><div class="NLM_p">At first glance then the idea that CCR1 plays a role in multiple sclerosis would appear to be quite strong. However, each of the studies described above has some potential caveats. For example, while it is quite true that neutralizing antibodies to the CCR1 ligand CCL3 blocked disease, this chemokine is also a ligand for CCR5<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and we cannot rule out that the beneficial effects seen in this model could be accounted for by blocking the activity of both receptors. This idea is supported by the fact that in contrast to the almost complete inhibition of disease by neutralizing antibodies to CCL3,<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> the deletion of CCR1 only inhibited disease by 50% in the MOG model.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Interestingly CCR1 is almost always coexpressed with CCR5 in human multiple sclerosis lesions especially in early lesions;<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> thus, it remains a formal possibility that both CCR1 and CCR5 and potentially other chemokine receptors might play a role in the pathophysiology of the disease. Furthermore CCR1 is constitutively expressed on neutrophils in rodents but mainly on monocytes and activated T lymphocytes in humans. This clearly reflects cell type differences that could also influence the outcome of animal models of disease, and this has to be taken into consideration when extrapolating successful studies showing efficacy of a compound in an animal model of disease to the clinical disease in humans. For example, the hyperacute EAE model of multiple sclerosis in Lewis rats is characterized by a short incubation period, severe paralysis, high mortality, and abundant neutrophil infiltrates. Therefore, it remains a possibility that the positive response observed for the Berlex CCR1 antagonist in this model of multiple sclerosis could be mediated by the suppression of CCR1 expressing neutrophils, which are not the driving force of the human form of the disease.</div><div class="NLM_p">Since we do not yet have specific clinical markers to be able to stratify patients into chemokine receptor-specific subpopulations, then the selection of specific responders in a clinical trial is exceedingly difficult and could also account for the observed clinical failures. The mechanisms of action of two of the clinically approved multiple sclerosis treatments target adhesion molecules that block the migration of all activated T cells (natiluzumab) or cause the retention of activated T cells in the lymph nodes where they accumulate (fingolomid), thus strongly intervening in the pathophysiology of disease.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> In contrast blocking individual chemokine receptors on cells that can respond to more than one receptor will clearly not be as effective as either of these two therapies. Thus, the failure of chemokine receptor antagonists in clinical trials for multiple sclerosis can probably be ascribed to some combination of the issues discussed above.</div><div class="NLM_p">A striking example of the difficulty in selecting an appropriate chemokine receptor as a target for disease intervention is provided by the failures of the CCR5 antagonists <b>20</b>, <b>21</b>, and <b>28</b> in clinical trials for rheumatoid arthritis.<a onclick="showRef(event, 'ref184 ref221'); return false;" href="javascript:void(0);" class="ref ref184 ref221">(184, 221)</a> Since the costs of running human clinical trials can run into hundreds of millions of dollars, pharmaceutical companies do not generally enter into them lightly. So what led three major pharmaceutical companies, Astra-Zeneca, Pfizer, and Schering-Plough, to pursue CCR5 antagonists as a potential therapy for rheumatoid arthritis?</div><div class="NLM_p">There are several lines of evidence for a role of CCR5 in rheumatoid arthritis. First, synovial tissue from patients with rheumatoid arthritis shows abundant expression of CCR5 and its ligands.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> In addition, CCR5 expression has been shown to be significantly increased on macrophages in the synovial fluid and synovial tissue of patients with rheumatoid arthritis.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Second, Met-RANTES, which blocks both CCR1 and CCR5, caused the amelioration of adjuvant-induced arthritis in Lewis rats.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> Third, the small molecule CCR5 inhibitors SCH-X (structure not disclosed) and <b>24</b> were efficacious in CIA models of disease in rhesus monkeys and in mice, respectively.<a onclick="showRef(event, 'ref223 ref224'); return false;" href="javascript:void(0);" class="ref ref223 ref224">(223, 224)</a> Finally, individuals who have a 32 base pair deletion in the gene for CCR5 (CCR5-Î32 allele), which abolishes receptor expression in homozygotes, appear to be protected from developing rheumatoid arthritis because this gene mutation was significantly lower in rheumatoid arthritis patients than in healthy individuals.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a></div><div class="NLM_p">Thus, on the basis of the studies presented above, it would appear that the evidence to target CCR5 in rheumatoid arthritis was pretty solid. However, the following points need to be considered. First, expression of CCR5 on inflamed synovial tissue is not by itself evidence for a role of the protein in the disease process, especially since a variety of other chemokine receptors such as CCR1, CCR2, and CXCR3 have all been shown to be expressed in rheumatoid tissue and could all play a role in disease pathology. Second, the therapeutic effect of the antagonist Met RANTES in the AIA-model of rheumatoid arthritis could equally well have been due to the inhibition of CCR1. Third, the CIA studies with the CCR5 inhibitors SCH-X and <b>24</b> involved small numbers of animals, 5 in the monkey study and 10 in the mouse study, and the antagonists were given prophylactically and not therapeutically. In addition the induction of arthritis in the mouse CIA model resulted in a massive leukocyte infiltration into the joints consisting mainly of neutrophils, which is clearly not consistent with the pathophysiology of the human disease. Finally, part of the rationale for treating rheumatoid arthritis patients with a CCR5 inhibitor is based on the finding that individuals expressing the Î32 mutation of CCR5 appear to be protected from the disease. However, it is possible that the genetic deletion of CCR5 has quite different effects on the immune response than that induced by simply blocking the receptor with a small molecule inhibitor, and this may account for the failure of the antagonist in treating rheumatoid arthritis patients.</div><div class="NLM_p">Thus, it is obvious from this discussion that the preclinical evidence for a role of CCR5 in the pathophysiology of rheumatoid arthritis is not as strong as first indicated. It is of course possible that CCR5 may not be a clinically relevant target for the treatment of rheumatoid arthritis; however, another reason to consider for the failure of these programs is the possible deleterious effect of CCR5 antagonists on Tregs (the CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell population). Tregs express CCR5 and are important mediators of peripheral tolerance. It is known that deficiency of these cells is associated with autoimmune inflammation in some animal models of autoimmune disease. Thus, blocking CCR5 on Tregs might counterbalance the beneficial effects of inhibiting the receptor on autoreactive Th1 cells involved in the inflammation associated with rheumatoid arthritis. This topic is further discussed in the context of the dual CCR2/CCR5 inhibitors later.</div><div class="NLM_p">A key question in any drug discovery program targeting chemokine receptors is what degree of receptor blockade is required to achieve a therapeutically beneficial effect. This is quite difficult to answer with any precision, but it seems that it needs to be greater than 90%.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The degree of receptor blockade for three different CCR1 antagonists in clinical trials for rheumatoid arthritis was recently compared. The three drugs were <b>2</b> and <b>3</b>, which failed to show efficacy in phase II trials,<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97, 98)</a> and <b>4</b> which has demonstrated clinical efficacy in phase II trials.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> An estimate of the degree of CCR1 coverage achieved on blood monocytes with the various CCR1 antagonists tested clinically was assessed with a monocyte chemotaxis assay. A comparison of the blood plasma levels achieved in the clinic with oral doses of these compounds revealed that the level of unoccupied CCR1 was around 17â26% for <b>2</b>, 3â6% for <b>3</b>, and 1â4% for <b>4</b>.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> On the basis of these data, it is highly likely that the failure of <b>2</b> was partly due to an inability of the drug to block sufficient receptors to prevent CCR1 activation. The data presented suggest that almost complete antagonism is required for 24 h a day for clinical efficacy. Thus, successful agents will necessarily require excellent human pharmacokinetics and/or a very slow receptor off rate to achieve complete pharmacodynamic blockade of the receptor system being antagonized.</div><div class="NLM_p">The failure of the Pfizer CCR1 antagonist, <b>3</b>, in clinical trials does not, however, appear to be a result of receptor occupancy. In contrast it has been speculated that it might be ascribed to the design of the clinical trial.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> It was observed that patients in the placebo arm of this 12-week clinical trial had a higher than usual ACR20 score (an American College of Rheumatology criterion used to assess efficacy of a drug in an arthritis trial). This might have made it more difficult to get a statistically significant response in patients treated with the CCR1 antagonist compared to patients given placebo. In addition the dosing regimen and the formulation of the drug used in the failed phase II trial differed from that used in the much smaller 1b trial,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> which had previously demonstrated efficacy of the drug in rheumatoid arthritis.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">Another possibility to account for the failure of chemokine receptors in clinical trials might be because the clinical indication that the drug was tested in was not therapeutically appropriate (as discussed above for CCR5 in rheumatoid arthritis). A good example of this is provided by the three failed clinical trials targeting CCR2 for the treatment of rheumatoid arthritis: two small molecule antagonists <b>7</b> and <b>8</b> and a neutralizing monoclonal antibody MLN1202 (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). It is possible that these failures reflect the likelihood that CCR2 does not represent an appropriate target for rheumatoid arthritis. Indeed the evidence for a role of CCR2 in the pathophysiology of rheumatoid arthritis is somewhat contradictory. For example, CCR2 gene deletion studies in mice show that the disease score is exacerbated in a type II collagen-induced arthritis model in CCR2 knockout mice compared to their wild-type littermates.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> In contrast a potent and selective small molecule antagonist of the mouse CCR2 receptor significantly attenuated the disease score in a rat model of adjuvant-induced arthritis.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Furthermore recent studies demonstrate that peripheral blood monocyte migration from rheumatoid arthritis patients in response to synovial fluid from these patients cannot be effectively blocked by targeting CCR2 or CCR5 or both but can be effectively blocked with CCR1, suggesting that blocking CCR2 is therapeutically not important for the treatment of rheumatoid arthritis.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a></div><div class="NLM_p last">Another example of pursuing a clinically irrelevant target with a chemokine receptor antagonist is provided by the failure of the CXCR3 antagonist <b>35</b> in clinical trials for psoriasis (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Evidence for a role of CXCR3 in the pathophysiology of psoriasis is mainly provided by the fact that CXCR3 shows strong expression in activated T cells of the Th1 phenotype. Skin biopsies from patients with psoriasis showed increased expression of the CXCR3 ligands CXCL10, CXCL9, and CXCL11, which correlated with CXCR3 expression by infiltrating T-cells, suggesting a functional interaction between locally produced chemokines and CXCR3-expressing T cells.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> Beyond these âguilt by association studiesâ, evidence for a role of CXCR3 in psoriasis was provided by a number of indirect studies. First, blocking activated T cells of the Th1 phenotype in an adjuvant induced peritonitis model<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> or in an allograft transplant survival model,<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> with a neutralizing CXCR3 antibody, demonstrated efficacy. Second, the CXCR3 antagonist <b>35</b> was able to inhibit cellular recruitment of immune cells in a bleomycin induced lung injury model;<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> however, this might not be enough to make a difference in psoriasis, which is driven by cell types other than CXCR3-expressing T lymphocytes.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> Thus, in conclusion none of these indirect studies have really confirmed a role for CXCR3 in psoriasis.</div></div><div id="sec10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Promiscuous Chemokine Receptor Antagonists</h3><div class="NLM_p">Promiscuous small molecules that are able to target several GPCRs are well-known in the literature, and this topic has been discussed in a number of excellent reviews.<a onclick="showRef(event, 'ref232 ref233'); return false;" href="javascript:void(0);" class="ref ref232 ref233">(232, 233)</a> The classic example of a promiscuous drug is Zyprexa, a tricyclic benzodiazepine that binds with high potency to 14 different GPCRs and that is used to treat schizophrenia and bipolar disorder.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> Promiscuity of small molecule antagonists can, however, be somewhat of a double edged sword. On the one hand it can give rise to undesirable side effects. On the other it might be beneficial in treating complex diseases where more than one receptor plays a role. We will give examples of the pros and cons of promiscuous antagonists in drug development in this review.</div><div class="NLM_p">A number of dual chemokine receptor antagonists have been described in the literature.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> These are mostly to the highly related receptors CCR1 and CCR3, which share around 59% sequence identity, or to the CCR2 and CCR5 receptors which share around 72% sequence identity, but others have also been described.</div><div class="NLM_p">Three examples of CCR1/CCR3 dual antagonists have been described in the literature. The first is a 2-(benzothiazolylthio)acetamide compound from Takeda (<b>38</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>) which binds both receptors with IC<sub>50</sub> of 450 and 32 nM, respectively.<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a> Similarly the antagonist UCB 35625 (<b>39</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>) is a potent antagonist for both receptors inhibiting chemotaxis by CCL3 in CCR1 with an IC<sub>50</sub> of 9.6 nM and CCL11 in CCR3 with an IC<sub>50</sub> of 93.7 nM.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a> Banyu have identified several potent CCR1/CCR3 dual antagonists exemplified by compound 2q-1 (<b>40</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>), which is a quaternary ammonium compound with IC<sub>50</sub> of 0.9 and 0.58 nM, respectively.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a></div><figure id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Promiscuous chemokine receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the CCR2/CCR5 receptors two compounds from Takeda, <b>24</b> and <b>25</b>, are potent inhibitors of this receptor pair.<a onclick="showRef(event, 'ref169 ref238'); return false;" href="javascript:void(0);" class="ref ref169 ref238">(169, 238)</a> Of interest here also is the recent disclosure by Incyte of compound <b>9</b>, which is a dual CCR2/CCR5 antagonist<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> and structurally similar to the Merck CCR2 antagonist compound <b>7</b>, a tetrahydro-3-trifluoromethyl-1,6-naphthyridine, which not surprisingly is also a potent CCR5 antagonist.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a></div><div class="NLM_p">In a recent patent application Novartis disclosed dual CCR2/CCR5 inhibitors.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> Lead optimization using a high throughput scintillation proximity binding assay of their compound library identified a number of structures as CCR2 antagonists. One of these, a highly lipophillic benzothiophene with modest CCR2 affinity, underwent optimization to generate a series of benzoxepines that were less lipophilic and more potent CCR2 receptor antagonists. These molecules were then further optimized to generate a series of 4-substituted indoles of which NIBR-6145 was the lead compound (<b>41</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>).<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> This compound had high potency on human and rodent CCR2/CCR5, no cardiovascular problems (the absence of any QT prolongation in a monkey telemetry study), no interactions with any cytochrome p450 subtypes examined, and good pharmacokinetic properties with a long terminal half-life. The compound was efficacious in an in vivo peritoneal monocyte migration assay in the rat and in a mouse dextran sodium sulfate (DSS) colitis model as well as in an acute mouse EAE model of multiple sclerosis. At a dose of 3 mg/kg given orally in monkeys it easily achieved 90% or greater blockade of both CCR2 and CCR5. Recently Novartis disclosed that they had initiated clinical trials with <b>41</b> for the treatment of AIDS.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> The phase I studies involved 56 normal subjects who were given seven ascending doses of drug. The drug was well tolerated, and there were no significant safety concerns. A receptor occupancy of greater than 90% was achieved for both CCR2 and CCR5 receptors. On the basis of this positive outcome, the drug is continuing its clinical development.</div><div class="NLM_p">The promiscuous antagonists discussed so far all bind to highly related chemokine receptors such as the CCR1/CCR3 and CCR2/CCR5 type; however, there are examples of antagonists that bind totally unrelated chemokine receptors illustrated by the recent disclosure of a dual CXCR2/CCR2 receptor antagonist.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> The chemokine receptors CXCR2 and CCR2 belong to two different classes and have less than 20% sequence homology; however, scientists at AstraZeneca disclosed a series of thiazolo[4,5-<i>d</i>]pyrimidines that were potent dual chemokine receptor antagonists. One of these compounds, <b>30a</b>, inhibited calcium transients in cells expressing CXCR2 and CCR2 with IC<sub>50</sub> values of 1 and 8 nM, respectively (<b>42</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>).</div><div class="NLM_p">Even more interesting is the dual antagonist of the CCR3 and H<sub>1</sub> histamine receptors YM-344484 (<b>43</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>).<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> These two receptors have limited homology; less than 14% are activated by totally unrelated ligands, a protein, and a biogenic amine, and yet both are potently inhibited by a single non-peptide. This compound inhibits both the CCL11-induced Ca<sup>2+</sup> influx in human CCR3-expressing cells (<i>K</i><sub>i</sub> of 1.8 nM) and histamine-induced Ca<sup>2+</sup> influx in histamine H<sub>1</sub> receptor-expressing PC3 cells (<i>K</i><sub>i</sub> of 47 nM).<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> It is likely that compound <b>43</b> inhibits both CCR3 and the H<sub>1</sub> receptor by binding to a site in the minor or major binding pockets as do most chemokine receptor antagonists.<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(243)</a> Given the fact that several small molecule chemokine receptor antagonists have tertiary amine groups, it is likely that some of these compounds will have activity at aminergic GPCRs. Furthermore it also emphasizes that it is possible to obtain dual antagonists for GPCRs that have highly dissimilar ligands. Since these receptors play an important role in atopic diseases such as asthma, then antagonism of this receptor pair by a single drug might prove to be a more effective therapeutic to treat these inflammatory diseases than targeting each receptor separately (see also compound <b>18</b>, a dual antagonist of these two receptors that showed a modest effect in clinical trials for treating allergic rhinitis).</div><div class="NLM_p">Our discussion so far has centered only on a description of the molecular properties of dual chemokine receptor antagonists. We have not yet touched upon their utility or possible deleterious side effects. The potential therapeutic benefits of blocking multiple chemokine receptors are illustrated by two recent studies. In the first example two totally unrelated chemokine receptors, CCR5 and CXCR3, both of which are important proinflammatory receptors in autoimmunity, were targeted using knockout mice and receptor neutralizing antibodies.<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> Both CCR5 and CXCR3 have previously been shown to play a role in organ transplant rejection mainly by the induction of infiltrating T cells into the transplanted organs.<a onclick="showRef(event, 'ref230 ref245'); return false;" href="javascript:void(0);" class="ref ref230 ref245">(230, 245)</a> A heterotopic heart transplantation model in BALB/c to B6/129 mice deficient in CCR5 was carried out in the absence and presence of neutralizing antibodies to CXCR3.<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> Recipient mice were then assessed daily for allograft function. The donor hearts in the CCR5 deficient control group were all rejected at 6 days after transplantation. The survival of the donor hearts in the CCR5 deficient mice receiving control antibody and in the wild-type mice receiving anti-CXCR3 antibodies was prolonged to 29 and 34 days, respectively. However, the animals receiving a combined blockade of CXCR3 and CCR5 had a greater than 15-fold prolonged allograft survival compared to the control group; all of the allografts survived for greater than 100 days, after which the study was terminated. In addition, the donor hearts did not display any of the signs that are characteristic of chronic rejection. In summary these studies demonstrate that blocking the chemokine receptors CCR5 and CXCR3 with dual antagonists could be beneficial in acute organ transplantation rejection.</div><div class="NLM_p">In the second example the unrelated chemokine receptors CCR2 and CX3CR1, which have been independently shown to be important in the development of coronary artery disease,<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> were targeted by using a small molecule antagonist in association with a receptor gene deletion. MRL-677 is a small molecule CCR2 antagonist (structure not disclosed) (IC<sub>50</sub> = 1.8 nM) that is able to block macrophage trafficking in a mouse peritoneal thioglycollate model.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> The drug was used in an intimal hyperplasia model in both wild type and CXCR3-deficient mice. Blocking CCR2 with the antagonist resulted in a 56% decrease in the vascular injury response in normal animals. Mice in which both CCR2 and CX3CR1 pathways were targeted had an 88% decrease in the injury response.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> Thus, this study demonstrates that CCR2 and CXCR3 play nonredundant roles in vascular inflammation and further suggests that dual chemokine receptor antagonists could be therapeutically beneficial.</div><div class="NLM_p">On the basis of the examples above, it is clear that chemokine receptor antagonists that block multiple receptors might be useful in treating certain diseases. For example, a small molecule antagonist that would block CCR5 and CXCR4, the major co-receptors for HIV-1 infection of human cells, could be useful therapeutically as a fusion inhibitor to treat AIDS patients. Although the idea is quite attractive, it remains to be seen whether the design of dual GPCR inhibitors is possible. Two recent studies demonstrate that in principle this might be feasible.</div><div class="NLM_p">The first of these involves the unrelated angiotensin II (AT<sub>1</sub>) and endothelin (ET<sub>A</sub>) receptors. The ligands for these receptors, angiotensin II and endothelin, are potent vasoconstrictors, and AT<sub>1</sub> antagonists have already taken their place alongside ACE inhibitors as successful treatments for hypertension. Thus, it is expected that dual antagonists of these two receptors could be of greater benefit in the treatment of pulmonary hypertension, congestive heart failure, and arteriosclerosis. On the basis of this premise, scientists at Pharmacopiea designed a dual AT<sub>1</sub>/ET<sub>A</sub> receptor antagonist using known antagonists of each of these receptors as a starting point (<b>44</b> and <b>45</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>). The resulting dual antagonist PS433540 (<b>46</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) has successfully completed phase II clinical trials and was recently licensed to Retrophin who intends to develop it for orphan indications of severe kidney diseases.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a></div><figure id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Design of dual receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second example is provided by histamine and thromboxane, which play an important role in the pathogenesis of asthma. It is possible that a dual antagonist of their receptors, H<sub>1</sub> and TxA<sub>2</sub>, might be therapeutically useful in treating this disease. On the basis of this rationale, Oshima et al.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> utilized a approach similar to that described above for the AT<sub>1</sub> and ET<sub>A</sub> receptors to design dual histamine H<sub>1</sub> and thromboxane TxA<sub>2</sub> receptors for potential use as potent anti-inflammatory compounds to treat asthma. Their approach was based on the observation that compounds that had been discovered to be potent antagonists to both of these receptors contained a common benzoxepin core (<b>47</b> and <b>48</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>). The benzimidazole group is a key element that is crucial for the TxA<sub>2</sub> activity of <b>47</b>, and replacement with a tertiary amine (<b>49</b> Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) mimicked this activity, resulting in a dual antagonist that was active at both of these receptors. Clearly this approach and the one just discussed above worked well because highly potent templates to both receptors that had common core structures existed and these were tractable enough that a hybrid molecule that could interact with the binding pockets of both receptors could be designed. In such cases it is not really even necessary that the two receptors should share a similar binding domain.</div><div class="NLM_p last">In addition to the beneficial effects of dual receptor antagonists that we have discussed, however, are their potential for side effects. This is illustrated by the CCR2 antagonists, many of which, as we have seen, are also potent CCR5 antagonists. The failure of the CCR2 antagonist compound <b>7</b> in phase II clinical trials for rheumatoid arthritis has been ascribed to the possibility that it also inhibits CCR5 which is expressed on regulatory T cells in the inflamed synovium.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> This off-target effect of the drug could, by blocking CCR5, dampen the normally anti-inflammatory effects of regulatory T cells. This might offset any benefit gained from blocking CCR2 in rheumatoid arthritis and account in part for the failure of the drug in the clinic.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions and Future Directions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The historical success of pharmaceutical companies in targeting GPCRs has perhaps been a millstone around the necks of the various programs around the globe targeting chemokine receptors by small molecules. Compound libraries were screened with success, and lead compounds against several chemokine receptors were progressed into clinical development at great pace. When most of these drugs displayed little efficacy in the treatment of inflammatory disorders, there was much gnashing of teeth and a consensus emerged that the redundancy in the chemokine system meant that targeting single receptors was probably futile. Out of several multimillion dollar programs, only two drugs have obtained FDA approval, these from noninflammatory indications, where a single receptor appears to be responsible for the clinical symptoms (CCR5 in macrophagetrophic HIV-1 entry and CXCR4 in stem cell mobilization).</div><div class="NLM_p">However, after several false starts, there is now growing optimism that some of the chemokine receptor antagonists currently progressing through the clinic may become useful therapeutics in the treatment of inflammatory disease. As we come to realize the levels of receptor occupancy that are required from a compound to translate into in vivo efficacy, then it has been possible to successfully target a single chemokine receptor and achieve a positive clinical outcome, notably in the ongoing CCR1 and CCR9 antagonist trials for the treatment of rheumatoid arthritis and Crohnâs disease discussed earlier. Modulation of previously identified compounds to increase their levels of receptor occupancy or simply modulating the dosage of existing compounds may be fruitful.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> Similarly, several antagonist programs have unearthed small molecule agonists of chemokine receptors that may be useful therapeutically by desensitizing responses to endogenous agonists. A small molecule agonist of CXCR3 was recently shown to mimic the endogenous ligand CXCL10<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and showed efficacy in a murine model of rheumatoid arthritis.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a></div><div class="NLM_p">A more detailed understanding of the biology of chemokines and their receptors in homeostasis and disease is clearly required to enable their targeting with greater efficacy and to uncover additional therapeutic avenues for such drugs. For example, the chemokine eotaxin, originally identified as an eosinophil chemoattractant implicated in allergic inflammation, has recently been implicated in the pathogenesis of age-related macular degeneration (AMD)<a onclick="showRef(event, 'ref252'); return false;" href="javascript:void(0);" class="ref ref252">(252)</a> and cognitive dysfunction associated with aging<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a> in the absence of any eosinophilic involvement. A comprehensive understanding of tissue chemokine receptor expression in humans and rodents is highly desirable, and coupled with the use of conditional mouse models in which receptors are selectively deleted from discrete populations of cells, we may be able to unpack some of the complexities of chemokine signaling in the disease process.</div><div class="NLM_p">For some chemokines with apparently complex in vivo roles, the generation of transgenic mice in which distinct chemokine functions are disabled may be required. For example, the CXCR6/CXCL16 axis appears to be important in atherosclerosis, where the chemokine CXCL16 can function as both a scavenger receptor for OxLDL<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> and a ligand for CXCR6<sup>+</sup> Th1, T-cytotoxic 1, and NKT cells.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> However, individual deletion of ligand and receptor results in opposing pro- and antiatherosclerotic phenotypes (reviewed in ref <a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">255</a>). Likewise, for some receptors, targeting accessory proteins that are critical for function may be beneficial. For CCR2 and CCR5, binding of the nucleoporin known as FROUNT to the receptor C-terminus appears to be essential for directed migration,<a onclick="showRef(event, 'ref256 ref257'); return false;" href="javascript:void(0);" class="ref ref256 ref257">(256, 257)</a> adding another level of complexity to receptor signaling and suggesting alternative ways of targeting both receptors. Targeting of the receptor C-terminus may also be successful in the selective inhibition of nascent chemokine receptor trafficking, a poorly understood process clearly in need of more basic scientific research.</div><div class="NLM_p last">In summary, chemokine receptor antagonists still represent an extremely fruitful intervention therapy in the treatment of inflammatory and autoimmune diseases and several agents are still in late stage clinical trials. Despite the clinical failures discussed above, we remain cautiously optimistic that chemokine receptor antagonists can be of benefit in man. Their ultimate success, however, will depend on our ability to more clearly understand the role of chemokine receptors in driving the pathophysiology of complex autoimmune diseases than we currently do. This coupled with a parallel understanding of the animal models used, as predictors of the human disease, will also need to be more appreciated. Taken together, this information should help to target the correct receptors in treating human disease. Finally, much better clinical markers of the disease process in man will also be required not only to set up clinical trials more intelligently but also to ultimately monitor their progress. If we can make real progress in coming to grips with the issues discussed above, we might finally realize the promise of delivering chemokine receptor antagonists as registered drugs.</div></div><div class="NLM_back"><div class="NLM_notes" id="NOTES-d2227e3297-autogenerated"><p class="first last">The authors declare no competing financial interest.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm300682j" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46360" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46360" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Horuk</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology, University
of CaliforniaâDavis, 451 Health Sciences
Drive, Davis, California 95616, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0840677a7d634878696b6a6d646426666d7c"><span class="__cf_email__" data-cfemail="4c04233e39270c3c2d2f2e29202062222938">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Pease</span> - <span class="hlFld-Affiliation affiliation">Leukocyte Biology Section, National
Heart and Lung Institute, Faculty of Medicine, MRC & Asthma UK
Centre in Allergic Mechanisms of Asthma, Imperial College
London, London SW7 2AZ, U.K.</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">James Pease</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>James Pease</b> obtained a Ph.D. in Biochemistry from the University of Sheffield, U.K. He was a Postdoctoral Fellow at the NIH in the laboratory of Dr. Philip Murphy, where he gained valuable expertise in the biochemistry of chemokine receptors. Currently he is a Reader in the Leukocyte Biology Section at the National Heart and Lung Institute, Imperial College London and is a PI in the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma. At Imperial he has established a group working various aspects of chemokine biology. His group was the first to publish the characterization of a small molecule antagonist of CCR3 and has published several papers describing the activation and inactivation of chemokine receptors by a variety of agonists and antagonists.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Richard Horuk</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Richard Horuk</b> obtained a Ph.D. from the University of London under Professor Sir Thomas Blundell. He was a Postdoctoral Fellow in the laboratory of Dr. Martin Rodbell at the NIH. From there he joined Dupont where his research centered on interleukin-1 receptors. Then he joined Genentech where his research on chemokine receptors led to the discovery that the Duffy antigen, a portal of entry for the malarial parasite <i>Plasmodium vivax</i>, was also a chemokine receptor. These findings set the stage for the discovery that chemokine receptors were HIV-1 co-receptors. Horuk worked at Berlex BioSciences for 13 years where his research interests were centered on GPCRs. Currently he is a Visiting Professor in the Department of Pharmacology at the University of CaliforniaâDavis.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i23" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i23"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i24" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i24"> Abbreviations Used</h2><tr><td class="NLM_term">DPP-IV</td><td class="NLM_def"><p class="first last">dipetidylpeptidase-IV</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">sarcoma</p></td></tr><tr><td class="NLM_term">EAE</td><td class="NLM_def"><p class="first last">experimental autoimmune encephalomyelitis</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen induced arthritis</p></td></tr><tr><td class="NLM_term">AIA</td><td class="NLM_def"><p class="first last">adjuvant induced arthritis</p></td></tr><tr><td class="NLM_term">LTC<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene C<sub>4</sub></p></td></tr><tr><td class="NLM_term">PGD<sub>2</sub></td><td class="NLM_def"><p class="first last">prostaglandin D<sub>2</sub></p></td></tr><tr><td class="NLM_term">DC</td><td class="NLM_def"><p class="first last">dendritic cell</p></td></tr><tr><td class="NLM_term">BAL</td><td class="NLM_def"><p class="first last">bronchioalveolar lavage</p></td></tr><tr><td class="NLM_term">ApoE</td><td class="NLM_def"><p class="first last">apolipoprotein E</p></td></tr><tr><td class="NLM_term">Th1</td><td class="NLM_def"><p class="first last">T helper 1</p></td></tr><tr><td class="NLM_term">Th2</td><td class="NLM_def"><p class="first last">T helper 2</p></td></tr><tr><td class="NLM_term">Tregs</td><td class="NLM_def"><p class="first last">T regulatory cells</p></td></tr><tr><td class="NLM_term">THP-1</td><td class="NLM_def"><p class="first last">human acute monocytic leukemia cell line</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">ATL</td><td class="NLM_def"><p class="first last">adult T-cell leukemia</p></td></tr><tr><td class="NLM_term">MOG</td><td class="NLM_def"><p class="first last">myelin oligodendrocyte glycoprotein</p></td></tr><tr><td class="NLM_term">AMD</td><td class="NLM_def"><p class="first last">age-related macular degeneration</p></td></tr><tr><td class="NLM_term">NKT</td><td class="NLM_def"><p class="first last">natural killer T (cell)</p></td></tr><tr><td class="NLM_term">ECL</td><td class="NLM_def"><p class="first last">extracellular loop</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 257 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Zlotnik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshie, O.</span><span> </span><span class="NLM_article-title">Chemokines: a new classification system and their role in immunity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">â</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS1074-7613%2800%2980165-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10714678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslKqsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=121-127&author=A.+Zlotnikauthor=O.+Yoshie&title=Chemokines%3A+a+new+classification+system+and+their+role+in+immunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines: a new classification system and their role in immunity</span></div><div class="casAuthors">Zlotnik, Albert; Yoshie, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 47 refs.  Discussed are: proposed new classification for chemokine ligands; chemokines and dendritic cells; chemokines and lymphocyte development; chemokines and the lymphoid system; and chemokines and the Th1/Th2 responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27cDwPXyi7LVg90H21EOLACvtfcHk0lg9-0CG-Sjd9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslKqsL8%253D&md5=916082fe7a02a304ba377065fc8ca9a6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980165-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980165-X%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnik%26aufirst%3DA.%26aulast%3DYoshie%26aufirst%3DO.%26atitle%3DChemokines%253A%2520a%2520new%2520classification%2520system%2520and%2520their%2520role%2520in%2520immunity%26jtitle%3DImmunity%26date%3D2000%26volume%3D12%26spage%3D121%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span> </span><span class="NLM_article-title">The many roles of chemokines and chemokine receptors in inflammation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">â</span> <span class="NLM_lpage">621</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1056%2FNEJMra052723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16467548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlKisro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=610-621&author=I.+F.+Charoauthor=R.+M.+Ransohoff&title=The+many+roles+of+chemokines+and+chemokine+receptors+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of chemokines and chemokine receptors in inflammation</span></div><div class="casAuthors">Charo, Israel F.; Ransohoff, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The properties of chemokines and their receptors, as well as their roles in selected clin. disorders (inflammatory diseases, multiple sclerosis, metabolic disorders, insulin resistance and obesity-induced diabetes) are discussed.  Chemokines (chemotactic cytokines) are small heparin-binding proteins that direct the movement of circulating leukocytes to sites of inflammation or injury.  Chemokines and their receptors play a crucial part in directing the movement of mononuclear cells throughout the body, engendering the adaptive immune response and contributing to the pathogenesis of a variety of diseases.  Chemokine receptors are some of the most tractable drug targets in the huge battery of mols. that regulate inflammation and immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoACrHA9oILm7Vg90H21EOLACvtfcHk0lie-iRfaSfbnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlKisro%253D&md5=eb1814e624ae0f1af5b9df9dbda15a25</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra052723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra052723%26sid%3Dliteratum%253Aachs%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DThe%2520many%2520roles%2520of%2520chemokines%2520and%2520chemokine%2520receptors%2520in%2520inflammation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D610%26epage%3D621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Viola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span> </span><span class="NLM_article-title">Chemokines and their receptors: drug targets in immunity and inflammation</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1146%2Fannurev.pharmtox.48.121806.154841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17883327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFynu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=171-197&author=A.+Violaauthor=A.+D.+Luster&title=Chemokines+and+their+receptors%3A+drug+targets+in+immunity+and+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines and their receptors: drug targets in immunity and inflammation</span></div><div class="casAuthors">Viola, Antonella; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-197</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The chemokine system coordinates leukocyte migration in immunity and inflammation and is implicated in the pathogenesis of many human diseases.  Although several successful strategies have been identified to develop drugs targeting chemokines and their receptors, this has not yet resulted in many new therapeutics.  This is likely due to a complexity of the chemokine system, which was not initially appreciated, that is characterized by redundancy, pleiotropy, and differences among species.  Nevertheless, our understanding of chemokine biol. is continuing to grow and several promising drugs are currently being tested in late-stage clin. trials.  In this review, we examine the role of chemokines in health and diseases and discuss strategies to target the chemokine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW9ifo6UmRKrVg90H21EOLACvtfcHk0lie-iRfaSfbnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFynu78%253D&md5=74e0d77aba66fb33c242d8debeffe300</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.48.121806.154841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.48.121806.154841%26sid%3Dliteratum%253Aachs%26aulast%3DViola%26aufirst%3DA.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DChemokines%2520and%2520their%2520receptors%253A%2520drug%2520targets%2520in%2520immunity%2520and%2520inflammation%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2008%26volume%3D48%26spage%3D171%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Fredriksson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagerstrom, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schioth, H. B.</span><span> </span><span class="NLM_article-title">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="NLM_x">â</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fmol.63.6.1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=12761335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1256-1272&author=R.+Fredrikssonauthor=M.+C.+Lagerstromauthor=L.+G.+Lundinauthor=H.+B.+Schioth&title=The+G-protein-coupled+receptors+in+the+human+genome+form+five+main+families.+Phylogenetic+analysis%2C+paralogon+groups%2C+and+fingerprints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span></div><div class="casAuthors">Fredriksson, Robert; Lagerstrom, Malin C.; Lundin, Lars-Gustav; Schioth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1256-1272</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The superfamily of G-protein-coupled receptors (GPCRs) is very diverse in structure and function and its members are among the most pursued targets for drug development.  We identified more than 800 human GPCR sequences and simultaneously analyzed 342 unique functional nonolfactory human GPCR sequences with phylogenetic analyses.  Our results show, with high bootstrap support, five main families, named glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin, forming the GRAFS classification system.  The rhodopsin family is the largest and forms four main groups with 13 subbranches.  Positions of the GPCRs in chromosomal paralogons regions indicate the importance of tetraploidizations or local gene duplication events for their creation.  We also searched for "fingerprint" motifs using Hidden Markov Models delineating the putative inter-relationship of the GRAFS families.  We show several common structural features indicating that the human GPCRs in the GRAFS families share a common ancestor.  This study represents the first overall map of the GPCRs in a single mammalian genome.  Our novel approach of analyzing such large and diverse sequence sets may be useful for studies on GPCRs in other genomes and divergent protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdX4VhTsaDzrVg90H21EOLACvtfcHk0lie-iRfaSfbnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D&md5=504ea873ee8469cd0b6016bc94943836</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1124%2Fmol.63.6.1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.63.6.1256%26sid%3Dliteratum%253Aachs%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DLundin%26aufirst%3DL.%2BG.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DThe%2520G-protein-coupled%2520receptors%2520in%2520the%2520human%2520genome%2520form%2520five%2520main%2520families.%2520Phylogenetic%2520analysis%252C%2520paralogon%2520groups%252C%2520and%2520fingerprints%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D63%26spage%3D1256%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Murphy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebert, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXII. Nomenclature for chemokine receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">â</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=145-176&author=P.+M.+Murphyauthor=M.+Baggioliniauthor=I.+F.+Charoauthor=C.+A.+Hebertauthor=R.+Horukauthor=K.+Matsushimaauthor=L.+H.+Millerauthor=J.+J.+Oppenheimauthor=C.+A.+Power&title=International+Union+of+Pharmacology.+XXII.+Nomenclature+for+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DBaggiolini%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DHebert%26aufirst%3DC.%2BA.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DL.%2BH.%26aulast%3DOppenheim%26aufirst%3DJ.%2BJ.%26aulast%3DPower%26aufirst%3DC.%2BA.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXII.%2520Nomenclature%2520for%2520chemokine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D145%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Murphy, P. M.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">â</span> <span class="NLM_lpage">229</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=227-229&author=P.+M.+Murphy&title=International+Union+of+Pharmacology.+XXX.+Update+on+chemokine+receptor+nomenclature"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXX.%2520Update%2520on%2520chemokine%2520receptor%2520nomenclature%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D227%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Walsh, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, L. M.</span><span> </span><span class="NLM_article-title">Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States</span> <span class="citation_source-journal">Am. J. Public Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1463</span><span class="NLM_x">â</span> <span class="NLM_lpage">1466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2105%2FAJPH.90.9.1463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10983209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BD3cvktFGjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2000&pages=1463-1466&author=S.+J.+Walshauthor=L.+M.+Rau&title=Autoimmune+diseases%3A+a+leading+cause+of+death+among+young+and+middle-aged+women+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States</span></div><div class="casAuthors">Walsh S J; Rau L M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of public health</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1463-6</span>
        ISSN:<span class="NLM_cas:issn">0090-0036</span>.
    </div><div class="casAbstract">OBJECTIVES:  This study assessed the effect of autoimmune diseases on mortality among women.  METHODS:  Counts of autoimmune disease deaths were compared with frequencies of the 10 "official" leading causes of death among women in the United States in 1995.  RESULTS:  Autoimmune disease deaths exceeded the frequency of the 10th leading cause in every age category of women younger than 65 years and exceeded that for the eighth leading cause in the 15 to 24, 25 to 44, and 45 to 64 years age groups.  CONCLUSIONS:  Autoimmune diseases constitute a leading cause of death among young and middle-aged women.  This fact is obscured by current methods used to identify leading causes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQV1-yvWJIfLuQ4Pl9hzjQhfW6udTcc2ea8Jyps9KRknrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvktFGjug%253D%253D&md5=da035f5c196f17d3ae282107e56094c7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2105%2FAJPH.90.9.1463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.90.9.1463%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BJ.%26aulast%3DRau%26aufirst%3DL.%2BM.%26atitle%3DAutoimmune%2520diseases%253A%2520a%2520leading%2520cause%2520of%2520death%2520among%2520young%2520and%2520middle-aged%2520women%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2000%26volume%3D90%26spage%3D1463%26epage%3D1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Stoll, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span> </span><span class="NLM_article-title">Rheumatoid arthritis market</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">â</span> <span class="NLM_lpage">694</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=693-694&author=J.+G.+Stollauthor=U.+Yasothan&title=Rheumatoid+arthritis+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStoll%26aufirst%3DJ.%2BG.%26aulast%3DYasothan%26aufirst%3DU.%26atitle%3DRheumatoid%2520arthritis%2520market%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D693%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span>PRWeb. Global Autoimmune Disease Therapeutics Market To Exceed US$77 Billion by 2017, According to New Report by Global Industry Analysts, Inc. <a href="http://www.prweb.com/releases/autoimmune_disease/therapeutics_drugs/prweb8957282.htm" class="extLink">http://www.prweb.com/releases/autoimmune_disease/therapeutics_drugs/prweb8957282.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PRWeb.+Global+Autoimmune+Disease+Therapeutics+Market+To+Exceed+US%2477+Billion+by+2017%2C+According+to+New+Report+by+Global+Industry+Analysts%2C+Inc.+http%3A%2F%2Fwww.prweb.com%2Freleases%2Fautoimmune_disease%2Ftherapeutics_drugs%2Fprweb8957282.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">MacArthur, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novak, R. M.</span><span> </span><span class="NLM_article-title">Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">â</span> <span class="NLM_lpage">241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1086%2F589289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18532888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslWgu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=236-241&author=R.+D.+MacArthurauthor=R.+M.+Novak&title=Reviews+of+anti-infective+agents%3A+maraviroc%3A+the+first+of+a+new+class+of+antiretroviral+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Maraviroc: the first of a new class of antiretroviral agents</span></div><div class="casAuthors">MacArthur, Rodger D.; Novak, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-241</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target.  Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells.  In this review, we include the details of the discoveries that led to the development of this drug.  The drug's pharmacol., including pharmacokinetics and drug interactions, is discussed, as are the clin. efficacy studies that led to licensure.  HIV-1 mechanisms of resistance to maraviroc, assays to det. viral coreceptor use (tropism), drug safety, and clin. use of maraviroc are discussed at length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNBt7OWyIz37Vg90H21EOLACvtfcHk0lghs732sMPx8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslWgu78%253D&md5=06a299c0cdf678a94ed9f0f1b3bd23cb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1086%2F589289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F589289%26sid%3Dliteratum%253Aachs%26aulast%3DMacArthur%26aufirst%3DR.%2BD.%26aulast%3DNovak%26aufirst%3DR.%2BM.%26atitle%3DReviews%2520of%2520anti-infective%2520agents%253A%2520maraviroc%253A%2520the%2520first%2520of%2520a%2520new%2520class%2520of%2520antiretroviral%2520agents%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D47%26spage%3D236%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">â</span> <span class="NLM_lpage">1664</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=1655-1664&author=E.+De+Clercq&title=The+AMD3100+story%3A+the+path+to+the+discovery+of+a+stem+cell+mobilizer+%28Mozobil%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520AMD3100%2520story%253A%2520the%2520path%2520to%2520the%2520discovery%2520of%2520a%2520stem%2520cell%2520mobilizer%2520%2528Mozobil%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D77%26spage%3D1655%26epage%3D1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Brave, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ching Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocheltree, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope Miksinski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornoe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=282-288&author=M.+Braveauthor=A.+Farrellauthor=S.+Ching+Linauthor=T.+Ocheltreeauthor=S.+Pope+Miksinskiauthor=S.+L.+Leeauthor=H.+Saberauthor=J.+Fourieauthor=C.+Tornoeauthor=B.+Boothauthor=W.+Yuanauthor=K.+Heauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+review+summary%3A+Mozobil+in+combination+with+granulocyte+colony-stimulating+factor+to+mobilize+hematopoietic+stem+cells+to+the+peripheral+blood+for+collection+and+subsequent+autologous+transplantation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrave%26aufirst%3DM.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DChing%2BLin%26aufirst%3DS.%26aulast%3DOcheltree%26aufirst%3DT.%26aulast%3DPope%2BMiksinski%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%2BL.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DFourie%26aufirst%3DJ.%26aulast%3DTornoe%26aufirst%3DC.%26aulast%3DBooth%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520review%2520summary%253A%2520Mozobil%2520in%2520combination%2520with%2520granulocyte%2520colony-stimulating%2520factor%2520to%2520mobilize%2520hematopoietic%2520stem%2520cells%2520to%2520the%2520peripheral%2520blood%2520for%2520collection%2520and%2520subsequent%2520autologous%2520transplantation%26jtitle%3DOncology%26date%3D2010%26volume%3D78%26spage%3D282%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmead, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span> </span><span class="NLM_article-title">The use of GPCR structures in drug design</span> <span class="citation_source-journal">Adv. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2011&pages=1-36&author=M.+Congreveauthor=C.+Langmeadauthor=F.+H.+Marshall&title=The+use+of+GPCR+structures+in+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DLangmead%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DThe%2520use%2520of%2520GPCR%2520structures%2520in%2520drug%2520design%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2011%26volume%3D62%26spage%3D1%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Choi, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggineni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, J.</span><span> </span><span class="NLM_article-title">Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">â</span> <span class="NLM_lpage">994</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200568c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOlt7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=977-994&author=W.+T.+Choiauthor=S.+Duggineniauthor=Y.+Xuauthor=Z.+Huangauthor=J.+An&title=Drug+discovery+research+targeting+the+CXC+chemokine+receptor+4+%28CXCR4%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4)</span></div><div class="casAuthors">Choi, Won-Tak; Duggineni, Srinivas; Xu, Yan; Huang, Ziwei; An, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">977-994</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The CXC chemokine receptor 4 (CXCR4) is an attractive target for therapeutic intervention because of its involvement in the pathogenesis of a wide range of infectious, inflammatory, and other diseases.  There has been intensive biol., chem., and pharmaceutical research to understand the mol. mechanisms of chemokine-receptor interactions and the modulation of chemokine-receptor functions.  The ultimate goal is to translate these discoveries into novel treatment strategies for clin. applications.  This review describes and discusses some of the recent advances in medicinal chem. and drug discovery that involve CXCR4, which is implicated in human immunodeficiency virus (HIV)-1 infection, normal hematopoietic and neural stem cell migration, cancer-stromal cell interaction, solid tumors, and inflammation and autoimmune diseases such as rheumatoid arthritis and allergic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvqHX-IPaxrVg90H21EOLACvtfcHk0ljKz5zngA55rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOlt7jF&md5=c996a29f564ca4197139f4802dcbe061</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm200568c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200568c%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DW.%2BT.%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAn%26aufirst%3DJ.%26atitle%3DDrug%2520discovery%2520research%2520targeting%2520the%2520CXC%2520chemokine%2520receptor%25204%2520%2528CXCR4%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D977%26epage%3D994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Palczewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumasaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoshima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Trong, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teller, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenkamp, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyano, M.</span><span> </span><span class="NLM_article-title">Crystal structure of rhodopsin: a G protein-coupled receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">â</span> <span class="NLM_lpage">745</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1126%2Fscience.289.5480.739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10926528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslOqs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=739-745&author=K.+Palczewskiauthor=T.+Kumasakaauthor=T.+Horiauthor=C.+A.+Behnkeauthor=H.+Motoshimaauthor=B.+A.+Foxauthor=I.+Le+Trongauthor=D.+C.+Tellerauthor=T.+Okadaauthor=R.+E.+Stenkampauthor=M.+Yamamotoauthor=M.+Miyano&title=Crystal+structure+of+rhodopsin%3A+a+G+protein-coupled+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of rhodopsin: A G protein-coupled receptor</span></div><div class="casAuthors">Palczewski, Krzysztof; Kumasaka, Takashi; Hori, Tetsuya; Behnke, Craig A.; Motoshima, Hiroyuki; Fox, Brian A.; Le Trong, Isolde; Teller, David C.; Okada, Tetsuji; Stenkamp, Ronald E.; Yamamoto, Masaki; Miyano, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5480</span>),
    <span class="NLM_cas:pages">739-745</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) respond to a variety of different external stimuli and activate G proteins.  GPCRs share many structural features, including a bundle of seven transmembrane Î±-helixes connected by six loops of varying lengths.  We detd. the structure of rhodopsin from diffraction data extending to 2.8 angstroms resoln.  The highly organized structure in the extracellular region, including a conserved disulfide bridge, forms a basis for the arrangement of the seven-helix transmembrane motif.  The ground-state chromophore, 11-cis-retinal, holds the transmembrane region of the protein in the inactive conformation.  Interactions of the chromophore with a cluster of key residues det. the wavelength of the max. absorption.  Changes in these interactions among rhodopsins facilitate color discrimination.  Identification of a set of residues that mediate interactions between the transmembrane helixes and the cytoplasmic surface, where G-protein activation occurs, also suggests a possible structural change upon photoactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFTWGKYX8vqLVg90H21EOLACvtfcHk0lh7MMPs1s4aAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslOqs78%253D&md5=b3d229fc696247ec0f4a6efa10490922</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5480.739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5480.739%26sid%3Dliteratum%253Aachs%26aulast%3DPalczewski%26aufirst%3DK.%26aulast%3DKumasaka%26aufirst%3DT.%26aulast%3DHori%26aufirst%3DT.%26aulast%3DBehnke%26aufirst%3DC.%2BA.%26aulast%3DMotoshima%26aufirst%3DH.%26aulast%3DFox%26aufirst%3DB.%2BA.%26aulast%3DLe%2BTrong%26aufirst%3DI.%26aulast%3DTeller%26aufirst%3DD.%2BC.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DStenkamp%26aufirst%3DR.%2BE.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DMiyano%26aufirst%3DM.%26atitle%3DCrystal%2520structure%2520of%2520rhodopsin%253A%2520a%2520G%2520protein-coupled%2520receptor%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D739%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1258</span><span class="NLM_x">â</span> <span class="NLM_lpage">1265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258-1265&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.+J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-resolution+crystal+structure+of+an+engineered+human+beta2-adrenergic+G+protein-coupled+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human Î²2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the Î²2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human Î²2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the Î²2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0lh7MMPs1s4aAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520an%2520engineered%2520human%2520beta2-adrenergic%2520G%2520protein-coupled%2520receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26epage%3D1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenalti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handel, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">1066</span><span class="NLM_x">â</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1126%2Fscience.1194396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20929726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1066-1071&author=B.+Wuauthor=E.+Y.+Chienauthor=C.+D.+Molauthor=G.+Fenaltiauthor=W.+Liuauthor=V.+Katritchauthor=R.+Abagyanauthor=A.+Broounauthor=P.+Wellsauthor=F.+C.+Biauthor=D.+J.+Hamelauthor=P.+Kuhnauthor=T.+M.+Handelauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structures+of+the+CXCR4+chemokine+GPCR+with+small-molecule+and+cyclic+peptide+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists</span></div><div class="casAuthors">Wu, Beili; Chien, Ellen Y. T.; Mol, Clifford D.; Fenalti, Gustavo; Liu, Wei; Katritch, Vsevolod; Abagyan, Ruben; Brooun, Alexei; Wells, Peter; Bi, F. Christopher; Hamel, Damon J.; Kuhn, Peter; Handel, Tracy M.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1066-1071</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chemokine receptors are crit. regulators of cell migration in the context of immune surveillance, inflammation, and development.  The G protein-coupled chemokine receptor CXCR4 is specifically implicated in cancer metastasis and HIV-1 infection.  Here we report five independent crystal structures of CXCR4 bound to an antagonist small mol. IT1t and a cyclic peptide CVX15 at 2.5 to 3.2 angstrom resoln.  All structures reveal a consistent homodimer with an interface including helixes V and VI that may be involved in regulating signaling.  The location and shape of the ligand-binding sites differ from other G protein-coupled receptors and are closer to the extracellular surface.  These structures provide new clues about the interactions between CXCR4 and its natural ligand CXCL12, and with the HIV-1 glycoprotein gp120.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeofqcIJsBzLVg90H21EOLACvtfcHk0lh7MMPs1s4aAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurnM&md5=2d39cc2cff4adce72e63f427e568e35d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1194396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1194396%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DFenalti%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DHamel%26aufirst%3DD.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DHandel%26aufirst%3DT.%2BM.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructures%2520of%2520the%2520CXCR4%2520chemokine%2520GPCR%2520with%2520small-molecule%2520and%2520cyclic%2520peptide%2520antagonists%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1066%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. K.</span><span> </span><span class="NLM_article-title">Transduction of receptor signals by beta-arrestins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">â</span> <span class="NLM_lpage">517</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=512-517&author=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Transduction+of+receptor+signals+by+beta-arrestins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DTransduction%2520of%2520receptor%2520signals%2520by%2520beta-arrestins%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D512%26epage%3D517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Schwartz, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimurer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenkilde, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elling, C. E.</span><span> </span><span class="NLM_article-title">Molecular mechanism of 7TM receptor activationâa global toggle switch model</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">â</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=481-519&author=T.+W.+Schwartzauthor=T.+M.+Frimurerauthor=B.+Holstauthor=M.+M.+Rosenkildeauthor=C.+E.+Elling&title=Molecular+mechanism+of+7TM+receptor+activation%E2%80%94a+global+toggle+switch+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DElling%26aufirst%3DC.%2BE.%26atitle%3DMolecular%2520mechanism%2520of%25207TM%2520receptor%2520activation%25E2%2580%2594a%2520global%2520toggle%2520switch%2520model%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D481%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Monteclaro, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">19084</span><span class="NLM_x">â</span> <span class="NLM_lpage">19092</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=19084-19092&author=F.+S.+Monteclaroauthor=I.+F.+Charo&title=The+amino-terminal+extracellular+domain+of+the+MCP-1+receptor%2C+but+not+the+RANTES%2FMIP-1alpha+receptor%2C+confers+chemokine+selectivity.+Evidence+for+a+two-step+mechanism+for+MCP-1+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMonteclaro%26aufirst%3DF.%2BS.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DThe%2520amino-terminal%2520extracellular%2520domain%2520of%2520the%2520MCP-1%2520receptor%252C%2520but%2520not%2520the%2520RANTES%252FMIP-1alpha%2520receptor%252C%2520confers%2520chemokine%2520selectivity.%2520Evidence%2520for%2520a%2520two-step%2520mechanism%2520for%2520MCP-1%2520receptor%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D19084%26epage%3D19092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pease, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponath, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, P. M.</span><span> </span><span class="NLM_article-title">The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">19972</span><span class="NLM_x">â</span> <span class="NLM_lpage">19976</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=19972-19976&author=J.+E.+Peaseauthor=J.+Wangauthor=P.+D.+Ponathauthor=P.+M.+Murphy&title=The+N-terminal+extracellular+segments+of+the+chemokine+receptors+CCR1+and+CCR3+are+determinants+for+MIP-1alpha+and+eotaxin+binding%2C+respectively%2C+but+a+second+domain+is+essential+for+efficient+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPonath%26aufirst%3DP.%2BD.%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26atitle%3DThe%2520N-terminal%2520extracellular%2520segments%2520of%2520the%2520chemokine%2520receptors%2520CCR1%2520and%2520CCR3%2520are%2520determinants%2520for%2520MIP-1alpha%2520and%2520eotaxin%2520binding%252C%2520respectively%252C%2520but%2520a%2520second%2520domain%2520is%2520essential%2520for%2520efficient%2520receptor%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D19972%26epage%3D19976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Farzan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirzabekov, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolchinsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayabyab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodroski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, H.</span><span> </span><span class="NLM_article-title">Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">â</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=667-676&author=M.+Farzanauthor=T.+Mirzabekovauthor=P.+Kolchinskyauthor=R.+Wyattauthor=M.+Cayabyabauthor=N.+P.+Gerardauthor=C.+Gerardauthor=J.+Sodroskiauthor=H.+Choe&title=Tyrosine+sulfation+of+the+amino+terminus+of+CCR5+facilitates+HIV-1+entry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarzan%26aufirst%3DM.%26aulast%3DMirzabekov%26aufirst%3DT.%26aulast%3DKolchinsky%26aufirst%3DP.%26aulast%3DWyatt%26aufirst%3DR.%26aulast%3DCayabyab%26aufirst%3DM.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DChoe%26aufirst%3DH.%26atitle%3DTyrosine%2520sulfation%2520of%2520the%2520amino%2520terminus%2520of%2520CCR5%2520facilitates%2520HIV-1%2520entry%26jtitle%3DCell%26date%3D1999%26volume%3D96%26spage%3D667%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bannert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craig, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farzan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogah, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santo, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodroski, J.</span><span> </span><span class="NLM_article-title">Sialylated <i>O</i>-glycans and sulfated tyrosines in the NH<sub>2</sub>-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">1661</span><span class="NLM_x">â</span> <span class="NLM_lpage">1673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2001&pages=1661-1673&author=N.+Bannertauthor=S.+Craigauthor=M.+Farzanauthor=D.+Sogahauthor=N.+V.+Santoauthor=H.+Choeauthor=J.+Sodroski&title=Sialylated+O-glycans+and+sulfated+tyrosines+in+the+NH2-terminal+domain+of+CC+chemokine+receptor+5+contribute+to+high+affinity+binding+of+chemokines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBannert%26aufirst%3DN.%26aulast%3DCraig%26aufirst%3DS.%26aulast%3DFarzan%26aufirst%3DM.%26aulast%3DSogah%26aufirst%3DD.%26aulast%3DSanto%26aufirst%3DN.%2BV.%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DSodroski%26aufirst%3DJ.%26atitle%3DSialylated%2520O-glycans%2520and%2520sulfated%2520tyrosines%2520in%2520the%2520NH2-terminal%2520domain%2520of%2520CC%2520chemokine%2520receptor%25205%2520contribute%2520to%2520high%2520affinity%2520binding%2520of%2520chemokines%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2001%26volume%3D194%26spage%3D1661%26epage%3D1673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Rosenkilde, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benned-Jensen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimurer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, T. W.</span><span> </span><span class="NLM_article-title">The minor binding pocket: a major player in 7TM receptor activation</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">574</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=567-574&author=M.+M.+Rosenkildeauthor=T.+Benned-Jensenauthor=T.+M.+Frimurerauthor=T.+W.+Schwartz&title=The+minor+binding+pocket%3A+a+major+player+in+7TM+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DBenned-Jensen%26aufirst%3DT.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DThe%2520minor%2520binding%2520pocket%253A%2520a%2520major%2520player%2520in%25207TM%2520receptor%2520activation%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2010%26volume%3D31%26spage%3D567%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Van Damme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struyf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuyts, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Coillie, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menten, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schols, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meester, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proost, P.</span><span> </span><span class="NLM_article-title">The role of CD26/DPP IV in chemokine processing</span> <span class="citation_source-journal">Chem. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">â</span> <span class="NLM_lpage">56</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1159%2F000058725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10550929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSntLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=42-56&author=J.+Van+Dammeauthor=S.+Struyfauthor=A.+Wuytsauthor=E.+Van+Coillieauthor=P.+Mentenauthor=D.+Scholsauthor=S.+Sozzaniauthor=I.+De+Meesterauthor=P.+Proost&title=The+role+of+CD26%2FDPP+IV+in+chemokine+processing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The role of CD26/DPP IV in chemokine processing</span></div><div class="casAuthors">Van Damme, Jo; Struyf, Sofie; Wuyts, Anja; Van Coillie, Els; Menten, Patricia; Schols, Dominique; Sozzani, Silvano; De Meester, Ingrid; Proost, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">Chemokines</span>),
    <span class="NLM_cas:pages">42-56</span>CODEN:
                <span class="NLM_cas:coden">CHMIEP</span>;
        ISSN:<span class="NLM_cas:issn">1015-0145</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review with 30 refs. describing the effects of dipeptidyl peptidase IV (DPP IV) on a large group of small inflammatory cytokines, chemokines.  For each individual chemoattractant the different biol. consequences of processing by CD26/DPP IV are evaluated in comparison with the intact mol.  These examples show that chemokines are important natural substrates for CD26/DPP IV and illustrate the impact of this serine protease in immune processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr355UtDqr_l7Vg90H21EOLACvtfcHk0lg3oX3EjkdmEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSntLs%253D&md5=606fca67ff327c49b71dc2d5cff9c082</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1159%2F000058725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000058725%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DStruyf%26aufirst%3DS.%26aulast%3DWuyts%26aufirst%3DA.%26aulast%3DVan%2BCoillie%26aufirst%3DE.%26aulast%3DMenten%26aufirst%3DP.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DProost%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520CD26%252FDPP%2520IV%2520in%2520chemokine%2520processing%26jtitle%3DChem.%2520Immunol.%26date%3D1999%26volume%3D72%26spage%3D42%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borlat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alouani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offord, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span> </span><span class="NLM_article-title">Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">32478</span><span class="NLM_x">â</span> <span class="NLM_lpage">32485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=32478-32485&author=A.+E.+Proudfootauthor=R.+Buserauthor=F.+Borlatauthor=S.+Alouaniauthor=D.+Solerauthor=R.+E.+Offordauthor=J.+M.+Schroderauthor=C.+A.+Powerauthor=T.+N.+Wells&title=Amino-terminally+modified+RANTES+analogues+demonstrate+differential+effects+on+RANTES+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DBuser%26aufirst%3DR.%26aulast%3DBorlat%26aufirst%3DF.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DOfford%26aufirst%3DR.%2BE.%26aulast%3DSchroder%26aufirst%3DJ.%2BM.%26aulast%3DPower%26aufirst%3DC.%2BA.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DAmino-terminally%2520modified%2520RANTES%2520analogues%2520demonstrate%2520differential%2520effects%2520on%2520RANTES%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D32478%26epage%3D32485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Wise, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchesnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Fonseca, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span> </span><span class="NLM_article-title">Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">27935</span><span class="NLM_x">â</span> <span class="NLM_lpage">27943</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=27935-27943&author=E.+L.+Wiseauthor=C.+Duchesnesauthor=P.+C.+da+Fonsecaauthor=R.+A.+Allenauthor=T.+J.+Williamsauthor=J.+E.+Pease&title=Small+molecule+receptor+agonists+and+antagonists+of+CCR3+provide+insight+into+mechanisms+of+chemokine+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DE.%2BL.%26aulast%3DDuchesnes%26aufirst%3DC.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%26aulast%3DAllen%26aufirst%3DR.%2BA.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DSmall%2520molecule%2520receptor%2520agonists%2520and%2520antagonists%2520of%2520CCR3%2520provide%2520insight%2520into%2520mechanisms%2520of%2520chemokine%2520receptor%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D27935%26epage%3D27943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Nedjai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroke, I. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klon, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidehi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span> </span><span class="NLM_article-title">Small-molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">912</span><span class="NLM_x">â</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1476-5381.2011.01660.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2011&pages=912-923&author=B.+Nedjaiauthor=H.+Liauthor=I.+L.+Strokeauthor=E.+L.+Wiseauthor=M.+L.+Webbauthor=J.+R.+Merrittauthor=I.+Hendersonauthor=A.+E.+Klonauthor=A.+G.+Coleauthor=R.+Horukauthor=N.+Vaidehiauthor=J.+E.+Pease&title=Small-molecule+chemokine+mimetics+suggest+a+molecular+basis+for+the+observation+that+CXCL10+and+CXCL11+are+allosteric+ligands+of+CXCR3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01660.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01660.x%26sid%3Dliteratum%253Aachs%26aulast%3DNedjai%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DStroke%26aufirst%3DI.%2BL.%26aulast%3DWise%26aufirst%3DE.%2BL.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMerritt%26aufirst%3DJ.%2BR.%26aulast%3DHenderson%26aufirst%3DI.%26aulast%3DKlon%26aufirst%3DA.%2BE.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DSmall-molecule%2520chemokine%2520mimetics%2520suggest%2520a%2520molecular%2520basis%2520for%2520the%2520observation%2520that%2520CXCL10%2520and%2520CXCL11%2520are%2520allosteric%2520ligands%2520of%2520CXCR3%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D166%26spage%3D912%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Weathington, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Houwelingen, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noerager, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraneveld, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galin, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkerts, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nijkamp, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blalock, J. E.</span><span> </span><span class="NLM_article-title">A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">â</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnm1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16474398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGnt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=317-323&author=N.+M.+Weathingtonauthor=A.+H.+van+Houwelingenauthor=B.+D.+Noeragerauthor=P.+L.+Jacksonauthor=A.+D.+Kraneveldauthor=F.+S.+Galinauthor=G.+Folkertsauthor=F.+P.+Nijkampauthor=J.+E.+Blalock&title=A+novel+peptide+CXCR+ligand+derived+from+extracellular+matrix+degradation+during+airway+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation</span></div><div class="casAuthors">Weathington, Nathaniel M.; van Houwelingen, Anneke H.; Noerager, Brett D.; Jackson, Patricia L.; Kraneveld, Aletta D.; Galin, F. Shawn; Folkerts, Gert; Nijkamp, Frans P.; Blalock, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-323</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors describe the tripeptide neutrophil chemoattractant N-acetyl Pro-Gly-Pro (PGP), derived from the breakdown of extracellular matrix (ECM), which shares sequence and structural homol. with an important domain on alpha chemokines.  PGP caused chemotaxis and prodn. of superoxide through CXC receptors, and administration of peptide caused recruitment of neutrophils (PMNs) into lungs of control, but not CXCR2-deficient mice.  PGP was generated in mouse lung after exposure to lipopolysaccharide, and in vivo and in vitro blockade of PGP with monoclonal antibody suppressed PMN responses as much as chemokine-specific monoclonal antibody.  Extended PGP treatment caused alveolar enlargement and right ventricular hypertrophy in mice.  PGP was detectable in substantial concns. in a majority of bronchoalveolar lavage samples from individuals with chronic obstructive pulmonary disease, but not control individuals.  Thus, PGP's activity links degrdn. of ECM with neutrophil recruitment in airway inflammation, and PGP may be a biomarker and therapeutic target for neutrophilic inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvVY_4dt4eLVg90H21EOLACvtfcHk0lgrm8Q5YzmF1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGnt70%253D&md5=4e9e953a275d3ff89e3f0c312abe2774</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnm1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1361%26sid%3Dliteratum%253Aachs%26aulast%3DWeathington%26aufirst%3DN.%2BM.%26aulast%3Dvan%2BHouwelingen%26aufirst%3DA.%2BH.%26aulast%3DNoerager%26aufirst%3DB.%2BD.%26aulast%3DJackson%26aufirst%3DP.%2BL.%26aulast%3DKraneveld%26aufirst%3DA.%2BD.%26aulast%3DGalin%26aufirst%3DF.%2BS.%26aulast%3DFolkerts%26aufirst%3DG.%26aulast%3DNijkamp%26aufirst%3DF.%2BP.%26aulast%3DBlalock%26aufirst%3DJ.%2BE.%26atitle%3DA%2520novel%2520peptide%2520CXCR%2520ligand%2520derived%2520from%2520extracellular%2520matrix%2520degradation%2520during%2520airway%2520inflammation%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D317%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Andrews, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wreggett, K. A.</span><span> </span><span class="NLM_article-title">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">â</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fmol.107.039321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18042736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=855-867&author=G.+Andrewsauthor=C.+Jonesauthor=K.+A.+Wreggett&title=An+intracellular+allosteric+site+for+a+specific+class+of+antagonists+of+the+CC+chemokine+G+protein-coupled+receptors+CCR4+and+CCR5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span></div><div class="casAuthors">Andrews, Glen; Jones, Carolyn; Wreggett, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A novel mechanism for antagonism of the human chemokine receptors CCR4 and CCR5 has been discovered with a series of small-mol. compds. that seems to interact with an allosteric, intracellular site on the receptor.  The existence of this site is supported by a series of observations: (1) intracellular access of these antagonists is required for their activity; (2) specific, saturable binding of a radiolabeled antagonist requires the presence of CCR4; and (3) through engineering receptor chimeras by reciprocal transfer of C-terminal domains between CCR4 and CCR5, compd. binding and the selective structure-activity relationships for antagonism of these receptors seem to be assocd. with the integrity of that intracellular region.  Published antagonists from other chem. series do not seem to bind to the novel site, and their interaction with either CCR4 or CCR5 is not affected by alteration of the C-terminal domain.  The precise location of the proposed binding site remains to be detd., but the known close assocn. of the C-terminal domain, including helix 8, as a proposed intracellular region that interacts with transduction proteins (e.g., G proteins and Î²-arrestin) suggests that this could be a generic allosteric site for chemokine receptors and perhaps more broadly for class A G protein-coupled receptors.  The existence of such a site that can be targeted for drug discovery has implications for screening assays for receptor antagonists, which would need, therefore, to consider compd. properties for access to this intracellular site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAPVG6Nu0Wf7Vg90H21EOLACvtfcHk0lgrm8Q5YzmF1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D&md5=f3624c421bac61365f63ea1389dffea0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039321%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DWreggett%26aufirst%3DK.%2BA.%26atitle%3DAn%2520intracellular%2520allosteric%2520site%2520for%2520a%2520specific%2520class%2520of%2520antagonists%2520of%2520the%2520CC%2520chemokine%2520G%2520protein-coupled%2520receptors%2520CCR4%2520and%2520CCR5%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Feng, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, G.</span><span> </span><span class="NLM_article-title">Selective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">33400</span><span class="NLM_x">â</span> <span class="NLM_lpage">33407</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=33400-33407&author=G.+J.+Fengauthor=E.+Kellettauthor=C.+A.+Scorerauthor=J.+Wildeauthor=J.+H.+Whiteauthor=G.+Milligan&title=Selective+interactions+between+helix+VIII+of+the+human+mu-opioid+receptors+and+the+C+terminus+of+periplakin+disrupt+G+protein+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DG.%2BJ.%26aulast%3DKellett%26aufirst%3DE.%26aulast%3DScorer%26aufirst%3DC.%2BA.%26aulast%3DWilde%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DJ.%2BH.%26aulast%3DMilligan%26aufirst%3DG.%26atitle%3DSelective%2520interactions%2520between%2520helix%2520VIII%2520of%2520the%2520human%2520mu-opioid%2520receptors%2520and%2520the%2520C%2520terminus%2520of%2520periplakin%2520disrupt%2520G%2520protein%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D33400%26epage%3D33407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sobocki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliatti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobelt, G.</span><span> </span><span class="NLM_article-title">Estimation of the cost of MS in Europe: extrapolations from a multinational cost study</span> <span class="citation_source-journal">Mult. Scler.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">â</span> <span class="NLM_lpage">1064</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1177%2F1352458507077941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17623729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BD2srnt1Wjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1054-1064&author=P.+Sobockiauthor=M.+Pugliattiauthor=K.+Lauerauthor=G.+Kobelt&title=Estimation+of+the+cost+of+MS+in+Europe%3A+extrapolations+from+a+multinational+cost+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of the cost of MS in Europe: extrapolations from a multinational cost study</span></div><div class="casAuthors">Sobocki P; Pugliatti M; Lauer K; Kobelt G</div><div class="citationInfo"><span class="NLM_cas:title">Multiple sclerosis (Houndmills, Basingstoke, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1054-64</span>
        ISSN:<span class="NLM_cas:issn">1352-4585</span>.
    </div><div class="casAbstract">The present study aims at estimating the total cost of MS in Europe based on actual cost data from nine countries and published epidemiological evidence.  The epidemiological data are reported as 12 months prevalence estimates and cost data calculated as annual cost per patient at given levels of disease severity.  Cost data are extrapolated to the rest of Europe based on a model, using economic indexes adjusting for price level differences in different sectors between countries.  The aggregated annual cost estimates are presented in Euro for 2005.  In 28 European countries with a population of 466 million, an estimated 380 000 individuals are affected by MS.  The total annual cost of MS in Europe is estimated at 12.5 billion in year 2005, corresponding to a cost of 27 per European inhabitant.  Direct costs represent slightly more than half of the total cost (6.0 billion).  Informal care is estimated at 3.2 billion, and indirect costs due to morbidity at 3.2 billion.  Thus, the largest component of costs is found outside the formal health care sector.  Although our model appears to predict costs reasonably well, when comparing to previous national studies not included in the estimates, there are considerable uncertainties when extrapolating cost data across countries even within Europe.  These weaknesses can only be overcome by collecting primary data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFMgVF7CkElOqrn-c4Of3KfW6udTcc2eZehrJ26cGaJ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srnt1Wjug%253D%253D&md5=0a4cb54ca11b7bad8735a2116f102b8f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1177%2F1352458507077941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1352458507077941%26sid%3Dliteratum%253Aachs%26aulast%3DSobocki%26aufirst%3DP.%26aulast%3DPugliatti%26aufirst%3DM.%26aulast%3DLauer%26aufirst%3DK.%26aulast%3DKobelt%26aufirst%3DG.%26atitle%3DEstimation%2520of%2520the%2520cost%2520of%2520MS%2520in%2520Europe%253A%2520extrapolations%2520from%2520a%2520multinational%2520cost%2520study%26jtitle%3DMult.%2520Scler.%26date%3D2007%26volume%3D13%26spage%3D1054%26epage%3D1064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Lassmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruck, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchinetti, C.</span><span> </span><span class="NLM_article-title">Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=115-121&author=H.+Lassmannauthor=W.+Bruckauthor=C.+Lucchinetti&title=Heterogeneity+of+multiple+sclerosis+pathogenesis%3A+implications+for+diagnosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLassmann%26aufirst%3DH.%26aulast%3DBruck%26aufirst%3DW.%26aulast%3DLucchinetti%26aufirst%3DC.%26atitle%3DHeterogeneity%2520of%2520multiple%2520sclerosis%2520pathogenesis%253A%2520implications%2520for%2520diagnosis%2520and%2520therapy%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D115%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Trebst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivisakk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathcart, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellebjerg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span> </span><span class="NLM_article-title">CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1701</span><span class="NLM_x">â</span> <span class="NLM_lpage">1710</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0002-9440%2810%2963017-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11696431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BD3Mnltl2rsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2001&pages=1701-1710&author=C.+Trebstauthor=T.+L.+Sorensenauthor=P.+Kivisakkauthor=M.+K.+Cathcartauthor=J.+Hesselgesserauthor=R.+Horukauthor=F.+Sellebjergauthor=H.+Lassmannauthor=R.+M.+Ransohoff&title=CCR1%2B%2FCCR5%2B+mononuclear+phagocytes+accumulate+in+the+central+nervous+system+of+patients+with+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis</span></div><div class="casAuthors">Trebst C; Sorensen T L; Kivisakk P; Cathcart M K; Hesselgesser J; Horuk R; Sellebjerg F; Lassmann H; Ransohoff R M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1701-10</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">Mononuclear phagocytes (monocytes, macrophages, and microglia) are considered central to multiple sclerosis (MS) pathogenesis.  Molecular cues that mediate mononuclear phagocyte accumulation and activation in the central nervous system (CNS) of MS patients may include chemokines RANTES/CCL5 and macrophage inflammatory protein-1alpha/CCL3.  We analyzed expression of CCR1 and CCR5, the monocyte receptors for these chemokines, on circulating and cerebrospinal fluid CD14+ cells, and in MS brain lesions.  Approximately 70% of cerebrospinal fluid monocytes were CCR1+/CCR5+, regardless of the presence of CNS pathology, compared to less than 20% of circulating monocytes.  In active MS lesions CCR1+/CCR5+ monocytes were found in perivascular cell cuffs and at the demyelinating edges of evolving lesions.  Mononuclear phagocytes in early demyelinating stages comprised CCR1+/CCR5+ hematogenous monocytes and CCR1-/CCR5- resident microglial cells.  In later stages, phagocytic macrophages were uniformly CCR1-/CCR5+.  Cultured in vitro, adherent monocytes/macrophages up-regulated CCR5 and down-regulated CCR1 expression, compared to freshly-isolated monocytes.  Taken together, these findings suggest that monocytes competent to enter the CNS compartment derive from a minority CCR1+/CCR5+ population in the circulating pool.  In the presence of ligand, these cells will be retained in the CNS.  During further activation in lesions, infiltrating monocytes down-regulate CCR1 but not CCR5, whereas microglia up-regulate CCR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThPeYGkwTkA3thwrmtH4OBfW6udTcc2eZehrJ26cGaJ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mnltl2rsQ%253D%253D&md5=1d769e0990604e0a5c1a745b73f9a135</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963017-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963017-9%26sid%3Dliteratum%253Aachs%26aulast%3DTrebst%26aufirst%3DC.%26aulast%3DSorensen%26aufirst%3DT.%2BL.%26aulast%3DKivisakk%26aufirst%3DP.%26aulast%3DCathcart%26aufirst%3DM.%2BK.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DSellebjerg%26aufirst%3DF.%26aulast%3DLassmann%26aufirst%3DH.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DCCR1%252B%252FCCR5%252B%2520mononuclear%2520phagocytes%2520accumulate%2520in%2520the%2520central%2520nervous%2520system%2520of%2520patients%2520with%2520multiple%2520sclerosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2001%26volume%3D159%26spage%3D1701%26epage%3D1710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Balashov, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">6873</span><span class="NLM_x">â</span> <span class="NLM_lpage">6878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=6873-6878&author=K.+E.+Balashovauthor=J.+B.+Rottmanauthor=H.+L.+Weinerauthor=W.+W.+Hancock&title=CCR5%28%2B%29+and+CXCR3%28%2B%29+T+cells+are+increased+in+multiple+sclerosis+and+their+ligands+MIP-1alpha+and+IP-10+are+expressed+in+demyelinating+brain+lesions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBalashov%26aufirst%3DK.%2BE.%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DWeiner%26aufirst%3DH.%2BL.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DCCR5%2528%252B%2529%2520and%2520CXCR3%2528%252B%2529%2520T%2520cells%2520are%2520increased%2520in%2520multiple%2520sclerosis%2520and%2520their%2520ligands%2520MIP-1alpha%2520and%2520IP-10%2520are%2520expressed%2520in%2520demyelinating%2520brain%2520lesions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D6873%26epage%3D6878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">McManus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brosnan, C. F.</span><span> </span><span class="NLM_article-title">MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study</span> <span class="citation_source-journal">J. Neuroimmunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">â</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0165-5728%2898%2900002-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9655469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1cXjsVensro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1998&pages=20-29&author=C.+McManusauthor=J.+W.+Bermanauthor=F.+M.+Brettauthor=H.+Stauntonauthor=M.+Farrellauthor=C.+F.+Brosnan&title=MCP-1%2C+MCP-2+and+MCP-3+expression+in+multiple+sclerosis+lesions%3A+an+immunohistochemical+and+in+situ+hybridization+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study</span></div><div class="casAuthors">McManus, Carrie; Berman, Joan W.; Brett, Francesca M.; Staunton, Hugh; Farrell, Michael; Brosnan, Celia F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Chemokines are low mol. wt. chemotactic cytokines that have been shown to play a central role in the perivascular transmigration and accumulation of specific subsets of leukocytes at sites of tissue damage.  Two major families have been defined depending on the positioning of four conserved cysteines.  The CXC chemokines predominantly attract neutrophils, whereas the CC chemokines predominantly attract monocytes and other leukocyte cell types.  Members of the monocyte chemotactic protein (MCP)-1 family form a major component of the CC family of chemokines and are considered the principal chemokines involved in the recruitment of monocytes/macrophages and activated lymphocytes.  In this study the authors addressed the expression and distribution of MCP-1, -2 and -3 in multiple sclerosis (MS) lesions of differing ages and levels of inflammatory activity using immunohistochem. and in situ hybridization.  In acute and chronic-active MS lesions immunoreactivity for MCP-1, -2 and -3 was prominent throughout the lesion center with reactivity diminishing abruptly at the lesion edge.  Hypertrophic astrocytes were strongly reactive and inflammatory cells showed variable reactivity.  Outside of the lesion only hypertrophic astrocytes were reactive.  The results obtained by in situ hybridization for MCP-1 were in agreement with those obtained by immunostaining.  In more chronic lesions immunoreactivity for MCP-1, -2 and -3 was considerably diminished, and in chronic-silent lesions immunoreactivity was restricted to a few scattered reactive astrocytes.  Normal control brains showed no immunoreactivity for MCP-1, -2 and -3.  Although the cellular distribution of all three members of this family was similar, antibodies to MCP-3 gave prominent staining of the extracellular matrix that was not noted for MCP-1 and -2.  These results support the conclusion that members of the MCP family of chemokines are involved in the development of MS lesions in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiccq9m1hZirVg90H21EOLACvtfcHk0lgsWInZepk5yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsVensro%253D&md5=d7dc5ae69381b1ef1a6722bb647b9eb0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0165-5728%2898%2900002-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-5728%252898%252900002-2%26sid%3Dliteratum%253Aachs%26aulast%3DMcManus%26aufirst%3DC.%26aulast%3DBerman%26aufirst%3DJ.%2BW.%26aulast%3DBrett%26aufirst%3DF.%2BM.%26aulast%3DStaunton%26aufirst%3DH.%26aulast%3DFarrell%26aufirst%3DM.%26aulast%3DBrosnan%26aufirst%3DC.%2BF.%26atitle%3DMCP-1%252C%2520MCP-2%2520and%2520MCP-3%2520expression%2520in%2520multiple%2520sclerosis%2520lesions%253A%2520an%2520immunohistochemical%2520and%2520in%2520situ%2520hybridization%2520study%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D1998%26volume%3D86%26spage%3D20%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Steinman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamvil, S. S.</span><span> </span><span class="NLM_article-title">Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis</span> <span class="citation_source-journal">Trends Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">â</span> <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.it.2005.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16153891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeiu7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=565-571&author=L.+Steinmanauthor=S.+S.+Zamvil&title=Virtues+and+pitfalls+of+EAE+for+the+development+of+therapies+for+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis</span></div><div class="casAuthors">Steinman, Lawrence; Zamvil, Scott S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">565-571</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Exptl. autoimmune encephalomyelitis (EAE) is a useful model for aiding the development of new treatments for MS.  All therapies approved for MS ameliorate EAE.  Two approved medications, glatiramer acetate and Natalizumab, were developed directly from studies in EAE.  Several trials are ongoing in MS after success in EAE, including altered peptide ligands of myelin, DNA vaccines and statins.  However, EAE has failed to predict the outcome of certain approaches.  The reasons underlying such failures are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_U2n_C7oLLVg90H21EOLACvtfcHk0lgsWInZepk5yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeiu7rO&md5=e33fd4b3f813fa896663ab39ed22f4c5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2005.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2005.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DSteinman%26aufirst%3DL.%26aulast%3DZamvil%26aufirst%3DS.%2BS.%26atitle%3DVirtues%2520and%2520pitfalls%2520of%2520EAE%2520for%2520the%2520development%2520of%2520therapies%2520for%2520multiple%2520sclerosis%26jtitle%3DTrends%2520Immunol.%26date%3D2005%26volume%3D26%26spage%3D565%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazarakis, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Macrophage inflammatory protein-1a. A novel chemotactic cytokine for macrophages in rheumatoid arthritis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">â</span> <span class="NLM_lpage">928</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1994&pages=921-928&author=A.+E.+Kochauthor=S.+E.+Kunkelauthor=S.+E.+Harlowauthor=D.+D.+Mazarakisauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Macrophage+inflammatory+protein-1a.+A+novel+chemotactic+cytokine+for+macrophages+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BE.%26aulast%3DHarlow%26aufirst%3DS.%2BE.%26aulast%3DMazarakis%26aufirst%3DD.%2BD.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DMacrophage%2520inflammatory%2520protein-1a.%2520A%2520novel%2520chemotactic%2520cytokine%2520for%2520macrophages%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1994%26volume%3D93%26spage%3D921%26epage%3D928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Macchioni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boiardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meliconi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulsatelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maldini, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvarani, C.</span><span> </span><span class="NLM_article-title">Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">â</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9489827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVGgu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1998&pages=320-325&author=P.+Macchioniauthor=L.+Boiardiauthor=R.+Meliconiauthor=L.+Pulsatelliauthor=M.+C.+Maldiniauthor=R.+Ruggeriauthor=A.+Facchiniauthor=C.+Salvarani&title=Serum+chemokines+in+patients+with+psoriatic+arthritis+treated+with+cyclosporin+A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A</span></div><div class="casAuthors">Macchioni, Pierluigi; Boiardi, Luigi; Meliconi, Riccardo; Pulsatelli, Lia; Maldini, Mario Casadei; Ruggeri, Romina; Facchini, Andrea; Salvarani, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">320-325</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">The levels of serum chemokines were evaluated in patients with psoriatic arthritis (PsA) before and during cyclosporin A (CyA) treatment.  Sixteen outpatients with active PsA were followed for 6 mo during low dosage CyA treatment.  Serum chemokines of the C-X-C and C-C groups were detd. by ELISA at the baseline.  Serum RANTES levels were measured at 2 mo intervals for 6 mo.  Serum chemokine levels were related with clin. and lab. disease activity variables.  Serum interleukin 8 and macrophage inflammatory protein 1Î± levels were undetectable at baseline.  Mean serum growth related gene product-Î± and monocyte chemoattractant protein 1 values were reduced and serum RANTES were elevated compared to controls.  CyA treatment did not change serum RANTES levels.  Patients with PsA with persistently normal serum RANTES levels (4 patients) had a more favorable clin. and lab. response to CyA compared to patients with persistently high serum levels (6 patients).  Serum RANTES levels are higher in patients with PsA than in a control population.  CyA treatment does not change RANTES values.  Patients with PsA with persistently normal RANTES levels have a better response to CyA treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrypKodjYIr1bVg90H21EOLACvtfcHk0lgsWInZepk5yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVGgu7k%253D&md5=c11da9f0694474d85697ef2dd170f373</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacchioni%26aufirst%3DP.%26aulast%3DBoiardi%26aufirst%3DL.%26aulast%3DMeliconi%26aufirst%3DR.%26aulast%3DPulsatelli%26aufirst%3DL.%26aulast%3DMaldini%26aufirst%3DM.%2BC.%26aulast%3DRuggeri%26aufirst%3DR.%26aulast%3DFacchini%26aufirst%3DA.%26aulast%3DSalvarani%26aufirst%3DC.%26atitle%3DSerum%2520chemokines%2520in%2520patients%2520with%2520psoriatic%2520arthritis%2520treated%2520with%2520cyclosporin%2520A%26jtitle%3DJ.%2520Rheumatol.%26date%3D1998%26volume%3D25%26spage%3D320%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Kasama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lincoln, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span> </span><span class="NLM_article-title">Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2868</span><span class="NLM_x">â</span> <span class="NLM_lpage">2876</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2868-2876&author=T.+Kasamaauthor=R.+M.+Strieterauthor=N.+W.+Lukacsauthor=P.+M.+Lincolnauthor=M.+D.+Burdickauthor=S.+L.+Kunkel&title=Interleukin-10+expression+and+chemokine+regulation+during+the+evolution+of+murine+type+II+collagen-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKasama%26aufirst%3DT.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DLincoln%26aufirst%3DP.%2BM.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26atitle%3DInterleukin-10%2520expression%2520and%2520chemokine%2520regulation%2520during%2520the%2520evolution%2520of%2520murine%2520type%2520II%2520collagen-induced%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1995%26volume%3D95%26spage%3D2868%26epage%3D2876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Szekanecz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szucs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span> </span><span class="NLM_article-title">Chemokines in rheumatic diseases</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">â</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2174%2F138945006775270231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16454702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XitlOkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=91-102&author=Z.+Szekaneczauthor=G.+Szucsauthor=S.+Szantoauthor=A.+E.+Koch&title=Chemokines+in+rheumatic+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines in rheumatic diseases</span></div><div class="casAuthors">Szekanecz, Zoltan; Szucs, Gabriella; Szanto, Sandor; Koch, Alisa E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-102</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chemotactic cytokines, termed chemokines, mediate the ingress of leukocytes into the inflamed synovium.  In this review, authors discuss the role of the most relevant chemokines and chemokine receptors involved in chronic inflammatory rheumatic diseases.  Rheumatoid arthritis was chosen as a prototype to discuss these issues, as the majority of studies on the role of chemokines in inflammatory diseases were carried out in arthritis.  However, other rheumatic diseases including systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, mixed connective tissue disease, polymyositis/dermatomyositis, antiphospholipid syndrome and systemic vasculitides are also discussed in this context.  Apart from discussing the pathogenic role of chemokines and their receptors, authors also review the regulation of chemokine prodn. by other inflammatory mediators, as well as the important relevance of chemokines for antirheumatic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcKteMDUIu7bVg90H21EOLACvtfcHk0lh4Socp5KHf7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitlOkuw%253D%253D&md5=7e04aa1cee025048120172ede7c91fb1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F138945006775270231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945006775270231%26sid%3Dliteratum%253Aachs%26aulast%3DSzekanecz%26aufirst%3DZ.%26aulast%3DSzucs%26aufirst%3DG.%26aulast%3DSzanto%26aufirst%3DS.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26atitle%3DChemokines%2520in%2520rheumatic%2520diseases%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2006%26volume%3D7%26spage%3D91%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Barnes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufhold, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, H. D.</span><span> </span><span class="NLM_article-title">Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2910</span><span class="NLM_x">â</span> <span class="NLM_lpage">2919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1998&pages=2910-2919&author=D.+A.+Barnesauthor=J.+Tseauthor=M.+Kaufholdauthor=M.+Owenauthor=J.+Hesselgesserauthor=R.+Strieterauthor=R.+Horukauthor=H.+D.+Perez&title=Polyclonal+antibody+directed+against+human+RANTES+ameliorates+disease+in+the+Lewis+rat+adjuvant-induced+arthritis+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DD.%2BA.%26aulast%3DTse%26aufirst%3DJ.%26aulast%3DKaufhold%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DM.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DStrieter%26aufirst%3DR.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DPerez%26aufirst%3DH.%2BD.%26atitle%3DPolyclonal%2520antibody%2520directed%2520against%2520human%2520RANTES%2520ameliorates%2520disease%2520in%2520the%2520Lewis%2520rat%2520adjuvant-induced%2520arthritis%2520model%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D101%26spage%3D2910%26epage%3D2919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Haas, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span> </span><span class="NLM_article-title">Chemokine receptor expression in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3718</span><span class="NLM_x">â</span> <span class="NLM_lpage">3730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.21476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16320322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvF2jtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=3718-3730&author=C.+S.+Haasauthor=R.+J.+Martinezauthor=N.+Attiaauthor=G.+K.+Hainesauthor=P.+L.+Campbellauthor=A.+E.+Koch&title=Chemokine+receptor+expression+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor expression in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Haas, Christian S.; Martinez, Rita J.; Attia, Naweah; Haines, G. Kenneth, III; Campbell, Phillip L.; Koch, Alisa E.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3718-3730</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Chemokine receptors mediate leukocyte migration into inflamed rheumatoid arthritis (RA) synovial tissue (ST).  Knowledge of their distribution is crucial for understanding the evolution of the inflammatory process.  In this study, we used rat adjuvant-induced arthritis (AIA), a model for RA, to define the temporospatial expression of chemokine receptors.  ST from rats with AIA was immuno-stained, the percentage of cells expressing each receptor was detd., and findings were correlated with levels of inflammation.  Chemokine receptor expression was evaluated on rat macrophages in vitro.  CCR1, a receptor for macrophage inflammatory protein 1Î± (MIP-1Î±)/CCL3 and RANTES/CCL5, exhibited high constitutive expression on macrophages in AIA.  CCR5, binding MIP-1Î±/CCL3 and RANTES/CCL5, was up-regulated on ST macrophages during the course of AIA, correlating with macrophage expression of CCR2, a receptor for monocyte chemoattractant protein 1/CCL2.  Endothelial cell (EC) CCR2 was down-regulated as arthritis progressed, inversely correlating with inflammation.  CCR3, another RANTES/CCL5 receptor, was constitutively high on macrophages in vivo and in vitro, with down-regulation during AIA.  CXCR4, a receptor for stromal cell-derived factor 1/CXCL12), was prominently up-regulated on ECs, preceding the peak of inflammation.  These findings show that (1) constitutive expression of CCR1 on macrophages remains high during AIA; (2) CCR2 and CCR3 may play a role in initial recruitment of leukocytes to ST in AIA; (3) macrophage expression of CCR2 and CCR5 may be important for sustaining inflammatory changes; and (4) EC CXCR4 may be a harbinger of inflammatory changes.  The results may help guide chemokine receptor blockade-targeting treatment strategies in inflammatory arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPd5t51UwjCrVg90H21EOLACvtfcHk0lh4Socp5KHf7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvF2jtg%253D%253D&md5=b46bb398191284340b72899e04911ce4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fart.21476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21476%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DC.%2BS.%26aulast%3DMartinez%26aufirst%3DR.%2BJ.%26aulast%3DAttia%26aufirst%3DN.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DCampbell%26aufirst%3DP.%2BL.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26atitle%3DChemokine%2520receptor%2520expression%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26spage%3D3718%26epage%3D3730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinders-Blankert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">â</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1136%2Fard.2005.037176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16107514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFCjt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=294-300&author=J.+J.+Haringmanauthor=T.+J.+Smeetsauthor=P.+Reinders-Blankertauthor=P.+P.+Tak&title=Chemokine+and+chemokine+receptor+expression+in+paired+peripheral+blood+mononuclear+cells+and+synovial+tissue+of+patients+with+rheumatoid+arthritis%2C+osteoarthritis%2C+and+reactive+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis</span></div><div class="casAuthors">Haringman, J. J.; Smeets, T. J. M.; Reinders-Blankert, P.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">294-300</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Chemokine receptors and chemokines have a crucial rote in leukocyte recruitment into inflamed tissue.  To examine the expression of an extensive no. of chemokines and receptors in a unique bank of paired samples of synovial tissue (ST) and peripheral blood (PB) from patients with different forms of arthritis to assist in identifying suitable targets for therapeutic intervention.  Synovial biopsy specimens were obtained from 23 patients with rheumatoid arthritis (RA), 16 with osteoarthritis, and 8 with reactive arthritis.  ST chemokine (CCL2/MCP-1, CCL5/RANTES, CCL7/MCP-3, CCL8/MCP-2, CCL14/HCC-1, CCL15/HCC-2, CCL16/HCC-4), chemokine receptor (CCR1, CCR2b, CCR5, CXCR4), and CD13 expression was analyzed by immunohistochem. and two color immunofluorescence.  Chemokine receptor expression (CCR1, CCR3, CCR5, CCR6, CCR7) on PB cells was studied by flow cytometry.  Non-parametric tests were used for statistical anal.  Abundant expression of CCR1, CXCR4, and CCR5 was found in all forms of arthritis, with a specific increase of CCL5 and CCL15 in RA.  CCL7, CCL8, CCL14, CCL15, and CCL16 were detected for the first time in ST.  The results for PB anal. were comparable among different arthritides.  Interestingly, compared with healthy controls, significantly lower expression of CCR1 (p < 0.005) and CCR5 (p < 0.05) by PB monocytes in the patient groups was seen.  A variety of chemokines and receptors might have an important role in several inflammatory joint disorders.  Although other receptors are involved as well, migration of CCR1+ and CCR5+ cells towards the synovial compartment may play a part in the effector phase of various forms of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQKWYcbrV2VrVg90H21EOLACvtfcHk0lh4Socp5KHf7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFCjt70%253D&md5=21c7053e182323bcc45cabd1ad86ec3b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fard.2005.037176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2005.037176%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DReinders-Blankert%26aufirst%3DP.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DChemokine%2520and%2520chemokine%2520receptor%2520expression%2520in%2520paired%2520peripheral%2520blood%2520mononuclear%2520cells%2520and%2520synovial%2520tissue%2520of%2520patients%2520with%2520rheumatoid%2520arthritis%252C%2520osteoarthritis%252C%2520and%2520reactive%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2006%26volume%3D65%26spage%3D294%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Amat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamim, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terricabras, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godessart, N.</span><span> </span><span class="NLM_article-title">Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">â</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fsj.bjp.0706912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17016504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtF2jsbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=666-675&author=M.+Amatauthor=C.+F.+Benjamimauthor=L.+M.+Williamsauthor=N.+Pratsauthor=E.+Terricabrasauthor=J.+Beletaauthor=S.+L.+Kunkelauthor=N.+Godessart&title=Pharmacological+blockade+of+CCR1+ameliorates+murine+arthritis+and+alters+cytokine+networks+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo</span></div><div class="casAuthors">Amat, M.; Benjamim, C. F.; Williams, L. M.; Prats, N.; Terricabras, E.; Beleta, J.; Kunkel, S. L.; Godessart, N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">666-675</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: The chemokine receptor CCR1 is a potential target for the treatment of rheumatoid arthritis.  To explore the impact of CCR1 blockade in exptl. arthritis and the underlying mechanisms, the authors used J-113863, a nonpeptide antagonist of the mouse receptor.  Compd. J-113863 was tested in collagen-induced arthritis (CIA) and three models of acute inflammation; Staphylococcus enterotoxin B (SEB)-induced interleukin-2 (IL-2), delayed-type hypersensitivity (DTH) response, and lipopolysaccharide (LPS)-induced tumor necrosis factorÎ± (TNFÎ±) prodn.  In the LPS model, CCR1 knockout, adrenalectomized, or IL-10-depleted mice were also used.  Prodn. of TNFÎ± by mouse macrophages and human synovial membrane samples in vitro were also studied.  Treatment of arthritic mice with J-113863 improved paw inflammation and joint damage, and dramatically decreased cell infiltration into joints.  The compd. did not inhibit IL-2 or DTH, but reduced plasma TNFÎ± levels in LPS-treated mice.  Surprisingly, CCR1 knockout mice produced more TNFÎ± than controls in response to LPS, and J-113863 decreased TNFÎ± also in CCR1 null mice, indicating that its effect was unrelated to CCR1.  Adrenalectomy or neutralization of IL-10 did not prevent inhibition of TNFÎ± prodn. by J-113863.  The compd. did not inhibit mouse TNFÎ± in vitro, but did induce a trend towards increased TNFÎ± release in cells from synovial membranes of rheumatoid arthritis patients.  CCR1 blockade improves the development of CIA, probably via inhibition of inflammatory cell recruitment.  However, results from both CCR1-deficient mice and human synovial membranes suggest that, in some exptl. settings, blocking CCR1 could enhance TNF prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFvI5jX9gLZrVg90H21EOLACvtfcHk0lhj87vy5u2A7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtF2jsbrN&md5=f2ecf8d089d543ebaa5ca4210d8d210c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706912%26sid%3Dliteratum%253Aachs%26aulast%3DAmat%26aufirst%3DM.%26aulast%3DBenjamim%26aufirst%3DC.%2BF.%26aulast%3DWilliams%26aufirst%3DL.%2BM.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DTerricabras%26aufirst%3DE.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DGodessart%26aufirst%3DN.%26atitle%3DPharmacological%2520blockade%2520of%2520CCR1%2520ameliorates%2520murine%2520arthritis%2520and%2520alters%2520cytokine%2520networks%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D666%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwinderman, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">â</span> <span class="NLM_lpage">721</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1136%2Fard.62.8.715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=12860725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFWmsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2003&pages=715-721&author=J.+J.+Haringmanauthor=M.+C.+Kraanauthor=T.+J.+Smeetsauthor=K.+H.+Zwindermanauthor=P.+P.+Tak&title=Chemokine+blockade+and+chronic+inflammatory+disease%3A+proof+of+concept+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis</span></div><div class="casAuthors">Haringman, J. J.; Kraan, M. C.; Smeets, T. J. M.; Zwinderman, K. H.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">715-721</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Chemokines and their receptors are considered important contributors in cell migration and inflammation in chronic inflammatory disorders.  Chemokines affecting monocytes/macrophages are considered potential therapeutic targets, but no studies of the effects of blocking the chemokine repertoire in humans with a chronic inflammatory disease have been reported.  Objective: To carry out a double blind, placebo controlled, phase Ib clin. trial with a specific, oral CCR1 antagonist.  Methods: 16 Patients with active rheumatoid arthritis (RA) were randomized 3:1 to active:placebo treatment for 14 days.  Synovial biopsy specimens were obtained on days 1 and 15.  Immunohistochem. was used to detect the presence of various cell types before and after treatment and the results measured by digital image anal.  Results before and after treatment were compared by paired t test, and a two sample t test was used to compare the changes from baseline in the two groups.  Results: All patients completed the study.  A significant redn. in the no. of macrophages (p=0.016), intimal macrophages (p=0.026), and CCR1+cells (p=0.049) in patients treated with the chemokine antagonist compared with the placebo group occurred in the synovium.  Significant decreases in overall cellularity, intimal lining layer cellularity, CD4+ T cells, and CD8+ T cells also occurred in treated patients.  Cells lacking CCR1 were not affected.  Trends towards clin. improvement were seen in the treated patients but not in the placebo group.  Severe side effects were not reported.  Conclusion: Specific chemokine receptor blockade can result in relevant biol. effects in patients with active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPU559hSiRE7Vg90H21EOLACvtfcHk0lhj87vy5u2A7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFWmsbc%253D&md5=7f247997f6aa952c0d1513d3b79eba85</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1136%2Fard.62.8.715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.62.8.715%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DKraan%26aufirst%3DM.%2BC.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DZwinderman%26aufirst%3DK.%2BH.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DChemokine%2520blockade%2520and%2520chronic%2520inflammatory%2520disease%253A%2520proof%2520of%2520concept%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2003%26volume%3D62%26spage%3D715%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlow, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evanoff, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">772</span><span class="NLM_x">â</span> <span class="NLM_lpage">779</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=772-779&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=L.+A.+Harlowauthor=B.+Johnsonauthor=H.+L.+Evanoffauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Enhanced+production+of+monocyte+chemoattractant+protein-1+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DHarlow%26aufirst%3DL.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DEvanoff%26aufirst%3DH.%2BL.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DEnhanced%2520production%2520of%2520monocyte%2520chemoattractant%2520protein-1%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1992%26volume%3D90%26spage%3D772%26epage%3D779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Villiger, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terkeltaub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, M.</span><span> </span><span class="NLM_article-title">Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">â</span> <span class="NLM_lpage">496</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=488-496&author=P.+M.+Villigerauthor=R.+Terkeltaubauthor=M.+Lotz&title=Monocyte+chemoattractant+protein-1+%28MCP-1%29+expression+in+human+articular+cartilage.+Induction+by+peptide+regulatory+factors+and+differential+effects+of+dexamethasone+and+retinoic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilliger%26aufirst%3DP.%2BM.%26aulast%3DTerkeltaub%26aufirst%3DR.%26aulast%3DLotz%26aufirst%3DM.%26atitle%3DMonocyte%2520chemoattractant%2520protein-1%2520%2528MCP-1%2529%2520expression%2520in%2520human%2520articular%2520cartilage.%2520Induction%2520by%2520peptide%2520regulatory%2520factors%2520and%2520differential%2520effects%2520of%2520dexamethasone%2520and%2520retinoic%2520acid%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1992%26volume%3D90%26spage%3D488%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Katschke, K. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruth, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponath, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span> </span><span class="NLM_article-title">Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">â</span> <span class="NLM_lpage">1032</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2F1529-0131%28200105%2944%3A5%3C1022%3A%3AAID-ANR181%3E3.0.CO%3B2-N" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11352233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1M%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1022-1032&author=K.+J.+Katschkeauthor=J.+B.+Rottmanauthor=J.+H.+Ruthauthor=S.+Qinauthor=L.+Wuauthor=G.+LaRosaauthor=P.+Ponathauthor=C.+C.+Parkauthor=R.+M.+Popeauthor=A.+E.+Koch&title=Differential+expression+of+chemokine+receptors+on+peripheral+blood%2C+synovial+fluid%2C+and+synovial+tissue+monocytes%2Fmacrophages+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis</span></div><div class="casAuthors">Katschke, Kenneth J., Jr.; Rottman, James B.; Ruth, Jeffrey H.; Qin, Shixin; Wu, Lijun; LaRosa, Gregory; Ponath, Paul; Park, Christy C.; Pope, Richard M.; Koch, Alisa E.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1022-1032</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Since it is likely that monocytes utilize chemokines to migrate to the rheumatoid arthritis (RA) joint, the authors investigated the expression of C-C chemokine receptors (CCR) 1-6 and C-X-C receptor 3 (CXCR3) in the peripheral blood (PB), synovial fluid (SF), and synovial tissue of patients with RA as well as in the PB of normal subjects.  The authors compared chemokine receptor expression on CD14+ monocytes from normal PB, RA PB, and RA SF using 2-color flow cytometry.  Correlations with patient clin. data were detd.  Chemokine and receptor expression were investigated in RA synovial tissue by immunohistochem. and 2-color immunofluorescence to identify CD68+ macrophages.  Most normal PB monocytes expressed CCR1 (87%) and CCR2 (84%), but not CCRs 3, 4, 5, or 6 or CXCR3.  RA PB monocytes expressed CCR1 (56%) and CCR2 (76%), with significantly more expressing CCR3 (18%), CCR4 (38%), and CCR5 (17%) compared with normal PB monocytes.  Significantly fewer SF monocytes from RA patients expressed CCR1 (17%), CCR2 (24%), and CCR4 (6%) while significantly more expressed CCR3 (35%) and CCR5 (47%) compared with RA and normal PB monocytes; CCR6 and CXCR3 were rarely detected.  Clin., the erythrocyte sedimentation rate was inversely correlated with the expression of CCR1 and CCR4 by RA PB, and CCR5 expression by RA SF was correlated with the SF white blood cell count.  CCR1-, CCR2-, and CCR5-immunoreactive cells were found in RA synovial tissue and colocalized with CD68+ macrophages.  RA synovial tissue RANTES (regulated upon activation, normally T cell expressed and secreted chemokine)- and monocyte chemoattractant protein 1-immunoreactive cells colocalized with CCR1 and CCR2, resp., on serial sections.  Macrophage inflammatory protein 1Î± (MIP-1Î±) was principally restricted to vascular endothelium, and MIP-1Î²+ macrophages were found throughout the sections.  Monocytes mainly express CCR1 and CCR2 in normal and RA PB, CCR3 and CCR5 in RA PB and RA SF, and CCR4 in RA PB.  The differential expression of chemokine receptors suggests that certain receptors aid in monocyte recruitment from the circulation while others are important in monocyte retention in the joint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ-GDTU1Qjx7Vg90H21EOLACvtfcHk0lhj87vy5u2A7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1M%253D&md5=7f946d9bc0bfd58a8149ae2537128d4c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F1529-0131%28200105%2944%3A5%3C1022%3A%3AAID-ANR181%3E3.0.CO%3B2-N&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1529-0131%2528200105%252944%253A5%253C1022%253A%253AAID-ANR181%253E3.0.CO%253B2-N%26sid%3Dliteratum%253Aachs%26aulast%3DKatschke%26aufirst%3DK.%2BJ.%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DRuth%26aufirst%3DJ.%2BH.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLaRosa%26aufirst%3DG.%26aulast%3DPonath%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DC.%2BC.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26atitle%3DDifferential%2520expression%2520of%2520chemokine%2520receptors%2520on%2520peripheral%2520blood%252C%2520synovial%2520fluid%252C%2520and%2520synovial%2520tissue%2520monocytes%252Fmacrophages%2520in%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2001%26volume%3D44%26spage%3D1022%26epage%3D1032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evanhoff, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Synovial tissue macrophage as a source of the chemotactic cytokine IL-8</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">2187</span><span class="NLM_x">â</span> <span class="NLM_lpage">2195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=1991&pages=2187-2195&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=J.+C.+Burrowsauthor=H.+L.+Evanhoffauthor=G.+K.+Hainesauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Synovial+tissue+macrophage+as+a+source+of+the+chemotactic+cytokine+IL-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DBurrows%26aufirst%3DJ.%2BC.%26aulast%3DEvanhoff%26aufirst%3DH.%2BL.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DSynovial%2520tissue%2520macrophage%2520as%2520a%2520source%2520of%2520the%2520chemotactic%2520cytokine%2520IL-8%26jtitle%3DJ.%2520Immunol.%26date%3D1991%26volume%3D147%26spage%3D2187%26epage%3D2195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halloran, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">3660</span><span class="NLM_x">â</span> <span class="NLM_lpage">3666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=3660-3666&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=M.+R.+Shahauthor=S.+Hosakaauthor=M.+M.+Halloranauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Growth-related+gene+product+alpha.+A+chemotactic+cytokine+for+neutrophils+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DShah%26aufirst%3DM.%2BR.%26aulast%3DHosaka%26aufirst%3DS.%26aulast%3DHalloran%26aufirst%3DM.%2BM.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DGrowth-related%2520gene%2520product%2520alpha.%2520A%2520chemotactic%2520cytokine%2520for%2520neutrophils%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26spage%3D3660%26epage%3D3666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Patel, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachariah, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whichard, L. P.</span><span> </span><span class="NLM_article-title">CXCR3 and CCR5 ligands in rheumatoid arthritis synovium</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1006%2Fclim.2000.4957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11141325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1Wis78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=39-45&author=D.+D.+Patelauthor=J.+P.+Zachariahauthor=L.+P.+Whichard&title=CXCR3+and+CCR5+ligands+in+rheumatoid+arthritis+synovium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR3 and CCR5 ligands in rheumatoid arthritis synovium</span></div><div class="casAuthors">Patel, Dhavalkumar D.; Zachariah, Jason P.; Whichard, Leona P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Orlando, Florida)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-45</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The pathogenesis of rheumatoid arthritis (RA) may be mediated by Th1-type T cells.  Since chemokine receptors CXCR3 and CCR5 are preferentially expressed on Th1 cells, we tested the expression and regulation of several chemokines, including those that signal through CXCR3 (interferon-Î³-inducible protein of 10 kDa, IP-10, CXCL10; and monokine induced by interferon-Î³, Mig, CXCL9) and CCR5 (macrophage inflammatory protein (Mip)-1Î±, CCL3; and Mip-1Î², CCL4) in RA synovial fluids, synovial tissues, and blood.  Synovial fluid (SF) protein levels of IP-10 (32.1 Â± 10.5 ng/mL), Mig (15.0 Â± 6.4 ng/mL), Mip-1Î² (0.7 Â± 0.3 ng/mL), and Mip-1Î± (0.8 Â± 0.1 ng/mL) were 100-, 50-, 25-, and 2-fold elevated in RASF compared to control SF (P < 0.001, P < 0.001, P < 0.001, and P < 0.02, resp.).  Tissue levels of IP-10, Mig, and Mip-1Î² were significantly higher in RA than in OA (P < 0.01).  Serum levels of IP-10 (3.1 Â± 1.2 ng/mL) were higher in patients with seropos. RA compared to controls (1.2 Â± 0.2 ng/mL) (P < 0.02).  There was a gradient of IP-10, Mig, Mip-1Î±, and Mip-1Î² from the blood into the synovial fluid in RA.  Infiltrating T cells around high endothelial venules in RA synovium and 90 Â± 3% of SF CD3+CD4+ T cells expressed CXCR3, and 85 Â± 2% of SF CD3+CD4+ T cells expressed CCR5.  Chemokines, including IP-10, Mig, Mip-1Î±, and Mip-1Î², may participate in the selective recruitment of CCR5+CXCR3+ T cells to the inflamed synovium.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLszSt-Oyv87Vg90H21EOLACvtfcHk0lgkT4ceigsLUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1Wis78%253D&md5=7c010f394ed3d7e247c2ddf7ef9322ec</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1006%2Fclim.2000.4957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fclim.2000.4957%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DD.%2BD.%26aulast%3DZachariah%26aufirst%3DJ.%2BP.%26aulast%3DWhichard%26aufirst%3DL.%2BP.%26atitle%3DCXCR3%2520and%2520CCR5%2520ligands%2520in%2520rheumatoid%2520arthritis%2520synovium%26jtitle%3DClin.%2520Immunol.%26date%3D2001%26volume%3D98%26spage%3D39%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Kim, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisvert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, E. C.</span><span> </span><span class="NLM_article-title">Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">â</span> <span class="NLM_lpage">601</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2001&pages=595-601&author=C.+H.+Kimauthor=E.+J.+Kunkelauthor=J.+Boisvertauthor=B.+Johnstonauthor=J.+J.+Campbellauthor=M.+C.+Genoveseauthor=H.+B.+Greenbergauthor=E.+C.+Butcher&title=Bonzo%2FCXCR6+expression+defines+type+1-polarized+T-cell+subsets+with+extralymphoid+tissue+homing+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DKunkel%26aufirst%3DE.%2BJ.%26aulast%3DBoisvert%26aufirst%3DJ.%26aulast%3DJohnston%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DJ.%2BJ.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenberg%26aufirst%3DH.%2BB.%26aulast%3DButcher%26aufirst%3DE.%2BC.%26atitle%3DBonzo%252FCXCR6%2520expression%2520defines%2520type%25201-polarized%2520T-cell%2520subsets%2520with%2520extralymphoid%2520tissue%2520homing%2520potential%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2001%26volume%3D107%26spage%3D595%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Kay, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phipps, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. S.</span><span> </span><span class="NLM_article-title">A role for eosinophils in airway remodelling in asthma</span> <span class="citation_source-journal">Trends Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">â</span> <span class="NLM_lpage">482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.it.2004.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15324740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFWmu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=477-482&author=A.+B.+Kayauthor=S.+Phippsauthor=D.+S.+Robinson&title=A+role+for+eosinophils+in+airway+remodelling+in+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A role for eosinophils in airway remodelling in asthma</span></div><div class="casAuthors">Kay, A. Barry; Phipps, Simon; Robinson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the years, the role of the eosinophil in asthma and allergic processes has been disputed.  Recent human expts. using a humanized monoclonal antibody to interleukin-5 (IL-5), and animal studies involving specific IL-5 gene deletion, indicates that eosinophils might control downstream repair and remodelling processes.  Eosinophils are a rich source of fibrogenic factors, particularly transforming growth factor-Î² (TGF-Î²), the latent form of which is activated by epithelial-cell expression of the integrin Î±vÎ²6.  The emerging role for the eosinophil in airway remodelling might be important in future anti-asthma strategies.  However, more effective eosinophil-depleting agents than anti-IL-5 are required before the definitive role of this cell type in asthma airway pathophysiol. can be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogri2K-7lQrrVg90H21EOLACvtfcHk0ljhEOIhi61n5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFWmu70%253D&md5=ca49cd95134e9b00d3e2c34f73f2d6ae</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2004.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2004.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DKay%26aufirst%3DA.%2BB.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DD.%2BS.%26atitle%3DA%2520role%2520for%2520eosinophils%2520in%2520airway%2520remodelling%2520in%2520asthma%26jtitle%3DTrends%2520Immunol.%26date%3D2004%26volume%3D25%26spage%3D477%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Toda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S. J.</span><span> </span><span class="NLM_article-title">Impact of engagement of FcepsilonRI and CC chemokine receptor 1 on mast cell activation and motility</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">48443</span><span class="NLM_x">â</span> <span class="NLM_lpage">48448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=48443-48448&author=M.+Todaauthor=M.+Dawsonauthor=T.+Nakamuraauthor=P.+M.+Munroauthor=R.+M.+Richardsonauthor=M.+Baillyauthor=S.+J.+Ono&title=Impact+of+engagement+of+FcepsilonRI+and+CC+chemokine+receptor+1+on+mast+cell+activation+and+motility"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DMunro%26aufirst%3DP.%2BM.%26aulast%3DRichardson%26aufirst%3DR.%2BM.%26aulast%3DBailly%26aufirst%3DM.%26aulast%3DOno%26aufirst%3DS.%2BJ.%26atitle%3DImpact%2520of%2520engagement%2520of%2520FcepsilonRI%2520and%2520CC%2520chemokine%2520receptor%25201%2520on%2520mast%2520cell%2520activation%2520and%2520motility%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D48443%26epage%3D48448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Miyazaki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung-Chau, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S. J.</span><span> </span><span class="NLM_article-title">Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">434</span><span class="NLM_x">â</span> <span class="NLM_lpage">442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=434-442&author=D.+Miyazakiauthor=T.+Nakamuraauthor=M.+Todaauthor=K.+W.+Cheung-Chauauthor=R.+M.+Richardsonauthor=S.+J.+Ono&title=Macrophage+inflammatory+protein-1alpha+as+a+costimulatory+signal+for+mast+cell-mediated+immediate+hypersensitivity+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DToda%26aufirst%3DM.%26aulast%3DCheung-Chau%26aufirst%3DK.%2BW.%26aulast%3DRichardson%26aufirst%3DR.%2BM.%26aulast%3DOno%26aufirst%3DS.%2BJ.%26atitle%3DMacrophage%2520inflammatory%2520protein-1alpha%2520as%2520a%2520costimulatory%2520signal%2520for%2520mast%2520cell-mediated%2520immediate%2520hypersensitivity%2520reactions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D434%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Power, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alouani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark-Lewis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span> </span><span class="NLM_article-title">Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">â</span> <span class="NLM_lpage">835</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=1997&pages=825-835&author=C.+A.+Powerauthor=D.+J.+Churchauthor=A.+Meyerauthor=S.+Alouaniauthor=A.+E.+Proudfootauthor=I.+Clark-Lewisauthor=S.+Sozzaniauthor=A.+Mantovaniauthor=T.+N.+Wells&title=Cloning+and+characterization+of+a+specific+receptor+for+the+novel+CC+chemokine+MIP-3alpha+from+lung+dendritic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPower%26aufirst%3DC.%2BA.%26aulast%3DChurch%26aufirst%3DD.%2BJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DClark-Lewis%26aufirst%3DI.%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DCloning%2520and%2520characterization%2520of%2520a%2520specific%2520receptor%2520for%2520the%2520novel%2520CC%2520chemokine%2520MIP-3alpha%2520from%2520lung%2520dendritic%2520cells%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1997%26volume%3D186%26spage%3D825%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Pilette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durham, S. R.</span><span> </span><span class="NLM_article-title">CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">884</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1183%2F09031936.04.00102504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15219001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsF2qtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=876-884&author=C.+Piletteauthor=J.+N.+Francisauthor=S.+J.+Tillauthor=S.+R.+Durham&title=CCR4+ligands+are+up-regulated+in+the+airways+of+atopic+asthmatics+after+segmental+allergen+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge</span></div><div class="casAuthors">Pilette, C.; Francis, J. N.; Till, S. J.; Durham, S. R.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">876-882</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">T-helper (Th) 2 cytokines are thought to mediate most features of allergic inflammation in atopic asthma.  However, it remains unclear whether chemokine pathways direct selective recruitment of Th2 cells to the airways during human allergic responses.  Bronchoalveolar lavage (BAL) was performed in 15 non-smoking mild atopic asthmatics before and 24 h after a fiberoptic segmental allergen challenge, and chemokines related to T-cell recruitment were assayed by ELISA.  The Th2-related C-C chemokine (CCR)4 ligands, macrophage-derived chemokine/C-C chemokine ligand (CCL)22 and thymus and activation-regulated chemokine/CCL17, were increased in BAL after challenge.  These chemokines correlated with lymphocyte nos. and with interleukin (IL)-5 and IL-13 in post-challenge BAL.  In contrast, 2 out of 3 putative Th1-related chemokines did not change.  There were no alterations in monokine induced by interferon (IFN)-Î³/CXC chemokine ligand (CXCL)9 or macrophage inflammatory protein-1Î±/CCL3; whereas an increase in IFN-induced protein-10 kDa/CXCL10 was obsd., which did not correlate with the T-cell influx.  In peripheral mononuclear cells from atopic donors, CCL22 and CCL17 were induced by IL-4 and IL-13, further supporting the relation between CCL22/CCL17 and Th2 cytokines.  Finally, CCL22 was able to trigger actin polymn. in peripheral CD4+ T-cells expressing CCR4.  Thus, CCR4 ligands are up-regulated in the airways of atopic asthmatics following allergen exposure, contribute to the T-cell influx to the airways, and are closely related to the Th2-cytokine response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxovHfR7rtPLVg90H21EOLACvtfcHk0ljhEOIhi61n5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsF2qtLo%253D&md5=465701fdcf4b858e0f863c045c36d9cd</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00102504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00102504%26sid%3Dliteratum%253Aachs%26aulast%3DPilette%26aufirst%3DC.%26aulast%3DFrancis%26aufirst%3DJ.%2BN.%26aulast%3DTill%26aufirst%3DS.%2BJ.%26aulast%3DDurham%26aufirst%3DS.%2BR.%26atitle%3DCCR4%2520ligands%2520are%2520up-regulated%2520in%2520the%2520airways%2520of%2520atopic%2520asthmatics%2520after%2520segmental%2520allergen%2520challenge%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D23%26spage%3D876%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Panina-Bordignon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Lucia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellettato, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonsanti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miotto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrigoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinigaglia, F.</span><span> </span><span class="NLM_article-title">The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1357</span><span class="NLM_x">â</span> <span class="NLM_lpage">1364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2001&pages=1357-1364&author=P.+Panina-Bordignonauthor=A.+Papiauthor=M.+Marianiauthor=P.+Di+Luciaauthor=G.+Casoniauthor=C.+Bellettatoauthor=C.+Buonsantiauthor=D.+Miottoauthor=C.+Mappauthor=A.+Villaauthor=G.+Arrigoniauthor=L.+M.+Fabbriauthor=F.+Sinigaglia&title=The+C-C+chemokine+receptors+CCR4+and+CCR8+identify+airway+T+cells+of+allergen-challenged+atopic+asthmatics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPanina-Bordignon%26aufirst%3DP.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DM.%26aulast%3DDi%2BLucia%26aufirst%3DP.%26aulast%3DCasoni%26aufirst%3DG.%26aulast%3DBellettato%26aufirst%3DC.%26aulast%3DBuonsanti%26aufirst%3DC.%26aulast%3DMiotto%26aufirst%3DD.%26aulast%3DMapp%26aufirst%3DC.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DArrigoni%26aufirst%3DG.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DSinigaglia%26aufirst%3DF.%26atitle%3DThe%2520C-C%2520chemokine%2520receptors%2520CCR4%2520and%2520CCR8%2520identify%2520airway%2520T%2520cells%2520of%2520allergen-challenged%2520atopic%2520asthmatics%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2001%26volume%3D107%26spage%3D1357%26epage%3D1364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Mutalithas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raport, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolbeck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brightling, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavord, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardlaw, A. J.</span><span> </span><span class="NLM_article-title">Expression of CCR8 is increased in asthma</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1175</span><span class="NLM_x">â</span> <span class="NLM_lpage">1185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1365-2222.2010.03504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20455898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGlsbzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=1175-1185&author=K.+Mutalithasauthor=C.+Guillenauthor=C.+Raportauthor=R.+Kolbeckauthor=D.+Solerauthor=C.+E.+Brightlingauthor=I.+D.+Pavordauthor=A.+J.+Wardlaw&title=Expression+of+CCR8+is+increased+in+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of CCR8 is increased in asthma</span></div><div class="casAuthors">Mutalithas, K.; Guillen, C.; Raport, C.; Kolbeck, R.; Soler, D.; Brightling, C. E.; Pavord, I. D.; Wardlaw, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Allergy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1175-1185</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background Chemokines and their receptors could play key roles in the recruitment of T cells to the asthmatic lung.  CCR8 is preferentially expressed on T-helper type 2 cells, and is thought to play a role in the pathogenesis of human asthma.  Objective Det. the expression of CCR8 on T cells in blood, bronchoalveolar lavage (BAL) and bronchial mucosa from asthmatics and normal subjects.  Methods CCR8 expression in blood and BAL from asthma and normal subjects was studied using flow cytometry.  CCR8 expression on IFN-Î³+ and IL-4+/IL-13+ blood and BALT cells was studied following stimulation with Phorbol-Myristate-Acetate and Calcium Ionophore.  Paraffin-embedded bronchial biopsies were used to study CCR8 in bronchial epithelium.  Results The percentage of CD3+ cells expressing CCR8 in the blood was higher in asthmatics (4.7Â±0.4%) compared with normal subjects (3.0Â±0.4%; P<0.01).  There was an approx. sixfold enrichment of CCR8 on IL-4+/IL-13+ cells compared with IFN-Î³+ T cells (P<0.001) in both asthmatic and normal subjects in both blood and BAL.  Significantly more BAL T cells expressed CCR8 in asthmatic (8.6Â±0.8%) compared with normal subjects (3.9Â±0.7%) (P<0.01).  In paired blood-BAL samples from asthmatics, significantly more CCR8+CD3+ T cells were present in BAL (9.0Â±0.9%) than in blood (5.6Â±0.9%; P<0.05).  There were more CCR8-pos. cells in bronchial biopsies from asthmatic (93Â±11 cells/mm2) compared with normal subjects (30Â±16 cells/mm2) (P<0.05).  The ligand CCL1 was increased in the BAL of asthmatics compared with normal subjects (35Â±6 vs. 12.9Â±7 pg/mL; P<0.05).  Conclusion There may be a role for CCR8 in the recruitment of T cells to the lung in asthmatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoagMgrbtncLVg90H21EOLACvtfcHk0lhK3oQOkSL-9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGlsbzP&md5=67f8ec3d746b375053c33a59c07aff8c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2010.03504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2010.03504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMutalithas%26aufirst%3DK.%26aulast%3DGuillen%26aufirst%3DC.%26aulast%3DRaport%26aufirst%3DC.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DBrightling%26aufirst%3DC.%2BE.%26aulast%3DPavord%26aufirst%3DI.%2BD.%26aulast%3DWardlaw%26aufirst%3DA.%2BJ.%26atitle%3DExpression%2520of%2520CCR8%2520is%2520increased%2520in%2520asthma%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2010%26volume%3D40%26spage%3D1175%26epage%3D1185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Ying, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ringler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daugherty, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durham, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A. B.</span><span> </span><span class="NLM_article-title">Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">â</span> <span class="NLM_lpage">3516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=3507-3516&author=S.+Yingauthor=D.+S.+Robinsonauthor=Q.+Mengauthor=J.+Rottmanauthor=R.+Kennedyauthor=D.+J.+Ringlerauthor=C.+R.+Mackayauthor=B.+L.+Daughertyauthor=M.+S.+Springerauthor=S.+R.+Durhamauthor=T.+J.+Williamsauthor=A.+B.+Kay&title=Enhanced+expression+of+eotaxin+and+CCR3+mRNA+and+protein+in+atopic+asthma.+Association+with+airway+hyperresponsiveness+and+predominant+co-localization+of+eotaxin+mRNA+to+bronchial+epithelial+and+endothelial+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DD.%2BS.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DRottman%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DR.%26aulast%3DRingler%26aufirst%3DD.%2BJ.%26aulast%3DMackay%26aufirst%3DC.%2BR.%26aulast%3DDaugherty%26aufirst%3DB.%2BL.%26aulast%3DSpringer%26aufirst%3DM.%2BS.%26aulast%3DDurham%26aufirst%3DS.%2BR.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DKay%26aufirst%3DA.%2BB.%26atitle%3DEnhanced%2520expression%2520of%2520eotaxin%2520and%2520CCR3%2520mRNA%2520and%2520protein%2520in%2520atopic%2520asthma.%2520Association%2520with%2520airway%2520hyperresponsiveness%2520and%2520predominant%2520co-localization%2520of%2520eotaxin%2520mRNA%2520to%2520bronchial%2520epithelial%2520and%2520endothelial%2520cells%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1997%26volume%3D27%26spage%3D3507%26epage%3D3516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Ying, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeibecoglou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macfarlane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A. B.</span><span> </span><span class="NLM_article-title">Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">6321</span><span class="NLM_x">â</span> <span class="NLM_lpage">6329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10570327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1MXns12rtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1999&pages=6321-6329&author=S.+Yingauthor=Q.+Mengauthor=K.+Zeibecoglouauthor=D.+S.+Robinsonauthor=A.+Macfarlaneauthor=M.+Humbertauthor=A.+B.+Kay&title=Eosinophil+chemotactic+chemokines+%28eotaxin%2C+eotaxin-2%2C+RANTES%2C+monocyte+chemoattractant+protein-3+%28MCP-3%29%2C+and+MCP-4%29%2C+and+C-C+chemokine+receptor+3+expression+in+bronchial+biopsies+from+atopic+and+nonatopic+%28intrinsic%29+asthmatics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C Chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics</span></div><div class="casAuthors">Ying, Sun; Meng, Qiu; Zeibecoglou, Kyriaki; Robinson, Douglas S.; Macfarlane, Alison; Humbert, Marc; Kay, A. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6321-6329</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Atopic (AA) and nonatopic (NAA) asthma are characterized by chronic inflammation and local tissue eosinophilia.  Many C-C chemokines are potent eosinophil chemoattractants and act predominantly via the CCR3.  The authors examd. the expression of eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), MCP-4, and CCR3 in the bronchial mucosa from atopic (AA) and nonatopic (intrinsic; NAA) asthmatics and compared their findings with atopic (AC) and nonatopic non-asthmatic controls (NC).  Cryostat sections were processed for immunohistochem. (IHC), in situ hybridization (ISH), and double IHC/ISH.  Compared with AC and NC, the nos. of EG2+ cells and the cells expressing mRNA for eotaxin, eotaxin-2, RANTES, MCP-3, MCP-4, and CCR3 were increased in AA and NAA.  Nonsignificant differences in these variants were obsd. between AA and NAA and between AC and NC.  Correlations between the cells expressing eotaxin or CCR3 and EG2+ eosinophils in the bronchial tissue were also obsd. for both AA and NAA.  Moreover, in the total asthmatic group (AA + NAA) there was an inverse correlation between the expression of eotaxin and that of the histamine PC20.  Sequential IHC/ISH showed that cytokeratin+ epithelial cells, CD31+ endothelial cells, and CD68+ macrophages were the major sources of eotaxin, eotaxin-2, RANTES, MCP-3, and MCP-4.  There was no different distribution of cells expressing mRNA for these chemokines between atopic and nonatopic asthma.  Thus, multiple C-C chemokines, acting at least in part via CCR3, contribute to bronchial eosinophilia in both atopic and nonatopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHTNwkvqpJbLVg90H21EOLACvtfcHk0lhK3oQOkSL-9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns12rtb4%253D&md5=d3c7f1b65877ea74177bd6e6dfef2dcc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DZeibecoglou%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DD.%2BS.%26aulast%3DMacfarlane%26aufirst%3DA.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DKay%26aufirst%3DA.%2BB.%26atitle%3DEosinophil%2520chemotactic%2520chemokines%2520%2528eotaxin%252C%2520eotaxin-2%252C%2520RANTES%252C%2520monocyte%2520chemoattractant%2520protein-3%2520%2528MCP-3%2529%252C%2520and%2520MCP-4%2529%252C%2520and%2520C-C%2520chemokine%2520receptor%25203%2520expression%2520in%2520bronchial%2520biopsies%2520from%2520atopic%2520and%2520nonatopic%2520%2528intrinsic%2529%2520asthmatics%26jtitle%3DJ.%2520Immunol.%26date%3D1999%26volume%3D163%26spage%3D6321%26epage%3D6329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Yamada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, Y.</span><span> </span><span class="NLM_article-title">Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum</span> <span class="citation_source-journal">Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">â</span> <span class="NLM_lpage">397</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=392-397&author=H.+Yamadaauthor=M.+Yamaguchiauthor=K.+Yamamotoauthor=T.+Nakajimaauthor=K.+Hiraiauthor=Y.+Moritaauthor=Y.+Sano&title=Eotaxin+in+induced+sputum+of+asthmatics%3A+relationship+with+eosinophils+and+eosinophil+cationic+protein+in+sputum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DHirai%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DY.%26aulast%3DSano%26aufirst%3DY.%26atitle%3DEotaxin%2520in%2520induced%2520sputum%2520of%2520asthmatics%253A%2520relationship%2520with%2520eosinophils%2520and%2520eosinophil%2520cationic%2520protein%2520in%2520sputum%26jtitle%3DAllergy%26date%3D2000%26volume%3D55%26spage%3D392%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Sallusto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanzavecchia, A.</span><span> </span><span class="NLM_article-title">Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">â</span> <span class="NLM_lpage">2007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=2005-2007&author=F.+Sallustoauthor=C.+R.+Mackayauthor=A.+Lanzavecchia&title=Selective+expression+of+the+eotaxin+receptor+CCR3+by+human+T+helper+2+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSallusto%26aufirst%3DF.%26aulast%3DMackay%26aufirst%3DC.%2BR.%26aulast%3DLanzavecchia%26aufirst%3DA.%26atitle%3DSelective%2520expression%2520of%2520the%2520eotaxin%2520receptor%2520CCR3%2520by%2520human%2520T%2520helper%25202%2520cells%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D2005%26epage%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Mantovani, A.</span><span> </span><span class="NLM_article-title">The chemokine system: redundancy for robust outputs</span> <span class="citation_source-journal">Immunol. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0167-5699%2899%2901469-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10354549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVGrsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=254-257&author=A.+Mantovani&title=The+chemokine+system%3A+redundancy+for+robust+outputs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The chemokine system: redundancy for robust outputs</span></div><div class="casAuthors">Mantovani, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Today</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">254-257</span>CODEN:
                <span class="NLM_cas:coden">IMTOD8</span>;
        ISSN:<span class="NLM_cas:issn">0167-4919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review and discussion with 39 refs.  Chemokines are redundant in their action on target cells and promiscuous in receptor usage.  Moreover, certain cells concomitantly produce several chemokines with an overlapping spectrum of action.  Here, the author argues that such robustness provides a conceptual framework to understand these intriguing aspects of the chemokine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LLmCSctuuLVg90H21EOLACvtfcHk0lh62Z9MhKTotA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVGrsLo%253D&md5=90752c5cf7c7ddc626934d079b0c565c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS0167-5699%2899%2901469-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-5699%252899%252901469-3%26sid%3Dliteratum%253Aachs%26aulast%3DMantovani%26aufirst%3DA.%26atitle%3DThe%2520chemokine%2520system%253A%2520redundancy%2520for%2520robust%2520outputs%26jtitle%3DImmunol.%2520Today%26date%3D1999%26volume%3D20%26spage%3D254%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csizmadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">â</span> <span class="NLM_lpage">44</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2000&pages=35-44&author=W.+Gaoauthor=P.+S.+Tophamauthor=J.+A.+Kingauthor=S.+T.+Smileyauthor=V.+Csizmadiaauthor=B.+Luauthor=C.+J.+Gerardauthor=W.+W.+Hancock&title=Targeting+of+the+chemokine+receptor+CCR1+suppresses+development+of+acute+and+chronic+cardiac+allograft+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26aulast%3DTopham%26aufirst%3DP.%2BS.%26aulast%3DKing%26aufirst%3DJ.%2BA.%26aulast%3DSmiley%26aufirst%3DS.%2BT.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DGerard%26aufirst%3DC.%2BJ.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DTargeting%2520of%2520the%2520chemokine%2520receptor%2520CCR1%2520suppresses%2520development%2520of%2520acute%2520and%2520chronic%2520cardiac%2520allograft%2520rejection%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D105%26spage%3D35%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavin, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2372</span><span class="NLM_x">â</span> <span class="NLM_lpage">2377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2000&pages=2372-2377&author=J.+B.+Rottmanauthor=A.+J.+Slavinauthor=R.+Silvaauthor=H.+L.+Weinerauthor=C.+G.+Gerardauthor=W.+W.+Hancock&title=Leukocyte+recruitment+during+onset+of+experimental+allergic+encephalomyelitis+is+CCR1+dependent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DSlavin%26aufirst%3DA.%2BJ.%26aulast%3DSilva%26aufirst%3DR.%26aulast%3DWeiner%26aufirst%3DH.%2BL.%26aulast%3DGerard%26aufirst%3DC.%2BG.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DLeukocyte%2520recruitment%2520during%2520onset%2520of%2520experimental%2520allergic%2520encephalomyelitis%2520is%2520CCR1%2520dependent%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2000%26volume%3D30%26spage%3D2372%26epage%3D2377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Potteaux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combadiere, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esposito, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merval, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardouin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedgui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallat, Z.</span><span> </span><span class="NLM_article-title">Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice</span> <span class="citation_source-journal">Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">â</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2119%2F2005-00028.Potteaux" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16491201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVelsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=16-20&author=S.+Potteauxauthor=C.+Combadiereauthor=B.+Espositoauthor=S.+Casanovaauthor=R.+Mervalauthor=P.+Ardouinauthor=J.+L.+Gaoauthor=P.+M.+Murphyauthor=A.+Tedguiauthor=Z.+Mallat&title=Chemokine+receptor+CCR1+disruption+in+bone+marrow+cells+enhances+atherosclerotic+lesion+development+and+inflammation+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice</span></div><div class="casAuthors">Potteaux, Stephane; Combadiere, Christophe; Esposito, Bruno; Casanova, Saveria; Merval, Regine; Ardouin, Patrice; Gao, Ji-Liang; Murphy, Philip M.; Tedgui, Alain; Mallat, Ziad</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Manhasset, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1-12</span>),
    <span class="NLM_cas:pages">16-20</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Feinstein Institute for Medical Research</span>)
        </div><div class="casAbstract">Several chemokines or chemokine receptors are involved in atherogenesis.  CCR1 is expressed by macrophages and lymphocytes, two major cell types involved in the progression of atherosclerosis, and binds to lesion-expressed ligands.  We examd. the direct role of the blood-borne chemokine receptor CCR1 in atherosclerosis by transplanting bone marrow cells from either CCR1+/+ or CCR1-/- mice into low-d. lipoprotein-receptor (LDLr)-deficient mice.  After exposure to an atherogenic diet for 8 wk, no differences in fatty streak size or compn. were detected between the 2 groups.  After 12 wk of atherogenic diet, however, an unexpected 70% increase in atherosclerotic lesion size in the thoracic aorta was detected in the CCR1-/- mice, accompanied by a 37% increase in the aortic sinus lesion area.  CCR1-/- mice showed enhanced basal and Con A-stimulated IFN-Î³ prodn. by spleen T cells and enhanced plaque inflammation.  In conclusion, blood-borne CCR1 alters the immuno-inflammatory response in atherosclerosis and prevents excessive plaque growth and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMKMl3uIv1h7Vg90H21EOLACvtfcHk0lh62Z9MhKTotA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVelsr8%253D&md5=768117a187d37f0f7d1211a2de7d9533</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2119%2F2005-00028.Potteaux&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252F2005-00028.Potteaux%26sid%3Dliteratum%253Aachs%26aulast%3DPotteaux%26aufirst%3DS.%26aulast%3DCombadiere%26aufirst%3DC.%26aulast%3DEsposito%26aufirst%3DB.%26aulast%3DCasanova%26aufirst%3DS.%26aulast%3DMerval%26aufirst%3DR.%26aulast%3DArdouin%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DTedgui%26aufirst%3DA.%26aulast%3DMallat%26aufirst%3DZ.%26atitle%3DChemokine%2520receptor%2520CCR1%2520disruption%2520in%2520bone%2520marrow%2520cells%2520enhances%2520atherosclerotic%2520lesion%2520development%2520and%2520inflammation%2520in%2520mice%26jtitle%3DMol.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D16%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Boring, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chensue, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farese, R. V.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broxmeyer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2552</span><span class="NLM_x">â</span> <span class="NLM_lpage">2561</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1997&pages=2552-2561&author=L.+Boringauthor=J.+Goslingauthor=S.+W.+Chensueauthor=S.+L.+Kunkelauthor=R.+V.+Fareseauthor=H.+E.+Broxmeyerauthor=I.+F.+Charo&title=Impaired+monocyte+migration+and+reduced+type+1+%28Th1%29+cytokine+responses+in+C-C+chemokine+receptor+2+knockout+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoring%26aufirst%3DL.%26aulast%3DGosling%26aufirst%3DJ.%26aulast%3DChensue%26aufirst%3DS.%2BW.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DFarese%26aufirst%3DR.%2BV.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DImpaired%2520monocyte%2520migration%2520and%2520reduced%2520type%25201%2520%2528Th1%2529%2520cytokine%2520responses%2520in%2520C-C%2520chemokine%2520receptor%25202%2520knockout%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D100%26spage%3D2552%26epage%3D2561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Peters, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">7072</span><span class="NLM_x">â</span> <span class="NLM_lpage">7077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2000&pages=7072-7077&author=W.+Petersauthor=M.+Dupuisauthor=I.+F.+Charo&title=A+mechanism+for+the+impaired+IFN-gamma+production+in+C-C+chemokine+receptor+2+%28CCR2%29+knockout+mice%3A+role+of+CCR2+in+linking+the+innate+and+adaptive+immune+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DW.%26aulast%3DDupuis%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DA%2520mechanism%2520for%2520the%2520impaired%2520IFN-gamma%2520production%2520in%2520C-C%2520chemokine%2520receptor%25202%2520%2528CCR2%2529%2520knockout%2520mice%253A%2520role%2520of%2520CCR2%2520in%2520linking%2520the%2520innate%2520and%2520adaptive%2520immune%2520responses%26jtitle%3DJ.%2520Immunol.%26date%3D2000%26volume%3D165%26spage%3D7072%26epage%3D7077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Peters, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, J. D.</span><span> </span><span class="NLM_article-title">Chemokine receptor 2 serves an early and essential role in resistance to <i>Mycobacterium tuberculosis</i></span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">7958</span><span class="NLM_x">â</span> <span class="NLM_lpage">7963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=7958-7963&author=W.+Petersauthor=H.+M.+Scottauthor=H.+F.+Chambersauthor=J.+L.+Flynnauthor=I.+F.+Charoauthor=J.+D.+Ernst&title=Chemokine+receptor+2+serves+an+early+and+essential+role+in+resistance+to+Mycobacterium+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DW.%26aulast%3DScott%26aufirst%3DH.%2BM.%26aulast%3DChambers%26aufirst%3DH.%2BF.%26aulast%3DFlynn%26aufirst%3DJ.%2BL.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DErnst%26aufirst%3DJ.%2BD.%26atitle%3DChemokine%2520receptor%25202%2520serves%2520an%2520early%2520and%2520essential%2520role%2520in%2520resistance%2520to%2520Mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D7958%26epage%3D7963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Blease, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrad, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standiford, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boring, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C. M.</span><span> </span><span class="NLM_article-title">Enhanced pulmonary allergic responses to Aspergillus in CCR2â/â mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">2603</span><span class="NLM_x">â</span> <span class="NLM_lpage">2611</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2000&pages=2603-2611&author=K.+Bleaseauthor=B.+Mehradauthor=T.+J.+Standifordauthor=N.+W.+Lukacsauthor=J.+Goslingauthor=L.+Boringauthor=I.+F.+Charoauthor=S.+L.+Kunkelauthor=C.+M.+Hogaboam&title=Enhanced+pulmonary+allergic+responses+to+Aspergillus+in+CCR2%E2%80%93%2F%E2%80%93+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DMehrad%26aufirst%3DB.%26aulast%3DStandiford%26aufirst%3DT.%2BJ.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DGosling%26aufirst%3DJ.%26aulast%3DBoring%26aufirst%3DL.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26atitle%3DEnhanced%2520pulmonary%2520allergic%2520responses%2520to%2520Aspergillus%2520in%2520CCR2%25E2%2580%2593%252F%25E2%2580%2593%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2000%26volume%3D165%26spage%3D2603%26epage%3D2611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Gonzalo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albar, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Ramos, J. C.</span><span> </span><span class="NLM_article-title">The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">188</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">â</span> <span class="NLM_lpage">167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=1998&pages=157-167&author=J.+A.+Gonzaloauthor=C.+M.+Lloydauthor=D.+Wenauthor=J.+P.+Albarauthor=T.+N.+Wellsauthor=A.+Proudfootauthor=A.+C.+Martinezauthor=M.+Dorfauthor=T.+Bjerkeauthor=A.+J.+Coyleauthor=J.+C.+Gutierrez-Ramos&title=The+coordinated+action+of+CC+chemokines+in+the+lung+orchestrates+allergic+inflammation+and+airway+hyperresponsiveness"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalo%26aufirst%3DJ.%2BA.%26aulast%3DLloyd%26aufirst%3DC.%2BM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DAlbar%26aufirst%3DJ.%2BP.%26aulast%3DWells%26aufirst%3DT.%2BN.%26aulast%3DProudfoot%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DA.%2BC.%26aulast%3DDorf%26aufirst%3DM.%26aulast%3DBjerke%26aufirst%3DT.%26aulast%3DCoyle%26aufirst%3DA.%2BJ.%26aulast%3DGutierrez-Ramos%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520coordinated%2520action%2520of%2520CC%2520chemokines%2520in%2520the%2520lung%2520orchestrates%2520allergic%2520inflammation%2520and%2520airway%2520hyperresponsiveness%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D188%26spage%3D157%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Collington, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallgren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rollins, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austen, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurish, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, C. L.</span><span> </span><span class="NLM_article-title">The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">6114</span><span class="NLM_x">â</span> <span class="NLM_lpage">6123</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=6114-6123&author=S.+J.+Collingtonauthor=J.+Hallgrenauthor=J.+E.+Peaseauthor=T.+G.+Jonesauthor=B.+J.+Rollinsauthor=J.+Westwickauthor=K.+F.+Austenauthor=T.+J.+Williamsauthor=M.+F.+Gurishauthor=C.+L.+Weller&title=The+role+of+the+CCL2%2FCCR2+axis+in+mouse+mast+cell+migration+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCollington%26aufirst%3DS.%2BJ.%26aulast%3DHallgren%26aufirst%3DJ.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DJones%26aufirst%3DT.%2BG.%26aulast%3DRollins%26aufirst%3DB.%2BJ.%26aulast%3DWestwick%26aufirst%3DJ.%26aulast%3DAusten%26aufirst%3DK.%2BF.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DGurish%26aufirst%3DM.%2BF.%26aulast%3DWeller%26aufirst%3DC.%2BL.%26atitle%3DThe%2520role%2520of%2520the%2520CCL2%252FCCR2%2520axis%2520in%2520mouse%2520mast%2520cell%2520migration%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D6114%26epage%3D6123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Boring, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleary, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">Decreased lesion formation in CCR2â/â mice reveals a role for chemokines in the initiation of atherosclerosis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">394</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">â</span> <span class="NLM_lpage">897</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=1998&pages=894-897&author=L.+Boringauthor=J.+Goslingauthor=M.+Clearyauthor=I.+F.+Charo&title=Decreased+lesion+formation+in+CCR2%E2%80%93%2F%E2%80%93+mice+reveals+a+role+for+chemokines+in+the+initiation+of+atherosclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoring%26aufirst%3DL.%26aulast%3DGosling%26aufirst%3DJ.%26aulast%3DCleary%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DDecreased%2520lesion%2520formation%2520in%2520CCR2%25E2%2580%2593%252F%25E2%2580%2593%2520mice%2520reveals%2520a%2520role%2520for%2520chemokines%2520in%2520the%2520initiation%2520of%2520atherosclerosis%26jtitle%3DNature%26date%3D1998%26volume%3D394%26spage%3D894%26epage%3D897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Humbles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Garawi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span> </span><span class="NLM_article-title">The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">â</span> <span class="NLM_lpage">1484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1479-1484&author=A.+A.+Humblesauthor=B.+Luauthor=D.+S.+Friendauthor=S.+Okinagaauthor=J.+Loraauthor=A.+Al-Garawiauthor=T.+R.+Martinauthor=N.+P.+Gerardauthor=C.+Gerard&title=The+murine+CCR3+receptor+regulates+both+the+role+of+eosinophils+and+mast+cells+in+allergen-induced+airway+inflammation+and+hyperresponsiveness"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHumbles%26aufirst%3DA.%2BA.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DFriend%26aufirst%3DD.%2BS.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DLora%26aufirst%3DJ.%26aulast%3DAl-Garawi%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DT.%2BR.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26atitle%3DThe%2520murine%2520CCR3%2520receptor%2520regulates%2520both%2520the%2520role%2520of%2520eosinophils%2520and%2520mast%2520cells%2520in%2520allergen-induced%2520airway%2520inflammation%2520and%2520hyperresponsiveness%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D1479%26epage%3D1484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryce, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laouini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yalcindag, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alenius, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oettgen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geha, R. S.</span><span> </span><span class="NLM_article-title">CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">â</span> <span class="NLM_lpage">628</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=621-628&author=W.+Maauthor=P.+J.+Bryceauthor=A.+A.+Humblesauthor=D.+Laouiniauthor=A.+Yalcindagauthor=H.+Aleniusauthor=D.+S.+Friendauthor=H.+C.+Oettgenauthor=C.+Gerardauthor=R.+S.+Geha&title=CCR3+is+essential+for+skin+eosinophilia+and+airway+hyperresponsiveness+in+a+murine+model+of+allergic+skin+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DW.%26aulast%3DBryce%26aufirst%3DP.%2BJ.%26aulast%3DHumbles%26aufirst%3DA.%2BA.%26aulast%3DLaouini%26aufirst%3DD.%26aulast%3DYalcindag%26aufirst%3DA.%26aulast%3DAlenius%26aufirst%3DH.%26aulast%3DFriend%26aufirst%3DD.%2BS.%26aulast%3DOettgen%26aufirst%3DH.%2BC.%26aulast%3DGerard%26aufirst%3DC.%26aulast%3DGeha%26aufirst%3DR.%2BS.%26atitle%3DCCR3%2520is%2520essential%2520for%2520skin%2520eosinophilia%2520and%2520airway%2520hyperresponsiveness%2520in%2520a%2520murine%2520model%2520of%2520allergic%2520skin%2520inflammation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D621%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Collington, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, C. L.</span><span> </span><span class="NLM_article-title">The function of CCR3 on mouse bone marrow-derived mast cells in vitro</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2010&pages=115-124&author=S.+J.+Collingtonauthor=J.+Westwickauthor=T.+J.+Williamsauthor=C.+L.+Weller&title=The+function+of+CCR3+on+mouse+bone+marrow-derived+mast+cells+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCollington%26aufirst%3DS.%2BJ.%26aulast%3DWestwick%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DWeller%26aufirst%3DC.%2BL.%26atitle%3DThe%2520function%2520of%2520CCR3%2520on%2520mouse%2520bone%2520marrow-derived%2520mast%2520cells%2520in%2520vitro%26jtitle%3DImmunology%26date%3D2010%26volume%3D129%26spage%3D115%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Chvatchko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogewerf, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alouani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conquet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span> </span><span class="NLM_article-title">A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">1755</span><span class="NLM_x">â</span> <span class="NLM_lpage">1764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=1755-1764&author=Y.+Chvatchkoauthor=A.+J.+Hoogewerfauthor=A.+Meyerauthor=S.+Alouaniauthor=P.+Juillardauthor=R.+Buserauthor=F.+Conquetauthor=A.+E.+Proudfootauthor=T.+N.+Wellsauthor=C.+A.+Power&title=A+key+role+for+CC+chemokine+receptor+4+in+lipopolysaccharide-induced+endotoxic+shock"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChvatchko%26aufirst%3DY.%26aulast%3DHoogewerf%26aufirst%3DA.%2BJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DJuillard%26aufirst%3DP.%26aulast%3DBuser%26aufirst%3DR.%26aulast%3DConquet%26aufirst%3DF.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DWells%26aufirst%3DT.%2BN.%26aulast%3DPower%26aufirst%3DC.%2BA.%26atitle%3DA%2520key%2520role%2520for%2520CC%2520chemokine%2520receptor%25204%2520in%2520lipopolysaccharide-induced%2520endotoxic%2520shock%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D1755%26epage%3D1764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Lloyd, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Ramos, J. C.</span><span> </span><span class="NLM_article-title">CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">â</span> <span class="NLM_lpage">274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=265-274&author=C.+M.+Lloydauthor=T.+Delaneyauthor=T.+Nguyenauthor=J.+Tianauthor=A.+C.+Martinezauthor=A.+J.+Coyleauthor=J.+C.+Gutierrez-Ramos&title=CC+chemokine+receptor+%28CCR%293%2Feotaxin+is+followed+by+CCR4%2Fmonocyte-derived+chemokine+in+mediating+pulmonary+T+helper+lymphocyte+type+2+recruitment+after+serial+antigen+challenge+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DC.%2BM.%26aulast%3DDelaney%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DA.%2BC.%26aulast%3DCoyle%26aufirst%3DA.%2BJ.%26aulast%3DGutierrez-Ramos%26aufirst%3DJ.%2BC.%26atitle%3DCC%2520chemokine%2520receptor%2520%2528CCR%25293%252Feotaxin%2520is%2520followed%2520by%2520CCR4%252Fmonocyte-derived%2520chemokine%2520in%2520mediating%2520pulmonary%2520T%2520helper%2520lymphocyte%2520type%25202%2520recruitment%2520after%2520serial%2520antigen%2520challenge%2520in%2520vivo%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D265%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Iellem, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recalde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panina-Bordignon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinigaglia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAmbrosio, D.</span><span> </span><span class="NLM_article-title">Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by cd4(+)cd25(+) regulatory T cells</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">â</span> <span class="NLM_lpage">854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2001&pages=847-854&author=A.+Iellemauthor=M.+Marianiauthor=R.+Langauthor=H.+Recaldeauthor=P.+Panina-Bordignonauthor=F.+Sinigagliaauthor=D.+D%E2%80%99Ambrosio&title=Unique+chemotactic+response+profile+and+specific+expression+of+chemokine+receptors+CCR4+and+CCR8+by+cd4%28%2B%29cd25%28%2B%29+regulatory+T+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIellem%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DM.%26aulast%3DLang%26aufirst%3DR.%26aulast%3DRecalde%26aufirst%3DH.%26aulast%3DPanina-Bordignon%26aufirst%3DP.%26aulast%3DSinigaglia%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DD.%26atitle%3DUnique%2520chemotactic%2520response%2520profile%2520and%2520specific%2520expression%2520of%2520chemokine%2520receptors%2520CCR4%2520and%2520CCR8%2520by%2520cd4%2528%252B%2529cd25%2528%252B%2529%2520regulatory%2520T%2520cells%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2001%26volume%3D194%26spage%3D847%26epage%3D854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Bernhagen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krohn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lue, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zernecke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenen, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgiev, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schober, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kooistra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingerle-Rowson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghezzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleemann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McColl, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, C.</span><span> </span><span class="NLM_article-title">MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnm1567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17435771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvVOhu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=587-596&author=J.+Bernhagenauthor=R.+Krohnauthor=H.+Lueauthor=J.+L.+Gregoryauthor=A.+Zerneckeauthor=R.+R.+Koenenauthor=M.+Deworauthor=I.+Georgievauthor=A.+Schoberauthor=L.+Lengauthor=T.+Kooistraauthor=G.+Fingerle-Rowsonauthor=P.+Ghezziauthor=R.+Kleemannauthor=S.+R.+McCollauthor=R.+Bucalaauthor=M.+J.+Hickeyauthor=C.+Weber&title=MIF+is+a+noncognate+ligand+of+CXC+chemokine+receptors+in+inflammatory+and+atherogenic+cell+recruitment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment</span></div><div class="casAuthors">Bernhagen, Juergen; Krohn, Regina; Lue, Hongqi; Gregory, Julia L.; Zernecke, Alma; Koenen, Rory R.; Dewor, Manfred; Georgiev, Ivan; Schober, Andreas; Leng, Lin; Kooistra, Teake; Fingerle-Rowson, Guenter; Ghezzi, Pietro; Kleemann, Robert; McColl, Shaun R.; Bucala, Richard; Hickey, Michael J.; Weber, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">587-596</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The cytokine macrophage migration inhibitory factor (MIF) plays a crit. role in inflammatory diseases and atherogenesis.  The authors identify the chemokine receptors CXCR2 and CXCR4 as functional receptors for MIF.  MIF triggered GÎ±i- and integrin-dependent arrest and chemotaxis of monocytes and T cells, rapid integrin activation, and calcium influx through CXCR2 or CXCR4.  MIF competed with cognate ligands for CXCR4 and CXCR2 binding, and directly bound to CXCR2.  CXCR2 and CD74 formed a receptor complex, and monocyte arrest elicited by MIF in inflamed or atherosclerotic arteries involved both CXCR2 and CD74.  In vivo, Mif deficiency impaired monocyte adhesion to the arterial wall in atherosclerosis-prone mice, and MIF-induced leukocyte recruitment required Il8rb (which encodes Cxcr2).  Blockade of Mif but not of canonical ligands of Cxcr2 or Cxcr4 in mice with advanced atherosclerosis led to plaque regression and reduced monocyte and T-cell content in plaques.  By activating both CXCR2 and CXCR4, MIF displays chemokine-like functions and acts as a major regulator of inflammatory cell recruitment and atherogenesis.  Targeting MIF in individuals with manifest atherosclerosis can potentially be used to treat this condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQOsX-ruaMLVg90H21EOLACvtfcHk0ljbtunKwzrKtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvVOhu7s%253D&md5=313a9a2158474e79f27fb59b7a62daab</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnm1567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1567%26sid%3Dliteratum%253Aachs%26aulast%3DBernhagen%26aufirst%3DJ.%26aulast%3DKrohn%26aufirst%3DR.%26aulast%3DLue%26aufirst%3DH.%26aulast%3DGregory%26aufirst%3DJ.%2BL.%26aulast%3DZernecke%26aufirst%3DA.%26aulast%3DKoenen%26aufirst%3DR.%2BR.%26aulast%3DDewor%26aufirst%3DM.%26aulast%3DGeorgiev%26aufirst%3DI.%26aulast%3DSchober%26aufirst%3DA.%26aulast%3DLeng%26aufirst%3DL.%26aulast%3DKooistra%26aufirst%3DT.%26aulast%3DFingerle-Rowson%26aufirst%3DG.%26aulast%3DGhezzi%26aufirst%3DP.%26aulast%3DKleemann%26aufirst%3DR.%26aulast%3DMcColl%26aufirst%3DS.%2BR.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DWeber%26aufirst%3DC.%26atitle%3DMIF%2520is%2520a%2520noncognate%2520ligand%2520of%2520CXC%2520chemokine%2520receptors%2520in%2520inflammatory%2520and%2520atherogenic%2520cell%2520recruitment%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D587%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Cacalano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts-Meek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hultgren, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. W.</span><span> </span><span class="NLM_article-title">Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">â</span> <span class="NLM_lpage">684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1994&pages=682-684&author=G.+Cacalanoauthor=J.+Leeauthor=K.+Kiklyauthor=A.+M.+Ryanauthor=S.+Pitts-Meekauthor=B.+Hultgrenauthor=W.+I.+Woodauthor=M.+W.+Moore&title=Neutrophil+and+B+cell+expansion+in+mice+that+lack+the+murine+IL-8+receptor+homolog"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCacalano%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKikly%26aufirst%3DK.%26aulast%3DRyan%26aufirst%3DA.%2BM.%26aulast%3DPitts-Meek%26aufirst%3DS.%26aulast%3DHultgren%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DW.%2BI.%26aulast%3DMoore%26aufirst%3DM.%2BW.%26atitle%3DNeutrophil%2520and%2520B%2520cell%2520expansion%2520in%2520mice%2520that%2520lack%2520the%2520murine%2520IL-8%2520receptor%2520homolog%26jtitle%3DScience%26date%3D1994%26volume%3D265%26spage%3D682%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patera, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pong-Kennedy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfra, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassileva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif-Rodriguez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opdenakker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Damme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span> </span><span class="NLM_article-title">Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">11658</span><span class="NLM_x">â</span> <span class="NLM_lpage">11666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=11658-11666&author=X.+Fanauthor=A.+C.+Pateraauthor=A.+Pong-Kennedyauthor=G.+Denoauthor=W.+Gonsiorekauthor=D.+J.+Manfraauthor=G.+Vassilevaauthor=M.+Zengauthor=C.+Jacksonauthor=L.+Sullivanauthor=W.+Sharif-Rodriguezauthor=G.+Opdenakkerauthor=J.+Van+Dammeauthor=J.+A.+Hedrickauthor=D.+Lundellauthor=S.+A.+Liraauthor=R.+W.+Hipkin&title=Murine+CXCR1+is+a+functional+receptor+for+GCP-2%2FCXCL6+and+interleukin-8%2FCXCL8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DX.%26aulast%3DPatera%26aufirst%3DA.%2BC.%26aulast%3DPong-Kennedy%26aufirst%3DA.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DManfra%26aufirst%3DD.%2BJ.%26aulast%3DVassileva%26aufirst%3DG.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DSharif-Rodriguez%26aufirst%3DW.%26aulast%3DOpdenakker%26aufirst%3DG.%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DHedrick%26aufirst%3DJ.%2BA.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DLira%26aufirst%3DS.%2BA.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DMurine%2520CXCR1%2520is%2520a%2520functional%2520receptor%2520for%2520GCP-2%252FCXCL6%2520and%2520interleukin-8%252FCXCL8%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D11658%26epage%3D11666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Abonia, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austen, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rollins, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flavell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuziel, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koni, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurish, M. F.</span><span> </span><span class="NLM_article-title">Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">4308</span><span class="NLM_x">â</span> <span class="NLM_lpage">4313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=4308-4313&author=J.+P.+Aboniaauthor=K.+F.+Austenauthor=B.+J.+Rollinsauthor=S.+K.+Joshiauthor=R.+A.+Flavellauthor=W.+A.+Kuzielauthor=P.+A.+Koniauthor=M.+F.+Gurish&title=Constitutive+homing+of+mast+cell+progenitors+to+the+intestine+depends+on+autologous+expression+of+the+chemokine+receptor+CXCR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbonia%26aufirst%3DJ.%2BP.%26aulast%3DAusten%26aufirst%3DK.%2BF.%26aulast%3DRollins%26aufirst%3DB.%2BJ.%26aulast%3DJoshi%26aufirst%3DS.%2BK.%26aulast%3DFlavell%26aufirst%3DR.%2BA.%26aulast%3DKuziel%26aufirst%3DW.%2BA.%26aulast%3DKoni%26aufirst%3DP.%2BA.%26aulast%3DGurish%26aufirst%3DM.%2BF.%26atitle%3DConstitutive%2520homing%2520of%2520mast%2520cell%2520progenitors%2520to%2520the%2520intestine%2520depends%2520on%2520autologous%2520expression%2520of%2520the%2520chemokine%2520receptor%2520CXCR2%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D4308%26epage%3D4313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Eash, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenbaum, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalan, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, D. C.</span><span> </span><span class="NLM_article-title">CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2423</span><span class="NLM_x">â</span> <span class="NLM_lpage">2431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2423-2431&author=K.+J.+Eashauthor=A.+M.+Greenbaumauthor=P.+K.+Gopalanauthor=D.+C.+Link&title=CXCR2+and+CXCR4+antagonistically+regulate+neutrophil+trafficking+from+murine+bone+marrow"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEash%26aufirst%3DK.%2BJ.%26aulast%3DGreenbaum%26aufirst%3DA.%2BM.%26aulast%3DGopalan%26aufirst%3DP.%2BK.%26aulast%3DLink%26aufirst%3DD.%2BC.%26atitle%3DCXCR2%2520and%2520CXCR4%2520antagonistically%2520regulate%2520neutrophil%2520trafficking%2520from%2520murine%2520bone%2520marrow%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2423%26epage%3D2431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Del Rio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salinas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denkers, E. Y.</span><span> </span><span class="NLM_article-title">CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during <i>Toxoplasma gondii</i> infection</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">6503</span><span class="NLM_x">â</span> <span class="NLM_lpage">6509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2001&pages=6503-6509&author=L.+Del+Rioauthor=S.+Bennounaauthor=J.+Salinasauthor=E.+Y.+Denkers&title=CXCR2+deficiency+confers+impaired+neutrophil+recruitment+and+increased+susceptibility+during+Toxoplasma+gondii+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BRio%26aufirst%3DL.%26aulast%3DBennouna%26aufirst%3DS.%26aulast%3DSalinas%26aufirst%3DJ.%26aulast%3DDenkers%26aufirst%3DE.%2BY.%26atitle%3DCXCR2%2520deficiency%2520confers%2520impaired%2520neutrophil%2520recruitment%2520and%2520increased%2520susceptibility%2520during%2520Toxoplasma%2520gondii%2520infection%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D167%26spage%3D6503%26epage%3D6509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Tsai, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ffrench-Constant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geertman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. H.</span><span> </span><span class="NLM_article-title">The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=373-383&author=H.+H.+Tsaiauthor=E.+Frostauthor=V.+Toauthor=S.+Robinsonauthor=C.+Ffrench-Constantauthor=R.+Geertmanauthor=R.+M.+Ransohoffauthor=R.+H.+Miller&title=The+chemokine+receptor+CXCR2+controls+positioning+of+oligodendrocyte+precursors+in+developing+spinal+cord+by+arresting+their+migration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DH.%2BH.%26aulast%3DFrost%26aufirst%3DE.%26aulast%3DTo%26aufirst%3DV.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DFfrench-Constant%26aufirst%3DC.%26aulast%3DGeertman%26aufirst%3DR.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BH.%26atitle%3DThe%2520chemokine%2520receptor%2520CXCR2%2520controls%2520positioning%2520of%2520oligodendrocyte%2520precursors%2520in%2520developing%2520spinal%2520cord%2520by%2520arresting%2520their%2520migration%26jtitle%3DCell%26date%3D2002%26volume%3D110%26spage%3D373%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belkadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darnall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotleur, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padovani-Claudio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span> </span><span class="NLM_article-title">CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis</span> <span class="citation_source-journal">Nat. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnn.2491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20154684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=319-326&author=L.+Liuauthor=A.+Belkadiauthor=L.+Darnallauthor=T.+Huauthor=C.+Drescherauthor=A.+C.+Cotleurauthor=D.+Padovani-Claudioauthor=T.+Heauthor=K.+Choiauthor=T.+E.+Laneauthor=R.+H.+Millerauthor=R.+M.+Ransohoff&title=CXCR2-positive+neutrophils+are+essential+for+cuprizone-induced+demyelination%3A+relevance+to+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis</span></div><div class="casAuthors">Liu, LiPing; Belkadi, Abdelmadjid; Darnall, Lindsey; Hu, Taofang; Drescher, Caitlin; Cotleur, Anne C.; Padovani-Claudio, Dolly; He, Tao; Choi, Karen; Lane, Thomas E.; Miller, Robert H.; Ransohoff, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Multiple sclerosis is an inflammatory demyelinating disorder of the CNS.  Recent studies have suggested diverse mechanisms as underlying demyelination, including a subset of lesions induced by an interaction between metabolic insult to oligodendrocytes and inflammatory mediators.  For mice of susceptible strains, cuprizone feeding results in oligodendrocyte cell loss and demyelination of the corpus callosum.  Remyelination ensues and has been extensively studied.  Cuprizone-induced demyelination remains incompletely characterized.  The authors found that mice lacking the type 2 CXC chemokine receptor (CXCR2) were relatively resistant to cuprizone-induced demyelination and that circulating CXCR2-pos. neutrophils were important for cuprizone-induced demyelination.  The authors' findings support a two-hit process of cuprizone-induced demyelination, supporting the idea that multiple sclerosis pathogenesis features extensive oligodendrocyte cell loss.  These data suggest that cuprizone-induced demyelination is useful for modeling certain aspects of multiple sclerosis pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Eqy955jzILVg90H21EOLACvtfcHk0ljexKF-a-tmjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsr8%253D&md5=6c4e4623a163c9b71d0a1c5741ba70b0</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnn.2491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2491%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBelkadi%26aufirst%3DA.%26aulast%3DDarnall%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DDrescher%26aufirst%3DC.%26aulast%3DCotleur%26aufirst%3DA.%2BC.%26aulast%3DPadovani-Claudio%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DT.%2BE.%26aulast%3DMiller%26aufirst%3DR.%2BH.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DCXCR2-positive%2520neutrophils%2520are%2520essential%2520for%2520cuprizone-induced%2520demyelination%253A%2520relevance%2520to%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Neurosci.%26date%3D2010%26volume%3D13%26spage%3D319%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Boisvert, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtiss, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terkeltaub, R. A.</span><span> </span><span class="NLM_article-title">A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor- deficient mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">â</span> <span class="NLM_lpage">363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1998&pages=353-363&author=W.+A.+Boisvertauthor=R.+Santiagoauthor=L.+K.+Curtissauthor=R.+A.+Terkeltaub&title=A+leukocyte+homologue+of+the+IL-8+receptor+CXCR-2+mediates+the+accumulation+of+macrophages+in+atherosclerotic+lesions+of+LDL+receptor-+deficient+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoisvert%26aufirst%3DW.%2BA.%26aulast%3DSantiago%26aufirst%3DR.%26aulast%3DCurtiss%26aufirst%3DL.%2BK.%26aulast%3DTerkeltaub%26aufirst%3DR.%2BA.%26atitle%3DA%2520leukocyte%2520homologue%2520of%2520the%2520IL-8%2520receptor%2520CXCR-2%2520mediates%2520the%2520accumulation%2520of%2520macrophages%2520in%2520atherosclerotic%2520lesions%2520of%2520LDL%2520receptor-%2520deficient%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D101%26spage%3D353%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Horuk, R.</span><span> </span><span class="NLM_article-title">Chemokine receptor antagonists: overcoming developmental hurdles</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnrd2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19079127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt12j" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=23-33&author=R.+Horuk&title=Chemokine+receptor+antagonists%3A+overcoming+developmental+hurdles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor antagonists: overcoming developmental hurdles</span></div><div class="casAuthors">Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokine receptors have a key role in the pathogenesis of autoimmune diseases, inflammation and viral infection.  However, with the exception of selective CCR5 antagonists for HIV, the promise of obtaining new therapeutics related to chemokine receptors has not yet been realized.  This article highlights some of the recent failures in the clin. trials of chemokine receptor antagonists and explores possible reasons as to why this might have occurred.  Such reasons include the lack of predictability of animal models and redundancy of the target.  A potential soln. could be to develop drugs that target more than one receptor - known as polypharmacol. - which could be a novel way to generate effective therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFMos9Ccf_G7Vg90H21EOLACvtfcHk0liuAqCfghQ66w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt12j&md5=831294beadc398d0dc3007a26da96d39</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnrd2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2734%26sid%3Dliteratum%253Aachs%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DChemokine%2520receptor%2520antagonists%253A%2520overcoming%2520developmental%2520hurdles%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D23%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span>Study To Investigate the Efficacy of a Non-Hormonal Drug against Endometriosis Associated Pelvic Pain. <a href="http://clinicaltrials.gov/ct2/show/NCT00185341?term=CCR1&amp;rank=1" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00185341?term=CCR1&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+To+Investigate+the+Efficacy+of+a+Non-Hormonal+Drug+against+Endometriosis+Associated+Pelvic+Pain.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00185341%3Fterm%3DCCR1%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span>MLN 3701 Sanofi-Aventis Phase Change I, Europe. <a href="http://business.highbeam.com/436989/article-1G1-160617066/mln-3701-sanofiaventis-phase-change-europe" class="extLink">http://business.highbeam.com/436989/article-1G1-160617066/mln-3701-sanofiaventis-phase-change-europe</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MLN+3701+Sanofi-Aventis+Phase+Change+I%2C+Europe.+http%3A%2F%2Fbusiness.highbeam.com%2F436989%2Farticle-1G1-160617066%2Fmln-3701-sanofiaventis-phase-change-europe."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Carson, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffee, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. B.</span><span> </span><span class="NLM_article-title">CCR1 Antagonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=149-158&author=K.+G.+Carsonauthor=B.+D.+Jaffeeauthor=G.+B.+Harriman&title=CCR1+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarson%26aufirst%3DK.%2BG.%26aulast%3DJaffee%26aufirst%3DB.%2BD.%26aulast%3DHarriman%26aufirst%3DG.%2BB.%26atitle%3DCCR1%2520Antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2004%26volume%3D39%26spage%3D149%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Ng, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghannam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M. M.</span><span> </span><span class="NLM_article-title">Discovery of novel non-peptide CCR1 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4680</span><span class="NLM_x">â</span> <span class="NLM_lpage">4694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990316l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4680-4694&author=H.+P.+Ngauthor=K.+Mayauthor=J.+G.+Baumanauthor=A.+Ghannamauthor=I.+Islamauthor=M.+Liangauthor=R.+Horukauthor=J.+Hesselgesserauthor=R.+M.+Sniderauthor=H.+D.+Perezauthor=M.+M.+Morrissey&title=Discovery+of+novel+non-peptide+CCR1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm990316l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990316l%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DH.%2BP.%26aulast%3DMay%26aufirst%3DK.%26aulast%3DBauman%26aufirst%3DJ.%2BG.%26aulast%3DGhannam%26aufirst%3DA.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DSnider%26aufirst%3DR.%2BM.%26aulast%3DPerez%26aufirst%3DH.%2BD.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26atitle%3DDiscovery%2520of%2520novel%2520non-peptide%2520CCR1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4680%26epage%3D4694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Vallet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raje, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishitsuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhetri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pozzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitkreutz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiziltepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocio, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaghela, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirstea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccadoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3744</span><span class="NLM_x">â</span> <span class="NLM_lpage">3752</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3744-3752&author=S.+Valletauthor=N.+Rajeauthor=K.+Ishitsukaauthor=T.+Hideshimaauthor=K.+Podarauthor=S.+Chhetriauthor=S.+Pozziauthor=I.+Breitkreutzauthor=T.+Kiziltepeauthor=H.+Yasuiauthor=E.+M.+Ocioauthor=N.+Shiraishiauthor=J.+Jinauthor=Y.+Okawaauthor=H.+Ikedaauthor=S.+Mukherjeeauthor=N.+Vaghelaauthor=D.+Cirsteaauthor=M.+Ladettoauthor=M.+Boccadoroauthor=K.+C.+Anderson&title=MLN3897%2C+a+novel+CCR1+inhibitor%2C+impairs+osteoclastogenesis+and+inhibits+the+interaction+of+multiple+myeloma+cells+and+osteoclasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVallet%26aufirst%3DS.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DIshitsuka%26aufirst%3DK.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DChhetri%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26aulast%3DBreitkreutz%26aufirst%3DI.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DShiraishi%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DVaghela%26aufirst%3DN.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DLadetto%26aufirst%3DM.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DMLN3897%252C%2520a%2520novel%2520CCR1%2520inhibitor%252C%2520impairs%2520osteoclastogenesis%2520and%2520inhibits%2520the%2520interaction%2520of%2520multiple%2520myeloma%2520cells%2520and%2520osteoclasts%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3744%26epage%3D3752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Vergunst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Moltke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzkin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3572</span><span class="NLM_x">â</span> <span class="NLM_lpage">3581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.24978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19950299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=3572-3581&author=C.+E.+Vergunstauthor=D.+M.+Gerlagauthor=L.+von+Moltkeauthor=M.+Karolauthor=T.+Wyantauthor=X.+Chiauthor=E.+Matzkinauthor=T.+Leachauthor=P.+P.+Tak&title=MLN3897+plus+methotrexate+in+patients+with+rheumatoid+arthritis%3A+safety%2C+efficacy%2C+pharmacokinetics%2C+and+pharmacodynamics+of+an+oral+CCR1+antagonist+in+a+phase+IIa%2C+double-blind%2C+placebo-controlled%2C+randomized%2C+proof-of-concept+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study</span></div><div class="casAuthors">Vergunst, Clarissa E.; Gerlag, Danielle M.; von Moltke, Lisa; Karol, Michael; Wyant, Tim; Chi, Xuedong; Matzkin, Ellen; Leach, Timothy; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3572-3581</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX).  Methods: In this phase IIa, proof-of-concept study, patients meeting the American College of Rheumatol. (ACR) criteria for RA who had been taking MTX for â¥6 mo with evidence of active disease were randomly assigned to receive either 10 mg oral MLN3897 or matching placebo once daily for 12 wk (days 1-83) while continuing to receive MTX once a week.  Clin. assessments, safety monitoring, and sampling for pharmacokinetic and pharmacodynamic analyses were performed throughout the study.  The primary efficacy end point was the difference in the percentage of patients meeting the ACR 20% improvement criteria (achieving an ACR20 response) on day 84 in the MLN3897-treated group compared with that in the placebo-treated group.  Results: MLN3897 was well tolerated, with no evidence of systemic immunosuppression.  In the intent-to-treat population, there was no significant difference in day 84 ACR20 response rates between MLN3897-treated patients and placebo-treated patients (35% vs. 33%, resp.; P = 0.72).  Results were similar for the per-protocol population.  Pharmacokinetic analyses demonstrated no interactions between MLN3897 and MTX.  MLN3897 was assocd. with a high degree of CCR1 occupancy (â¥90% on days 28, 56, and 84 in 82% of patients, by macrophage inflammatory protein la internalization assay).  Conclusion: MLN3897 at a concn. of 10 mg once daily had no discernible activity in patients with RA who were also receiving MTX.  The results suggest that CCR1 antagonism is unlikely to be a viable strategy for the treatment of RA when used in isolation at the receptor occupancy levels reached in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrypG1Ywf-kC7Vg90H21EOLACvtfcHk0liuAqCfghQ66w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb7O&md5=c4ad5b338d4c2448889fef196cff0d78</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fart.24978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24978%26sid%3Dliteratum%253Aachs%26aulast%3DVergunst%26aufirst%3DC.%2BE.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3Dvon%2BMoltke%26aufirst%3DL.%26aulast%3DKarol%26aufirst%3DM.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DChi%26aufirst%3DX.%26aulast%3DMatzkin%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DT.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DMLN3897%2520plus%2520methotrexate%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%253A%2520safety%252C%2520efficacy%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520an%2520oral%2520CCR1%2520antagonist%2520in%2520a%2520phase%2520IIa%252C%2520double-blind%252C%2520placebo-controlled%252C%2520randomized%252C%2520proof-of-concept%2520study%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D3572%26epage%3D3581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Gladue, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">CCR1 antagonists: what have we learned from clinical trials</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1268</span><span class="NLM_x">â</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2174%2F156802610791561237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20536425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSktb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=1268-1277&author=R.+P.+Gladueauthor=M.+F.+Brownauthor=S.+H.+Zwillich&title=CCR1+antagonists%3A+what+have+we+learned+from+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">CCR1 antagonists: what have we learned from clinical trials</span></div><div class="casAuthors">Gladue, Ronald P.; Brown, Matthew F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1268-1277</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The identification of chemokines and their receptors as potent mediators of leukocyte infiltration raised interest in the potential role of these proteins on disease pathogenesis.  This is exemplified by the chemokine receptor, CCR1, which has been shown to be up-regulated in a no. of human diseases, the implications of which have been suggested by animal models where inhibition of CCR1 or its ligands have shown beneficial effects.  These data support the possibility that a CCR1 antagonist will provide therapeutic benefit to patients with inflammatory diseases.  Over the last several years, several of these antagonists entered clin. trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD.  This review will describe the evidence that supported the role of CCR1 in these diseases, the results from clin. trials, and provide perspectives on what has been learned from these trials for potential application / consideration to other studies with chemokine receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozbINoudZvwLVg90H21EOLACvtfcHk0libDw3mVObEgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSktb7L&md5=bc6af7c7df8e5c4c100f850b895c9175</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F156802610791561237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610791561237%26sid%3Dliteratum%253Aachs%26aulast%3DGladue%26aufirst%3DR.%2BP.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DCCR1%2520antagonists%253A%2520what%2520have%2520we%2520learned%2520from%2520clinical%2520trials%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D1268%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Gladue, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tylaska, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogborne, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neote, K. S.</span><span> </span><span class="NLM_article-title">The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">3141</span><span class="NLM_x">â</span> <span class="NLM_lpage">3148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.4049%2Fjimmunol.176.5.3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16493073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=3141-3148&author=R.+P.+Gladueauthor=S.+H.+Coleauthor=M.+L.+Roachauthor=L.+A.+Tylaskaauthor=R.+T.+Nelsonauthor=R.+M.+Shepardauthor=J.+D.+McNeishauthor=K.+T.+Ogborneauthor=K.+S.+Neote&title=The+human+specific+CCR1+antagonist+CP-481%2C715+inhibits+cell+infiltration+and+inflammatory+responses+in+human+CCR1+transgenic+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The Human Specific CCR1 Antagonist CP-481715 Inhibits Cell Infiltration and Inflammatory Responses in Human CCR1 Transgenic Mice</span></div><div class="casAuthors">Gladue, Ronald P.; Cole, Susan H.; Roach, Marsha L.; Tylaska, Laurie A.; Nelson, Robin T.; Shepard, Richard M.; McNeish, John D.; Ogborne, Kevin T.; Neote, Kuldeep S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3141-3148</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">We previously described the in vitro characteristics of the potent and selective CCR1 antagonist, CP-481715.  In addn. to being selective for CCR1 vs. other chemokine receptors, CP-481715 is also specific for human CCR1 (hCCR1), preventing its evaluation in classical animal models.  To address this, we generated mice whereby murine CCR1 was replaced by hCCR1 (knockin) and used these animals to assess the anti-inflammatory properties of CP-481715.  Cells isolated from hCCR1 knockin mice were shown to express hCCR1 and migrate in response to both murine CCR1 and hCCR1 ligands.  Furthermore, this migration is inhibited by CP-481715 at dose levels comparable to those obtained with human cells.  In animal models of cell infiltration, CP-481715 inhibited CCL3-induced neutrophil infiltration into skin or into an air pouch with an ED50 of 0.2 mg/kg.  CP-481715 did not inhibit cell infiltration in wild-type animals expressing murine CCR1.  In a more generalized model of inflammation, delayed-type hypersensitivity, CP-481715 significantly inhibited footpad swelling and decreased the amt. of IFN-Î³ and IL-2 produced by isolated spleen cells from sensitized animals.  It did not, however, induce tolerance to a subsequent challenge.  These studies illustrate the utility of hCCR1 knockin animals to assess the activity of human specific CCR1 antagonists; demonstrate the ability of the CCR1 antagonist CP-481,715 to inhibit cell infiltration, inflammation, and Th1 cytokine responses in these animals; and suggest that CP-481,715 may be useful to modulate inflammatory responses in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1zjHkTdkoArVg90H21EOLACvtfcHk0libDw3mVObEgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7o%253D&md5=5f30e7c431259c6bd073021f22875eb6</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.5.3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.5.3141%26sid%3Dliteratum%253Aachs%26aulast%3DGladue%26aufirst%3DR.%2BP.%26aulast%3DCole%26aufirst%3DS.%2BH.%26aulast%3DRoach%26aufirst%3DM.%2BL.%26aulast%3DTylaska%26aufirst%3DL.%2BA.%26aulast%3DNelson%26aufirst%3DR.%2BT.%26aulast%3DShepard%26aufirst%3DR.%2BM.%26aulast%3DMcNeish%26aufirst%3DJ.%2BD.%26aulast%3DOgborne%26aufirst%3DK.%2BT.%26aulast%3DNeote%26aufirst%3DK.%2BS.%26atitle%3DThe%2520human%2520specific%2520CCR1%2520antagonist%2520CP-481%252C715%2520inhibits%2520cell%2520infiltration%2520and%2520inflammatory%2520responses%2520in%2520human%2520CCR1%2520transgenic%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D3141%26epage%3D3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Zhang, P.; Pennell, A. M. K.; Wright, J. J. K.; Wei, C.; Leleti, M. R.; Li, Y.; Li, L.; Xu, Y.</span><span> </span><span class="NLM_article-title">Azaindazole Compounds and Methods of Use</span>. US 7,524,845,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=P.+Zhang&author=A.+M.+K.+Pennell&author=J.+J.+K.+Wright&author=C.+Wei&author=M.+R.+Leleti&author=Y.+Li&author=L.+Li&author=Y.+Xu&title=Azaindazole+Compounds+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DAzaindazole%2520Compounds%2520and%2520Methods%2520of%2520Use%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Dairaghi, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">â</span> <span class="NLM_lpage">734</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fclpt.2011.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21451509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltVGntrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=726-734&author=D.+J.+Dairaghiauthor=P.+Zhangauthor=Y.+Wangauthor=L.+C.+Seitzauthor=D.+A.+Johnsonauthor=S.+Miaoauthor=L.+S.+Ertlauthor=Y.+Zengauthor=J.+P.+Powersauthor=A.+M.+Pennellauthor=P.+Bekkerauthor=T.+J.+Schallauthor=J.+C.+Jaen&title=Pharmacokinetic+and+pharmacodynamic+evaluation+of+the+novel+CCR1+antagonist+CCX354+in+healthy+human+subjects%3A+implications+for+selection+of+clinical+dose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose</span></div><div class="casAuthors">Dairaghi, D. J.; Zhang, P.; Wang, Y.; Seitz, L. C.; Johnson, D. A.; Miao, S.; Ertl, L. S.; Zeng, Y.; Powers, J. P.; Pennell, A. M.; Bekker, P.; Schall, T. J.; Jaen, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">726-734</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The safety and pharmacokinetic (PK)/pharmacodynamic (PD) profile of the novel CCR1 antagonist CCX354 was evaluated in double-blind, placebo-controlled, single- and multiple-dose phase I studies (1-300 mg/day oral doses).  CCX354 was well tolerated and displayed a linear dose-exposure profile, with half-life approaching 7 h at the 300-mg dose.  The extent of CCR1 receptor blockade on blood monocytes, which correlated well with plasma concns. of the drug, was assessed using fluorescently labeled CCL3 binding in whole blood from phase I subjects.  High levels of receptor coverage at the 12-h time point were achieved after a single dose of 100 mg CCX354.  Preclin. studies indicate that effective blockade of inflammatory cell infiltration into tissues requires â¥90% CCR1 inhibition on blood leukocytes at all times.  The comparison of the properties of CCX354 with those published for other CCR1 antagonists has informed the dose selection for ongoing clin. development of CCX354 in rheumatoid arthritis (RA).  Clin. Pharmacol. & Therapeutics (2011) 89 5, 726-734. doi:10.1038/clpt.2011.33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9eP6NqC1T_7Vg90H21EOLACvtfcHk0lgHiP1G2Sc8-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltVGntrY%253D&md5=421113bb424cf42c66b34fc404155cc1</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.33%26sid%3Dliteratum%253Aachs%26aulast%3DDairaghi%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSeitz%26aufirst%3DL.%2BC.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DErtl%26aufirst%3DL.%2BS.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DPennell%26aufirst%3DA.%2BM.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520evaluation%2520of%2520the%2520novel%2520CCR1%2520antagonist%2520CCX354%2520in%2520healthy%2520human%2520subjects%253A%2520implications%2520for%2520selection%2520of%2520clinical%2520dose%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D726%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Tak, P. P.; Balanescu, A.; Tseluyko, V.; Bojin, S.; Drescher, E.; Dairaghi, D.; Miao, S.; Marchesin, V.; Jaen, J.; Bekker, P.; Schall, T. J.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase 2 Rheumatoid Arthritis Study</span>. Presented at the 2011 American College of Rheumatology/Association of Reproductive Health Professionals (ACR/ARHP) Annual Meeting, Chicago, IL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="https://acr.confex.com/acr/2011/webprogram/Paper24548.html" class="extLink">https://acr.confex.com/acr/2011/webprogram/Paper24548.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+P.+Tak&author=A.+Balanescu&author=V.+Tseluyko&author=S.+Bojin&author=E.+Drescher&author=D.+Dairaghi&author=S.+Miao&author=V.+Marchesin&author=J.+Jaen&author=P.+Bekker&author=T.+J.+Schall&title=Safety+and+Efficacy+of+Oral+Chemokine+Receptor+1+Antagonist+CCX354-C+in+a+Phase+2+Rheumatoid+Arthritis+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Oral%2520Chemokine%2520Receptor%25201%2520Antagonist%2520CCX354-C%2520in%2520a%2520Phase%25202%2520Rheumatoid%2520Arthritis%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span>Merck's Research Pipeline and Selected Licensing Partners. Annual Report 2004. <a href="http://www.merck.com/finance/annualreport/ar2004/research_pipeline/" class="extLink">http://www.merck.com/finance/annualreport/ar2004/research_pipeline/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Merck%27s+Research+Pipeline+and+Selected+Licensing+Partners.+Annual+Report+2004.+http%3A%2F%2Fwww.merck.com%2Ffinance%2Fannualreport%2Far2004%2Fresearch_pipeline%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Naya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, N.</span><span> </span><span class="NLM_article-title">Structureâactivity relationships of xanthene carboxamides, novel CCR1 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">884</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=875-884&author=A.+Nayaauthor=M.+Ishikawaauthor=K.+Matsudaauthor=K.+Ohwakiauthor=T.+Saekiauthor=K.+Noguchiauthor=N.+Ohtake&title=Structure%E2%80%93activity+relationships+of+xanthene+carboxamides%2C+novel+CCR1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaya%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DOhwaki%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DOhtake%26aufirst%3DN.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%2520xanthene%2520carboxamides%252C%2520novel%2520CCR1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D875%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Kerstjens, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjermer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span> </span><span class="NLM_article-title">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1297</span><span class="NLM_x">â</span> <span class="NLM_lpage">1303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.rmed.2010.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20466530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=1297-1303&author=H.+A.+Kerstjensauthor=L.+Bjermerauthor=L.+Erikssonauthor=K.+Dahlstromauthor=J.+Vestbo&title=Tolerability+and+efficacy+of+inhaled+AZD4818%2C+a+CCR1+antagonist%2C+in+moderate+to+severe+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span></div><div class="casAuthors">Kerstjens Huib A; Bjermer Leif; Eriksson Leif; Dahlstrom Kerstin; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1297-303</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in patients with COPD.  METHODS:  This double-blind, placebo-controlled study (NCT00629239) randomised patients with moderate to severe COPD to AZD4818 300mug or placebo twice daily via Turbuhaler((R)) for 4 weeks.  Safety, lung function, functional capacity and health status measures were measured.  Plasma concentrations of AZD4818 were measured after the first dose and after 2 and 4 weeks' treatment.  RESULTS:  Sixty-five patients (47 male; median age 65.6 years) received AZD4818 (n=33) or placebo (n=32).  There was no statistically significant difference between AZD4818 and placebo in change from baseline to endpoint for FEV(1) (AZD4818-placebo: 0.026L, p=0.69), morning PEF (-6L/min, p=0.23), or other lung function measures.  There was no difference between treatment groups in the 6-min walk test, MMRC dyspnoea index, BODE index and CCQ scores.  Plasma concentrations indicated that patients were exposed to AZD4818 as expected.  AZD4818 was well tolerated: 27 treatment-related adverse events (13 with AZD4818, 14 with placebo), 2 serious adverse events (both AZD4818: exacerbation [considered not treatment-related] and deep vein thrombosis [considered treatment-related]) and 11 discontinuations (7 with AZD4818).  CONCLUSIONS:  Inhaled AZD4818 was well tolerated at 300mug twice daily for 4 weeks in patients with COPD; however, there was no indication of a beneficial treatment effect despite exposure as expected.  These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReNiH0l3TS4ZWtyewyzkyLfW6udTcc2ebzYm27sjZn-bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D&md5=157554642d8a8d754ca22d56328ce6f7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DKerstjens%26aufirst%3DH.%2BA.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DEriksson%26aufirst%3DL.%26aulast%3DDahlstrom%26aufirst%3DK.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DTolerability%2520and%2520efficacy%2520of%2520inhaled%2520AZD4818%252C%2520a%2520CCR1%2520antagonist%252C%2520in%2520moderate%2520to%2520severe%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2010%26volume%3D104%26spage%3D1297%26epage%3D1303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Butora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicario, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3636</span><span class="NLM_x">â</span> <span class="NLM_lpage">3641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3636-3641&author=G.+Butoraauthor=R.+Jiaoauthor=W.+H.+Parsonsauthor=P.+P.+Vicarioauthor=H.+Jinauthor=J.+M.+Ayalaauthor=M.+A.+Cascieriauthor=L.+Yang&title=3-Amino-1-alkyl-cyclopentane+carboxamides+as+small+molecule+antagonists+of+the+human+and+murine+CC+chemokine+receptor+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DButora%26aufirst%3DG.%26aulast%3DJiao%26aufirst%3DR.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DVicario%26aufirst%3DP.%2BP.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DAyala%26aufirst%3DJ.%2BM.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DL.%26atitle%3D3-Amino-1-alkyl-cyclopentane%2520carboxamides%2520as%2520small%2520molecule%2520antagonists%2520of%2520the%2520human%2520and%2520murine%2520CC%2520chemokine%2520receptor%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3636%26epage%3D3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Butora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morriello, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothandaraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiadeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasternak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacCoss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicario, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4715</span><span class="NLM_x">â</span> <span class="NLM_lpage">4722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4715-4722&author=G.+Butoraauthor=G.+J.+Morrielloauthor=S.+Kothandaramanauthor=D.+Guiadeenauthor=A.+Pasternakauthor=W.+H.+Parsonsauthor=M.+MacCossauthor=P.+P.+Vicarioauthor=M.+A.+Cascieriauthor=L.+Yang&title=4-Amino-2-alkyl-butyramides+as+small+molecule+CCR2+antagonists+with+favorable+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DButora%26aufirst%3DG.%26aulast%3DMorriello%26aufirst%3DG.%2BJ.%26aulast%3DKothandaraman%26aufirst%3DS.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DVicario%26aufirst%3DP.%2BP.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DL.%26atitle%3D4-Amino-2-alkyl-butyramides%2520as%2520small%2520molecule%2520CCR2%2520antagonists%2520with%2520favorable%2520pharmacokinetic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4715%26epage%3D4722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Yang, L.; Jiao, R. X.; Moyes, C.; Morriello, G.; Butora, G.; Shankaran, K.; Pasternak, A.; Goble, S. D.; Zhou, C.; MacCoss, M.; Cumiskey, A. M.; Peterson, L.; Forrest, M.; Ayala, J.; Jin, H.; DeMartino, J.; Mills, S. G.</span><span> </span><span class="NLM_article-title">The Discovery of MK-0812, a Potent and Selective CCR2 Antagonist</span>. Presented at the 233rd National Meeting of the American Chemical Society, Chicago, IL, Mar 25â29,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.acsmedchem.org/mediabstracts2007.pdf" class="extLink">www.acsmedchem.org/mediabstracts2007.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Yang&author=R.+X.+Jiao&author=C.+Moyes&author=G.+Morriello&author=G.+Butora&author=K.+Shankaran&author=A.+Pasternak&author=S.+D.+Goble&author=C.+Zhou&author=M.+MacCoss&author=A.+M.+Cumiskey&author=L.+Peterson&author=M.+Forrest&author=J.+Ayala&author=H.+Jin&author=J.+DeMartino&author=S.+G.+Mills&title=The+Discovery+of+MK-0812%2C+a+Potent+and+Selective+CCR2+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26atitle%3DThe%2520Discovery%2520of%2520MK-0812%252C%2520a%2520Potent%2520and%2520Selective%2520CCR2%2520Antagonist%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span>ClinicalTrials.gov. A Study To Assess the Effects of MK0812 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis As Measured by Magnetic Resonance Imaging (MRI). <a href="http://clinicaltrials.gov/ct2/show/record/NCT00239655" class="extLink">http://clinicaltrials.gov/ct2/show/record/NCT00239655</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Study+To+Assess+the+Effects+of+MK0812+on+Disease+Activity+in+Patients+with+Relapsing-Remitting+Multiple+Sclerosis+As+Measured+by+Magnetic+Resonance+Imaging+%28MRI%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00239655."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Abbadie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindia, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudgett, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayne, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span> </span><span class="NLM_article-title">Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">7947</span><span class="NLM_x">â</span> <span class="NLM_lpage">7952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=7947-7952&author=C.+Abbadieauthor=J.+A.+Lindiaauthor=A.+M.+Cumiskeyauthor=L.+B.+Petersonauthor=J.+S.+Mudgettauthor=E.+K.+Bayneauthor=J.+A.+DeMartinoauthor=D.+E.+MacIntyreauthor=M.+J.+Forrest&title=Impaired+neuropathic+pain+responses+in+mice+lacking+the+chemokine+receptor+CCR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbbadie%26aufirst%3DC.%26aulast%3DLindia%26aufirst%3DJ.%2BA.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DMudgett%26aufirst%3DJ.%2BS.%26aulast%3DBayne%26aufirst%3DE.%2BK.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26atitle%3DImpaired%2520neuropathic%2520pain%2520responses%2520in%2520mice%2520lacking%2520the%2520chemokine%2520receptor%2520CCR2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D7947%26epage%3D7952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Abbadie, C.; Lindia, J. A.; Wang, H.</span><span> </span><span class="NLM_article-title">CCR2 Antagonists for Treatment of Neuropathic Pain</span>. US 20060205761,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+Abbadie&author=J.+A.+Lindia&author=H.+Wang&title=CCR2+Antagonists+for+Treatment+of+Neuropathic+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbbadie%26aufirst%3DC.%26atitle%3DCCR2%2520Antagonists%2520for%2520Treatment%2520of%2520Neuropathic%2520Pain%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Brodmerkel, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leffet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">5370</span><span class="NLM_x">â</span> <span class="NLM_lpage">5378</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2005&pages=5370-5378&author=C.+M.+Brodmerkelauthor=R.+Huberauthor=M.+Covingtonauthor=S.+Diamondauthor=L.+Hallauthor=R.+Collinsauthor=L.+Leffetauthor=K.+Gallagherauthor=P.+Feldmanauthor=P.+Collierauthor=M.+Stowauthor=X.+Guauthor=F.+Baribaudauthor=N.+Shinauthor=B.+Thomasauthor=T.+Burnauthor=G.+Hollisauthor=S.+Yeleswaramauthor=K.+Solomonauthor=S.+Friedmanauthor=A.+Wangauthor=C.+B.+Xueauthor=R.+C.+Newtonauthor=P.+Scherleauthor=K.+Vaddi&title=Discovery+and+pharmacological+characterization+of+a+novel+rodent-active+CCR2+antagonist%2C+INCB3344"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrodmerkel%26aufirst%3DC.%2BM.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DGallagher%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DP.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DStow%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DXue%26aufirst%3DC.%2BB.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520pharmacological%2520characterization%2520of%2520a%2520novel%2520rodent-active%2520CCR2%2520antagonist%252C%2520INCB3344%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D175%26spage%3D5370%26epage%3D5378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Xue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharief, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span> </span><span class="NLM_article-title">Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">450</span><span class="NLM_x">â</span> <span class="NLM_lpage">454</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200030q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=450-454&author=C.+Xueauthor=H.+Fengauthor=G.+Caoauthor=T.+Huangauthor=J.+Glennauthor=R.+Anandauthor=D.+Meloniauthor=K.+Zhangauthor=L.+Kongauthor=A.+Wangauthor=Y.+Zhangauthor=C.+Zhengauthor=M.+Xiaauthor=L.+Chenauthor=T.+Tanakaauthor=Q.+Hanauthor=D.+J.+Robinsonauthor=D.+Modiauthor=L.+Storaceauthor=L.+Shaoauthor=V.+Shariefauthor=M.+Liauthor=L.+G.+Galyaauthor=M.+Covingtonauthor=P.+Scherleauthor=S.+Diamondauthor=T.+Emmauthor=S.+Yeleswaramauthor=N.+Contelauthor=K.+Vaddiauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=B.+Metcalf&title=Discovery+of+INCB3284%2C+a+potent%2C+selective%2C+and+orally+bioavailable+hCCR2+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fml200030q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200030q%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DRobinson%26aufirst%3DD.%2BJ.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DStorace%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DSharief%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%2BG.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DContel%26aufirst%3DN.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DMetcalf%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520INCB3284%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520hCCR2%2520antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D450%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Hughes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutzler, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahinski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span> </span><span class="NLM_article-title">Discovery of ((1<i>S</i>,3<i>R</i>)-1-isopropyl-3-((3<i>S</i>,4<i>S</i>)-3-methoxy-tetrahydro-2<i>H</i>-pyran-4-ylamino)cyclopent yl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2626</span><span class="NLM_x">â</span> <span class="NLM_lpage">2630</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2626-2630&author=R.+O.+Hughesauthor=D.+J.+Rogierauthor=R.+Devrajauthor=C.+Zhengauthor=G.+Caoauthor=H.+Fengauthor=M.+Xiaauthor=R.+Anandauthor=L.+Xingauthor=J.+Glennauthor=K.+Zhangauthor=M.+Covingtonauthor=P.+A.+Mortonauthor=J.+M.+Hutzlerauthor=J.+W.+Davisauthor=P.+Scherleauthor=F.+Baribaudauthor=A.+Bahinskiauthor=Z.+L.+Moauthor=R.+Newtonauthor=B.+Metcalfauthor=C.+B.+Xue&title=Discovery+of+%28%281S%2C3R%29-1-isopropyl-3-%28%283S%2C4S%29-3-methoxy-tetrahydro-2H-pyran-4-ylamino%29cyclopent+yl%29%284-%285-%28trifluoromethyl%29pyridazin-3-yl%29piperazin-1-yl%29methanone%2C+PF-4254196%2C+a+CCR2+antagonist+with+an+improved+cardiovascular+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DR.%2BO.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DDevraj%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DMorton%26aufirst%3DP.%2BA.%26aulast%3DHutzler%26aufirst%3DJ.%2BM.%26aulast%3DDavis%26aufirst%3DJ.%2BW.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DBahinski%26aufirst%3DA.%26aulast%3DMo%26aufirst%3DZ.%2BL.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DC.%2BB.%26atitle%3DDiscovery%2520of%2520%2528%25281S%252C3R%2529-1-isopropyl-3-%2528%25283S%252C4S%2529-3-methoxy-tetrahydro-2H-pyran-4-ylamino%2529cyclopent%2520yl%2529%25284-%25285-%2528trifluoromethyl%2529pyridazin-3-yl%2529piperazin-1-yl%2529methanone%252C%2520PF-4254196%252C%2520a%2520CCR2%2520antagonist%2520with%2520an%2520improved%2520cardiovascular%2520profile%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2626%26epage%3D2630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Trujillo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1827</span><span class="NLM_x">â</span> <span class="NLM_lpage">1831</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1827-1831&author=J.+I.+Trujilloauthor=W.+Huangauthor=R.+O.+Hughesauthor=D.+J.+Rogierauthor=S.+R.+Turnerauthor=R.+Devrajauthor=P.+A.+Mortonauthor=C.+B.+Xueauthor=G.+Chaoauthor=M.+B.+Covingtonauthor=R.+C.+Newtonauthor=B.+Metcalf&title=Design+and+synthesis+of+novel+CCR2+antagonists%3A+investigation+of+non-aryl%2Fheteroaryl+binding+motifs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DHughes%26aufirst%3DR.%2BO.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DTurner%26aufirst%3DS.%2BR.%26aulast%3DDevraj%26aufirst%3DR.%26aulast%3DMorton%26aufirst%3DP.%2BA.%26aulast%3DXue%26aufirst%3DC.%2BB.%26aulast%3DChao%26aufirst%3DG.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520CCR2%2520antagonists%253A%2520investigation%2520of%2520non-aryl%252Fheteroaryl%2520binding%2520motifs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1827%26epage%3D1831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span> </span><span class="NLM_article-title">Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1442</span><span class="NLM_x">â</span> <span class="NLM_lpage">1446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1442-1446&author=C.+Zhengauthor=G.+Caoauthor=M.+Xiaauthor=H.+Fengauthor=J.+Glennauthor=R.+Anandauthor=K.+Zhangauthor=T.+Huangauthor=A.+Wangauthor=L.+Kongauthor=M.+Liauthor=L.+Galyaauthor=R.+O.+Hughesauthor=R.+Devrajauthor=P.+A.+Mortonauthor=D.+J.+Rogierauthor=M.+Covingtonauthor=F.+Baribaudauthor=N.+Shinauthor=P.+Scherleauthor=S.+Diamondauthor=S.+Yeleswaramauthor=K.+Vaddiauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=B.+Metcalfauthor=C.+B.+Xue&title=Discovery+of+INCB10820%2FPF-4178903%2C+a+potent%2C+selective%2C+and+orally+bioavailable+dual+CCR2+and+CCR5+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DHughes%26aufirst%3DR.%2BO.%26aulast%3DDevraj%26aufirst%3DR.%26aulast%3DMorton%26aufirst%3DP.%2BA.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DN.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DC.%2BB.%26atitle%3DDiscovery%2520of%2520INCB10820%252FPF-4178903%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520dual%2520CCR2%2520and%2520CCR5%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1442%26epage%3D1446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span>Incyte Announces First Quarter Financial Results and Provides Update on Drug Discovery and Development Programs. <a href="http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&amp;newsId=20060504005114&amp;newsLang=en" class="extLink">http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060504005114&newsLang=en</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Incyte+Announces+First+Quarter+Financial+Results+and+Provides+Update+on+Drug+Discovery+and+Development+Programs.+http%3A%2F%2Fwww.businesswire.com%2Fportal%2Fsite%2Fgoogle%2Findex.jsp%3FndmViewId%3Dnews_view%26newsId%3D20060504005114%26newsLang%3Den"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span>Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Subjects with Osteoarthritic Pain of the Knee. <a href="http://clinicaltrials.gov/ct2/show/NCT00689273?term=CCR2&amp;rank=4" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00689273?term=CCR2&rank=4</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Phase+2+Study+in+Subjects+with+Osteoarthritic+Pain+of+the+Knee.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00689273%3Fterm%3DCCR2%26rank%3D4."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Gilbert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lekstrom-Himes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span> </span><span class="NLM_article-title">Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">906</span><span class="NLM_x">â</span> <span class="NLM_lpage">911</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2011&pages=906-911&author=J.+Gilbertauthor=J.+Lekstrom-Himesauthor=D.+Donaldsonauthor=Y.+Leeauthor=M.+Huauthor=J.+Xuauthor=T.+Wyantauthor=M.+Davidson&title=Effect+of+CC+chemokine+receptor+2+CCR2+blockade+on+serum+C-reactive+protein+in+individuals+at+atherosclerotic+risk+and+with+a+single+nucleotide+polymorphism+of+the+monocyte+chemoattractant+protein-1+promoter+region"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26aulast%3DDonaldson%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DDavidson%26aufirst%3DM.%26atitle%3DEffect%2520of%2520CC%2520chemokine%2520receptor%25202%2520CCR2%2520blockade%2520on%2520serum%2520C-reactive%2520protein%2520in%2520individuals%2520at%2520atherosclerotic%2520risk%2520and%2520with%2520a%2520single%2520nucleotide%2520polymorphism%2520of%2520the%2520monocyte%2520chemoattractant%2520protein-1%2520promoter%2520region%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2011%26volume%3D107%26spage%3D906%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Sharrack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span> </span><span class="NLM_article-title">Frequent MRI study of a novel CCR2 antagonist in relapsing-remitting multiple sclerosis</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 11</span><span class="NLM_x">) </span> <span class="NLM_fpage">S74</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=S74&issue=Suppl.+11&author=B.+Sharrackauthor=T.+Leachauthor=E.+Jacobsonauthor=D.+D.+Donaldsonauthor=X.+Xuauthor=M.+Hu&title=Frequent+MRI+study+of+a+novel+CCR2+antagonist+in+relapsing-remitting+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharrack%26aufirst%3DB.%26aulast%3DLeach%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DE.%26aulast%3DDonaldson%26aufirst%3DD.%2BD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DFrequent%2520MRI%2520study%2520of%2520a%2520novel%2520CCR2%2520antagonist%2520in%2520relapsing-remitting%2520multiple%2520sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2007%26volume%3D62%26issue%3DSuppl.%252011%26spage%3DS74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Vergunst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopatinskaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klareskog, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Bosch, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinant, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baeten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1931</span><span class="NLM_x">â</span> <span class="NLM_lpage">1939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.23591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18576354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=1931-1939&author=C.+E.+Vergunstauthor=D.+M.+Gerlagauthor=L.+Lopatinskayaauthor=L.+Klareskogauthor=M.+D.+Smithauthor=F.+van+den+Boschauthor=H.+J.+Dinantauthor=Y.+Leeauthor=T.+Wyantauthor=E.+W.+Jacobsonauthor=D.+Baetenauthor=P.+P.+Tak&title=Modulation+of+CCR2+in+rheumatoid+arthritis%3A+a+double-blind%2C+randomized%2C+placebo-controlled+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial</span></div><div class="casAuthors">Vergunst, Clarissa E.; Gerlag, Danielle M.; Lopatinskaya, Luba; Klareskog, L.; Smith, M. D.; van den Bosch, F.; Dinant, Huib J.; Lee, Yih; Wyant, Timothy; Jacobson, Eric W.; Baeten, Dominique; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1931-1939</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: CCR2 is a chemokine receptor expressed by monocytes, macrophages, and a subset of T cells.  Its ligand, CCL2 (monocyte chemotactic protein 1), is abundantly present in the synovium of patients with rheumatoid arthritis (RA).  Blocking CCR2 prevents CCL2-mediated chemotaxis in vitro and modulates arthritis in animal models of RA.  In this study we examd. the effects of CCR2 blockade on synovial inflammation in RA.  Methods: The study was designed as a phase IIa clin. trial with a human CCR2 blocking antibody (MLN1202) in patients with active RA.  Thirty-two patients received 3 infusions, over a period of 6 wk, with either placebo (n = 9) or anti-CCR2 monoclonal antibody at 0.5 mg/kg (n = 7), 1.5 mg/kg (n = 7), or 4.0 mg/kg (n = 9).  Safety was monitored with lab. tests, immunotoxicity assessments, and documenting of adverse events, and European League Against Rheumatism and American College of Rheumatol. response criteria were used to assess clin. improvement.  Synovial tissue was obtained at baseline and after 43 days of treatment, for pharmacodynamic anal. using immunohistochem. and digital image anal.  The Kruskal-Wallis test was used to compare groups, and the Wilcoxon signed rank test was used to assess changes within the groups.  Results: All patients completed the study.  Treatment with CCR2 blocking antibody reduced the levels of free CCR2 on CD14+ monocytes by at least 57% and up to 94% (P < 0.001), demonstrating the biol. activity of the compd.  However, there was no redn. in the levels or expression of any of the synovial biomarkers.  Accordingly, no clin. improvement was obsd.  Conclusion: Treatment with anti-CCR2 blocking antibody did not result in amelioration of synovial inflammation in active RA.  The results do not support the notion that blockade of CCR2 may be sufficient to induce clin. improvement in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsazWDrk2LlbVg90H21EOLACvtfcHk0lgsSTBmrguvOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkurs%253D&md5=fa636d4f933ec772ee3dd9e96e378a72</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fart.23591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.23591%26sid%3Dliteratum%253Aachs%26aulast%3DVergunst%26aufirst%3DC.%2BE.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DLopatinskaya%26aufirst%3DL.%26aulast%3DKlareskog%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DF.%26aulast%3DDinant%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DBaeten%26aufirst%3DD.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DModulation%2520of%2520CCR2%2520in%2520rheumatoid%2520arthritis%253A%2520a%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520clinical%2520trial%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D1931%26epage%3D1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Charvat, T. T.; Hu, C.; Jin, J.; Li, Y.; Melikian, A.; Pennell, A. M. K.; Punna, S.; Ungashe, S.; Zeng, Y.</span><span> </span><span class="NLM_article-title">Triazolyl Pyridyl Benzenesulfonamides</span>. US 20080039504,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+T.+Charvat&author=C.+Hu&author=J.+Jin&author=Y.+Li&author=A.+Melikian&author=A.+M.+K.+Pennell&author=S.+Punna&author=S.+Ungashe&author=Y.+Zeng&title=Triazolyl+Pyridyl+Benzenesulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharvat%26aufirst%3DT.%2BT.%26atitle%3DTriazolyl%2520Pyridyl%2520Benzenesulfonamides%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Krasinski, A.; Punna, S.; Ungashe, S.; Wang, Q.; Zeng, Y.</span><span> </span><span class="NLM_article-title">Fused Heteroaryl Pyridyl and Phenyl Benzenesulfonamides as CCR2 Modulators for the Treatment of Inflammation</span>. US 7,884,110,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Krasinski&author=S.+Punna&author=S.+Ungashe&author=Q.+Wang&author=Y.+Zeng&title=Fused+Heteroaryl+Pyridyl+and+Phenyl+Benzenesulfonamides+as+CCR2+Modulators+for+the+Treatment+of+Inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKrasinski%26aufirst%3DA.%26atitle%3DFused%2520Heteroaryl%2520Pyridyl%2520and%2520Phenyl%2520Benzenesulfonamides%2520as%2520CCR2%2520Modulators%2520for%2520the%2520Treatment%2520of%2520Inflammation%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span>Chemocentryx/Inc. <a href="http://www.secinfo.com/d14D5a.t6zp.htm" class="extLink">http://www.secinfo.com/d14D5a.t6zp.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chemocentryx%2FInc.+http%3A%2F%2Fwww.secinfo.com%2Fd14D5a.t6zp.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Sullivan, T. J.; Dairaghi, D. J.; Krasinski, A.; Miao, Z.; Wang, Y.; Zhao, B. N.; Baumgart, T.; Berahovich, R.; Ertl, L. S.; Pennell, A.; Seitz, L.; Miao, S.; Ungashe, S.; Wei, Z.; Johnson, D.; Boring, L.; Tsou, C. L.; Charo, I. F.; Bekker, P.; Schall, T. J.; Jaen, J. C.</span><span> </span><span class="NLM_article-title">Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications</span>.  <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span> [Online early access]. DOI: <span class="refDoi">Â DOI: 10.1124/jpet.111.190918</span> . Published Online: Feb 29,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.111.190918" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=T.+J.+Sullivan&author=D.+J.+Dairaghi&author=A.+Krasinski&author=Z.+Miao&author=Y.+Wang&author=B.+N.+Zhao&author=T.+Baumgart&author=R.+Berahovich&author=L.+S.+Ertl&author=A.+Pennell&author=L.+Seitz&author=S.+Miao&author=S.+Ungashe&author=Z.+Wei&author=D.+Johnson&author=L.+Boring&author=C.+L.+Tsou&author=I.+F.+Charo&author=P.+Bekker&author=T.+J.+Schall&author=J.+C.+Jaen&title=Characterization+of+CCX140-B%2C+an+orally+bioavailable+antagonist+of+the+CCR2+chemokine+receptor%2C+for+the+treatment+of+type+2+diabetes+and+associated+complications&doi=10.1124%2Fjpet.111.190918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.190918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.190918%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DT.%2BJ.%26atitle%3DCharacterization%2520of%2520CCX140-B%252C%2520an%2520orally%2520bioavailable%2520antagonist%2520of%2520the%2520CCR2%2520chemokine%2520receptor%252C%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520and%2520associated%2520complications%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26doi%3D10.1124%2Fjpet.111.190918%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Hanefeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouni-Berthold, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melichar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesela, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T. J.</span><span> </span><span class="NLM_article-title">Oral chemokine receptor 2 antagonist CCX140-B shows safety and efficacy in type 2 diabetes mellitus</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">A85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=A85&author=M.+Hanefeldauthor=E.+Schellauthor=I.+Gouni-Bertholdauthor=M.+Melicharauthor=I.+Veselaauthor=T.+Sullivanauthor=S.+Miaoauthor=D.+Johnsonauthor=J.+Jaenauthor=P.+Bekkerauthor=T.+J.+Schall&title=Oral+chemokine+receptor+2+antagonist+CCX140-B+shows+safety+and+efficacy+in+type+2+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanefeld%26aufirst%3DM.%26aulast%3DSchell%26aufirst%3DE.%26aulast%3DGouni-Berthold%26aufirst%3DI.%26aulast%3DMelichar%26aufirst%3DM.%26aulast%3DVesela%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DT.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DJaen%26aufirst%3DJ.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26atitle%3DOral%2520chemokine%2520receptor%25202%2520antagonist%2520CCX140-B%2520shows%2520safety%2520and%2520efficacy%2520in%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDiabetes%26date%3D2011%26volume%3D60%26spage%3DA85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherney, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangion, I. K.</span><span> </span><span class="NLM_article-title">Advances in the discovery of CC chemokine receptor 2 antagonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=211-227&author=P.+H.+Carterauthor=R.+J.+Cherneyauthor=I.+K.+Mangion&title=Advances+in+the+discovery+of+CC+chemokine+receptor+2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DMangion%26aufirst%3DI.%2BK.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520CC%2520chemokine%2520receptor%25202%2520antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D211%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherney, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandlekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span> </span><span class="NLM_article-title">Discovery of an orally-bioavailable CC chemokine receptor 2 antagonist derived from an acyclic diaminoalcohol backbone</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3311</span><span class="NLM_x">â</span> <span class="NLM_lpage">3316</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3311-3316&author=P.+H.+Carterauthor=G.+D.+Brownauthor=S.+R.+Kingauthor=M.+E.+Vossauthor=A.+J.+Tebbenauthor=R.+J.+Cherneyauthor=S.+Mandlekarauthor=Y.+C.+Loauthor=G.+Yangauthor=P.+B.+Millerauthor=P.+A.+Scherleauthor=Q.+Zhaoauthor=C.+P.+Decicco&title=Discovery+of+an+orally-bioavailable+CC+chemokine+receptor+2+antagonist+derived+from+an+acyclic+diaminoalcohol+backbone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DKing%26aufirst%3DS.%2BR.%26aulast%3DVoss%26aufirst%3DM.%2BE.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DLo%26aufirst%3DY.%2BC.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DP.%2BB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26atitle%3DDiscovery%2520of%2520an%2520orally-bioavailable%2520CC%2520chemokine%2520receptor%25202%2520antagonist%2520derived%2520from%2520an%2520acyclic%2520diaminoalcohol%2520backbone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3311%26epage%3D3316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span>BMS-741672 for Diabetic Neuropathic Pain. <a href="http://clinicaltrials.gov/show/NCT00683423" class="extLink">http://clinicaltrials.gov/show/NCT00683423</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BMS-741672+for+Diabetic+Neuropathic+Pain.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT00683423."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span>Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance. <a href="http://clinicaltrials.gov/ct2/show/NCT00699790?term=CCR2&amp;rank=1" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00699790?term=CCR2&rank=1</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Proof+of+Confidence+Study+of+CCR2+Antagonist+%28BMS-741672%29+in+Insulin+Resistance.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00699790%3Fterm%3DCCR2%26rank%3D1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Lagu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerchak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaviya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavender, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachter, M.</span><span> </span><span class="NLM_article-title">Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4382</span><span class="NLM_x">â</span> <span class="NLM_lpage">4386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4382-4386&author=B.+Laguauthor=C.+Gerchakauthor=M.+Panauthor=C.+Houauthor=M.+Singerauthor=R.+Malaviyaauthor=M.+Matheisauthor=G.+Oliniauthor=D.+Cavenderauthor=M.+Wachter&title=Potent+and+selective+CC-chemokine+receptor-2+%28CCR2%29+antagonists+as+a+potential+treatment+for+asthma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DGerchak%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DMalaviya%26aufirst%3DR.%26aulast%3DMatheis%26aufirst%3DM.%26aulast%3DOlini%26aufirst%3DG.%26aulast%3DCavender%26aufirst%3DD.%26aulast%3DWachter%26aufirst%3DM.%26atitle%3DPotent%2520and%2520selective%2520CC-chemokine%2520receptor-2%2520%2528CCR2%2529%2520antagonists%2520as%2520a%2520potential%2520treatment%2520for%2520asthma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4382%26epage%3D4386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufnagel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâNeill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, Z.</span><span> </span><span class="NLM_article-title">Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6042</span><span class="NLM_x">â</span> <span class="NLM_lpage">6048</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6042-6048&author=X.+Zhangauthor=H.+Hufnagelauthor=C.+Houauthor=E.+Opasauthor=S.+McKenneyauthor=C.+Cryslerauthor=J.+O%E2%80%99Neillauthor=D.+Johnsonauthor=Z.+Sui&title=Design%2C+synthesis+and+SAR+of+indazole+and+benzoisoxazole+containing+4-azetidinyl-1-aryl-cyclohexanes+as+CCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHufnagel%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DOpas%26aufirst%3DE.%26aulast%3DMcKenney%26aufirst%3DS.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DSui%26aufirst%3DZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520SAR%2520of%2520indazole%2520and%2520benzoisoxazole%2520containing%25204-azetidinyl-1-aryl-cyclohexanes%2520as%2520CCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6042%26epage%3D6048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufnagel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markotan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, Z.</span><span> </span><span class="NLM_article-title">Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5577</span><span class="NLM_x">â</span> <span class="NLM_lpage">5582</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5577-5582&author=X.+Zhangauthor=H.+Hufnagelauthor=T.+Markotanauthor=J.+Lanterauthor=C.+Caiauthor=C.+Houauthor=M.+Singerauthor=E.+Opasauthor=S.+McKenneyauthor=C.+Cryslerauthor=D.+Johnsonauthor=Z.+Sui&title=Overcoming+hERG+activity+in+the+discovery+of+a+series+of+4-azetidinyl-1-aryl-cyclohexanes+as+CCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHufnagel%26aufirst%3DH.%26aulast%3DMarkotan%26aufirst%3DT.%26aulast%3DLanter%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DOpas%26aufirst%3DE.%26aulast%3DMcKenney%26aufirst%3DS.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DSui%26aufirst%3DZ.%26atitle%3DOvercoming%2520hERG%2520activity%2520in%2520the%2520discovery%2520of%2520a%2520series%2520of%25204-azetidinyl-1-aryl-cyclohexanes%2520as%2520CCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5577%26epage%3D5582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Hou, C.; Singer, M.; Matheis, M.</span>; <span> </span><span class="NLM_article-title">JNJ-17166864, a Selective CCR2 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases</span>. Presented at the 104th International Conference American Thoracic Society, Toronto, Canada,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Hou&author=M.+Singer&author=M.+Matheis&title=JNJ-17166864%2C+a+Selective+CCR2+Antagonist+with+Potential+Therapeutic+Implications+for+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DC.%26atitle%3DJNJ-17166864%252C%2520a%2520Selective%2520CCR2%2520Antagonist%2520with%2520Potential%2520Therapeutic%2520Implications%2520for%2520Inflammatory%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santella, J. B.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncia, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1645</span><span class="NLM_x">â</span> <span class="NLM_lpage">1649</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1645-1649&author=J.+G.+Varnesauthor=D.+S.+Gardnerauthor=J.+B.+Santellaauthor=J.+V.+Dunciaauthor=M.+Estrellaauthor=P.+S.+Watsonauthor=C.+M.+Clarkauthor=S.+S.+Koauthor=P.+Welchauthor=M.+Covingtonauthor=N.+Stowellauthor=E.+Wadmanauthor=P.+Daviesauthor=K.+Solomonauthor=R.+C.+Newtonauthor=G.+L.+Trainorauthor=C.+P.+Deciccoauthor=D.+A.+Wacker&title=Discovery+of+N-propylurea+3-benzylpiperidines+as+selective+CC+chemokine+receptor-3+%28CCR3%29+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DEstrella%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DP.%2BS.%26aulast%3DClark%26aufirst%3DC.%2BM.%26aulast%3DKo%26aufirst%3DS.%2BS.%26aulast%3DWelch%26aufirst%3DP.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DStowell%26aufirst%3DN.%26aulast%3DWadman%26aufirst%3DE.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520of%2520N-propylurea%25203-benzylpiperidines%2520as%2520selective%2520CC%2520chemokine%2520receptor-3%2520%2528CCR3%2529%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1645%26epage%3D1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">De Lucca, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, U. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncia, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santella, J. B.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liauw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span> </span><span class="NLM_article-title">Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2194</span><span class="NLM_x">â</span> <span class="NLM_lpage">2211</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049530m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2194-2211&author=G.+V.+De+Luccaauthor=U.+T.+Kimauthor=B.+J.+Vargoauthor=J.+V.+Dunciaauthor=J.+B.+Santellaauthor=D.+S.+Gardnerauthor=C.+Zhengauthor=A.+Liauwauthor=Z.+Wangauthor=G.+Emmettauthor=D.+A.+Wackerauthor=P.+K.+Welchauthor=M.+Covingtonauthor=N.+C.+Stowellauthor=E.+A.+Wadmanauthor=A.+M.+Dasauthor=P.+Daviesauthor=S.+Yeleswaramauthor=D.+M.+Gradenauthor=K.+A.+Solomonauthor=R.+C.+Newtonauthor=G.+L.+Trainorauthor=C.+P.+Deciccoauthor=S.+S.+Ko&title=Discovery+of+CC+chemokine+receptor-3+%28CCR3%29+antagonists+with+picomolar+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm049530m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049530m%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DKim%26aufirst%3DU.%2BT.%26aulast%3DVargo%26aufirst%3DB.%2BJ.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DLiauw%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DEmmett%26aufirst%3DG.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DWelch%26aufirst%3DP.%2BK.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DStowell%26aufirst%3DN.%2BC.%26aulast%3DWadman%26aufirst%3DE.%2BA.%26aulast%3DDas%26aufirst%3DA.%2BM.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DGraden%26aufirst%3DD.%2BM.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DDiscovery%2520of%2520CC%2520chemokine%2520receptor-3%2520%2528CCR3%2529%2520antagonists%2520with%2520picomolar%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2194%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Pruitt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bostrom, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlovsky, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span> </span><span class="NLM_article-title">CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2992</span><span class="NLM_x">â</span> <span class="NLM_lpage">2997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2992-2997&author=J.+R.+Pruittauthor=D.+G.+Battauthor=D.+A.+Wackerauthor=L.+L.+Bostromauthor=S.+K.+Bookerauthor=E.+McLaughlinauthor=G.+C.+Houghtonauthor=J.+G.+Varnesauthor=D.+D.+Christauthor=M.+Covingtonauthor=A.+M.+Dasauthor=P.+Daviesauthor=D.+Gradenauthor=I.+Karivauthor=Y.+Orlovskyauthor=N.+C.+Stowellauthor=K.+G.+Vaddiauthor=E.+A.+Wadmanauthor=P.+K.+Welchauthor=S.+Yeleswaramauthor=K.+A.+Solomonauthor=R.+C.+Newtonauthor=C.+P.+Deciccoauthor=P.+H.+Carterauthor=S.+S.+Ko&title=CC+chemokine+receptor-3+%28CCR3%29+antagonists%3A+improving+the+selectivity+of+DPC168+by+reducing+central+ring+lipophilicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPruitt%26aufirst%3DJ.%2BR.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DBostrom%26aufirst%3DL.%2BL.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DMcLaughlin%26aufirst%3DE.%26aulast%3DHoughton%26aufirst%3DG.%2BC.%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DA.%2BM.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DGraden%26aufirst%3DD.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DOrlovsky%26aufirst%3DY.%26aulast%3DStowell%26aufirst%3DN.%2BC.%26aulast%3DVaddi%26aufirst%3DK.%2BG.%26aulast%3DWadman%26aufirst%3DE.%2BA.%26aulast%3DWelch%26aufirst%3DP.%2BK.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DCC%2520chemokine%2520receptor-3%2520%2528CCR3%2529%2520antagonists%253A%2520improving%2520the%2520selectivity%2520of%2520DPC168%2520by%2520reducing%2520central%2520ring%2520lipophilicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2992%26epage%3D2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Santella, J. B.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLucca, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandlekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncia, J. V.</span><span> </span><span class="NLM_article-title">From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">â</span> <span class="NLM_lpage">585</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=576-585&author=J.+B.+Santellaauthor=D.+S.+Gardnerauthor=W.+Yaoauthor=C.+Shiauthor=P.+Reddyauthor=A.+J.+Tebbenauthor=G.+V.+DeLuccaauthor=D.+A.+Wackerauthor=P.+S.+Watsonauthor=P.+K.+Welchauthor=E.+A.+Wadmanauthor=P.+Daviesauthor=K.+A.+Solomonauthor=D.+M.+Gradenauthor=S.+Yeleswaramauthor=S.+Mandlekarauthor=I.+Karivauthor=C.+P.+Deciccoauthor=S.+S.+Koauthor=P.+H.+Carterauthor=J.+V.+Duncia&title=From+rigid+cyclic+templates+to+conformationally+stabilized+acyclic+scaffolds.+Part+I%3A+the+discovery+of+CCR3+antagonist+development+candidate+BMS-639623+with+picomolar+inhibition+potency+against+eosinophil+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DDeLucca%26aufirst%3DG.%2BV.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DWatson%26aufirst%3DP.%2BS.%26aulast%3DWelch%26aufirst%3DP.%2BK.%26aulast%3DWadman%26aufirst%3DE.%2BA.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DGraden%26aufirst%3DD.%2BM.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DKo%26aufirst%3DS.%2BS.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26atitle%3DFrom%2520rigid%2520cyclic%2520templates%2520to%2520conformationally%2520stabilized%2520acyclic%2520scaffolds.%2520Part%2520I%253A%2520the%2520discovery%2520of%2520CCR3%2520antagonist%2520development%2520candidate%2520BMS-639623%2520with%2520picomolar%2520inhibition%2520potency%2520against%2520eosinophil%2520chemotaxis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D576%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Murdoch, R. D.</span> Presented at the 4th James Black Conference, The Challenges of Drug Discovery and Development, University of Hertfordshire, U.K., Sep 3,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Murdoch%2C+R.+D.+Presented+at+the+4th+James+Black+Conference%2C+The+Challenges+of+Drug+Discovery+and+Development%2C+University+of+Hertfordshire%2C+U.K.%2C+Sep+3%2C+2006."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMurdoch%26aufirst%3DR.%2BD.%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span>ClinicalTrials.gov. Oral GW766944 (Oral CCR3 Antagonist). <a href="http://clinicaltrials.gov/ct2/show/NCT01160224" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01160224</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Oral+GW766944+%28Oral+CCR3+Antagonist%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01160224."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Greiff, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlstrom-Emanuelsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erjefalt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widegren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, M.</span><span> </span><span class="NLM_article-title">Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1186%2F1465-9921-11-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20047687" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1-9&author=L.+Greiffauthor=C.+Ahlstrom-Emanuelssonauthor=A.+Bahlauthor=T.+Bengtssonauthor=K.+Dahlstromauthor=J.+Erjefaltauthor=H.+Widegrenauthor=M.+Andersson&title=Effects+of+a+dual+CCR3+and+H1-antagonist+on+symptoms+and+eosinophilic+inflammation+in+allergic+rhinitis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-17%26sid%3Dliteratum%253Aachs%26aulast%3DGreiff%26aufirst%3DL.%26aulast%3DAhlstrom-Emanuelsson%26aufirst%3DC.%26aulast%3DBahl%26aufirst%3DA.%26aulast%3DBengtsson%26aufirst%3DT.%26aulast%3DDahlstrom%26aufirst%3DK.%26aulast%3DErjefalt%26aufirst%3DJ.%26aulast%3DWidegren%26aufirst%3DH.%26aulast%3DAndersson%26aufirst%3DM.%26atitle%3DEffects%2520of%2520a%2520dual%2520CCR3%2520and%2520H1-antagonist%2520on%2520symptoms%2520and%2520eosinophilic%2520inflammation%2520in%2520allergic%2520rhinitis%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Pascoe, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bangert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stary, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stingl, G.</span><span> </span><span class="NLM_article-title">QAP642, a CCR3 antagonist, attenuates eotaxin induced eosnlophil accumulation in the skin</span> <span class="citation_source-journal">Am. J. Resp. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">A484</span><div class="note"><p class="first last"> (abstracts issue)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2007&pages=A484&author=S.+J.+Pascoeauthor=C.+Bangertauthor=M.+Bartlettauthor=G.+Staryauthor=G.+Stingl&title=QAP642%2C+a+CCR3+antagonist%2C+attenuates+eotaxin+induced+eosnlophil+accumulation+in+the+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPascoe%26aufirst%3DS.%2BJ.%26aulast%3DBangert%26aufirst%3DC.%26aulast%3DBartlett%26aufirst%3DM.%26aulast%3DStary%26aufirst%3DG.%26aulast%3DStingl%26aufirst%3DG.%26atitle%3DQAP642%252C%2520a%2520CCR3%2520antagonist%252C%2520attenuates%2520eotaxin%2520induced%2520eosnlophil%2520accumulation%2520in%2520the%2520skin%26jtitle%3DAm.%2520J.%2520Resp.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D175%26spage%3DA484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Toda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohbayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aye, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S. J.</span><span> </span><span class="NLM_article-title">Mechanisms of leukocyte trafficking in allergic diseases: insights into new therapies targeting chemokines and chemokine receptors</span> <span class="citation_source-journal">Expert Rev. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">â</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1586%2F1744666X.3.3.351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20477679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsV2qtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=351-364&author=M.+Todaauthor=T.+Nakamuraauthor=M.+Ohbayashiauthor=Y.+Ikedaauthor=M.+Dawsonauthor=C.+C.+Ayeauthor=D.+Miyazakiauthor=S.+J.+Ono&title=Mechanisms+of+leukocyte+trafficking+in+allergic+diseases%3A+insights+into+new+therapies+targeting+chemokines+and+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of leukocyte trafficking in allergic diseases: insights into new therapies targeting chemokines and chemokine receptors</span></div><div class="casAuthors">Toda, Masako; Nakamura, Takao; Ohbayashi, Masaharu; Ikeda, Yoshifumi; Dawson, Maria; Aye, Cho Cho; Miyazaki, Dai; Ono, Santa Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-364</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Marked inflammatory infiltration by activated leukocytes is a characteristic feature of allergic diseases.  Elucidation of the mechanisms of leukocyte trafficking in allergic diseases would identify targets to establish novel anti-inflammatory strategies for treatment of these diseases.  Leukocyte trafficking is controlled by tissue-specific expression of chemokines and chemokine receptor expression on the leukocyte surface.  Here, we review the role of chemokines and their receptors in leukocyte trafficking to inflammatory sites in allergic diseases and discuss therapeutic strategies targeting chemokine networks for treatment of these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4d5hMMm2mLVg90H21EOLACvtfcHk0li3JOkDAIip1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsV2qtrw%253D&md5=9b979e00136f85125a56ad13f8d36364</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1586%2F1744666X.3.3.351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F1744666X.3.3.351%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DOhbayashi%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DDawson%26aufirst%3DM.%26aulast%3DAye%26aufirst%3DC.%2BC.%26aulast%3DMiyazaki%26aufirst%3DD.%26aulast%3DOno%26aufirst%3DS.%2BJ.%26atitle%3DMechanisms%2520of%2520leukocyte%2520trafficking%2520in%2520allergic%2520diseases%253A%2520insights%2520into%2520new%2520therapies%2520targeting%2520chemokines%2520and%2520chemokine%2520receptors%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2007%26volume%3D3%26spage%3D351%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Gauvreau, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulet, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baatjes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschesnes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strinich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzi, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâByrne, P. M.</span><span> </span><span class="NLM_article-title">Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">â</span> <span class="NLM_lpage">958</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1164%2Frccm.200708-1251OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18244953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1Ohs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2008&pages=952-958&author=G.+M.+Gauvreauauthor=L.+P.+Bouletauthor=D.+W.+Cockcroftauthor=A.+Baatjesauthor=J.+Coteauthor=F.+Deschesnesauthor=B.+Davisauthor=T.+Strinichauthor=K.+Howieauthor=M.+Duongauthor=R.+M.+Watsonauthor=P.+M.+Renziauthor=P.+M.+O%E2%80%99Byrne&title=Antisense+therapy+against+CCR3+and+the+common+beta+chain+attenuates+allergen-induced+eosinophilic+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses</span></div><div class="casAuthors">Gauvreau, Gail M.; Boulet, Louis Philippe; Cockcroft, Donald W.; Baatjes, Adrian; Cote, Johanne; Deschesnes, Francine; Davis, Beth; Strinich, Tara; Howie, Karen; Duong, MyLinh; Watson, Richard M.; Renzi, Paolo M.; O'Byrne, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">952-958</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (Î²c) of IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptors.  Objectives: This study examd. the effects of inhaled TPI ASM8 on sputum cellular influx, CCR3 and Î²c mRNA and protein levels, and the airway physiol. response after inhaled allergen.  Methods: Seventeen subjects with mild atopic asthma were randomized in a crossover study to inhale 1,500 Î¼g TPI ASM8 or placebo by nebulizer, once daily for 4 days.  On Day 3, subjects underwent allergen inhalation challenge.  Sputum samples were collected before and after allergen.  CCR3 and Î²c protein levels were measured by flow cytometry, mRNA was measured using real-time quant. polymerase chain reaction, and the FEV1 was measured over 7 h after challenge.  Measurements and Main Results: Compared with placebo, TPI ASM8 inhibited sputum eosinophil influx by 46% (P = 0.02) and blunted the increase in total cells (63%) after allergen challenge.  TPI ASM8 significantly reduced the early asthmatic response (P = 0.04) with a trend for the late asthmatic response (P = 0.08).  The allergen-induced (Day 2 to Day 3) levels of Î²c mRNA and CCR3 mRNA in sputum-derived cells were inhibited by TPI ASM8 (P = 0.039 and P = 0.054, resp.), with no significant effects on the cell surface protein expression of CCR3 and Î²c (P > 0.05).  No serious adverse events were reported.  Conclusions: TPI ASM8 attenuates the allergen-induced increase in target gene mRNA and airway responses in subjects with mild asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpegpWtd6yuGrVg90H21EOLACvtfcHk0li3JOkDAIip1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1Ohs7Y%253D&md5=2186d226b9894b7a73bf3b3ff098df96</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1164%2Frccm.200708-1251OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200708-1251OC%26sid%3Dliteratum%253Aachs%26aulast%3DGauvreau%26aufirst%3DG.%2BM.%26aulast%3DBoulet%26aufirst%3DL.%2BP.%26aulast%3DCockcroft%26aufirst%3DD.%2BW.%26aulast%3DBaatjes%26aufirst%3DA.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DDeschesnes%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DB.%26aulast%3DStrinich%26aufirst%3DT.%26aulast%3DHowie%26aufirst%3DK.%26aulast%3DDuong%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DR.%2BM.%26aulast%3DRenzi%26aufirst%3DP.%2BM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26atitle%3DAntisense%2520therapy%2520against%2520CCR3%2520and%2520the%2520common%2520beta%2520chain%2520attenuates%2520allergen-induced%2520eosinophilic%2520responses%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D177%26spage%3D952%26epage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Imaoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babirad, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehmi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvreau, G. M.</span><span> </span><span class="NLM_article-title">TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1740</span><span class="NLM_x">â</span> <span class="NLM_lpage">1746</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1365-2222.2011.03816.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21762225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2ntrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=1740-1746&author=H.+Imaokaauthor=H.+Campbellauthor=I.+Babiradauthor=R.+M.+Watsonauthor=M.+Mistryauthor=R.+Sehmiauthor=G.+M.+Gauvreau&title=TPI+ASM8+reduces+eosinophil+progenitors+in+sputum+after+allergen+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge</span></div><div class="casAuthors">Imaoka, H.; Campbell, H.; Babirad, I.; Watson, R. M.; Mistry, M.; Sehmi, R.; Gauvreau, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Allergy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1740-1746</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides (AON), one targeting the common beta chain (Î²c) of the IL-3/IL-5/GM-CSF receptors and the other targeting the chemokine receptor CCR3.  Inhalation of TPI ASM8 significantly improves lung function and sputum eosinophilia after allergen inhalation challenge in asthmatics.  Objective This study assessed whether TPI ASM8 reduces airway levels of haemopoietic progenitor cells.  Methods This open-label study was conducted in 14 stable, allergic mild asthmatic subjects with early- and late-phase allergen-induced bronchoconstriction.  Subjects underwent allergen challenges after 4-day treatment with placebo, 4 mg b.i.d. and 8 mg o.d. of TPI ASM8.  Sputum was induced before, 7 and 24 h after allergen challenges for progenitor measurements.  Treatments were sepd. by 2-3 wk.  Results TPI ASM8 reduced allergen-induced sputum eosinophils, and the early and late asthmatic responses (P<0.05).  TPI ASM8 also reduced the no. of CD34+CCR3+ cells (F= 0.004) and CD34+IL-5RÎ±+ cells (P= 0.016), and the proportion of CD34+ cells expressing H-5RÎ± (P= 0.036).  Conclusions and Clin. Relevance TPI ASM8 was safe and well tolerated.  The results of this study demonstrate blocking of CCR3 and Î²c expression by TPI ASM8 significantly inhibits the accumulation of eosinophils and eosinophil progenitors in the airways after allergen challenge.  Inhibition of airway progenitor cell accumulation presents a novel therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcTHNNaWhBTLVg90H21EOLACvtfcHk0li3JOkDAIip1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2ntrw%253D&md5=bea38bc6f1d7216a609817c418bbc792</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2011.03816.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2011.03816.x%26sid%3Dliteratum%253Aachs%26aulast%3DImaoka%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DH.%26aulast%3DBabirad%26aufirst%3DI.%26aulast%3DWatson%26aufirst%3DR.%2BM.%26aulast%3DMistry%26aufirst%3DM.%26aulast%3DSehmi%26aufirst%3DR.%26aulast%3DGauvreau%26aufirst%3DG.%2BM.%26atitle%3DTPI%2520ASM8%2520reduces%2520eosinophil%2520progenitors%2520in%2520sputum%2520after%2520allergen%2520challenge%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2011%26volume%3D41%26spage%3D1740%26epage%3D1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akatsuka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shitara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utsunomiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">7529</span><span class="NLM_x">â</span> <span class="NLM_lpage">7539</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1158%2F1078-0432.CCR-04-0983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15569983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVanur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7529-7539&author=T.+Ishidaauthor=S.+Iidaauthor=Y.+Akatsukaauthor=T.+Ishiiauthor=M.+Miyazakiauthor=H.+Komatsuauthor=H.+Inagakiauthor=N.+Okadaauthor=T.+Fujitaauthor=K.+Shitaraauthor=S.+Akinagaauthor=T.+Takahashiauthor=A.+Utsunomiyaauthor=R.+Ueda&title=The+CC+chemokine+receptor+4+as+a+novel+specific+molecular+target+for+immunotherapy+in+adult+T-cell+leukemia%2Flymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma</span></div><div class="casAuthors">Ishida, Takashi; Iida, Shinsuke; Akatsuka, Yoshiki; Ishii, Toshihiko; Miyazaki, Mikinori; Komatsu, Hirokazu; Inagaki, Hiroshi; Okada, Noriko; Fujita, Teizo; Shitara, Kenya; Akinaga, Shiro; Takahashi, Toshitada; Utsunomiya, Atae; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7529-7539</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm with dismal prognosis, and no optimal therapy has been developed.  The authors tested the defucosylated chimeric anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, KM2760, to develop a novel immunotherapy for this refractory tumor.  In the presence of peripheral blood mononuclear cells (PBMCs) from healthy adult donors, KM2760 induced CCR4-specific antibody-dependent cellular cytotoxicity (ADCC) against CCR4-pos. ATLL cell lines and primary tumor cells obtained from ATLL patients.  The authors next examd. the KM2760-induced ADCC against primary ATLL cells in an autologous setting.  Antibody-dependent cellular cytotoxicity mediated by autologous effector cells was generally lower than that mediated by allogeneic control effector cells.  However, a robust ADCC activity was induced in some cases, which was comparable with that mediated by allogeneic effector cells.  This suggests that the ATLL patients' PBMCs retain substantial ADCC-effector function, although the optimal conditions for maximal effect have not yet been detd.  In addn., the authors also found a high expression of FoxP3 mRNA and protein, a hallmark of regulatory T cells, in ATLL cells, indicating the possibility that ATLL cells originated from regulatory T cells.  KM2760 reduced FoxP3 mRNA expression in normal PBMCs along with CCR4 mRNA by lysis of CCR4+ T cells in vitro.  Thus, not only the CCR4 mol. could be a suitable target for the novel antibody-based therapy for patients with ATLL but also KM2760 may induce effective tumor immunity by reducing the no. of regulatory T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFKhZ41A4cTrVg90H21EOLACvtfcHk0liuAcREROkjRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVanur%252FP&md5=a3a4c4bbd792aa62dbbbb11771190a7f</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0983%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DAkatsuka%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DOkada%26aufirst%3DN.%26aulast%3DFujita%26aufirst%3DT.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DUtsunomiya%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DThe%2520CC%2520chemokine%2520receptor%25204%2520as%2520a%2520novel%2520specific%2520molecular%2520target%2520for%2520immunotherapy%2520in%2520adult%2520T-cell%2520leukemia%252Flymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7529%26epage%3D7539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Pease, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span> </span><span class="NLM_article-title">Chemokine receptor antagonists:Part 1</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1517%2F13543770802641346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19441897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=39-58&author=J.+E.+Peaseauthor=R.+Horuk&title=Chemokine+receptor+antagonists%3APart+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor antagonists: Part 1</span></div><div class="casAuthors">Pease, James E.; Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-58</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Chemokines were originally defined as host defense proteins, however, their biol. role goes well beyond this simple description of their function as immune cell chemoattractants, and they have since been shown to be involved in a no. of other biol. processes, including growth regulation, hematopoiesis, embryol. development, angiogenesis, and HIV-1 infection.  Because of their diverse role in autoimmune diseases and AIDS, chemokines and their receptors, which belong to the G-protein-coupled receptor superfamily, have been considered good drug targets by the pharmaceutical industry.  In the first part of this two-part review, we highlight recent developments in the chemokine receptor antagonist field both in the peer reviewed and in the patent literature for the CC chemokine receptors CCR1, CCR2, CCR3, and CCR4.  A no. of chemokine receptor antagonists have made the transition from lead compds. to clin. candidates, some of which are described here.  Although there has been no clin. success yet for antagonists targeting the group of receptors discussed here, the compds. have been invaluable in generating information that should pave the way for producing successful therapeutics in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp97IrxM1COU7Vg90H21EOLACvtfcHk0liuAcREROkjRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtw%253D%253D&md5=4452f7ab2618212991c97c9f5243483c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1517%2F13543770802641346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770802641346%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DChemokine%2520receptor%2520antagonists%253APart%25201%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D39%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utsunomiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobinai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uike, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uozumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomonaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">â</span> <span class="NLM_lpage">1598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1200%2FJCO.2009.25.3575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20177026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFGht7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1591-1598&author=K.+Yamamotoauthor=A.+Utsunomiyaauthor=K.+Tobinaiauthor=K.+Tsukasakiauthor=N.+Uikeauthor=K.+Uozumiauthor=K.+Yamaguchiauthor=Y.+Yamadaauthor=S.+Hanadaauthor=K.+Tamuraauthor=S.+Nakamuraauthor=H.+Inagakiauthor=K.+Ohshimaauthor=H.+Kiyoiauthor=T.+Ishidaauthor=K.+Matsushimaauthor=S.+Akinagaauthor=M.+Oguraauthor=M.+Tomonagaauthor=R.+Ueda&title=Phase+I+study+of+KW-0761%2C+a+defucosylated+humanized+anti-CCR4+antibody%2C+in+relapsed+patients+with+adult+T-cell+leukemia-lymphoma+and+peripheral+T-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma</span></div><div class="casAuthors">Yamamoto, Kazuhito; Utsunomiya, Atae; Tobinai, Kensei; Tsukasaki, Kunihiro; Uike, Naokuni; Uozumi, Kimiharu; Yamaguchi, Kazunari; Yamada, Yasuaki; Hanada, Shuichi; Tamura, Kazuo; Nakamura, Shigeo; Inagaki, Hiroshi; Ohshima, Koichi; Kiyoi, Hitoshi; Ishida, Takashi; Matsushima, Kouji; Akinaga, Shiro; Ogura, Michinori; Tomonaga, Masao; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1591-1598</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose KW-0761, a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody, exerts a strong antibody-dependent cellular cytotoxic effect.  This phase I study assessed the safety, pharmacokinetics, recommended phase II dose and efficacy of KW-0761 in patients with relapsed CCR4-pos. adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL).  Patients and Methods Sixteen patients received KW-0761 once a week for 4 wk by i.v. infusion.  Doses were escalated, starting at 0.01, 0.1, 0.5, and finally 1.0 mg/kg by a 3 + 3 design.  Results Fifteen patients completed the protocol treatment.  Only one patient, at the 1.0 mg/kg dose, developed grade 3 dose-limiting toxicities, skin rash, and febrile neutropenia, and grade 4 neutropenia.  Other treatment-related grade 3 to 4 toxicities were lymphopenia (n = 10), neutropenia (n = 3), leukopenia (n = 2), herpes zoster (n = 1), and acute infusion reaction/cytokine release syndrome (n = 1).  Neither the frequency nor severity of toxicities increased with dose escalation.  The max. tolerated dose was not reached.  Therefore, the recommended phase II dose was detd. to be 1.0 mg/kg.  No patients had detectable levels of anti-KW-0761 antibody.  The plasma max. and trough, and the area under the curve of 0 to 7 days of KW-0761, tended to increase dose and frequency dependently.  Five patients (31%; 95% CI, 11% to 59%) achieved objective responses: two complete (0.1; 1.0 mg/kg) and three partial (0.01; 2 at 1.0 mg/kg) responses.  Conclusion KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-pos. ATL or PTCL.  Subsequent phase II studies at the 1.0 mg/kg dose are thus warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzVwF97DSVUbVg90H21EOLACvtfcHk0liuAcREROkjRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFGht7w%253D&md5=8717c3ccf58f4b3484ec94eced9c1da3</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.3575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.3575%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DUtsunomiya%26aufirst%3DA.%26aulast%3DTobinai%26aufirst%3DK.%26aulast%3DTsukasaki%26aufirst%3DK.%26aulast%3DUike%26aufirst%3DN.%26aulast%3DUozumi%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DHanada%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DOhshima%26aufirst%3DK.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DOgura%26aufirst%3DM.%26aulast%3DTomonaga%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DPhase%2520I%2520study%2520of%2520KW-0761%252C%2520a%2520defucosylated%2520humanized%2520anti-CCR4%2520antibody%252C%2520in%2520relapsed%2520patients%2520with%2520adult%2520T-cell%2520leukemia-lymphoma%2520and%2520peripheral%2520T-cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1591%26epage%3D1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uike, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utsunomiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saburi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzushima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishitsuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomonaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobinai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">â</span> <span class="NLM_lpage">842</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1200%2FJCO.2011.37.3472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=22312108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC38XntV2lsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=837-842&author=T.+Ishidaauthor=T.+Johauthor=N.+Uikeauthor=K.+Yamamotoauthor=A.+Utsunomiyaauthor=S.+Yoshidaauthor=Y.+Saburiauthor=T.+Miyamotoauthor=S.+Takemotoauthor=H.+Suzushimaauthor=K.+Tsukasakiauthor=K.+Nosakaauthor=H.+Fujiwaraauthor=K.+Ishitsukaauthor=H.+Inagakiauthor=M.+Oguraauthor=S.+Akinagaauthor=M.+Tomonagaauthor=K.+Tobinaiauthor=R.+Ueda&title=Defucosylated+anti-CCR4+monoclonal+antibody+%28KW-0761%29+for+relapsed+adult+T-cell+leukemia-lymphoma%3A+a+multicenter+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study</span></div><div class="casAuthors">Ishida, Takashi; Joh, Tatsuro; Uike, Naokuni; Yamamoto, Kazuhito; Utsunomiya, Atae; Yoshida, Shinichiro; Saburi, Yoshio; Miyamoto, Toshihiro; Takemoto, Shigeki; Suzushima, Hitoshi; Tsukasaki, Kunihiro; Nosaka, Kisato; Fujiwara, Hiroshi; Ishitsuka, Kenji; Inagaki, Hiroshi; Ogura, Michinori; Akinaga, Shiro; Tomonaga, Masao; Tobinai, Kensei; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">837-842</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Adult T-cell leukemia-lymphoma (ATL) is usually resistant to conventional chemotherapies, and there are few other treatment options.  Because CC chemokine receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL.  Patients and Methods A multicenter phase II study of KW-0761 for patients with relapsed, aggressive CCR4-pos. ATL was conducted to evaluate efficacy, pharmacokinetic profile, and safety.  The primary end point was overall response rate, and secondary end points included progression-free and overall survival from the first dose of KW-0761.  Patients received i.v. infusions of KW-0761 once per wk for 8 wk at a dose of 1.0 mg/kg.  Results Of 28 patients enrolled onto the study, 27 received at least one infusion of KW-0761.  Objective responses were noted in 13 of 26 evaluable patients, including eight complete responses, with an overall response rate of 50% (95% CI, 30% to 70%).  Median progression-free and overall survival were 5.2 and 13.7 mo, resp.  The mean half-life period after the eighth infusion was 422 Â± 147 h (Â± std. deviation).  The most common adverse events were infusion reactions (89%) and skin rashes (63%), which were manageable and reversible in all cases.  Conclusion KW-0761 demonstrated clin. meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile.  Further investigation of KW-0761 for treatment of ATL and other T-cell neoplasms is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-wLRDV_T-BbVg90H21EOLACvtfcHk0ljiP_c7-KxL0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntV2lsbo%253D&md5=ae7f200acf6076c2e41c0346c13df859</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.37.3472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.37.3472%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DT.%26aulast%3DUike%26aufirst%3DN.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DUtsunomiya%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DSaburi%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DTakemoto%26aufirst%3DS.%26aulast%3DSuzushima%26aufirst%3DH.%26aulast%3DTsukasaki%26aufirst%3DK.%26aulast%3DNosaka%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DH.%26aulast%3DIshitsuka%26aufirst%3DK.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DOgura%26aufirst%3DM.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DTomonaga%26aufirst%3DM.%26aulast%3DTobinai%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DDefucosylated%2520anti-CCR4%2520monoclonal%2520antibody%2520%2528KW-0761%2529%2520for%2520relapsed%2520adult%2520T-cell%2520leukemia-lymphoma%253A%2520a%2520multicenter%2520phase%2520II%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D837%26epage%3D842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Procopiou, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Needham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slack, R. J.</span><span> </span><span class="NLM_article-title">Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2730</span><span class="NLM_x">â</span> <span class="NLM_lpage">2733</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2730-2733&author=P.+A.+Procopiouauthor=A.+J.+Fordauthor=R.+H.+Gravesauthor=D.+A.+Hallauthor=S.+T.+Hodgsonauthor=Y.+M.+Lacroixauthor=D.+Needhamauthor=R.+J.+Slack&title=Lead+optimisation+of+the+N1+substituent+of+a+novel+series+of+indazole+arylsulfonamides+as+CCR4+antagonists+and+identification+of+a+candidate+for+clinical+investigation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DLacroix%26aufirst%3DY.%2BM.%26aulast%3DNeedham%26aufirst%3DD.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26atitle%3DLead%2520optimisation%2520of%2520the%2520N1%2520substituent%2520of%2520a%2520novel%2520series%2520of%2520indazole%2520arylsulfonamides%2520as%2520CCR4%2520antagonists%2520and%2520identification%2520of%2520a%2520candidate%2520for%2520clinical%2520investigation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2730%26epage%3D2733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span>Intravenous Microdose Pharmacokinetic (PK) Study with [14C]-GSK2239633. <a href="http://clinicaltrials.gov/show/NCT01086462" class="extLink">http://clinicaltrials.gov/show/NCT01086462</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Intravenous+Microdose+Pharmacokinetic+%28PK%29+Study+with+%5B14C%5D-GSK2239633.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01086462."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Moore, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trkola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragic, T.</span><span> </span><span class="NLM_article-title">Co-receptors for HIV-1 entry</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0952-7915%2897%2980110-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9287172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK2sXlvVyqur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=551-562&author=J.+P.+Mooreauthor=A.+Trkolaauthor=T.+Dragic&title=Co-receptors+for+HIV-1+entry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Co-receptors for HIV-1 entry</span></div><div class="casAuthors">Moore, John P.; Trkola, Alexandra; Dragic, Tatjana</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-562</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review and discussion with 93 refs.  HIV-1 enters its target cells by fusion at the plasma membrane.  The primary cellular receptor for HIV is CD4, but this mol. is insufficient to permit viral fusion.  During 1996, the necessary entry co-factors (co-receptors or second receptors) were identified as being members of the seven-transmembrane-spanning receptor family fusin: CXCR4 for T-tropic strains and CCR5, principally, for M-tropic strains.  The co-receptor functions of these proteins are inhibited by their natural Î±- and Î²-chemokine ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNiow88ydm7Vg90H21EOLACvtfcHk0ljiP_c7-KxL0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvVyqur0%253D&md5=d8805ccf35f191ea797470f08effd7a1</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2897%2980110-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252897%252980110-0%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DJ.%2BP.%26aulast%3DTrkola%26aufirst%3DA.%26aulast%3DDragic%26aufirst%3DT.%26atitle%3DCo-receptors%2520for%2520HIV-1%2520entry%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1997%26volume%3D9%26spage%3D551%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, D.</span><span> </span><span class="NLM_article-title">The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">â</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0079-6468%2805%2943007-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15850827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXps1Citbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=239-271&author=A.+Woodauthor=D.+Armour&title=The+discovery+of+the+CCR5+receptor+antagonist%2C+UK-427%2C857%2C+a+new+agent+for+the+treatment+of+HIV+infection+and+AIDS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS</span></div><div class="casAuthors">Wood, Anthony; Armour, Duncan</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-271</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The drug discovery program that led to the identification of UK-427,857, a prototype CCR5 antagonist with excellent potency against lab-adapted and primary HIV-1 isolates, as a clin. candidate for the treatment of HIV is described.  In particular, strategies for minimizing cardiac toxicity while maintaining ADME properties commensurate with low dose are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIJQwMygW-grVg90H21EOLACvtfcHk0ljvCklTtLHPvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXps1Citbg%253D&md5=8c4bb50b02b7e6d8cfa13d844e39017c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2805%2943007-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252805%252943007-6%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DA.%26aulast%3DArmour%26aufirst%3DD.%26atitle%3DThe%2520discovery%2520of%2520the%2520CCR5%2520receptor%2520antagonist%252C%2520UK-427%252C857%252C%2520a%2520new%2520agent%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%2520and%2520AIDS%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D43%26spage%3D239%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Armour, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groot, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span> </span><span class="NLM_article-title">The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">706</span><span class="NLM_x">â</span> <span class="NLM_lpage">709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=706-709&author=D.+Armourauthor=M.+J.+de+Grootauthor=M.+Edwardsauthor=M.+Perrosauthor=D.+A.+Priceauthor=B.+L.+Stammenauthor=A.+Wood&title=The+discovery+of+CCR5+receptor+antagonists+for+the+treatment+of+HIV+infection%3A+hit-to-lead+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArmour%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DM.%2BJ.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DPerros%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DStammen%26aufirst%3DB.%2BL.%26aulast%3DWood%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520CCR5%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%253A%2520hit-to-lead%2520studies%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D706%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Dorr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macartney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Burchnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros, M.</span><span> </span><span class="NLM_article-title">Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4721</span><span class="NLM_x">â</span> <span class="NLM_lpage">4732</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=4721-4732&author=P.+Dorrauthor=M.+Westbyauthor=S.+Dobbsauthor=P.+Griffinauthor=B.+Irvineauthor=M.+Macartneyauthor=J.+Moriauthor=G.+Rickettauthor=C.+Smith-Burchnellauthor=C.+Napierauthor=R.+Websterauthor=D.+Armourauthor=D.+Priceauthor=B.+Stammenauthor=A.+Woodauthor=M.+Perros&title=Maraviroc+%28UK-427%2C857%29%2C+a+potent%2C+orally+bioavailable%2C+and+selective+small-molecule+inhibitor+of+chemokine+receptor+CCR5+with+broad-spectrum+anti-human+immunodeficiency+virus+type+1+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorr%26aufirst%3DP.%26aulast%3DWestby%26aufirst%3DM.%26aulast%3DDobbs%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DIrvine%26aufirst%3DB.%26aulast%3DMacartney%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DRickett%26aufirst%3DG.%26aulast%3DSmith-Burchnell%26aufirst%3DC.%26aulast%3DNapier%26aufirst%3DC.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DArmour%26aufirst%3DD.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DPerros%26aufirst%3DM.%26atitle%3DMaraviroc%2520%2528UK-427%252C857%2529%252C%2520a%2520potent%252C%2520orally%2520bioavailable%252C%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520chemokine%2520receptor%2520CCR5%2520with%2520broad-spectrum%2520anti-human%2520immunodeficiency%2520virus%2520type%25201%2520activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D4721%26epage%3D4732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Fatkenheuer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pozniak, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plettenberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staszewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoepelman, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goebel, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockstroh, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Ryst, E.</span><span> </span><span class="NLM_article-title">Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">â</span> <span class="NLM_lpage">1172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1170-1172&author=G.+Fatkenheuerauthor=A.+L.+Pozniakauthor=M.+A.+Johnsonauthor=A.+Plettenbergauthor=S.+Staszewskiauthor=A.+I.+Hoepelmanauthor=M.+S.+Saagauthor=F.+D.+Goebelauthor=J.+K.+Rockstrohauthor=B.+J.+Dezubeauthor=T.+M.+Jenkinsauthor=C.+Medhurstauthor=J.+F.+Sullivanauthor=C.+Ridgwayauthor=S.+Abelauthor=I.+T.+Jamesauthor=M.+Youleauthor=E.+van+der+Ryst&title=Efficacy+of+short-term+monotherapy+with+maraviroc%2C+a+new+CCR5+antagonist%2C+in+patients+infected+with+HIV-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFatkenheuer%26aufirst%3DG.%26aulast%3DPozniak%26aufirst%3DA.%2BL.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DPlettenberg%26aufirst%3DA.%26aulast%3DStaszewski%26aufirst%3DS.%26aulast%3DHoepelman%26aufirst%3DA.%2BI.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DGoebel%26aufirst%3DF.%2BD.%26aulast%3DRockstroh%26aufirst%3DJ.%2BK.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJenkins%26aufirst%3DT.%2BM.%26aulast%3DMedhurst%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DJ.%2BF.%26aulast%3DRidgway%26aufirst%3DC.%26aulast%3DAbel%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DI.%2BT.%26aulast%3DYoule%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BRyst%26aufirst%3DE.%26atitle%3DEfficacy%2520of%2520short-term%2520monotherapy%2520with%2520maraviroc%252C%2520a%2520new%2520CCR5%2520antagonist%252C%2520in%2520patients%2520infected%2520with%2520HIV-1%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D1170%26epage%3D1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Lieberman-Blum, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandres, J. C.</span><span> </span><span class="NLM_article-title">Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">â</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0149-2918%2808%2980048-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18691983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVyitL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=1228-1250&author=S.+S.+Lieberman-Blumauthor=H.+B.+Fungauthor=J.+C.+Bandres&title=Maraviroc%3A+a+CCR5-receptor+antagonist+for+the+treatment+of+HIV-1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection</span></div><div class="casAuthors">Lieberman-Blum, Sharon S.; Fung, Horatio B.; Bandres, Juan C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1228-1250</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The emergence of viral resistance is one of the greatest challenges in the treatment of HIV infection.  Maraviroc is the first member of a new class of antiretroviral medications, the CCR5-receptor antagonists.  It is approved by the US Food and Drug Administration (FDA) for use in combination with other antiretroviral agents in treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1.  Objective: This article provides an overview of the pharmacol., efficacy, and tolerability of maraviroc in the treatment of HIV-1 infection.  Methods: Relevant information was identified through a search of MEDLINE (Jan. 2000-May 2008) using the terms maraviroc, UK-427,857, and CCR5-receptor antagonist.  Also consulted were abstrs. from the International AIDS Society Conference, the Conference on Retroviruses and Opportunistic Infections, and other relevant scientific meetings.  Addnl. publications were found by searching the ref. lists of the identified articles and the FDA Web site.  Results: Maraviroc is a selective, reversible, small-mol. CCR5-receptor antagonist.  In vitro, it has potent anti-HIV-1 activity, with a mean 90% inhibitory concn. of 2.0 nmol/L.  It is widely distributed, with a Vd of â¼194 L.  Maraviroc is moderately metabolized in the liver (65.3%), primarily via the cytochrome P 450 3A4 isoenzyme.  It has an elimination t1/2 of 15.9 to 22.9 h.  Until more data are available, maraviroc should be avoided in patients with severe hepatic insufficiency; dose adjustment does not appear to be necessary on the basis of age, sex, or renal function.  In 2 Phase IIb/III studies, maraviroc 300 mg PO QD or BID was found to be more efficacious than placebo in reducing the viral load at 48 wk in treatment-experienced, CCR5-tropic HIV-1-infected patients receiving an optimized background regimen (difference vs placebo-QD arm: -0.89 log10 copies/mL [97.5% CI, -1.17 to -0.62]; BID arm: -1.05 log10 copies/mL [97.5% CI, -1.33 to -0.78]).  The proportion of patients with a viral load <50 copies/mL was 43.2% in the QD arm and 45.5% in the BID arm, compared with 16.7% in the placebo arm (P < 0.001, both treatment arms vs placebo).  In treatment-naive patients infected with CCR5-tropic virus only, maraviroc 300 mg PO BID was not noninferior to oral efavirenz 600 mg QD (difference = -4.2%; lower bound of the 1-sided 97.5% CI, -10.9 [predefined statistical cutoff for noninferiority, -10]).  Maraviroc was generally well tolerated in clin. trials.  The most frequently reported (â¥5%) adverse events were upper respiratory tract infection (20.0%), cough (12.7%), pyrexia (12.0%), rash (9.6%), musculoskeletal complaints (8.7%), gastrointestinal and abdominal pain (8.2%), dizziness (8.2%), appetite disorders (7.3%), insomnia (7.0%), herpes infection (6.8%), sinusitis (6.3%), joint complaints (6.1%), bronchitis (5.9%), and constipation (5.4%).  The recommended dose of maraviroc differs based on concomitant medications, ranging from 150 to 600 mg BID.  Conclusion: When used in combination with other antiretroviral agents, maraviroc appears to be a promising agent for treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo73dWGTL6Me7Vg90H21EOLACvtfcHk0ljvCklTtLHPvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVyitL0%253D&md5=f0923816dd986856a3dd6c3e11a3c45d</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2FS0149-2918%2808%2980048-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-2918%252808%252980048-3%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman-Blum%26aufirst%3DS.%2BS.%26aulast%3DFung%26aufirst%3DH.%2BB.%26aulast%3DBandres%26aufirst%3DJ.%2BC.%26atitle%3DMaraviroc%253A%2520a%2520CCR5-receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520HIV-1%2520infection%26jtitle%3DClin.%2520Ther.%26date%3D2008%26volume%3D30%26spage%3D1228%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Palani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clader, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B. M.</span><span> </span><span class="NLM_article-title">Discovery of 4-[(<i>Z</i>)-(4-bromophenyl)- (ethoxyimino)methyl]-1â²-[(2,4- dimethyl-3- pyridinyl)carbonyl]-4â²-methyl-1,4â²- bipiperidine <i>N</i>-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3339</span><span class="NLM_x">â</span> <span class="NLM_lpage">3342</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm015526o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3339-3342&author=A.+Palaniauthor=S.+Shapiroauthor=J.+W.+Claderauthor=W.+J.+Greenleeauthor=K.+Coxauthor=J.+Strizkiauthor=M.+Endresauthor=B.+M.+Baroudy&title=Discovery+of+4-%5B%28Z%29-%284-bromophenyl%29-+%28ethoxyimino%29methyl%5D-1%E2%80%B2-%5B%282%2C4-+dimethyl-3-+pyridinyl%29carbonyl%5D-4%E2%80%B2-methyl-1%2C4%E2%80%B2-+bipiperidine+N-oxide+%28SCH+351125%29%3A+an+orally+bioavailable+human+CCR5+antagonist+for+the+treatment+of+HIV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fjm015526o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm015526o%26sid%3Dliteratum%253Aachs%26aulast%3DPalani%26aufirst%3DA.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DStrizki%26aufirst%3DJ.%26aulast%3DEndres%26aufirst%3DM.%26aulast%3DBaroudy%26aufirst%3DB.%2BM.%26atitle%3DDiscovery%2520of%25204-%255B%2528Z%2529-%25284-bromophenyl%2529-%2520%2528ethoxyimino%2529methyl%255D-1%25E2%2580%25B2-%255B%25282%252C4-%2520dimethyl-3-%2520pyridinyl%2529carbonyl%255D-4%25E2%2580%25B2-methyl-1%252C4%25E2%2580%25B2-%2520bipiperidine%2520N-oxide%2520%2528SCH%2520351125%2529%253A%2520an%2520orally%2520bioavailable%2520human%2520CCR5%2520antagonist%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3339%26epage%3D3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">McCombie, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagat, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vice, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. C.</span><span> </span><span class="NLM_article-title">Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=567-571&author=S.+W.+McCombieauthor=J.+R.+Tagatauthor=S.+F.+Viceauthor=S.+I.+Linauthor=R.+Steensmaauthor=A.+Palaniauthor=B.+R.+Neustadtauthor=B.+M.+Baroudyauthor=J.+M.+Strizkiauthor=M.+Endresauthor=K.+Coxauthor=N.+Danauthor=C.+C.+Chou&title=Piperazine-based+CCR5+antagonists+as+HIV-1+inhibitors.+III%3A+Synthesis%2C+antiviral+and+pharmacokinetic+profiles+of+symmetrical+heteroaryl+carboxamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCombie%26aufirst%3DS.%2BW.%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DVice%26aufirst%3DS.%2BF.%26aulast%3DLin%26aufirst%3DS.%2BI.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DPalani%26aufirst%3DA.%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DBaroudy%26aufirst%3DB.%2BM.%26aulast%3DStrizki%26aufirst%3DJ.%2BM.%26aulast%3DEndres%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DDan%26aufirst%3DN.%26aulast%3DChou%26aufirst%3DC.%2BC.%26atitle%3DPiperazine-based%2520CCR5%2520antagonists%2520as%2520HIV-1%2520inhibitors.%2520III%253A%2520Synthesis%252C%2520antiviral%2520and%2520pharmacokinetic%2520profiles%2520of%2520symmetrical%2520heteroaryl%2520carboxamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D567%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Este, J. A.</span><span> </span><span class="NLM_article-title">SCH-351125 and SCH-350634. Schering-Plough</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=379-383&author=J.+A.+Este&title=SCH-351125+and+SCH-350634.+Schering-Plough"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEste%26aufirst%3DJ.%2BA.%26atitle%3DSCH-351125%2520and%2520SCH-350634.%2520Schering-Plough%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D379%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Tagat, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCombie, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazareno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labroli, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, R.</span><span> </span><span class="NLM_article-title">Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(<i>R</i>)-4-(trifluoromethyl)phenyl]ethyl-3(<i>S</i>)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">â</span> <span class="NLM_lpage">2408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0304515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2405-2408&author=J.+R.+Tagatauthor=S.+W.+McCombieauthor=D.+Nazarenoauthor=M.+A.+Labroliauthor=Y.+Xiaoauthor=R.+W.+Steensmaauthor=J.+M.+Strizkiauthor=B.+M.+Baroudyauthor=K.+Coxauthor=J.+Lachowiczauthor=G.+Vartyauthor=R.+Watkins&title=Piperazine-based+CCR5+antagonists+as+HIV-1+inhibitors.+IV.+Discovery+of+1-%5B%284%2C6-dimethyl-5-pyrimidinyl%29carbonyl%5D-4-%5B4-%5B2-methoxy-1%28R%29-4-%28trifluoromethyl%29phenyl%5Dethyl-3%28S%29-methyl-1-piperazinyl%5D-4-methylpiperidine+%28Sch-417690%2FSch-D%29%2C+a+potent%2C+highly+selective%2C+and+orally+bioavailable+CCR5+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjm0304515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0304515%26sid%3Dliteratum%253Aachs%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DMcCombie%26aufirst%3DS.%2BW.%26aulast%3DNazareno%26aufirst%3DD.%26aulast%3DLabroli%26aufirst%3DM.%2BA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DSteensma%26aufirst%3DR.%2BW.%26aulast%3DStrizki%26aufirst%3DJ.%2BM.%26aulast%3DBaroudy%26aufirst%3DB.%2BM.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DVarty%26aufirst%3DG.%26aulast%3DWatkins%26aufirst%3DR.%26atitle%3DPiperazine-based%2520CCR5%2520antagonists%2520as%2520HIV-1%2520inhibitors.%2520IV.%2520Discovery%2520of%25201-%255B%25284%252C6-dimethyl-5-pyrimidinyl%2529carbonyl%255D-4-%255B4-%255B2-methoxy-1%2528R%2529-4-%2528trifluoromethyl%2529phenyl%255Dethyl-3%2528S%2529-methyl-1-piperazinyl%255D-4-methylpiperidine%2520%2528Sch-417690%252FSch-D%2529%252C%2520a%2520potent%252C%2520highly%2520selective%252C%2520and%2520orally%2520bioavailable%2520CCR5%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2405%26epage%3D2408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span>Aidsmap. Second Company Halts CCR5 Inhibitor Study in Another Blow to New Drug Class. <a href="http://www.aidsmap.com/Second-company-halts-CCR5-inhibitor-study-in-another-blow-to-new-drug-class/page/1422234/" class="extLink">http://www.aidsmap.com/Second-company-halts-CCR5-inhibitor-study-in-another-blow-to-new-drug-class/page/1422234/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Aidsmap.+Second+Company+Halts+CCR5+Inhibitor+Study+in+Another+Blow+to+New+Drug+Class.+http%3A%2F%2Fwww.aidsmap.com%2FSecond-company-halts-CCR5-inhibitor-study-in-another-blow-to-new-drug-class%2Fpage%2F1422234%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Gulick, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flexner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skolnik, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krambrink, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greaves, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zolopa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuritzkes, D. R.</span><span> </span><span class="NLM_article-title">Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">196</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">â</span> <span class="NLM_lpage">312</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1086%2F518797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17570119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVygs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2007&pages=304-312&author=R.+M.+Gulickauthor=Z.+Suauthor=C.+Flexnerauthor=M.+D.+Hughesauthor=P.+R.+Skolnikauthor=T.+J.+Wilkinauthor=R.+Grossauthor=A.+Krambrinkauthor=E.+Coakleyauthor=W.+L.+Greavesauthor=A.+Zolopaauthor=R.+Reichmanauthor=C.+Godfreyauthor=M.+Hirschauthor=D.+R.+Kuritzkes&title=Phase+2+study+of+the+safety+and+efficacy+of+vicriviroc%2C+a+CCR5+inhibitor%2C+in+HIV-1-infected%2C+treatment-experienced+patients%3A+AIDS+clinical+trials+group+5211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211</span></div><div class="casAuthors">Gulick, Roy M.; Su, Zhaohui; Flexner, Charles; Hughes, Michael D.; Skolnik, Paul R.; Wilkin, Timothy J.; Gross, Robert; Krambrink, Amy; Coakley, Eoin; Greaves, Wayne L.; Zolopa, Andrew; Reichman, Richard; Godfrey, Catherine; Hirsch, Martin; Kuritzkes, Daniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-312</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study.  Methods: The present study was a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficiency virus (HIV)-infected subjects experiencing virol. failure while receiving a ritonavir-contg. regimen with an HIV-1 RNA level â¥5000 copies/mL and CCR5-using virus.  Vicriviroc at 5, 10, or 15 mg or placebo was added to the failing regimen for 14 days, after which the antiretroviral regimen was optimized.  The primary end point was the change in plasma HIV-1 RNA levels at day 14; secondary end points included safety/tolerability and HIV-1 RNA changes at week 24.  Results: One hundred eighteen subjects were randomized with a median HIV-1 RNA level of 36,380 (4.56 log10) copies/mL and a median CD4 cell count of 146 cells/mm3.  At 14 days and 24 wk, mean changes in HIV-1 RNA level (log10 copies/mL) were greater in the vicriviroc groups (-0.87 and -1.51 [5 mg], -1.15 and -1.86 [10 mg], and -0.92 and -1.68 [15 mg]) than in the placebo group (+0.06 and -0.29) (P<.01).  Grade 3/4 adverse events were similar across groups.  Malignancies occurred in 6 subjects randomized to vicriviroc and in 2 to placebo.  Conclusions: In HIV-1-infected, treatment-experienced patients, vicriviroc demonstrated potent virol. suppression through 24 wk.  The relationship of vicriviroc to malignancy is uncertain.  Further development of vicriviroc in treatment-experienced patients is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpo9-4RFsxrVg90H21EOLACvtfcHk0lja6xQ5vPjEUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVygs7w%253D&md5=9a36e6a182f0a590c5c2d38572062ffa</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1086%2F518797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F518797%26sid%3Dliteratum%253Aachs%26aulast%3DGulick%26aufirst%3DR.%2BM.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DFlexner%26aufirst%3DC.%26aulast%3DHughes%26aufirst%3DM.%2BD.%26aulast%3DSkolnik%26aufirst%3DP.%2BR.%26aulast%3DWilkin%26aufirst%3DT.%2BJ.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DKrambrink%26aufirst%3DA.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DGreaves%26aufirst%3DW.%2BL.%26aulast%3DZolopa%26aufirst%3DA.%26aulast%3DReichman%26aufirst%3DR.%26aulast%3DGodfrey%26aufirst%3DC.%26aulast%3DHirsch%26aufirst%3DM.%26aulast%3DKuritzkes%26aufirst%3DD.%2BR.%26atitle%3DPhase%25202%2520study%2520of%2520the%2520safety%2520and%2520efficacy%2520of%2520vicriviroc%252C%2520a%2520CCR5%2520inhibitor%252C%2520in%2520HIV-1-infected%252C%2520treatment-experienced%2520patients%253A%2520AIDS%2520clinical%2520trials%2520group%25205211%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2007%26volume%3D196%26spage%3D304%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span>AIDSMEDS. Merck Terminates Development of Its HIV Entry Inhibitor, Vicriviroc. <a href="http://www.aidsmeds.com/articles/hiv_vicriviroc_merck_1667_18742.shtml" class="extLink">http://www.aidsmeds.com/articles/hiv_vicriviroc_merck_1667_18742.shtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AIDSMEDS.+Merck+Terminates+Development+of+Its+HIV+Entry+Inhibitor%2C+Vicriviroc.+http%3A%2F%2Fwww.aidsmeds.com%2Farticles%2Fhiv_vicriviroc_merck_1667_18742.shtml."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaoka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moravek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyanagi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">8654</span><span class="NLM_x">â</span> <span class="NLM_lpage">8662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1128%2FJVI.78.16.8654-8662.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15280474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslSmtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=8654-8662&author=K.+Maedaauthor=H.+Nakataauthor=Y.+Kohauthor=T.+Miyakawaauthor=H.+Ogataauthor=Y.+Takaokaauthor=S.+Shibayamaauthor=K.+Sagawaauthor=D.+Fukushimaauthor=J.+Moravekauthor=Y.+Koyanagiauthor=H.+Mitsuya&title=Spirodiketopiperazine-based+CCR5+inhibitor+which+preserves+CC-chemokine%2FCCR5+interactions+and+exerts+potent+activity+against+R5+human+immunodeficiency+virus+type+1+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro</span></div><div class="casAuthors">Maeda, Kenji; Nakata, Hirotomo; Koh, Yasuhiro; Miyakawa, Toshikazu; Ogata, Hiromi; Takaoka, Yoshikazu; Shibayama, Shiro; Sagawa, Kenji; Fukushima, Daikichi; Moravek, Joseph; Koyanangi, Yoshio; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8654-8662</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We identified a novel spirodiketopiperazine (SDP) deriv., AK602/ONO4128/GW873140, which specifically blocked the binding of macrophage inflammatory protein 1Î± (MIP-1Î±) to CCR5 with a high affinity (Kd of â3 nM), potently blocked human immunodeficiency virus type 1 (HIV-1) gp120/CCR5 binding and exerted potent activity against a wide spectrum of lab. and primary R5 HIV-1 isolates, including multidrug-resistant HIV-1 (HIV-1MDR) (50% inhibitory concn. values of 0.1 to 0.6 nM) in vitro.  AK602 competitively blocked the binding to CCR5 expressed on Chinese hamster ovary cells of two monoclonal antibodies, 45523, directed against multidomain epitopes of CCR5, and 45531, specific against the C-terminal half of the second extracellular loop (ECL2B) of CCR5.  AK602, despite its much greater anti-HIV-1 activity than other previously published CCR5 inhibitors, including TAK-779 and SCH-C, preserved RANTES (regulated on activation normal T-cell expressed and secreted) and MIP-1Î² binding to CCR5+ cells and their functions, including CC-chemokine-induced chemotaxis and CCR5 internalization, while TAK-779 and SCH-C fully blocked the CC-chemokine/CCR5 interactions.  Pharmacokinetic studies revealed favorable oral bioavailability in rodents.  These data warrant further development of AK602 as a potential therapeutic for HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6GrcsfDbiybVg90H21EOLACvtfcHk0lgC_qmIVM-X-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslSmtbg%253D&md5=c89226433dd565f24f37b51b3504d780</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.16.8654-8662.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.16.8654-8662.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DMiyakawa%26aufirst%3DT.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DTakaoka%26aufirst%3DY.%26aulast%3DShibayama%26aufirst%3DS.%26aulast%3DSagawa%26aufirst%3DK.%26aulast%3DFukushima%26aufirst%3DD.%26aulast%3DMoravek%26aufirst%3DJ.%26aulast%3DKoyanagi%26aufirst%3DY.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DSpirodiketopiperazine-based%2520CCR5%2520inhibitor%2520which%2520preserves%2520CC-chemokine%252FCCR5%2520interactions%2520and%2520exerts%2520potent%2520activity%2520against%2520R5%2520human%2520immunodeficiency%2520virus%2520type%25201%2520in%2520vitro%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D8654%26epage%3D8662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shachoy-Clark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâMara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piscitelli, S. C.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2802</span><span class="NLM_x">â</span> <span class="NLM_lpage">2806</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=2802-2806&author=K.+K.+Adkisonauthor=A.+Shachoy-Clarkauthor=L.+Fangauthor=Y.+Louauthor=K.+O%E2%80%99Maraauthor=M.+M.+Berreyauthor=S.+C.+Piscitelli&title=Pharmacokinetics+and+short-term+safety+of+873140%2C+a+novel+CCR5+antagonist%2C+in+healthy+adult+subjects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DShachoy-Clark%26aufirst%3DA.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Mara%26aufirst%3DK.%26aulast%3DBerrey%26aufirst%3DM.%2BM.%26aulast%3DPiscitelli%26aufirst%3DS.%2BC.%26atitle%3DPharmacokinetics%2520and%2520short-term%2520safety%2520of%2520873140%252C%2520a%2520novel%2520CCR5%2520antagonist%252C%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2802%26epage%3D2806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Nichols, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonny, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabeya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clumeck, N.</span><span> </span><span class="NLM_article-title">Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">â</span> <span class="NLM_lpage">865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1128%2FAAC.00821-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18070967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFalsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=858-865&author=W.+G.+Nicholsauthor=H.+M.+Steelauthor=T.+Bonnyauthor=K.+Adkisonauthor=L.+Curtisauthor=J.+Millardauthor=K.+Kabeyaauthor=N.+Clumeck&title=Hepatotoxicity+observed+in+clinical+trials+of+aplaviroc+%28GW873140%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)</span></div><div class="casAuthors">Nichols, W. G.; Steel, H. M.; Bonny, T.; Adkison, K.; Curtis, L.; Millard, J.; Kabeya, K.; Clumeck, N.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">858-865</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Aplaviroc (APL) was a new CCR5 antagonist that was investigated in two dose-ranging studies with antiretroviral therapy-naive, human immunodeficiency virus-infected adults: ASCENT, in which 147 subjects were randomized 2:2:1 to receive zidovudine-lamivudine (ZDV-3TC) plus APL 600 mg twice a day (BID), APL 800 mg BID, or efavirenz (EFV), resp., and EPIC, in which 195 subjects were randomized 2:2:2:1 to receive lopinavir-ritonavir (LPV-RTV) plus APL 200 mg BID, APL 400 mg BID, APL 800 mg once a day, or ZDV-3TC BID, resp.  Both studies (and, ultimately, the clin. development of APL) were discontinued after a mean of 14 wk of therapy because of higher than anticipated severe liver toxicity; grade 2 or higher treatment-emergent elevations in alanine aminotransferase (ALT) levels were obsd. in 17/281 (6.0%) APL recipients but only 2/55 (3.6%) control recipients, while grade 2 or higher elevations in total bilirubin levels occurred in 29/281 (10.3%) APL recipients but only 4/55 (7.3%) controls.  Two APL recipients developed grade 3 or higher treatment-emergent elevations in both ALT and total bilirubin levels, and one of these individuals had a severe case of hepatic cytolysis that was attributed to APL.  Despite the high intersubject variability in APL plasma exposures, a Pearson correlation anal. of the combined study data did not reveal any significant assocns. between plasma concns. and the liver enzyme elevations obsd. during the study.  The mechanism for the idiosyncratic hepatotoxicity obsd. in the clin. trials of APL is unknown but is likely intrinsic to the mol. rather than its novel mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_qgm3ocb7DLVg90H21EOLACvtfcHk0lgC_qmIVM-X-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFalsL8%253D&md5=e8ed6796bd0c8673fcd8e3e10a61de90</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1128%2FAAC.00821-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00821-07%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DW.%2BG.%26aulast%3DSteel%26aufirst%3DH.%2BM.%26aulast%3DBonny%26aufirst%3DT.%26aulast%3DAdkison%26aufirst%3DK.%26aulast%3DCurtis%26aufirst%3DL.%26aulast%3DMillard%26aufirst%3DJ.%26aulast%3DKabeya%26aufirst%3DK.%26aulast%3DClumeck%26aufirst%3DN.%26atitle%3DHepatotoxicity%2520observed%2520in%2520clinical%2520trials%2520of%2520aplaviroc%2520%2528GW873140%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D858%26epage%3D865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Moyle, G.</span><span> </span><span class="NLM_article-title">The Last Word on Aplaviroc: A CCR5 Antagonist with Poor Efficacy</span>.  <span class="citation_source-book">The Body</span>; <span class="NLM_publisher-name">Remedy Health Media, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span><a href="http://www.thebody.com/content/confs/hiv8/art39205.html" class="extLink">http://www.thebody.com/content/confs/hiv8/art39205.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=G.+Moyle&title=The+Body"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMoyle%26aufirst%3DG.%26atitle%3DThe%2520Last%2520Word%2520on%2520Aplaviroc%253A%2520A%2520CCR5%2520Antagonist%2520with%2520Poor%2520Efficacy%26btitle%3DThe%2520Body%26pub%3DRemedy%2520Health%2520Media%252C%2520LLC%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okonogi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meguro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">5698</span><span class="NLM_x">â</span> <span class="NLM_lpage">5703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=5698-5703&author=M.+Babaauthor=O.+Nishimuraauthor=N.+Kanzakiauthor=M.+Okamotoauthor=H.+Sawadaauthor=Y.+Iizawaauthor=M.+Shiraishiauthor=Y.+Aramakiauthor=K.+Okonogiauthor=Y.+Ogawaauthor=K.+Meguroauthor=M.+Fujino&title=A+small-molecule%2C+nonpeptide+CCR5+antagonist+with+highly+potent+and+selective+anti-HIV-1+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DO.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DShiraishi%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DOkonogi%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DMeguro%26aufirst%3DK.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DA%2520small-molecule%252C%2520nonpeptide%2520CCR5%2520antagonist%2520with%2520highly%2520potent%2520and%2520selective%2520anti-HIV-1%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D5698%26epage%3D5703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Shiraishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">â</span> <span class="NLM_lpage">2063</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9906264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGhsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2049-2063&author=M.+Shiraishiauthor=Y.+Aramakiauthor=M.+Setoauthor=H.+Imotoauthor=Y.+Nishikawaauthor=N.+Kanzakiauthor=M.+Okamotoauthor=H.+Sawadaauthor=O.+Nishimuraauthor=M.+Babaauthor=M.+Fujino&title=Discovery+of+novel%2C+potent%2C+and+selective+small-molecule+CCR5+antagonists+as+anti-HIV-1+agents%3A+synthesis+and+biological+evaluation+of+anilide+derivatives+with+a+quaternary+ammonium+moiety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety</span></div><div class="casAuthors">Shiraishi, Mitsuru; Aramaki, Yoshio; Seto, Masaki; Imoto, Hiroshi; Nishikawa, Youichi; Kanzaki, Naoyuki; Okamoto, Mika; Sawada, Hidekazu; Nishimura, Osamu; Baba, Masanori; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2049-2063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The search for new small-mol. CCR5 antagonists by high-throughput screening (HTS) of the Takeda chem. library using [125I]RANTES and CHO/CCR5 cells led to the discovery of lead compds. with a quaternary ammonium or phosphonium moiety, which were synthesized to investigate new MCP-1 receptor antagonists.  A series of novel anilide derivs. with a quaternary ammonium moiety were designed, synthesized, and tested for their CCR5 antagonistic activity.  Through the optimization of lead compds., we have found N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium chloride as a highly potent and selective nonpeptide CCR5 antagonist with a IC50 value of 1.4 nM in the binding assay.  The synthesis and structure-activity relationships of the title compds. and their related compds. are detailed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuJ_2cLr9HB7Vg90H21EOLACvtfcHk0lgCt_cl2_91JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGhsrc%253D&md5=fa4bc03a80d858423cfe7c4f73a53523</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm9906264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9906264%26sid%3Dliteratum%253Aachs%26aulast%3DShiraishi%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DImoto%26aufirst%3DH.%26aulast%3DNishikawa%26aufirst%3DY.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DNishimura%26aufirst%3DO.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%252C%2520potent%252C%2520and%2520selective%2520small-molecule%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520anilide%2520derivatives%2520with%2520a%2520quaternary%2520ammonium%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2049%26epage%3D2063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span> </span><span class="NLM_article-title">TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4584</span><span class="NLM_x">â</span> <span class="NLM_lpage">4591</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=4584-4591&author=M.+Babaauthor=K.+Takashimaauthor=H.+Miyakeauthor=N.+Kanzakiauthor=K.+Teshimaauthor=X.+Wangauthor=M.+Shiraishiauthor=Y.+Iizawa&title=TAK-652+inhibits+CCR5-mediated+human+immunodeficiency+virus+type+1+infection+in+vitro+and+has+favorable+pharmacokinetics+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTeshima%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShiraishi%26aufirst%3DM.%26aulast%3DIizawa%26aufirst%3DY.%26atitle%3DTAK-652%2520inhibits%2520CCR5-mediated%2520human%2520immunodeficiency%2520virus%2520type%25201%2520infection%2520in%2520vitro%2520and%2520has%2520favorable%2520pharmacokinetics%2520in%2520humans%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D4584%26epage%3D4591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span> </span><span class="NLM_article-title">Orally active CCR5 antagonists as anti-HIV-1 agents 2: synthesis and biological activities of anilide derivatives containing a pyridine <i>N</i>-oxide moiety</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">â</span> <span class="NLM_lpage">829</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=818-829&author=M.+Setoauthor=Y.+Aramakiauthor=H.+Imotoauthor=K.+Aikawaauthor=T.+Odaauthor=N.+Kanzakiauthor=Y.+Iizawaauthor=M.+Babaauthor=M.+Shiraishi&title=Orally+active+CCR5+antagonists+as+anti-HIV-1+agents+2%3A+synthesis+and+biological+activities+of+anilide+derivatives+containing+a+pyridine+N-oxide+moiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DImoto%26aufirst%3DH.%26aulast%3DAikawa%26aufirst%3DK.%26aulast%3DOda%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShiraishi%26aufirst%3DM.%26atitle%3DOrally%2520active%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%25202%253A%2520synthesis%2520and%2520biological%2520activities%2520of%2520anilide%2520derivatives%2520containing%2520a%2520pyridine%2520N-oxide%2520moiety%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2004%26volume%3D52%26spage%3D818%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span> </span><span class="NLM_article-title">Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">â</span> <span class="NLM_lpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=577-590&author=M.+Setoauthor=Y.+Aramakiauthor=T.+Okawaauthor=N.+Miyamotoauthor=K.+Aikawaauthor=N.+Kanzakiauthor=S.+Niwaauthor=Y.+Iizawaauthor=M.+Babaauthor=M.+Shiraishi&title=Orally+active+CCR5+antagonists+as+anti-HIV-1+agents%3A+synthesis+and+biological+activity+of+1-benzothiepine+1%2C1-dioxide+and+1-benzazepine+derivatives+containing+a+tertiary+amine+moiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DOkawa%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DAikawa%26aufirst%3DK.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DNiwa%26aufirst%3DS.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShiraishi%26aufirst%3DM.%26atitle%3DOrally%2520active%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%253A%2520synthesis%2520and%2520biological%2520activity%2520of%25201-benzothiepine%25201%252C1-dioxide%2520and%25201-benzazepine%2520derivatives%2520containing%2520a%2520tertiary%2520amine%2520moiety%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2004%26volume%3D52%26spage%3D577%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span>Takeda To License CCR5 Antagonists for Treatment of HIV Infection to Tobira Therapeutics, Inc. <a href="http://www.takeda.com/press/article_27377.html" class="extLink">http://www.takeda.com/press/article_27377.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Takeda+To+License+CCR5+Antagonists+for+Treatment+of+HIV+Infection+to+Tobira+Therapeutics%2C+Inc.+http%3A%2F%2Fwww.takeda.com%2Fpress%2Farticle_27377.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dejesus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galindez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palleja, S. M.</span><span> </span><span class="NLM_article-title">Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects</span> <span class="citation_source-journal">J. Acquired Immune Defic. Syndr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1097%2FQAI.0b013e318213c2c0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21317794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFyhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2011&pages=118-125&author=J.+Lalezariauthor=J.+Gatheauthor=C.+Brinsonauthor=M.+Thompsonauthor=C.+Cohenauthor=E.+Dejesusauthor=J.+Galindezauthor=J.+A.+Ernstauthor=D.+E.+Martinauthor=S.+M.+Palleja&title=Safety%2C+efficacy%2C+and+pharmacokinetics+of+TBR-652%2C+a+CCR5%2FCCR2+antagonist%2C+in+HIV-1-infected%2C+treatment-experienced%2C+CCR5+antagonist-naive+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1-Infected, Treatment-Experienced, CCR5 Antagonist-Naive Subjects</span></div><div class="casAuthors">Lalezari, Jacob; Gathe, Joseph; Brinson, Cynthia; Thompson, Melanie; Cohen, Calvin; Dejesus, Edwin; Galindez, Jorge; Ernst, Jerome A.; Martin, David E.; Palleja, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-125</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: To det. the antiviral activity, pharmacokinetics, pharmacodynamics, safety, and tolerability of several dose levels of oral TBR-652 monotherapy in HIV-1-infected, antiretroviral experienced, CCR5 antagonist-naive subjects.  Design: Double-blind placebo-controlled study in the United States and Argentina.  Methods: Subjects were randomized in a ratio of 4:1 per dose level to TBR-652 (25, 50, 75, 100, or 150 mg) or placebo, taken once daily for 10 days.  Changes from baseline in HIV-1 RNA and CD4 cell counts were measured through day 40 and for monocyte chemotactic protein-1 (MCP-1), high-sensitivity C-reactive protein (hs-CRP), and IL-6 at day 10.  Pharmacokinetic data were analyzed using noncompartmental statistics.  Lab. and clin. adverse events (AEs) and ECG changes were recorded.  Results: Maximum median redns. in HIV-1 RNA values for the 25, 50, 75, and 150 mg doses were -0.7, -1.6, -1.8, and -1.7 log10 copies per mL, resp.  All changes were significant.  Median time to nadir was 10-11 days.  Suppression persisted well into the posttreatment period.  Mean MCP-1 increased significantly by day 10 in the 50-mg and 150-mg dose groups.  Effects on CD4 cell counts, hs-CRP, and IL-6 levels were negligible.  TBR-652 was generally safe and well tolerated, with no withdrawals due to AEs.  Conclusions: TBR-652 caused significant redns. in HIV-1 RNA at all doses.  Significant increases in MCP-1 levels suggested a strong CCR2 blockade.  TBR-652 was generally well tolerated with no dose-limiting AEs.  Pharmacodynamics indicate that TBR-652 warrants further investigation as an unboosted once-daily oral CCR5 antagonist with potentially important CCR2-mediated anti-inflammatory effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhtZ1heEtEJrVg90H21EOLACvtfcHk0lhmqg3i_sCZOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFyhsL4%253D&md5=9314a830e5558eacc49cff18904b13d7</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e318213c2c0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e318213c2c0%26sid%3Dliteratum%253Aachs%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DGathe%26aufirst%3DJ.%26aulast%3DBrinson%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DC.%26aulast%3DDejesus%26aufirst%3DE.%26aulast%3DGalindez%26aufirst%3DJ.%26aulast%3DErnst%26aufirst%3DJ.%2BA.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26aulast%3DPalleja%26aufirst%3DS.%2BM.%26atitle%3DSafety%252C%2520efficacy%252C%2520and%2520pharmacokinetics%2520of%2520TBR-652%252C%2520a%2520CCR5%252FCCR2%2520antagonist%252C%2520in%2520HIV-1-infected%252C%2520treatment-experienced%252C%2520CCR5%2520antagonist-naive%2520subjects%26jtitle%3DJ.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2011%26volume%3D57%26spage%3D118%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Xue, C.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span> </span><span class="NLM_article-title">Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">â</span> <span class="NLM_lpage">487</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml1001536" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=483-487&author=C.-B.+Xueauthor=L.+Chenauthor=G.+Caoauthor=K.+Zhangauthor=A.+Wangauthor=D.+Meloniauthor=J.+Glennauthor=R.+Anandauthor=M.+Xiaauthor=L.+Kongauthor=T.+Huangauthor=H.+Fengauthor=C.+Zhengauthor=M.+Liauthor=L.+Galyaauthor=J.+Zhouauthor=N.+Shinauthor=F.+Baribaudauthor=K.+Solomonauthor=P.+Scherleauthor=B.+Zhaoauthor=S.+Diamondauthor=T.+Emmauthor=D.+Kellerauthor=N.+Contelauthor=S.+Yeleswaramauthor=K.+Vaddiauthor=G.+Hollisauthor=R.+Newtonauthor=S.+Friedmanauthor=B.+Metcalf&title=Discovery+of+INCB9471%2C+a+potent%2C+selective%2C+and+orally+bioavailable+CCR5+antagonist+with+potent+anti-HIV-1+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Fml1001536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001536%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.-B.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DN.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DKeller%26aufirst%3DD.%26aulast%3DContel%26aufirst%3DN.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DMetcalf%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520INCB9471%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520CCR5%2520antagonist%2520with%2520potent%2520anti-HIV-1%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D483%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlapati, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerniak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span> </span><span class="NLM_article-title">Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">â</span> <span class="NLM_lpage">239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.111.179531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21459966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFChsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=228-239&author=N.+Shinauthor=K.+Solomonauthor=N.+Zhouauthor=K.+H.+Wangauthor=V.+Garlapatiauthor=B.+Thomasauthor=Y.+Liauthor=M.+Covingtonauthor=F.+Baribaudauthor=S.+Erickson-Viitanenauthor=P.+Czerniakauthor=N.+Contelauthor=P.+Liuauthor=T.+Burnauthor=G.+Hollisauthor=S.+Yeleswaramauthor=K.+Vaddiauthor=C.+B.+Xueauthor=B.+Metcalfauthor=S.+Friedmanauthor=P.+Scherleauthor=R.+Newton&title=Identification+and+characterization+of+INCB9471%2C+an+allosteric+noncompetitive+small-molecule+antagonist+of+C-C+chemokine+receptor+5+with+potent+inhibitory+activity+against+monocyte+migration+and+HIV-1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection</span></div><div class="casAuthors">Shin, Niu; Solomon, Kim; Zhou, Naiming; Wang, Kathy He; Garlapati, Vasudha; Thomas, Beth; Li, Yanlong; Covington, Maryanne; Baribaud, Frederic; Erickson-Viitanen, Susan; Czerniak, Phil; Contel, Nancy; Liu, Phillip; Burn, Timothy; Hollis, Gregory; Yeleswaram, Swamy; Vaddi, Kris; Xue, Chu-Biao; Metcalf, Brian; Friedman, Steve; Scherle, Peggy; Newton, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-239</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">C-C chemokine receptor 5 (CCR5) is a clin. proven target for inhibition of HIV-1 infection and a potential target for various inflammatory diseases.  In this article, we describe 5-[(4-{(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-4,6-dimethylpyrimidine dihydrochloride (INCB9471), a potent and specific inhibitor of human CCR5 that has been proven to be safe and efficacious in viral load redn. in phase I and II human clin. trails.  INCB9471 was identified using a primary human monocyte-based radioligand competition binding assay.  It potently inhibited macrophage inflammatory protein-1Î²-induced monocyte migration and infection of peripheral blood mononuclear cells by a panel of R5-HIV-1 strains.  The results from binding and signaling studies using incremental amts. of INCB9471 demonstrated INCB9471 as a noncompetitive CCR5 inhibitor.  The CCR5 residues that are essential for interaction with INCB9471 were identified by site-specific mutagenesis studies.  INCB9471 rapidly assocs. with but slowly dissocs. from CCR5.  When INCB9471 was compared with three CCR5 antagonists that had been tested in clin. trials, the potency of INCB9471 in blocking CCR5 ligand binding was similar to those of 4,6-dimethyl-5-{[4-methyl-4-((3S)-3-methyl-4-{(1R0-2-(methyloxy)-1-[4-(trifluoromethyl) phenyl]ethyl}-1-piperazingyl)-1-piperidinyl]carbonyl}pyrimidine (SCH-D; vicriviroc), 4-{[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxyl)methyl]-2, 5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenyl]oxy}benzoic acid hydrochloride (873140; aplaviroc), and 4,4-difluoro-N-((1S)-3-{(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenylpropyl)cyclohexanecarboxamide (UK427857; maraviroc).  Its inhibitory activity against CCR5-mediated Ca2+ mobilization was also similar to those of SCH-D and 873140.  Further anal. suggested that INCB9471 and UK427857 may have different binding sites on CCR5.  The significance of two CCR5 antagonists with different binding sites is discussed in the context of potentially overcoming drug-resistant HIV-1 strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZXJIXoWpxVbVg90H21EOLACvtfcHk0lhmqg3i_sCZOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFChsr8%253D&md5=cd5e8e0e33c10197981439fa3ff8db0d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.179531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.179531%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DN.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DGarlapati%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DCzerniak%26aufirst%3DP.%26aulast%3DContel%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DXue%26aufirst%3DC.%2BB.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DNewton%26aufirst%3DR.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520INCB9471%252C%2520an%2520allosteric%2520noncompetitive%2520small-molecule%2520antagonist%2520of%2520C-C%2520chemokine%2520receptor%25205%2520with%2520potent%2520inhibitory%2520activity%2520against%2520monocyte%2520migration%2520and%2520HIV-1%2520infection%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D228%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Cohen, C.; DeJesus, E.; Mills, A.; Pierone, G.; Kumar, P.; Ruane, P.; Elion, R.; Fusco, G.; Levy, R.; Solomon, K.</span><span> </span><span class="NLM_article-title">Potent Antiretroviral Activity of the Once Daily Antagonist INCB009471 over 14 Days of Monotherapy</span>. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Cohen&author=E.+DeJesus&author=A.+Mills&author=G.+Pierone&author=P.+Kumar&author=P.+Ruane&author=R.+Elion&author=G.+Fusco&author=R.+Levy&author=K.+Solomon&title=Potent+Antiretroviral+Activity+of+the+Once+Daily+Antagonist+INCB009471+over+14+Days+of+Monotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DC.%26atitle%3DPotent%2520Antiretroviral%2520Activity%2520of%2520the%2520Once%2520Daily%2520Antagonist%2520INCB009471%2520over%252014%2520Days%2520of%2520Monotherapy%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Dalton, P.</span><span> </span><span class="NLM_article-title">Incyte Halts Development of Promising New CCR5 Drug</span>.  <span class="citation_source-book">The Body</span>; <span class="NLM_publisher-name">Remedy Health Media, LLC</span>: <span class="NLM_publisher-loc">New York</span>; <a href="http://www.thebody.com/content/art46326.html" class="extLink">http://www.thebody.com/content/art46326.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dalton%2C+P.+Incyte+Halts+Development+of+Promising+New+CCR5+Drug.+The+Body%3B+Remedy+Health+Media%2C+LLC%3A+New+York%3B+http%3A%2F%2Fwww.thebody.com%2Fcontent%2Fart46326.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDalton%26aufirst%3DP.%26atitle%3DIncyte%2520Halts%2520Development%2520of%2520Promising%2520New%2520CCR5%2520Drug%26btitle%3DThe%2520Body%26pub%3DRemedy%2520Health%2520Media%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Burrows, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillery, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamlin, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span> </span><span class="NLM_article-title">Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=25-28&author=J.+N.+Burrowsauthor=J.+G.+Cummingauthor=S.+M.+Filleryauthor=G.+A.+Hamlinauthor=J.+A.+Hudsonauthor=R.+J.+Jacksonauthor=S.+McLaughlinauthor=J.+S.+Shaw&title=Modulators+of+the+human+CCR5+receptor.+Part+1%3A+Discovery+and+initial+SAR+of+1-%283%2C3-diphenylpropyl%29-piperidinyl+amides+and+ureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DFillery%26aufirst%3DS.%2BM.%26aulast%3DHamlin%26aufirst%3DG.%2BA.%26aulast%3DHudson%26aufirst%3DJ.%2BA.%26aulast%3DJackson%26aufirst%3DR.%2BJ.%26aulast%3DMcLaughlin%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26atitle%3DModulators%2520of%2520the%2520human%2520CCR5%2520receptor.%2520Part%25201%253A%2520Discovery%2520and%2520initial%2520SAR%2520of%25201-%25283%252C3-diphenylpropyl%2529-piperidinyl%2520amides%2520and%2520ureas%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D25%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grime, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span> </span><span class="NLM_article-title">Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5012</span><span class="NLM_x">â</span> <span class="NLM_lpage">5015</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=5012-5015&author=J.+G.+Cummingauthor=A.+E.+Cooperauthor=K.+Grimeauthor=C.+J.+Loganauthor=S.+McLaughlinauthor=J.+Oldfieldauthor=J.+S.+Shawauthor=H.+Tuckerauthor=J.+Winterauthor=D.+Whittaker&title=Modulators+of+the+human+CCR5+receptor.+Part+2%3A+SAR+of+substituted+1-%283%2C3-diphenylpropyl%29-piperidinyl+phenylacetamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DLogan%26aufirst%3DC.%2BJ.%26aulast%3DMcLaughlin%26aufirst%3DS.%26aulast%3DOldfield%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26aulast%3DTucker%26aufirst%3DH.%26aulast%3DWinter%26aufirst%3DJ.%26aulast%3DWhittaker%26aufirst%3DD.%26atitle%3DModulators%2520of%2520the%2520human%2520CCR5%2520receptor.%2520Part%25202%253A%2520SAR%2520of%2520substituted%25201-%25283%252C3-diphenylpropyl%2529-piperidinyl%2520phenylacetamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D5012%26epage%3D5015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faull, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grime, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span> </span><span class="NLM_article-title">Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3533</span><span class="NLM_x">â</span> <span class="NLM_lpage">3536</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3533-3536&author=J.+G.+Cummingauthor=S.+J.+Brownauthor=A.+E.+Cooperauthor=A.+W.+Faullauthor=A.+P.+Flynnauthor=K.+Grimeauthor=J.+Oldfieldauthor=J.+S.+Shawauthor=E.+Shepherdauthor=H.+Tuckerauthor=D.+Whittaker&title=Modulators+of+the+human+CCR5+receptor.+Part+3%3A+SAR+of+substituted+1-%5B3-%284-methanesulfonylphenyl%29-3-phenylpropyl%5D-piperidinyl+phenylacetamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFaull%26aufirst%3DA.%2BW.%26aulast%3DFlynn%26aufirst%3DA.%2BP.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DOldfield%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26aulast%3DShepherd%26aufirst%3DE.%26aulast%3DTucker%26aufirst%3DH.%26aulast%3DWhittaker%26aufirst%3DD.%26atitle%3DModulators%2520of%2520the%2520human%2520CCR5%2520receptor.%2520Part%25203%253A%2520SAR%2520of%2520substituted%25201-%255B3-%25284-methanesulfonylphenyl%2529-3-phenylpropyl%255D-piperidinyl%2520phenylacetamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3533%26epage%3D3536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Highton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faull, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J.</span><span> </span><span class="NLM_article-title">Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">â</span> <span class="NLM_lpage">1659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1655-1659&author=J.+G.+Cummingauthor=H.+Tuckerauthor=J.+Oldfieldauthor=C.+Fieldingauthor=A.+Hightonauthor=A.+Faullauthor=M.+Wildauthor=D.+Brownauthor=S.+Wellsauthor=J.+Shaw&title=Balancing+hERG+affinity+and+absorption+in+the+discovery+of+AZD5672%2C+an+orally+active+CCR5+antagonist+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DTucker%26aufirst%3DH.%26aulast%3DOldfield%26aufirst%3DJ.%26aulast%3DFielding%26aufirst%3DC.%26aulast%3DHighton%26aufirst%3DA.%26aulast%3DFaull%26aufirst%3DA.%26aulast%3DWild%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DJ.%26atitle%3DBalancing%2520hERG%2520affinity%2520and%2520absorption%2520in%2520the%2520discovery%2520of%2520AZD5672%252C%2520an%2520orally%2520active%2520CCR5%2520antagonist%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1655%26epage%3D1659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vencovsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekanecz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braddock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">3154</span><span class="NLM_x">â</span> <span class="NLM_lpage">3160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.27652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20662070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=3154-3160&author=D.+M.+Gerlagauthor=S.+Hollisauthor=M.+Laytonauthor=J.+Vencovskyauthor=Z.+Szekaneczauthor=M.+Braddockauthor=P.+P.+Tak&title=Preclinical+and+clinical+investigation+of+a+CCR5+antagonist%2C+AZD5672%2C+in+patients+with+rheumatoid+arthritis+receiving+methotrexate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate</span></div><div class="casAuthors">Gerlag, Danielle M.; Hollis, Sally; Layton, Mark; Vencovsky, Jiri; Szekanecz, Zoltan; Braddock, Martin; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3154-3160</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. To investigate both the preclin. effects of blocking the chemokine receptor CCR5 and the clin. effects of this approach on the signs and symptoms of rheumatoid arthritis (RA) in patients with active disease.  Methods. Preclin. evaluations of AZD5672, a small-mol. antagonist of CCR5, were performed, including studies of ligand binding and chemotaxis.  The pharmacokinetics of AZD5672 were assessed in both single- and multiple-dose studies in healthy volunteers.  A randomized, placebo-controlled, phase IIb study was conducted in patients with active RA receiving methotrexate.  Treatment arms were AZD5672 (20, 50, 100, or 150 mg orally, once daily), matched placebo, or open-label etanercept (50 mg s.c., once weekly).  The primary end point was the proportion of patients achieving a 20% improvement response on the American College of Rheumatol. improvement criteria (ACR20) at week 12.  Secondary end points included the ACR20 over time, as well as 50% (ACR50) and 70% (ACR70) improvement responses, changes in individual components of the ACR improvement criteria, and disease activity measured with the Disease Activity Score based on the 28-joint count.  Results. AZD5672 was a highly potent and selective antagonist of CCR5, displaying nonproportional steady-state pharmacokinetics while inhibiting internalization of CCR5 in an ex vivo macrophage inflammatory protein 1Î² stimulation assay in which AZD5672 was evaluated over the 20-150-mg dose range.  In the phase IIb study testing this dose range in patients with RA (n = 371 patients randomized to received treatment), AZD5672 was generally well tolerated, with no unexpected adverse events.  There was no statistically significant difference in the proportion of patients achieving an ACR20 response at week 12 between those receiving any dose of AZD5672 and those receiving placebo; etanercept was significantly more efficacious than AZD5672 and placebo.  Conclusion. Despite a clear rationale for targeting CCR5, this clin. study showed that AZD5672, administered orally, did not have any clin. benefit, suggesting that CCR5 antagonism alone is unlikely to be a viable therapeutic strategy in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNMtJlWPEReLVg90H21EOLACvtfcHk0lg52wA5EeqvgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrP&md5=78b9ccb1c6e3fd325a5abe24c703751b</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1002%2Fart.27652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27652%26sid%3Dliteratum%253Aachs%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DLayton%26aufirst%3DM.%26aulast%3DVencovsky%26aufirst%3DJ.%26aulast%3DSzekanecz%26aufirst%3DZ.%26aulast%3DBraddock%26aufirst%3DM.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DPreclinical%2520and%2520clinical%2520investigation%2520of%2520a%2520CCR5%2520antagonist%252C%2520AZD5672%252C%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520receiving%2520methotrexate%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D3154%26epage%3D3160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Jacobson, J.; Thompson, M.; Fischl, M.</span><span> </span><span class="NLM_article-title">Phase 2a Study of PRO 140 in HIV-Infected Adults</span>. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009), San Francisco, CA 2009; Abstract H-1229.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jacobson%2C+J.%3B+Thompson%2C+M.%3B+Fischl%2C+M.+Phase+2a+Study+of+PRO+140+in+HIV-Infected+Adults.+Presented+at+the+49th+Interscience+Conference+on+Antimicrobial+Agents+and+Chemotherapy+%28ICAAC+2009%29%2C+San+Francisco%2C+CA+2009%3B+Abstract+H-1229."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DJ.%26atitle%3DPhase%25202a%2520Study%2520of%2520PRO%2520140%2520in%2520HIV-Infected%2520Adults" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadavalli, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Para, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dejesus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novello, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">â</span> <span class="NLM_lpage">727</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1086%2F527327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18266604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFSmsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2008&pages=721-727&author=J.+Lalezariauthor=G.+K.+Yadavalliauthor=M.+Paraauthor=G.+Richmondauthor=E.+Dejesusauthor=S.+J.+Brownauthor=W.+Caiauthor=C.+Chenauthor=J.+Zhongauthor=L.+A.+Novelloauthor=M.+M.+Ledermanauthor=G.+M.+Subramanian&title=Safety%2C+pharmacokinetics%2C+and+antiviral+activity+of+HGS004%2C+a+novel+fully+human+IgG4+monoclonal+antibody+against+CCR5%2C+in+HIV-1-infected+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV1-1-infected patients</span></div><div class="casAuthors">Lalezari, Jacob; Yadavalli, Gopal K.; Para, Michael; Richmond, Gary; DeJesus, Edwin; Brown, Stephen J.; Cai, Wendy; Chen, Cecil; Zhong, John; Novello, Lu Anne; Lederman, Michael M.; Subramanian, G. Mani</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-727</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">HGS004 is a fully human Ig (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5) with robust in vitro activity against a diverse panel of CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates.  A single-blind, randomized, placebo-controlled study was conducted in patients infected with CCR5-tropic HIV-1 to evaluate the safety, pharmacokinetics, and antiviral activity of HGS004.  Sixty-three subjects were randomized into 5 dose cohorts (0.4, 2, 8, 20, and 40 mg/kg) and received a single i.v. dose of HGS004 or placebo.  HGS004 was well tolerated, and no dose-limiting toxicities were obsd.  Pharmacokinetics were nonlinear across the 0.4-40-mg/kg dose range, with dose-proportional increases in max. concn., although the area under the curve increased more than proportionally to dose.  High levels of receptor occupancy were obsd. for up to 28 days in the higher-dose cohorts.  Plasma HIV-1 RNA redns. of > 1 log10 at day 14 were obsd. in 14 (54%) of 26 subjects in the 8-, 20-, and 40-mg/kg cohorts.  In the 40-mg/kg cohort, 4 of 10 subjects had a >1 log10, HIV-1 RNA redn. at day 28.  Drug concns. relative to isolate sensitivity (the ratio of the concn. at day 14 to IC90) predicted antiviral response on day 14.  HGS004 is safe and well tolerated and demonstrates meaningful antiviral activity when administered to patients infected with CCRS-tropic HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF9geFO64f_LVg90H21EOLACvtfcHk0lh9bB7vCVB6vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFSmsL8%253D&md5=9618f150676a1871bf17bb54269a29f8</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1086%2F527327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F527327%26sid%3Dliteratum%253Aachs%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DYadavalli%26aufirst%3DG.%2BK.%26aulast%3DPara%26aufirst%3DM.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DDejesus%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DCai%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DNovello%26aufirst%3DL.%2BA.%26aulast%3DLederman%26aufirst%3DM.%2BM.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520antiviral%2520activity%2520of%2520HGS004%252C%2520a%2520novel%2520fully%2520human%2520IgG4%2520monoclonal%2520antibody%2520against%2520CCR5%252C%2520in%2520HIV-1-infected%2520patients%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D197%26spage%3D721%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Miltz, W.</span><span> </span><span class="NLM_article-title">Dual CCR2/ CCR5Antagonists: A New Approach for the Treatment of Autoimmune Diseases</span>. Presented at the 235th National Meeting of the American Chemical Society, New Orleans, LA,  Apr 6â10,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span><a href="http://oasys2.confex.com/acs/235nm/techprogram/S26267.HTM" class="extLink">http://oasys2.confex.com/acs/235nm/techprogram/S26267.HTM</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=W.+Miltz&title=Dual+CCR2%2F+CCR5Antagonists%3A+A+New+Approach+for+the+Treatment+of+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMiltz%26aufirst%3DW.%26atitle%3DDual%2520CCR2%252F%2520CCR5Antagonists%253A%2520A%2520New%2520Approach%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Urnov, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebar, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, P. D.</span><span> </span><span class="NLM_article-title">Genome editing with engineered zinc finger nucleases</span> <span class="citation_source-journal">Nat. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">â</span> <span class="NLM_lpage">646</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnrg2842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20717154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCnurzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=636-646&author=F.+D.+Urnovauthor=E.+J.+Rebarauthor=M.+C.+Holmesauthor=H.+S.+Zhangauthor=P.+D.+Gregory&title=Genome+editing+with+engineered+zinc+finger+nucleases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Genome editing with engineered zinc finger nucleases</span></div><div class="casAuthors">Urnov, Fyodor D.; Rebar, Edward J.; Holmes, Michael C.; Zhang, H. Steve; Gregory, Philip D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-646</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Zinc finger nucleases (ZFNs) are versatile tools for making precise modifications to genomes, and their use is now established in a range of model systems.  ZFNs are also showing potential in human gene therapy, and several clin. trials are underway.  Reverse genetics in model organisms such as Drosophila melanogaster, Arabidopsis thaliana, zebrafish and rats, efficient genome engineering in human embryonic stem and induced pluripotent stem cells, targeted integration in crop plants, and HIV resistance in immune cells - this broad range of outcomes has resulted from the application of the same core technol.: targeted genome cleavage by engineered, sequence-specific zinc finger nucleases followed by gene modification during subsequent repair.  Such 'genome editing' is now established in human cells and a no. of model organisms, thus opening the door to a range of new exptl. and therapeutic possibilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLqJej0w25drVg90H21EOLACvtfcHk0lh9bB7vCVB6vw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCnurzE&md5=23222b7a08e0ddddd083f69e6f53af5f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fnrg2842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2842%26sid%3Dliteratum%253Aachs%26aulast%3DUrnov%26aufirst%3DF.%2BD.%26aulast%3DRebar%26aufirst%3DE.%2BJ.%26aulast%3DHolmes%26aufirst%3DM.%2BC.%26aulast%3DZhang%26aufirst%3DH.%2BS.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26atitle%3DGenome%2520editing%2520with%2520engineered%2520zinc%2520finger%2520nucleases%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2010%26volume%3D11%26spage%3D636%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paxton, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceradini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuhlmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landau, N. R.</span><span> </span><span class="NLM_article-title">Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">â</span> <span class="NLM_lpage">377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1996&pages=367-377&author=R.+Liuauthor=W.+A.+Paxtonauthor=S.+Choeauthor=D.+Ceradiniauthor=S.+R.+Martinauthor=R.+Horukauthor=M.+E.+MacDonaldauthor=H.+Stuhlmannauthor=R.+A.+Koupauthor=N.+R.+Landau&title=Homozygous+defect+in+HIV-1+coreceptor+accounts+for+resistance+of+some+multiply-exposed+individuals+to+HIV-1+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPaxton%26aufirst%3DW.%2BA.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DCeradini%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DS.%2BR.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DMacDonald%26aufirst%3DM.%2BE.%26aulast%3DStuhlmann%26aufirst%3DH.%26aulast%3DKoup%26aufirst%3DR.%2BA.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26atitle%3DHomozygous%2520defect%2520in%2520HIV-1%2520coreceptor%2520accounts%2520for%2520resistance%2520of%2520some%2520multiply-exposed%2520individuals%2520to%2520HIV-1%2520infection%26jtitle%3DCell%26date%3D1996%26volume%3D86%26spage%3D367%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Saruta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Q. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanesyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleshner, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadakis, K. A.</span><span> </span><span class="NLM_article-title">Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohnâs disease</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">3293</span><span class="NLM_x">â</span> <span class="NLM_lpage">3300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2007&pages=3293-3300&author=M.+Sarutaauthor=Q.+T.+Yuauthor=A.+Avanesyanauthor=P.+R.+Fleshnerauthor=S.+R.+Targanauthor=K.+A.+Papadakis&title=Phenotype+and+effector+function+of+CC+chemokine+receptor+9-expressing+lymphocytes+in+small+intestinal+Crohn%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaruta%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DQ.%2BT.%26aulast%3DAvanesyan%26aufirst%3DA.%26aulast%3DFleshner%26aufirst%3DP.%2BR.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DPapadakis%26aufirst%3DK.%2BA.%26atitle%3DPhenotype%2520and%2520effector%2520function%2520of%2520CC%2520chemokine%2520receptor%25209-expressing%2520lymphocytes%2520in%2520small%2520intestinal%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Immunol.%26date%3D2007%26volume%3D178%26spage%3D3293%26epage%3D3300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Ungashe, S.; Wright, J. J.; Pennell, A.</span><span> </span><span class="NLM_article-title">Aryl Sulfonamides</span>. US 7,932,252,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Ungashe&author=J.+J.+Wright&author=A.+Pennell&title=Aryl+Sulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUngashe%26aufirst%3DS.%26atitle%3DAryl%2520Sulfonamides%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span>Vercirnon. <a href="http://www.chemspider.com/Chemical-Structure.8518913.html" class="extLink">http://www.chemspider.com/Chemical-Structure.8518913.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vercirnon.+http%3A%2F%2Fwww.chemspider.com%2FChemical-Structure.8518913.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Walters, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgart, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairaghi, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penfold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ungashe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T. J.</span><span> </span><span class="NLM_article-title">Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">â</span> <span class="NLM_lpage">69</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.110.169714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20660125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=61-69&author=M.+J.+Waltersauthor=Y.+Wangauthor=N.+Laiauthor=T.+Baumgartauthor=B.+N.+Zhaoauthor=D.+J.+Dairaghiauthor=P.+Bekkerauthor=L.+S.+Ertlauthor=M.+E.+Penfoldauthor=J.+C.+Jaenauthor=S.+Keshavauthor=E.+Wendtauthor=A.+Pennellauthor=S.+Ungasheauthor=Z.+Weiauthor=J.+J.+Wrightauthor=T.+J.+Schall&title=Characterization+of+CCX282-B%2C+an+orally+bioavailable+antagonist+of+the+CCR9+chemokine+receptor%2C+for+treatment+of+inflammatory+bowel+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease</span></div><div class="casAuthors">Walters, Matthew J.; Wang, Yu; Lai, Nu; Baumgart, Trageen; Zhao, Bin N.; Dairaghi, Daniel J.; Bekker, Pirow; Ertl, Linda S.; Penfold, Mark E. T.; Jaen, Juan C.; Keshav, Satish; Wendt, Emily; Pennell, Andrew; Ungashe, Solomon; Wei, Zheng; Wright, J. J. Kim; Schall, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chemokine system represents a diverse group of G protein-coupled receptors responsible for orchestrating cell recruitment under both homeostatic and inflammatory conditions.  Chemokine receptor 9 (CCR9) is a chemokine receptor known to be central for migration of immune cells into the intestine.  Its only ligand, CCL25, is expressed at the mucosal surface of the intestine and is known to be elevated in intestinal inflammation.  To date, there are no reports of small-mol. antagonists targeting CCR9.  We report, for the first time, the discovery of a small mol., CCX282-B, which is an orally bioavailable, selective, and potent antagonist of human CCR9.  CCX282-B inhibited CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, resp.  In the presence of 100% human serum, CCX282-B inhibited CCR9-mediated chemotaxis with an IC50 of 33 nM, and the addn. of Î±1-acid glycoprotein did not affect its potency.  CCX282-B inhibited chemotaxis of primary CCR9-expressing cells to CCL25 with an IC50 of 6.8 nM.  CCX282-B was an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, resp.  CCX282-B also inhibited mouse and rat CCR9-mediated chemotaxis.  Inhibition of CCR9 with CCX282-B results in normalization of Crohn's disease such as histopathol. assocd. with the TNFÎARE mice.  Anal. of the plasma level of drug assocd. with this improvement provides an understanding of the pharmacokinetic/pharmacodynamic relationship for CCR9 antagonists in the treatment of intestinal inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvKRxhmslqLVg90H21EOLACvtfcHk0lhpLVp0uly-dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3I&md5=0d7903a7e25721ede33196f8e32f0e87</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.169714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.169714%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DN.%26aulast%3DBaumgart%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DB.%2BN.%26aulast%3DDairaghi%26aufirst%3DD.%2BJ.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DErtl%26aufirst%3DL.%2BS.%26aulast%3DPenfold%26aufirst%3DM.%2BE.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DKeshav%26aufirst%3DS.%26aulast%3DWendt%26aufirst%3DE.%26aulast%3DPennell%26aufirst%3DA.%26aulast%3DUngashe%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26atitle%3DCharacterization%2520of%2520CCX282-B%252C%2520an%2520orally%2520bioavailable%2520antagonist%2520of%2520the%2520CCR9%2520chemokine%2520receptor%252C%2520for%2520treatment%2520of%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D61%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Keshav, S.</span><span> </span><span class="NLM_article-title">CCX282-B, an Orally Active Inhibitor of Chemokine Receptor CCR9, in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Moderate to Severe Crohnâs Disease</span>. Presented at the 14th United European Gastroenterology Week (UEGW 2006), Berlin,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+Keshav&title=CCX282-B%2C+an+Orally+Active+Inhibitor+of+Chemokine+Receptor+CCR9%2C+in+a+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Phase+2+Study+in+Moderate+to+Severe+Crohn%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKeshav%26aufirst%3DS.%26atitle%3DCCX282-B%252C%2520an%2520Orally%2520Active%2520Inhibitor%2520of%2520Chemokine%2520Receptor%2520CCR9%252C%2520in%2520a%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25202%2520Study%2520in%2520Moderate%2520to%2520Severe%2520Crohn%25E2%2580%2599s%2520Disease%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurewicz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">10095</span><span class="NLM_x">â</span> <span class="NLM_lpage">10098</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1074%2Fjbc.273.17.10095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9553055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=10095-10098&author=J.+R.+Whiteauthor=J.+M.+Leeauthor=P.+R.+Youngauthor=R.+P.+Hertzbergauthor=A.+J.+Jurewiczauthor=M.+A.+Chaikinauthor=K.+Widdowsonauthor=J.+J.+Foleyauthor=L.+D.+Martinauthor=D.+E.+Griswoldauthor=H.+M.+Sarau&title=Identification+of+a+potent%2C+selective+non-peptide+CXCR2+antagonist+that+inhibits+interleukin-8-induced+neutrophil+migration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span></div><div class="casAuthors">White, John R.; Lee, Judithann M.; Young, Peter R.; Hertzberg, Robert P.; Jurewicz, Anthony J.; Chaikin, Margery A.; Widdowson, Katherine; Foley, James J.; Martin, Lenox D.; Griswold, Don E.; Sarau, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">10095-10098</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Interleukin-8 (IL-8) and closely related Glu-Leu-Arg (ELR) contg. CXC chemokines, including growth-related oncogene (GRO)Î±, GROÎ², GROÎ³, and epithelial cell-derived neutrophil-activating peptide-78 (ENA-78), are potent neutrophil chemotactic and activating peptides, which are proposed to be major mediators of inflammation.  IL-8 activates neutrophils by binding to two distinct seven-transmembrane (7-TMR) G-protein coupled receptors CXCR1 (IL-8RA) and CXCR2 (IL-8RB), while GROÎ±, GROÎ², GROÎ³, and ENA-78 bind to and activate only CXCR2.  A chem. lead, which selectively inhibited CXCR2 was discovered by high throughput screening and chem. optimized.  SB 225002 (N-(2-hydroxy-4-nitrophenyl)-N'-(2-bromophenyl)urea) is the first reported potent and selective non-peptide inhibitor of a chemokine receptor.  It is an antagonist of 125I-IL-8 binding to CXCR2 with an IC50 = 22 nM.  SB 225002 showed > 150-fold selectivity over CXCR1 and four other 7-TMRs tested.  In vitro, SB 225002 potently inhibited human and rabbit neutrophil chemotaxis induced by both IL-8 and GROÎ±.  In vivo, SB 225002 selectively blocked IL-8-induced neutrophil margination in rabbits.  The present findings suggest that CXCR2 is responsible for neutrophil chemotaxis and margination induced by IL-8.  This selective antagonist will be a useful tool compd. to define the role of CXCR2 in inflammatory diseases where neutrophils play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO6PNyFAVGW7Vg90H21EOLACvtfcHk0lhpLVp0uly-dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D&md5=28b894f2ff3672653a92f3ff5230d1ac</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.17.10095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.17.10095%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DWiddowson%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%2520non-peptide%2520CXCR2%2520antagonist%2520that%2520inhibits%2520interleukin-8-induced%2520neutrophil%2520migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D10095%26epage%3D10098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutledge, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleland, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurewicz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1319</span><span class="NLM_x">â</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034248l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1319-1321&author=K.+L.+Widdowsonauthor=J.+D.+Elliottauthor=D.+F.+Veberauthor=H.+Nieauthor=M.+C.+Rutledgeauthor=B.+W.+McClelandauthor=J.+N.+Xiangauthor=A.+J.+Jurewiczauthor=R.+P.+Hertzbergauthor=J.+J.+Foleyauthor=D.+E.+Griswoldauthor=L.+Martinauthor=J.+M.+Leeauthor=J.+R.+Whiteauthor=H.+M.+Sarau&title=Evaluation+of+potent+and+selective+small-molecule+antagonists+for+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm034248l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034248l%26sid%3Dliteratum%253Aachs%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DNie%26aufirst%3DH.%26aulast%3DRutledge%26aufirst%3DM.%2BC.%26aulast%3DMcCleland%26aufirst%3DB.%2BW.%26aulast%3DXiang%26aufirst%3DJ.%2BN.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DMartin%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DEvaluation%2520of%2520potent%2520and%2520selective%2520small-molecule%2520antagonists%2520for%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1319%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleland, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nord, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorycki, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Discovery of potent and orally bioavailable <i>N</i>,<i>N</i>â²-diarylurea antagonists for the CXCR2 chemokine receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4375</span><span class="NLM_x">â</span> <span class="NLM_lpage">4378</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4375-4378&author=Q.+Jinauthor=H.+Nieauthor=B.+W.+McClelandauthor=K.+L.+Widdowsonauthor=M.+R.+Palovichauthor=J.+D.+Elliottauthor=R.+M.+Goodmanauthor=M.+Burmanauthor=H.+M.+Sarauauthor=K.+W.+Wardauthor=M.+Nordauthor=B.+M.+Orrauthor=P.+D.+Goryckiauthor=J.+Busch-Petersen&title=Discovery+of+potent+and+orally+bioavailable+N%2CN%E2%80%B2-diarylurea+antagonists+for+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DNie%26aufirst%3DH.%26aulast%3DMcCleland%26aufirst%3DB.%2BW.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DGoodman%26aufirst%3DR.%2BM.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DNord%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DB.%2BM.%26aulast%3DGorycki%26aufirst%3DP.%2BD.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520bioavailable%2520N%252CN%25E2%2580%25B2-diarylurea%2520antagonists%2520for%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4375%26epage%3D4378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">Lazaar, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexis, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&author=A.+L.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0likKkzqbj3VWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D282%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Allegretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bitondo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cioccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bello, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantucci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span> </span><span class="NLM_article-title">2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4312</span><span class="NLM_x">â</span> <span class="NLM_lpage">4331</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049082i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4312-4331&author=M.+Allegrettiauthor=R.+Bertiniauthor=M.+C.+Cestaauthor=C.+Bizzarriauthor=R.+Di+Bitondoauthor=V.+Di+Cioccioauthor=E.+Gallieraauthor=V.+Berdiniauthor=A.+Topaiauthor=G.+Zampellaauthor=V.+Russoauthor=N.+Di+Belloauthor=G.+Nanoauthor=L.+Nicoliniauthor=M.+Locatiauthor=P.+Fantucciauthor=S.+Florioauthor=F.+Colotta&title=2-Arylpropionic+CXC+chemokine+receptor+1+%28CXCR1%29+ligands+as+novel+noncompetitive+CXCL8+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Fjm049082i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049082i%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DDi%2BCioccio%26aufirst%3DV.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DTopai%26aufirst%3DA.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DV.%26aulast%3DDi%2BBello%26aufirst%3DN.%26aulast%3DNano%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DL.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DFantucci%26aufirst%3DP.%26aulast%3DFlorio%26aufirst%3DS.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3D2-Arylpropionic%2520CXC%2520chemokine%2520receptor%25201%2520%2528CXCR1%2529%2520ligands%2520as%2520novel%2520noncompetitive%2520CXCL8%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4312%26epage%3D4331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Ginestier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebel, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korkaya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabaud, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charafe-Jauffret, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dontu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicha, M. S.</span><span> </span><span class="NLM_article-title">CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=485-497&author=C.+Ginestierauthor=S.+Liuauthor=M.+E.+Diebelauthor=H.+Korkayaauthor=M.+Luoauthor=M.+Brownauthor=J.+Wicinskiauthor=O.+Cabaudauthor=E.+Charafe-Jauffretauthor=D.+Birnbaumauthor=J.+L.+Guanauthor=G.+Dontuauthor=M.+S.+Wicha&title=CXCR1+blockade+selectively+targets+human+breast+cancer+stem+cells+in+vitro+and+in+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDiebel%26aufirst%3DM.%2BE.%26aulast%3DKorkaya%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DWicinski%26aufirst%3DJ.%26aulast%3DCabaud%26aufirst%3DO.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DBirnbaum%26aufirst%3DD.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26aulast%3DDontu%26aufirst%3DG.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26atitle%3DCXCR1%2520blockade%2520selectively%2520targets%2520human%2520breast%2520cancer%2520stem%2520cells%2520in%2520vitro%2520and%2520in%2520xenografts%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D485%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">Suling, L.; Korkaya, H.; Wicha, M. S.</span><span> </span><span class="NLM_article-title">Are Cancer Stem Cells Ready for Prime Time?</span> <span class="citation_source-book">The Scientist</span>; LabX Media Group: New York; <a href="http://the-scientist.com/2012/04/01/are-cancer-stem-cells-ready-for-prime-time/" class="extLink">http://the-scientist.com/2012/04/01/are-cancer-stem-cells-ready-for-prime-time/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Suling%2C+L.%3B+Korkaya%2C+H.%3B+Wicha%2C+M.+S.+Are+Cancer+Stem+Cells+Ready+for+Prime+Time%3FThe+Scientist%3B+LabX+Media+Group%3A+New+York%3B+http%3A%2F%2Fthe-scientist.com%2F2012%2F04%2F01%2Fare-cancer-stem-cells-ready-for-prime-time%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSuling%26aufirst%3DL.%26atitle%3DAre%2520Cancer%2520Stem%2520Cells%2520Ready%2520for%2520Prime%2520Time%253F%26btitle%3DThe%2520Scientist" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biju, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rindgen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Ezel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terminelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozgur, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span> </span><span class="NLM_article-title">Discovery of 2-hydroxy-<i>N</i>,<i>N</i>-dimethyl-3-{2-[[(<i>R</i>)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7603</span><span class="NLM_x">â</span> <span class="NLM_lpage">7606</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0609622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7603-7606&author=M.+P.+Dwyerauthor=Y.+Yuauthor=J.+Chaoauthor=C.+Akiauthor=P.+Bijuauthor=V.+Girijavallabhanauthor=D.+Rindgenauthor=R.+Bondauthor=R.+Mayer-Ezelauthor=J.+Jakwayauthor=R.+W.+Hipkinauthor=J.+Fossettaauthor=W.+Gonsiorekauthor=H.+Bianauthor=X.+Fanauthor=C.+Terminelliauthor=J.+Fineauthor=D.+Lundellauthor=J.+R.+Merrittauthor=L.+L.+Rokoszauthor=B.+Kaiserauthor=G.+Liauthor=W.+Wangauthor=T.+Staufferauthor=L.+Ozgurauthor=J.+Baldwinauthor=A.+G.+Taveras&title=Discovery+of+2-hydroxy-N%2CN-dimethyl-3-%7B2-%5B%5B%28R%29-1-%285-+methylfuran-2-yl%29propyl%5Damino%5D-3%2C4-dioxocyclobut-1-enylamino%7Dbenzamide+%28SCH+527123%29%3A+a+potent%2C+orally+bioavailable+CXCR2%2FCXCR1+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm0609622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0609622%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DAki%26aufirst%3DC.%26aulast%3DBiju%26aufirst%3DP.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DRindgen%26aufirst%3DD.%26aulast%3DBond%26aufirst%3DR.%26aulast%3DMayer-Ezel%26aufirst%3DR.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DTerminelli%26aufirst%3DC.%26aulast%3DFine%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DJ.%2BR.%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DKaiser%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DStauffer%26aufirst%3DT.%26aulast%3DOzgur%26aufirst%3DL.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-hydroxy-N%252CN-dimethyl-3-%257B2-%255B%255B%2528R%2529-1-%25285-%2520methylfuran-2-yl%2529propyl%255Damino%255D-3%252C4-dioxocyclobut-1-enylamino%257Dbenzamide%2520%2528SCH%2520527123%2529%253A%2520a%2520potent%252C%2520orally%2520bioavailable%2520CXCR2%252FCXCR1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7603%26epage%3D7606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.106.118927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17496166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=477-485&author=W.+Gonsiorekauthor=X.+Fanauthor=D.+Heskauthor=J.+Fossettaauthor=H.+Qiuauthor=J.+Jakwayauthor=M.+Billahauthor=M.+Dwyerauthor=J.+Chaoauthor=G.+Denoauthor=A.+Taverasauthor=D.+J.+Lundellauthor=R.+W.+Hipkin&title=Pharmacological+characterization+of+Sch527123%2C+a+potent+allosteric+CXCR1%2FCXCR2+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span></div><div class="casAuthors">Gonsiorek, Waldemar; Fan, Xuedong; Hesk, David; Fossetta, James; Qiu, Hongchen; Jakway, James; Billah, Motasim; Dwyer, Michael; Chao, Jianhua; Deno, Gregory; Taveras, Art; Lundell, Daniel J.; Hipkin, R. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In neutrophils, growth-related protein-Î± (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2.  The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small mol. antagonists for these receptors.  The data presented herein describe the pharmacol. of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2.  Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist.  Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine.  The pharmacol. specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors.  To measure compd. affinity, we characterized [3H]Sch527123 in both equil. and nonequil. binding analyses.  Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible.  Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9Â±0.3 nM), the compd. is CXCR2-selective (Kd = 0.049Â±0.004 nM).  Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb79iH3wA1yrVg90H21EOLACvtfcHk0ljNtZROe0lDhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D&md5=37691994ca29fa4dfe33d094d0cd9b93</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.118927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.118927%26sid%3Dliteratum%253Aachs%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DPharmacological%2520characterization%2520of%2520Sch527123%252C%2520a%2520potent%2520allosteric%2520CXCR1%252FCXCR2%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnicozzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celly, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rindgen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billah, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey, J. A.</span><span> </span><span class="NLM_article-title">A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">â</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.106.119040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17496165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=486-493&author=R.+W.+Chapmanauthor=M.+Minnicozziauthor=C.+S.+Cellyauthor=J.+E.+Phillipsauthor=T.+T.+Kungauthor=R.+W.+Hipkinauthor=X.+Fanauthor=D.+Rindgenauthor=G.+Denoauthor=R.+Bondauthor=W.+Gonsiorekauthor=M.+M.+Billahauthor=J.+S.+Fineauthor=J.+A.+Hey&title=A+novel%2C+orally+active+CXCR1%2F2+receptor+antagonist%2C+Sch527123%2C+inhibits+neutrophil+recruitment%2C+mucus+production%2C+and+goblet+cell+hyperplasia+in+animal+models+of+pulmonary+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation</span></div><div class="casAuthors">Chapman, Richard W.; Minnicozzi, Michael; Celly, Chander S.; Phillips, Jonathan E.; Kung, Ted T.; Hipkin, R. William; Fan, Xuedong; Rindgen, Diane; Deno, Gregory; Bond, Richard; Gonsiorek, Waldemar; Billah, Motasim M.; Fine, Jay S.; Hey, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">486-493</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sch527123 [2-hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide] is a potent, selective antagonist of the human CXCR1 and CXCR2 receptors.  Here we describe its pharmacol. properties at rodent CXCR2 and at the CXCR1 and CXCR2 receptors in the cynomolgus monkey, as well as its in vivo activity in models demonstrating prominent pulmonary neutrophilia, goblet cell hyperplasia, and mucus prodn.  Sch527123 bound with high affinity to the CXCR2 receptors of mouse (Kd = 0.20 nM), rat (Kd = 0.20 nM), and cynomolgus monkey (Kd = 0.08 nM) and was a potent antagonist of CXCR2-mediated chemotaxis (IC50 â¼3-6 nM).  In contrast, Sch527123 bound to cynomolgus CXCR1 with lesser affinity (Kd = 41 nM) and weakly inhibited cynomolgus CXCR1-mediated chemotaxis (IC50 â¼1000 nM).  Oral treatment with Sch527123 blocked pulmonary neutrophilia (ED50 = 1.2 mg/kg) and goblet cell hyperplasia (32-38% inhibition at 1-3 mg/kg) in mice following the intranasal lipopolysaccharide (LPS) administration.  In rats, Sch527123 suppressed the pulmonary neutrophilia (ED50 = 1.8 mg/kg) and increase in bronchoalveolar lavage (BAL) mucin content (ED50 = <0.1 mg/kg) induced by intratracheal (i.t.) LPS.  Sch527123 also suppressed the pulmonary neutrophilia (ED50 = 1.3 mg/kg), goblet cell hyperplasia (ED50 = 0.7 mg/kg), and increase in BAL mucin content (ED50 = <1 mg/kg) in rats after i.t. administration of vanadium pentoxide.  In cynomolgus monkeys, Sch527123 reduced the pulmonary neutrophilia induced by repeat bronchoscopy and lavage (ED50 = 0.3 mg/kg).  Therefore, Sch527123 may offer benefit for the treatment of inflammatory lung disorders in which pulmonary neutrophilia and mucus hypersecretion are important components of the underlying disease pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9jt7WBXMZ5bVg90H21EOLACvtfcHk0ljNtZROe0lDhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7g%253D&md5=825742c8a19cd163e9275658974cfcbf</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.119040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.119040%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DMinnicozzi%26aufirst%3DM.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DKung%26aufirst%3DT.%2BT.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DRindgen%26aufirst%3DD.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DBond%26aufirst%3DR.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DBillah%26aufirst%3DM.%2BM.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26aulast%3DHey%26aufirst%3DJ.%2BA.%26atitle%3DA%2520novel%252C%2520orally%2520active%2520CXCR1%252F2%2520receptor%2520antagonist%252C%2520Sch527123%252C%2520inhibits%2520neutrophil%2520recruitment%252C%2520mucus%2520production%252C%2520and%2520goblet%2520cell%2520hyperplasia%2520in%2520animal%2520models%2520of%2520pulmonary%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D486%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group">Holz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalilieh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig-Sengpiel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stryszak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span> </span><span class="NLM_article-title">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">564</span><span class="NLM_x">â</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1183%2F09031936.00048509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19643947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=564-570&author=O.+Holzauthor=S.+Khaliliehauthor=A.+Ludwig-Sengpielauthor=H.+Watzauthor=P.+Stryszakauthor=P.+Soniauthor=M.+Tsaiauthor=J.+Sadehauthor=H.+Magnussen&title=SCH527123%2C+a+novel+CXCR2+antagonist%2C+inhibits+ozone-induced+neutrophilia+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span></div><div class="casAuthors">Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-570</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease.  The purpose of this proof-of-principle study was to det. whether SCH527123 inhibits ozone-induced neutrophil recruitment in healthy humans.  In a randomized, double-blind, placebo-controlled, three-way crossover study, oral SCH527123 (50 mg once daily, 4 days), prednisolone (50 mg once), or placebo was alternated with 2-wk washouts.  18 Healthy ozone responders (>20% increase in sputum neutrophils) underwent ozone challenge tests (250 ppb, 3 h intermittent exercise) 1 h after the last treatment dose.  Sputum was induced at 3 h post-challenge.  After SCH527123 treatment, the ozone challenge resulted in significantly lower sputum neutrophil counts (0.13 Ã 106 mL-1) compared with prednisolone (0.84 Ã 106/mL-1; p < 0.001) or placebo (2.98 Ã 106 mL-1; p < 0.001).  Comparable results were obtained for total cell count, percentage of sputum neutrophils, and for interleukin-8 and myeloperoxidase in sputum supernatant.  Post-challenge, SCH527123 inhibited neutrophilia in peripheral blood but significantly less than in sputum.  All treatments were safe and well tolerated.  SCH527123 causes significant attenuation of ozone-induced airway neutrophilia in healthy subjects.  Further evaluation in a large trial of patients with pulmonary disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwysQ82AncbVg90H21EOLACvtfcHk0lgKi6OH67UFLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D&md5=ae0702b5eb1122d2c919a4130b3f471e</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1183%2F09031936.00048509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00048509%26sid%3Dliteratum%253Aachs%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DKhalilieh%26aufirst%3DS.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSoni%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DSadeh%26aufirst%3DJ.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DSCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520inhibits%2520ozone-induced%2520neutrophilia%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D564%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group">Jenh, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinsley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodny, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span> </span><span class="NLM_article-title">A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection</span> <span class="citation_source-journal">BMC Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1186%2F1471-2172-13-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=22435930" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=13-22&author=C.+H.+Jenhauthor=M.+A.+Coxauthor=L.+Cuiauthor=E.+P.+Reichauthor=L.+Sullivanauthor=S.+C.+Chenauthor=D.+Kinsleyauthor=S.+Qianauthor=S.+H.+Kimauthor=S.+Rosenblumauthor=J.+Kozlowskiauthor=J.+S.+Fineauthor=P.+J.+Zavodnyauthor=D.+Lundell&title=A+selective+and+potent+CXCR3+antagonist+SCH+546738+attenuates+the+development+of+autoimmune+diseases+and+delays+graft+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1186%2F1471-2172-13-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2172-13-2%26sid%3Dliteratum%253Aachs%26aulast%3DJenh%26aufirst%3DC.%2BH.%26aulast%3DCox%26aufirst%3DM.%2BA.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DReich%26aufirst%3DE.%2BP.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DKinsley%26aufirst%3DD.%26aulast%3DQian%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DRosenblum%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26aulast%3DZavodny%26aufirst%3DP.%2BJ.%26aulast%3DLundell%26aufirst%3DD.%26atitle%3DA%2520selective%2520and%2520potent%2520CXCR3%2520antagonist%2520SCH%2520546738%2520attenuates%2520the%2520development%2520of%2520autoimmune%2520diseases%2520and%2520delays%2520graft%2520rejection%26jtitle%3DBMC%2520Immunol.%26date%3D2012%26volume%3D13%26spage%3D13%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebsworth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sablan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairaghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J.</span><span> </span><span class="NLM_article-title">Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3339</span><span class="NLM_x">â</span> <span class="NLM_lpage">3343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3339-3343&author=M.+Johnsonauthor=A.+R.+Liauthor=J.+Liuauthor=Z.+Fuauthor=L.+Zhuauthor=S.+Miaoauthor=X.+Wangauthor=Q.+Xuauthor=A.+Huangauthor=A.+Marcusauthor=F.+Xuauthor=K.+Ebsworthauthor=E.+Sablanauthor=J.+Danaoauthor=J.+Kumerauthor=D.+Dairaghiauthor=C.+Lawrenceauthor=T.+Sullivanauthor=G.+Tonnauthor=T.+Schallauthor=T.+Collinsauthor=J.+Medina&title=Discovery+and+optimization+of+a+series+of+quinazolinone-derived+antagonists+of+CXCR3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DMarcus%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DEbsworth%26aufirst%3DK.%26aulast%3DSablan%26aufirst%3DE.%26aulast%3DDanao%26aufirst%3DJ.%26aulast%3DKumer%26aufirst%3DJ.%26aulast%3DDairaghi%26aufirst%3DD.%26aulast%3DLawrence%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DT.%26aulast%3DTonn%26aufirst%3DG.%26aulast%3DSchall%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DT.%26aulast%3DMedina%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520series%2520of%2520quinazolinone-derived%2520antagonists%2520of%2520CXCR3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3339%26epage%3D3343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group">Tonn, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Lengerich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. K.</span><span> </span><span class="NLM_article-title">An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (<i>R</i>)-<i>N</i>-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-<i>d</i>]pyrimidin-2-yl]-ethy l}-<i>N</i>-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=502-513&author=G.+R.+Tonnauthor=S.+G.+Wongauthor=S.+C.+Wongauthor=M.+G.+Johnsonauthor=J.+Maauthor=R.+Choauthor=L.+C.+Florenauthor=K.+Kerseyauthor=K.+Berryauthor=A.+P.+Marcusauthor=X.+Wangauthor=B.+Van+Lengerichauthor=J.+C.+Medinaauthor=P.+G.+Pearsonauthor=B.+K.+Wong&title=An+inhibitory+metabolite+leads+to+dose-+and+time-dependent+pharmacokinetics+of+%28R%29-N-%7B1-%5B3-%284-ethoxy-phenyl%29-4-oxo-3%2C4-dihydro-pyrido%5B2%2C3-d%5Dpyrimidin-2-yl%5D-ethy+l%7D-N-pyridin-3-yl-methyl-2-%284-trifluoromethoxy-phenyl%29-acetamide+%28AMG+487%29+in+human+subjects+after+multiple+dosing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DWong%26aufirst%3DS.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DFloren%26aufirst%3DL.%2BC.%26aulast%3DKersey%26aufirst%3DK.%26aulast%3DBerry%26aufirst%3DK.%26aulast%3DMarcus%26aufirst%3DA.%2BP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DVan%2BLengerich%26aufirst%3DB.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DWong%26aufirst%3DB.%2BK.%26atitle%3DAn%2520inhibitory%2520metabolite%2520leads%2520to%2520dose-%2520and%2520time-dependent%2520pharmacokinetics%2520of%2520%2528R%2529-N-%257B1-%255B3-%25284-ethoxy-phenyl%2529-4-oxo-3%252C4-dihydro-pyrido%255B2%252C3-d%255Dpyrimidin-2-yl%255D-ethy%2520l%257D-N-pyridin-3-yl-methyl-2-%25284-trifluoromethoxy-phenyl%2529-acetamide%2520%2528AMG%2520487%2529%2520in%2520human%2520subjects%2520after%2520multiple%2520dosing%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D502%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group">Peled, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabovsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandbank, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenzana-Seisdedos, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petit, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Hur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alon, R.</span><span> </span><span class="NLM_article-title">The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">â</span> <span class="NLM_lpage">1211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=1199-1211&author=A.+Peledauthor=V.+Grabovskyauthor=L.+Hablerauthor=J.+Sandbankauthor=F.+Arenzana-Seisdedosauthor=I.+Petitauthor=H.+Ben-Hurauthor=T.+Lapidotauthor=R.+Alon&title=The+chemokine+SDF-1+stimulates+integrin-mediated+arrest+of+CD34%28%2B%29+cells+on+vascular+endothelium+under+shear+flow"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeled%26aufirst%3DA.%26aulast%3DGrabovsky%26aufirst%3DV.%26aulast%3DHabler%26aufirst%3DL.%26aulast%3DSandbank%26aufirst%3DJ.%26aulast%3DArenzana-Seisdedos%26aufirst%3DF.%26aulast%3DPetit%26aufirst%3DI.%26aulast%3DBen-Hur%26aufirst%3DH.%26aulast%3DLapidot%26aufirst%3DT.%26aulast%3DAlon%26aufirst%3DR.%26atitle%3DThe%2520chemokine%2520SDF-1%2520stimulates%2520integrin-mediated%2520arrest%2520of%2520CD34%2528%252B%2529%2520cells%2520on%2520vascular%2520endothelium%2520under%2520shear%2520flow%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3D1199%26epage%3D1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group">Broxmeyer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orschell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapp, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hangoc, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plett, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liles, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham-Evans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srour, E. F.</span><span> </span><span class="NLM_article-title">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">201</span><span class="NLM_x">, </span> <span class="NLM_fpage">1307</span><span class="NLM_x">â</span> <span class="NLM_lpage">1318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1084%2Fjem.20041385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15837815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=1307-1318&author=H.+E.+Broxmeyerauthor=C.+M.+Orschellauthor=D.+W.+Clappauthor=G.+Hangocauthor=S.+Cooperauthor=P.+A.+Plettauthor=W.+C.+Lilesauthor=X.+Liauthor=B.+Graham-Evansauthor=T.+B.+Campbellauthor=G.+Calandraauthor=G.+Bridgerauthor=D.+C.+Daleauthor=E.+F.+Srour&title=Rapid+mobilization+of+murine+and+human+hematopoietic+stem+and+progenitor+cells+with+AMD3100%2C+a+CXCR4+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span></div><div class="casAuthors">Broxmeyer, Hal E.; Orschell, Christie M.; Clapp, D. Wade; Hangoc, Giao; Cooper, Scott; Plett, P. Artur; Liles, W. Conrad; Li, Xiaxin; Graham-Evans, Barbara; Campbell, Timothy B.; Calandra, Gary; Bridger, Gary; Dale, David C.; Srour, Edward F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1307-1318</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Improving approaches for hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization is clin. important because increased nos. of these cells are needed for enhanced transplantation.  Chemokine stromal cell derived factor-1 (also known as CXCL12) is believed to be involved in retention of HSCs and HPCs in bone marrow.  AMD3100, a selective antagonist of CXCL12 that binds to its receptor, CXCR4, was evaluated in murine and human systems for mobilizing capacity, alone and in combination with granulocyte colony-stimulating factor (G-CSF).  AMD3100 induced rapid mobilization of mouse and human HPCs and synergistically augmented G-CSF-induced mobilization of HPCs.  AMD3100 also mobilized murine long-term repopulating (LTR) cells that engrafted primary and secondary lethally-irradiated mice, and human CD34+ cells that can repopulate nonobese diabetic-severe combined immunodeficiency (SCID) mice.  AMD3100 synergized with G-CSF to mobilize murine LTR cells and human SCID repopulating cells (SRCs).  Human CD34+ cells isolated after treatment with G-CSF plus AMD3100 expressed a phenotype that was characteristic of highly engrafting mouse HSCs.  Synergy of AMD3100 and G-CSF in mobilization was due to enhanced nos. and perhaps other characteristics of the mobilized cells.  These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clin. potential of AMD3100 for HSC mobilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDUgOByTJX07Vg90H21EOLACvtfcHk0lgz2-Axo7q60A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D&md5=e5942dc81a7687a8b7c10f9542cbf29d</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041385%26sid%3Dliteratum%253Aachs%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DOrschell%26aufirst%3DC.%2BM.%26aulast%3DClapp%26aufirst%3DD.%2BW.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DPlett%26aufirst%3DP.%2BA.%26aulast%3DLiles%26aufirst%3DW.%2BC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGraham-Evans%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DT.%2BB.%26aulast%3DCalandra%26aufirst%3DG.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DSrour%26aufirst%3DE.%2BF.%26atitle%3DRapid%2520mobilization%2520of%2520murine%2520and%2520human%2520hematopoietic%2520stem%2520and%2520progenitor%2520cells%2520with%2520AMD3100%252C%2520a%2520CXCR4%2520antagonist%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D1307%26epage%3D1318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group">DiPersio, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micallef, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stiff, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolwell, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maziarz, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nademanee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, G.</span><span> </span><span class="NLM_article-title">Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkinâs lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4767</span><span class="NLM_x">â</span> <span class="NLM_lpage">4773</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1200%2FJCO.2008.20.7209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19720922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4767-4773&author=J.+F.+DiPersioauthor=I.+N.+Micallefauthor=P.+J.+Stiffauthor=B.+J.+Bolwellauthor=R.+T.+Maziarzauthor=E.+Jacobsenauthor=A.+Nademaneeauthor=J.+McCartyauthor=G.+Bridgerauthor=G.+Calandra&title=Phase+III+prospective+randomized+double-blind+placebo-controlled+trial+of+plerixafor+plus+granulocyte+colony-stimulating+factor+compared+with+placebo+plus+granulocyte+colony-stimulating+factor+for+autologous+stem-cell+mobilization+and+transplantation+for+patients+with+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma</span></div><div class="casAuthors">DiPersio, John F.; Micallef, Ivana N.; Stiff, Patrick J.; Bolwell, Brian J.; Maziarz, Richard T.; Jacobsen, Eric; Nademanee, Auayporn; McCarty, John; Bridger, Gary; Calandra, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">4767-4773</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients.  Patients and Methods: This is a phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study.  Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible.  Patients received granulocyte colony-stimulating factor (G-CSF; 10 Î¼g/kg) s.c. daily for up to 8 days.  Beginning on evening of day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 Î¼g/kg) or placebo s.c.  Starting on day 5, patients began daily apheresis for up to 4 days or until â¥ 5 Ã 106 CD34+ cells/kg were collected.  The primary end point was the percentage of patients who collected â¥ 5 Ã 106 CD34+ cells/kg in 4 or fewer apheresis days.  Results: This report presents all data for all patients (n = 298) through 12 mo follow-up.  Eighty-nine (59%) of 150 patients in the plerixafor group and 29 (20%) of 148 patients in the placebo group met the primary end point (P < .001).  One hundred thirty-five patients (90%) in plerixafor group and 82 patients (55%) in placebo group underwent transplantation after initial mobilization.  Median time to engraftment was similar in both groups.  The most common plerixafor-assocd. adverse events were GI disorders and injection site reactions.  Conclusion: Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYjfnL3AIfbbVg90H21EOLACvtfcHk0lgz2-Axo7q60A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbI&md5=b2e30e8f1372875267ca61af49ee96cd</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.7209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.7209%26sid%3Dliteratum%253Aachs%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26aulast%3DMicallef%26aufirst%3DI.%2BN.%26aulast%3DStiff%26aufirst%3DP.%2BJ.%26aulast%3DBolwell%26aufirst%3DB.%2BJ.%26aulast%3DMaziarz%26aufirst%3DR.%2BT.%26aulast%3DJacobsen%26aufirst%3DE.%26aulast%3DNademanee%26aufirst%3DA.%26aulast%3DMcCarty%26aufirst%3DJ.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DCalandra%26aufirst%3DG.%26atitle%3DPhase%2520III%2520prospective%2520randomized%2520double-blind%2520placebo-controlled%2520trial%2520of%2520plerixafor%2520plus%2520granulocyte%2520colony-stimulating%2520factor%2520compared%2520with%2520placebo%2520plus%2520granulocyte%2520colony-stimulating%2520factor%2520for%2520autologous%2520stem-cell%2520mobilization%2520and%2520transplantation%2520for%2520patients%2520with%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4767%26epage%3D4773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group">Shia, K. S.; Hakimelahi, G. H.; Zhu, J. L.; Yen, C. F.; Huang, Y. H.; Xiang, Y.; Chen, H. C.; Changhua, C. W.</span><span> </span><span class="NLM_article-title">Polyamine Compounds for Treating Chemokine Receptor Mediated Diseases</span>. US 7,399,776,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+S.+Shia&author=G.+H.+Hakimelahi&author=J.+L.+Zhu&author=C.+F.+Yen&author=Y.+H.+Huang&author=Y.+Xiang&author=H.+C.+Chen&author=C.+W.+Changhua&title=Polyamine+Compounds+for+Treating+Chemokine+Receptor+Mediated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShia%26aufirst%3DK.%2BS.%26atitle%3DPolyamine%2520Compounds%2520for%2520Treating%2520Chemokine%2520Receptor%2520Mediated%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group">Chung, D. T.; Chang, L.; Huang, Y.; Tsai, C.; Hsu, C.; King, C. R.; Yuan, J. H.; Yen, C.; Chen, Y.; Lu, Y. C.; Hsu, M.</span><span> </span><span class="NLM_article-title">TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial</span>. Presented at the 51st ASH Meeting, New Orleans, LA,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=D.+T.+Chung&author=L.+Chang&author=Y.+Huang&author=C.+Tsai&author=C.+Hsu&author=C.+R.+King&author=J.+H.+Yuan&author=C.+Yen&author=Y.+Chen&author=Y.+C.+Lu&author=M.+Hsu&title=TG-0054%2C+a+Novel+and+Potent+Stem+Cell+Mobilizer%2C+Displays+Excellent+PK%2FPD+and+Safety+Profile+in+Phase+I+Trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DD.%2BT.%26atitle%3DTG-0054%252C%2520a%2520Novel%2520and%2520Potent%2520Stem%2520Cell%2520Mobilizer%252C%2520Displays%2520Excellent%2520PK%252FPD%2520and%2520Safety%2520Profile%2520in%2520Phase%2520I%2520Trial%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group">Zumbrunn, J.; Demarco, S. J.; Lociuro, S.; Vrijbloed, J. W.; Gombert, F.; Mukherjee, R.; Moehle, K.; Obrecht, D.; Robinson, J. A.; Henze, H.; Romagnoli, B.; Ludin, C.</span><span> </span><span class="NLM_article-title">Template Fixed 8 Hairpin Peptidomimetics with CXCR4 Antagonizing Activity</span>. US 7,786,078,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Zumbrunn&author=S.+J.+Demarco&author=S.+Lociuro&author=J.+W.+Vrijbloed&author=F.+Gombert&author=R.+Mukherjee&author=K.+Moehle&author=D.+Obrecht&author=J.+A.+Robinson&author=H.+Henze&author=B.+Romagnoli&author=C.+Ludin&title=Template+Fixed+8+Hairpin+Peptidomimetics+with+CXCR4+Antagonizing+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZumbrunn%26aufirst%3DJ.%26atitle%3DTemplate%2520Fixed%25208%2520Hairpin%2520Peptidomimetics%2520with%2520CXCR4%2520Antagonizing%2520Activity%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group">Roccaro, A. M.; Sacco, A.; Kuhne, M.; Azab, A. K.; Maiso, P.; Zhang, Y.; Liu, Y.; Azab, F.; Issa, G. C.; Quang, P.; Ngo, H. T.; Pan, C.; Choen, L.; Cardarelli, P. M.; Ghobrial, I. M.</span><span> </span><span class="NLM_article-title">The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma</span>. Presented at 53rd ASH Meeting, San Diego CA,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 1844.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+M.+Roccaro&author=A.+Sacco&author=M.+Kuhne&author=A.+K.+Azab&author=P.+Maiso&author=Y.+Zhang&author=Y.+Liu&author=F.+Azab&author=G.+C.+Issa&author=P.+Quang&author=H.+T.+Ngo&author=C.+Pan&author=L.+Choen&author=P.+M.+Cardarelli&author=I.+M.+Ghobrial&title=The+New+CXCR4+Inhibitor+MDX-1338+Exerts+Anti-Tumor+Activity+in+Multiple+Myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26atitle%3DThe%2520New%2520CXCR4%2520Inhibitor%2520MDX-1338%2520Exerts%2520Anti-Tumor%2520Activity%2520in%2520Multiple%2520Myeloma%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group">Fujii, N.; Tamamura, H.; Hori, A.</span><span> </span><span class="NLM_article-title">CXCR4 Antagonist and Use Thereof</span>. US 8,017,585,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Fujii&author=H.+Tamamura&author=A.+Hori&title=CXCR4+Antagonist+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DN.%26atitle%3DCXCR4%2520Antagonist%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span> </span><span class="NLM_article-title">Is CCR2 the right chemokine receptor to target in rheumatoid arthritis?</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">â</span> <span class="NLM_lpage">1891</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.23590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18576326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=1889-1891&author=A.+E.+Proudfoot&title=Is+CCR2+the+right+chemokine+receptor+to+target+in+rheumatoid+arthritis%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Is CCR2 the right chemokine receptor to target in rheumatoid arthritis?</span></div><div class="casAuthors">Proudfoot, Amanda E. I.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1889-1891</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A polemic in response to Vergunst et al. (Arthritis Rheum. 2008, 58, 1931-9) is given.  In their study, Vergunst et al. describes the lack of efficacy of a neutralizing antibody against CCR2, MLN12O2, in a relatively small phase IIa clin. trial in patients with rheumatoid arthritis (RA).  The authors argued on the drawn statistical conclusion about clin. effectiveness due to the very small no. of patients analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoInK80K2hJVbVg90H21EOLACvtfcHk0ljnOJE0UmY7gQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkur8%253D&md5=be0bb74e09ddc1e88fbfc3ff23cbe2d0</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1002%2Fart.23590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.23590%26sid%3Dliteratum%253Aachs%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26atitle%3DIs%2520CCR2%2520the%2520right%2520chemokine%2520receptor%2520to%2520target%2520in%2520rheumatoid%2520arthritis%253F%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D1889%26epage%3D1891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group">Karpus, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRae, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S. D.</span><span> </span><span class="NLM_article-title">An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">â</span> <span class="NLM_lpage">5010</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=5003-5010&author=W.+J.+Karpusauthor=N.+W.+Lukacsauthor=B.+L.+McRaeauthor=R.+M.+Strieterauthor=S.+L.+Kunkelauthor=S.+D.+Miller&title=An+important+role+for+the+chemokine+macrophage+inflammatory+protein-1+alpha+in+the+pathogenesis+of+the+T+cell-mediated+autoimmune+disease%2C+experimental+autoimmune+encephalomyelitis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarpus%26aufirst%3DW.%2BJ.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DMcRae%26aufirst%3DB.%2BL.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DMiller%26aufirst%3DS.%2BD.%26atitle%3DAn%2520important%2520role%2520for%2520the%2520chemokine%2520macrophage%2520inflammatory%2520protein-1%2520alpha%2520in%2520the%2520pathogenesis%2520of%2520the%2520T%2520cell-mediated%2520autoimmune%2520disease%252C%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26spage%3D5003%26epage%3D5010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group">Liang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghannam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oanh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergona, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taub, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunning, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, H. D.</span><span> </span><span class="NLM_article-title">Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">19000</span><span class="NLM_x">â</span> <span class="NLM_lpage">19008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=19000-19008&author=M.+Liangauthor=C.+Mallariauthor=M.+Rosserauthor=H.+P.+Ngauthor=K.+Mayauthor=S.+Monahanauthor=J.+G.+Baumanauthor=I.+Islamauthor=A.+Ghannamauthor=B.+Buckmanauthor=K.+Shawauthor=G.+P.+Weiauthor=W.+Xuauthor=Z.+Zhaoauthor=E.+Hoauthor=J.+Shenauthor=H.+Oanhauthor=B.+Subramanyamauthor=R.+Vergonaauthor=D.+Taubauthor=L.+Dunningauthor=S.+Harveyauthor=R.+M.+Sniderauthor=J.+Hesselgesserauthor=M.+M.+Morrisseyauthor=H.+D.+Perez&title=Identification+and+characterization+of+a+potent%2C+selective%2C+and+orally+active+antagonist+of+the+CC+chemokine+receptor-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DMallari%26aufirst%3DC.%26aulast%3DRosser%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DH.%2BP.%26aulast%3DMay%26aufirst%3DK.%26aulast%3DMonahan%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DJ.%2BG.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DGhannam%26aufirst%3DA.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DShaw%26aufirst%3DK.%26aulast%3DWei%26aufirst%3DG.%2BP.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DE.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DOanh%26aufirst%3DH.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DTaub%26aufirst%3DD.%26aulast%3DDunning%26aufirst%3DL.%26aulast%3DHarvey%26aufirst%3DS.%26aulast%3DSnider%26aufirst%3DR.%2BM.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26aulast%3DPerez%26aufirst%3DH.%2BD.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520antagonist%2520of%2520the%2520CC%2520chemokine%2520receptor-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D19000%26epage%3D19008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group">Aktas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kury, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieseier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, H. P.</span><span> </span><span class="NLM_article-title">Fingolimod is a potential novel therapy for multiple sclerosis</span> <span class="citation_source-journal">Nat. Rev. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnrneurol.2010.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20551946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFKgt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=373-382&author=O.+Aktasauthor=P.+Kuryauthor=B.+Kieseierauthor=H.+P.+Hartung&title=Fingolimod+is+a+potential+novel+therapy+for+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod is a potential novel therapy for multiple sclerosis</span></div><div class="casAuthors">Aktas, Orhan; Kuery, Patrick; Kieseier, Bernd; Hartung, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">373-382</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Only moderately effective therapies are currently available for the treatment of multiple sclerosis (MS).  New treatments for MS that have neuroprotective properties as well as anti-inflammatory effects are needed.  Fingolimod could be one such potential treatment.  In this article, Aktas et al. examine the underlying biol. actions of this prospective new therapy, review the data from phase II and phase III oral fingolimod clin. trials and provide an update on the emerging field of sphingosine-1-phosphate receptor-mediated therapies for MS.  Fingolimod (also known as FTY720) is an orally available sphingosine-1-phosphate (S1P) receptor modulator that has unique and potent immunoregulatory properties.  Mechanistic studies indicate that on phosphorylation fingolimod can bind with high affinity to S1P1 receptors.  Persistent modulation of lymphocyte S1P1 receptors by fingolimod and the subsequent internalization of these receptors inhibits lymphocyte egress from the lymph nodes, and prevents these cells from infiltrating inflammatory lesions in the CNS.  Results of two phase III studies-FREEDOMS and TRANSFORMS-support previous phase II trial observations indicating that fingolimod exerts powerful anti-inflammatory effects in relapsing-remitting multiple sclerosis (MS).  Fingolimod might, therefore, be one of the first orally active drug therapies available for the treatment of relapsing-remitting MS.  Moreover, results from preclin. studies suggest that fingolimod might promote neural repair in vivo.  In this article, we review the background to these findings, present the proposed immunol. and neurobiol. profile of fingolimod, discuss the data from the FREEDOMS and TRANSFORMS trials, and provide an expert opinion regarding the future of next-generation S1P receptor modulators for MS therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbGeDeonkrpLVg90H21EOLACvtfcHk0lixf9AAPPo62w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFKgt7s%253D&md5=11690f6c74fe1fcb1fee8325d1f7b066</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2010.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2010.76%26sid%3Dliteratum%253Aachs%26aulast%3DAktas%26aufirst%3DO.%26aulast%3DKury%26aufirst%3DP.%26aulast%3DKieseier%26aufirst%3DB.%26aulast%3DHartung%26aufirst%3DH.%2BP.%26atitle%3DFingolimod%2520is%2520a%2520potential%2520novel%2520therapy%2520for%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2010%26volume%3D6%26spage%3D373%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group">Fleishaker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Meijide, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohen, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeiher, B. G.</span><span> </span><span class="NLM_article-title">Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">R11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=R11&author=D.+L.+Fleishakerauthor=J.+A.+Garcia+Meijideauthor=A.+Petrovauthor=M.+D.+Kohenauthor=X.+Wangauthor=S.+Menonauthor=T.+C.+Stockauthor=C.+A.+Mebusauthor=J.+M.+Goodrichauthor=H.+B.+Mayerauthor=B.+G.+Zeiher&title=Maraviroc%2C+a+chemokine+receptor-5+antagonist%2C+fails+to+demonstrate+efficacy+in+the+treatment+of+patients+with+rheumatoid+arthritis+in+a+randomized%2C+double-blind+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleishaker%26aufirst%3DD.%2BL.%26aulast%3DGarcia%2BMeijide%26aufirst%3DJ.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DKohen%26aufirst%3DM.%2BD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DMebus%26aufirst%3DC.%2BA.%26aulast%3DGoodrich%26aufirst%3DJ.%2BM.%26aulast%3DMayer%26aufirst%3DH.%2BB.%26aulast%3DZeiher%26aufirst%3DB.%2BG.%26atitle%3DMaraviroc%252C%2520a%2520chemokine%2520receptor-5%2520antagonist%252C%2520fails%2520to%2520demonstrate%2520efficacy%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520rheumatoid%2520arthritis%2520in%2520a%2520randomized%252C%2520double-blind%2520placebo-controlled%2520trial%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2012%26volume%3D14%26spage%3DR11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group">Plater-Zyberk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogewerf, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span> </span><span class="NLM_article-title">Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice</span> <span class="citation_source-journal">Immunol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0165-2478%2897%2900075-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9232436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK2sXksl2ns7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=117-120&author=C.+Plater-Zyberkauthor=A.+J.+Hoogewerfauthor=A.+E.+Proudfootauthor=C.+A.+Powerauthor=T.+N.+Wells&title=Effect+of+a+CC+chemokine+receptor+antagonist+on+collagen+induced+arthritis+in+DBA%2F1+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice</span></div><div class="casAuthors">Plater-Zyberk, Christine; Hoogewerf, Arlene J.; Proudfoot, Amanda E. I.; Power, Christine A.; Wells, Timothy N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">117-120</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Chemokines are small proteins that selectively activate and recruit leukocytes to sites of inflammation.  Several of them, including the CC chemokines, MIP-1Î±, MIP-1Î², MCP-1, and the CXC chemokines IL-8, GRO-Î±, ENA-78 have been identified in rheumatoid synovium, implicating a potential role for these mols. in rheumatoid arthritis.  We have investigated the expression patterns of CC chemokine receptors in the joints of mice with collagen-induced arthritis, a model for human rheumatoid arthritis.  In addn., we have investigated the incidence and severity of arthritis in mice receiving administration of MetRANTES, a modified chemokine which is a nanomolar antagonist of certain CC chemokine receptors.  The mRNA expression pattern of the chemokines and their receptors in the joints of arthritic mice was investigated using reverse transcriptase-PCR and in situ hybridization.  An upregulation of the CC chemokine receptors mCCR1, mCCR2, mCCR3 and mCCR5 was found in the joints from arthritic mice, compared to control animals.  In addn., injections of MetRANTES reduced the incidence of disease in a dose dependent manner.  Furthermore, in MetRANTES-treated mice that did develop arthritis a significantly lower severity of disease was obsd. compared with control animals.  Our data clearly demonstrate a role for CC chemokines and their receptors in inflammatory joint destruction and support the use of chemokine receptor antagonists as potential tools to control inflammatory diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohSfRz-zJvBrVg90H21EOLACvtfcHk0lixf9AAPPo62w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksl2ns7k%253D&md5=1eb75a63bd534805d058f34eec462078</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2FS0165-2478%2897%2900075-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-2478%252897%252900075-8%26sid%3Dliteratum%253Aachs%26aulast%3DPlater-Zyberk%26aufirst%3DC.%26aulast%3DHoogewerf%26aufirst%3DA.%2BJ.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DPower%26aufirst%3DC.%2BA.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DEffect%2520of%2520a%2520CC%2520chemokine%2520receptor%2520antagonist%2520on%2520collagen%2520induced%2520arthritis%2520in%2520DBA%252F1%2520mice%26jtitle%3DImmunol.%2520Lett.%26date%3D1997%26volume%3D57%26spage%3D117%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group">Vierboom, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodny, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagat, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliese-Sivo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCombie, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celebi-Paul, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remarque, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, B.</span><span> </span><span class="NLM_article-title">Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">â</span> <span class="NLM_lpage">636</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.20850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15693002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Gjtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=627-636&author=M.+P.+Vierboomauthor=P.+J.+Zavodnyauthor=C.+C.+Chouauthor=J.+R.+Tagatauthor=C.+Pugliese-Sivoauthor=J.+Strizkiauthor=R.+W.+Steensmaauthor=S.+W.+McCombieauthor=L.+Celebi-Paulauthor=E.+Remarqueauthor=M.+Jonkerauthor=S.+K.+Narulaauthor=B.+Hart&title=Inhibition+of+the+development+of+collagen-induced+arthritis+in+rhesus+monkeys+by+a+small+molecular+weight+antagonist+of+CCR5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5</span></div><div class="casAuthors">Vierboom, Michel P. M.; Zavodny, Paul J.; Chou, Chuan-Chu; Tagat, Jayaram R.; Pugliese-Sivo, Catherine; Strizki, Julie; Steensma, Ruo W.; McCombie, Stuart W.; Celebi-Paul, Liesbeth; Remarque, Ed; Jonker, Margreet; Narula, Satwant K.; 't Hart, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-636</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: Collagen-induced arthritis (CIA) in the rhesus monkey is a nonhuman primate model of rheumatoid arthritis (RA).  The close phylogenetic relationship between humans and the rhesus monkey makes this model useful for the preclin. safety and efficacy testing of new therapies that are inactive in animals more distinctly related to humans.  In this study, we tested the therapeutic potential of a novel, small mol. wt. antagonist of CCR5, SCH-X, in this model.  Methods: CIA was induced in 10 rhesus monkeys.  The animals were allocated to receive SCH-X or saline as the control (n = 5 in each group).  Treatment was initiated on the day of CIA induction and continued for 45 days.  Monkeys were monitored before and 63 days after CIA induction for macroscopic signs of clin. arthritis, such as soft-tissue swelling and body wt.  Furthermore, markers of inflammation and joint degrdn. were monitored to follow the disease course.  Results: Only 2 of 5 animals in the SCH-X-treated group displayed prominent soft-tissue swelling, compared with all 5 saline-treated monkeys.  In addn. to the suppression of joint inflammation, treatment with SCH-X resulted in a redn. in joint destruction, as demonstrated by lower rates of urinary excretion of collagen crosslinks, with confirmation by histol.  Whereas in all saline-treated monkeys, marked erosion of joint cartilage was obsd., this was absent in 4 of the 5 SCH-X-treated monkeys.  Conclusion: The systemic effects of treatment with SCH-X were a suppressed acute-phase reaction (redn. in C-reactive protein level) in the 3 treated monkeys with CIA that remained asymptomatic, and an altered antibody response toward type II collagen.  The results suggest that the CCR5 antagonist SCH-X might have a strong clin. potential for treatment during periods of active inflammation, as seen in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAV6q5T21UrLVg90H21EOLACvtfcHk0lixf9AAPPo62w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Gjtbg%253D&md5=ceb5108f15ff73ddfc114cd24880be91</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1002%2Fart.20850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.20850%26sid%3Dliteratum%253Aachs%26aulast%3DVierboom%26aufirst%3DM.%2BP.%26aulast%3DZavodny%26aufirst%3DP.%2BJ.%26aulast%3DChou%26aufirst%3DC.%2BC.%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DPugliese-Sivo%26aufirst%3DC.%26aulast%3DStrizki%26aufirst%3DJ.%26aulast%3DSteensma%26aufirst%3DR.%2BW.%26aulast%3DMcCombie%26aufirst%3DS.%2BW.%26aulast%3DCelebi-Paul%26aufirst%3DL.%26aulast%3DRemarque%26aufirst%3DE.%26aulast%3DJonker%26aufirst%3DM.%26aulast%3DNarula%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520the%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520rhesus%2520monkeys%2520by%2520a%2520small%2520molecular%2520weight%2520antagonist%2520of%2520CCR5%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26spage%3D627%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group">Yang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obika, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaoka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, H.</span><span> </span><span class="NLM_article-title">A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2124</span><span class="NLM_x">â</span> <span class="NLM_lpage">2132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=2124-2132&author=Y.+F.+Yangauthor=T.+Mukaiauthor=P.+Gaoauthor=N.+Yamaguchiauthor=S.+Onoauthor=H.+Iwakiauthor=S.+Obikaauthor=T.+Imanishiauthor=T.+Tsujimuraauthor=T.+Hamaokaauthor=H.+Fujiwara&title=A+non-peptide+CCR5+antagonist+inhibits+collagen-induced+arthritis+by+modulating+T+cell+migration+without+affecting+anti-collagen+T+cell+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DMukai%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DYamaguchi%26aufirst%3DN.%26aulast%3DOno%26aufirst%3DS.%26aulast%3DIwaki%26aufirst%3DH.%26aulast%3DObika%26aufirst%3DS.%26aulast%3DImanishi%26aufirst%3DT.%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DHamaoka%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DH.%26atitle%3DA%2520non-peptide%2520CCR5%2520antagonist%2520inhibits%2520collagen-induced%2520arthritis%2520by%2520modulating%2520T%2520cell%2520migration%2520without%2520affecting%2520anti-collagen%2520T%2520cell%2520responses%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26spage%3D2124%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group">Pokorny, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeoman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Highton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, L.</span><span> </span><span class="NLM_article-title">Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">4897</span><span class="NLM_x">â</span> <span class="NLM_lpage">490</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1136%2Fard.2004.023333" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4897-490&author=V.+Pokornyauthor=F.+McQueenauthor=S.+Yeomanauthor=M.+Merrimanauthor=T.+Merrimanauthor=A.+Harrisonauthor=J.+Hightonauthor=L.+McLean&title=Evidence+for+negative+association+of+the+chemokine+receptor+CCR5+d32+polymorphism+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.023333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.023333%26sid%3Dliteratum%253Aachs%26aulast%3DPokorny%26aufirst%3DV.%26aulast%3DMcQueen%26aufirst%3DF.%26aulast%3DYeoman%26aufirst%3DS.%26aulast%3DMerriman%26aufirst%3DM.%26aulast%3DMerriman%26aufirst%3DT.%26aulast%3DHarrison%26aufirst%3DA.%26aulast%3DHighton%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DL.%26atitle%3DEvidence%2520for%2520negative%2520association%2520of%2520the%2520chemokine%2520receptor%2520CCR5%2520d32%2520polymorphism%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2004%26volume%3D64%26spage%3D4897%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group">Bruhl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cihak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plachy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupp, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenzel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakarami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwart, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stangassinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlondorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, M.</span><span> </span><span class="NLM_article-title">Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">890</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2004&pages=890-898&author=H.+Bruhlauthor=J.+Cihakauthor=M.+A.+Schneiderauthor=J.+Plachyauthor=T.+Ruppauthor=I.+Wenzelauthor=M.+Shakaramiauthor=S.+Milzauthor=J.+W.+Ellwartauthor=M.+Stangassingerauthor=D.+Schlondorffauthor=M.+Mack&title=Dual+role+of+CCR2+during+initiation+and+progression+of+collagen-induced+arthritis%3A+evidence+for+regulatory+activity+of+CCR2%2B+T+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruhl%26aufirst%3DH.%26aulast%3DCihak%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%2BA.%26aulast%3DPlachy%26aufirst%3DJ.%26aulast%3DRupp%26aufirst%3DT.%26aulast%3DWenzel%26aufirst%3DI.%26aulast%3DShakarami%26aufirst%3DM.%26aulast%3DMilz%26aufirst%3DS.%26aulast%3DEllwart%26aufirst%3DJ.%2BW.%26aulast%3DStangassinger%26aufirst%3DM.%26aulast%3DSchlondorff%26aufirst%3DD.%26aulast%3DMack%26aufirst%3DM.%26atitle%3DDual%2520role%2520of%2520CCR2%2520during%2520initiation%2520and%2520progression%2520of%2520collagen-induced%2520arthritis%253A%2520evidence%2520for%2520regulatory%2520activity%2520of%2520CCR2%252B%2520T%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2004%26volume%3D172%26spage%3D890%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group">Lebre, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergunst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aarrass, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedquist, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21772&author=M.+C.+Lebreauthor=C.+E.+Vergunstauthor=I.+Y.+Choiauthor=S.+Aarrassauthor=A.+S.+Oliveiraauthor=T.+Wyantauthor=R.+Horukauthor=K.+A.+Reedquistauthor=P.+P.+Tak&title=Why+CCR2+and+CCR5+blockade+failed+and+why+CCR1+blockade+might+still+be+effective+in+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLebre%26aufirst%3DM.%2BC.%26aulast%3DVergunst%26aufirst%3DC.%2BE.%26aulast%3DChoi%26aufirst%3DI.%2BY.%26aulast%3DAarrass%26aufirst%3DS.%26aulast%3DOliveira%26aufirst%3DA.%2BS.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DReedquist%26aufirst%3DK.%2BA.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DWhy%2520CCR2%2520and%2520CCR5%2520blockade%2520failed%2520and%2520why%2520CCR1%2520blockade%2520might%2520still%2520be%2520effective%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group">Flier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boorsma, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Beek, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieboer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoof, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tensen, C. P.</span><span> </span><span class="NLM_article-title">Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">â</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2F1096-9896%28200108%29194%3A4%3C397%3A%3AAID-PATH899%3E3.0.CO%3B2-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11523046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslWku70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2001&pages=398-405&author=J.+Flierauthor=D.+M.+Boorsmaauthor=P.+J.+van+Beekauthor=C.+Nieboerauthor=T.+J.+Stoofauthor=R.+Willemzeauthor=C.+P.+Tensen&title=Differential+expression+of+CXCR3+targeting+chemokines+CXCL10%2C+CXCL9%2C+and+CXCL11+in+different+types+of+skin+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation</span></div><div class="casAuthors">Flier, Jacoba; Boorsma, Dick M.; van Beek, Peter J.; Nieboer, Cees; Stoof, Tom J.; Willemze, Rein; Tensen, Comelis P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-405</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Recruitment of activated T-cells to the skin is a common feature in a wide variety of inflammatory skin diseases.  As CXCR3 activating chemokines CXCL10 (IP-10), CXCL9 (Mig), and CXCL11 (IP-9/I-TAC) specifically attract activated T-cells, this study addressed the question of whether differences in the expression of these chemokines correlate with the site and cellular compn. of the skin infiltrates in different types of inflammatory skin disease.  Skin biopsies from lichen planus, chronic discoid lupus erythematosus, allergic patch test reactions, psoriasis, and Jessner's lymphocytic infiltration of the skin were investigated for chemokine expression using RNA in situ hybridization, and for the expression of CXCR3 using immunohistochem.  The results showed differential expression of CXCL10, CXCL9, and CXCL11, which correlated with differences in the localization and cellular compn. of the infiltrates.  Whereas CXCL10 and CXCL11 were mainly expressed by basal keratinocytes, CXCL9 mRNA expression was located predominantly in the dermal infiltrates.  Correlation with immunohistochem. data suggested that macrophages and activated keratinocytes were the main producers of these chemokines.  CXCR3 was expressed by a majority of both CD4+ and CD8+ infiltrating T-cells, suggesting a functional interaction between locally produced chemokines and CXCR3-expressing T-cells.  In conclusion, these findings indicate that these CXCR3 activating chemokines play a significant role in the recruitment and maintenance of T-cell infiltrates in the inflammatory skin diseases studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo4eW7-3RwxLVg90H21EOLACvtfcHk0lgoeiE6zSn5qQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslWku70%253D&md5=796edd18e109b4ff5d8d2ebed5bcb8fc</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1002%2F1096-9896%28200108%29194%3A4%3C397%3A%3AAID-PATH899%3E3.0.CO%3B2-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1096-9896%2528200108%2529194%253A4%253C397%253A%253AAID-PATH899%253E3.0.CO%253B2-S%26sid%3Dliteratum%253Aachs%26aulast%3DFlier%26aufirst%3DJ.%26aulast%3DBoorsma%26aufirst%3DD.%2BM.%26aulast%3Dvan%2BBeek%26aufirst%3DP.%2BJ.%26aulast%3DNieboer%26aufirst%3DC.%26aulast%3DStoof%26aufirst%3DT.%2BJ.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DTensen%26aufirst%3DC.%2BP.%26atitle%3DDifferential%2520expression%2520of%2520CXCR3%2520targeting%2520chemokines%2520CXCL10%252C%2520CXCL9%252C%2520and%2520CXCL11%2520in%2520different%2520types%2520of%2520skin%2520inflammation%26jtitle%3DJ.%2520Pathol.%26date%3D2001%26volume%3D194%26spage%3D398%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group">Xie, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudgett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicker, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span> </span><span class="NLM_article-title">Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1189%2Fjlb.1102573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=12773510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFegtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2003&pages=771-780&author=J.+H.+Xieauthor=N.+Nomuraauthor=M.+Luauthor=S.+L.+Chenauthor=G.+E.+Kochauthor=Y.+Wengauthor=R.+Rosaauthor=J.+Di+Salvoauthor=J.+Mudgettauthor=L.+B.+Petersonauthor=L.+S.+Wickerauthor=J.+A.+DeMartino&title=Antibody-mediated+blockade+of+the+CXCR3+chemokine+receptor+results+in+diminished+recruitment+of+T+helper+1+cells+into+sites+of+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation</span></div><div class="casAuthors">Xie, Jenny H.; Nomura, Naomi; Lu, Min; Chen, Shiow-Ling; Koch, Greg E.; Weng, Youmin; Rosa, Raymond; Di Salvo, Jerry; Mudgett, John; Peterson, Laurence B.; Wicker, Linda S.; DeMartino, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">771-780</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Naive T cells, when activated by specific antigen and cytokines, up-regulate adhesion mols. as well as chemokine receptors on their surface, which allows them to migrate to inflamed tissues.  Human studies have shown that CXCR3 is one of the chemokine receptors that is induced during T cell activation.  Moreover, CXCR3-pos. T cells are enriched at inflammatory sites in patients with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.  In this study, we use a mouse model of inflammation to demonstrate that CXCR3 is required for activated T cell transmigration to inflamed tissue.  Using an anti- mCXCR3 antibody, we have shown that in vitro-differentiated Th1 and Th2 cells up-regulated CXCR3 upon stimulation with specific antigen/major histocompatibility complex.  However, only Th1 cells, when adoptively transferred to syngeneic recipients, are efficiently recruited to the peritoneum in an adjuvant-induced peritonitis model.  Furthermore, the neutralizing anti-mCXCR3 antibody profoundly inhibits the recruitment of Th1 cells to the inflamed peritoneum.  Real-time, quant. reverse transcriptase-polymerase chain reaction anal. demonstrates that the CXCR3 ligands, interferon (IFN)-inducible protein 10 (CXCL10) and IFN-inducible T cell Î± chemoattractant (CXCL11), are among the many chemokines induced in the adjuvant-treated peritoneum.  The anti-mCXCR3 antibody is also effective in inhibiting a delayed-type hypersensitivity response, which is largely mediated by enhanced trafficking of activated T cells to peripheral inflammatory sites.  Collectively, our results suggest that CXCR3 has a crit. role in T cell transmigration to sites of inflammation and thus, may serve as a mol. target for anti-inflammatory therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr3rVCjsbnBbVg90H21EOLACvtfcHk0lgoeiE6zSn5qQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFegtro%253D&md5=8aece82b771041b3cf858f943ce7d3c6</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1102573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1102573%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%2BL.%26aulast%3DKoch%26aufirst%3DG.%2BE.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DRosa%26aufirst%3DR.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DMudgett%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DWicker%26aufirst%3DL.%2BS.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26atitle%3DAntibody-mediated%2520blockade%2520of%2520the%2520CXCR3%2520chemokine%2520receptor%2520results%2520in%2520diminished%2520recruitment%2520of%2520T%2520helper%25201%2520cells%2520into%2520sites%2520of%2520inflammation%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2003%26volume%3D73%26spage%3D771%26epage%3D780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group">Hancock, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csizmadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span> </span><span class="NLM_article-title">Requirement of the chemokine receptor CXCR3 for acute allograft rejection</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">1515</span><span class="NLM_x">â</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1515-1520&author=W.+W.+Hancockauthor=B.+Luauthor=W.+Gaoauthor=V.+Csizmadiaauthor=K.+Faiaauthor=J.+A.+Kingauthor=S.+T.+Smileyauthor=M.+Lingauthor=N.+P.+Gerardauthor=C.+Gerard&title=Requirement+of+the+chemokine+receptor+CXCR3+for+acute+allograft+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DFaia%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DJ.%2BA.%26aulast%3DSmiley%26aufirst%3DS.%2BT.%26aulast%3DLing%26aufirst%3DM.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26atitle%3DRequirement%2520of%2520the%2520chemokine%2520receptor%2520CXCR3%2520for%2520acute%2520allograft%2520rejection%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1515%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group">Clark, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupper, T. S.</span><span> </span><span class="NLM_article-title">Misbehaving macrophages in the pathogenesis of psoriasis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2084</span><span class="NLM_x">â</span> <span class="NLM_lpage">2087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2084-2087&author=R.+A.+Clarkauthor=T.+S.+Kupper&title=Misbehaving+macrophages+in+the+pathogenesis+of+psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DR.%2BA.%26aulast%3DKupper%26aufirst%3DT.%2BS.%26atitle%3DMisbehaving%2520macrophages%2520in%2520the%2520pathogenesis%2520of%2520psoriasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2084%26epage%3D2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgoeiE6zSn5qQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">â</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lg_rTivjYCZAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calligaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tye, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D. T.</span><span> </span><span class="NLM_article-title">Radioreceptor binding profile of the atypical antipsychotic olanzapine</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">â</span> <span class="NLM_lpage">96</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=87-96&author=F.+P.+Bymasterauthor=D.+O.+Calligaroauthor=J.+F.+Falconeauthor=R.+D.+Marshauthor=N.+A.+Mooreauthor=N.+C.+Tyeauthor=P.+Seemanauthor=D.+T.+Wong&title=Radioreceptor+binding+profile+of+the+atypical+antipsychotic+olanzapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DR.%2BD.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DTye%26aufirst%3DN.%2BC.%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DD.%2BT.%26atitle%3DRadioreceptor%2520binding%2520profile%2520of%2520the%2520atypical%2520antipsychotic%2520olanzapine%26jtitle%3DNeuropsychopharmacology%26date%3D1996%26volume%3D14%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group">Naya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, N.</span><span> </span><span class="NLM_article-title">Structureâactivity relationships of 2-(benzothiazolylthio)acetamide class of CCR3 selective antagonist</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">â</span> <span class="NLM_lpage">701</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=697-701&author=A.+Nayaauthor=K.+Kobayashiauthor=M.+Ishikawaauthor=K.+Ohwakiauthor=T.+Saekiauthor=K.+Noguchiauthor=N.+Ohtake&title=Structure%E2%80%93activity+relationships+of+2-%28benzothiazolylthio%29acetamide+class+of+CCR3+selective+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaya%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DOhwaki%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DOhtake%26aufirst%3DN.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%25202-%2528benzothiazolylthio%2529acetamide%2520class%2520of%2520CCR3%2520selective%2520antagonist%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2003%26volume%3D51%26spage%3D697%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group">Sabroe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Keulen, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorritsma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapham, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span> </span><span class="NLM_article-title">A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">25985</span><span class="NLM_x">â</span> <span class="NLM_lpage">25992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=25985-25992&author=I.+Sabroeauthor=M.+J.+Peckauthor=B.+J.+Van+Keulenauthor=A.+Jorritsmaauthor=G.+Simmonsauthor=P.+R.+Claphamauthor=T.+J.+Williamsauthor=J.+E.+Pease&title=A+small+molecule+antagonist+of+chemokine+receptors+CCR1+and+CCR3.+Potent+inhibition+of+eosinophil+function+and+CCR3-mediated+HIV-1+entry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSabroe%26aufirst%3DI.%26aulast%3DPeck%26aufirst%3DM.%2BJ.%26aulast%3DVan%2BKeulen%26aufirst%3DB.%2BJ.%26aulast%3DJorritsma%26aufirst%3DA.%26aulast%3DSimmons%26aufirst%3DG.%26aulast%3DClapham%26aufirst%3DP.%2BR.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DA%2520small%2520molecule%2520antagonist%2520of%2520chemokine%2520receptors%2520CCR1%2520and%2520CCR3.%2520Potent%2520inhibition%2520of%2520eosinophil%2520function%2520and%2520CCR3-mediated%2520HIV-1%2520entry%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D25985%26epage%3D25992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group">Naya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, N.</span><span> </span><span class="NLM_article-title">Discovery of a novel CCR3 selective antagonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">â</span> <span class="NLM_lpage">1223</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1219-1223&author=A.+Nayaauthor=K.+Kobayashiauthor=M.+Ishikawaauthor=K.+Ohwakiauthor=T.+Saekiauthor=K.+Noguchiauthor=N.+Ohtake&title=Discovery+of+a+novel+CCR3+selective+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaya%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DOhwaki%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DOhtake%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520CCR3%2520selective%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1219%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuze, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span> </span><span class="NLM_article-title">Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2037</span><span class="NLM_x">â</span> <span class="NLM_lpage">2048</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0509703" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVCjsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2037-2048&author=M.+Setoauthor=K.+Aikawaauthor=N.+Miyamotoauthor=Y.+Aramakiauthor=N.+Kanzakiauthor=K.+Takashimaauthor=Y.+Kuzeauthor=Y.+Iizawaauthor=M.+Babaauthor=M.+Shiraishi&title=Highly+potent+and+orally+active+CCR5+antagonists+as+anti-HIV-1+agents%3A+synthesis+and+biological+activities+of+1-benzazocine+derivatives+containing+a+sulfoxide+moiety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent and Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activities of 1-Benzazocine Derivatives Containing a Sulfoxide Moiety</span></div><div class="casAuthors">Seto, Masaki; Aikawa, Katsuji; Miyamoto, Naoki; Aramaki, Yoshio; Kanzaki, Naoyuki; Takashima, Katsunori; Kuze, Yoji; Iizawa, Yuji; Baba, Masanori; Shiraishi, Mitsuru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2037-2048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. modification was performed on the orally bioavailable and potent CCR5 antagonist sulfoxide compd. I, mainly focusing on replacement of the [6,7]-fused 1-benzazepine nucleus.  Ring-expanded [6,8]-, [6,9]-, and [6,10]-fused compds. contg. S-sulfoxide moieties were prepd. and evaluated for biol. activities which led to 1-benzazocine and 1-benzazonine compds. that exhibited potent inhibitory activities.  1-Benzazocine compds. possessing the S-sulfoxide moiety showed greater potency than I in a fusion assay.  Further investigation in a multi-round infection assay showed that the 1-isobutyl-1-benzazocine compd. II, contg. the S-[[(1-propyl-1H-imidazol)-5-yl]methyl]sulfinyl group, showed the most potent anti-HIV-1 activity.  II (TAK-652) also inhibited the replication of six macrophage-tropic HIV-1 clin. isolates in peripheral blood mononuclear cells.  It was also absorbed after oral administration in rats, dogs, and monkeys and was thus selected as a clin. candidate.  The synthesis and biol. activity of II and derivs. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6VVfNAhytC7Vg90H21EOLACvtfcHk0lg_rTivjYCZAA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVCjsrY%253D&md5=e579dea40031ca3ac3d7b2d96875ab4c</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1021%2Fjm0509703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0509703%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DAikawa%26aufirst%3DK.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTakashima%26aufirst%3DK.%26aulast%3DKuze%26aufirst%3DY.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShiraishi%26aufirst%3DM.%26atitle%3DHighly%2520potent%2520and%2520orally%2520active%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%253A%2520synthesis%2520and%2520biological%2520activities%2520of%25201-benzazocine%2520derivatives%2520containing%2520a%2520sulfoxide%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2037%26epage%3D2048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group">Hersperger, R.; Janser, P.; Pfenninger, E.; Wuethrich, H. J.; Miltz, W.</span><span> </span><span class="NLM_article-title">Chemokine Receptor Antagonists</span>. US 20070155721,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=R.+Hersperger&author=P.+Janser&author=E.+Pfenninger&author=H.+J.+Wuethrich&author=W.+Miltz&title=Chemokine+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHersperger%26aufirst%3DR.%26atitle%3DChemokine%2520Receptor%2520Antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group">Cole, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasiliou, S.</span><span> </span><span class="NLM_article-title">Highlights from the 50th interscience conference on anti-microbial agents and chemotherapy (ICAAC)</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">â</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1358%2Fdof.2010.035.012.1583180" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=1045-1067&author=P.+Coleauthor=S.+Vasiliou&title=Highlights+from+the+50th+interscience+conference+on+anti-microbial+agents+and+chemotherapy+%28ICAAC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.012.1583180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.012.1583180%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DP.%26aulast%3DVasiliou%26aufirst%3DS.%26atitle%3DHighlights%2520from%2520the%252050th%2520interscience%2520conference%2520on%2520anti-microbial%2520agents%2520and%2520chemotherapy%2520%2528ICAAC%2529%26jtitle%3DDrugs%2520Future%26date%3D2010%26volume%3D35%26spage%3D1045%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group">Walters, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cage, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grahames, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, R.</span><span> </span><span class="NLM_article-title">Evaluation of a series of bicyclic CXCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">798</span><span class="NLM_x">â</span> <span class="NLM_lpage">803</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=798-803&author=I.+Waltersauthor=C.+Austinauthor=R.+Austinauthor=R.+Bonnertauthor=P.+Cageauthor=M.+Christieauthor=M.+Ebdenauthor=S.+Gardinerauthor=C.+Grahamesauthor=S.+Hillauthor=F.+Huntauthor=R.+Jewellauthor=S.+Lewisauthor=I.+Martinauthor=N.+Davidauthor=R.+David&title=Evaluation+of+a+series+of+bicyclic+CXCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DAustin%26aufirst%3DR.%26aulast%3DBonnert%26aufirst%3DR.%26aulast%3DCage%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DEbden%26aufirst%3DM.%26aulast%3DGardiner%26aufirst%3DS.%26aulast%3DGrahames%26aufirst%3DC.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DI.%26aulast%3DDavid%26aufirst%3DN.%26aulast%3DDavid%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520a%2520series%2520of%2520bicyclic%2520CXCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D798%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group">Suzuki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morokata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morihira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takizawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, Y.</span><span> </span><span class="NLM_article-title">A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">563</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.ejphar.2007.01.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17336292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksV2ktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=563&publication_year=2007&pages=224-232&author=K.+Suzukiauthor=T.+Morokataauthor=K.+Morihiraauthor=I.+Satoauthor=S.+Takizawaauthor=M.+Kanekoauthor=K.+Takahashiauthor=Y.+Shimizu&title=A+dual+antagonist+for+chemokine+CCR3+receptor+and+histamine+H1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor</span></div><div class="casAuthors">Suzuki, Keiko; Morokata, Tatsuaki; Morihira, Koichiro; Sato, Ippei; Takizawa, Satoko; Kaneko, Masayuki; Takahashi, Koichiro; Shimizu, Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">563</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">224-232</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Eosinophilic chemokines and histamine play distinct but important roles in allergic diseases.  Inhibition of both eosinophilic chemokines and histamine, therefore, is an ideal strategy for the treatment of allergic inflammation, such as asthma, allergic rhinitis, and atopic dermatitis.  YM-344484 was found to potently inhibit both the CCL11-induced Ca2+ influx in human CCR3-expressing cells (Kb = 1.8 nM) and histamine-induced Ca2+ influx in histamine H1 receptor-expressing PC3 cells (Kb = 47 nM).  YM-344484 also inhibited the CCL11-induced chemotaxis of human CCR3-expressing cells (IC50 = 6.2 nM) and CCL11-induced eosinophil-derived neurotoxin release from human eosinophils (IC50 = 19 nM).  Orally administered YM-344484 inhibited the increase in histamine-induced vascular permeability in mice (82% inhibition at a dose of 10 mg/kg) and the accumulation of eosinophils in a mouse asthma model (74% at a dose of 300 mg/kg).  These results indicate that YM-344484, a novel and functional dual antagonist for chemokine CCR3 receptor and histamine H1 receptor, is an attractive candidate for development as a novel anti-allergic inflammation drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRXmYzSP8LcbVg90H21EOLACvtfcHk0lggddbO5z1Dfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksV2ktLw%253D&md5=9ee198a3dfca217f9a738d392a6d8ab4</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2007.01.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2007.01.074%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMorokata%26aufirst%3DT.%26aulast%3DMorihira%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DI.%26aulast%3DTakizawa%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DY.%26atitle%3DA%2520dual%2520antagonist%2520for%2520chemokine%2520CCR3%2520receptor%2520and%2520histamine%2520H1%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D563%26spage%3D224%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group">Melancon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmitte, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">â</span> <span class="NLM_lpage">1464</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201139r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SmurnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1445-1464&author=B.+J.+Melanconauthor=C.+R.+Hopkinsauthor=M.+R.+Woodauthor=K.+A.+Emmitteauthor=C.+M.+Niswenderauthor=A.+Christopoulosauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Allosteric+modulation+of+seven+transmembrane+spanning+receptors%3A+theory%2C+practice%2C+and+opportunities+for+central+nervous+system+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery</span></div><div class="casAuthors">Melancon, Bruce J.; Hopkins, Corey R.; Wood, Michael R.; Emmitte, Kyle A.; Niswender, Colleen M.; Christopoulos, Arthur; Conn, P. Jeffrey; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1445-1464</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of Seven transmembrane spanning receptors and the opportunities for CNS drug discovery is reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlr4lj_Wp-O7Vg90H21EOLACvtfcHk0lggddbO5z1Dfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SmurnJ&md5=7c70f066f1581f1ff327c0dce37bb0e1</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Fjm201139r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201139r%26sid%3Dliteratum%253Aachs%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DAllosteric%2520modulation%2520of%2520seven%2520transmembrane%2520spanning%2520receptors%253A%2520theory%252C%2520practice%252C%2520and%2520opportunities%2520for%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1445%26epage%3D1464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group">Schnickel, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shefizadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishbein, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belperio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardehali, A.</span><span> </span><span class="NLM_article-title">Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">4714</span><span class="NLM_x">â</span> <span class="NLM_lpage">4721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=4714-4721&author=G.+T.+Schnickelauthor=S.+Bastaniauthor=G.+R.+Hsiehauthor=A.+Shefizadehauthor=R.+Bhatiaauthor=M.+C.+Fishbeinauthor=J.+Belperioauthor=A.+Ardehali&title=Combined+CXCR3%2FCCR5+blockade+attenuates+acute+and+chronic+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchnickel%26aufirst%3DG.%2BT.%26aulast%3DBastani%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DG.%2BR.%26aulast%3DShefizadeh%26aufirst%3DA.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DBelperio%26aufirst%3DJ.%26aulast%3DArdehali%26aufirst%3DA.%26atitle%3DCombined%2520CXCR3%252FCCR5%2520blockade%2520attenuates%2520acute%2520and%2520chronic%2520rejection%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D4714%26epage%3D4721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faia, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csizmadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danoff, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Beneficial effects of targeting CCR5 in allograft recipients</span> <span class="citation_source-journal">Transplantation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">â</span> <span class="NLM_lpage">1205</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2001&pages=1199-1205&author=W.+Gaoauthor=K.+L.+Faiaauthor=V.+Csizmadiaauthor=S.+T.+Smileyauthor=D.+Solerauthor=J.+A.+Kingauthor=T.+M.+Danoffauthor=W.+W.+Hancock&title=Beneficial+effects+of+targeting+CCR5+in+allograft+recipients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26aulast%3DFaia%26aufirst%3DK.%2BL.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DS.%2BT.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DJ.%2BA.%26aulast%3DDanoff%26aufirst%3DT.%2BM.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DBeneficial%2520effects%2520of%2520targeting%2520CCR5%2520in%2520allograft%2520recipients%26jtitle%3DTransplantation%26date%3D2001%26volume%3D72%26spage%3D1199%26epage%3D1205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergis, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosin, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, C. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusa, M. D.</span><span> </span><span class="NLM_article-title">The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemiaâreperfusion injury</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1526</span><span class="NLM_x">â</span> <span class="NLM_lpage">1537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fki.2008.500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18843253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVajtrbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1526-1537&author=L.+Liauthor=L.+Huangauthor=S.+S.+Sungauthor=A.+L.+Vergisauthor=D.+L.+Rosinauthor=C.+E.+Roseauthor=P.+I.+Loboauthor=M.+D.+Okusa&title=The+chemokine+receptors+CCR2+and+CX3CR1+mediate+monocyte%2Fmacrophage+trafficking+in+kidney+ischemia%E2%80%93reperfusion+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury</span></div><div class="casAuthors">Li, Li; Huang, Liping; Sung, Sun-Sang J.; Vergis, Amy L.; Rosin, Diane L.; Rose, C. Edward, Jr.; Lobo, Peter I.; Okusa, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1526-1537</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chemokines and their receptors such as CCR2 and CX3CR1 mediate leukocyte adhesion and migration into injured tissue.  To further define mechanisms of monocyte trafficking during kidney injury we identified two groups of F4/80-pos. cells (F4/80low and F4/80high) in the normal mouse kidney that phenotypically correspond to macrophages and dendritic cells, resp.  Following ischemia and 3 h of reperfusion, there was a large influx of F4/80low inflamed monocytes, but not dendritic cells, into the kidney.  These monocytes produced TNF-Î±, IL-6, IL-1Î± and IL-12.  Ischemic injury induced in CCR2-/- mice or in CCR2+/+ mice, made chimeric with CCR2-/- bone marrow, resulted in lower plasma creatinine levels and their kidneys had fewer infiltrated F4/80low macrophages compared to control mice.  CX3CR1 expression contributed to monocyte recruitment into inflamed kidneys, as ischemic injury in CX3CR1-/- mice was reduced, with fewer F4/80low macrophages than controls.  Monocytes transferred from CCR2+/+ or CX3CR1+/- mice migrated into reperfused kidneys better than monocytes from either CCR2-/- or CX3CR1-/- mice.  Adoptive transfer of monocytes from CCR2+/+ mice, but not CCR2-/- mice, reversed the protective effect in CCR2-/- mice following ischemia-reperfusion.  Egress of CD11b+Ly6Chigh monocytes from blood into inflamed kidneys was CCR2- and CX3CR1-dependent.  Our study shows that inflamed monocyte migration, through CCR2- and CX3CR1-dependent mechanisms, plays a crit. role in kidney injury following ischemia reperfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcUXO2HFE4q7Vg90H21EOLACvtfcHk0litXJRxwemrSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVajtrbF&md5=1316985a3b7692ee0efbef19ecf2834d</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1038%2Fki.2008.500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2008.500%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DSung%26aufirst%3DS.%2BS.%26aulast%3DVergis%26aufirst%3DA.%2BL.%26aulast%3DRosin%26aufirst%3DD.%2BL.%26aulast%3DRose%26aufirst%3DC.%2BE.%26aulast%3DLobo%26aufirst%3DP.%2BI.%26aulast%3DOkusa%26aufirst%3DM.%2BD.%26atitle%3DThe%2520chemokine%2520receptors%2520CCR2%2520and%2520CX3CR1%2520mediate%2520monocyte%252Fmacrophage%2520trafficking%2520in%2520kidney%2520ischemia%25E2%2580%2593reperfusion%2520injury%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D74%26spage%3D1526%26epage%3D1537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group">Jerath, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, A. M.</span><span> </span><span class="NLM_article-title">Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation</span> <span class="citation_source-journal">Thromb. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1186%2F1477-9560-8-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20836883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BC3cfkvFGisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=14&author=M.+R.+Jerathauthor=P.+Liuauthor=M.+Struthersauthor=J.+A.+Demartinoauthor=R.+Pengauthor=L.+B.+Petersonauthor=A.+M.+Cumiskeyauthor=L.+Yangauthor=M.+Rojasauthor=D.+D.+Patelauthor=A.+M.+Fong&title=Dual+targeting+of+CCR2+and+CX3CR1+in+an+arterial+injury+model+of+vascular+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation</span></div><div class="casAuthors">Jerath Maya R; Liu Peng; Struthers Mary; Demartino Julie A; Peng Roche; Peterson Laurence B; Cumiskey Anne-Marie; Yang Lihu; Rojas Mauricio; Patel Dhavalkumar D; Fong Alan M</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The chemokine receptors CCR2 and CX3CR1 are important in the development of coronary artery disease.  The purpose of this study is to analyze the effect of a novel CCR2 inhibitor in conjunction with CX3CR1 deletion on vascular inflammation.  METHODS:  The novel CCR2 antagonist MRL-677 was characterized using an in vivo model of monocyte migration.  To determine the relative roles of CCR2 and CX3CR1 in vascular remodeling, normal or CX3CR1 deficient mice were treated with MRL-677.  After 14 days, the level of intimal hyperplasia in the artery was visualized by paraffin sectioning and histology of the hind limbs.  RESULTS:  MRL-677 is a CCR2 antagonist that is effective in blocking macrophage trafficking in a peritoneal thioglycollate model.  Intimal hyperplasia resulting from vascular injury was also assessed in mice.  Based on the whole-blood potency of MRL-677, sufficient drug levels were maintained for the entire 14 day experimental period to afford good coverage of mCCR2 with MRL-677.  Blocking CCR2 with MRL-677 resulted in a 56% decrease in the vascular injury response (n = 9, p < 0.05) in normal animals.  Mice in which both CCR2 and CX3CR1 pathways were targeted (CX3CR1 KO mice given MRL-677) had an 88% decrease in the injury response (n = 6, p = 0.009).  CONCLUSION:  In this study we have shown that blocking CCR2 with a low molecular weight antagonist ameliorates the inflammatory response to vascular injury.  The protective effect of CCR2 blockade is increased in the presence of CX3CR1 deficiency suggesting that CX3CR1 and CCR2 have non-redundant functions in the progression of vascular inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC23SCD_Mi61MGsG_HTXYFfW6udTcc2ebCxP_6X0NElrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfkvFGisg%253D%253D&md5=0c48415369f27e5edbaa099293da04fb</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1186%2F1477-9560-8-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1477-9560-8-14%26sid%3Dliteratum%253Aachs%26aulast%3DJerath%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DDemartino%26aufirst%3DJ.%2BA.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DRojas%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DD.%2BD.%26aulast%3DFong%26aufirst%3DA.%2BM.%26atitle%3DDual%2520targeting%2520of%2520CCR2%2520and%2520CX3CR1%2520in%2520an%2520arterial%2520injury%2520model%2520of%2520vascular%2520inflammation%26jtitle%3DThromb.%2520J.%26date%3D2010%26volume%3D8%26spage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span>BusinessWire. Ligand Licenses DARA Program to Retrophin. <a href="http://www.businesswire.com/news/home/20120221005513/en/Ligand-Licenses-DARA-Program-Retrophin" class="extLink">http://www.businesswire.com/news/home/20120221005513/en/Ligand-Licenses-DARA-Program-Retrophin</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BusinessWire.+Ligand+Licenses+DARA+Program+to+Retrophin.+http%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20120221005513%2Fen%2FLigand-Licenses-DARA-Program-Retrophin."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group">Ohshima, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harakawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span> </span><span class="NLM_article-title">Dibenz[<i>b</i>,<i>e</i>]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">â</span> <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00055a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=417-420&author=E.+Ohshimaauthor=H.+Takamiauthor=H.+Harakawaauthor=H.+Satoauthor=H.+Obaseauthor=I.+Mikiauthor=A.+Ishiiauthor=H.+Ishiiauthor=Y.+Sasakiauthor=K.+Ohmoriauthor=A.+Karasawaauthor=K.+Kubo&title=Dibenz%5Bb%2Ce%5Doxepin+derivatives%3A+novel+antiallergic+agents+possessing+thromboxane+A2+and+histamine+H1+dual+antagonizing+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1021%2Fjm00055a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00055a013%26sid%3Dliteratum%253Aachs%26aulast%3DOhshima%26aufirst%3DE.%26aulast%3DTakami%26aufirst%3DH.%26aulast%3DHarakawa%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DObase%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DI.%26aulast%3DIshii%26aufirst%3DA.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DOhmori%26aufirst%3DK.%26aulast%3DKarasawa%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DK.%26atitle%3DDibenz%255Bb%252Ce%255Doxepin%2520derivatives%253A%2520novel%2520antiallergic%2520agents%2520possessing%2520thromboxane%2520A2%2520and%2520histamine%2520H1%2520dual%2520antagonizing%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D417%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group">Schall, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span> </span><span class="NLM_article-title">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">â</span> <span class="NLM_lpage">363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnri2972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21494268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=355-363&author=T.+J.+Schallauthor=A.+E.+Proudfoot&title=Overcoming+hurdles+in+developing+successful+drugs+targeting+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span></div><div class="casAuthors">Schall, Thomas J.; Proudfoot, Amanda E. I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokines and their receptors are central to the inflammatory process and are attractive therapeutic targets.  Drugs that inhibit chemokine receptors are approved for the treatment of HIV infection and for stem cell mobilization, but none have been approved yet for the treatment of inflammatory and/or autoimmune diseases.  We analyze the challenges of developing chemokine receptor antagonists, and propose that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies.  We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJxZhyoAteTLVg90H21EOLACvtfcHk0ljxC0fLSNzspg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D&md5=3173fc889bd22b7d7e19bd138a599897</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1038%2Fnri2972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2972%26sid%3Dliteratum%253Aachs%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26atitle%3DOvercoming%2520hurdles%2520in%2520developing%2520successful%2520drugs%2520targeting%2520chemokine%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2011%26volume%3D11%26spage%3D355%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group">OâBoyle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willet, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavin, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hine, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, J. A.</span><span> </span><span class="NLM_article-title">Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4598</span><span class="NLM_x">â</span> <span class="NLM_lpage">4603</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=4598-4603&author=G.+O%E2%80%99Boyleauthor=C.+R.+Foxauthor=H.+R.+Waldenauthor=J.+D.+Willetauthor=E.+R.+Mavinauthor=D.+W.+Hineauthor=J.+M.+Palmerauthor=C.+E.+Barkerauthor=C.+A.+Lambauthor=S.+Aliauthor=J.+A.+Kirby&title=Chemokine+receptor+CXCR3+agonist+prevents+human+T-cell+migration+in+a+humanized+model+of+arthritic+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DG.%26aulast%3DFox%26aufirst%3DC.%2BR.%26aulast%3DWalden%26aufirst%3DH.%2BR.%26aulast%3DWillet%26aufirst%3DJ.%2BD.%26aulast%3DMavin%26aufirst%3DE.%2BR.%26aulast%3DHine%26aufirst%3DD.%2BW.%26aulast%3DPalmer%26aufirst%3DJ.%2BM.%26aulast%3DBarker%26aufirst%3DC.%2BE.%26aulast%3DLamb%26aufirst%3DC.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DKirby%26aufirst%3DJ.%2BA.%26atitle%3DChemokine%2520receptor%2520CXCR3%2520agonist%2520prevents%2520human%2520T-cell%2520migration%2520in%2520a%2520humanized%2520model%2520of%2520arthritic%2520inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D4598%26epage%3D4603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group">Takeda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffi, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nozaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albuquerque, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dridi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisler, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geisen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munitz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambati, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishibashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grisanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartnett, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambati, J.</span><span> </span><span class="NLM_article-title">CCR3 is a target for age-related macular degeneration diagnosis and therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">460</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">â</span> <span class="NLM_lpage">230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=460&publication_year=2009&pages=225-230&author=A.+Takedaauthor=J.+Z.+Baffiauthor=M.+E.+Kleinmanauthor=W.+G.+Choauthor=M.+Nozakiauthor=K.+Yamadaauthor=H.+Kanekoauthor=R.+J.+Albuquerqueauthor=S.+Dridiauthor=K.+Saitoauthor=B.+J.+Raislerauthor=S.+J.+Buddauthor=P.+Geisenauthor=A.+Munitzauthor=B.+K.+Ambatiauthor=M.+G.+Greenauthor=T.+Ishibashiauthor=J.+D.+Wrightauthor=A.+A.+Humblesauthor=C.+J.+Gerardauthor=Y.+Oguraauthor=Y.+Panauthor=J.+R.+Smithauthor=S.+Grisantiauthor=M.+E.+Hartnettauthor=M.+E.+Rothenbergauthor=J.+Ambati&title=CCR3+is+a+target+for+age-related+macular+degeneration+diagnosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DA.%26aulast%3DBaffi%26aufirst%3DJ.%2BZ.%26aulast%3DKleinman%26aufirst%3DM.%2BE.%26aulast%3DCho%26aufirst%3DW.%2BG.%26aulast%3DNozaki%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DAlbuquerque%26aufirst%3DR.%2BJ.%26aulast%3DDridi%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DRaisler%26aufirst%3DB.%2BJ.%26aulast%3DBudd%26aufirst%3DS.%2BJ.%26aulast%3DGeisen%26aufirst%3DP.%26aulast%3DMunitz%26aufirst%3DA.%26aulast%3DAmbati%26aufirst%3DB.%2BK.%26aulast%3DGreen%26aufirst%3DM.%2BG.%26aulast%3DIshibashi%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DJ.%2BD.%26aulast%3DHumbles%26aufirst%3DA.%2BA.%26aulast%3DGerard%26aufirst%3DC.%2BJ.%26aulast%3DOgura%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DGrisanti%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DM.%2BE.%26aulast%3DRothenberg%26aufirst%3DM.%2BE.%26aulast%3DAmbati%26aufirst%3DJ.%26atitle%3DCCR3%2520is%2520a%2520target%2520for%2520age-related%2520macular%2520degeneration%2520diagnosis%2520and%2520therapy%26jtitle%3DNature%26date%3D2009%26volume%3D460%26spage%3D225%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group">Villeda, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosher, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britschgi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fainberg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucin, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czirr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couillard-Despres, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aigner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peskind, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasko, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rando, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss-Coray, T.</span><span> </span><span class="NLM_article-title">The ageing systemic milieu negatively regulates neurogenesis and cognitive function</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">477</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">â</span> <span class="NLM_lpage">94</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=90-94&author=S.+A.+Villedaauthor=J.+Luoauthor=K.+I.+Mosherauthor=B.+Zouauthor=M.+Britschgiauthor=G.+Bieriauthor=T.+M.+Stanauthor=N.+Fainbergauthor=Z.+Dingauthor=A.+Eggelauthor=K.+M.+Lucinauthor=E.+Czirrauthor=J.+S.+Parkauthor=S.+Couillard-Despresauthor=L.+Aignerauthor=G.+Liauthor=E.+R.+Peskindauthor=J.+A.+Kayeauthor=J.+F.+Quinnauthor=D.+R.+Galaskoauthor=X.+S.+Xieauthor=T.+A.+Randoauthor=T.+Wyss-Coray&title=The+ageing+systemic+milieu+negatively+regulates+neurogenesis+and+cognitive+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilleda%26aufirst%3DS.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMosher%26aufirst%3DK.%2BI.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DBritschgi%26aufirst%3DM.%26aulast%3DBieri%26aufirst%3DG.%26aulast%3DStan%26aufirst%3DT.%2BM.%26aulast%3DFainberg%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DEggel%26aufirst%3DA.%26aulast%3DLucin%26aufirst%3DK.%2BM.%26aulast%3DCzirr%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DCouillard-Despres%26aufirst%3DS.%26aulast%3DAigner%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPeskind%26aufirst%3DE.%2BR.%26aulast%3DKaye%26aufirst%3DJ.%2BA.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DGalasko%26aufirst%3DD.%2BR.%26aulast%3DXie%26aufirst%3DX.%2BS.%26aulast%3DRando%26aufirst%3DT.%2BA.%26aulast%3DWyss-Coray%26aufirst%3DT.%26atitle%3DThe%2520ageing%2520systemic%2520milieu%2520negatively%2520regulates%2520neurogenesis%2520and%2520cognitive%2520function%26jtitle%3DNature%26date%3D2011%26volume%3D477%26spage%3D90%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group">Shimaoka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kume, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohsumi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshie, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonehara, S.</span><span> </span><span class="NLM_article-title">Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">â</span> <span class="NLM_lpage">274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1189%2Fjlb.1003465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=14634054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFKnt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=267-274&author=T.+Shimaokaauthor=T.+Nakayamaauthor=N.+Fukumotoauthor=N.+Kumeauthor=S.+Takahashiauthor=J.+Yamaguchiauthor=M.+Minamiauthor=K.+Hayashidaauthor=T.+Kitaauthor=J.+Ohsumiauthor=O.+Yoshieauthor=S.+Yonehara&title=Cell+surface-anchored+SR-PSOX%2FCXC+chemokine+ligand+16+mediates+firm+adhesion+of+CXC+chemokine+receptor+6-expressing+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells</span></div><div class="casAuthors">Shimaoka, Takeshi; Nakayama, Takashi; Fukumoto, Noriko; Kume, Noriaki; Takahashi, Shu; Yamaguchi, Junko; Minami, Manabu; Hayashida, Kazutaka; Kita, Toru; Ohsumi, Jun; Yoshie, Osamu; Yonehara, Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-274</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Direct contacts between dendritic cells (DCs) and T cells or natural killer T (NKT) cells play important roles in primary and secondary immune responses.  SR-PSOX/CXC chemokine ligand 16 (CXCL16), which is selectively expressed on DCs and macrophages, is a scavenger receptor for oxidized low-d. lipoprotein and also the chemokine ligand for a G protein-coupled receptor CXC chemokine receptor 6 (CXCR6), expressed on activated T cells and NKT cells.  SR-PSOX/CXCL16 is the second transmembrane-type chemokine with a chemokine domain fused to a mucin-like stalk, a structure very similar to that of fractalkine (FNK).  Here, we demonstrate that SR-PSOX/CXCL16 functions as a cell adhesion mol. for cells expressing CXCR6 in the same manner that FNK functions as a cell adhesion mol. for cells expressing CX3C chemokine receptor 1 (CX3CR1) without requiring CX3CR1-mediated signal transduction or integrin activation.  The chemokine domain of SR-PSOX/CXCL16 mediated the adhesion of CXCR6-expressing cells, which was not impaired by treatment with pertussis toxin, a GÎ±i protein blocker, which inhibited chemotaxis of CXCR6-expressing cells induced by SR-PSOX/CXCL16.  Furthermore, the adhesion activity was up-regulated by treatment of SR-PSOX/CXCL16-expressing cells with a metalloprotease inhibitor, which increased surface expression levels of SR-PSOX/CXCL16.  Thus, SR-PSOX/CXCL16 is a unique mol. that not only attracts T cells and NKT cells toward DCs but also supports their firm adhesion to DCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbzkIQb5hFbVg90H21EOLACvtfcHk0ljtTVRcAKNMWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFKnt7Y%253D&md5=696a00c998088299d30e90a4b07f721d</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1003465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1003465%26sid%3Dliteratum%253Aachs%26aulast%3DShimaoka%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DFukumoto%26aufirst%3DN.%26aulast%3DKume%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DMinami%26aufirst%3DM.%26aulast%3DHayashida%26aufirst%3DK.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DOhsumi%26aufirst%3DJ.%26aulast%3DYoshie%26aufirst%3DO.%26aulast%3DYonehara%26aufirst%3DS.%26atitle%3DCell%2520surface-anchored%2520SR-PSOX%252FCXC%2520chemokine%2520ligand%252016%2520mediates%2520firm%2520adhesion%2520of%2520CXC%2520chemokine%2520receptor%25206-expressing%2520cells%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2004%26volume%3D75%26spage%3D267%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group">Sheikine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirsjo, A.</span><span> </span><span class="NLM_article-title">CXCL16/SR-PSOXâa friend or a foe in atherosclerosis?</span> <span class="citation_source-journal">Atherosclerosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">â</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2008&pages=487-495&author=Y.+Sheikineauthor=A.+Sirsjo&title=CXCL16%2FSR-PSOX%E2%80%94a+friend+or+a+foe+in+atherosclerosis%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSheikine%26aufirst%3DY.%26aulast%3DSirsjo%26aufirst%3DA.%26atitle%3DCXCL16%252FSR-PSOX%25E2%2580%2594a%2520friend%2520or%2520a%2520foe%2520in%2520atherosclerosis%253F%26jtitle%3DAtherosclerosis%26date%3D2008%26volume%3D197%26spage%3D487%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group">Terashima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poonpiriya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motomura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanegasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span> </span><span class="NLM_article-title">Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">â</span> <span class="NLM_lpage">835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fni1222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15995708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlSisLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=827-835&author=Y.+Terashimaauthor=N.+Onaiauthor=M.+Muraiauthor=M.+Enomotoauthor=V.+Poonpiriyaauthor=T.+Hamadaauthor=K.+Motomuraauthor=M.+Suwaauthor=T.+Ezakiauthor=T.+Hagaauthor=S.+Kanegasakiauthor=K.+Matsushima&title=Pivotal+function+for+cytoplasmic+protein+FROUNT+in+CCR2-mediated+monocyte+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis</span></div><div class="casAuthors">Terashima, Yuya; Onai, Nobuyuki; Murai, Masako; Enomoto, Masahiko; Poonpiriya, Vongsakorn; Hamada, Tsuyoshi; Motomura, Kazushi; Suwa, Makiko; Ezaki, Taichi; Haga, Tatsuya; Kanegasaki, Shiro; Matsushima, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-835</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ligation of the chemokine receptor CCR2 on monocytes and macrophages with its ligand CCL2 results in activation of the cascade consisting of phosphatidylinositol-3-OH kinase (PI(3)K), the small G protein Rac and lamellipodium protrusion.  The authors show here that a unique clathrin heavy-chain repeat homol. protein, FROUNT, directly bound activated CCR2 and formed clusters at the cell front during chemotaxis.  Overexpression of FROUNT amplified the chemokine-elicited PI(3)K-Rac-lamellipodium protrusion cascade and subsequent chemotaxis.  Blocking FROUNT function by using a truncated mutant or antisense strategy substantially diminished signaling via CCR2.  In a mouse peritonitis model, suppression of endogenous FROUNT markedly prevented macrophage infiltration.  Thus, FROUNT links activated CCR2 to the PI(3)K-Rac-lamellipodium protrusion cascade and could be a therapeutic target in chronic inflammatory immune diseases assocd. with macrophage infiltration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfaqLVEW9Cp7Vg90H21EOLACvtfcHk0ljtTVRcAKNMWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlSisLo%253D&md5=5067ce5c5705892030b2567e815222c3</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1038%2Fni1222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1222%26sid%3Dliteratum%253Aachs%26aulast%3DTerashima%26aufirst%3DY.%26aulast%3DOnai%26aufirst%3DN.%26aulast%3DMurai%26aufirst%3DM.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DPoonpiriya%26aufirst%3DV.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DMotomura%26aufirst%3DK.%26aulast%3DSuwa%26aufirst%3DM.%26aulast%3DEzaki%26aufirst%3DT.%26aulast%3DHaga%26aufirst%3DT.%26aulast%3DKanegasaki%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DK.%26atitle%3DPivotal%2520function%2520for%2520cytoplasmic%2520protein%2520FROUNT%2520in%2520CCR2-mediated%2520monocyte%2520chemotaxis%26jtitle%3DNat.%2520Immunol.%26date%3D2005%26volume%3D6%26spage%3D827%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group">Toda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanegasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span> </span><span class="NLM_article-title">FROUNT is a common regulator of CCR2 and CCR5 signaling to control directional migration</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">6387</span><span class="NLM_x">â</span> <span class="NLM_lpage">6394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=6387-6394&author=E.+Todaauthor=Y.+Terashimaauthor=T.+Satoauthor=K.+Hiroseauthor=S.+Kanegasakiauthor=K.+Matsushima&title=FROUNT+is+a+common+regulator+of+CCR2+and+CCR5+signaling+to+control+directional+migration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DE.%26aulast%3DTerashima%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DHirose%26aufirst%3DK.%26aulast%3DKanegasaki%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DK.%26atitle%3DFROUNT%2520is%2520a%2520common%2520regulator%2520of%2520CCR2%2520and%2520CCR5%2520signaling%2520to%2520control%2520directional%2520migration%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D6387%26epage%3D6394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 73 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Michael G. Yang, Zili Xiao, Rulin Zhao, Andrew J. Tebben, Bei Wang, Robert J. Cherney, Douglas G. Batt, Gregory D. Brown, Mary Ellen Cvijic, John V. Duncia, Michael A. Gallela, Daniel S. Gardner, Purnima Khandelwal, Mary F. Malley, Jian Pang, Anne V. Rose, Joseph B. Santella, III, Amy A. Sarjeant, Songmei Xu, Arvind Mathur, Sandhya Mandlekar, Ragini Vuppugalla, Qihong Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Percy H. Carter</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 969-975. <a href="https://doi.org/10.1021/acsmedchemlett.1c00082" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00082%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BBMS-753426%25253A%252BA%252BPotent%252BOrally%252BBioavailable%252BAntagonist%252Bof%252BCC%252BChemokine%252BReceptor%252B2%26aulast%3DYang%26aufirst%3DMichael%2BG.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05022021%26date%3D20052021%26date%3D25052021%26volume%3D12%26issue%3D6%26spage%3D969%26epage%3D975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brooke
M. Katzman, Bryan D. Cox, Anthony R. Prosser, Ana A. Alcaraz, Brigitte Murat, Madeleine HÃ©roux, Andrew Tebben, Yong Zhang, Gretchen M. Schroeder, James P. Snyder, Lawrence J. Wilson, <span class="NLM_string-name hlFld-ContribAuthor">Dennis C. Liotta</span>. </span><span class="cited-content_cbyCitation_article-title">Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 67-73. <a href="https://doi.org/10.1021/acsmedchemlett.8b00441" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00441%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTetrahydroisoquinoline%252BCXCR4%252BAntagonists%252BAdopt%252Ba%252BHybrid%252BBinding%252BMode%252Bwithin%252Bthe%252BPeptide%252BSubpocket%252Bof%252Bthe%252BCXCR4%252BReceptor%26aulast%3DKatzman%26aufirst%3DBrooke%2BM.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24092018%26date%3D30112018%26date%3D10122018%26date%3D30112018%26volume%3D10%26issue%3D1%26spage%3D67%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Natalia
V. Ortiz ZacarÃ­as, Jacobus P. D. van Veldhoven, Laura Portner, Eric van Spronsen, Salviana Ullo, Margo Veenhuizen, Wijnand J. C. van der Velden, Annelien J. M. Zweemer, Roy M. Kreekel, Kenny Oenema, Eelke B. Lenselink, Laura H. Heitman, <span class="NLM_string-name hlFld-ContribAuthor">Adriaan P. IJzerman</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9146-9161. <a href="https://doi.org/10.1021/acs.jmedchem.8b00605" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00605%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolone%252BDerivatives%252Bas%252BIntracellular%252BAllosteric%252BModulators%252Bfor%252BChemokine%252BReceptors%25253A%252BSelective%252Band%252BDual-Targeting%252BInhibitors%252Bof%252BCC%252BChemokine%252BReceptors%252B1%252Band%252B2%26aulast%3DOrtiz%2BZacar%25C3%25ADas%26aufirst%3DNatalia%2BV.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16042018%26date%3D11102018%26date%3D26092018%26volume%3D61%26issue%3D20%26spage%3D9146%26epage%3D9161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elnaz Menhaji-Klotz, Kevin D. Hesp, Allyn T. Londregan, Amit S. Kalgutkar, David W. Piotrowski, Markus Boehm, Kun Song, Tim Ryder, Kevin Beaumont, Rhys M. Jones, Karen Atkinson, Janice A. Brown, John Litchfield, Jun Xiao, Daniel P. Canterbury, Kristen Burford, Benjamin A. Thuma, Chris Limberakis, Wenhua Jiao, Scott W. Bagley, Saket Agarwal, Danielle Crowell, Stephen Pazdziorko, Jessica Ward, David A. Price, <span class="NLM_string-name hlFld-ContribAuthor">Valerie Clerin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Small-Molecule Modulator of CâXâC Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (8)
                                     , 3685-3696. <a href="https://doi.org/10.1021/acs.jmedchem.8b00190" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00190%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BSmall-Molecule%252BModulator%252Bof%252BC%2525E2%252580%252593X%2525E2%252580%252593C%252BChemokine%252BReceptor%252BType%252B7%252Bas%252Ba%252BTreatment%252Bfor%252BCardiac%252BFibrosis%26aulast%3DMenhaji-Klotz%26aufirst%3DElnaz%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05022018%26date%3D17042018%26date%3D08042018%26volume%3D61%26issue%3D8%26spage%3D3685%26epage%3D3696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas  Kindon</span>, <span class="hlFld-ContribAuthor ">Glen  Andrews</span>, <span class="hlFld-ContribAuthor ">Andrew  Baxter</span>, <span class="hlFld-ContribAuthor ">David  Cheshire</span>, <span class="hlFld-ContribAuthor ">Paul  Hemsley</span>, <span class="hlFld-ContribAuthor ">Timothy  Johnson</span>, <span class="hlFld-ContribAuthor ">Yu-Zhen  Liu</span>, <span class="hlFld-ContribAuthor ">Dermot  McGinnity</span>, <span class="hlFld-ContribAuthor ">Mark  McHale</span>, <span class="hlFld-ContribAuthor ">Antonio  Mete</span>, <span class="hlFld-ContribAuthor ">James  Reuberson</span>, <span class="hlFld-ContribAuthor ">Bryan  Roberts</span>, <span class="hlFld-ContribAuthor ">John  Steele</span>, <span class="hlFld-ContribAuthor ">Barry  Teobald</span>, <span class="hlFld-ContribAuthor ">John  Unitt</span>, <span class="hlFld-ContribAuthor ">Deborah  Vaughan</span>, <span class="hlFld-ContribAuthor ">Iain  Walters</span>, and <span class="hlFld-ContribAuthor ">Michael J.  Stocks</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (9)
                                     , 981-986. <a href="https://doi.org/10.1021/acsmedchemlett.7b00315" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00315%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BAZD-2098%252Band%252BAZD-1678%25252C%252BTwo%252BPotent%252Band%252BBioavailable%252BCCR4%252BReceptor%252BAntagonists%26aulast%3DKindon%26aufirst%3DNicholas%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D03082017%26date%3D01092017%26date%3D06092017%26date%3D14092017%26date%3D01092017%26volume%3D8%26issue%3D9%26spage%3D981%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen P.  Andrews</span> and <span class="hlFld-ContribAuthor ">Rhona J.  Cox</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule CXCR3 Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (7)
                                     , 2894-2917. <a href="https://doi.org/10.1021/acs.jmedchem.5b01337" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01337</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01337%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BCXCR3%252BAntagonists%26aulast%3DAndrews%26aufirst%3DStephen%2BP.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D28082015%26date%3D04112015%26date%3D14042016%26volume%3D59%26issue%3D7%26spage%3D2894%26epage%3D2917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Panayiotis A.  Procopiou</span>, <span class="hlFld-ContribAuthor ">John W.  Barrett</span>, <span class="hlFld-ContribAuthor ">Nicholas P.  Barton</span>, <span class="hlFld-ContribAuthor ">Malcolm  Begg</span>, <span class="hlFld-ContribAuthor ">David  Clapham</span>, <span class="hlFld-ContribAuthor ">Royston C. B.  Copley</span>, <span class="hlFld-ContribAuthor ">Alison J.  Ford</span>, <span class="hlFld-ContribAuthor ">Rebecca H.  Graves</span>, <span class="hlFld-ContribAuthor ">David A.  Hall</span>, <span class="hlFld-ContribAuthor ">Ashley P.  Hancock</span>, <span class="hlFld-ContribAuthor ">Alan P.  Hill</span>, <span class="hlFld-ContribAuthor ">Heather  Hobbs</span>, <span class="hlFld-ContribAuthor ">Simon T.  Hodgson</span>, <span class="hlFld-ContribAuthor ">Coline  Jumeaux</span>, <span class="hlFld-ContribAuthor ">Yannick M. L.  Lacroix</span>, <span class="hlFld-ContribAuthor ">Afjal H.  Miah</span>, <span class="hlFld-ContribAuthor ">Karen M. L.  Morriss</span>, <span class="hlFld-ContribAuthor ">Deborah  Needham</span>, <span class="hlFld-ContribAuthor ">Emma B.  Sheriff</span>, <span class="hlFld-ContribAuthor ">Robert J.  Slack</span>, <span class="hlFld-ContribAuthor ">Claire E.  Smith</span>, <span class="hlFld-ContribAuthor ">Steven L.  Sollis</span>, and <span class="hlFld-ContribAuthor ">Hugo  Staton</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and StructureâActivity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (5)
                                     , 1946-1960. <a href="https://doi.org/10.1021/jm301572h" title="DOI URL">https://doi.org/10.1021/jm301572h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301572h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301572h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BIndazole%252BArylsulfonamides%252Bas%252BAllosteric%252BCC-Chemokine%252BReceptor%252B4%252B%252528CCR4%252529%252BAntagonists%26aulast%3DProcopiou%26aufirst%3DPanayiotis%2BA.%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D24102012%26date%3D27022013%26date%3D14032013%26date%3D14022013%26volume%3D56%26issue%3D5%26spage%3D1946%26epage%3D1960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang  Liu</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Tatsunori  Sato</span>, <span class="hlFld-ContribAuthor ">Sarah  White</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic tailor-made amino acids in the design of modern pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112736. <a href="https://doi.org/10.1016/j.ejmech.2020.112736" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112736%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCyclic%252Btailor-made%252Bamino%252Bacids%252Bin%252Bthe%252Bdesign%252Bof%252Bmodern%252Bpharmaceuticals%26aulast%3DLiu%26aufirst%3DJiang%26date%3D2020%26volume%3D208%26spage%3D112736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Sarah  White</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Graham</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Tatsunori  Sato</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">TailorâMade Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (50)
                                     , 11349-11390. <a href="https://doi.org/10.1002/chem.202000617" title="DOI URL">https://doi.org/10.1002/chem.202000617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202000617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202000617%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DTailor%2525E2%252580%252590Made%252BAmino%252BAcids%252Band%252BFluorinated%252BMotifs%252Bas%252BProminent%252BTraits%252Bin%252BModern%252BPharmaceuticals%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D50%26spage%3D11349%26epage%3D11390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshiyuki  Kiyasu</span>, <span class="hlFld-ContribAuthor ">Kenji  Kawada</span>, <span class="hlFld-ContribAuthor ">Hideyo  Hirai</span>, <span class="hlFld-ContribAuthor ">Ryotaro  Ogawa</span>, <span class="hlFld-ContribAuthor ">Keita  Hanada</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Masui</span>, <span class="hlFld-ContribAuthor ">Gen  Nishikawa</span>, <span class="hlFld-ContribAuthor ">Takamasa  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Rei  Mizuno</span>, <span class="hlFld-ContribAuthor ">Yoshiro  Itatani</span>, <span class="hlFld-ContribAuthor ">Masayuki  Kai</span>, <span class="hlFld-ContribAuthor ">Makoto Mark  Taketo</span>, <span class="hlFld-ContribAuthor ">Yoshiharu  Sakai</span>. </span><span class="cited-content_cbyCitation_article-title">Disruption of CCR1-mediated myeloid cell accumulation suppresses colorectal cancer progression in mice. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2020,</strong> <em>487 </em>, 53-62. <a href="https://doi.org/10.1016/j.canlet.2020.05.028" title="DOI URL">https://doi.org/10.1016/j.canlet.2020.05.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2020.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2020.05.028%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DDisruption%252Bof%252BCCR1-mediated%252Bmyeloid%252Bcell%252Baccumulation%252Bsuppresses%252Bcolorectal%252Bcancer%252Bprogression%252Bin%252Bmice%26aulast%3DKiyasu%26aufirst%3DYoshiyuki%26date%3D2020%26volume%3D487%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-Yuan  Cui</span>, <span class="hlFld-ContribAuthor ">Shi-Feng  Chu</span>, <span class="hlFld-ContribAuthor ">Nai-Hong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">The role of chemokines and chemokine receptors in multiple sclerosis. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2020,</strong> <em>83 </em>, 106314. <a href="https://doi.org/10.1016/j.intimp.2020.106314" title="DOI URL">https://doi.org/10.1016/j.intimp.2020.106314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2020.106314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2020.106314%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DThe%252Brole%252Bof%252Bchemokines%252Band%252Bchemokine%252Breceptors%252Bin%252Bmultiple%252Bsclerosis%26aulast%3DCui%26aufirst%3DLi-Yuan%26date%3D2020%26volume%3D83%26spage%3D106314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline A.  Anderson</span>, <span class="hlFld-ContribAuthor ">Pallavi  Patel</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Viney</span>, <span class="hlFld-ContribAuthor ">Rhian M.  Phillips</span>, <span class="hlFld-ContribAuthor ">Roberto  Solari</span>, <span class="hlFld-ContribAuthor ">James E.  Pease</span>. </span><span class="cited-content_cbyCitation_article-title">A degradatory fate for CCR4 suggests a primary role in Th2 inflammation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Leukocyte Biology</span><span> <strong>2020,</strong> <em>107 </em>
                                    (3)
                                     , 455-466. <a href="https://doi.org/10.1002/JLB.2A0120-089RR" title="DOI URL">https://doi.org/10.1002/JLB.2A0120-089RR</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/JLB.2A0120-089RR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2FJLB.2A0120-089RR%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Leukocyte%2520Biology%26atitle%3DA%252Bdegradatory%252Bfate%252Bfor%252BCCR4%252Bsuggests%252Ba%252Bprimary%252Brole%252Bin%252BTh2%252Binflammation%26aulast%3DAnderson%26aufirst%3DCaroline%2BA.%26date%3D2020%26date%3D2020%26volume%3D107%26issue%3D3%26spage%3D455%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yifan  Zhan</span>, <span class="hlFld-ContribAuthor ">Nancy  Wang</span>, <span class="hlFld-ContribAuthor ">Ajithkumar  Vasanthakumar</span>, <span class="hlFld-ContribAuthor ">Yuxia  Zhang</span>, <span class="hlFld-ContribAuthor ">Michael  Chopin</span>, <span class="hlFld-ContribAuthor ">Stephen L.  Nutt</span>, <span class="hlFld-ContribAuthor ">Axel  Kallies</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Lew</span>. </span><span class="cited-content_cbyCitation_article-title">CCR2 enhances CD25 expression by FoxP3+ regulatory T cells and regulates their abundance independently of chemotaxis and CCR2+ myeloid cells. </span><span class="cited-content_cbyCitation_journal-name">Cellular & Molecular Immunology</span><span> <strong>2020,</strong> <em>17 </em>
                                    (2)
                                     , 123-132. <a href="https://doi.org/10.1038/s41423-018-0187-8" title="DOI URL">https://doi.org/10.1038/s41423-018-0187-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41423-018-0187-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41423-018-0187-8%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520%2526%2520Molecular%2520Immunology%26atitle%3DCCR2%252Benhances%252BCD25%252Bexpression%252Bby%252BFoxP3%25252B%252Bregulatory%252BT%252Bcells%252Band%252Bregulates%252Btheir%252Babundance%252Bindependently%252Bof%252Bchemotaxis%252Band%252BCCR2%25252B%252Bmyeloid%252Bcells%26aulast%3DZhan%26aufirst%3DYifan%26date%3D2020%26date%3D2018%26volume%3D17%26issue%3D2%26spage%3D123%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yesim A  Tahirovic</span>, <span class="hlFld-ContribAuthor ">Sameshnee  Pelly</span>, <span class="hlFld-ContribAuthor ">Edgars  Jecs</span>, <span class="hlFld-ContribAuthor ">Eric J  Miller</span>, <span class="hlFld-ContribAuthor ">Savita K  Sharma</span>, <span class="hlFld-ContribAuthor ">Dennis C  Liotta</span>, <span class="hlFld-ContribAuthor ">Lawrence J  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (2)
                                     , 87-101. <a href="https://doi.org/10.1080/13543776.2020.1707186" title="DOI URL">https://doi.org/10.1080/13543776.2020.1707186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1707186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1707186%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall%252Bmolecule%252Band%252Bpeptide-based%252BCXCR4%252Bmodulators%252Bas%252Btherapeutic%252Bagents.%252BA%252Bpatent%252Breview%252Bfor%252Bthe%252Bperiod%252Bfrom%252B2010%252Bto%252B2018%26aulast%3DTahirovic%26aufirst%3DYesim%2BA%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D2%26spage%3D87%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Horuk</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokine Receptors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-7. <a href="https://doi.org/10.1007/978-3-030-21573-6_39-1" title="DOI URL">https://doi.org/10.1007/978-3-030-21573-6_39-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-21573-6_39-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-21573-6_39-1%26sid%3Dliteratum%253Aachs%26atitle%3DChemokine%252BReceptors%26aulast%3DHoruk%26aufirst%3DRichard%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D7%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DEncyclopedia%252Bof%252BMolecular%252BPharmacology%26aulast%3DOffermanns%26aufirst%3DStefan%26date%3D2020%26volume%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Karel D.  Klika</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Tatsunori  Sato</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of fluorine-containing amino acids for drug design. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111826. <a href="https://doi.org/10.1016/j.ejmech.2019.111826" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111826</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111826%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplications%252Bof%252Bfluorine-containing%252Bamino%252Bacids%252Bfor%252Bdrug%252Bdesign%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2020%26volume%3D186%26spage%3D111826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Fantuzzi</span>, <span class="hlFld-ContribAuthor ">Maria  Tagliamonte</span>, <span class="hlFld-ContribAuthor ">Maria Cristina  Gauzzi</span>, <span class="hlFld-ContribAuthor ">Lucia  Lopalco</span>. </span><span class="cited-content_cbyCitation_article-title">Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. </span><span class="cited-content_cbyCitation_journal-name">Cellular and Molecular Life Sciences</span><span> <strong>2019,</strong> <em>76 </em>
                                    (24)
                                     , 4869-4886. <a href="https://doi.org/10.1007/s00018-019-03255-6" title="DOI URL">https://doi.org/10.1007/s00018-019-03255-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00018-019-03255-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00018-019-03255-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520and%2520Molecular%2520Life%2520Sciences%26atitle%3DDual%252BCCR5%25252FCCR2%252Btargeting%25253A%252Bopportunities%252Bfor%252Bthe%252Bcure%252Bof%252Bcomplex%252Bdisorders%26aulast%3DFantuzzi%26aufirst%3DLaura%26date%3D2019%26date%3D2019%26volume%3D76%26issue%3D24%26spage%3D4869%26epage%3D4886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vladimir  Bobkov</span>, <span class="hlFld-ContribAuthor ">Marta  Arimont</span>, <span class="hlFld-ContribAuthor ">AurÃ©lien  Zarca</span>, <span class="hlFld-ContribAuthor ">Timo W.M.  De Groof</span>, <span class="hlFld-ContribAuthor ">Bas  van der Woning</span>, <span class="hlFld-ContribAuthor ">Hans  de Haard</span>, <span class="hlFld-ContribAuthor ">Martine J.  Smit</span>. </span><span class="cited-content_cbyCitation_article-title">Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2019,</strong> <em>96 </em>
                                    (6)
                                     , 753-764. <a href="https://doi.org/10.1124/mol.119.116954" title="DOI URL">https://doi.org/10.1124/mol.119.116954</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/mol.119.116954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmol.119.116954%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DAntibodies%252BTargeting%252BChemokine%252BReceptors%252BCXCR4%252Band%252BACKR3%26aulast%3DBobkov%26aufirst%3DVladimir%26date%3D2019%26date%3D2019%26volume%3D96%26issue%3D6%26spage%3D753%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer  Goldblatt</span>, <span class="hlFld-ContribAuthor ">Richard Ashley  Lawrenson</span>, <span class="hlFld-ContribAuthor ">Luke  Muir</span>, <span class="hlFld-ContribAuthor ">Saloni  Dattani</span>, <span class="hlFld-ContribAuthor ">Ashley  Hoffland</span>, <span class="hlFld-ContribAuthor ">Tomoko  Tsuchiya</span>, <span class="hlFld-ContribAuthor ">Shiro  Kanegasaki</span>, <span class="hlFld-ContribAuthor ">Shiranee  Sriskandan</span>, <span class="hlFld-ContribAuthor ">James E.  Pease</span>. </span><span class="cited-content_cbyCitation_article-title">A Requirement for Neutrophil Glycosaminoglycans in Chemokine:Receptor Interactions Is Revealed by the Streptococcal Protease SpyCEP. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2019,</strong> <em>202 </em>
                                    (11)
                                     , 3246-3255. <a href="https://doi.org/10.4049/jimmunol.1801688" title="DOI URL">https://doi.org/10.4049/jimmunol.1801688</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1801688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1801688%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DA%252BRequirement%252Bfor%252BNeutrophil%252BGlycosaminoglycans%252Bin%252BChemokine%25253AReceptor%252BInteractions%252BIs%252BRevealed%252Bby%252Bthe%252BStreptococcal%252BProtease%252BSpyCEP%26aulast%3DGoldblatt%26aufirst%3DJennifer%26date%3D2019%26date%3D2019%26volume%3D202%26issue%3D11%26spage%3D3246%26epage%3D3255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna-Katharina  Apel</span>, <span class="hlFld-ContribAuthor ">Robert K.Y.  Cheng</span>, <span class="hlFld-ContribAuthor ">Christofer S.  Tautermann</span>, <span class="hlFld-ContribAuthor ">Michael  Brauchle</span>, <span class="hlFld-ContribAuthor ">Chia-Ying  Huang</span>, <span class="hlFld-ContribAuthor ">Alexander  Pautsch</span>, <span class="hlFld-ContribAuthor ">Michael  Hennig</span>, <span class="hlFld-ContribAuthor ">Herbert  Nar</span>, <span class="hlFld-ContribAuthor ">Gisela  Schnapp</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal Structure of CC Chemokine Receptor 2A in Complex with an Orthosteric Antagonist Provides Insights for the Design of Selective Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Structure</span><span> <strong>2019,</strong> <em>27 </em>
                                    (3)
                                     , 427-438.e5. <a href="https://doi.org/10.1016/j.str.2018.10.027" title="DOI URL">https://doi.org/10.1016/j.str.2018.10.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.str.2018.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.str.2018.10.027%26sid%3Dliteratum%253Aachs%26jtitle%3DStructure%26atitle%3DCrystal%252BStructure%252Bof%252BCC%252BChemokine%252BReceptor%252B2A%252Bin%252BComplex%252Bwith%252Ban%252BOrthosteric%252BAntagonist%252BProvides%252BInsights%252Bfor%252Bthe%252BDesign%252Bof%252BSelective%252BAntagonists%26aulast%3DApel%26aufirst%3DAnna-Katharina%26date%3D2019%26volume%3D27%26issue%3D3%26spage%3D427%26epage%3D438.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sk Abdul  Amin</span>, <span class="hlFld-ContribAuthor ">Nilanjan  Adhikari</span>, <span class="hlFld-ContribAuthor ">Sandip Kumar  Baidya</span>, <span class="hlFld-ContribAuthor ">Shovanlal  Gayen</span>, <span class="hlFld-ContribAuthor ">Tarun  Jha</span>. </span><span class="cited-content_cbyCitation_article-title">Structural refinement and prediction of potential CCR2 antagonists through validated multi-QSAR modeling studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em>37 </em>
                                    (1)
                                     , 75-94. <a href="https://doi.org/10.1080/07391102.2017.1418679" title="DOI URL">https://doi.org/10.1080/07391102.2017.1418679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2017.1418679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2017.1418679%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DStructural%252Brefinement%252Band%252Bprediction%252Bof%252Bpotential%252BCCR2%252Bantagonists%252Bthrough%252Bvalidated%252Bmulti-QSAR%252Bmodeling%252Bstudies%26aulast%3DAmin%26aufirst%3DSk%2BAbdul%26date%3D2019%26date%3D2018%26volume%3D37%26issue%3D1%26spage%3D75%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Argyle</span>, <span class="hlFld-ContribAuthor ">Takanori  Kitamura</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fimmu.2018.02629" title="DOI URL">https://doi.org/10.3389/fimmu.2018.02629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2018.02629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2018.02629%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DTargeting%252BMacrophage-Recruiting%252BChemokines%252Bas%252Ba%252BNovel%252BTherapeutic%252BStrategy%252Bto%252BPrevent%252Bthe%252BProgression%252Bof%252BSolid%252BTumors%26aulast%3DArgyle%26aufirst%3DDavid%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-Huai  Qin</span>, <span class="hlFld-ContribAuthor ">Zhi-Long  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Xie</span>, <span class="hlFld-ContribAuthor ">Ya-Qiu  Long</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (12)
                                     , 3559-3572. <a href="https://doi.org/10.1016/j.bmc.2018.05.027" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.05.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.05.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bsynthesis%252Bof%252B6%25252C7%25252C8%25252C9-tetrahydro-5H-pyrido%25255B4%25252C3-c%25255Dazepin-5-one-based%252Bnovel%252Bchemotype%252BCCR2%252Bantagonists%252Bvia%252Bscaffold%252Bhopping%252Bstrategy%26aulast%3DQin%26aufirst%3DLi-Huai%26date%3D2018%26volume%3D26%26issue%3D12%26spage%3D3559%26epage%3D3572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jason B.  Cross</span>, <span class="hlFld-ContribAuthor ">Jan  Romero</span>, <span class="hlFld-ContribAuthor ">Alexander  Heifetz</span>, <span class="hlFld-ContribAuthor ">Eric  Humphries</span>, <span class="hlFld-ContribAuthor ">Katie  Hall</span>, <span class="hlFld-ContribAuthor ">Yuchuan  Wu</span>, <span class="hlFld-ContribAuthor ">Sabrina  Stucka</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Haoqun  Chandonnet</span>, <span class="hlFld-ContribAuthor ">Blaise  Lippa</span>, <span class="hlFld-ContribAuthor ">M. Dominic  Ryan</span>, <span class="hlFld-ContribAuthor ">J. Christian  Baber</span>. </span><span class="cited-content_cbyCitation_article-title">In-silico guided discovery of novel CCR9 antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2018,</strong> <em>32 </em>
                                    (4)
                                     , 573-582. <a href="https://doi.org/10.1007/s10822-018-0113-2" title="DOI URL">https://doi.org/10.1007/s10822-018-0113-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-018-0113-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-018-0113-2%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DIn-silico%252Bguided%252Bdiscovery%252Bof%252Bnovel%252BCCR9%252Bantagonists%26aulast%3DZhang%26aufirst%3DXin%26date%3D2018%26date%3D2018%26volume%3D32%26issue%3D4%26spage%3D573%26epage%3D582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maxime  De Laere</span>, <span class="hlFld-ContribAuthor ">Zwi N  Berneman</span>, <span class="hlFld-ContribAuthor ">Nathalie  Cools</span>. </span><span class="cited-content_cbyCitation_article-title">To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuropathology & Experimental Neurology</span><span> <strong>2018,</strong> <em>77 </em>
                                    (3)
                                     , 178-192. <a href="https://doi.org/10.1093/jnen/nlx114" title="DOI URL">https://doi.org/10.1093/jnen/nlx114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/jnen/nlx114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fjnen%2Fnlx114%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuropathology%2520%2526%2520Experimental%2520Neurology%26atitle%3DTo%252Bthe%252BBrain%252Band%252BBack%25253A%252BMigratory%252BPaths%252Bof%252BDendritic%252BCells%252Bin%252BMultiple%252BSclerosis%26aulast%3DDe%2BLaere%26aufirst%3DMaxime%26date%3D2018%26date%3D2018%26volume%3D77%26issue%3D3%26spage%3D178%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Horuk</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokine Receptor CCR1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1065-1074. <a href="https://doi.org/10.1007/978-3-319-67199-4_406" title="DOI URL">https://doi.org/10.1007/978-3-319-67199-4_406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-67199-4_406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-67199-4_406%26sid%3Dliteratum%253Aachs%26atitle%3DChemokine%252BReceptor%252BCCR1%26aulast%3DHoruk%26aufirst%3DRichard%26date%3D2018%26date%3D2018%26spage%3D1065%26epage%3D1074%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DEncyclopedia%252Bof%252BSignaling%252BMolecules%26aulast%3DChoi%26aufirst%3DSangdun%26date%3D2018%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohaned  Ahmed</span>, <span class="hlFld-ContribAuthor ">Haneen A.  Basheer</span>, <span class="hlFld-ContribAuthor ">Jose M.  Ayuso</span>, <span class="hlFld-ContribAuthor ">Djevdet  Ahmet</span>, <span class="hlFld-ContribAuthor ">Marco  Mazzini</span>, <span class="hlFld-ContribAuthor ">Roshan  Patel</span>, <span class="hlFld-ContribAuthor ">Steven D.  Shnyder</span>, <span class="hlFld-ContribAuthor ">Victoria  Vinader</span>, <span class="hlFld-ContribAuthor ">Kamyar  Afarinkia</span>. </span><span class="cited-content_cbyCitation_article-title">Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-00949-4" title="DOI URL">https://doi.org/10.1038/s41598-017-00949-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-00949-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-00949-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DAgarose%252BSpot%252Bas%252Ba%252BComparative%252BMethod%252Bfor%252Bin%252Bsitu%252BAnalysis%252Bof%252BSimultaneous%252BChemotactic%252BResponses%252Bto%252BMultiple%252BChemokines%26aulast%3DAhmed%26aufirst%3DMohaned%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivan  Guryanov</span>, <span class="hlFld-ContribAuthor ">Sabrina  Cipriani</span>, <span class="hlFld-ContribAuthor ">Stefano  Fiorucci</span>, <span class="hlFld-ContribAuthor ">Natalia  Zashikhina</span>, <span class="hlFld-ContribAuthor ">Silvia  MarchianÃ²</span>, <span class="hlFld-ContribAuthor ">Paolo  Scarpelli</span>, <span class="hlFld-ContribAuthor ">Viktor  Korzhikov-Vlakh</span>, <span class="hlFld-ContribAuthor ">Ekaterina  Popova</span>, <span class="hlFld-ContribAuthor ">Evgenia  Korzhikova-Vlakh</span>, <span class="hlFld-ContribAuthor ">Barbara  Biondi</span>, <span class="hlFld-ContribAuthor ">Fernando  Formaggio</span>, <span class="hlFld-ContribAuthor ">Tatiana  Tennikova</span>. </span><span class="cited-content_cbyCitation_article-title">Nanotraps with biomimetic surface as decoys for chemokines. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine: Nanotechnology, Biology and Medicine</span><span> <strong>2017,</strong> <em>13 </em>
                                    (8)
                                     , 2575-2585. <a href="https://doi.org/10.1016/j.nano.2017.07.006" title="DOI URL">https://doi.org/10.1016/j.nano.2017.07.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nano.2017.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nano.2017.07.006%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%253A%2520Nanotechnology%252C%2520Biology%2520and%2520Medicine%26atitle%3DNanotraps%252Bwith%252Bbiomimetic%252Bsurface%252Bas%252Bdecoys%252Bfor%252Bchemokines%26aulast%3DGuryanov%26aufirst%3DIvan%26date%3D2017%26volume%3D13%26issue%3D8%26spage%3D2575%26epage%3D2585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Jun  Zhang</span>, <span class="hlFld-ContribAuthor ">Bao-Chun  Jiang</span>, <span class="hlFld-ContribAuthor ">Yong-Jing  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokines in neuronâglial cell interaction and pathogenesis of neuropathic pain. </span><span class="cited-content_cbyCitation_journal-name">Cellular and Molecular Life Sciences</span><span> <strong>2017,</strong> <em>74 </em>
                                    (18)
                                     , 3275-3291. <a href="https://doi.org/10.1007/s00018-017-2513-1" title="DOI URL">https://doi.org/10.1007/s00018-017-2513-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00018-017-2513-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00018-017-2513-1%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520and%2520Molecular%2520Life%2520Sciences%26atitle%3DChemokines%252Bin%252Bneuron%2525E2%252580%252593glial%252Bcell%252Binteraction%252Band%252Bpathogenesis%252Bof%252Bneuropathic%252Bpain%26aulast%3DZhang%26aufirst%3DZhi-Jun%26date%3D2017%26date%3D2017%26volume%3D74%26issue%3D18%26spage%3D3275%26epage%3D3291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irina  Kufareva</span>, <span class="hlFld-ContribAuthor ">Martin  Gustavsson</span>, <span class="hlFld-ContribAuthor ">Yi  Zheng</span>, <span class="hlFld-ContribAuthor ">Bryan S.  Stephens</span>, <span class="hlFld-ContribAuthor ">Tracy M.  Handel</span>. </span><span class="cited-content_cbyCitation_article-title">What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Biophysics</span><span> <strong>2017,</strong> <em>46 </em>
                                    (1)
                                     , 175-198. <a href="https://doi.org/10.1146/annurev-biophys-051013-022942" title="DOI URL">https://doi.org/10.1146/annurev-biophys-051013-022942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-biophys-051013-022942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-biophys-051013-022942%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Biophysics%26atitle%3DWhat%252BDo%252BStructures%252BTell%252BUs%252BAbout%252BChemokine%252BReceptor%252BFunction%252Band%252BAntagonism%25253F%26aulast%3DKufareva%26aufirst%3DIrina%26date%3D2017%26volume%3D46%26issue%3D1%26spage%3D175%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vincent  Vanheule</span>, <span class="hlFld-ContribAuthor ">Daiane  Boff</span>, <span class="hlFld-ContribAuthor ">Anneleen  Mortier</span>, <span class="hlFld-ContribAuthor ">Rik  Janssens</span>, <span class="hlFld-ContribAuthor ">BjÃ¶rn  Petri</span>, <span class="hlFld-ContribAuthor ">Elzbieta  Kolaczkowska</span>, <span class="hlFld-ContribAuthor ">Paul  Kubes</span>, <span class="hlFld-ContribAuthor ">Nele  Berghmans</span>, <span class="hlFld-ContribAuthor ">Sofie  Struyf</span>, <span class="hlFld-ContribAuthor ">Andreas J.  Kungl</span>, <span class="hlFld-ContribAuthor ">Mauro Martins  Teixeira</span>, <span class="hlFld-ContribAuthor ">Flavio Almeida  Amaral</span>, <span class="hlFld-ContribAuthor ">Paul  Proost</span>. </span><span class="cited-content_cbyCitation_article-title">CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2017,</strong> <em>8 </em><a href="https://doi.org/10.3389/fimmu.2017.00530" title="DOI URL">https://doi.org/10.3389/fimmu.2017.00530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2017.00530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2017.00530%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DCXCL9-Derived%252BPeptides%252BDifferentially%252BInhibit%252BNeutrophil%252BMigration%252BIn%252BVivo%252Bthrough%252BInterference%252Bwith%252BGlycosaminoglycan%252BInteractions%26aulast%3DVanheule%26aufirst%3DVincent%26date%3D2017%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba A.  Abd El Razik</span>, <span class="hlFld-ContribAuthor ">Mona H.  Badr</span>, <span class="hlFld-ContribAuthor ">Attia H.  Atta</span>, <span class="hlFld-ContribAuthor ">Samar M.  Mouneir</span>, <span class="hlFld-ContribAuthor ">Marwa M.  Abu-Serie</span>. </span><span class="cited-content_cbyCitation_article-title">Benzodioxole-Pyrazole Hybrids as Anti-Inflammatory and Analgesic Agents with COX-1,2/5-LOX Inhibition and Antioxidant Potential. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2017,</strong> <em>350 </em>
                                    (5)
                                     , 1700026. <a href="https://doi.org/10.1002/ardp.201700026" title="DOI URL">https://doi.org/10.1002/ardp.201700026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201700026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201700026%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DBenzodioxole-Pyrazole%252BHybrids%252Bas%252BAnti-Inflammatory%252Band%252BAnalgesic%252BAgents%252Bwith%252BCOX-1%25252C2%25252F5-LOX%252BInhibition%252Band%252BAntioxidant%252BPotential%26aulast%3DAbd%2BEl%2BRazik%26aufirst%3DHeba%2BA.%26date%3D2017%26date%3D2017%26volume%3D350%26issue%3D5%26spage%3D1700026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James E.  Pease</span>. </span><span class="cited-content_cbyCitation_article-title">Designing small molecule CXCR3 antagonists. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2017,</strong> <em>12 </em>
                                    (2)
                                     , 159-168. <a href="https://doi.org/10.1080/17460441.2017.1268597" title="DOI URL">https://doi.org/10.1080/17460441.2017.1268597</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2017.1268597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2017.1268597%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DDesigning%252Bsmall%252Bmolecule%252BCXCR3%252Bantagonists%26aulast%3DPease%26aufirst%3DJames%2BE.%26date%3D2017%26date%3D2016%26volume%3D12%26issue%3D2%26spage%3D159%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Stone</span>, <span class="hlFld-ContribAuthor ">Jenni  Hayward</span>, <span class="hlFld-ContribAuthor ">Cheng  Huang</span>, <span class="hlFld-ContribAuthor ">Zil  E. Huma</span>, <span class="hlFld-ContribAuthor ">Julie  Sanchez</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Regulation of the Chemokine-Receptor Network. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2017,</strong> <em>18 </em>
                                    (2)
                                     , 342. <a href="https://doi.org/10.3390/ijms18020342" title="DOI URL">https://doi.org/10.3390/ijms18020342</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms18020342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms18020342%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMechanisms%252Bof%252BRegulation%252Bof%252Bthe%252BChemokine-Receptor%252BNetwork%26aulast%3DStone%26aufirst%3DMartin%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D2%26spage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Congreve</span>, <span class="hlFld-ContribAuthor ">A.  Bortolato</span>, <span class="hlFld-ContribAuthor ">G.  Brown</span>, <span class="hlFld-ContribAuthor ">R.M.  Cooke</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling and Design for Membrane Protein Targets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 145-188. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12358-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12358-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12358-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12358-3%26sid%3Dliteratum%253Aachs%26atitle%3DModeling%252Band%252BDesign%252Bfor%252BMembrane%252BProtein%252BTargets%26aulast%3DCongreve%26aufirst%3DM.%26date%3D2017%26spage%3D145%26epage%3D188%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T.G. Murali  Dhar</span>, <span class="hlFld-ContribAuthor ">A.J.  Dyckman</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of Small-Molecule Immunology ResearchâChanges Since CMC II. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 395-419. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12401-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12401-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12401-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12401-1%26sid%3Dliteratum%253Aachs%26atitle%3DEvolution%252Bof%252BSmall-Molecule%252BImmunology%252BResearch%2525E2%252580%252594Changes%252BSince%252BCMC%252BII%26aulast%3DDhar%26aufirst%3DT.G.%2BMurali%26date%3D2017%26spage%3D395%26epage%3D419%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Zheng</span>, <span class="hlFld-ContribAuthor ">Ling  Qin</span>, <span class="hlFld-ContribAuthor ">Natalia V. Ortiz  ZacarÃ­as</span>, <span class="hlFld-ContribAuthor ">Henk  de Vries</span>, <span class="hlFld-ContribAuthor ">Gye Won  Han</span>, <span class="hlFld-ContribAuthor ">Martin  Gustavsson</span>, <span class="hlFld-ContribAuthor ">Marta  Dabros</span>, <span class="hlFld-ContribAuthor ">Chunxia  Zhao</span>, <span class="hlFld-ContribAuthor ">Robert J.  Cherney</span>, <span class="hlFld-ContribAuthor ">Percy  Carter</span>, <span class="hlFld-ContribAuthor ">Dean  Stamos</span>, <span class="hlFld-ContribAuthor ">Ruben  Abagyan</span>, <span class="hlFld-ContribAuthor ">Vadim  Cherezov</span>, <span class="hlFld-ContribAuthor ">Raymond C.  Stevens</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>, <span class="hlFld-ContribAuthor ">Laura H.  Heitman</span>, <span class="hlFld-ContribAuthor ">Andrew  Tebben</span>, <span class="hlFld-ContribAuthor ">Irina  Kufareva</span>, <span class="hlFld-ContribAuthor ">Tracy M.  Handel</span>. </span><span class="cited-content_cbyCitation_article-title">Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2016,</strong> <em>540 </em>
                                    (7633)
                                     , 458-461. <a href="https://doi.org/10.1038/nature20605" title="DOI URL">https://doi.org/10.1038/nature20605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nature20605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnature20605%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DStructure%252Bof%252BCC%252Bchemokine%252Breceptor%252B2%252Bwith%252Borthosteric%252Band%252Ballosteric%252Bantagonists%26aulast%3DZheng%26aufirst%3DYi%26date%3D2016%26date%3D2016%26volume%3D540%26issue%3D7633%26spage%3D458%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine  Oswald</span>, <span class="hlFld-ContribAuthor ">Mathieu  Rappas</span>, <span class="hlFld-ContribAuthor ">James  Kean</span>, <span class="hlFld-ContribAuthor ">Andrew S.  DorÃ©</span>, <span class="hlFld-ContribAuthor ">James C.  Errey</span>, <span class="hlFld-ContribAuthor ">Kirstie  Bennett</span>, <span class="hlFld-ContribAuthor ">Francesca  Deflorian</span>, <span class="hlFld-ContribAuthor ">John A.  Christopher</span>, <span class="hlFld-ContribAuthor ">Ali  Jazayeri</span>, <span class="hlFld-ContribAuthor ">Jonathan S.  Mason</span>, <span class="hlFld-ContribAuthor ">Miles  Congreve</span>, <span class="hlFld-ContribAuthor ">Robert M.  Cooke</span>, <span class="hlFld-ContribAuthor ">Fiona H.  Marshall</span>. </span><span class="cited-content_cbyCitation_article-title">Intracellular allosteric antagonism of the CCR9 receptor. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2016,</strong> <em>540 </em>
                                    (7633)
                                     , 462-465. <a href="https://doi.org/10.1038/nature20606" title="DOI URL">https://doi.org/10.1038/nature20606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nature20606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnature20606%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DIntracellular%252Ballosteric%252Bantagonism%252Bof%252Bthe%252BCCR9%252Breceptor%26aulast%3DOswald%26aufirst%3DChristine%26date%3D2016%26date%3D2016%26volume%3D540%26issue%3D7633%26spage%3D462%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galina N.  Lipunova</span>, <span class="hlFld-ContribAuthor ">Emiliya V.  Nosova</span>, <span class="hlFld-ContribAuthor ">Valery N.  Charushin</span>, <span class="hlFld-ContribAuthor ">Oleg N.  Chupakhin</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-containing indazoles: Synthesis and biological activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2016,</strong> <em>192 </em>, 1-21. <a href="https://doi.org/10.1016/j.jfluchem.2016.10.007" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2016.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2016.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2016.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DFluorine-containing%252Bindazoles%25253A%252BSynthesis%252Band%252Bbiological%252Bactivity%26aulast%3DLipunova%26aufirst%3DGalina%2BN.%26date%3D2016%26volume%3D192%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle B.  Kim</span>, <span class="hlFld-ContribAuthor ">Kyle E.  Giesler</span>, <span class="hlFld-ContribAuthor ">Yesim A.  Tahirovic</span>, <span class="hlFld-ContribAuthor ">Valarie M.  Truax</span>, <span class="hlFld-ContribAuthor ">Dennis C.  Liotta</span>, <span class="hlFld-ContribAuthor ">Lawrence J.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2016,</strong> <em>25 </em>
                                    (12)
                                     , 1377-1392. <a href="https://doi.org/10.1080/13543784.2016.1254615" title="DOI URL">https://doi.org/10.1080/13543784.2016.1254615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2016.1254615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2016.1254615%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DCCR5%252Breceptor%252Bantagonists%252Bin%252Bpreclinical%252Bto%252Bphase%252BII%252Bclinical%252Bdevelopment%252Bfor%252Btreatment%252Bof%252BHIV%26aulast%3DKim%26aufirst%3DMichelle%2BB.%26date%3D2016%26date%3D2016%26volume%3D25%26issue%3D12%26spage%3D1377%26epage%3D1392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olga  Schulz</span>, <span class="hlFld-ContribAuthor ">Swantje I.  Hammerschmidt</span>, <span class="hlFld-ContribAuthor ">G. Leandros  Moschovakis</span>, <span class="hlFld-ContribAuthor ">Reinhold  FÃ¶rster</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokines and Chemokine Receptors in Lymphoid Tissue Dynamics. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Immunology</span><span> <strong>2016,</strong> <em>34 </em>
                                    (1)
                                     , 203-242. <a href="https://doi.org/10.1146/annurev-immunol-041015-055649" title="DOI URL">https://doi.org/10.1146/annurev-immunol-041015-055649</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-immunol-041015-055649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-immunol-041015-055649%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Immunology%26atitle%3DChemokines%252Band%252BChemokine%252BReceptors%252Bin%252BLymphoid%252BTissue%252BDynamics%26aulast%3DSchulz%26aufirst%3DOlga%26date%3D2016%26volume%3D34%26issue%3D1%26spage%3D203%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Fabao  Zhao</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>114 </em>, 65-78. <a href="https://doi.org/10.1016/j.ejmech.2016.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnon-peptide%252Bsmall%252Bmolecular%252BCXCR4%252Bantagonists%252Bas%252Banti-HIV%252Bagents%25253A%252BRecent%252Badvances%252Band%252Bfuture%252Bopportunities%26aulast%3DZhang%26aufirst%3DHeng%26date%3D2016%26volume%3D114%26spage%3D65%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Horuk</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokine Receptor CCR1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 1-9. <a href="https://doi.org/10.1007/978-1-4614-6438-9_406-1" title="DOI URL">https://doi.org/10.1007/978-1-4614-6438-9_406-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4614-6438-9_406-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4614-6438-9_406-1%26sid%3Dliteratum%253Aachs%26atitle%3DChemokine%252BReceptor%252BCCR1%26aulast%3DHoruk%26aufirst%3DRichard%26date%3D2016%26date%3D2016%26spage%3D1%26epage%3D9%26pub%3DSpringer%2520New%2520York%26atitle%3DEncyclopedia%252Bof%252BSignaling%252BMolecules%26aulast%3DChoi%26aufirst%3DSangdun%26date%3D2016%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Horuk</span>. </span><span class="cited-content_cbyCitation_article-title">CCR1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 260-268. <a href="https://doi.org/10.1007/978-3-7643-8550-7_153" title="DOI URL">https://doi.org/10.1007/978-3-7643-8550-7_153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-7643-8550-7_153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-7643-8550-7_153%26sid%3Dliteratum%253Aachs%26atitle%3DCCR1%26aulast%3DHoruk%26aufirst%3DRichard%26date%3D2016%26date%3D2017%26spage%3D260%26epage%3D268%26pub%3DSpringer%2520Basel%26atitle%3DCompendium%252Bof%252BInflammatory%252BDiseases%26aulast%3DParnham%26aufirst%3DMichael%2BJ.%26date%3D2016%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naatasha  Isahak</span>, <span class="hlFld-ContribAuthor ">Julie  Sanchez</span>, <span class="hlFld-ContribAuthor ">SÃ©bastien  Perrier</span>, <span class="hlFld-ContribAuthor ">Martin J.  Stone</span>, <span class="hlFld-ContribAuthor ">Richard J.  Payne</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of polymers and nanoparticles bearing polystyrene sulfonate brushes for chemokine binding. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2016,</strong> <em>14 </em>
                                    (24)
                                     , 5652-5658. <a href="https://doi.org/10.1039/C6OB00270F" title="DOI URL">https://doi.org/10.1039/C6OB00270F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6OB00270F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6OB00270F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bpolymers%252Band%252Bnanoparticles%252Bbearing%252Bpolystyrene%252Bsulfonate%252Bbrushes%252Bfor%252Bchemokine%252Bbinding%26aulast%3DIsahak%26aufirst%3DNaatasha%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D24%26spage%3D5652%26epage%3D5658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saggere Muralikrishna  Shasthry</span>, <span class="hlFld-ContribAuthor ">Shiv Kumar  Sarin</span>. </span><span class="cited-content_cbyCitation_article-title">New treatment options for alcoholic hepatitis. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2016,</strong> <em>22 </em>
                                    (15)
                                     , 3892. <a href="https://doi.org/10.3748/wjg.v22.i15.3892" title="DOI URL">https://doi.org/10.3748/wjg.v22.i15.3892</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v22.i15.3892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v22.i15.3892%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DNew%252Btreatment%252Boptions%252Bfor%252Balcoholic%252Bhepatitis%26aulast%3DShasthry%26aufirst%3DSaggere%2BMuralikrishna%26date%3D2016%26volume%3D22%26issue%3D15%26spage%3D3892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marija  Mladic</span>, <span class="hlFld-ContribAuthor ">Danny J.  Scholten</span>, <span class="hlFld-ContribAuthor ">Wilfried M.A.  Niessen</span>, <span class="hlFld-ContribAuthor ">Govert W.  Somsen</span>, <span class="hlFld-ContribAuthor ">Martine J.  Smit</span>, <span class="hlFld-ContribAuthor ">Jeroen  Kool</span>. </span><span class="cited-content_cbyCitation_article-title">At-line coupling of LCâMS to bioaffinity and selectivity assessment for metabolic profiling of ligands towards chemokine receptors CXCR1 and CXCR2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography B</span><span> <strong>2015,</strong> <em>1002 </em>, 42-53. <a href="https://doi.org/10.1016/j.jchromb.2015.08.004" title="DOI URL">https://doi.org/10.1016/j.jchromb.2015.08.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jchromb.2015.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jchromb.2015.08.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520B%26atitle%3DAt-line%252Bcoupling%252Bof%252BLC%2525E2%252580%252593MS%252Bto%252Bbioaffinity%252Band%252Bselectivity%252Bassessment%252Bfor%252Bmetabolic%252Bprofiling%252Bof%252Bligands%252Btowards%252Bchemokine%252Breceptors%252BCXCR1%252Band%252BCXCR2%26aulast%3DMladic%26aufirst%3DMarija%26date%3D2015%26volume%3D1002%26spage%3D42%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ann Kathrin  Strunz</span>, <span class="hlFld-ContribAuthor ">Annelien J.M.  Zweemer</span>, <span class="hlFld-ContribAuthor ">Christina  Weiss</span>, <span class="hlFld-ContribAuthor ">Dirk  Schepmann</span>, <span class="hlFld-ContribAuthor ">Anna  Junker</span>, <span class="hlFld-ContribAuthor ">Laura H.  Heitman</span>, <span class="hlFld-ContribAuthor ">Michael  Koch</span>, <span class="hlFld-ContribAuthor ">Bernhard  WÃ¼nsch</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (14)
                                     , 4034-4049. <a href="https://doi.org/10.1016/j.bmc.2015.02.019" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bspirocyclic%252Bantagonists%252Bof%252BCCR2%252B%252528chemokine%252BCC%252Breceptor%252Bsubtype%252B2%252529%26aulast%3DStrunz%26aufirst%3DAnn%2BKathrin%26date%3D2015%26volume%3D23%26issue%3D14%26spage%3D4034%26epage%3D4049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design Strategies for Targeting G-Protein-Coupled Receptors (GPCRs). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 199-216. <a href="https://doi.org/10.1002/9783527665211.ch9" title="DOI URL">https://doi.org/10.1002/9783527665211.ch9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527665211.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527665211.ch9%26sid%3Dliteratum%253Aachs%26atitle%3DStructure-Based%252BDesign%252BStrategies%252Bfor%252BTargeting%252BG-Protein-Coupled%252BReceptors%252B%252528GPCRs%252529%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2015%26date%3D2015%26spage%3D199%26epage%3D216%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DStructure-Based%252BDesign%252Bof%252BDrugs%252Band%252BOther%252BBioactive%252BMolecules%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Belinda  Nedjai</span>, <span class="hlFld-ContribAuthor ">Jonathan M  Viney</span>, <span class="hlFld-ContribAuthor ">Hubert  Li</span>, <span class="hlFld-ContribAuthor ">Caroline  Hull</span>, <span class="hlFld-ContribAuthor ">Caroline A  Anderson</span>, <span class="hlFld-ContribAuthor ">Tomoki  Horie</span>, <span class="hlFld-ContribAuthor ">Richard  Horuk</span>, <span class="hlFld-ContribAuthor ">Nagarajan  Vaidehi</span>, <span class="hlFld-ContribAuthor ">James E  Pease</span>. </span><span class="cited-content_cbyCitation_article-title">CXCR
              3 antagonist
              VUF
              10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist
              TAK
              â779. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2015,</strong> <em>172 </em>
                                    (7)
                                     , 1822-1833. <a href="https://doi.org/10.1111/bph.13027" title="DOI URL">https://doi.org/10.1111/bph.13027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.13027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.13027%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DCXCR%252B3%252Bantagonist%252BVUF%252B10085%252Bbinds%252Bto%252Ban%252Bintrahelical%252Bsite%252Bdistinct%252Bfrom%252Bthat%252Bof%252Bthe%252Bbroad%252Bspectrum%252Bantagonist%252BTAK%252B%2525E2%252580%252590779%26aulast%3DNedjai%26aufirst%3DBelinda%26date%3D2015%26date%3D2015%26volume%3D172%26issue%3D7%26spage%3D1822%26epage%3D1833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nkateko M.I.  Mayevu</span>, <span class="hlFld-ContribAuthor ">Han  Choe</span>, <span class="hlFld-ContribAuthor ">Ruben  Abagyan</span>, <span class="hlFld-ContribAuthor ">Jae Young  Seong</span>, <span class="hlFld-ContribAuthor ">Robert P.  Millar</span>, <span class="hlFld-ContribAuthor ">Arieh A.  Katz</span>, <span class="hlFld-ContribAuthor ">Colleen A.  Flanagan</span>. </span><span class="cited-content_cbyCitation_article-title">Histidine7.36(305) in the conserved peptide receptor activation domain of the gonadotropin releasing hormone receptor couples peptide binding and receptor activation. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Endocrinology</span><span> <strong>2015,</strong> <em>402 </em>, 95-106. <a href="https://doi.org/10.1016/j.mce.2015.01.008" title="DOI URL">https://doi.org/10.1016/j.mce.2015.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mce.2015.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mce.2015.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Endocrinology%26atitle%3DHistidine7.36%252528305%252529%252Bin%252Bthe%252Bconserved%252Bpeptide%252Breceptor%252Bactivation%252Bdomain%252Bof%252Bthe%252Bgonadotropin%252Breleasing%252Bhormone%252Breceptor%252Bcouples%252Bpeptide%252Bbinding%252Band%252Breceptor%252Bactivation%26aulast%3DMayevu%26aufirst%3DNkateko%2BM.I.%26date%3D2015%26volume%3D402%26spage%3D95%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evan A.  Yost</span>, <span class="hlFld-ContribAuthor ">Thomas R.  Hynes</span>, <span class="hlFld-ContribAuthor ">Cassandra M.  Hartle</span>, <span class="hlFld-ContribAuthor ">Braden J.  Ott</span>, <span class="hlFld-ContribAuthor ">Catherine H.  Berlot</span>, . </span><span class="cited-content_cbyCitation_article-title">Inhibition of G-Protein Î²Î³ Signaling Enhances T Cell Receptor-Stimulated Interleukin 2 Transcription in CD4+ T Helper Cells. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2015,</strong> <em>10 </em>
                                    (1)
                                     , e0116575. <a href="https://doi.org/10.1371/journal.pone.0116575" title="DOI URL">https://doi.org/10.1371/journal.pone.0116575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0116575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0116575%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DInhibition%252Bof%252BG-Protein%252B%2525CE%2525B2%2525CE%2525B3%252BSignaling%252BEnhances%252BT%252BCell%252BReceptor-Stimulated%252BInterleukin%252B2%252BTranscription%252Bin%252BCD4%25252B%252BT%252BHelper%252BCells%26aulast%3DYost%26aufirst%3DEvan%2BA.%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D1%26spage%3De0116575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan M.  Kriegl</span>, <span class="hlFld-ContribAuthor ">Domnic  Martyres</span>, <span class="hlFld-ContribAuthor ">Marc A.  Grundl</span>, <span class="hlFld-ContribAuthor ">Ralf  Anderskewitz</span>, <span class="hlFld-ContribAuthor ">Horst  Dollinger</span>, <span class="hlFld-ContribAuthor ">Georg  Rast</span>, <span class="hlFld-ContribAuthor ">Bernhard  Schmid</span>, <span class="hlFld-ContribAuthor ">Peter  Seither</span>, <span class="hlFld-ContribAuthor ">Christofer S.  Tautermann</span>. </span><span class="cited-content_cbyCitation_article-title">Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: Insights from a receptor model. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (2)
                                     , 229-235. <a href="https://doi.org/10.1016/j.bmcl.2014.11.063" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.11.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.11.063%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRodent%252Bselectivity%252Bof%252Bpiperidine-4-yl-1H-indoles%25252C%252Ba%252Bseries%252Bof%252BCC%252Bchemokine%252Breceptor-3%252B%252528CCR3%252529%252Bantagonists%25253A%252BInsights%252Bfrom%252Ba%252Breceptor%252Bmodel%26aulast%3DKriegl%26aufirst%3DJan%2BM.%26date%3D2015%26volume%3D25%26issue%3D2%26spage%3D229%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberto  Solari</span>, <span class="hlFld-ContribAuthor ">James E.  Pease</span>, <span class="hlFld-ContribAuthor ">Malcolm  Begg</span>. </span><span class="cited-content_cbyCitation_article-title">âChemokine receptors as therapeutic targets: Why arenât there more drugs?â. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2015,</strong> <em>746 </em>, 363-367. <a href="https://doi.org/10.1016/j.ejphar.2014.06.060" title="DOI URL">https://doi.org/10.1016/j.ejphar.2014.06.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2014.06.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2014.06.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3D%2525E2%252580%25259CChemokine%252Breceptors%252Bas%252Btherapeutic%252Btargets%25253A%252BWhy%252Baren%2525E2%252580%252599t%252Bthere%252Bmore%252Bdrugs%25253F%2525E2%252580%25259D%26aulast%3DSolari%26aufirst%3DRoberto%26date%3D2015%26volume%3D746%26spage%3D363%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changdev G.  Gadhe</span>, <span class="hlFld-ContribAuthor ">Mi-hyun  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies. </span><span class="cited-content_cbyCitation_journal-name">Molecular BioSystems</span><span> <strong>2015,</strong> <em>11 </em>
                                    (2)
                                     , 618-634. <a href="https://doi.org/10.1039/C4MB00568F" title="DOI URL">https://doi.org/10.1039/C4MB00568F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MB00568F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MB00568F%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520BioSystems%26atitle%3DInsights%252Binto%252Bthe%252Bbinding%252Bmodes%252Bof%252BCC%252Bchemokine%252Breceptor%252B4%252B%252528CCR4%252529%252Binhibitors%25253A%252Ba%252Bcombined%252Bapproach%252Binvolving%252Bhomology%252Bmodelling%25252C%252Bdocking%25252C%252Band%252Bmolecular%252Bdynamics%252Bsimulation%252Bstudies%26aulast%3DGadhe%26aufirst%3DChangdev%2BG.%26date%3D2015%26date%3D2015%26volume%3D11%26issue%3D2%26spage%3D618%26epage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Gao</span>, <span class="hlFld-ContribAuthor ">Mingjiang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokines and alcoholic hepatitis: are chemokines good therapeutic targets?. </span><span class="cited-content_cbyCitation_journal-name">Gut</span><span> <strong>2014,</strong> <em>63 </em>
                                    (11)
                                     , 1683-1684. <a href="https://doi.org/10.1136/gutjnl-2013-306603" title="DOI URL">https://doi.org/10.1136/gutjnl-2013-306603</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/gutjnl-2013-306603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fgutjnl-2013-306603%26sid%3Dliteratum%253Aachs%26jtitle%3DGut%26atitle%3DChemokines%252Band%252Balcoholic%252Bhepatitis%25253A%252Bare%252Bchemokines%252Bgood%252Btherapeutic%252Btargets%25253F%26aulast%3DGao%26aufirst%3DBin%26date%3D2014%26date%3D2014%26volume%3D63%26issue%3D11%26spage%3D1683%26epage%3D1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clare L  Tower</span>, <span class="hlFld-ContribAuthor ">Sylvia  Lui</span>, <span class="hlFld-ContribAuthor ">Rebecca L  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Are chemokines therapeutic targets for the prevention of preterm labor?. </span><span class="cited-content_cbyCitation_journal-name">Immunotherapy</span><span> <strong>2014,</strong> <em>6 </em>
                                    (8)
                                     , 901-904. <a href="https://doi.org/10.2217/imt.14.70" title="DOI URL">https://doi.org/10.2217/imt.14.70</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/imt.14.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fimt.14.70%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunotherapy%26atitle%3DAre%252Bchemokines%252Btherapeutic%252Btargets%252Bfor%252Bthe%252Bprevention%252Bof%252Bpreterm%252Blabor%25253F%26aulast%3DTower%26aufirst%3DClare%2BL%26date%3D2014%26volume%3D6%26issue%3D8%26spage%3D901%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James Edward  Pease</span>, <span class="hlFld-ContribAuthor ">Richard  Horuk</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2014,</strong> <em>9 </em>
                                    (5)
                                     , 467-483. <a href="https://doi.org/10.1517/17460441.2014.897324" title="DOI URL">https://doi.org/10.1517/17460441.2014.897324</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2014.897324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2014.897324%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DRecent%252Bprogress%252Bin%252Bthe%252Bdevelopment%252Bof%252Bantagonists%252Bto%252Bthe%252Bchemokine%252Breceptors%252BCCR3%252Band%252BCCR4%26aulast%3DPease%26aufirst%3DJames%2BEdward%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D5%26spage%3D467%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suri  Moonsamy</span>, <span class="hlFld-ContribAuthor ">Radha  Dash</span>, <span class="hlFld-ContribAuthor ">Mahmoud  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated Computational Tools for Identification of CCR5 Antagonists as Potential HIV-1 Entry Inhibitors: Homology Modeling, Virtual Screening, Molecular Dynamics Simulations and 3D QSAR Analysis. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2014,</strong> <em>19 </em>
                                    (4)
                                     , 5243-5265. <a href="https://doi.org/10.3390/molecules19045243" title="DOI URL">https://doi.org/10.3390/molecules19045243</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules19045243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules19045243%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIntegrated%252BComputational%252BTools%252Bfor%252BIdentification%252Bof%252BCCR5%252BAntagonists%252Bas%252BPotential%252BHIV-1%252BEntry%252BInhibitors%25253A%252BHomology%252BModeling%25252C%252BVirtual%252BScreening%25252C%252BMolecular%252BDynamics%252BSimulations%252Band%252B3D%252BQSAR%252BAnalysis%26aulast%3DMoonsamy%26aufirst%3DSuri%26date%3D2014%26date%3D2014%26volume%3D19%26issue%3D4%26spage%3D5243%26epage%3D5265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Junker</span>, <span class="hlFld-ContribAuthor ">Artur Kamil  Kokornaczyk</span>, <span class="hlFld-ContribAuthor ">Ann Kathrin  Strunz</span>, <span class="hlFld-ContribAuthor ">Bernhard  WÃ¼nsch</span>. </span><span class="cited-content_cbyCitation_article-title">Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 187-241. <a href="https://doi.org/10.1007/7355_2014_40" title="DOI URL">https://doi.org/10.1007/7355_2014_40</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2014_40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2014_40%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252Band%252BDual%252BTargeting%252Bof%252BCCR2%252Band%252BCCR5%252BReceptors%25253A%252BA%252BCurrent%252BOverview%26aulast%3DJunker%26aufirst%3DAnna%26date%3D2014%26date%3D2014%26spage%3D187%26epage%3D241%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DChemokines%26aulast%3DTschammer%26aufirst%3DNuska%26date%3D2015%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irina  Kufareva</span>, <span class="hlFld-ContribAuthor ">Ruben  Abagyan</span>, <span class="hlFld-ContribAuthor ">Tracy M.  Handel</span>. </span><span class="cited-content_cbyCitation_article-title">Role of 3D Structures in Understanding, Predicting, and Designing Molecular Interactions in the Chemokine Receptor Family. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 41-85. <a href="https://doi.org/10.1007/7355_2014_77" title="DOI URL">https://doi.org/10.1007/7355_2014_77</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2014_77&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2014_77%26sid%3Dliteratum%253Aachs%26atitle%3DRole%252Bof%252B3D%252BStructures%252Bin%252BUnderstanding%25252C%252BPredicting%25252C%252Band%252BDesigning%252BMolecular%252BInteractions%252Bin%252Bthe%252BChemokine%252BReceptor%252BFamily%26aulast%3DKufareva%26aufirst%3DIrina%26date%3D2014%26date%3D2014%26spage%3D41%26epage%3D85%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DChemokines%26aulast%3DTschammer%26aufirst%3DNuska%26date%3D2015%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colleen A.  Flanagan</span>. </span><span class="cited-content_cbyCitation_article-title">Receptor Conformation and Constitutive Activity in CCR5 Chemokine Receptor Function and HIV Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 215-263. <a href="https://doi.org/10.1016/B978-0-12-417197-8.00008-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-417197-8.00008-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-417197-8.00008-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-417197-8.00008-0%26sid%3Dliteratum%253Aachs%26atitle%3DReceptor%252BConformation%252Band%252BConstitutive%252BActivity%252Bin%252BCCR5%252BChemokine%252BReceptor%252BFunction%252Band%252BHIV%252BInfection%26aulast%3DFlanagan%26aufirst%3DColleen%2BA.%26date%3D2014%26spage%3D215%26epage%3D263%26pub%3DElsevier%26atitle%3DPharmacology%252B%252526%252BTherapeutics%252Bof%252BConstitutively%252BActive%252BReceptors%26date%3D2014%26volume%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Afjal H.  Miah</span>, <span class="hlFld-ContribAuthor ">Royston C. B.  Copley</span>, <span class="hlFld-ContribAuthor ">Daniel  O'Flynn</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Percy</span>, <span class="hlFld-ContribAuthor ">Panayiotis A.  Procopiou</span>. </span><span class="cited-content_cbyCitation_article-title">Lead identification and structureâactivity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2014,</strong> <em>12 </em>
                                    (11)
                                     , 1779. <a href="https://doi.org/10.1039/c3ob42443j" title="DOI URL">https://doi.org/10.1039/c3ob42443j</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c3ob42443j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc3ob42443j%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DLead%252Bidentification%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Bheteroarylpyrazole%252Barylsulfonamides%252Bas%252Ballosteric%252BCC-chemokine%252Breceptor%252B4%252B%252528CCR4%252529%252Bantagonists%26aulast%3DMiah%26aufirst%3DAfjal%2BH.%26date%3D2014%26volume%3D12%26issue%3D11%26spage%3D1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francoise  Bachelerie</span>, <span class="hlFld-ContribAuthor ">Adit  Ben-Baruch</span>, <span class="hlFld-ContribAuthor ">Amanda M.  Burkhardt</span>, <span class="hlFld-ContribAuthor ">Christophe  Combadiere</span>, <span class="hlFld-ContribAuthor ">Joshua M.  Farber</span>, <span class="hlFld-ContribAuthor ">Gerard J.  Graham</span>, <span class="hlFld-ContribAuthor ">Richard  Horuk</span>, <span class="hlFld-ContribAuthor ">Alexander Hovard  Sparre-Ulrich</span>, <span class="hlFld-ContribAuthor ">Massimo  Locati</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Luster</span>, <span class="hlFld-ContribAuthor ">Alberto  Mantovani</span>, <span class="hlFld-ContribAuthor ">Kouji  Matsushima</span>, <span class="hlFld-ContribAuthor ">Philip M.  Murphy</span>, <span class="hlFld-ContribAuthor ">Robert  Nibbs</span>, <span class="hlFld-ContribAuthor ">Hisayuki  Nomiyama</span>, <span class="hlFld-ContribAuthor ">Christine A.  Power</span>, <span class="hlFld-ContribAuthor ">Amanda E. I.  Proudfoot</span>, <span class="hlFld-ContribAuthor ">Mette M.  Rosenkilde</span>, <span class="hlFld-ContribAuthor ">Antal  Rot</span>, <span class="hlFld-ContribAuthor ">Silvano  Sozzani</span>, <span class="hlFld-ContribAuthor ">Marcus  Thelen</span>, <span class="hlFld-ContribAuthor ">Osamu  Yoshie</span>, <span class="hlFld-ContribAuthor ">Albert  Zlotnik</span>, . </span><span class="cited-content_cbyCitation_article-title">International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2014,</strong> <em>66 </em>
                                    (1)
                                     , 1-79. <a href="https://doi.org/10.1124/pr.113.007724" title="DOI URL">https://doi.org/10.1124/pr.113.007724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.113.007724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.113.007724%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DInternational%252BUnion%252Bof%252BBasic%252Band%252BClinical%252BPharmacology.%252BLXXXIX.%252BUpdate%252Bon%252Bthe%252BExtended%252BFamily%252Bof%252BChemokine%252BReceptors%252Band%252BIntroducing%252Ba%252BNew%252BNomenclature%252Bfor%252BAtypical%252BChemokine%252BReceptors%26aulast%3DBachelerie%26aufirst%3DFrancoise%26date%3D2014%26date%3D2013%26volume%3D66%26issue%3D1%26spage%3D1%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Goda  Muralidhar</span>, <span class="hlFld-ContribAuthor ">Maria  Barbolina</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokine Receptors in Epithelial Ovarian Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2014,</strong> <em>15 </em>
                                    (1)
                                     , 361-376. <a href="https://doi.org/10.3390/ijms15010361" title="DOI URL">https://doi.org/10.3390/ijms15010361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms15010361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms15010361%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DChemokine%252BReceptors%252Bin%252BEpithelial%252BOvarian%252BCancer%26aulast%3DMuralidhar%26aufirst%3DGoda%26date%3D2014%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D361%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon P  Fricker</span>, <span class="hlFld-ContribAuthor ">Markus  Metz</span>. </span><span class="cited-content_cbyCitation_article-title">Chemokine receptor modeling: an interdisciplinary approach to drug design. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2014,</strong> <em>6 </em>
                                    (1)
                                     , 91-114. <a href="https://doi.org/10.4155/fmc.13.194" title="DOI URL">https://doi.org/10.4155/fmc.13.194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.13.194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.13.194%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DChemokine%252Breceptor%252Bmodeling%25253A%252Ban%252Binterdisciplinary%252Bapproach%252Bto%252Bdrug%252Bdesign%26aulast%3DFricker%26aufirst%3DSimon%2BP%26date%3D2014%26volume%3D6%26issue%3D1%26spage%3D91%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy  Sullivan</span>, <span class="hlFld-ContribAuthor ">Zhenhua  Miao</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Dairaghi</span>, <span class="hlFld-ContribAuthor ">Antoni  Krasinski</span>, <span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Bin N.  Zhao</span>, <span class="hlFld-ContribAuthor ">Trageen  Baumgart</span>, <span class="hlFld-ContribAuthor ">Linda S.  Ertl</span>, <span class="hlFld-ContribAuthor ">Andrew  Pennell</span>, <span class="hlFld-ContribAuthor ">Lisa  Seitz</span>, <span class="hlFld-ContribAuthor ">Jay  Powers</span>, <span class="hlFld-ContribAuthor ">Ruiping  Zhao</span>, <span class="hlFld-ContribAuthor ">Solomon  Ungashe</span>, <span class="hlFld-ContribAuthor ">Zheng  Wei</span>, <span class="hlFld-ContribAuthor ">Landin  Boring</span>, <span class="hlFld-ContribAuthor ">Chia-Lin  Tsou</span>, <span class="hlFld-ContribAuthor ">Israel  Charo</span>, <span class="hlFld-ContribAuthor ">Robert D.  Berahovich</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Schall</span>, <span class="hlFld-ContribAuthor ">Juan C.  Jaen</span>. </span><span class="cited-content_cbyCitation_article-title">CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Renal Physiology</span><span> <strong>2013,</strong> <em>305 </em>
                                    (9)
                                     , F1288-F1297. <a href="https://doi.org/10.1152/ajprenal.00316.2013" title="DOI URL">https://doi.org/10.1152/ajprenal.00316.2013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajprenal.00316.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajprenal.00316.2013%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Renal%2520Physiology%26atitle%3DCCR2%252Bantagonist%252BCCX140-B%252Bprovides%252Brenal%252Band%252Bglycemic%252Bbenefits%252Bin%252Bdiabetic%252Btransgenic%252Bhuman%252BCCR2%252Bknockin%252Bmice%26aulast%3DSullivan%26aufirst%3DTimothy%26date%3D2013%26volume%3D305%26issue%3D9%26spage%3DF1288%26epage%3DF1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Campbell</span>, <span class="hlFld-ContribAuthor ">Pamela  Maxwell</span>, <span class="hlFld-ContribAuthor ">David  Waugh</span>. </span><span class="cited-content_cbyCitation_article-title">Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2013,</strong> <em>6 </em>
                                    (8)
                                     , 929-959. <a href="https://doi.org/10.3390/ph6080929" title="DOI URL">https://doi.org/10.3390/ph6080929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph6080929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph6080929%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DRationale%252Band%252BMeans%252Bto%252BTarget%252BPro-Inflammatory%252BInterleukin-8%252B%252528CXCL8%252529%252BSignaling%252Bin%252BCancer%26aulast%3DCampbell%26aufirst%3DLaura%26date%3D2013%26date%3D2013%26volume%3D6%26issue%3D8%26spage%3D929%26epage%3D959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Xu</span>, <span class="hlFld-ContribAuthor ">Srinivas  Duggineni</span>, <span class="hlFld-ContribAuthor ">Stephen  Espitia</span>, <span class="hlFld-ContribAuthor ">Douglas D.  Richman</span>, <span class="hlFld-ContribAuthor ">Jing  An</span>, <span class="hlFld-ContribAuthor ">Ziwei  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">A synthetic bivalent ligand of CXCR4 inhibits HIV infection. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2013,</strong> <em>435 </em>
                                    (4)
                                     , 646-650. <a href="https://doi.org/10.1016/j.bbrc.2013.05.038" title="DOI URL">https://doi.org/10.1016/j.bbrc.2013.05.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2013.05.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2013.05.038%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DA%252Bsynthetic%252Bbivalent%252Bligand%252Bof%252BCXCR4%252Binhibits%252BHIV%252Binfection%26aulast%3DXu%26aufirst%3DYan%26date%3D2013%26volume%3D435%26issue%3D4%26spage%3D646%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Percy H  Carter</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 â 2012. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2013,</strong> <em>23 </em>
                                    (5)
                                     , 549-568. <a href="https://doi.org/10.1517/13543776.2013.771168" title="DOI URL">https://doi.org/10.1517/13543776.2013.771168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2013.771168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2013.771168%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DProgress%252Bin%252Bthe%252Bdiscovery%252Bof%252BCC%252Bchemokine%252Breceptor%252B2%252Bantagonists%25252C%252B2009%252B%2525E2%252580%252593%252B2012%26aulast%3DCarter%26aufirst%3DPercy%2BH%26date%3D2013%26date%3D2013%26volume%3D23%26issue%3D5%26spage%3D549%26epage%3D568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Penglie  Zhang</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Dairaghi</span>, <span class="hlFld-ContribAuthor ">Juan C.  Jaen</span>, <span class="hlFld-ContribAuthor ">Jay P.  Powers</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery and Development of CCR1 Antagonists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 133-147. <a href="https://doi.org/10.1016/B978-0-12-417150-3.00010-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-417150-3.00010-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-417150-3.00010-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-417150-3.00010-7%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Band%252BDevelopment%252Bof%252BCCR1%252BAntagonists%26aulast%3DZhang%26aufirst%3DPenglie%26date%3D2013%26spage%3D133%26epage%3D147%26pub%3DElsevier%26date%3D2013%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Braja Gopal  Das</span>, <span class="hlFld-ContribAuthor ">Prasanta  Ghorai</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective direct reductive amination of ketones with electron-deficient amines using Re2O7/NaPF6 catalyst. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2013,</strong> <em>11 </em>
                                    (26)
                                     , 4379. <a href="https://doi.org/10.1039/c3ob40918j" title="DOI URL">https://doi.org/10.1039/c3ob40918j</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c3ob40918j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc3ob40918j%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DStereoselective%252Bdirect%252Breductive%252Bamination%252Bof%252Bketones%252Bwith%252Belectron-deficient%252Bamines%252Busing%252BRe2O7%25252FNaPF6%252Bcatalyst%26aulast%3DDas%26aufirst%3DBraja%2BGopal%26date%3D2013%26volume%3D11%26issue%3D26%26spage%3D4379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Agonist and antagonist binding pockets in GPCRs. Model of the crystal structure of the inactive state of CXCR4 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ODU">3ODU</a>) as viewed from the extracellular face. TM helices are numbered (Roman numerals) and the extracellular loops (ECLs) marked. Major and minor binding pockets are denoted by dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemokine receptor activation and inactivation. Panels AâD show cartoons of receptor activated by chemokines (red) or small molecule agonists (yellow) or inactivated by intrahelical small molecule antagonists (green) or intracellular antagonists (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. CCR1 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CCR2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. CCR3 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. CCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. CCR5 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. CCR9 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. CXCR1 and CXCR2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. CXCR3 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. CXCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Promiscuous chemokine receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/medium/jm-2012-00682j_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Design of dual receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-22/jm300682j/production/images/large/jm-2012-00682j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300682j&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 257 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Zlotnik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshie, O.</span><span> </span><span class="NLM_article-title">Chemokines: a new classification system and their role in immunity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">â</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS1074-7613%2800%2980165-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10714678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslKqsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=121-127&author=A.+Zlotnikauthor=O.+Yoshie&title=Chemokines%3A+a+new+classification+system+and+their+role+in+immunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines: a new classification system and their role in immunity</span></div><div class="casAuthors">Zlotnik, Albert; Yoshie, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 47 refs.  Discussed are: proposed new classification for chemokine ligands; chemokines and dendritic cells; chemokines and lymphocyte development; chemokines and the lymphoid system; and chemokines and the Th1/Th2 responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27cDwPXyi7LVg90H21EOLACvtfcHk0liuUealXADsag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslKqsL8%253D&md5=916082fe7a02a304ba377065fc8ca9a6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980165-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980165-X%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnik%26aufirst%3DA.%26aulast%3DYoshie%26aufirst%3DO.%26atitle%3DChemokines%253A%2520a%2520new%2520classification%2520system%2520and%2520their%2520role%2520in%2520immunity%26jtitle%3DImmunity%26date%3D2000%26volume%3D12%26spage%3D121%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span> </span><span class="NLM_article-title">The many roles of chemokines and chemokine receptors in inflammation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">â</span> <span class="NLM_lpage">621</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1056%2FNEJMra052723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16467548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlKisro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=610-621&author=I.+F.+Charoauthor=R.+M.+Ransohoff&title=The+many+roles+of+chemokines+and+chemokine+receptors+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of chemokines and chemokine receptors in inflammation</span></div><div class="casAuthors">Charo, Israel F.; Ransohoff, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The properties of chemokines and their receptors, as well as their roles in selected clin. disorders (inflammatory diseases, multiple sclerosis, metabolic disorders, insulin resistance and obesity-induced diabetes) are discussed.  Chemokines (chemotactic cytokines) are small heparin-binding proteins that direct the movement of circulating leukocytes to sites of inflammation or injury.  Chemokines and their receptors play a crucial part in directing the movement of mononuclear cells throughout the body, engendering the adaptive immune response and contributing to the pathogenesis of a variety of diseases.  Chemokine receptors are some of the most tractable drug targets in the huge battery of mols. that regulate inflammation and immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoACrHA9oILm7Vg90H21EOLACvtfcHk0ljeXeyxwpTtqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlKisro%253D&md5=eb1814e624ae0f1af5b9df9dbda15a25</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra052723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra052723%26sid%3Dliteratum%253Aachs%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DThe%2520many%2520roles%2520of%2520chemokines%2520and%2520chemokine%2520receptors%2520in%2520inflammation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D610%26epage%3D621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Viola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span> </span><span class="NLM_article-title">Chemokines and their receptors: drug targets in immunity and inflammation</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1146%2Fannurev.pharmtox.48.121806.154841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17883327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFynu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=171-197&author=A.+Violaauthor=A.+D.+Luster&title=Chemokines+and+their+receptors%3A+drug+targets+in+immunity+and+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines and their receptors: drug targets in immunity and inflammation</span></div><div class="casAuthors">Viola, Antonella; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-197</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The chemokine system coordinates leukocyte migration in immunity and inflammation and is implicated in the pathogenesis of many human diseases.  Although several successful strategies have been identified to develop drugs targeting chemokines and their receptors, this has not yet resulted in many new therapeutics.  This is likely due to a complexity of the chemokine system, which was not initially appreciated, that is characterized by redundancy, pleiotropy, and differences among species.  Nevertheless, our understanding of chemokine biol. is continuing to grow and several promising drugs are currently being tested in late-stage clin. trials.  In this review, we examine the role of chemokines in health and diseases and discuss strategies to target the chemokine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW9ifo6UmRKrVg90H21EOLACvtfcHk0ljeXeyxwpTtqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFynu78%253D&md5=74e0d77aba66fb33c242d8debeffe300</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.48.121806.154841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.48.121806.154841%26sid%3Dliteratum%253Aachs%26aulast%3DViola%26aufirst%3DA.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DChemokines%2520and%2520their%2520receptors%253A%2520drug%2520targets%2520in%2520immunity%2520and%2520inflammation%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2008%26volume%3D48%26spage%3D171%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Fredriksson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagerstrom, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schioth, H. B.</span><span> </span><span class="NLM_article-title">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="NLM_x">â</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fmol.63.6.1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=12761335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1256-1272&author=R.+Fredrikssonauthor=M.+C.+Lagerstromauthor=L.+G.+Lundinauthor=H.+B.+Schioth&title=The+G-protein-coupled+receptors+in+the+human+genome+form+five+main+families.+Phylogenetic+analysis%2C+paralogon+groups%2C+and+fingerprints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</span></div><div class="casAuthors">Fredriksson, Robert; Lagerstrom, Malin C.; Lundin, Lars-Gustav; Schioth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1256-1272</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The superfamily of G-protein-coupled receptors (GPCRs) is very diverse in structure and function and its members are among the most pursued targets for drug development.  We identified more than 800 human GPCR sequences and simultaneously analyzed 342 unique functional nonolfactory human GPCR sequences with phylogenetic analyses.  Our results show, with high bootstrap support, five main families, named glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin, forming the GRAFS classification system.  The rhodopsin family is the largest and forms four main groups with 13 subbranches.  Positions of the GPCRs in chromosomal paralogons regions indicate the importance of tetraploidizations or local gene duplication events for their creation.  We also searched for "fingerprint" motifs using Hidden Markov Models delineating the putative inter-relationship of the GRAFS families.  We show several common structural features indicating that the human GPCRs in the GRAFS families share a common ancestor.  This study represents the first overall map of the GPCRs in a single mammalian genome.  Our novel approach of analyzing such large and diverse sequence sets may be useful for studies on GPCRs in other genomes and divergent protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdX4VhTsaDzrVg90H21EOLACvtfcHk0ljeXeyxwpTtqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Shu7k%253D&md5=504ea873ee8469cd0b6016bc94943836</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1124%2Fmol.63.6.1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.63.6.1256%26sid%3Dliteratum%253Aachs%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DLagerstrom%26aufirst%3DM.%2BC.%26aulast%3DLundin%26aufirst%3DL.%2BG.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DThe%2520G-protein-coupled%2520receptors%2520in%2520the%2520human%2520genome%2520form%2520five%2520main%2520families.%2520Phylogenetic%2520analysis%252C%2520paralogon%2520groups%252C%2520and%2520fingerprints%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D63%26spage%3D1256%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Murphy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggiolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebert, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXII. Nomenclature for chemokine receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">â</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2000&pages=145-176&author=P.+M.+Murphyauthor=M.+Baggioliniauthor=I.+F.+Charoauthor=C.+A.+Hebertauthor=R.+Horukauthor=K.+Matsushimaauthor=L.+H.+Millerauthor=J.+J.+Oppenheimauthor=C.+A.+Power&title=International+Union+of+Pharmacology.+XXII.+Nomenclature+for+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DBaggiolini%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DHebert%26aufirst%3DC.%2BA.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DL.%2BH.%26aulast%3DOppenheim%26aufirst%3DJ.%2BJ.%26aulast%3DPower%26aufirst%3DC.%2BA.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXII.%2520Nomenclature%2520for%2520chemokine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2000%26volume%3D52%26spage%3D145%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Murphy, P. M.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">â</span> <span class="NLM_lpage">229</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=227-229&author=P.+M.+Murphy&title=International+Union+of+Pharmacology.+XXX.+Update+on+chemokine+receptor+nomenclature"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXX.%2520Update%2520on%2520chemokine%2520receptor%2520nomenclature%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D227%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Walsh, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rau, L. M.</span><span> </span><span class="NLM_article-title">Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States</span> <span class="citation_source-journal">Am. J. Public Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1463</span><span class="NLM_x">â</span> <span class="NLM_lpage">1466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2105%2FAJPH.90.9.1463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10983209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BD3cvktFGjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2000&pages=1463-1466&author=S.+J.+Walshauthor=L.+M.+Rau&title=Autoimmune+diseases%3A+a+leading+cause+of+death+among+young+and+middle-aged+women+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States</span></div><div class="casAuthors">Walsh S J; Rau L M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of public health</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1463-6</span>
        ISSN:<span class="NLM_cas:issn">0090-0036</span>.
    </div><div class="casAbstract">OBJECTIVES:  This study assessed the effect of autoimmune diseases on mortality among women.  METHODS:  Counts of autoimmune disease deaths were compared with frequencies of the 10 "official" leading causes of death among women in the United States in 1995.  RESULTS:  Autoimmune disease deaths exceeded the frequency of the 10th leading cause in every age category of women younger than 65 years and exceeded that for the eighth leading cause in the 15 to 24, 25 to 44, and 45 to 64 years age groups.  CONCLUSIONS:  Autoimmune diseases constitute a leading cause of death among young and middle-aged women.  This fact is obscured by current methods used to identify leading causes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQV1-yvWJIfLuQ4Pl9hzjQhfW6udTcc2eYkD-gXlREGVLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvktFGjug%253D%253D&md5=da035f5c196f17d3ae282107e56094c7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2105%2FAJPH.90.9.1463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.90.9.1463%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BJ.%26aulast%3DRau%26aufirst%3DL.%2BM.%26atitle%3DAutoimmune%2520diseases%253A%2520a%2520leading%2520cause%2520of%2520death%2520among%2520young%2520and%2520middle-aged%2520women%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2000%26volume%3D90%26spage%3D1463%26epage%3D1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Stoll, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span> </span><span class="NLM_article-title">Rheumatoid arthritis market</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">â</span> <span class="NLM_lpage">694</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=693-694&author=J.+G.+Stollauthor=U.+Yasothan&title=Rheumatoid+arthritis+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStoll%26aufirst%3DJ.%2BG.%26aulast%3DYasothan%26aufirst%3DU.%26atitle%3DRheumatoid%2520arthritis%2520market%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D693%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span>PRWeb. Global Autoimmune Disease Therapeutics Market To Exceed US$77 Billion by 2017, According to New Report by Global Industry Analysts, Inc. <a href="http://www.prweb.com/releases/autoimmune_disease/therapeutics_drugs/prweb8957282.htm" class="extLink">http://www.prweb.com/releases/autoimmune_disease/therapeutics_drugs/prweb8957282.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PRWeb.+Global+Autoimmune+Disease+Therapeutics+Market+To+Exceed+US%2477+Billion+by+2017%2C+According+to+New+Report+by+Global+Industry+Analysts%2C+Inc.+http%3A%2F%2Fwww.prweb.com%2Freleases%2Fautoimmune_disease%2Ftherapeutics_drugs%2Fprweb8957282.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">MacArthur, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novak, R. M.</span><span> </span><span class="NLM_article-title">Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">â</span> <span class="NLM_lpage">241</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1086%2F589289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18532888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslWgu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=236-241&author=R.+D.+MacArthurauthor=R.+M.+Novak&title=Reviews+of+anti-infective+agents%3A+maraviroc%3A+the+first+of+a+new+class+of+antiretroviral+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Maraviroc: the first of a new class of antiretroviral agents</span></div><div class="casAuthors">MacArthur, Rodger D.; Novak, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-241</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target.  Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells.  In this review, we include the details of the discoveries that led to the development of this drug.  The drug's pharmacol., including pharmacokinetics and drug interactions, is discussed, as are the clin. efficacy studies that led to licensure.  HIV-1 mechanisms of resistance to maraviroc, assays to det. viral coreceptor use (tropism), drug safety, and clin. use of maraviroc are discussed at length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNBt7OWyIz37Vg90H21EOLACvtfcHk0liK15_T2s80pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslWgu78%253D&md5=06a299c0cdf678a94ed9f0f1b3bd23cb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1086%2F589289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F589289%26sid%3Dliteratum%253Aachs%26aulast%3DMacArthur%26aufirst%3DR.%2BD.%26aulast%3DNovak%26aufirst%3DR.%2BM.%26atitle%3DReviews%2520of%2520anti-infective%2520agents%253A%2520maraviroc%253A%2520the%2520first%2520of%2520a%2520new%2520class%2520of%2520antiretroviral%2520agents%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D47%26spage%3D236%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">â</span> <span class="NLM_lpage">1664</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=1655-1664&author=E.+De+Clercq&title=The+AMD3100+story%3A+the+path+to+the+discovery+of+a+stem+cell+mobilizer+%28Mozobil%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520AMD3100%2520story%253A%2520the%2520path%2520to%2520the%2520discovery%2520of%2520a%2520stem%2520cell%2520mobilizer%2520%2528Mozobil%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D77%26spage%3D1655%26epage%3D1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Brave, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ching Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocheltree, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope Miksinski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornoe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=282-288&author=M.+Braveauthor=A.+Farrellauthor=S.+Ching+Linauthor=T.+Ocheltreeauthor=S.+Pope+Miksinskiauthor=S.+L.+Leeauthor=H.+Saberauthor=J.+Fourieauthor=C.+Tornoeauthor=B.+Boothauthor=W.+Yuanauthor=K.+Heauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+review+summary%3A+Mozobil+in+combination+with+granulocyte+colony-stimulating+factor+to+mobilize+hematopoietic+stem+cells+to+the+peripheral+blood+for+collection+and+subsequent+autologous+transplantation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrave%26aufirst%3DM.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DChing%2BLin%26aufirst%3DS.%26aulast%3DOcheltree%26aufirst%3DT.%26aulast%3DPope%2BMiksinski%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%2BL.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DFourie%26aufirst%3DJ.%26aulast%3DTornoe%26aufirst%3DC.%26aulast%3DBooth%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520review%2520summary%253A%2520Mozobil%2520in%2520combination%2520with%2520granulocyte%2520colony-stimulating%2520factor%2520to%2520mobilize%2520hematopoietic%2520stem%2520cells%2520to%2520the%2520peripheral%2520blood%2520for%2520collection%2520and%2520subsequent%2520autologous%2520transplantation%26jtitle%3DOncology%26date%3D2010%26volume%3D78%26spage%3D282%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmead, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span> </span><span class="NLM_article-title">The use of GPCR structures in drug design</span> <span class="citation_source-journal">Adv. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2011&pages=1-36&author=M.+Congreveauthor=C.+Langmeadauthor=F.+H.+Marshall&title=The+use+of+GPCR+structures+in+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DLangmead%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DThe%2520use%2520of%2520GPCR%2520structures%2520in%2520drug%2520design%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2011%26volume%3D62%26spage%3D1%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Choi, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggineni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, J.</span><span> </span><span class="NLM_article-title">Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">â</span> <span class="NLM_lpage">994</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200568c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOlt7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=977-994&author=W.+T.+Choiauthor=S.+Duggineniauthor=Y.+Xuauthor=Z.+Huangauthor=J.+An&title=Drug+discovery+research+targeting+the+CXC+chemokine+receptor+4+%28CXCR4%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4)</span></div><div class="casAuthors">Choi, Won-Tak; Duggineni, Srinivas; Xu, Yan; Huang, Ziwei; An, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">977-994</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The CXC chemokine receptor 4 (CXCR4) is an attractive target for therapeutic intervention because of its involvement in the pathogenesis of a wide range of infectious, inflammatory, and other diseases.  There has been intensive biol., chem., and pharmaceutical research to understand the mol. mechanisms of chemokine-receptor interactions and the modulation of chemokine-receptor functions.  The ultimate goal is to translate these discoveries into novel treatment strategies for clin. applications.  This review describes and discusses some of the recent advances in medicinal chem. and drug discovery that involve CXCR4, which is implicated in human immunodeficiency virus (HIV)-1 infection, normal hematopoietic and neural stem cell migration, cancer-stromal cell interaction, solid tumors, and inflammation and autoimmune diseases such as rheumatoid arthritis and allergic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvqHX-IPaxrVg90H21EOLACvtfcHk0liK15_T2s80pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOlt7jF&md5=c996a29f564ca4197139f4802dcbe061</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm200568c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200568c%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DW.%2BT.%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAn%26aufirst%3DJ.%26atitle%3DDrug%2520discovery%2520research%2520targeting%2520the%2520CXC%2520chemokine%2520receptor%25204%2520%2528CXCR4%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D977%26epage%3D994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Palczewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumasaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motoshima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Trong, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teller, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenkamp, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyano, M.</span><span> </span><span class="NLM_article-title">Crystal structure of rhodopsin: a G protein-coupled receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">â</span> <span class="NLM_lpage">745</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1126%2Fscience.289.5480.739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10926528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslOqs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=739-745&author=K.+Palczewskiauthor=T.+Kumasakaauthor=T.+Horiauthor=C.+A.+Behnkeauthor=H.+Motoshimaauthor=B.+A.+Foxauthor=I.+Le+Trongauthor=D.+C.+Tellerauthor=T.+Okadaauthor=R.+E.+Stenkampauthor=M.+Yamamotoauthor=M.+Miyano&title=Crystal+structure+of+rhodopsin%3A+a+G+protein-coupled+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of rhodopsin: A G protein-coupled receptor</span></div><div class="casAuthors">Palczewski, Krzysztof; Kumasaka, Takashi; Hori, Tetsuya; Behnke, Craig A.; Motoshima, Hiroyuki; Fox, Brian A.; Le Trong, Isolde; Teller, David C.; Okada, Tetsuji; Stenkamp, Ronald E.; Yamamoto, Masaki; Miyano, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5480</span>),
    <span class="NLM_cas:pages">739-745</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) respond to a variety of different external stimuli and activate G proteins.  GPCRs share many structural features, including a bundle of seven transmembrane Î±-helixes connected by six loops of varying lengths.  We detd. the structure of rhodopsin from diffraction data extending to 2.8 angstroms resoln.  The highly organized structure in the extracellular region, including a conserved disulfide bridge, forms a basis for the arrangement of the seven-helix transmembrane motif.  The ground-state chromophore, 11-cis-retinal, holds the transmembrane region of the protein in the inactive conformation.  Interactions of the chromophore with a cluster of key residues det. the wavelength of the max. absorption.  Changes in these interactions among rhodopsins facilitate color discrimination.  Identification of a set of residues that mediate interactions between the transmembrane helixes and the cytoplasmic surface, where G-protein activation occurs, also suggests a possible structural change upon photoactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFTWGKYX8vqLVg90H21EOLACvtfcHk0lg4qbbAT0wc3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslOqs78%253D&md5=b3d229fc696247ec0f4a6efa10490922</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5480.739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5480.739%26sid%3Dliteratum%253Aachs%26aulast%3DPalczewski%26aufirst%3DK.%26aulast%3DKumasaka%26aufirst%3DT.%26aulast%3DHori%26aufirst%3DT.%26aulast%3DBehnke%26aufirst%3DC.%2BA.%26aulast%3DMotoshima%26aufirst%3DH.%26aulast%3DFox%26aufirst%3DB.%2BA.%26aulast%3DLe%2BTrong%26aufirst%3DI.%26aulast%3DTeller%26aufirst%3DD.%2BC.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DStenkamp%26aufirst%3DR.%2BE.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DMiyano%26aufirst%3DM.%26atitle%3DCrystal%2520structure%2520of%2520rhodopsin%253A%2520a%2520G%2520protein-coupled%2520receptor%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D739%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1258</span><span class="NLM_x">â</span> <span class="NLM_lpage">1265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258-1265&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.+J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-resolution+crystal+structure+of+an+engineered+human+beta2-adrenergic+G+protein-coupled+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human Î²2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the Î²2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human Î²2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the Î²2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0lg4qbbAT0wc3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520an%2520engineered%2520human%2520beta2-adrenergic%2520G%2520protein-coupled%2520receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26epage%3D1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenalti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handel, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">1066</span><span class="NLM_x">â</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1126%2Fscience.1194396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20929726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1066-1071&author=B.+Wuauthor=E.+Y.+Chienauthor=C.+D.+Molauthor=G.+Fenaltiauthor=W.+Liuauthor=V.+Katritchauthor=R.+Abagyanauthor=A.+Broounauthor=P.+Wellsauthor=F.+C.+Biauthor=D.+J.+Hamelauthor=P.+Kuhnauthor=T.+M.+Handelauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structures+of+the+CXCR4+chemokine+GPCR+with+small-molecule+and+cyclic+peptide+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists</span></div><div class="casAuthors">Wu, Beili; Chien, Ellen Y. T.; Mol, Clifford D.; Fenalti, Gustavo; Liu, Wei; Katritch, Vsevolod; Abagyan, Ruben; Brooun, Alexei; Wells, Peter; Bi, F. Christopher; Hamel, Damon J.; Kuhn, Peter; Handel, Tracy M.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1066-1071</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chemokine receptors are crit. regulators of cell migration in the context of immune surveillance, inflammation, and development.  The G protein-coupled chemokine receptor CXCR4 is specifically implicated in cancer metastasis and HIV-1 infection.  Here we report five independent crystal structures of CXCR4 bound to an antagonist small mol. IT1t and a cyclic peptide CVX15 at 2.5 to 3.2 angstrom resoln.  All structures reveal a consistent homodimer with an interface including helixes V and VI that may be involved in regulating signaling.  The location and shape of the ligand-binding sites differ from other G protein-coupled receptors and are closer to the extracellular surface.  These structures provide new clues about the interactions between CXCR4 and its natural ligand CXCL12, and with the HIV-1 glycoprotein gp120.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeofqcIJsBzLVg90H21EOLACvtfcHk0lg4qbbAT0wc3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurnM&md5=2d39cc2cff4adce72e63f427e568e35d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1194396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1194396%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DFenalti%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DHamel%26aufirst%3DD.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DHandel%26aufirst%3DT.%2BM.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructures%2520of%2520the%2520CXCR4%2520chemokine%2520GPCR%2520with%2520small-molecule%2520and%2520cyclic%2520peptide%2520antagonists%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1066%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. K.</span><span> </span><span class="NLM_article-title">Transduction of receptor signals by beta-arrestins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">â</span> <span class="NLM_lpage">517</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=512-517&author=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Transduction+of+receptor+signals+by+beta-arrestins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DTransduction%2520of%2520receptor%2520signals%2520by%2520beta-arrestins%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D512%26epage%3D517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Schwartz, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimurer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenkilde, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elling, C. E.</span><span> </span><span class="NLM_article-title">Molecular mechanism of 7TM receptor activationâa global toggle switch model</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">â</span> <span class="NLM_lpage">519</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=481-519&author=T.+W.+Schwartzauthor=T.+M.+Frimurerauthor=B.+Holstauthor=M.+M.+Rosenkildeauthor=C.+E.+Elling&title=Molecular+mechanism+of+7TM+receptor+activation%E2%80%94a+global+toggle+switch+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DElling%26aufirst%3DC.%2BE.%26atitle%3DMolecular%2520mechanism%2520of%25207TM%2520receptor%2520activation%25E2%2580%2594a%2520global%2520toggle%2520switch%2520model%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D481%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Monteclaro, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">19084</span><span class="NLM_x">â</span> <span class="NLM_lpage">19092</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=19084-19092&author=F.+S.+Monteclaroauthor=I.+F.+Charo&title=The+amino-terminal+extracellular+domain+of+the+MCP-1+receptor%2C+but+not+the+RANTES%2FMIP-1alpha+receptor%2C+confers+chemokine+selectivity.+Evidence+for+a+two-step+mechanism+for+MCP-1+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMonteclaro%26aufirst%3DF.%2BS.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DThe%2520amino-terminal%2520extracellular%2520domain%2520of%2520the%2520MCP-1%2520receptor%252C%2520but%2520not%2520the%2520RANTES%252FMIP-1alpha%2520receptor%252C%2520confers%2520chemokine%2520selectivity.%2520Evidence%2520for%2520a%2520two-step%2520mechanism%2520for%2520MCP-1%2520receptor%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D19084%26epage%3D19092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pease, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponath, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, P. M.</span><span> </span><span class="NLM_article-title">The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">19972</span><span class="NLM_x">â</span> <span class="NLM_lpage">19976</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=19972-19976&author=J.+E.+Peaseauthor=J.+Wangauthor=P.+D.+Ponathauthor=P.+M.+Murphy&title=The+N-terminal+extracellular+segments+of+the+chemokine+receptors+CCR1+and+CCR3+are+determinants+for+MIP-1alpha+and+eotaxin+binding%2C+respectively%2C+but+a+second+domain+is+essential+for+efficient+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPonath%26aufirst%3DP.%2BD.%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26atitle%3DThe%2520N-terminal%2520extracellular%2520segments%2520of%2520the%2520chemokine%2520receptors%2520CCR1%2520and%2520CCR3%2520are%2520determinants%2520for%2520MIP-1alpha%2520and%2520eotaxin%2520binding%252C%2520respectively%252C%2520but%2520a%2520second%2520domain%2520is%2520essential%2520for%2520efficient%2520receptor%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D19972%26epage%3D19976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Farzan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirzabekov, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolchinsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayabyab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodroski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, H.</span><span> </span><span class="NLM_article-title">Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">â</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=667-676&author=M.+Farzanauthor=T.+Mirzabekovauthor=P.+Kolchinskyauthor=R.+Wyattauthor=M.+Cayabyabauthor=N.+P.+Gerardauthor=C.+Gerardauthor=J.+Sodroskiauthor=H.+Choe&title=Tyrosine+sulfation+of+the+amino+terminus+of+CCR5+facilitates+HIV-1+entry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarzan%26aufirst%3DM.%26aulast%3DMirzabekov%26aufirst%3DT.%26aulast%3DKolchinsky%26aufirst%3DP.%26aulast%3DWyatt%26aufirst%3DR.%26aulast%3DCayabyab%26aufirst%3DM.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26aulast%3DSodroski%26aufirst%3DJ.%26aulast%3DChoe%26aufirst%3DH.%26atitle%3DTyrosine%2520sulfation%2520of%2520the%2520amino%2520terminus%2520of%2520CCR5%2520facilitates%2520HIV-1%2520entry%26jtitle%3DCell%26date%3D1999%26volume%3D96%26spage%3D667%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bannert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craig, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farzan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogah, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santo, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodroski, J.</span><span> </span><span class="NLM_article-title">Sialylated <i>O</i>-glycans and sulfated tyrosines in the NH<sub>2</sub>-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">1661</span><span class="NLM_x">â</span> <span class="NLM_lpage">1673</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2001&pages=1661-1673&author=N.+Bannertauthor=S.+Craigauthor=M.+Farzanauthor=D.+Sogahauthor=N.+V.+Santoauthor=H.+Choeauthor=J.+Sodroski&title=Sialylated+O-glycans+and+sulfated+tyrosines+in+the+NH2-terminal+domain+of+CC+chemokine+receptor+5+contribute+to+high+affinity+binding+of+chemokines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBannert%26aufirst%3DN.%26aulast%3DCraig%26aufirst%3DS.%26aulast%3DFarzan%26aufirst%3DM.%26aulast%3DSogah%26aufirst%3DD.%26aulast%3DSanto%26aufirst%3DN.%2BV.%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DSodroski%26aufirst%3DJ.%26atitle%3DSialylated%2520O-glycans%2520and%2520sulfated%2520tyrosines%2520in%2520the%2520NH2-terminal%2520domain%2520of%2520CC%2520chemokine%2520receptor%25205%2520contribute%2520to%2520high%2520affinity%2520binding%2520of%2520chemokines%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2001%26volume%3D194%26spage%3D1661%26epage%3D1673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Rosenkilde, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benned-Jensen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimurer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, T. W.</span><span> </span><span class="NLM_article-title">The minor binding pocket: a major player in 7TM receptor activation</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">574</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=567-574&author=M.+M.+Rosenkildeauthor=T.+Benned-Jensenauthor=T.+M.+Frimurerauthor=T.+W.+Schwartz&title=The+minor+binding+pocket%3A+a+major+player+in+7TM+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenkilde%26aufirst%3DM.%2BM.%26aulast%3DBenned-Jensen%26aufirst%3DT.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DThe%2520minor%2520binding%2520pocket%253A%2520a%2520major%2520player%2520in%25207TM%2520receptor%2520activation%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2010%26volume%3D31%26spage%3D567%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Van Damme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struyf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuyts, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Coillie, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menten, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schols, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Meester, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proost, P.</span><span> </span><span class="NLM_article-title">The role of CD26/DPP IV in chemokine processing</span> <span class="citation_source-journal">Chem. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">â</span> <span class="NLM_lpage">56</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1159%2F000058725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10550929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSntLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=42-56&author=J.+Van+Dammeauthor=S.+Struyfauthor=A.+Wuytsauthor=E.+Van+Coillieauthor=P.+Mentenauthor=D.+Scholsauthor=S.+Sozzaniauthor=I.+De+Meesterauthor=P.+Proost&title=The+role+of+CD26%2FDPP+IV+in+chemokine+processing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The role of CD26/DPP IV in chemokine processing</span></div><div class="casAuthors">Van Damme, Jo; Struyf, Sofie; Wuyts, Anja; Van Coillie, Els; Menten, Patricia; Schols, Dominique; Sozzani, Silvano; De Meester, Ingrid; Proost, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">Chemokines</span>),
    <span class="NLM_cas:pages">42-56</span>CODEN:
                <span class="NLM_cas:coden">CHMIEP</span>;
        ISSN:<span class="NLM_cas:issn">1015-0145</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review with 30 refs. describing the effects of dipeptidyl peptidase IV (DPP IV) on a large group of small inflammatory cytokines, chemokines.  For each individual chemoattractant the different biol. consequences of processing by CD26/DPP IV are evaluated in comparison with the intact mol.  These examples show that chemokines are important natural substrates for CD26/DPP IV and illustrate the impact of this serine protease in immune processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr355UtDqr_l7Vg90H21EOLACvtfcHk0ljHxH6j1NQ21w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSntLs%253D&md5=606fca67ff327c49b71dc2d5cff9c082</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1159%2F000058725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000058725%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DStruyf%26aufirst%3DS.%26aulast%3DWuyts%26aufirst%3DA.%26aulast%3DVan%2BCoillie%26aufirst%3DE.%26aulast%3DMenten%26aufirst%3DP.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DProost%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520CD26%252FDPP%2520IV%2520in%2520chemokine%2520processing%26jtitle%3DChem.%2520Immunol.%26date%3D1999%26volume%3D72%26spage%3D42%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borlat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alouani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offord, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span> </span><span class="NLM_article-title">Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">32478</span><span class="NLM_x">â</span> <span class="NLM_lpage">32485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=32478-32485&author=A.+E.+Proudfootauthor=R.+Buserauthor=F.+Borlatauthor=S.+Alouaniauthor=D.+Solerauthor=R.+E.+Offordauthor=J.+M.+Schroderauthor=C.+A.+Powerauthor=T.+N.+Wells&title=Amino-terminally+modified+RANTES+analogues+demonstrate+differential+effects+on+RANTES+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DBuser%26aufirst%3DR.%26aulast%3DBorlat%26aufirst%3DF.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DOfford%26aufirst%3DR.%2BE.%26aulast%3DSchroder%26aufirst%3DJ.%2BM.%26aulast%3DPower%26aufirst%3DC.%2BA.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DAmino-terminally%2520modified%2520RANTES%2520analogues%2520demonstrate%2520differential%2520effects%2520on%2520RANTES%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D32478%26epage%3D32485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Wise, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchesnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Fonseca, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span> </span><span class="NLM_article-title">Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">27935</span><span class="NLM_x">â</span> <span class="NLM_lpage">27943</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=27935-27943&author=E.+L.+Wiseauthor=C.+Duchesnesauthor=P.+C.+da+Fonsecaauthor=R.+A.+Allenauthor=T.+J.+Williamsauthor=J.+E.+Pease&title=Small+molecule+receptor+agonists+and+antagonists+of+CCR3+provide+insight+into+mechanisms+of+chemokine+receptor+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DE.%2BL.%26aulast%3DDuchesnes%26aufirst%3DC.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%26aulast%3DAllen%26aufirst%3DR.%2BA.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DSmall%2520molecule%2520receptor%2520agonists%2520and%2520antagonists%2520of%2520CCR3%2520provide%2520insight%2520into%2520mechanisms%2520of%2520chemokine%2520receptor%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D27935%26epage%3D27943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Nedjai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroke, I. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klon, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidehi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span> </span><span class="NLM_article-title">Small-molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">912</span><span class="NLM_x">â</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1476-5381.2011.01660.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2011&pages=912-923&author=B.+Nedjaiauthor=H.+Liauthor=I.+L.+Strokeauthor=E.+L.+Wiseauthor=M.+L.+Webbauthor=J.+R.+Merrittauthor=I.+Hendersonauthor=A.+E.+Klonauthor=A.+G.+Coleauthor=R.+Horukauthor=N.+Vaidehiauthor=J.+E.+Pease&title=Small-molecule+chemokine+mimetics+suggest+a+molecular+basis+for+the+observation+that+CXCL10+and+CXCL11+are+allosteric+ligands+of+CXCR3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01660.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01660.x%26sid%3Dliteratum%253Aachs%26aulast%3DNedjai%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DStroke%26aufirst%3DI.%2BL.%26aulast%3DWise%26aufirst%3DE.%2BL.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMerritt%26aufirst%3DJ.%2BR.%26aulast%3DHenderson%26aufirst%3DI.%26aulast%3DKlon%26aufirst%3DA.%2BE.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DSmall-molecule%2520chemokine%2520mimetics%2520suggest%2520a%2520molecular%2520basis%2520for%2520the%2520observation%2520that%2520CXCL10%2520and%2520CXCL11%2520are%2520allosteric%2520ligands%2520of%2520CXCR3%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D166%26spage%3D912%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Weathington, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Houwelingen, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noerager, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraneveld, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galin, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkerts, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nijkamp, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blalock, J. E.</span><span> </span><span class="NLM_article-title">A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">â</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnm1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16474398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGnt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=317-323&author=N.+M.+Weathingtonauthor=A.+H.+van+Houwelingenauthor=B.+D.+Noeragerauthor=P.+L.+Jacksonauthor=A.+D.+Kraneveldauthor=F.+S.+Galinauthor=G.+Folkertsauthor=F.+P.+Nijkampauthor=J.+E.+Blalock&title=A+novel+peptide+CXCR+ligand+derived+from+extracellular+matrix+degradation+during+airway+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation</span></div><div class="casAuthors">Weathington, Nathaniel M.; van Houwelingen, Anneke H.; Noerager, Brett D.; Jackson, Patricia L.; Kraneveld, Aletta D.; Galin, F. Shawn; Folkerts, Gert; Nijkamp, Frans P.; Blalock, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-323</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors describe the tripeptide neutrophil chemoattractant N-acetyl Pro-Gly-Pro (PGP), derived from the breakdown of extracellular matrix (ECM), which shares sequence and structural homol. with an important domain on alpha chemokines.  PGP caused chemotaxis and prodn. of superoxide through CXC receptors, and administration of peptide caused recruitment of neutrophils (PMNs) into lungs of control, but not CXCR2-deficient mice.  PGP was generated in mouse lung after exposure to lipopolysaccharide, and in vivo and in vitro blockade of PGP with monoclonal antibody suppressed PMN responses as much as chemokine-specific monoclonal antibody.  Extended PGP treatment caused alveolar enlargement and right ventricular hypertrophy in mice.  PGP was detectable in substantial concns. in a majority of bronchoalveolar lavage samples from individuals with chronic obstructive pulmonary disease, but not control individuals.  Thus, PGP's activity links degrdn. of ECM with neutrophil recruitment in airway inflammation, and PGP may be a biomarker and therapeutic target for neutrophilic inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvVY_4dt4eLVg90H21EOLACvtfcHk0ljHxH6j1NQ21w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGnt70%253D&md5=4e9e953a275d3ff89e3f0c312abe2774</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnm1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1361%26sid%3Dliteratum%253Aachs%26aulast%3DWeathington%26aufirst%3DN.%2BM.%26aulast%3Dvan%2BHouwelingen%26aufirst%3DA.%2BH.%26aulast%3DNoerager%26aufirst%3DB.%2BD.%26aulast%3DJackson%26aufirst%3DP.%2BL.%26aulast%3DKraneveld%26aufirst%3DA.%2BD.%26aulast%3DGalin%26aufirst%3DF.%2BS.%26aulast%3DFolkerts%26aufirst%3DG.%26aulast%3DNijkamp%26aufirst%3DF.%2BP.%26aulast%3DBlalock%26aufirst%3DJ.%2BE.%26atitle%3DA%2520novel%2520peptide%2520CXCR%2520ligand%2520derived%2520from%2520extracellular%2520matrix%2520degradation%2520during%2520airway%2520inflammation%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D317%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Andrews, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wreggett, K. A.</span><span> </span><span class="NLM_article-title">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">â</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fmol.107.039321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18042736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=855-867&author=G.+Andrewsauthor=C.+Jonesauthor=K.+A.+Wreggett&title=An+intracellular+allosteric+site+for+a+specific+class+of+antagonists+of+the+CC+chemokine+G+protein-coupled+receptors+CCR4+and+CCR5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span></div><div class="casAuthors">Andrews, Glen; Jones, Carolyn; Wreggett, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A novel mechanism for antagonism of the human chemokine receptors CCR4 and CCR5 has been discovered with a series of small-mol. compds. that seems to interact with an allosteric, intracellular site on the receptor.  The existence of this site is supported by a series of observations: (1) intracellular access of these antagonists is required for their activity; (2) specific, saturable binding of a radiolabeled antagonist requires the presence of CCR4; and (3) through engineering receptor chimeras by reciprocal transfer of C-terminal domains between CCR4 and CCR5, compd. binding and the selective structure-activity relationships for antagonism of these receptors seem to be assocd. with the integrity of that intracellular region.  Published antagonists from other chem. series do not seem to bind to the novel site, and their interaction with either CCR4 or CCR5 is not affected by alteration of the C-terminal domain.  The precise location of the proposed binding site remains to be detd., but the known close assocn. of the C-terminal domain, including helix 8, as a proposed intracellular region that interacts with transduction proteins (e.g., G proteins and Î²-arrestin) suggests that this could be a generic allosteric site for chemokine receptors and perhaps more broadly for class A G protein-coupled receptors.  The existence of such a site that can be targeted for drug discovery has implications for screening assays for receptor antagonists, which would need, therefore, to consider compd. properties for access to this intracellular site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAPVG6Nu0Wf7Vg90H21EOLACvtfcHk0lijxF8_AI4Ieg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D&md5=f3624c421bac61365f63ea1389dffea0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039321%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DWreggett%26aufirst%3DK.%2BA.%26atitle%3DAn%2520intracellular%2520allosteric%2520site%2520for%2520a%2520specific%2520class%2520of%2520antagonists%2520of%2520the%2520CC%2520chemokine%2520G%2520protein-coupled%2520receptors%2520CCR4%2520and%2520CCR5%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Feng, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellett, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, G.</span><span> </span><span class="NLM_article-title">Selective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">33400</span><span class="NLM_x">â</span> <span class="NLM_lpage">33407</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=33400-33407&author=G.+J.+Fengauthor=E.+Kellettauthor=C.+A.+Scorerauthor=J.+Wildeauthor=J.+H.+Whiteauthor=G.+Milligan&title=Selective+interactions+between+helix+VIII+of+the+human+mu-opioid+receptors+and+the+C+terminus+of+periplakin+disrupt+G+protein+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DG.%2BJ.%26aulast%3DKellett%26aufirst%3DE.%26aulast%3DScorer%26aufirst%3DC.%2BA.%26aulast%3DWilde%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DJ.%2BH.%26aulast%3DMilligan%26aufirst%3DG.%26atitle%3DSelective%2520interactions%2520between%2520helix%2520VIII%2520of%2520the%2520human%2520mu-opioid%2520receptors%2520and%2520the%2520C%2520terminus%2520of%2520periplakin%2520disrupt%2520G%2520protein%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D33400%26epage%3D33407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sobocki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliatti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobelt, G.</span><span> </span><span class="NLM_article-title">Estimation of the cost of MS in Europe: extrapolations from a multinational cost study</span> <span class="citation_source-journal">Mult. Scler.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">â</span> <span class="NLM_lpage">1064</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1177%2F1352458507077941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17623729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BD2srnt1Wjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1054-1064&author=P.+Sobockiauthor=M.+Pugliattiauthor=K.+Lauerauthor=G.+Kobelt&title=Estimation+of+the+cost+of+MS+in+Europe%3A+extrapolations+from+a+multinational+cost+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of the cost of MS in Europe: extrapolations from a multinational cost study</span></div><div class="casAuthors">Sobocki P; Pugliatti M; Lauer K; Kobelt G</div><div class="citationInfo"><span class="NLM_cas:title">Multiple sclerosis (Houndmills, Basingstoke, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1054-64</span>
        ISSN:<span class="NLM_cas:issn">1352-4585</span>.
    </div><div class="casAbstract">The present study aims at estimating the total cost of MS in Europe based on actual cost data from nine countries and published epidemiological evidence.  The epidemiological data are reported as 12 months prevalence estimates and cost data calculated as annual cost per patient at given levels of disease severity.  Cost data are extrapolated to the rest of Europe based on a model, using economic indexes adjusting for price level differences in different sectors between countries.  The aggregated annual cost estimates are presented in Euro for 2005.  In 28 European countries with a population of 466 million, an estimated 380 000 individuals are affected by MS.  The total annual cost of MS in Europe is estimated at 12.5 billion in year 2005, corresponding to a cost of 27 per European inhabitant.  Direct costs represent slightly more than half of the total cost (6.0 billion).  Informal care is estimated at 3.2 billion, and indirect costs due to morbidity at 3.2 billion.  Thus, the largest component of costs is found outside the formal health care sector.  Although our model appears to predict costs reasonably well, when comparing to previous national studies not included in the estimates, there are considerable uncertainties when extrapolating cost data across countries even within Europe.  These weaknesses can only be overcome by collecting primary data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFMgVF7CkElOqrn-c4Of3KfW6udTcc2eYpSuKtHlETXrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srnt1Wjug%253D%253D&md5=0a4cb54ca11b7bad8735a2116f102b8f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1177%2F1352458507077941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1352458507077941%26sid%3Dliteratum%253Aachs%26aulast%3DSobocki%26aufirst%3DP.%26aulast%3DPugliatti%26aufirst%3DM.%26aulast%3DLauer%26aufirst%3DK.%26aulast%3DKobelt%26aufirst%3DG.%26atitle%3DEstimation%2520of%2520the%2520cost%2520of%2520MS%2520in%2520Europe%253A%2520extrapolations%2520from%2520a%2520multinational%2520cost%2520study%26jtitle%3DMult.%2520Scler.%26date%3D2007%26volume%3D13%26spage%3D1054%26epage%3D1064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Lassmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruck, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchinetti, C.</span><span> </span><span class="NLM_article-title">Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=115-121&author=H.+Lassmannauthor=W.+Bruckauthor=C.+Lucchinetti&title=Heterogeneity+of+multiple+sclerosis+pathogenesis%3A+implications+for+diagnosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLassmann%26aufirst%3DH.%26aulast%3DBruck%26aufirst%3DW.%26aulast%3DLucchinetti%26aufirst%3DC.%26atitle%3DHeterogeneity%2520of%2520multiple%2520sclerosis%2520pathogenesis%253A%2520implications%2520for%2520diagnosis%2520and%2520therapy%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D115%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Trebst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivisakk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathcart, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellebjerg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span> </span><span class="NLM_article-title">CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">1701</span><span class="NLM_x">â</span> <span class="NLM_lpage">1710</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0002-9440%2810%2963017-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11696431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BD3Mnltl2rsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2001&pages=1701-1710&author=C.+Trebstauthor=T.+L.+Sorensenauthor=P.+Kivisakkauthor=M.+K.+Cathcartauthor=J.+Hesselgesserauthor=R.+Horukauthor=F.+Sellebjergauthor=H.+Lassmannauthor=R.+M.+Ransohoff&title=CCR1%2B%2FCCR5%2B+mononuclear+phagocytes+accumulate+in+the+central+nervous+system+of+patients+with+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis</span></div><div class="casAuthors">Trebst C; Sorensen T L; Kivisakk P; Cathcart M K; Hesselgesser J; Horuk R; Sellebjerg F; Lassmann H; Ransohoff R M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1701-10</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">Mononuclear phagocytes (monocytes, macrophages, and microglia) are considered central to multiple sclerosis (MS) pathogenesis.  Molecular cues that mediate mononuclear phagocyte accumulation and activation in the central nervous system (CNS) of MS patients may include chemokines RANTES/CCL5 and macrophage inflammatory protein-1alpha/CCL3.  We analyzed expression of CCR1 and CCR5, the monocyte receptors for these chemokines, on circulating and cerebrospinal fluid CD14+ cells, and in MS brain lesions.  Approximately 70% of cerebrospinal fluid monocytes were CCR1+/CCR5+, regardless of the presence of CNS pathology, compared to less than 20% of circulating monocytes.  In active MS lesions CCR1+/CCR5+ monocytes were found in perivascular cell cuffs and at the demyelinating edges of evolving lesions.  Mononuclear phagocytes in early demyelinating stages comprised CCR1+/CCR5+ hematogenous monocytes and CCR1-/CCR5- resident microglial cells.  In later stages, phagocytic macrophages were uniformly CCR1-/CCR5+.  Cultured in vitro, adherent monocytes/macrophages up-regulated CCR5 and down-regulated CCR1 expression, compared to freshly-isolated monocytes.  Taken together, these findings suggest that monocytes competent to enter the CNS compartment derive from a minority CCR1+/CCR5+ population in the circulating pool.  In the presence of ligand, these cells will be retained in the CNS.  During further activation in lesions, infiltrating monocytes down-regulate CCR1 but not CCR5, whereas microglia up-regulate CCR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThPeYGkwTkA3thwrmtH4OBfW6udTcc2eYpSuKtHlETXrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mnltl2rsQ%253D%253D&md5=1d769e0990604e0a5c1a745b73f9a135</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963017-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963017-9%26sid%3Dliteratum%253Aachs%26aulast%3DTrebst%26aufirst%3DC.%26aulast%3DSorensen%26aufirst%3DT.%2BL.%26aulast%3DKivisakk%26aufirst%3DP.%26aulast%3DCathcart%26aufirst%3DM.%2BK.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DSellebjerg%26aufirst%3DF.%26aulast%3DLassmann%26aufirst%3DH.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DCCR1%252B%252FCCR5%252B%2520mononuclear%2520phagocytes%2520accumulate%2520in%2520the%2520central%2520nervous%2520system%2520of%2520patients%2520with%2520multiple%2520sclerosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2001%26volume%3D159%26spage%3D1701%26epage%3D1710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Balashov, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">6873</span><span class="NLM_x">â</span> <span class="NLM_lpage">6878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=6873-6878&author=K.+E.+Balashovauthor=J.+B.+Rottmanauthor=H.+L.+Weinerauthor=W.+W.+Hancock&title=CCR5%28%2B%29+and+CXCR3%28%2B%29+T+cells+are+increased+in+multiple+sclerosis+and+their+ligands+MIP-1alpha+and+IP-10+are+expressed+in+demyelinating+brain+lesions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBalashov%26aufirst%3DK.%2BE.%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DWeiner%26aufirst%3DH.%2BL.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DCCR5%2528%252B%2529%2520and%2520CXCR3%2528%252B%2529%2520T%2520cells%2520are%2520increased%2520in%2520multiple%2520sclerosis%2520and%2520their%2520ligands%2520MIP-1alpha%2520and%2520IP-10%2520are%2520expressed%2520in%2520demyelinating%2520brain%2520lesions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D6873%26epage%3D6878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">McManus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brosnan, C. F.</span><span> </span><span class="NLM_article-title">MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study</span> <span class="citation_source-journal">J. Neuroimmunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">â</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0165-5728%2898%2900002-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9655469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1cXjsVensro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1998&pages=20-29&author=C.+McManusauthor=J.+W.+Bermanauthor=F.+M.+Brettauthor=H.+Stauntonauthor=M.+Farrellauthor=C.+F.+Brosnan&title=MCP-1%2C+MCP-2+and+MCP-3+expression+in+multiple+sclerosis+lesions%3A+an+immunohistochemical+and+in+situ+hybridization+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study</span></div><div class="casAuthors">McManus, Carrie; Berman, Joan W.; Brett, Francesca M.; Staunton, Hugh; Farrell, Michael; Brosnan, Celia F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Chemokines are low mol. wt. chemotactic cytokines that have been shown to play a central role in the perivascular transmigration and accumulation of specific subsets of leukocytes at sites of tissue damage.  Two major families have been defined depending on the positioning of four conserved cysteines.  The CXC chemokines predominantly attract neutrophils, whereas the CC chemokines predominantly attract monocytes and other leukocyte cell types.  Members of the monocyte chemotactic protein (MCP)-1 family form a major component of the CC family of chemokines and are considered the principal chemokines involved in the recruitment of monocytes/macrophages and activated lymphocytes.  In this study the authors addressed the expression and distribution of MCP-1, -2 and -3 in multiple sclerosis (MS) lesions of differing ages and levels of inflammatory activity using immunohistochem. and in situ hybridization.  In acute and chronic-active MS lesions immunoreactivity for MCP-1, -2 and -3 was prominent throughout the lesion center with reactivity diminishing abruptly at the lesion edge.  Hypertrophic astrocytes were strongly reactive and inflammatory cells showed variable reactivity.  Outside of the lesion only hypertrophic astrocytes were reactive.  The results obtained by in situ hybridization for MCP-1 were in agreement with those obtained by immunostaining.  In more chronic lesions immunoreactivity for MCP-1, -2 and -3 was considerably diminished, and in chronic-silent lesions immunoreactivity was restricted to a few scattered reactive astrocytes.  Normal control brains showed no immunoreactivity for MCP-1, -2 and -3.  Although the cellular distribution of all three members of this family was similar, antibodies to MCP-3 gave prominent staining of the extracellular matrix that was not noted for MCP-1 and -2.  These results support the conclusion that members of the MCP family of chemokines are involved in the development of MS lesions in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiccq9m1hZirVg90H21EOLACvtfcHk0lhEflITDikxIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsVensro%253D&md5=d7dc5ae69381b1ef1a6722bb647b9eb0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0165-5728%2898%2900002-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-5728%252898%252900002-2%26sid%3Dliteratum%253Aachs%26aulast%3DMcManus%26aufirst%3DC.%26aulast%3DBerman%26aufirst%3DJ.%2BW.%26aulast%3DBrett%26aufirst%3DF.%2BM.%26aulast%3DStaunton%26aufirst%3DH.%26aulast%3DFarrell%26aufirst%3DM.%26aulast%3DBrosnan%26aufirst%3DC.%2BF.%26atitle%3DMCP-1%252C%2520MCP-2%2520and%2520MCP-3%2520expression%2520in%2520multiple%2520sclerosis%2520lesions%253A%2520an%2520immunohistochemical%2520and%2520in%2520situ%2520hybridization%2520study%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D1998%26volume%3D86%26spage%3D20%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Steinman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamvil, S. S.</span><span> </span><span class="NLM_article-title">Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis</span> <span class="citation_source-journal">Trends Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">â</span> <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.it.2005.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16153891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeiu7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=565-571&author=L.+Steinmanauthor=S.+S.+Zamvil&title=Virtues+and+pitfalls+of+EAE+for+the+development+of+therapies+for+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis</span></div><div class="casAuthors">Steinman, Lawrence; Zamvil, Scott S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">565-571</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Exptl. autoimmune encephalomyelitis (EAE) is a useful model for aiding the development of new treatments for MS.  All therapies approved for MS ameliorate EAE.  Two approved medications, glatiramer acetate and Natalizumab, were developed directly from studies in EAE.  Several trials are ongoing in MS after success in EAE, including altered peptide ligands of myelin, DNA vaccines and statins.  However, EAE has failed to predict the outcome of certain approaches.  The reasons underlying such failures are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_U2n_C7oLLVg90H21EOLACvtfcHk0lhEflITDikxIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeiu7rO&md5=e33fd4b3f813fa896663ab39ed22f4c5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2005.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2005.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DSteinman%26aufirst%3DL.%26aulast%3DZamvil%26aufirst%3DS.%2BS.%26atitle%3DVirtues%2520and%2520pitfalls%2520of%2520EAE%2520for%2520the%2520development%2520of%2520therapies%2520for%2520multiple%2520sclerosis%26jtitle%3DTrends%2520Immunol.%26date%3D2005%26volume%3D26%26spage%3D565%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlow, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazarakis, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Macrophage inflammatory protein-1a. A novel chemotactic cytokine for macrophages in rheumatoid arthritis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">921</span><span class="NLM_x">â</span> <span class="NLM_lpage">928</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1994&pages=921-928&author=A.+E.+Kochauthor=S.+E.+Kunkelauthor=S.+E.+Harlowauthor=D.+D.+Mazarakisauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Macrophage+inflammatory+protein-1a.+A+novel+chemotactic+cytokine+for+macrophages+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BE.%26aulast%3DHarlow%26aufirst%3DS.%2BE.%26aulast%3DMazarakis%26aufirst%3DD.%2BD.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DMacrophage%2520inflammatory%2520protein-1a.%2520A%2520novel%2520chemotactic%2520cytokine%2520for%2520macrophages%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1994%26volume%3D93%26spage%3D921%26epage%3D928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Macchioni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boiardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meliconi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulsatelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maldini, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvarani, C.</span><span> </span><span class="NLM_article-title">Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">â</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9489827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVGgu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1998&pages=320-325&author=P.+Macchioniauthor=L.+Boiardiauthor=R.+Meliconiauthor=L.+Pulsatelliauthor=M.+C.+Maldiniauthor=R.+Ruggeriauthor=A.+Facchiniauthor=C.+Salvarani&title=Serum+chemokines+in+patients+with+psoriatic+arthritis+treated+with+cyclosporin+A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A</span></div><div class="casAuthors">Macchioni, Pierluigi; Boiardi, Luigi; Meliconi, Riccardo; Pulsatelli, Lia; Maldini, Mario Casadei; Ruggeri, Romina; Facchini, Andrea; Salvarani, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">320-325</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">The levels of serum chemokines were evaluated in patients with psoriatic arthritis (PsA) before and during cyclosporin A (CyA) treatment.  Sixteen outpatients with active PsA were followed for 6 mo during low dosage CyA treatment.  Serum chemokines of the C-X-C and C-C groups were detd. by ELISA at the baseline.  Serum RANTES levels were measured at 2 mo intervals for 6 mo.  Serum chemokine levels were related with clin. and lab. disease activity variables.  Serum interleukin 8 and macrophage inflammatory protein 1Î± levels were undetectable at baseline.  Mean serum growth related gene product-Î± and monocyte chemoattractant protein 1 values were reduced and serum RANTES were elevated compared to controls.  CyA treatment did not change serum RANTES levels.  Patients with PsA with persistently normal serum RANTES levels (4 patients) had a more favorable clin. and lab. response to CyA compared to patients with persistently high serum levels (6 patients).  Serum RANTES levels are higher in patients with PsA than in a control population.  CyA treatment does not change RANTES values.  Patients with PsA with persistently normal RANTES levels have a better response to CyA treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrypKodjYIr1bVg90H21EOLACvtfcHk0lgMiu3_JWzzag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVGgu7k%253D&md5=c11da9f0694474d85697ef2dd170f373</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacchioni%26aufirst%3DP.%26aulast%3DBoiardi%26aufirst%3DL.%26aulast%3DMeliconi%26aufirst%3DR.%26aulast%3DPulsatelli%26aufirst%3DL.%26aulast%3DMaldini%26aufirst%3DM.%2BC.%26aulast%3DRuggeri%26aufirst%3DR.%26aulast%3DFacchini%26aufirst%3DA.%26aulast%3DSalvarani%26aufirst%3DC.%26atitle%3DSerum%2520chemokines%2520in%2520patients%2520with%2520psoriatic%2520arthritis%2520treated%2520with%2520cyclosporin%2520A%26jtitle%3DJ.%2520Rheumatol.%26date%3D1998%26volume%3D25%26spage%3D320%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Kasama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lincoln, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span> </span><span class="NLM_article-title">Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2868</span><span class="NLM_x">â</span> <span class="NLM_lpage">2876</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2868-2876&author=T.+Kasamaauthor=R.+M.+Strieterauthor=N.+W.+Lukacsauthor=P.+M.+Lincolnauthor=M.+D.+Burdickauthor=S.+L.+Kunkel&title=Interleukin-10+expression+and+chemokine+regulation+during+the+evolution+of+murine+type+II+collagen-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKasama%26aufirst%3DT.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DLincoln%26aufirst%3DP.%2BM.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26atitle%3DInterleukin-10%2520expression%2520and%2520chemokine%2520regulation%2520during%2520the%2520evolution%2520of%2520murine%2520type%2520II%2520collagen-induced%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1995%26volume%3D95%26spage%3D2868%26epage%3D2876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Szekanecz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szucs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span> </span><span class="NLM_article-title">Chemokines in rheumatic diseases</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">â</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2174%2F138945006775270231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16454702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XitlOkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=91-102&author=Z.+Szekaneczauthor=G.+Szucsauthor=S.+Szantoauthor=A.+E.+Koch&title=Chemokines+in+rheumatic+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines in rheumatic diseases</span></div><div class="casAuthors">Szekanecz, Zoltan; Szucs, Gabriella; Szanto, Sandor; Koch, Alisa E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-102</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chemotactic cytokines, termed chemokines, mediate the ingress of leukocytes into the inflamed synovium.  In this review, authors discuss the role of the most relevant chemokines and chemokine receptors involved in chronic inflammatory rheumatic diseases.  Rheumatoid arthritis was chosen as a prototype to discuss these issues, as the majority of studies on the role of chemokines in inflammatory diseases were carried out in arthritis.  However, other rheumatic diseases including systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, mixed connective tissue disease, polymyositis/dermatomyositis, antiphospholipid syndrome and systemic vasculitides are also discussed in this context.  Apart from discussing the pathogenic role of chemokines and their receptors, authors also review the regulation of chemokine prodn. by other inflammatory mediators, as well as the important relevance of chemokines for antirheumatic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcKteMDUIu7bVg90H21EOLACvtfcHk0lgMiu3_JWzzag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitlOkuw%253D%253D&md5=7e04aa1cee025048120172ede7c91fb1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F138945006775270231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945006775270231%26sid%3Dliteratum%253Aachs%26aulast%3DSzekanecz%26aufirst%3DZ.%26aulast%3DSzucs%26aufirst%3DG.%26aulast%3DSzanto%26aufirst%3DS.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26atitle%3DChemokines%2520in%2520rheumatic%2520diseases%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2006%26volume%3D7%26spage%3D91%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Barnes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufhold, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, H. D.</span><span> </span><span class="NLM_article-title">Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2910</span><span class="NLM_x">â</span> <span class="NLM_lpage">2919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1998&pages=2910-2919&author=D.+A.+Barnesauthor=J.+Tseauthor=M.+Kaufholdauthor=M.+Owenauthor=J.+Hesselgesserauthor=R.+Strieterauthor=R.+Horukauthor=H.+D.+Perez&title=Polyclonal+antibody+directed+against+human+RANTES+ameliorates+disease+in+the+Lewis+rat+adjuvant-induced+arthritis+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DD.%2BA.%26aulast%3DTse%26aufirst%3DJ.%26aulast%3DKaufhold%26aufirst%3DM.%26aulast%3DOwen%26aufirst%3DM.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DStrieter%26aufirst%3DR.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DPerez%26aufirst%3DH.%2BD.%26atitle%3DPolyclonal%2520antibody%2520directed%2520against%2520human%2520RANTES%2520ameliorates%2520disease%2520in%2520the%2520Lewis%2520rat%2520adjuvant-induced%2520arthritis%2520model%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D101%26spage%3D2910%26epage%3D2919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Haas, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span> </span><span class="NLM_article-title">Chemokine receptor expression in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3718</span><span class="NLM_x">â</span> <span class="NLM_lpage">3730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.21476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16320322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvF2jtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=3718-3730&author=C.+S.+Haasauthor=R.+J.+Martinezauthor=N.+Attiaauthor=G.+K.+Hainesauthor=P.+L.+Campbellauthor=A.+E.+Koch&title=Chemokine+receptor+expression+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor expression in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Haas, Christian S.; Martinez, Rita J.; Attia, Naweah; Haines, G. Kenneth, III; Campbell, Phillip L.; Koch, Alisa E.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3718-3730</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Chemokine receptors mediate leukocyte migration into inflamed rheumatoid arthritis (RA) synovial tissue (ST).  Knowledge of their distribution is crucial for understanding the evolution of the inflammatory process.  In this study, we used rat adjuvant-induced arthritis (AIA), a model for RA, to define the temporospatial expression of chemokine receptors.  ST from rats with AIA was immuno-stained, the percentage of cells expressing each receptor was detd., and findings were correlated with levels of inflammation.  Chemokine receptor expression was evaluated on rat macrophages in vitro.  CCR1, a receptor for macrophage inflammatory protein 1Î± (MIP-1Î±)/CCL3 and RANTES/CCL5, exhibited high constitutive expression on macrophages in AIA.  CCR5, binding MIP-1Î±/CCL3 and RANTES/CCL5, was up-regulated on ST macrophages during the course of AIA, correlating with macrophage expression of CCR2, a receptor for monocyte chemoattractant protein 1/CCL2.  Endothelial cell (EC) CCR2 was down-regulated as arthritis progressed, inversely correlating with inflammation.  CCR3, another RANTES/CCL5 receptor, was constitutively high on macrophages in vivo and in vitro, with down-regulation during AIA.  CXCR4, a receptor for stromal cell-derived factor 1/CXCL12), was prominently up-regulated on ECs, preceding the peak of inflammation.  These findings show that (1) constitutive expression of CCR1 on macrophages remains high during AIA; (2) CCR2 and CCR3 may play a role in initial recruitment of leukocytes to ST in AIA; (3) macrophage expression of CCR2 and CCR5 may be important for sustaining inflammatory changes; and (4) EC CXCR4 may be a harbinger of inflammatory changes.  The results may help guide chemokine receptor blockade-targeting treatment strategies in inflammatory arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPd5t51UwjCrVg90H21EOLACvtfcHk0lgMiu3_JWzzag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvF2jtg%253D%253D&md5=b46bb398191284340b72899e04911ce4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fart.21476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.21476%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DC.%2BS.%26aulast%3DMartinez%26aufirst%3DR.%2BJ.%26aulast%3DAttia%26aufirst%3DN.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DCampbell%26aufirst%3DP.%2BL.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26atitle%3DChemokine%2520receptor%2520expression%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26spage%3D3718%26epage%3D3730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinders-Blankert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">â</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1136%2Fard.2005.037176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16107514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFCjt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=294-300&author=J.+J.+Haringmanauthor=T.+J.+Smeetsauthor=P.+Reinders-Blankertauthor=P.+P.+Tak&title=Chemokine+and+chemokine+receptor+expression+in+paired+peripheral+blood+mononuclear+cells+and+synovial+tissue+of+patients+with+rheumatoid+arthritis%2C+osteoarthritis%2C+and+reactive+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis</span></div><div class="casAuthors">Haringman, J. J.; Smeets, T. J. M.; Reinders-Blankert, P.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">294-300</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Chemokine receptors and chemokines have a crucial rote in leukocyte recruitment into inflamed tissue.  To examine the expression of an extensive no. of chemokines and receptors in a unique bank of paired samples of synovial tissue (ST) and peripheral blood (PB) from patients with different forms of arthritis to assist in identifying suitable targets for therapeutic intervention.  Synovial biopsy specimens were obtained from 23 patients with rheumatoid arthritis (RA), 16 with osteoarthritis, and 8 with reactive arthritis.  ST chemokine (CCL2/MCP-1, CCL5/RANTES, CCL7/MCP-3, CCL8/MCP-2, CCL14/HCC-1, CCL15/HCC-2, CCL16/HCC-4), chemokine receptor (CCR1, CCR2b, CCR5, CXCR4), and CD13 expression was analyzed by immunohistochem. and two color immunofluorescence.  Chemokine receptor expression (CCR1, CCR3, CCR5, CCR6, CCR7) on PB cells was studied by flow cytometry.  Non-parametric tests were used for statistical anal.  Abundant expression of CCR1, CXCR4, and CCR5 was found in all forms of arthritis, with a specific increase of CCL5 and CCL15 in RA.  CCL7, CCL8, CCL14, CCL15, and CCL16 were detected for the first time in ST.  The results for PB anal. were comparable among different arthritides.  Interestingly, compared with healthy controls, significantly lower expression of CCR1 (p < 0.005) and CCR5 (p < 0.05) by PB monocytes in the patient groups was seen.  A variety of chemokines and receptors might have an important role in several inflammatory joint disorders.  Although other receptors are involved as well, migration of CCR1+ and CCR5+ cells towards the synovial compartment may play a part in the effector phase of various forms of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQKWYcbrV2VrVg90H21EOLACvtfcHk0lgBTYDeY1mM5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFCjt70%253D&md5=21c7053e182323bcc45cabd1ad86ec3b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fard.2005.037176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2005.037176%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DReinders-Blankert%26aufirst%3DP.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DChemokine%2520and%2520chemokine%2520receptor%2520expression%2520in%2520paired%2520peripheral%2520blood%2520mononuclear%2520cells%2520and%2520synovial%2520tissue%2520of%2520patients%2520with%2520rheumatoid%2520arthritis%252C%2520osteoarthritis%252C%2520and%2520reactive%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2006%26volume%3D65%26spage%3D294%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Amat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamim, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terricabras, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godessart, N.</span><span> </span><span class="NLM_article-title">Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">â</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fsj.bjp.0706912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17016504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtF2jsbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=666-675&author=M.+Amatauthor=C.+F.+Benjamimauthor=L.+M.+Williamsauthor=N.+Pratsauthor=E.+Terricabrasauthor=J.+Beletaauthor=S.+L.+Kunkelauthor=N.+Godessart&title=Pharmacological+blockade+of+CCR1+ameliorates+murine+arthritis+and+alters+cytokine+networks+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo</span></div><div class="casAuthors">Amat, M.; Benjamim, C. F.; Williams, L. M.; Prats, N.; Terricabras, E.; Beleta, J.; Kunkel, S. L.; Godessart, N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">666-675</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: The chemokine receptor CCR1 is a potential target for the treatment of rheumatoid arthritis.  To explore the impact of CCR1 blockade in exptl. arthritis and the underlying mechanisms, the authors used J-113863, a nonpeptide antagonist of the mouse receptor.  Compd. J-113863 was tested in collagen-induced arthritis (CIA) and three models of acute inflammation; Staphylococcus enterotoxin B (SEB)-induced interleukin-2 (IL-2), delayed-type hypersensitivity (DTH) response, and lipopolysaccharide (LPS)-induced tumor necrosis factorÎ± (TNFÎ±) prodn.  In the LPS model, CCR1 knockout, adrenalectomized, or IL-10-depleted mice were also used.  Prodn. of TNFÎ± by mouse macrophages and human synovial membrane samples in vitro were also studied.  Treatment of arthritic mice with J-113863 improved paw inflammation and joint damage, and dramatically decreased cell infiltration into joints.  The compd. did not inhibit IL-2 or DTH, but reduced plasma TNFÎ± levels in LPS-treated mice.  Surprisingly, CCR1 knockout mice produced more TNFÎ± than controls in response to LPS, and J-113863 decreased TNFÎ± also in CCR1 null mice, indicating that its effect was unrelated to CCR1.  Adrenalectomy or neutralization of IL-10 did not prevent inhibition of TNFÎ± prodn. by J-113863.  The compd. did not inhibit mouse TNFÎ± in vitro, but did induce a trend towards increased TNFÎ± release in cells from synovial membranes of rheumatoid arthritis patients.  CCR1 blockade improves the development of CIA, probably via inhibition of inflammatory cell recruitment.  However, results from both CCR1-deficient mice and human synovial membranes suggest that, in some exptl. settings, blocking CCR1 could enhance TNF prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFvI5jX9gLZrVg90H21EOLACvtfcHk0lgBTYDeY1mM5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtF2jsbrN&md5=f2ecf8d089d543ebaa5ca4210d8d210c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706912%26sid%3Dliteratum%253Aachs%26aulast%3DAmat%26aufirst%3DM.%26aulast%3DBenjamim%26aufirst%3DC.%2BF.%26aulast%3DWilliams%26aufirst%3DL.%2BM.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DTerricabras%26aufirst%3DE.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DGodessart%26aufirst%3DN.%26atitle%3DPharmacological%2520blockade%2520of%2520CCR1%2520ameliorates%2520murine%2520arthritis%2520and%2520alters%2520cytokine%2520networks%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D666%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwinderman, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">â</span> <span class="NLM_lpage">721</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1136%2Fard.62.8.715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=12860725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFWmsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2003&pages=715-721&author=J.+J.+Haringmanauthor=M.+C.+Kraanauthor=T.+J.+Smeetsauthor=K.+H.+Zwindermanauthor=P.+P.+Tak&title=Chemokine+blockade+and+chronic+inflammatory+disease%3A+proof+of+concept+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis</span></div><div class="casAuthors">Haringman, J. J.; Kraan, M. C.; Smeets, T. J. M.; Zwinderman, K. H.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">715-721</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Chemokines and their receptors are considered important contributors in cell migration and inflammation in chronic inflammatory disorders.  Chemokines affecting monocytes/macrophages are considered potential therapeutic targets, but no studies of the effects of blocking the chemokine repertoire in humans with a chronic inflammatory disease have been reported.  Objective: To carry out a double blind, placebo controlled, phase Ib clin. trial with a specific, oral CCR1 antagonist.  Methods: 16 Patients with active rheumatoid arthritis (RA) were randomized 3:1 to active:placebo treatment for 14 days.  Synovial biopsy specimens were obtained on days 1 and 15.  Immunohistochem. was used to detect the presence of various cell types before and after treatment and the results measured by digital image anal.  Results before and after treatment were compared by paired t test, and a two sample t test was used to compare the changes from baseline in the two groups.  Results: All patients completed the study.  A significant redn. in the no. of macrophages (p=0.016), intimal macrophages (p=0.026), and CCR1+cells (p=0.049) in patients treated with the chemokine antagonist compared with the placebo group occurred in the synovium.  Significant decreases in overall cellularity, intimal lining layer cellularity, CD4+ T cells, and CD8+ T cells also occurred in treated patients.  Cells lacking CCR1 were not affected.  Trends towards clin. improvement were seen in the treated patients but not in the placebo group.  Severe side effects were not reported.  Conclusion: Specific chemokine receptor blockade can result in relevant biol. effects in patients with active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPU559hSiRE7Vg90H21EOLACvtfcHk0lgBTYDeY1mM5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFWmsbc%253D&md5=7f247997f6aa952c0d1513d3b79eba85</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1136%2Fard.62.8.715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.62.8.715%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DKraan%26aufirst%3DM.%2BC.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DZwinderman%26aufirst%3DK.%2BH.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DChemokine%2520blockade%2520and%2520chronic%2520inflammatory%2520disease%253A%2520proof%2520of%2520concept%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2003%26volume%3D62%26spage%3D715%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlow, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evanoff, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">772</span><span class="NLM_x">â</span> <span class="NLM_lpage">779</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=772-779&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=L.+A.+Harlowauthor=B.+Johnsonauthor=H.+L.+Evanoffauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Enhanced+production+of+monocyte+chemoattractant+protein-1+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DHarlow%26aufirst%3DL.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DEvanoff%26aufirst%3DH.%2BL.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DEnhanced%2520production%2520of%2520monocyte%2520chemoattractant%2520protein-1%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1992%26volume%3D90%26spage%3D772%26epage%3D779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Villiger, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terkeltaub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, M.</span><span> </span><span class="NLM_article-title">Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">â</span> <span class="NLM_lpage">496</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=488-496&author=P.+M.+Villigerauthor=R.+Terkeltaubauthor=M.+Lotz&title=Monocyte+chemoattractant+protein-1+%28MCP-1%29+expression+in+human+articular+cartilage.+Induction+by+peptide+regulatory+factors+and+differential+effects+of+dexamethasone+and+retinoic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilliger%26aufirst%3DP.%2BM.%26aulast%3DTerkeltaub%26aufirst%3DR.%26aulast%3DLotz%26aufirst%3DM.%26atitle%3DMonocyte%2520chemoattractant%2520protein-1%2520%2528MCP-1%2529%2520expression%2520in%2520human%2520articular%2520cartilage.%2520Induction%2520by%2520peptide%2520regulatory%2520factors%2520and%2520differential%2520effects%2520of%2520dexamethasone%2520and%2520retinoic%2520acid%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1992%26volume%3D90%26spage%3D488%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Katschke, K. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruth, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponath, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span> </span><span class="NLM_article-title">Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">â</span> <span class="NLM_lpage">1032</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2F1529-0131%28200105%2944%3A5%3C1022%3A%3AAID-ANR181%3E3.0.CO%3B2-N" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11352233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1M%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1022-1032&author=K.+J.+Katschkeauthor=J.+B.+Rottmanauthor=J.+H.+Ruthauthor=S.+Qinauthor=L.+Wuauthor=G.+LaRosaauthor=P.+Ponathauthor=C.+C.+Parkauthor=R.+M.+Popeauthor=A.+E.+Koch&title=Differential+expression+of+chemokine+receptors+on+peripheral+blood%2C+synovial+fluid%2C+and+synovial+tissue+monocytes%2Fmacrophages+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis</span></div><div class="casAuthors">Katschke, Kenneth J., Jr.; Rottman, James B.; Ruth, Jeffrey H.; Qin, Shixin; Wu, Lijun; LaRosa, Gregory; Ponath, Paul; Park, Christy C.; Pope, Richard M.; Koch, Alisa E.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1022-1032</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Since it is likely that monocytes utilize chemokines to migrate to the rheumatoid arthritis (RA) joint, the authors investigated the expression of C-C chemokine receptors (CCR) 1-6 and C-X-C receptor 3 (CXCR3) in the peripheral blood (PB), synovial fluid (SF), and synovial tissue of patients with RA as well as in the PB of normal subjects.  The authors compared chemokine receptor expression on CD14+ monocytes from normal PB, RA PB, and RA SF using 2-color flow cytometry.  Correlations with patient clin. data were detd.  Chemokine and receptor expression were investigated in RA synovial tissue by immunohistochem. and 2-color immunofluorescence to identify CD68+ macrophages.  Most normal PB monocytes expressed CCR1 (87%) and CCR2 (84%), but not CCRs 3, 4, 5, or 6 or CXCR3.  RA PB monocytes expressed CCR1 (56%) and CCR2 (76%), with significantly more expressing CCR3 (18%), CCR4 (38%), and CCR5 (17%) compared with normal PB monocytes.  Significantly fewer SF monocytes from RA patients expressed CCR1 (17%), CCR2 (24%), and CCR4 (6%) while significantly more expressed CCR3 (35%) and CCR5 (47%) compared with RA and normal PB monocytes; CCR6 and CXCR3 were rarely detected.  Clin., the erythrocyte sedimentation rate was inversely correlated with the expression of CCR1 and CCR4 by RA PB, and CCR5 expression by RA SF was correlated with the SF white blood cell count.  CCR1-, CCR2-, and CCR5-immunoreactive cells were found in RA synovial tissue and colocalized with CD68+ macrophages.  RA synovial tissue RANTES (regulated upon activation, normally T cell expressed and secreted chemokine)- and monocyte chemoattractant protein 1-immunoreactive cells colocalized with CCR1 and CCR2, resp., on serial sections.  Macrophage inflammatory protein 1Î± (MIP-1Î±) was principally restricted to vascular endothelium, and MIP-1Î²+ macrophages were found throughout the sections.  Monocytes mainly express CCR1 and CCR2 in normal and RA PB, CCR3 and CCR5 in RA PB and RA SF, and CCR4 in RA PB.  The differential expression of chemokine receptors suggests that certain receptors aid in monocyte recruitment from the circulation while others are important in monocyte retention in the joint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ-GDTU1Qjx7Vg90H21EOLACvtfcHk0lirDw2239Bl-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1M%253D&md5=7f946d9bc0bfd58a8149ae2537128d4c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F1529-0131%28200105%2944%3A5%3C1022%3A%3AAID-ANR181%3E3.0.CO%3B2-N&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1529-0131%2528200105%252944%253A5%253C1022%253A%253AAID-ANR181%253E3.0.CO%253B2-N%26sid%3Dliteratum%253Aachs%26aulast%3DKatschke%26aufirst%3DK.%2BJ.%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DRuth%26aufirst%3DJ.%2BH.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLaRosa%26aufirst%3DG.%26aulast%3DPonath%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DC.%2BC.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26atitle%3DDifferential%2520expression%2520of%2520chemokine%2520receptors%2520on%2520peripheral%2520blood%252C%2520synovial%2520fluid%252C%2520and%2520synovial%2520tissue%2520monocytes%252Fmacrophages%2520in%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2001%26volume%3D44%26spage%3D1022%26epage%3D1032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evanhoff, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Synovial tissue macrophage as a source of the chemotactic cytokine IL-8</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">2187</span><span class="NLM_x">â</span> <span class="NLM_lpage">2195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=1991&pages=2187-2195&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=J.+C.+Burrowsauthor=H.+L.+Evanhoffauthor=G.+K.+Hainesauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Synovial+tissue+macrophage+as+a+source+of+the+chemotactic+cytokine+IL-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DBurrows%26aufirst%3DJ.%2BC.%26aulast%3DEvanhoff%26aufirst%3DH.%2BL.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DSynovial%2520tissue%2520macrophage%2520as%2520a%2520source%2520of%2520the%2520chemotactic%2520cytokine%2520IL-8%26jtitle%3DJ.%2520Immunol.%26date%3D1991%26volume%3D147%26spage%3D2187%26epage%3D2195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halloran, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span> </span><span class="NLM_article-title">Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">3660</span><span class="NLM_x">â</span> <span class="NLM_lpage">3666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=3660-3666&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=M.+R.+Shahauthor=S.+Hosakaauthor=M.+M.+Halloranauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Growth-related+gene+product+alpha.+A+chemotactic+cytokine+for+neutrophils+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DShah%26aufirst%3DM.%2BR.%26aulast%3DHosaka%26aufirst%3DS.%26aulast%3DHalloran%26aufirst%3DM.%2BM.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DGrowth-related%2520gene%2520product%2520alpha.%2520A%2520chemotactic%2520cytokine%2520for%2520neutrophils%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26spage%3D3660%26epage%3D3666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Patel, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachariah, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whichard, L. P.</span><span> </span><span class="NLM_article-title">CXCR3 and CCR5 ligands in rheumatoid arthritis synovium</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1006%2Fclim.2000.4957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11141325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1Wis78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=39-45&author=D.+D.+Patelauthor=J.+P.+Zachariahauthor=L.+P.+Whichard&title=CXCR3+and+CCR5+ligands+in+rheumatoid+arthritis+synovium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR3 and CCR5 ligands in rheumatoid arthritis synovium</span></div><div class="casAuthors">Patel, Dhavalkumar D.; Zachariah, Jason P.; Whichard, Leona P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Orlando, Florida)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-45</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The pathogenesis of rheumatoid arthritis (RA) may be mediated by Th1-type T cells.  Since chemokine receptors CXCR3 and CCR5 are preferentially expressed on Th1 cells, we tested the expression and regulation of several chemokines, including those that signal through CXCR3 (interferon-Î³-inducible protein of 10 kDa, IP-10, CXCL10; and monokine induced by interferon-Î³, Mig, CXCL9) and CCR5 (macrophage inflammatory protein (Mip)-1Î±, CCL3; and Mip-1Î², CCL4) in RA synovial fluids, synovial tissues, and blood.  Synovial fluid (SF) protein levels of IP-10 (32.1 Â± 10.5 ng/mL), Mig (15.0 Â± 6.4 ng/mL), Mip-1Î² (0.7 Â± 0.3 ng/mL), and Mip-1Î± (0.8 Â± 0.1 ng/mL) were 100-, 50-, 25-, and 2-fold elevated in RASF compared to control SF (P < 0.001, P < 0.001, P < 0.001, and P < 0.02, resp.).  Tissue levels of IP-10, Mig, and Mip-1Î² were significantly higher in RA than in OA (P < 0.01).  Serum levels of IP-10 (3.1 Â± 1.2 ng/mL) were higher in patients with seropos. RA compared to controls (1.2 Â± 0.2 ng/mL) (P < 0.02).  There was a gradient of IP-10, Mig, Mip-1Î±, and Mip-1Î² from the blood into the synovial fluid in RA.  Infiltrating T cells around high endothelial venules in RA synovium and 90 Â± 3% of SF CD3+CD4+ T cells expressed CXCR3, and 85 Â± 2% of SF CD3+CD4+ T cells expressed CCR5.  Chemokines, including IP-10, Mig, Mip-1Î±, and Mip-1Î², may participate in the selective recruitment of CCR5+CXCR3+ T cells to the inflamed synovium.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLszSt-Oyv87Vg90H21EOLACvtfcHk0lirDw2239Bl-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1Wis78%253D&md5=7c010f394ed3d7e247c2ddf7ef9322ec</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1006%2Fclim.2000.4957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fclim.2000.4957%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DD.%2BD.%26aulast%3DZachariah%26aufirst%3DJ.%2BP.%26aulast%3DWhichard%26aufirst%3DL.%2BP.%26atitle%3DCXCR3%2520and%2520CCR5%2520ligands%2520in%2520rheumatoid%2520arthritis%2520synovium%26jtitle%3DClin.%2520Immunol.%26date%3D2001%26volume%3D98%26spage%3D39%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Kim, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisvert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, E. C.</span><span> </span><span class="NLM_article-title">Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">â</span> <span class="NLM_lpage">601</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2001&pages=595-601&author=C.+H.+Kimauthor=E.+J.+Kunkelauthor=J.+Boisvertauthor=B.+Johnstonauthor=J.+J.+Campbellauthor=M.+C.+Genoveseauthor=H.+B.+Greenbergauthor=E.+C.+Butcher&title=Bonzo%2FCXCR6+expression+defines+type+1-polarized+T-cell+subsets+with+extralymphoid+tissue+homing+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DKunkel%26aufirst%3DE.%2BJ.%26aulast%3DBoisvert%26aufirst%3DJ.%26aulast%3DJohnston%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DJ.%2BJ.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenberg%26aufirst%3DH.%2BB.%26aulast%3DButcher%26aufirst%3DE.%2BC.%26atitle%3DBonzo%252FCXCR6%2520expression%2520defines%2520type%25201-polarized%2520T-cell%2520subsets%2520with%2520extralymphoid%2520tissue%2520homing%2520potential%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2001%26volume%3D107%26spage%3D595%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Kay, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phipps, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. S.</span><span> </span><span class="NLM_article-title">A role for eosinophils in airway remodelling in asthma</span> <span class="citation_source-journal">Trends Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">â</span> <span class="NLM_lpage">482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.it.2004.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15324740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvFWmu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=477-482&author=A.+B.+Kayauthor=S.+Phippsauthor=D.+S.+Robinson&title=A+role+for+eosinophils+in+airway+remodelling+in+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A role for eosinophils in airway remodelling in asthma</span></div><div class="casAuthors">Kay, A. Barry; Phipps, Simon; Robinson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the years, the role of the eosinophil in asthma and allergic processes has been disputed.  Recent human expts. using a humanized monoclonal antibody to interleukin-5 (IL-5), and animal studies involving specific IL-5 gene deletion, indicates that eosinophils might control downstream repair and remodelling processes.  Eosinophils are a rich source of fibrogenic factors, particularly transforming growth factor-Î² (TGF-Î²), the latent form of which is activated by epithelial-cell expression of the integrin Î±vÎ²6.  The emerging role for the eosinophil in airway remodelling might be important in future anti-asthma strategies.  However, more effective eosinophil-depleting agents than anti-IL-5 are required before the definitive role of this cell type in asthma airway pathophysiol. can be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogri2K-7lQrrVg90H21EOLACvtfcHk0lhkGWcYVsqkxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvFWmu70%253D&md5=ca49cd95134e9b00d3e2c34f73f2d6ae</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2004.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2004.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DKay%26aufirst%3DA.%2BB.%26aulast%3DPhipps%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DD.%2BS.%26atitle%3DA%2520role%2520for%2520eosinophils%2520in%2520airway%2520remodelling%2520in%2520asthma%26jtitle%3DTrends%2520Immunol.%26date%3D2004%26volume%3D25%26spage%3D477%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Toda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S. J.</span><span> </span><span class="NLM_article-title">Impact of engagement of FcepsilonRI and CC chemokine receptor 1 on mast cell activation and motility</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">48443</span><span class="NLM_x">â</span> <span class="NLM_lpage">48448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=48443-48448&author=M.+Todaauthor=M.+Dawsonauthor=T.+Nakamuraauthor=P.+M.+Munroauthor=R.+M.+Richardsonauthor=M.+Baillyauthor=S.+J.+Ono&title=Impact+of+engagement+of+FcepsilonRI+and+CC+chemokine+receptor+1+on+mast+cell+activation+and+motility"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DMunro%26aufirst%3DP.%2BM.%26aulast%3DRichardson%26aufirst%3DR.%2BM.%26aulast%3DBailly%26aufirst%3DM.%26aulast%3DOno%26aufirst%3DS.%2BJ.%26atitle%3DImpact%2520of%2520engagement%2520of%2520FcepsilonRI%2520and%2520CC%2520chemokine%2520receptor%25201%2520on%2520mast%2520cell%2520activation%2520and%2520motility%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D48443%26epage%3D48448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Miyazaki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung-Chau, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S. J.</span><span> </span><span class="NLM_article-title">Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">434</span><span class="NLM_x">â</span> <span class="NLM_lpage">442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=434-442&author=D.+Miyazakiauthor=T.+Nakamuraauthor=M.+Todaauthor=K.+W.+Cheung-Chauauthor=R.+M.+Richardsonauthor=S.+J.+Ono&title=Macrophage+inflammatory+protein-1alpha+as+a+costimulatory+signal+for+mast+cell-mediated+immediate+hypersensitivity+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DToda%26aufirst%3DM.%26aulast%3DCheung-Chau%26aufirst%3DK.%2BW.%26aulast%3DRichardson%26aufirst%3DR.%2BM.%26aulast%3DOno%26aufirst%3DS.%2BJ.%26atitle%3DMacrophage%2520inflammatory%2520protein-1alpha%2520as%2520a%2520costimulatory%2520signal%2520for%2520mast%2520cell-mediated%2520immediate%2520hypersensitivity%2520reactions%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D434%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Power, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alouani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark-Lewis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span> </span><span class="NLM_article-title">Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">â</span> <span class="NLM_lpage">835</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=1997&pages=825-835&author=C.+A.+Powerauthor=D.+J.+Churchauthor=A.+Meyerauthor=S.+Alouaniauthor=A.+E.+Proudfootauthor=I.+Clark-Lewisauthor=S.+Sozzaniauthor=A.+Mantovaniauthor=T.+N.+Wells&title=Cloning+and+characterization+of+a+specific+receptor+for+the+novel+CC+chemokine+MIP-3alpha+from+lung+dendritic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPower%26aufirst%3DC.%2BA.%26aulast%3DChurch%26aufirst%3DD.%2BJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DClark-Lewis%26aufirst%3DI.%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DCloning%2520and%2520characterization%2520of%2520a%2520specific%2520receptor%2520for%2520the%2520novel%2520CC%2520chemokine%2520MIP-3alpha%2520from%2520lung%2520dendritic%2520cells%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1997%26volume%3D186%26spage%3D825%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Pilette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durham, S. R.</span><span> </span><span class="NLM_article-title">CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">884</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1183%2F09031936.04.00102504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15219001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsF2qtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=876-884&author=C.+Piletteauthor=J.+N.+Francisauthor=S.+J.+Tillauthor=S.+R.+Durham&title=CCR4+ligands+are+up-regulated+in+the+airways+of+atopic+asthmatics+after+segmental+allergen+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge</span></div><div class="casAuthors">Pilette, C.; Francis, J. N.; Till, S. J.; Durham, S. R.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">876-882</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">T-helper (Th) 2 cytokines are thought to mediate most features of allergic inflammation in atopic asthma.  However, it remains unclear whether chemokine pathways direct selective recruitment of Th2 cells to the airways during human allergic responses.  Bronchoalveolar lavage (BAL) was performed in 15 non-smoking mild atopic asthmatics before and 24 h after a fiberoptic segmental allergen challenge, and chemokines related to T-cell recruitment were assayed by ELISA.  The Th2-related C-C chemokine (CCR)4 ligands, macrophage-derived chemokine/C-C chemokine ligand (CCL)22 and thymus and activation-regulated chemokine/CCL17, were increased in BAL after challenge.  These chemokines correlated with lymphocyte nos. and with interleukin (IL)-5 and IL-13 in post-challenge BAL.  In contrast, 2 out of 3 putative Th1-related chemokines did not change.  There were no alterations in monokine induced by interferon (IFN)-Î³/CXC chemokine ligand (CXCL)9 or macrophage inflammatory protein-1Î±/CCL3; whereas an increase in IFN-induced protein-10 kDa/CXCL10 was obsd., which did not correlate with the T-cell influx.  In peripheral mononuclear cells from atopic donors, CCL22 and CCL17 were induced by IL-4 and IL-13, further supporting the relation between CCL22/CCL17 and Th2 cytokines.  Finally, CCL22 was able to trigger actin polymn. in peripheral CD4+ T-cells expressing CCR4.  Thus, CCR4 ligands are up-regulated in the airways of atopic asthmatics following allergen exposure, contribute to the T-cell influx to the airways, and are closely related to the Th2-cytokine response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxovHfR7rtPLVg90H21EOLACvtfcHk0lhlrX3j5V21Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsF2qtLo%253D&md5=465701fdcf4b858e0f863c045c36d9cd</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00102504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00102504%26sid%3Dliteratum%253Aachs%26aulast%3DPilette%26aufirst%3DC.%26aulast%3DFrancis%26aufirst%3DJ.%2BN.%26aulast%3DTill%26aufirst%3DS.%2BJ.%26aulast%3DDurham%26aufirst%3DS.%2BR.%26atitle%3DCCR4%2520ligands%2520are%2520up-regulated%2520in%2520the%2520airways%2520of%2520atopic%2520asthmatics%2520after%2520segmental%2520allergen%2520challenge%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D23%26spage%3D876%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Panina-Bordignon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Lucia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellettato, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonsanti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miotto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrigoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinigaglia, F.</span><span> </span><span class="NLM_article-title">The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1357</span><span class="NLM_x">â</span> <span class="NLM_lpage">1364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2001&pages=1357-1364&author=P.+Panina-Bordignonauthor=A.+Papiauthor=M.+Marianiauthor=P.+Di+Luciaauthor=G.+Casoniauthor=C.+Bellettatoauthor=C.+Buonsantiauthor=D.+Miottoauthor=C.+Mappauthor=A.+Villaauthor=G.+Arrigoniauthor=L.+M.+Fabbriauthor=F.+Sinigaglia&title=The+C-C+chemokine+receptors+CCR4+and+CCR8+identify+airway+T+cells+of+allergen-challenged+atopic+asthmatics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPanina-Bordignon%26aufirst%3DP.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DM.%26aulast%3DDi%2BLucia%26aufirst%3DP.%26aulast%3DCasoni%26aufirst%3DG.%26aulast%3DBellettato%26aufirst%3DC.%26aulast%3DBuonsanti%26aufirst%3DC.%26aulast%3DMiotto%26aufirst%3DD.%26aulast%3DMapp%26aufirst%3DC.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DArrigoni%26aufirst%3DG.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DSinigaglia%26aufirst%3DF.%26atitle%3DThe%2520C-C%2520chemokine%2520receptors%2520CCR4%2520and%2520CCR8%2520identify%2520airway%2520T%2520cells%2520of%2520allergen-challenged%2520atopic%2520asthmatics%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2001%26volume%3D107%26spage%3D1357%26epage%3D1364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Mutalithas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raport, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolbeck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brightling, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavord, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardlaw, A. J.</span><span> </span><span class="NLM_article-title">Expression of CCR8 is increased in asthma</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1175</span><span class="NLM_x">â</span> <span class="NLM_lpage">1185</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1365-2222.2010.03504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20455898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGlsbzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=1175-1185&author=K.+Mutalithasauthor=C.+Guillenauthor=C.+Raportauthor=R.+Kolbeckauthor=D.+Solerauthor=C.+E.+Brightlingauthor=I.+D.+Pavordauthor=A.+J.+Wardlaw&title=Expression+of+CCR8+is+increased+in+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of CCR8 is increased in asthma</span></div><div class="casAuthors">Mutalithas, K.; Guillen, C.; Raport, C.; Kolbeck, R.; Soler, D.; Brightling, C. E.; Pavord, I. D.; Wardlaw, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Allergy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1175-1185</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background Chemokines and their receptors could play key roles in the recruitment of T cells to the asthmatic lung.  CCR8 is preferentially expressed on T-helper type 2 cells, and is thought to play a role in the pathogenesis of human asthma.  Objective Det. the expression of CCR8 on T cells in blood, bronchoalveolar lavage (BAL) and bronchial mucosa from asthmatics and normal subjects.  Methods CCR8 expression in blood and BAL from asthma and normal subjects was studied using flow cytometry.  CCR8 expression on IFN-Î³+ and IL-4+/IL-13+ blood and BALT cells was studied following stimulation with Phorbol-Myristate-Acetate and Calcium Ionophore.  Paraffin-embedded bronchial biopsies were used to study CCR8 in bronchial epithelium.  Results The percentage of CD3+ cells expressing CCR8 in the blood was higher in asthmatics (4.7Â±0.4%) compared with normal subjects (3.0Â±0.4%; P<0.01).  There was an approx. sixfold enrichment of CCR8 on IL-4+/IL-13+ cells compared with IFN-Î³+ T cells (P<0.001) in both asthmatic and normal subjects in both blood and BAL.  Significantly more BAL T cells expressed CCR8 in asthmatic (8.6Â±0.8%) compared with normal subjects (3.9Â±0.7%) (P<0.01).  In paired blood-BAL samples from asthmatics, significantly more CCR8+CD3+ T cells were present in BAL (9.0Â±0.9%) than in blood (5.6Â±0.9%; P<0.05).  There were more CCR8-pos. cells in bronchial biopsies from asthmatic (93Â±11 cells/mm2) compared with normal subjects (30Â±16 cells/mm2) (P<0.05).  The ligand CCL1 was increased in the BAL of asthmatics compared with normal subjects (35Â±6 vs. 12.9Â±7 pg/mL; P<0.05).  Conclusion There may be a role for CCR8 in the recruitment of T cells to the lung in asthmatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoagMgrbtncLVg90H21EOLACvtfcHk0lhlrX3j5V21Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGlsbzP&md5=67f8ec3d746b375053c33a59c07aff8c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2010.03504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2010.03504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMutalithas%26aufirst%3DK.%26aulast%3DGuillen%26aufirst%3DC.%26aulast%3DRaport%26aufirst%3DC.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DBrightling%26aufirst%3DC.%2BE.%26aulast%3DPavord%26aufirst%3DI.%2BD.%26aulast%3DWardlaw%26aufirst%3DA.%2BJ.%26atitle%3DExpression%2520of%2520CCR8%2520is%2520increased%2520in%2520asthma%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2010%26volume%3D40%26spage%3D1175%26epage%3D1185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Ying, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ringler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daugherty, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durham, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A. B.</span><span> </span><span class="NLM_article-title">Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">â</span> <span class="NLM_lpage">3516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=3507-3516&author=S.+Yingauthor=D.+S.+Robinsonauthor=Q.+Mengauthor=J.+Rottmanauthor=R.+Kennedyauthor=D.+J.+Ringlerauthor=C.+R.+Mackayauthor=B.+L.+Daughertyauthor=M.+S.+Springerauthor=S.+R.+Durhamauthor=T.+J.+Williamsauthor=A.+B.+Kay&title=Enhanced+expression+of+eotaxin+and+CCR3+mRNA+and+protein+in+atopic+asthma.+Association+with+airway+hyperresponsiveness+and+predominant+co-localization+of+eotaxin+mRNA+to+bronchial+epithelial+and+endothelial+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DD.%2BS.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DRottman%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DR.%26aulast%3DRingler%26aufirst%3DD.%2BJ.%26aulast%3DMackay%26aufirst%3DC.%2BR.%26aulast%3DDaugherty%26aufirst%3DB.%2BL.%26aulast%3DSpringer%26aufirst%3DM.%2BS.%26aulast%3DDurham%26aufirst%3DS.%2BR.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DKay%26aufirst%3DA.%2BB.%26atitle%3DEnhanced%2520expression%2520of%2520eotaxin%2520and%2520CCR3%2520mRNA%2520and%2520protein%2520in%2520atopic%2520asthma.%2520Association%2520with%2520airway%2520hyperresponsiveness%2520and%2520predominant%2520co-localization%2520of%2520eotaxin%2520mRNA%2520to%2520bronchial%2520epithelial%2520and%2520endothelial%2520cells%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1997%26volume%3D27%26spage%3D3507%26epage%3D3516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Ying, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeibecoglou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macfarlane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A. B.</span><span> </span><span class="NLM_article-title">Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">6321</span><span class="NLM_x">â</span> <span class="NLM_lpage">6329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10570327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1MXns12rtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1999&pages=6321-6329&author=S.+Yingauthor=Q.+Mengauthor=K.+Zeibecoglouauthor=D.+S.+Robinsonauthor=A.+Macfarlaneauthor=M.+Humbertauthor=A.+B.+Kay&title=Eosinophil+chemotactic+chemokines+%28eotaxin%2C+eotaxin-2%2C+RANTES%2C+monocyte+chemoattractant+protein-3+%28MCP-3%29%2C+and+MCP-4%29%2C+and+C-C+chemokine+receptor+3+expression+in+bronchial+biopsies+from+atopic+and+nonatopic+%28intrinsic%29+asthmatics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C Chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics</span></div><div class="casAuthors">Ying, Sun; Meng, Qiu; Zeibecoglou, Kyriaki; Robinson, Douglas S.; Macfarlane, Alison; Humbert, Marc; Kay, A. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6321-6329</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Atopic (AA) and nonatopic (NAA) asthma are characterized by chronic inflammation and local tissue eosinophilia.  Many C-C chemokines are potent eosinophil chemoattractants and act predominantly via the CCR3.  The authors examd. the expression of eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), MCP-4, and CCR3 in the bronchial mucosa from atopic (AA) and nonatopic (intrinsic; NAA) asthmatics and compared their findings with atopic (AC) and nonatopic non-asthmatic controls (NC).  Cryostat sections were processed for immunohistochem. (IHC), in situ hybridization (ISH), and double IHC/ISH.  Compared with AC and NC, the nos. of EG2+ cells and the cells expressing mRNA for eotaxin, eotaxin-2, RANTES, MCP-3, MCP-4, and CCR3 were increased in AA and NAA.  Nonsignificant differences in these variants were obsd. between AA and NAA and between AC and NC.  Correlations between the cells expressing eotaxin or CCR3 and EG2+ eosinophils in the bronchial tissue were also obsd. for both AA and NAA.  Moreover, in the total asthmatic group (AA + NAA) there was an inverse correlation between the expression of eotaxin and that of the histamine PC20.  Sequential IHC/ISH showed that cytokeratin+ epithelial cells, CD31+ endothelial cells, and CD68+ macrophages were the major sources of eotaxin, eotaxin-2, RANTES, MCP-3, and MCP-4.  There was no different distribution of cells expressing mRNA for these chemokines between atopic and nonatopic asthma.  Thus, multiple C-C chemokines, acting at least in part via CCR3, contribute to bronchial eosinophilia in both atopic and nonatopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHTNwkvqpJbLVg90H21EOLACvtfcHk0lg3USbV6_gZBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns12rtb4%253D&md5=d3c7f1b65877ea74177bd6e6dfef2dcc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DZeibecoglou%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DD.%2BS.%26aulast%3DMacfarlane%26aufirst%3DA.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DKay%26aufirst%3DA.%2BB.%26atitle%3DEosinophil%2520chemotactic%2520chemokines%2520%2528eotaxin%252C%2520eotaxin-2%252C%2520RANTES%252C%2520monocyte%2520chemoattractant%2520protein-3%2520%2528MCP-3%2529%252C%2520and%2520MCP-4%2529%252C%2520and%2520C-C%2520chemokine%2520receptor%25203%2520expression%2520in%2520bronchial%2520biopsies%2520from%2520atopic%2520and%2520nonatopic%2520%2528intrinsic%2529%2520asthmatics%26jtitle%3DJ.%2520Immunol.%26date%3D1999%26volume%3D163%26spage%3D6321%26epage%3D6329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Yamada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, Y.</span><span> </span><span class="NLM_article-title">Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum</span> <span class="citation_source-journal">Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">â</span> <span class="NLM_lpage">397</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=392-397&author=H.+Yamadaauthor=M.+Yamaguchiauthor=K.+Yamamotoauthor=T.+Nakajimaauthor=K.+Hiraiauthor=Y.+Moritaauthor=Y.+Sano&title=Eotaxin+in+induced+sputum+of+asthmatics%3A+relationship+with+eosinophils+and+eosinophil+cationic+protein+in+sputum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DHirai%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DY.%26aulast%3DSano%26aufirst%3DY.%26atitle%3DEotaxin%2520in%2520induced%2520sputum%2520of%2520asthmatics%253A%2520relationship%2520with%2520eosinophils%2520and%2520eosinophil%2520cationic%2520protein%2520in%2520sputum%26jtitle%3DAllergy%26date%3D2000%26volume%3D55%26spage%3D392%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Sallusto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanzavecchia, A.</span><span> </span><span class="NLM_article-title">Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">â</span> <span class="NLM_lpage">2007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=2005-2007&author=F.+Sallustoauthor=C.+R.+Mackayauthor=A.+Lanzavecchia&title=Selective+expression+of+the+eotaxin+receptor+CCR3+by+human+T+helper+2+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSallusto%26aufirst%3DF.%26aulast%3DMackay%26aufirst%3DC.%2BR.%26aulast%3DLanzavecchia%26aufirst%3DA.%26atitle%3DSelective%2520expression%2520of%2520the%2520eotaxin%2520receptor%2520CCR3%2520by%2520human%2520T%2520helper%25202%2520cells%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D2005%26epage%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Mantovani, A.</span><span> </span><span class="NLM_article-title">The chemokine system: redundancy for robust outputs</span> <span class="citation_source-journal">Immunol. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0167-5699%2899%2901469-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=10354549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1MXjvVGrsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=254-257&author=A.+Mantovani&title=The+chemokine+system%3A+redundancy+for+robust+outputs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The chemokine system: redundancy for robust outputs</span></div><div class="casAuthors">Mantovani, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Today</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">254-257</span>CODEN:
                <span class="NLM_cas:coden">IMTOD8</span>;
        ISSN:<span class="NLM_cas:issn">0167-4919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review and discussion with 39 refs.  Chemokines are redundant in their action on target cells and promiscuous in receptor usage.  Moreover, certain cells concomitantly produce several chemokines with an overlapping spectrum of action.  Here, the author argues that such robustness provides a conceptual framework to understand these intriguing aspects of the chemokine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LLmCSctuuLVg90H21EOLACvtfcHk0lg3USbV6_gZBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvVGrsLo%253D&md5=90752c5cf7c7ddc626934d079b0c565c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS0167-5699%2899%2901469-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-5699%252899%252901469-3%26sid%3Dliteratum%253Aachs%26aulast%3DMantovani%26aufirst%3DA.%26atitle%3DThe%2520chemokine%2520system%253A%2520redundancy%2520for%2520robust%2520outputs%26jtitle%3DImmunol.%2520Today%26date%3D1999%26volume%3D20%26spage%3D254%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csizmadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">â</span> <span class="NLM_lpage">44</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2000&pages=35-44&author=W.+Gaoauthor=P.+S.+Tophamauthor=J.+A.+Kingauthor=S.+T.+Smileyauthor=V.+Csizmadiaauthor=B.+Luauthor=C.+J.+Gerardauthor=W.+W.+Hancock&title=Targeting+of+the+chemokine+receptor+CCR1+suppresses+development+of+acute+and+chronic+cardiac+allograft+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26aulast%3DTopham%26aufirst%3DP.%2BS.%26aulast%3DKing%26aufirst%3DJ.%2BA.%26aulast%3DSmiley%26aufirst%3DS.%2BT.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DGerard%26aufirst%3DC.%2BJ.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DTargeting%2520of%2520the%2520chemokine%2520receptor%2520CCR1%2520suppresses%2520development%2520of%2520acute%2520and%2520chronic%2520cardiac%2520allograft%2520rejection%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D105%26spage%3D35%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Rottman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavin, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2372</span><span class="NLM_x">â</span> <span class="NLM_lpage">2377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2000&pages=2372-2377&author=J.+B.+Rottmanauthor=A.+J.+Slavinauthor=R.+Silvaauthor=H.+L.+Weinerauthor=C.+G.+Gerardauthor=W.+W.+Hancock&title=Leukocyte+recruitment+during+onset+of+experimental+allergic+encephalomyelitis+is+CCR1+dependent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRottman%26aufirst%3DJ.%2BB.%26aulast%3DSlavin%26aufirst%3DA.%2BJ.%26aulast%3DSilva%26aufirst%3DR.%26aulast%3DWeiner%26aufirst%3DH.%2BL.%26aulast%3DGerard%26aufirst%3DC.%2BG.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DLeukocyte%2520recruitment%2520during%2520onset%2520of%2520experimental%2520allergic%2520encephalomyelitis%2520is%2520CCR1%2520dependent%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2000%26volume%3D30%26spage%3D2372%26epage%3D2377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Potteaux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combadiere, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esposito, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merval, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardouin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedgui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallat, Z.</span><span> </span><span class="NLM_article-title">Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice</span> <span class="citation_source-journal">Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">â</span> <span class="NLM_lpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2119%2F2005-00028.Potteaux" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16491201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVelsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=16-20&author=S.+Potteauxauthor=C.+Combadiereauthor=B.+Espositoauthor=S.+Casanovaauthor=R.+Mervalauthor=P.+Ardouinauthor=J.+L.+Gaoauthor=P.+M.+Murphyauthor=A.+Tedguiauthor=Z.+Mallat&title=Chemokine+receptor+CCR1+disruption+in+bone+marrow+cells+enhances+atherosclerotic+lesion+development+and+inflammation+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice</span></div><div class="casAuthors">Potteaux, Stephane; Combadiere, Christophe; Esposito, Bruno; Casanova, Saveria; Merval, Regine; Ardouin, Patrice; Gao, Ji-Liang; Murphy, Philip M.; Tedgui, Alain; Mallat, Ziad</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Manhasset, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1-12</span>),
    <span class="NLM_cas:pages">16-20</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Feinstein Institute for Medical Research</span>)
        </div><div class="casAbstract">Several chemokines or chemokine receptors are involved in atherogenesis.  CCR1 is expressed by macrophages and lymphocytes, two major cell types involved in the progression of atherosclerosis, and binds to lesion-expressed ligands.  We examd. the direct role of the blood-borne chemokine receptor CCR1 in atherosclerosis by transplanting bone marrow cells from either CCR1+/+ or CCR1-/- mice into low-d. lipoprotein-receptor (LDLr)-deficient mice.  After exposure to an atherogenic diet for 8 wk, no differences in fatty streak size or compn. were detected between the 2 groups.  After 12 wk of atherogenic diet, however, an unexpected 70% increase in atherosclerotic lesion size in the thoracic aorta was detected in the CCR1-/- mice, accompanied by a 37% increase in the aortic sinus lesion area.  CCR1-/- mice showed enhanced basal and Con A-stimulated IFN-Î³ prodn. by spleen T cells and enhanced plaque inflammation.  In conclusion, blood-borne CCR1 alters the immuno-inflammatory response in atherosclerosis and prevents excessive plaque growth and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMKMl3uIv1h7Vg90H21EOLACvtfcHk0lhQjjExfgNtRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVelsr8%253D&md5=768117a187d37f0f7d1211a2de7d9533</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2119%2F2005-00028.Potteaux&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252F2005-00028.Potteaux%26sid%3Dliteratum%253Aachs%26aulast%3DPotteaux%26aufirst%3DS.%26aulast%3DCombadiere%26aufirst%3DC.%26aulast%3DEsposito%26aufirst%3DB.%26aulast%3DCasanova%26aufirst%3DS.%26aulast%3DMerval%26aufirst%3DR.%26aulast%3DArdouin%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DTedgui%26aufirst%3DA.%26aulast%3DMallat%26aufirst%3DZ.%26atitle%3DChemokine%2520receptor%2520CCR1%2520disruption%2520in%2520bone%2520marrow%2520cells%2520enhances%2520atherosclerotic%2520lesion%2520development%2520and%2520inflammation%2520in%2520mice%26jtitle%3DMol.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D16%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Boring, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chensue, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farese, R. V.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broxmeyer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2552</span><span class="NLM_x">â</span> <span class="NLM_lpage">2561</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1997&pages=2552-2561&author=L.+Boringauthor=J.+Goslingauthor=S.+W.+Chensueauthor=S.+L.+Kunkelauthor=R.+V.+Fareseauthor=H.+E.+Broxmeyerauthor=I.+F.+Charo&title=Impaired+monocyte+migration+and+reduced+type+1+%28Th1%29+cytokine+responses+in+C-C+chemokine+receptor+2+knockout+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoring%26aufirst%3DL.%26aulast%3DGosling%26aufirst%3DJ.%26aulast%3DChensue%26aufirst%3DS.%2BW.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DFarese%26aufirst%3DR.%2BV.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DImpaired%2520monocyte%2520migration%2520and%2520reduced%2520type%25201%2520%2528Th1%2529%2520cytokine%2520responses%2520in%2520C-C%2520chemokine%2520receptor%25202%2520knockout%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1997%26volume%3D100%26spage%3D2552%26epage%3D2561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Peters, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">7072</span><span class="NLM_x">â</span> <span class="NLM_lpage">7077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2000&pages=7072-7077&author=W.+Petersauthor=M.+Dupuisauthor=I.+F.+Charo&title=A+mechanism+for+the+impaired+IFN-gamma+production+in+C-C+chemokine+receptor+2+%28CCR2%29+knockout+mice%3A+role+of+CCR2+in+linking+the+innate+and+adaptive+immune+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DW.%26aulast%3DDupuis%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DA%2520mechanism%2520for%2520the%2520impaired%2520IFN-gamma%2520production%2520in%2520C-C%2520chemokine%2520receptor%25202%2520%2528CCR2%2529%2520knockout%2520mice%253A%2520role%2520of%2520CCR2%2520in%2520linking%2520the%2520innate%2520and%2520adaptive%2520immune%2520responses%26jtitle%3DJ.%2520Immunol.%26date%3D2000%26volume%3D165%26spage%3D7072%26epage%3D7077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Peters, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, J. D.</span><span> </span><span class="NLM_article-title">Chemokine receptor 2 serves an early and essential role in resistance to <i>Mycobacterium tuberculosis</i></span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">7958</span><span class="NLM_x">â</span> <span class="NLM_lpage">7963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=7958-7963&author=W.+Petersauthor=H.+M.+Scottauthor=H.+F.+Chambersauthor=J.+L.+Flynnauthor=I.+F.+Charoauthor=J.+D.+Ernst&title=Chemokine+receptor+2+serves+an+early+and+essential+role+in+resistance+to+Mycobacterium+tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DW.%26aulast%3DScott%26aufirst%3DH.%2BM.%26aulast%3DChambers%26aufirst%3DH.%2BF.%26aulast%3DFlynn%26aufirst%3DJ.%2BL.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DErnst%26aufirst%3DJ.%2BD.%26atitle%3DChemokine%2520receptor%25202%2520serves%2520an%2520early%2520and%2520essential%2520role%2520in%2520resistance%2520to%2520Mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D7958%26epage%3D7963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Blease, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrad, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standiford, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boring, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C. M.</span><span> </span><span class="NLM_article-title">Enhanced pulmonary allergic responses to Aspergillus in CCR2â/â mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">2603</span><span class="NLM_x">â</span> <span class="NLM_lpage">2611</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2000&pages=2603-2611&author=K.+Bleaseauthor=B.+Mehradauthor=T.+J.+Standifordauthor=N.+W.+Lukacsauthor=J.+Goslingauthor=L.+Boringauthor=I.+F.+Charoauthor=S.+L.+Kunkelauthor=C.+M.+Hogaboam&title=Enhanced+pulmonary+allergic+responses+to+Aspergillus+in+CCR2%E2%80%93%2F%E2%80%93+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DMehrad%26aufirst%3DB.%26aulast%3DStandiford%26aufirst%3DT.%2BJ.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DGosling%26aufirst%3DJ.%26aulast%3DBoring%26aufirst%3DL.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26atitle%3DEnhanced%2520pulmonary%2520allergic%2520responses%2520to%2520Aspergillus%2520in%2520CCR2%25E2%2580%2593%252F%25E2%2580%2593%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2000%26volume%3D165%26spage%3D2603%26epage%3D2611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Gonzalo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albar, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Ramos, J. C.</span><span> </span><span class="NLM_article-title">The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">188</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">â</span> <span class="NLM_lpage">167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=1998&pages=157-167&author=J.+A.+Gonzaloauthor=C.+M.+Lloydauthor=D.+Wenauthor=J.+P.+Albarauthor=T.+N.+Wellsauthor=A.+Proudfootauthor=A.+C.+Martinezauthor=M.+Dorfauthor=T.+Bjerkeauthor=A.+J.+Coyleauthor=J.+C.+Gutierrez-Ramos&title=The+coordinated+action+of+CC+chemokines+in+the+lung+orchestrates+allergic+inflammation+and+airway+hyperresponsiveness"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalo%26aufirst%3DJ.%2BA.%26aulast%3DLloyd%26aufirst%3DC.%2BM.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DAlbar%26aufirst%3DJ.%2BP.%26aulast%3DWells%26aufirst%3DT.%2BN.%26aulast%3DProudfoot%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DA.%2BC.%26aulast%3DDorf%26aufirst%3DM.%26aulast%3DBjerke%26aufirst%3DT.%26aulast%3DCoyle%26aufirst%3DA.%2BJ.%26aulast%3DGutierrez-Ramos%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520coordinated%2520action%2520of%2520CC%2520chemokines%2520in%2520the%2520lung%2520orchestrates%2520allergic%2520inflammation%2520and%2520airway%2520hyperresponsiveness%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1998%26volume%3D188%26spage%3D157%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Collington, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallgren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rollins, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austen, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurish, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, C. L.</span><span> </span><span class="NLM_article-title">The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">6114</span><span class="NLM_x">â</span> <span class="NLM_lpage">6123</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=6114-6123&author=S.+J.+Collingtonauthor=J.+Hallgrenauthor=J.+E.+Peaseauthor=T.+G.+Jonesauthor=B.+J.+Rollinsauthor=J.+Westwickauthor=K.+F.+Austenauthor=T.+J.+Williamsauthor=M.+F.+Gurishauthor=C.+L.+Weller&title=The+role+of+the+CCL2%2FCCR2+axis+in+mouse+mast+cell+migration+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCollington%26aufirst%3DS.%2BJ.%26aulast%3DHallgren%26aufirst%3DJ.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DJones%26aufirst%3DT.%2BG.%26aulast%3DRollins%26aufirst%3DB.%2BJ.%26aulast%3DWestwick%26aufirst%3DJ.%26aulast%3DAusten%26aufirst%3DK.%2BF.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DGurish%26aufirst%3DM.%2BF.%26aulast%3DWeller%26aufirst%3DC.%2BL.%26atitle%3DThe%2520role%2520of%2520the%2520CCL2%252FCCR2%2520axis%2520in%2520mouse%2520mast%2520cell%2520migration%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D6114%26epage%3D6123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Boring, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleary, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charo, I. F.</span><span> </span><span class="NLM_article-title">Decreased lesion formation in CCR2â/â mice reveals a role for chemokines in the initiation of atherosclerosis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">394</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">â</span> <span class="NLM_lpage">897</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=1998&pages=894-897&author=L.+Boringauthor=J.+Goslingauthor=M.+Clearyauthor=I.+F.+Charo&title=Decreased+lesion+formation+in+CCR2%E2%80%93%2F%E2%80%93+mice+reveals+a+role+for+chemokines+in+the+initiation+of+atherosclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoring%26aufirst%3DL.%26aulast%3DGosling%26aufirst%3DJ.%26aulast%3DCleary%26aufirst%3DM.%26aulast%3DCharo%26aufirst%3DI.%2BF.%26atitle%3DDecreased%2520lesion%2520formation%2520in%2520CCR2%25E2%2580%2593%252F%25E2%2580%2593%2520mice%2520reveals%2520a%2520role%2520for%2520chemokines%2520in%2520the%2520initiation%2520of%2520atherosclerosis%26jtitle%3DNature%26date%3D1998%26volume%3D394%26spage%3D894%26epage%3D897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Humbles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Garawi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span> </span><span class="NLM_article-title">The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">â</span> <span class="NLM_lpage">1484</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1479-1484&author=A.+A.+Humblesauthor=B.+Luauthor=D.+S.+Friendauthor=S.+Okinagaauthor=J.+Loraauthor=A.+Al-Garawiauthor=T.+R.+Martinauthor=N.+P.+Gerardauthor=C.+Gerard&title=The+murine+CCR3+receptor+regulates+both+the+role+of+eosinophils+and+mast+cells+in+allergen-induced+airway+inflammation+and+hyperresponsiveness"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHumbles%26aufirst%3DA.%2BA.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DFriend%26aufirst%3DD.%2BS.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DLora%26aufirst%3DJ.%26aulast%3DAl-Garawi%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DT.%2BR.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26atitle%3DThe%2520murine%2520CCR3%2520receptor%2520regulates%2520both%2520the%2520role%2520of%2520eosinophils%2520and%2520mast%2520cells%2520in%2520allergen-induced%2520airway%2520inflammation%2520and%2520hyperresponsiveness%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D1479%26epage%3D1484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryce, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laouini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yalcindag, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alenius, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friend, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oettgen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geha, R. S.</span><span> </span><span class="NLM_article-title">CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">â</span> <span class="NLM_lpage">628</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=621-628&author=W.+Maauthor=P.+J.+Bryceauthor=A.+A.+Humblesauthor=D.+Laouiniauthor=A.+Yalcindagauthor=H.+Aleniusauthor=D.+S.+Friendauthor=H.+C.+Oettgenauthor=C.+Gerardauthor=R.+S.+Geha&title=CCR3+is+essential+for+skin+eosinophilia+and+airway+hyperresponsiveness+in+a+murine+model+of+allergic+skin+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DW.%26aulast%3DBryce%26aufirst%3DP.%2BJ.%26aulast%3DHumbles%26aufirst%3DA.%2BA.%26aulast%3DLaouini%26aufirst%3DD.%26aulast%3DYalcindag%26aufirst%3DA.%26aulast%3DAlenius%26aufirst%3DH.%26aulast%3DFriend%26aufirst%3DD.%2BS.%26aulast%3DOettgen%26aufirst%3DH.%2BC.%26aulast%3DGerard%26aufirst%3DC.%26aulast%3DGeha%26aufirst%3DR.%2BS.%26atitle%3DCCR3%2520is%2520essential%2520for%2520skin%2520eosinophilia%2520and%2520airway%2520hyperresponsiveness%2520in%2520a%2520murine%2520model%2520of%2520allergic%2520skin%2520inflammation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D621%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Collington, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, C. L.</span><span> </span><span class="NLM_article-title">The function of CCR3 on mouse bone marrow-derived mast cells in vitro</span> <span class="citation_source-journal">Immunology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2010&pages=115-124&author=S.+J.+Collingtonauthor=J.+Westwickauthor=T.+J.+Williamsauthor=C.+L.+Weller&title=The+function+of+CCR3+on+mouse+bone+marrow-derived+mast+cells+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCollington%26aufirst%3DS.%2BJ.%26aulast%3DWestwick%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DWeller%26aufirst%3DC.%2BL.%26atitle%3DThe%2520function%2520of%2520CCR3%2520on%2520mouse%2520bone%2520marrow-derived%2520mast%2520cells%2520in%2520vitro%26jtitle%3DImmunology%26date%3D2010%26volume%3D129%26spage%3D115%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Chvatchko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogewerf, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alouani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conquet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span> </span><span class="NLM_article-title">A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">1755</span><span class="NLM_x">â</span> <span class="NLM_lpage">1764</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=1755-1764&author=Y.+Chvatchkoauthor=A.+J.+Hoogewerfauthor=A.+Meyerauthor=S.+Alouaniauthor=P.+Juillardauthor=R.+Buserauthor=F.+Conquetauthor=A.+E.+Proudfootauthor=T.+N.+Wellsauthor=C.+A.+Power&title=A+key+role+for+CC+chemokine+receptor+4+in+lipopolysaccharide-induced+endotoxic+shock"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChvatchko%26aufirst%3DY.%26aulast%3DHoogewerf%26aufirst%3DA.%2BJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAlouani%26aufirst%3DS.%26aulast%3DJuillard%26aufirst%3DP.%26aulast%3DBuser%26aufirst%3DR.%26aulast%3DConquet%26aufirst%3DF.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DWells%26aufirst%3DT.%2BN.%26aulast%3DPower%26aufirst%3DC.%2BA.%26atitle%3DA%2520key%2520role%2520for%2520CC%2520chemokine%2520receptor%25204%2520in%2520lipopolysaccharide-induced%2520endotoxic%2520shock%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D1755%26epage%3D1764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Lloyd, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyle, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Ramos, J. C.</span><span> </span><span class="NLM_article-title">CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">â</span> <span class="NLM_lpage">274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=265-274&author=C.+M.+Lloydauthor=T.+Delaneyauthor=T.+Nguyenauthor=J.+Tianauthor=A.+C.+Martinezauthor=A.+J.+Coyleauthor=J.+C.+Gutierrez-Ramos&title=CC+chemokine+receptor+%28CCR%293%2Feotaxin+is+followed+by+CCR4%2Fmonocyte-derived+chemokine+in+mediating+pulmonary+T+helper+lymphocyte+type+2+recruitment+after+serial+antigen+challenge+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DC.%2BM.%26aulast%3DDelaney%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DA.%2BC.%26aulast%3DCoyle%26aufirst%3DA.%2BJ.%26aulast%3DGutierrez-Ramos%26aufirst%3DJ.%2BC.%26atitle%3DCC%2520chemokine%2520receptor%2520%2528CCR%25293%252Feotaxin%2520is%2520followed%2520by%2520CCR4%252Fmonocyte-derived%2520chemokine%2520in%2520mediating%2520pulmonary%2520T%2520helper%2520lymphocyte%2520type%25202%2520recruitment%2520after%2520serial%2520antigen%2520challenge%2520in%2520vivo%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D265%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Iellem, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recalde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panina-Bordignon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinigaglia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAmbrosio, D.</span><span> </span><span class="NLM_article-title">Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by cd4(+)cd25(+) regulatory T cells</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">â</span> <span class="NLM_lpage">854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2001&pages=847-854&author=A.+Iellemauthor=M.+Marianiauthor=R.+Langauthor=H.+Recaldeauthor=P.+Panina-Bordignonauthor=F.+Sinigagliaauthor=D.+D%E2%80%99Ambrosio&title=Unique+chemotactic+response+profile+and+specific+expression+of+chemokine+receptors+CCR4+and+CCR8+by+cd4%28%2B%29cd25%28%2B%29+regulatory+T+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIellem%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DM.%26aulast%3DLang%26aufirst%3DR.%26aulast%3DRecalde%26aufirst%3DH.%26aulast%3DPanina-Bordignon%26aufirst%3DP.%26aulast%3DSinigaglia%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DD.%26atitle%3DUnique%2520chemotactic%2520response%2520profile%2520and%2520specific%2520expression%2520of%2520chemokine%2520receptors%2520CCR4%2520and%2520CCR8%2520by%2520cd4%2528%252B%2529cd25%2528%252B%2529%2520regulatory%2520T%2520cells%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2001%26volume%3D194%26spage%3D847%26epage%3D854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Bernhagen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krohn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lue, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zernecke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenen, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgiev, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schober, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kooistra, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingerle-Rowson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghezzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleemann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McColl, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, C.</span><span> </span><span class="NLM_article-title">MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnm1567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17435771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvVOhu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=587-596&author=J.+Bernhagenauthor=R.+Krohnauthor=H.+Lueauthor=J.+L.+Gregoryauthor=A.+Zerneckeauthor=R.+R.+Koenenauthor=M.+Deworauthor=I.+Georgievauthor=A.+Schoberauthor=L.+Lengauthor=T.+Kooistraauthor=G.+Fingerle-Rowsonauthor=P.+Ghezziauthor=R.+Kleemannauthor=S.+R.+McCollauthor=R.+Bucalaauthor=M.+J.+Hickeyauthor=C.+Weber&title=MIF+is+a+noncognate+ligand+of+CXC+chemokine+receptors+in+inflammatory+and+atherogenic+cell+recruitment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment</span></div><div class="casAuthors">Bernhagen, Juergen; Krohn, Regina; Lue, Hongqi; Gregory, Julia L.; Zernecke, Alma; Koenen, Rory R.; Dewor, Manfred; Georgiev, Ivan; Schober, Andreas; Leng, Lin; Kooistra, Teake; Fingerle-Rowson, Guenter; Ghezzi, Pietro; Kleemann, Robert; McColl, Shaun R.; Bucala, Richard; Hickey, Michael J.; Weber, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">587-596</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The cytokine macrophage migration inhibitory factor (MIF) plays a crit. role in inflammatory diseases and atherogenesis.  The authors identify the chemokine receptors CXCR2 and CXCR4 as functional receptors for MIF.  MIF triggered GÎ±i- and integrin-dependent arrest and chemotaxis of monocytes and T cells, rapid integrin activation, and calcium influx through CXCR2 or CXCR4.  MIF competed with cognate ligands for CXCR4 and CXCR2 binding, and directly bound to CXCR2.  CXCR2 and CD74 formed a receptor complex, and monocyte arrest elicited by MIF in inflamed or atherosclerotic arteries involved both CXCR2 and CD74.  In vivo, Mif deficiency impaired monocyte adhesion to the arterial wall in atherosclerosis-prone mice, and MIF-induced leukocyte recruitment required Il8rb (which encodes Cxcr2).  Blockade of Mif but not of canonical ligands of Cxcr2 or Cxcr4 in mice with advanced atherosclerosis led to plaque regression and reduced monocyte and T-cell content in plaques.  By activating both CXCR2 and CXCR4, MIF displays chemokine-like functions and acts as a major regulator of inflammatory cell recruitment and atherogenesis.  Targeting MIF in individuals with manifest atherosclerosis can potentially be used to treat this condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVQOsX-ruaMLVg90H21EOLACvtfcHk0liiEzaFccFqiA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvVOhu7s%253D&md5=313a9a2158474e79f27fb59b7a62daab</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnm1567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1567%26sid%3Dliteratum%253Aachs%26aulast%3DBernhagen%26aufirst%3DJ.%26aulast%3DKrohn%26aufirst%3DR.%26aulast%3DLue%26aufirst%3DH.%26aulast%3DGregory%26aufirst%3DJ.%2BL.%26aulast%3DZernecke%26aufirst%3DA.%26aulast%3DKoenen%26aufirst%3DR.%2BR.%26aulast%3DDewor%26aufirst%3DM.%26aulast%3DGeorgiev%26aufirst%3DI.%26aulast%3DSchober%26aufirst%3DA.%26aulast%3DLeng%26aufirst%3DL.%26aulast%3DKooistra%26aufirst%3DT.%26aulast%3DFingerle-Rowson%26aufirst%3DG.%26aulast%3DGhezzi%26aufirst%3DP.%26aulast%3DKleemann%26aufirst%3DR.%26aulast%3DMcColl%26aufirst%3DS.%2BR.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DWeber%26aufirst%3DC.%26atitle%3DMIF%2520is%2520a%2520noncognate%2520ligand%2520of%2520CXC%2520chemokine%2520receptors%2520in%2520inflammatory%2520and%2520atherogenic%2520cell%2520recruitment%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D587%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Cacalano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts-Meek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hultgren, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. W.</span><span> </span><span class="NLM_article-title">Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">â</span> <span class="NLM_lpage">684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1994&pages=682-684&author=G.+Cacalanoauthor=J.+Leeauthor=K.+Kiklyauthor=A.+M.+Ryanauthor=S.+Pitts-Meekauthor=B.+Hultgrenauthor=W.+I.+Woodauthor=M.+W.+Moore&title=Neutrophil+and+B+cell+expansion+in+mice+that+lack+the+murine+IL-8+receptor+homolog"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCacalano%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKikly%26aufirst%3DK.%26aulast%3DRyan%26aufirst%3DA.%2BM.%26aulast%3DPitts-Meek%26aufirst%3DS.%26aulast%3DHultgren%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DW.%2BI.%26aulast%3DMoore%26aufirst%3DM.%2BW.%26atitle%3DNeutrophil%2520and%2520B%2520cell%2520expansion%2520in%2520mice%2520that%2520lack%2520the%2520murine%2520IL-8%2520receptor%2520homolog%26jtitle%3DScience%26date%3D1994%26volume%3D265%26spage%3D682%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patera, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pong-Kennedy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfra, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassileva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif-Rodriguez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opdenakker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Damme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedrick, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span> </span><span class="NLM_article-title">Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">11658</span><span class="NLM_x">â</span> <span class="NLM_lpage">11666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=11658-11666&author=X.+Fanauthor=A.+C.+Pateraauthor=A.+Pong-Kennedyauthor=G.+Denoauthor=W.+Gonsiorekauthor=D.+J.+Manfraauthor=G.+Vassilevaauthor=M.+Zengauthor=C.+Jacksonauthor=L.+Sullivanauthor=W.+Sharif-Rodriguezauthor=G.+Opdenakkerauthor=J.+Van+Dammeauthor=J.+A.+Hedrickauthor=D.+Lundellauthor=S.+A.+Liraauthor=R.+W.+Hipkin&title=Murine+CXCR1+is+a+functional+receptor+for+GCP-2%2FCXCL6+and+interleukin-8%2FCXCL8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DX.%26aulast%3DPatera%26aufirst%3DA.%2BC.%26aulast%3DPong-Kennedy%26aufirst%3DA.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DManfra%26aufirst%3DD.%2BJ.%26aulast%3DVassileva%26aufirst%3DG.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DSharif-Rodriguez%26aufirst%3DW.%26aulast%3DOpdenakker%26aufirst%3DG.%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DHedrick%26aufirst%3DJ.%2BA.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DLira%26aufirst%3DS.%2BA.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DMurine%2520CXCR1%2520is%2520a%2520functional%2520receptor%2520for%2520GCP-2%252FCXCL6%2520and%2520interleukin-8%252FCXCL8%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D11658%26epage%3D11666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Abonia, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austen, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rollins, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flavell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuziel, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koni, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurish, M. F.</span><span> </span><span class="NLM_article-title">Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">4308</span><span class="NLM_x">â</span> <span class="NLM_lpage">4313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=4308-4313&author=J.+P.+Aboniaauthor=K.+F.+Austenauthor=B.+J.+Rollinsauthor=S.+K.+Joshiauthor=R.+A.+Flavellauthor=W.+A.+Kuzielauthor=P.+A.+Koniauthor=M.+F.+Gurish&title=Constitutive+homing+of+mast+cell+progenitors+to+the+intestine+depends+on+autologous+expression+of+the+chemokine+receptor+CXCR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbonia%26aufirst%3DJ.%2BP.%26aulast%3DAusten%26aufirst%3DK.%2BF.%26aulast%3DRollins%26aufirst%3DB.%2BJ.%26aulast%3DJoshi%26aufirst%3DS.%2BK.%26aulast%3DFlavell%26aufirst%3DR.%2BA.%26aulast%3DKuziel%26aufirst%3DW.%2BA.%26aulast%3DKoni%26aufirst%3DP.%2BA.%26aulast%3DGurish%26aufirst%3DM.%2BF.%26atitle%3DConstitutive%2520homing%2520of%2520mast%2520cell%2520progenitors%2520to%2520the%2520intestine%2520depends%2520on%2520autologous%2520expression%2520of%2520the%2520chemokine%2520receptor%2520CXCR2%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D4308%26epage%3D4313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Eash, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenbaum, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalan, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, D. C.</span><span> </span><span class="NLM_article-title">CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2423</span><span class="NLM_x">â</span> <span class="NLM_lpage">2431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2423-2431&author=K.+J.+Eashauthor=A.+M.+Greenbaumauthor=P.+K.+Gopalanauthor=D.+C.+Link&title=CXCR2+and+CXCR4+antagonistically+regulate+neutrophil+trafficking+from+murine+bone+marrow"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEash%26aufirst%3DK.%2BJ.%26aulast%3DGreenbaum%26aufirst%3DA.%2BM.%26aulast%3DGopalan%26aufirst%3DP.%2BK.%26aulast%3DLink%26aufirst%3DD.%2BC.%26atitle%3DCXCR2%2520and%2520CXCR4%2520antagonistically%2520regulate%2520neutrophil%2520trafficking%2520from%2520murine%2520bone%2520marrow%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2423%26epage%3D2431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Del Rio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salinas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denkers, E. Y.</span><span> </span><span class="NLM_article-title">CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during <i>Toxoplasma gondii</i> infection</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">6503</span><span class="NLM_x">â</span> <span class="NLM_lpage">6509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2001&pages=6503-6509&author=L.+Del+Rioauthor=S.+Bennounaauthor=J.+Salinasauthor=E.+Y.+Denkers&title=CXCR2+deficiency+confers+impaired+neutrophil+recruitment+and+increased+susceptibility+during+Toxoplasma+gondii+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BRio%26aufirst%3DL.%26aulast%3DBennouna%26aufirst%3DS.%26aulast%3DSalinas%26aufirst%3DJ.%26aulast%3DDenkers%26aufirst%3DE.%2BY.%26atitle%3DCXCR2%2520deficiency%2520confers%2520impaired%2520neutrophil%2520recruitment%2520and%2520increased%2520susceptibility%2520during%2520Toxoplasma%2520gondii%2520infection%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D167%26spage%3D6503%26epage%3D6509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Tsai, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ffrench-Constant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geertman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. H.</span><span> </span><span class="NLM_article-title">The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=373-383&author=H.+H.+Tsaiauthor=E.+Frostauthor=V.+Toauthor=S.+Robinsonauthor=C.+Ffrench-Constantauthor=R.+Geertmanauthor=R.+M.+Ransohoffauthor=R.+H.+Miller&title=The+chemokine+receptor+CXCR2+controls+positioning+of+oligodendrocyte+precursors+in+developing+spinal+cord+by+arresting+their+migration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DH.%2BH.%26aulast%3DFrost%26aufirst%3DE.%26aulast%3DTo%26aufirst%3DV.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DFfrench-Constant%26aufirst%3DC.%26aulast%3DGeertman%26aufirst%3DR.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BH.%26atitle%3DThe%2520chemokine%2520receptor%2520CXCR2%2520controls%2520positioning%2520of%2520oligodendrocyte%2520precursors%2520in%2520developing%2520spinal%2520cord%2520by%2520arresting%2520their%2520migration%26jtitle%3DCell%26date%3D2002%26volume%3D110%26spage%3D373%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belkadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darnall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotleur, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padovani-Claudio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransohoff, R. M.</span><span> </span><span class="NLM_article-title">CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis</span> <span class="citation_source-journal">Nat. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnn.2491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20154684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=319-326&author=L.+Liuauthor=A.+Belkadiauthor=L.+Darnallauthor=T.+Huauthor=C.+Drescherauthor=A.+C.+Cotleurauthor=D.+Padovani-Claudioauthor=T.+Heauthor=K.+Choiauthor=T.+E.+Laneauthor=R.+H.+Millerauthor=R.+M.+Ransohoff&title=CXCR2-positive+neutrophils+are+essential+for+cuprizone-induced+demyelination%3A+relevance+to+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis</span></div><div class="casAuthors">Liu, LiPing; Belkadi, Abdelmadjid; Darnall, Lindsey; Hu, Taofang; Drescher, Caitlin; Cotleur, Anne C.; Padovani-Claudio, Dolly; He, Tao; Choi, Karen; Lane, Thomas E.; Miller, Robert H.; Ransohoff, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Multiple sclerosis is an inflammatory demyelinating disorder of the CNS.  Recent studies have suggested diverse mechanisms as underlying demyelination, including a subset of lesions induced by an interaction between metabolic insult to oligodendrocytes and inflammatory mediators.  For mice of susceptible strains, cuprizone feeding results in oligodendrocyte cell loss and demyelination of the corpus callosum.  Remyelination ensues and has been extensively studied.  Cuprizone-induced demyelination remains incompletely characterized.  The authors found that mice lacking the type 2 CXC chemokine receptor (CXCR2) were relatively resistant to cuprizone-induced demyelination and that circulating CXCR2-pos. neutrophils were important for cuprizone-induced demyelination.  The authors' findings support a two-hit process of cuprizone-induced demyelination, supporting the idea that multiple sclerosis pathogenesis features extensive oligodendrocyte cell loss.  These data suggest that cuprizone-induced demyelination is useful for modeling certain aspects of multiple sclerosis pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Eqy955jzILVg90H21EOLACvtfcHk0lhhiqly1ugrZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFGmsr8%253D&md5=6c4e4623a163c9b71d0a1c5741ba70b0</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnn.2491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2491%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBelkadi%26aufirst%3DA.%26aulast%3DDarnall%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DDrescher%26aufirst%3DC.%26aulast%3DCotleur%26aufirst%3DA.%2BC.%26aulast%3DPadovani-Claudio%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DT.%2BE.%26aulast%3DMiller%26aufirst%3DR.%2BH.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DCXCR2-positive%2520neutrophils%2520are%2520essential%2520for%2520cuprizone-induced%2520demyelination%253A%2520relevance%2520to%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Neurosci.%26date%3D2010%26volume%3D13%26spage%3D319%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Boisvert, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtiss, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terkeltaub, R. A.</span><span> </span><span class="NLM_article-title">A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor- deficient mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">â</span> <span class="NLM_lpage">363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1998&pages=353-363&author=W.+A.+Boisvertauthor=R.+Santiagoauthor=L.+K.+Curtissauthor=R.+A.+Terkeltaub&title=A+leukocyte+homologue+of+the+IL-8+receptor+CXCR-2+mediates+the+accumulation+of+macrophages+in+atherosclerotic+lesions+of+LDL+receptor-+deficient+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoisvert%26aufirst%3DW.%2BA.%26aulast%3DSantiago%26aufirst%3DR.%26aulast%3DCurtiss%26aufirst%3DL.%2BK.%26aulast%3DTerkeltaub%26aufirst%3DR.%2BA.%26atitle%3DA%2520leukocyte%2520homologue%2520of%2520the%2520IL-8%2520receptor%2520CXCR-2%2520mediates%2520the%2520accumulation%2520of%2520macrophages%2520in%2520atherosclerotic%2520lesions%2520of%2520LDL%2520receptor-%2520deficient%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D101%26spage%3D353%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Horuk, R.</span><span> </span><span class="NLM_article-title">Chemokine receptor antagonists: overcoming developmental hurdles</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnrd2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19079127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt12j" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=23-33&author=R.+Horuk&title=Chemokine+receptor+antagonists%3A+overcoming+developmental+hurdles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor antagonists: overcoming developmental hurdles</span></div><div class="casAuthors">Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokine receptors have a key role in the pathogenesis of autoimmune diseases, inflammation and viral infection.  However, with the exception of selective CCR5 antagonists for HIV, the promise of obtaining new therapeutics related to chemokine receptors has not yet been realized.  This article highlights some of the recent failures in the clin. trials of chemokine receptor antagonists and explores possible reasons as to why this might have occurred.  Such reasons include the lack of predictability of animal models and redundancy of the target.  A potential soln. could be to develop drugs that target more than one receptor - known as polypharmacol. - which could be a novel way to generate effective therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFMos9Ccf_G7Vg90H21EOLACvtfcHk0lhhiqly1ugrZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt12j&md5=831294beadc398d0dc3007a26da96d39</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnrd2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2734%26sid%3Dliteratum%253Aachs%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DChemokine%2520receptor%2520antagonists%253A%2520overcoming%2520developmental%2520hurdles%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D23%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span>Study To Investigate the Efficacy of a Non-Hormonal Drug against Endometriosis Associated Pelvic Pain. <a href="http://clinicaltrials.gov/ct2/show/NCT00185341?term=CCR1&amp;rank=1" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00185341?term=CCR1&rank=1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+To+Investigate+the+Efficacy+of+a+Non-Hormonal+Drug+against+Endometriosis+Associated+Pelvic+Pain.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00185341%3Fterm%3DCCR1%26rank%3D1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span>MLN 3701 Sanofi-Aventis Phase Change I, Europe. <a href="http://business.highbeam.com/436989/article-1G1-160617066/mln-3701-sanofiaventis-phase-change-europe" class="extLink">http://business.highbeam.com/436989/article-1G1-160617066/mln-3701-sanofiaventis-phase-change-europe</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MLN+3701+Sanofi-Aventis+Phase+Change+I%2C+Europe.+http%3A%2F%2Fbusiness.highbeam.com%2F436989%2Farticle-1G1-160617066%2Fmln-3701-sanofiaventis-phase-change-europe."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Carson, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffee, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. B.</span><span> </span><span class="NLM_article-title">CCR1 Antagonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2004&pages=149-158&author=K.+G.+Carsonauthor=B.+D.+Jaffeeauthor=G.+B.+Harriman&title=CCR1+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarson%26aufirst%3DK.%2BG.%26aulast%3DJaffee%26aufirst%3DB.%2BD.%26aulast%3DHarriman%26aufirst%3DG.%2BB.%26atitle%3DCCR1%2520Antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2004%26volume%3D39%26spage%3D149%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Ng, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghannam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M. M.</span><span> </span><span class="NLM_article-title">Discovery of novel non-peptide CCR1 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4680</span><span class="NLM_x">â</span> <span class="NLM_lpage">4694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990316l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4680-4694&author=H.+P.+Ngauthor=K.+Mayauthor=J.+G.+Baumanauthor=A.+Ghannamauthor=I.+Islamauthor=M.+Liangauthor=R.+Horukauthor=J.+Hesselgesserauthor=R.+M.+Sniderauthor=H.+D.+Perezauthor=M.+M.+Morrissey&title=Discovery+of+novel+non-peptide+CCR1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm990316l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990316l%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DH.%2BP.%26aulast%3DMay%26aufirst%3DK.%26aulast%3DBauman%26aufirst%3DJ.%2BG.%26aulast%3DGhannam%26aufirst%3DA.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DSnider%26aufirst%3DR.%2BM.%26aulast%3DPerez%26aufirst%3DH.%2BD.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26atitle%3DDiscovery%2520of%2520novel%2520non-peptide%2520CCR1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4680%26epage%3D4694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Vallet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raje, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishitsuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhetri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pozzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitkreutz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiziltepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocio, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaghela, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirstea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccadoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3744</span><span class="NLM_x">â</span> <span class="NLM_lpage">3752</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3744-3752&author=S.+Valletauthor=N.+Rajeauthor=K.+Ishitsukaauthor=T.+Hideshimaauthor=K.+Podarauthor=S.+Chhetriauthor=S.+Pozziauthor=I.+Breitkreutzauthor=T.+Kiziltepeauthor=H.+Yasuiauthor=E.+M.+Ocioauthor=N.+Shiraishiauthor=J.+Jinauthor=Y.+Okawaauthor=H.+Ikedaauthor=S.+Mukherjeeauthor=N.+Vaghelaauthor=D.+Cirsteaauthor=M.+Ladettoauthor=M.+Boccadoroauthor=K.+C.+Anderson&title=MLN3897%2C+a+novel+CCR1+inhibitor%2C+impairs+osteoclastogenesis+and+inhibits+the+interaction+of+multiple+myeloma+cells+and+osteoclasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVallet%26aufirst%3DS.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DIshitsuka%26aufirst%3DK.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DChhetri%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26aulast%3DBreitkreutz%26aufirst%3DI.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DShiraishi%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DVaghela%26aufirst%3DN.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DLadetto%26aufirst%3DM.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DMLN3897%252C%2520a%2520novel%2520CCR1%2520inhibitor%252C%2520impairs%2520osteoclastogenesis%2520and%2520inhibits%2520the%2520interaction%2520of%2520multiple%2520myeloma%2520cells%2520and%2520osteoclasts%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3744%26epage%3D3752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Vergunst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Moltke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzkin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3572</span><span class="NLM_x">â</span> <span class="NLM_lpage">3581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.24978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19950299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=3572-3581&author=C.+E.+Vergunstauthor=D.+M.+Gerlagauthor=L.+von+Moltkeauthor=M.+Karolauthor=T.+Wyantauthor=X.+Chiauthor=E.+Matzkinauthor=T.+Leachauthor=P.+P.+Tak&title=MLN3897+plus+methotrexate+in+patients+with+rheumatoid+arthritis%3A+safety%2C+efficacy%2C+pharmacokinetics%2C+and+pharmacodynamics+of+an+oral+CCR1+antagonist+in+a+phase+IIa%2C+double-blind%2C+placebo-controlled%2C+randomized%2C+proof-of-concept+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study</span></div><div class="casAuthors">Vergunst, Clarissa E.; Gerlag, Danielle M.; von Moltke, Lisa; Karol, Michael; Wyant, Tim; Chi, Xuedong; Matzkin, Ellen; Leach, Timothy; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3572-3581</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX).  Methods: In this phase IIa, proof-of-concept study, patients meeting the American College of Rheumatol. (ACR) criteria for RA who had been taking MTX for â¥6 mo with evidence of active disease were randomly assigned to receive either 10 mg oral MLN3897 or matching placebo once daily for 12 wk (days 1-83) while continuing to receive MTX once a week.  Clin. assessments, safety monitoring, and sampling for pharmacokinetic and pharmacodynamic analyses were performed throughout the study.  The primary efficacy end point was the difference in the percentage of patients meeting the ACR 20% improvement criteria (achieving an ACR20 response) on day 84 in the MLN3897-treated group compared with that in the placebo-treated group.  Results: MLN3897 was well tolerated, with no evidence of systemic immunosuppression.  In the intent-to-treat population, there was no significant difference in day 84 ACR20 response rates between MLN3897-treated patients and placebo-treated patients (35% vs. 33%, resp.; P = 0.72).  Results were similar for the per-protocol population.  Pharmacokinetic analyses demonstrated no interactions between MLN3897 and MTX.  MLN3897 was assocd. with a high degree of CCR1 occupancy (â¥90% on days 28, 56, and 84 in 82% of patients, by macrophage inflammatory protein la internalization assay).  Conclusion: MLN3897 at a concn. of 10 mg once daily had no discernible activity in patients with RA who were also receiving MTX.  The results suggest that CCR1 antagonism is unlikely to be a viable strategy for the treatment of RA when used in isolation at the receptor occupancy levels reached in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrypG1Ywf-kC7Vg90H21EOLACvtfcHk0ljhyqo4flKVfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb7O&md5=c4ad5b338d4c2448889fef196cff0d78</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fart.24978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24978%26sid%3Dliteratum%253Aachs%26aulast%3DVergunst%26aufirst%3DC.%2BE.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3Dvon%2BMoltke%26aufirst%3DL.%26aulast%3DKarol%26aufirst%3DM.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DChi%26aufirst%3DX.%26aulast%3DMatzkin%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DT.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DMLN3897%2520plus%2520methotrexate%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%253A%2520safety%252C%2520efficacy%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520an%2520oral%2520CCR1%2520antagonist%2520in%2520a%2520phase%2520IIa%252C%2520double-blind%252C%2520placebo-controlled%252C%2520randomized%252C%2520proof-of-concept%2520study%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D3572%26epage%3D3581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Gladue, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">CCR1 antagonists: what have we learned from clinical trials</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1268</span><span class="NLM_x">â</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.2174%2F156802610791561237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20536425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSktb7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=1268-1277&author=R.+P.+Gladueauthor=M.+F.+Brownauthor=S.+H.+Zwillich&title=CCR1+antagonists%3A+what+have+we+learned+from+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">CCR1 antagonists: what have we learned from clinical trials</span></div><div class="casAuthors">Gladue, Ronald P.; Brown, Matthew F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1268-1277</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The identification of chemokines and their receptors as potent mediators of leukocyte infiltration raised interest in the potential role of these proteins on disease pathogenesis.  This is exemplified by the chemokine receptor, CCR1, which has been shown to be up-regulated in a no. of human diseases, the implications of which have been suggested by animal models where inhibition of CCR1 or its ligands have shown beneficial effects.  These data support the possibility that a CCR1 antagonist will provide therapeutic benefit to patients with inflammatory diseases.  Over the last several years, several of these antagonists entered clin. trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD.  This review will describe the evidence that supported the role of CCR1 in these diseases, the results from clin. trials, and provide perspectives on what has been learned from these trials for potential application / consideration to other studies with chemokine receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozbINoudZvwLVg90H21EOLACvtfcHk0ligsQmf9L7x_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSktb7L&md5=bc6af7c7df8e5c4c100f850b895c9175</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F156802610791561237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610791561237%26sid%3Dliteratum%253Aachs%26aulast%3DGladue%26aufirst%3DR.%2BP.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DCCR1%2520antagonists%253A%2520what%2520have%2520we%2520learned%2520from%2520clinical%2520trials%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D1268%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Gladue, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roach, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tylaska, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogborne, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neote, K. S.</span><span> </span><span class="NLM_article-title">The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">3141</span><span class="NLM_x">â</span> <span class="NLM_lpage">3148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.4049%2Fjimmunol.176.5.3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=16493073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=3141-3148&author=R.+P.+Gladueauthor=S.+H.+Coleauthor=M.+L.+Roachauthor=L.+A.+Tylaskaauthor=R.+T.+Nelsonauthor=R.+M.+Shepardauthor=J.+D.+McNeishauthor=K.+T.+Ogborneauthor=K.+S.+Neote&title=The+human+specific+CCR1+antagonist+CP-481%2C715+inhibits+cell+infiltration+and+inflammatory+responses+in+human+CCR1+transgenic+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The Human Specific CCR1 Antagonist CP-481715 Inhibits Cell Infiltration and Inflammatory Responses in Human CCR1 Transgenic Mice</span></div><div class="casAuthors">Gladue, Ronald P.; Cole, Susan H.; Roach, Marsha L.; Tylaska, Laurie A.; Nelson, Robin T.; Shepard, Richard M.; McNeish, John D.; Ogborne, Kevin T.; Neote, Kuldeep S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3141-3148</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">We previously described the in vitro characteristics of the potent and selective CCR1 antagonist, CP-481715.  In addn. to being selective for CCR1 vs. other chemokine receptors, CP-481715 is also specific for human CCR1 (hCCR1), preventing its evaluation in classical animal models.  To address this, we generated mice whereby murine CCR1 was replaced by hCCR1 (knockin) and used these animals to assess the anti-inflammatory properties of CP-481715.  Cells isolated from hCCR1 knockin mice were shown to express hCCR1 and migrate in response to both murine CCR1 and hCCR1 ligands.  Furthermore, this migration is inhibited by CP-481715 at dose levels comparable to those obtained with human cells.  In animal models of cell infiltration, CP-481715 inhibited CCL3-induced neutrophil infiltration into skin or into an air pouch with an ED50 of 0.2 mg/kg.  CP-481715 did not inhibit cell infiltration in wild-type animals expressing murine CCR1.  In a more generalized model of inflammation, delayed-type hypersensitivity, CP-481715 significantly inhibited footpad swelling and decreased the amt. of IFN-Î³ and IL-2 produced by isolated spleen cells from sensitized animals.  It did not, however, induce tolerance to a subsequent challenge.  These studies illustrate the utility of hCCR1 knockin animals to assess the activity of human specific CCR1 antagonists; demonstrate the ability of the CCR1 antagonist CP-481,715 to inhibit cell infiltration, inflammation, and Th1 cytokine responses in these animals; and suggest that CP-481,715 may be useful to modulate inflammatory responses in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1zjHkTdkoArVg90H21EOLACvtfcHk0ligsQmf9L7x_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1eru7o%253D&md5=5f30e7c431259c6bd073021f22875eb6</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.5.3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.5.3141%26sid%3Dliteratum%253Aachs%26aulast%3DGladue%26aufirst%3DR.%2BP.%26aulast%3DCole%26aufirst%3DS.%2BH.%26aulast%3DRoach%26aufirst%3DM.%2BL.%26aulast%3DTylaska%26aufirst%3DL.%2BA.%26aulast%3DNelson%26aufirst%3DR.%2BT.%26aulast%3DShepard%26aufirst%3DR.%2BM.%26aulast%3DMcNeish%26aufirst%3DJ.%2BD.%26aulast%3DOgborne%26aufirst%3DK.%2BT.%26aulast%3DNeote%26aufirst%3DK.%2BS.%26atitle%3DThe%2520human%2520specific%2520CCR1%2520antagonist%2520CP-481%252C715%2520inhibits%2520cell%2520infiltration%2520and%2520inflammatory%2520responses%2520in%2520human%2520CCR1%2520transgenic%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D3141%26epage%3D3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Zhang, P.; Pennell, A. M. K.; Wright, J. J. K.; Wei, C.; Leleti, M. R.; Li, Y.; Li, L.; Xu, Y.</span><span> </span><span class="NLM_article-title">Azaindazole Compounds and Methods of Use</span>. US 7,524,845,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=P.+Zhang&author=A.+M.+K.+Pennell&author=J.+J.+K.+Wright&author=C.+Wei&author=M.+R.+Leleti&author=Y.+Li&author=L.+Li&author=Y.+Xu&title=Azaindazole+Compounds+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DAzaindazole%2520Compounds%2520and%2520Methods%2520of%2520Use%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Dairaghi, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">â</span> <span class="NLM_lpage">734</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fclpt.2011.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21451509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltVGntrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=726-734&author=D.+J.+Dairaghiauthor=P.+Zhangauthor=Y.+Wangauthor=L.+C.+Seitzauthor=D.+A.+Johnsonauthor=S.+Miaoauthor=L.+S.+Ertlauthor=Y.+Zengauthor=J.+P.+Powersauthor=A.+M.+Pennellauthor=P.+Bekkerauthor=T.+J.+Schallauthor=J.+C.+Jaen&title=Pharmacokinetic+and+pharmacodynamic+evaluation+of+the+novel+CCR1+antagonist+CCX354+in+healthy+human+subjects%3A+implications+for+selection+of+clinical+dose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose</span></div><div class="casAuthors">Dairaghi, D. J.; Zhang, P.; Wang, Y.; Seitz, L. C.; Johnson, D. A.; Miao, S.; Ertl, L. S.; Zeng, Y.; Powers, J. P.; Pennell, A. M.; Bekker, P.; Schall, T. J.; Jaen, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">726-734</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The safety and pharmacokinetic (PK)/pharmacodynamic (PD) profile of the novel CCR1 antagonist CCX354 was evaluated in double-blind, placebo-controlled, single- and multiple-dose phase I studies (1-300 mg/day oral doses).  CCX354 was well tolerated and displayed a linear dose-exposure profile, with half-life approaching 7 h at the 300-mg dose.  The extent of CCR1 receptor blockade on blood monocytes, which correlated well with plasma concns. of the drug, was assessed using fluorescently labeled CCL3 binding in whole blood from phase I subjects.  High levels of receptor coverage at the 12-h time point were achieved after a single dose of 100 mg CCX354.  Preclin. studies indicate that effective blockade of inflammatory cell infiltration into tissues requires â¥90% CCR1 inhibition on blood leukocytes at all times.  The comparison of the properties of CCX354 with those published for other CCR1 antagonists has informed the dose selection for ongoing clin. development of CCX354 in rheumatoid arthritis (RA).  Clin. Pharmacol. & Therapeutics (2011) 89 5, 726-734. doi:10.1038/clpt.2011.33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9eP6NqC1T_7Vg90H21EOLACvtfcHk0ligsQmf9L7x_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltVGntrY%253D&md5=421113bb424cf42c66b34fc404155cc1</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.33%26sid%3Dliteratum%253Aachs%26aulast%3DDairaghi%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSeitz%26aufirst%3DL.%2BC.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DErtl%26aufirst%3DL.%2BS.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DPennell%26aufirst%3DA.%2BM.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520evaluation%2520of%2520the%2520novel%2520CCR1%2520antagonist%2520CCX354%2520in%2520healthy%2520human%2520subjects%253A%2520implications%2520for%2520selection%2520of%2520clinical%2520dose%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D726%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Tak, P. P.; Balanescu, A.; Tseluyko, V.; Bojin, S.; Drescher, E.; Dairaghi, D.; Miao, S.; Marchesin, V.; Jaen, J.; Bekker, P.; Schall, T. J.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase 2 Rheumatoid Arthritis Study</span>. Presented at the 2011 American College of Rheumatology/Association of Reproductive Health Professionals (ACR/ARHP) Annual Meeting, Chicago, IL,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="https://acr.confex.com/acr/2011/webprogram/Paper24548.html" class="extLink">https://acr.confex.com/acr/2011/webprogram/Paper24548.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+P.+Tak&author=A.+Balanescu&author=V.+Tseluyko&author=S.+Bojin&author=E.+Drescher&author=D.+Dairaghi&author=S.+Miao&author=V.+Marchesin&author=J.+Jaen&author=P.+Bekker&author=T.+J.+Schall&title=Safety+and+Efficacy+of+Oral+Chemokine+Receptor+1+Antagonist+CCX354-C+in+a+Phase+2+Rheumatoid+Arthritis+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Oral%2520Chemokine%2520Receptor%25201%2520Antagonist%2520CCX354-C%2520in%2520a%2520Phase%25202%2520Rheumatoid%2520Arthritis%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span>Merck's Research Pipeline and Selected Licensing Partners. Annual Report 2004. <a href="http://www.merck.com/finance/annualreport/ar2004/research_pipeline/" class="extLink">http://www.merck.com/finance/annualreport/ar2004/research_pipeline/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Merck%27s+Research+Pipeline+and+Selected+Licensing+Partners.+Annual+Report+2004.+http%3A%2F%2Fwww.merck.com%2Ffinance%2Fannualreport%2Far2004%2Fresearch_pipeline%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Naya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, N.</span><span> </span><span class="NLM_article-title">Structureâactivity relationships of xanthene carboxamides, novel CCR1 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">884</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=875-884&author=A.+Nayaauthor=M.+Ishikawaauthor=K.+Matsudaauthor=K.+Ohwakiauthor=T.+Saekiauthor=K.+Noguchiauthor=N.+Ohtake&title=Structure%E2%80%93activity+relationships+of+xanthene+carboxamides%2C+novel+CCR1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaya%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DOhwaki%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DOhtake%26aufirst%3DN.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%2520xanthene%2520carboxamides%252C%2520novel%2520CCR1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D875%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Kerstjens, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjermer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span> </span><span class="NLM_article-title">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1297</span><span class="NLM_x">â</span> <span class="NLM_lpage">1303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.rmed.2010.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20466530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=1297-1303&author=H.+A.+Kerstjensauthor=L.+Bjermerauthor=L.+Erikssonauthor=K.+Dahlstromauthor=J.+Vestbo&title=Tolerability+and+efficacy+of+inhaled+AZD4818%2C+a+CCR1+antagonist%2C+in+moderate+to+severe+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span></div><div class="casAuthors">Kerstjens Huib A; Bjermer Leif; Eriksson Leif; Dahlstrom Kerstin; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1297-303</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in patients with COPD.  METHODS:  This double-blind, placebo-controlled study (NCT00629239) randomised patients with moderate to severe COPD to AZD4818 300mug or placebo twice daily via Turbuhaler((R)) for 4 weeks.  Safety, lung function, functional capacity and health status measures were measured.  Plasma concentrations of AZD4818 were measured after the first dose and after 2 and 4 weeks' treatment.  RESULTS:  Sixty-five patients (47 male; median age 65.6 years) received AZD4818 (n=33) or placebo (n=32).  There was no statistically significant difference between AZD4818 and placebo in change from baseline to endpoint for FEV(1) (AZD4818-placebo: 0.026L, p=0.69), morning PEF (-6L/min, p=0.23), or other lung function measures.  There was no difference between treatment groups in the 6-min walk test, MMRC dyspnoea index, BODE index and CCQ scores.  Plasma concentrations indicated that patients were exposed to AZD4818 as expected.  AZD4818 was well tolerated: 27 treatment-related adverse events (13 with AZD4818, 14 with placebo), 2 serious adverse events (both AZD4818: exacerbation [considered not treatment-related] and deep vein thrombosis [considered treatment-related]) and 11 discontinuations (7 with AZD4818).  CONCLUSIONS:  Inhaled AZD4818 was well tolerated at 300mug twice daily for 4 weeks in patients with COPD; however, there was no indication of a beneficial treatment effect despite exposure as expected.  These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReNiH0l3TS4ZWtyewyzkyLfW6udTcc2eZ_SqEX-W4iQbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D&md5=157554642d8a8d754ca22d56328ce6f7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DKerstjens%26aufirst%3DH.%2BA.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DEriksson%26aufirst%3DL.%26aulast%3DDahlstrom%26aufirst%3DK.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DTolerability%2520and%2520efficacy%2520of%2520inhaled%2520AZD4818%252C%2520a%2520CCR1%2520antagonist%252C%2520in%2520moderate%2520to%2520severe%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2010%26volume%3D104%26spage%3D1297%26epage%3D1303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Butora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicario, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3636</span><span class="NLM_x">â</span> <span class="NLM_lpage">3641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3636-3641&author=G.+Butoraauthor=R.+Jiaoauthor=W.+H.+Parsonsauthor=P.+P.+Vicarioauthor=H.+Jinauthor=J.+M.+Ayalaauthor=M.+A.+Cascieriauthor=L.+Yang&title=3-Amino-1-alkyl-cyclopentane+carboxamides+as+small+molecule+antagonists+of+the+human+and+murine+CC+chemokine+receptor+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DButora%26aufirst%3DG.%26aulast%3DJiao%26aufirst%3DR.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DVicario%26aufirst%3DP.%2BP.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DAyala%26aufirst%3DJ.%2BM.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DL.%26atitle%3D3-Amino-1-alkyl-cyclopentane%2520carboxamides%2520as%2520small%2520molecule%2520antagonists%2520of%2520the%2520human%2520and%2520murine%2520CC%2520chemokine%2520receptor%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3636%26epage%3D3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Butora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morriello, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothandaraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiadeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasternak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacCoss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicario, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4715</span><span class="NLM_x">â</span> <span class="NLM_lpage">4722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4715-4722&author=G.+Butoraauthor=G.+J.+Morrielloauthor=S.+Kothandaramanauthor=D.+Guiadeenauthor=A.+Pasternakauthor=W.+H.+Parsonsauthor=M.+MacCossauthor=P.+P.+Vicarioauthor=M.+A.+Cascieriauthor=L.+Yang&title=4-Amino-2-alkyl-butyramides+as+small+molecule+CCR2+antagonists+with+favorable+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DButora%26aufirst%3DG.%26aulast%3DMorriello%26aufirst%3DG.%2BJ.%26aulast%3DKothandaraman%26aufirst%3DS.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DVicario%26aufirst%3DP.%2BP.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DL.%26atitle%3D4-Amino-2-alkyl-butyramides%2520as%2520small%2520molecule%2520CCR2%2520antagonists%2520with%2520favorable%2520pharmacokinetic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4715%26epage%3D4722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Yang, L.; Jiao, R. X.; Moyes, C.; Morriello, G.; Butora, G.; Shankaran, K.; Pasternak, A.; Goble, S. D.; Zhou, C.; MacCoss, M.; Cumiskey, A. M.; Peterson, L.; Forrest, M.; Ayala, J.; Jin, H.; DeMartino, J.; Mills, S. G.</span><span> </span><span class="NLM_article-title">The Discovery of MK-0812, a Potent and Selective CCR2 Antagonist</span>. Presented at the 233rd National Meeting of the American Chemical Society, Chicago, IL, Mar 25â29,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.acsmedchem.org/mediabstracts2007.pdf" class="extLink">www.acsmedchem.org/mediabstracts2007.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Yang&author=R.+X.+Jiao&author=C.+Moyes&author=G.+Morriello&author=G.+Butora&author=K.+Shankaran&author=A.+Pasternak&author=S.+D.+Goble&author=C.+Zhou&author=M.+MacCoss&author=A.+M.+Cumiskey&author=L.+Peterson&author=M.+Forrest&author=J.+Ayala&author=H.+Jin&author=J.+DeMartino&author=S.+G.+Mills&title=The+Discovery+of+MK-0812%2C+a+Potent+and+Selective+CCR2+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26atitle%3DThe%2520Discovery%2520of%2520MK-0812%252C%2520a%2520Potent%2520and%2520Selective%2520CCR2%2520Antagonist%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span>ClinicalTrials.gov. A Study To Assess the Effects of MK0812 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis As Measured by Magnetic Resonance Imaging (MRI). <a href="http://clinicaltrials.gov/ct2/show/record/NCT00239655" class="extLink">http://clinicaltrials.gov/ct2/show/record/NCT00239655</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Study+To+Assess+the+Effects+of+MK0812+on+Disease+Activity+in+Patients+with+Relapsing-Remitting+Multiple+Sclerosis+As+Measured+by+Magnetic+Resonance+Imaging+%28MRI%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00239655."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Abbadie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindia, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudgett, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayne, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span> </span><span class="NLM_article-title">Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">7947</span><span class="NLM_x">â</span> <span class="NLM_lpage">7952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=7947-7952&author=C.+Abbadieauthor=J.+A.+Lindiaauthor=A.+M.+Cumiskeyauthor=L.+B.+Petersonauthor=J.+S.+Mudgettauthor=E.+K.+Bayneauthor=J.+A.+DeMartinoauthor=D.+E.+MacIntyreauthor=M.+J.+Forrest&title=Impaired+neuropathic+pain+responses+in+mice+lacking+the+chemokine+receptor+CCR2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbbadie%26aufirst%3DC.%26aulast%3DLindia%26aufirst%3DJ.%2BA.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DMudgett%26aufirst%3DJ.%2BS.%26aulast%3DBayne%26aufirst%3DE.%2BK.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26atitle%3DImpaired%2520neuropathic%2520pain%2520responses%2520in%2520mice%2520lacking%2520the%2520chemokine%2520receptor%2520CCR2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D7947%26epage%3D7952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Abbadie, C.; Lindia, J. A.; Wang, H.</span><span> </span><span class="NLM_article-title">CCR2 Antagonists for Treatment of Neuropathic Pain</span>. US 20060205761,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+Abbadie&author=J.+A.+Lindia&author=H.+Wang&title=CCR2+Antagonists+for+Treatment+of+Neuropathic+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbbadie%26aufirst%3DC.%26atitle%3DCCR2%2520Antagonists%2520for%2520Treatment%2520of%2520Neuropathic%2520Pain%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Brodmerkel, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leffet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">5370</span><span class="NLM_x">â</span> <span class="NLM_lpage">5378</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2005&pages=5370-5378&author=C.+M.+Brodmerkelauthor=R.+Huberauthor=M.+Covingtonauthor=S.+Diamondauthor=L.+Hallauthor=R.+Collinsauthor=L.+Leffetauthor=K.+Gallagherauthor=P.+Feldmanauthor=P.+Collierauthor=M.+Stowauthor=X.+Guauthor=F.+Baribaudauthor=N.+Shinauthor=B.+Thomasauthor=T.+Burnauthor=G.+Hollisauthor=S.+Yeleswaramauthor=K.+Solomonauthor=S.+Friedmanauthor=A.+Wangauthor=C.+B.+Xueauthor=R.+C.+Newtonauthor=P.+Scherleauthor=K.+Vaddi&title=Discovery+and+pharmacological+characterization+of+a+novel+rodent-active+CCR2+antagonist%2C+INCB3344"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrodmerkel%26aufirst%3DC.%2BM.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DGallagher%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DP.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DStow%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DXue%26aufirst%3DC.%2BB.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520pharmacological%2520characterization%2520of%2520a%2520novel%2520rodent-active%2520CCR2%2520antagonist%252C%2520INCB3344%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D175%26spage%3D5370%26epage%3D5378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Xue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharief, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span> </span><span class="NLM_article-title">Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">450</span><span class="NLM_x">â</span> <span class="NLM_lpage">454</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200030q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=450-454&author=C.+Xueauthor=H.+Fengauthor=G.+Caoauthor=T.+Huangauthor=J.+Glennauthor=R.+Anandauthor=D.+Meloniauthor=K.+Zhangauthor=L.+Kongauthor=A.+Wangauthor=Y.+Zhangauthor=C.+Zhengauthor=M.+Xiaauthor=L.+Chenauthor=T.+Tanakaauthor=Q.+Hanauthor=D.+J.+Robinsonauthor=D.+Modiauthor=L.+Storaceauthor=L.+Shaoauthor=V.+Shariefauthor=M.+Liauthor=L.+G.+Galyaauthor=M.+Covingtonauthor=P.+Scherleauthor=S.+Diamondauthor=T.+Emmauthor=S.+Yeleswaramauthor=N.+Contelauthor=K.+Vaddiauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=B.+Metcalf&title=Discovery+of+INCB3284%2C+a+potent%2C+selective%2C+and+orally+bioavailable+hCCR2+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fml200030q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200030q%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DRobinson%26aufirst%3DD.%2BJ.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DStorace%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DSharief%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%2BG.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DContel%26aufirst%3DN.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DMetcalf%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520INCB3284%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520hCCR2%2520antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D450%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Hughes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutzler, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahinski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, Z. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span> </span><span class="NLM_article-title">Discovery of ((1<i>S</i>,3<i>R</i>)-1-isopropyl-3-((3<i>S</i>,4<i>S</i>)-3-methoxy-tetrahydro-2<i>H</i>-pyran-4-ylamino)cyclopent yl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2626</span><span class="NLM_x">â</span> <span class="NLM_lpage">2630</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2626-2630&author=R.+O.+Hughesauthor=D.+J.+Rogierauthor=R.+Devrajauthor=C.+Zhengauthor=G.+Caoauthor=H.+Fengauthor=M.+Xiaauthor=R.+Anandauthor=L.+Xingauthor=J.+Glennauthor=K.+Zhangauthor=M.+Covingtonauthor=P.+A.+Mortonauthor=J.+M.+Hutzlerauthor=J.+W.+Davisauthor=P.+Scherleauthor=F.+Baribaudauthor=A.+Bahinskiauthor=Z.+L.+Moauthor=R.+Newtonauthor=B.+Metcalfauthor=C.+B.+Xue&title=Discovery+of+%28%281S%2C3R%29-1-isopropyl-3-%28%283S%2C4S%29-3-methoxy-tetrahydro-2H-pyran-4-ylamino%29cyclopent+yl%29%284-%285-%28trifluoromethyl%29pyridazin-3-yl%29piperazin-1-yl%29methanone%2C+PF-4254196%2C+a+CCR2+antagonist+with+an+improved+cardiovascular+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DR.%2BO.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DDevraj%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DMorton%26aufirst%3DP.%2BA.%26aulast%3DHutzler%26aufirst%3DJ.%2BM.%26aulast%3DDavis%26aufirst%3DJ.%2BW.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DBahinski%26aufirst%3DA.%26aulast%3DMo%26aufirst%3DZ.%2BL.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DC.%2BB.%26atitle%3DDiscovery%2520of%2520%2528%25281S%252C3R%2529-1-isopropyl-3-%2528%25283S%252C4S%2529-3-methoxy-tetrahydro-2H-pyran-4-ylamino%2529cyclopent%2520yl%2529%25284-%25285-%2528trifluoromethyl%2529pyridazin-3-yl%2529piperazin-1-yl%2529methanone%252C%2520PF-4254196%252C%2520a%2520CCR2%2520antagonist%2520with%2520an%2520improved%2520cardiovascular%2520profile%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2626%26epage%3D2630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Trujillo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1827</span><span class="NLM_x">â</span> <span class="NLM_lpage">1831</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1827-1831&author=J.+I.+Trujilloauthor=W.+Huangauthor=R.+O.+Hughesauthor=D.+J.+Rogierauthor=S.+R.+Turnerauthor=R.+Devrajauthor=P.+A.+Mortonauthor=C.+B.+Xueauthor=G.+Chaoauthor=M.+B.+Covingtonauthor=R.+C.+Newtonauthor=B.+Metcalf&title=Design+and+synthesis+of+novel+CCR2+antagonists%3A+investigation+of+non-aryl%2Fheteroaryl+binding+motifs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DHughes%26aufirst%3DR.%2BO.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DTurner%26aufirst%3DS.%2BR.%26aulast%3DDevraj%26aufirst%3DR.%26aulast%3DMorton%26aufirst%3DP.%2BA.%26aulast%3DXue%26aufirst%3DC.%2BB.%26aulast%3DChao%26aufirst%3DG.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520CCR2%2520antagonists%253A%2520investigation%2520of%2520non-aryl%252Fheteroaryl%2520binding%2520motifs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1827%26epage%3D1831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span> </span><span class="NLM_article-title">Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1442</span><span class="NLM_x">â</span> <span class="NLM_lpage">1446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1442-1446&author=C.+Zhengauthor=G.+Caoauthor=M.+Xiaauthor=H.+Fengauthor=J.+Glennauthor=R.+Anandauthor=K.+Zhangauthor=T.+Huangauthor=A.+Wangauthor=L.+Kongauthor=M.+Liauthor=L.+Galyaauthor=R.+O.+Hughesauthor=R.+Devrajauthor=P.+A.+Mortonauthor=D.+J.+Rogierauthor=M.+Covingtonauthor=F.+Baribaudauthor=N.+Shinauthor=P.+Scherleauthor=S.+Diamondauthor=S.+Yeleswaramauthor=K.+Vaddiauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=B.+Metcalfauthor=C.+B.+Xue&title=Discovery+of+INCB10820%2FPF-4178903%2C+a+potent%2C+selective%2C+and+orally+bioavailable+dual+CCR2+and+CCR5+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DHughes%26aufirst%3DR.%2BO.%26aulast%3DDevraj%26aufirst%3DR.%26aulast%3DMorton%26aufirst%3DP.%2BA.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DN.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DC.%2BB.%26atitle%3DDiscovery%2520of%2520INCB10820%252FPF-4178903%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520dual%2520CCR2%2520and%2520CCR5%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1442%26epage%3D1446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span>Incyte Announces First Quarter Financial Results and Provides Update on Drug Discovery and Development Programs. <a href="http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&amp;newsId=20060504005114&amp;newsLang=en" class="extLink">http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060504005114&newsLang=en</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Incyte+Announces+First+Quarter+Financial+Results+and+Provides+Update+on+Drug+Discovery+and+Development+Programs.+http%3A%2F%2Fwww.businesswire.com%2Fportal%2Fsite%2Fgoogle%2Findex.jsp%3FndmViewId%3Dnews_view%26newsId%3D20060504005114%26newsLang%3Den"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span>Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Subjects with Osteoarthritic Pain of the Knee. <a href="http://clinicaltrials.gov/ct2/show/NCT00689273?term=CCR2&amp;rank=4" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00689273?term=CCR2&rank=4</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Phase+2+Study+in+Subjects+with+Osteoarthritic+Pain+of+the+Knee.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00689273%3Fterm%3DCCR2%26rank%3D4."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Gilbert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lekstrom-Himes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span> </span><span class="NLM_article-title">Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">906</span><span class="NLM_x">â</span> <span class="NLM_lpage">911</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2011&pages=906-911&author=J.+Gilbertauthor=J.+Lekstrom-Himesauthor=D.+Donaldsonauthor=Y.+Leeauthor=M.+Huauthor=J.+Xuauthor=T.+Wyantauthor=M.+Davidson&title=Effect+of+CC+chemokine+receptor+2+CCR2+blockade+on+serum+C-reactive+protein+in+individuals+at+atherosclerotic+risk+and+with+a+single+nucleotide+polymorphism+of+the+monocyte+chemoattractant+protein-1+promoter+region"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26aulast%3DDonaldson%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DDavidson%26aufirst%3DM.%26atitle%3DEffect%2520of%2520CC%2520chemokine%2520receptor%25202%2520CCR2%2520blockade%2520on%2520serum%2520C-reactive%2520protein%2520in%2520individuals%2520at%2520atherosclerotic%2520risk%2520and%2520with%2520a%2520single%2520nucleotide%2520polymorphism%2520of%2520the%2520monocyte%2520chemoattractant%2520protein-1%2520promoter%2520region%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2011%26volume%3D107%26spage%3D906%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Sharrack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span> </span><span class="NLM_article-title">Frequent MRI study of a novel CCR2 antagonist in relapsing-remitting multiple sclerosis</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 11</span><span class="NLM_x">) </span> <span class="NLM_fpage">S74</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=S74&issue=Suppl.+11&author=B.+Sharrackauthor=T.+Leachauthor=E.+Jacobsonauthor=D.+D.+Donaldsonauthor=X.+Xuauthor=M.+Hu&title=Frequent+MRI+study+of+a+novel+CCR2+antagonist+in+relapsing-remitting+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharrack%26aufirst%3DB.%26aulast%3DLeach%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DE.%26aulast%3DDonaldson%26aufirst%3DD.%2BD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DFrequent%2520MRI%2520study%2520of%2520a%2520novel%2520CCR2%2520antagonist%2520in%2520relapsing-remitting%2520multiple%2520sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2007%26volume%3D62%26issue%3DSuppl.%252011%26spage%3DS74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Vergunst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopatinskaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klareskog, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Bosch, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinant, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baeten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1931</span><span class="NLM_x">â</span> <span class="NLM_lpage">1939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.23591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18576354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=1931-1939&author=C.+E.+Vergunstauthor=D.+M.+Gerlagauthor=L.+Lopatinskayaauthor=L.+Klareskogauthor=M.+D.+Smithauthor=F.+van+den+Boschauthor=H.+J.+Dinantauthor=Y.+Leeauthor=T.+Wyantauthor=E.+W.+Jacobsonauthor=D.+Baetenauthor=P.+P.+Tak&title=Modulation+of+CCR2+in+rheumatoid+arthritis%3A+a+double-blind%2C+randomized%2C+placebo-controlled+clinical+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial</span></div><div class="casAuthors">Vergunst, Clarissa E.; Gerlag, Danielle M.; Lopatinskaya, Luba; Klareskog, L.; Smith, M. D.; van den Bosch, F.; Dinant, Huib J.; Lee, Yih; Wyant, Timothy; Jacobson, Eric W.; Baeten, Dominique; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1931-1939</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: CCR2 is a chemokine receptor expressed by monocytes, macrophages, and a subset of T cells.  Its ligand, CCL2 (monocyte chemotactic protein 1), is abundantly present in the synovium of patients with rheumatoid arthritis (RA).  Blocking CCR2 prevents CCL2-mediated chemotaxis in vitro and modulates arthritis in animal models of RA.  In this study we examd. the effects of CCR2 blockade on synovial inflammation in RA.  Methods: The study was designed as a phase IIa clin. trial with a human CCR2 blocking antibody (MLN1202) in patients with active RA.  Thirty-two patients received 3 infusions, over a period of 6 wk, with either placebo (n = 9) or anti-CCR2 monoclonal antibody at 0.5 mg/kg (n = 7), 1.5 mg/kg (n = 7), or 4.0 mg/kg (n = 9).  Safety was monitored with lab. tests, immunotoxicity assessments, and documenting of adverse events, and European League Against Rheumatism and American College of Rheumatol. response criteria were used to assess clin. improvement.  Synovial tissue was obtained at baseline and after 43 days of treatment, for pharmacodynamic anal. using immunohistochem. and digital image anal.  The Kruskal-Wallis test was used to compare groups, and the Wilcoxon signed rank test was used to assess changes within the groups.  Results: All patients completed the study.  Treatment with CCR2 blocking antibody reduced the levels of free CCR2 on CD14+ monocytes by at least 57% and up to 94% (P < 0.001), demonstrating the biol. activity of the compd.  However, there was no redn. in the levels or expression of any of the synovial biomarkers.  Accordingly, no clin. improvement was obsd.  Conclusion: Treatment with anti-CCR2 blocking antibody did not result in amelioration of synovial inflammation in active RA.  The results do not support the notion that blockade of CCR2 may be sufficient to induce clin. improvement in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsazWDrk2LlbVg90H21EOLACvtfcHk0liQnMULqVIbew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkurs%253D&md5=fa636d4f933ec772ee3dd9e96e378a72</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fart.23591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.23591%26sid%3Dliteratum%253Aachs%26aulast%3DVergunst%26aufirst%3DC.%2BE.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DLopatinskaya%26aufirst%3DL.%26aulast%3DKlareskog%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DF.%26aulast%3DDinant%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DBaeten%26aufirst%3DD.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DModulation%2520of%2520CCR2%2520in%2520rheumatoid%2520arthritis%253A%2520a%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520clinical%2520trial%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D1931%26epage%3D1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Charvat, T. T.; Hu, C.; Jin, J.; Li, Y.; Melikian, A.; Pennell, A. M. K.; Punna, S.; Ungashe, S.; Zeng, Y.</span><span> </span><span class="NLM_article-title">Triazolyl Pyridyl Benzenesulfonamides</span>. US 20080039504,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+T.+Charvat&author=C.+Hu&author=J.+Jin&author=Y.+Li&author=A.+Melikian&author=A.+M.+K.+Pennell&author=S.+Punna&author=S.+Ungashe&author=Y.+Zeng&title=Triazolyl+Pyridyl+Benzenesulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharvat%26aufirst%3DT.%2BT.%26atitle%3DTriazolyl%2520Pyridyl%2520Benzenesulfonamides%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Krasinski, A.; Punna, S.; Ungashe, S.; Wang, Q.; Zeng, Y.</span><span> </span><span class="NLM_article-title">Fused Heteroaryl Pyridyl and Phenyl Benzenesulfonamides as CCR2 Modulators for the Treatment of Inflammation</span>. US 7,884,110,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Krasinski&author=S.+Punna&author=S.+Ungashe&author=Q.+Wang&author=Y.+Zeng&title=Fused+Heteroaryl+Pyridyl+and+Phenyl+Benzenesulfonamides+as+CCR2+Modulators+for+the+Treatment+of+Inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKrasinski%26aufirst%3DA.%26atitle%3DFused%2520Heteroaryl%2520Pyridyl%2520and%2520Phenyl%2520Benzenesulfonamides%2520as%2520CCR2%2520Modulators%2520for%2520the%2520Treatment%2520of%2520Inflammation%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span>Chemocentryx/Inc. <a href="http://www.secinfo.com/d14D5a.t6zp.htm" class="extLink">http://www.secinfo.com/d14D5a.t6zp.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chemocentryx%2FInc.+http%3A%2F%2Fwww.secinfo.com%2Fd14D5a.t6zp.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Sullivan, T. J.; Dairaghi, D. J.; Krasinski, A.; Miao, Z.; Wang, Y.; Zhao, B. N.; Baumgart, T.; Berahovich, R.; Ertl, L. S.; Pennell, A.; Seitz, L.; Miao, S.; Ungashe, S.; Wei, Z.; Johnson, D.; Boring, L.; Tsou, C. L.; Charo, I. F.; Bekker, P.; Schall, T. J.; Jaen, J. C.</span><span> </span><span class="NLM_article-title">Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications</span>.  <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span> [Online early access]. DOI: <span class="refDoi">Â DOI: 10.1124/jpet.111.190918</span> . Published Online: Feb 29,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.111.190918" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=T.+J.+Sullivan&author=D.+J.+Dairaghi&author=A.+Krasinski&author=Z.+Miao&author=Y.+Wang&author=B.+N.+Zhao&author=T.+Baumgart&author=R.+Berahovich&author=L.+S.+Ertl&author=A.+Pennell&author=L.+Seitz&author=S.+Miao&author=S.+Ungashe&author=Z.+Wei&author=D.+Johnson&author=L.+Boring&author=C.+L.+Tsou&author=I.+F.+Charo&author=P.+Bekker&author=T.+J.+Schall&author=J.+C.+Jaen&title=Characterization+of+CCX140-B%2C+an+orally+bioavailable+antagonist+of+the+CCR2+chemokine+receptor%2C+for+the+treatment+of+type+2+diabetes+and+associated+complications&doi=10.1124%2Fjpet.111.190918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.190918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.190918%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DT.%2BJ.%26atitle%3DCharacterization%2520of%2520CCX140-B%252C%2520an%2520orally%2520bioavailable%2520antagonist%2520of%2520the%2520CCR2%2520chemokine%2520receptor%252C%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520and%2520associated%2520complications%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26doi%3D10.1124%2Fjpet.111.190918%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Hanefeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouni-Berthold, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melichar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesela, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T. J.</span><span> </span><span class="NLM_article-title">Oral chemokine receptor 2 antagonist CCX140-B shows safety and efficacy in type 2 diabetes mellitus</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">A85</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=A85&author=M.+Hanefeldauthor=E.+Schellauthor=I.+Gouni-Bertholdauthor=M.+Melicharauthor=I.+Veselaauthor=T.+Sullivanauthor=S.+Miaoauthor=D.+Johnsonauthor=J.+Jaenauthor=P.+Bekkerauthor=T.+J.+Schall&title=Oral+chemokine+receptor+2+antagonist+CCX140-B+shows+safety+and+efficacy+in+type+2+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanefeld%26aufirst%3DM.%26aulast%3DSchell%26aufirst%3DE.%26aulast%3DGouni-Berthold%26aufirst%3DI.%26aulast%3DMelichar%26aufirst%3DM.%26aulast%3DVesela%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DT.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DJaen%26aufirst%3DJ.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26atitle%3DOral%2520chemokine%2520receptor%25202%2520antagonist%2520CCX140-B%2520shows%2520safety%2520and%2520efficacy%2520in%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDiabetes%26date%3D2011%26volume%3D60%26spage%3DA85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherney, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangion, I. K.</span><span> </span><span class="NLM_article-title">Advances in the discovery of CC chemokine receptor 2 antagonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=211-227&author=P.+H.+Carterauthor=R.+J.+Cherneyauthor=I.+K.+Mangion&title=Advances+in+the+discovery+of+CC+chemokine+receptor+2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DMangion%26aufirst%3DI.%2BK.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520CC%2520chemokine%2520receptor%25202%2520antagonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D211%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherney, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandlekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span> </span><span class="NLM_article-title">Discovery of an orally-bioavailable CC chemokine receptor 2 antagonist derived from an acyclic diaminoalcohol backbone</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3311</span><span class="NLM_x">â</span> <span class="NLM_lpage">3316</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3311-3316&author=P.+H.+Carterauthor=G.+D.+Brownauthor=S.+R.+Kingauthor=M.+E.+Vossauthor=A.+J.+Tebbenauthor=R.+J.+Cherneyauthor=S.+Mandlekarauthor=Y.+C.+Loauthor=G.+Yangauthor=P.+B.+Millerauthor=P.+A.+Scherleauthor=Q.+Zhaoauthor=C.+P.+Decicco&title=Discovery+of+an+orally-bioavailable+CC+chemokine+receptor+2+antagonist+derived+from+an+acyclic+diaminoalcohol+backbone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DKing%26aufirst%3DS.%2BR.%26aulast%3DVoss%26aufirst%3DM.%2BE.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DCherney%26aufirst%3DR.%2BJ.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DLo%26aufirst%3DY.%2BC.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DP.%2BB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26atitle%3DDiscovery%2520of%2520an%2520orally-bioavailable%2520CC%2520chemokine%2520receptor%25202%2520antagonist%2520derived%2520from%2520an%2520acyclic%2520diaminoalcohol%2520backbone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3311%26epage%3D3316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span>BMS-741672 for Diabetic Neuropathic Pain. <a href="http://clinicaltrials.gov/show/NCT00683423" class="extLink">http://clinicaltrials.gov/show/NCT00683423</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BMS-741672+for+Diabetic+Neuropathic+Pain.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT00683423."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span>Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance. <a href="http://clinicaltrials.gov/ct2/show/NCT00699790?term=CCR2&amp;rank=1" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00699790?term=CCR2&rank=1</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Proof+of+Confidence+Study+of+CCR2+Antagonist+%28BMS-741672%29+in+Insulin+Resistance.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00699790%3Fterm%3DCCR2%26rank%3D1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Lagu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerchak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malaviya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavender, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachter, M.</span><span> </span><span class="NLM_article-title">Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4382</span><span class="NLM_x">â</span> <span class="NLM_lpage">4386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4382-4386&author=B.+Laguauthor=C.+Gerchakauthor=M.+Panauthor=C.+Houauthor=M.+Singerauthor=R.+Malaviyaauthor=M.+Matheisauthor=G.+Oliniauthor=D.+Cavenderauthor=M.+Wachter&title=Potent+and+selective+CC-chemokine+receptor-2+%28CCR2%29+antagonists+as+a+potential+treatment+for+asthma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DGerchak%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DMalaviya%26aufirst%3DR.%26aulast%3DMatheis%26aufirst%3DM.%26aulast%3DOlini%26aufirst%3DG.%26aulast%3DCavender%26aufirst%3DD.%26aulast%3DWachter%26aufirst%3DM.%26atitle%3DPotent%2520and%2520selective%2520CC-chemokine%2520receptor-2%2520%2528CCR2%2529%2520antagonists%2520as%2520a%2520potential%2520treatment%2520for%2520asthma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4382%26epage%3D4386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufnagel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâNeill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, Z.</span><span> </span><span class="NLM_article-title">Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6042</span><span class="NLM_x">â</span> <span class="NLM_lpage">6048</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6042-6048&author=X.+Zhangauthor=H.+Hufnagelauthor=C.+Houauthor=E.+Opasauthor=S.+McKenneyauthor=C.+Cryslerauthor=J.+O%E2%80%99Neillauthor=D.+Johnsonauthor=Z.+Sui&title=Design%2C+synthesis+and+SAR+of+indazole+and+benzoisoxazole+containing+4-azetidinyl-1-aryl-cyclohexanes+as+CCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHufnagel%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DOpas%26aufirst%3DE.%26aulast%3DMcKenney%26aufirst%3DS.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DSui%26aufirst%3DZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520SAR%2520of%2520indazole%2520and%2520benzoisoxazole%2520containing%25204-azetidinyl-1-aryl-cyclohexanes%2520as%2520CCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6042%26epage%3D6048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufnagel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markotan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, Z.</span><span> </span><span class="NLM_article-title">Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5577</span><span class="NLM_x">â</span> <span class="NLM_lpage">5582</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5577-5582&author=X.+Zhangauthor=H.+Hufnagelauthor=T.+Markotanauthor=J.+Lanterauthor=C.+Caiauthor=C.+Houauthor=M.+Singerauthor=E.+Opasauthor=S.+McKenneyauthor=C.+Cryslerauthor=D.+Johnsonauthor=Z.+Sui&title=Overcoming+hERG+activity+in+the+discovery+of+a+series+of+4-azetidinyl-1-aryl-cyclohexanes+as+CCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHufnagel%26aufirst%3DH.%26aulast%3DMarkotan%26aufirst%3DT.%26aulast%3DLanter%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DSinger%26aufirst%3DM.%26aulast%3DOpas%26aufirst%3DE.%26aulast%3DMcKenney%26aufirst%3DS.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DSui%26aufirst%3DZ.%26atitle%3DOvercoming%2520hERG%2520activity%2520in%2520the%2520discovery%2520of%2520a%2520series%2520of%25204-azetidinyl-1-aryl-cyclohexanes%2520as%2520CCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5577%26epage%3D5582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Hou, C.; Singer, M.; Matheis, M.</span>; <span> </span><span class="NLM_article-title">JNJ-17166864, a Selective CCR2 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases</span>. Presented at the 104th International Conference American Thoracic Society, Toronto, Canada,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Hou&author=M.+Singer&author=M.+Matheis&title=JNJ-17166864%2C+a+Selective+CCR2+Antagonist+with+Potential+Therapeutic+Implications+for+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DC.%26atitle%3DJNJ-17166864%252C%2520a%2520Selective%2520CCR2%2520Antagonist%2520with%2520Potential%2520Therapeutic%2520Implications%2520for%2520Inflammatory%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santella, J. B.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncia, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1645</span><span class="NLM_x">â</span> <span class="NLM_lpage">1649</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1645-1649&author=J.+G.+Varnesauthor=D.+S.+Gardnerauthor=J.+B.+Santellaauthor=J.+V.+Dunciaauthor=M.+Estrellaauthor=P.+S.+Watsonauthor=C.+M.+Clarkauthor=S.+S.+Koauthor=P.+Welchauthor=M.+Covingtonauthor=N.+Stowellauthor=E.+Wadmanauthor=P.+Daviesauthor=K.+Solomonauthor=R.+C.+Newtonauthor=G.+L.+Trainorauthor=C.+P.+Deciccoauthor=D.+A.+Wacker&title=Discovery+of+N-propylurea+3-benzylpiperidines+as+selective+CC+chemokine+receptor-3+%28CCR3%29+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DEstrella%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DP.%2BS.%26aulast%3DClark%26aufirst%3DC.%2BM.%26aulast%3DKo%26aufirst%3DS.%2BS.%26aulast%3DWelch%26aufirst%3DP.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DStowell%26aufirst%3DN.%26aulast%3DWadman%26aufirst%3DE.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520of%2520N-propylurea%25203-benzylpiperidines%2520as%2520selective%2520CC%2520chemokine%2520receptor-3%2520%2528CCR3%2529%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1645%26epage%3D1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">De Lucca, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, U. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncia, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santella, J. B.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liauw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span> </span><span class="NLM_article-title">Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2194</span><span class="NLM_x">â</span> <span class="NLM_lpage">2211</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049530m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2194-2211&author=G.+V.+De+Luccaauthor=U.+T.+Kimauthor=B.+J.+Vargoauthor=J.+V.+Dunciaauthor=J.+B.+Santellaauthor=D.+S.+Gardnerauthor=C.+Zhengauthor=A.+Liauwauthor=Z.+Wangauthor=G.+Emmettauthor=D.+A.+Wackerauthor=P.+K.+Welchauthor=M.+Covingtonauthor=N.+C.+Stowellauthor=E.+A.+Wadmanauthor=A.+M.+Dasauthor=P.+Daviesauthor=S.+Yeleswaramauthor=D.+M.+Gradenauthor=K.+A.+Solomonauthor=R.+C.+Newtonauthor=G.+L.+Trainorauthor=C.+P.+Deciccoauthor=S.+S.+Ko&title=Discovery+of+CC+chemokine+receptor-3+%28CCR3%29+antagonists+with+picomolar+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm049530m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049530m%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DKim%26aufirst%3DU.%2BT.%26aulast%3DVargo%26aufirst%3DB.%2BJ.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DLiauw%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DEmmett%26aufirst%3DG.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DWelch%26aufirst%3DP.%2BK.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DStowell%26aufirst%3DN.%2BC.%26aulast%3DWadman%26aufirst%3DE.%2BA.%26aulast%3DDas%26aufirst%3DA.%2BM.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DGraden%26aufirst%3DD.%2BM.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DDiscovery%2520of%2520CC%2520chemokine%2520receptor-3%2520%2528CCR3%2529%2520antagonists%2520with%2520picomolar%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2194%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Pruitt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bostrom, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christ, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlovsky, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span> </span><span class="NLM_article-title">CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2992</span><span class="NLM_x">â</span> <span class="NLM_lpage">2997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2992-2997&author=J.+R.+Pruittauthor=D.+G.+Battauthor=D.+A.+Wackerauthor=L.+L.+Bostromauthor=S.+K.+Bookerauthor=E.+McLaughlinauthor=G.+C.+Houghtonauthor=J.+G.+Varnesauthor=D.+D.+Christauthor=M.+Covingtonauthor=A.+M.+Dasauthor=P.+Daviesauthor=D.+Gradenauthor=I.+Karivauthor=Y.+Orlovskyauthor=N.+C.+Stowellauthor=K.+G.+Vaddiauthor=E.+A.+Wadmanauthor=P.+K.+Welchauthor=S.+Yeleswaramauthor=K.+A.+Solomonauthor=R.+C.+Newtonauthor=C.+P.+Deciccoauthor=P.+H.+Carterauthor=S.+S.+Ko&title=CC+chemokine+receptor-3+%28CCR3%29+antagonists%3A+improving+the+selectivity+of+DPC168+by+reducing+central+ring+lipophilicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPruitt%26aufirst%3DJ.%2BR.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DBostrom%26aufirst%3DL.%2BL.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DMcLaughlin%26aufirst%3DE.%26aulast%3DHoughton%26aufirst%3DG.%2BC.%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DA.%2BM.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DGraden%26aufirst%3DD.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DOrlovsky%26aufirst%3DY.%26aulast%3DStowell%26aufirst%3DN.%2BC.%26aulast%3DVaddi%26aufirst%3DK.%2BG.%26aulast%3DWadman%26aufirst%3DE.%2BA.%26aulast%3DWelch%26aufirst%3DP.%2BK.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DCC%2520chemokine%2520receptor-3%2520%2528CCR3%2529%2520antagonists%253A%2520improving%2520the%2520selectivity%2520of%2520DPC168%2520by%2520reducing%2520central%2520ring%2520lipophilicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2992%26epage%3D2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Santella, J. B.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLucca, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandlekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kariv, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decicco, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncia, J. V.</span><span> </span><span class="NLM_article-title">From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">â</span> <span class="NLM_lpage">585</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=576-585&author=J.+B.+Santellaauthor=D.+S.+Gardnerauthor=W.+Yaoauthor=C.+Shiauthor=P.+Reddyauthor=A.+J.+Tebbenauthor=G.+V.+DeLuccaauthor=D.+A.+Wackerauthor=P.+S.+Watsonauthor=P.+K.+Welchauthor=E.+A.+Wadmanauthor=P.+Daviesauthor=K.+A.+Solomonauthor=D.+M.+Gradenauthor=S.+Yeleswaramauthor=S.+Mandlekarauthor=I.+Karivauthor=C.+P.+Deciccoauthor=S.+S.+Koauthor=P.+H.+Carterauthor=J.+V.+Duncia&title=From+rigid+cyclic+templates+to+conformationally+stabilized+acyclic+scaffolds.+Part+I%3A+the+discovery+of+CCR3+antagonist+development+candidate+BMS-639623+with+picomolar+inhibition+potency+against+eosinophil+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantella%26aufirst%3DJ.%2BB.%26aulast%3DGardner%26aufirst%3DD.%2BS.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DDeLucca%26aufirst%3DG.%2BV.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DWatson%26aufirst%3DP.%2BS.%26aulast%3DWelch%26aufirst%3DP.%2BK.%26aulast%3DWadman%26aufirst%3DE.%2BA.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DK.%2BA.%26aulast%3DGraden%26aufirst%3DD.%2BM.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DKariv%26aufirst%3DI.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DKo%26aufirst%3DS.%2BS.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26atitle%3DFrom%2520rigid%2520cyclic%2520templates%2520to%2520conformationally%2520stabilized%2520acyclic%2520scaffolds.%2520Part%2520I%253A%2520the%2520discovery%2520of%2520CCR3%2520antagonist%2520development%2520candidate%2520BMS-639623%2520with%2520picomolar%2520inhibition%2520potency%2520against%2520eosinophil%2520chemotaxis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D576%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Murdoch, R. D.</span> Presented at the 4th James Black Conference, The Challenges of Drug Discovery and Development, University of Hertfordshire, U.K., Sep 3,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Murdoch%2C+R.+D.+Presented+at+the+4th+James+Black+Conference%2C+The+Challenges+of+Drug+Discovery+and+Development%2C+University+of+Hertfordshire%2C+U.K.%2C+Sep+3%2C+2006."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMurdoch%26aufirst%3DR.%2BD.%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span>ClinicalTrials.gov. Oral GW766944 (Oral CCR3 Antagonist). <a href="http://clinicaltrials.gov/ct2/show/NCT01160224" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01160224</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Oral+GW766944+%28Oral+CCR3+Antagonist%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01160224."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Greiff, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlstrom-Emanuelsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahl, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlstrom, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erjefalt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widegren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, M.</span><span> </span><span class="NLM_article-title">Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1186%2F1465-9921-11-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20047687" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1-9&author=L.+Greiffauthor=C.+Ahlstrom-Emanuelssonauthor=A.+Bahlauthor=T.+Bengtssonauthor=K.+Dahlstromauthor=J.+Erjefaltauthor=H.+Widegrenauthor=M.+Andersson&title=Effects+of+a+dual+CCR3+and+H1-antagonist+on+symptoms+and+eosinophilic+inflammation+in+allergic+rhinitis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-17%26sid%3Dliteratum%253Aachs%26aulast%3DGreiff%26aufirst%3DL.%26aulast%3DAhlstrom-Emanuelsson%26aufirst%3DC.%26aulast%3DBahl%26aufirst%3DA.%26aulast%3DBengtsson%26aufirst%3DT.%26aulast%3DDahlstrom%26aufirst%3DK.%26aulast%3DErjefalt%26aufirst%3DJ.%26aulast%3DWidegren%26aufirst%3DH.%26aulast%3DAndersson%26aufirst%3DM.%26atitle%3DEffects%2520of%2520a%2520dual%2520CCR3%2520and%2520H1-antagonist%2520on%2520symptoms%2520and%2520eosinophilic%2520inflammation%2520in%2520allergic%2520rhinitis%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Pascoe, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bangert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stary, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stingl, G.</span><span> </span><span class="NLM_article-title">QAP642, a CCR3 antagonist, attenuates eotaxin induced eosnlophil accumulation in the skin</span> <span class="citation_source-journal">Am. J. Resp. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">A484</span><div class="note"><p class="first last"> (abstracts issue)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2007&pages=A484&author=S.+J.+Pascoeauthor=C.+Bangertauthor=M.+Bartlettauthor=G.+Staryauthor=G.+Stingl&title=QAP642%2C+a+CCR3+antagonist%2C+attenuates+eotaxin+induced+eosnlophil+accumulation+in+the+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPascoe%26aufirst%3DS.%2BJ.%26aulast%3DBangert%26aufirst%3DC.%26aulast%3DBartlett%26aufirst%3DM.%26aulast%3DStary%26aufirst%3DG.%26aulast%3DStingl%26aufirst%3DG.%26atitle%3DQAP642%252C%2520a%2520CCR3%2520antagonist%252C%2520attenuates%2520eotaxin%2520induced%2520eosnlophil%2520accumulation%2520in%2520the%2520skin%26jtitle%3DAm.%2520J.%2520Resp.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D175%26spage%3DA484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Toda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohbayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aye, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S. J.</span><span> </span><span class="NLM_article-title">Mechanisms of leukocyte trafficking in allergic diseases: insights into new therapies targeting chemokines and chemokine receptors</span> <span class="citation_source-journal">Expert Rev. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">351</span><span class="NLM_x">â</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1586%2F1744666X.3.3.351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20477679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsV2qtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=351-364&author=M.+Todaauthor=T.+Nakamuraauthor=M.+Ohbayashiauthor=Y.+Ikedaauthor=M.+Dawsonauthor=C.+C.+Ayeauthor=D.+Miyazakiauthor=S.+J.+Ono&title=Mechanisms+of+leukocyte+trafficking+in+allergic+diseases%3A+insights+into+new+therapies+targeting+chemokines+and+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of leukocyte trafficking in allergic diseases: insights into new therapies targeting chemokines and chemokine receptors</span></div><div class="casAuthors">Toda, Masako; Nakamura, Takao; Ohbayashi, Masaharu; Ikeda, Yoshifumi; Dawson, Maria; Aye, Cho Cho; Miyazaki, Dai; Ono, Santa Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-364</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Marked inflammatory infiltration by activated leukocytes is a characteristic feature of allergic diseases.  Elucidation of the mechanisms of leukocyte trafficking in allergic diseases would identify targets to establish novel anti-inflammatory strategies for treatment of these diseases.  Leukocyte trafficking is controlled by tissue-specific expression of chemokines and chemokine receptor expression on the leukocyte surface.  Here, we review the role of chemokines and their receptors in leukocyte trafficking to inflammatory sites in allergic diseases and discuss therapeutic strategies targeting chemokine networks for treatment of these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok4d5hMMm2mLVg90H21EOLACvtfcHk0lgK0gSzPGPZZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsV2qtrw%253D&md5=9b979e00136f85125a56ad13f8d36364</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1586%2F1744666X.3.3.351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F1744666X.3.3.351%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DOhbayashi%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DDawson%26aufirst%3DM.%26aulast%3DAye%26aufirst%3DC.%2BC.%26aulast%3DMiyazaki%26aufirst%3DD.%26aulast%3DOno%26aufirst%3DS.%2BJ.%26atitle%3DMechanisms%2520of%2520leukocyte%2520trafficking%2520in%2520allergic%2520diseases%253A%2520insights%2520into%2520new%2520therapies%2520targeting%2520chemokines%2520and%2520chemokine%2520receptors%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2007%26volume%3D3%26spage%3D351%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Gauvreau, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulet, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baatjes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschesnes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strinich, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzi, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâByrne, P. M.</span><span> </span><span class="NLM_article-title">Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">â</span> <span class="NLM_lpage">958</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1164%2Frccm.200708-1251OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18244953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1Ohs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2008&pages=952-958&author=G.+M.+Gauvreauauthor=L.+P.+Bouletauthor=D.+W.+Cockcroftauthor=A.+Baatjesauthor=J.+Coteauthor=F.+Deschesnesauthor=B.+Davisauthor=T.+Strinichauthor=K.+Howieauthor=M.+Duongauthor=R.+M.+Watsonauthor=P.+M.+Renziauthor=P.+M.+O%E2%80%99Byrne&title=Antisense+therapy+against+CCR3+and+the+common+beta+chain+attenuates+allergen-induced+eosinophilic+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses</span></div><div class="casAuthors">Gauvreau, Gail M.; Boulet, Louis Philippe; Cockcroft, Donald W.; Baatjes, Adrian; Cote, Johanne; Deschesnes, Francine; Davis, Beth; Strinich, Tara; Howie, Karen; Duong, MyLinh; Watson, Richard M.; Renzi, Paolo M.; O'Byrne, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">952-958</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (Î²c) of IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptors.  Objectives: This study examd. the effects of inhaled TPI ASM8 on sputum cellular influx, CCR3 and Î²c mRNA and protein levels, and the airway physiol. response after inhaled allergen.  Methods: Seventeen subjects with mild atopic asthma were randomized in a crossover study to inhale 1,500 Î¼g TPI ASM8 or placebo by nebulizer, once daily for 4 days.  On Day 3, subjects underwent allergen inhalation challenge.  Sputum samples were collected before and after allergen.  CCR3 and Î²c protein levels were measured by flow cytometry, mRNA was measured using real-time quant. polymerase chain reaction, and the FEV1 was measured over 7 h after challenge.  Measurements and Main Results: Compared with placebo, TPI ASM8 inhibited sputum eosinophil influx by 46% (P = 0.02) and blunted the increase in total cells (63%) after allergen challenge.  TPI ASM8 significantly reduced the early asthmatic response (P = 0.04) with a trend for the late asthmatic response (P = 0.08).  The allergen-induced (Day 2 to Day 3) levels of Î²c mRNA and CCR3 mRNA in sputum-derived cells were inhibited by TPI ASM8 (P = 0.039 and P = 0.054, resp.), with no significant effects on the cell surface protein expression of CCR3 and Î²c (P > 0.05).  No serious adverse events were reported.  Conclusions: TPI ASM8 attenuates the allergen-induced increase in target gene mRNA and airway responses in subjects with mild asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpegpWtd6yuGrVg90H21EOLACvtfcHk0lgK0gSzPGPZZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1Ohs7Y%253D&md5=2186d226b9894b7a73bf3b3ff098df96</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1164%2Frccm.200708-1251OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200708-1251OC%26sid%3Dliteratum%253Aachs%26aulast%3DGauvreau%26aufirst%3DG.%2BM.%26aulast%3DBoulet%26aufirst%3DL.%2BP.%26aulast%3DCockcroft%26aufirst%3DD.%2BW.%26aulast%3DBaatjes%26aufirst%3DA.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DDeschesnes%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DB.%26aulast%3DStrinich%26aufirst%3DT.%26aulast%3DHowie%26aufirst%3DK.%26aulast%3DDuong%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DR.%2BM.%26aulast%3DRenzi%26aufirst%3DP.%2BM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26atitle%3DAntisense%2520therapy%2520against%2520CCR3%2520and%2520the%2520common%2520beta%2520chain%2520attenuates%2520allergen-induced%2520eosinophilic%2520responses%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D177%26spage%3D952%26epage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Imaoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babirad, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehmi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvreau, G. M.</span><span> </span><span class="NLM_article-title">TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1740</span><span class="NLM_x">â</span> <span class="NLM_lpage">1746</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1365-2222.2011.03816.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21762225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2ntrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=1740-1746&author=H.+Imaokaauthor=H.+Campbellauthor=I.+Babiradauthor=R.+M.+Watsonauthor=M.+Mistryauthor=R.+Sehmiauthor=G.+M.+Gauvreau&title=TPI+ASM8+reduces+eosinophil+progenitors+in+sputum+after+allergen+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge</span></div><div class="casAuthors">Imaoka, H.; Campbell, H.; Babirad, I.; Watson, R. M.; Mistry, M.; Sehmi, R.; Gauvreau, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Allergy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1740-1746</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides (AON), one targeting the common beta chain (Î²c) of the IL-3/IL-5/GM-CSF receptors and the other targeting the chemokine receptor CCR3.  Inhalation of TPI ASM8 significantly improves lung function and sputum eosinophilia after allergen inhalation challenge in asthmatics.  Objective This study assessed whether TPI ASM8 reduces airway levels of haemopoietic progenitor cells.  Methods This open-label study was conducted in 14 stable, allergic mild asthmatic subjects with early- and late-phase allergen-induced bronchoconstriction.  Subjects underwent allergen challenges after 4-day treatment with placebo, 4 mg b.i.d. and 8 mg o.d. of TPI ASM8.  Sputum was induced before, 7 and 24 h after allergen challenges for progenitor measurements.  Treatments were sepd. by 2-3 wk.  Results TPI ASM8 reduced allergen-induced sputum eosinophils, and the early and late asthmatic responses (P<0.05).  TPI ASM8 also reduced the no. of CD34+CCR3+ cells (F= 0.004) and CD34+IL-5RÎ±+ cells (P= 0.016), and the proportion of CD34+ cells expressing H-5RÎ± (P= 0.036).  Conclusions and Clin. Relevance TPI ASM8 was safe and well tolerated.  The results of this study demonstrate blocking of CCR3 and Î²c expression by TPI ASM8 significantly inhibits the accumulation of eosinophils and eosinophil progenitors in the airways after allergen challenge.  Inhibition of airway progenitor cell accumulation presents a novel therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcTHNNaWhBTLVg90H21EOLACvtfcHk0lgK0gSzPGPZZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2ntrw%253D&md5=bea38bc6f1d7216a609817c418bbc792</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2011.03816.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2011.03816.x%26sid%3Dliteratum%253Aachs%26aulast%3DImaoka%26aufirst%3DH.%26aulast%3DCampbell%26aufirst%3DH.%26aulast%3DBabirad%26aufirst%3DI.%26aulast%3DWatson%26aufirst%3DR.%2BM.%26aulast%3DMistry%26aufirst%3DM.%26aulast%3DSehmi%26aufirst%3DR.%26aulast%3DGauvreau%26aufirst%3DG.%2BM.%26atitle%3DTPI%2520ASM8%2520reduces%2520eosinophil%2520progenitors%2520in%2520sputum%2520after%2520allergen%2520challenge%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2011%26volume%3D41%26spage%3D1740%26epage%3D1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akatsuka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shitara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utsunomiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">7529</span><span class="NLM_x">â</span> <span class="NLM_lpage">7539</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1158%2F1078-0432.CCR-04-0983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15569983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVanur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7529-7539&author=T.+Ishidaauthor=S.+Iidaauthor=Y.+Akatsukaauthor=T.+Ishiiauthor=M.+Miyazakiauthor=H.+Komatsuauthor=H.+Inagakiauthor=N.+Okadaauthor=T.+Fujitaauthor=K.+Shitaraauthor=S.+Akinagaauthor=T.+Takahashiauthor=A.+Utsunomiyaauthor=R.+Ueda&title=The+CC+chemokine+receptor+4+as+a+novel+specific+molecular+target+for+immunotherapy+in+adult+T-cell+leukemia%2Flymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma</span></div><div class="casAuthors">Ishida, Takashi; Iida, Shinsuke; Akatsuka, Yoshiki; Ishii, Toshihiko; Miyazaki, Mikinori; Komatsu, Hirokazu; Inagaki, Hiroshi; Okada, Noriko; Fujita, Teizo; Shitara, Kenya; Akinaga, Shiro; Takahashi, Toshitada; Utsunomiya, Atae; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7529-7539</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm with dismal prognosis, and no optimal therapy has been developed.  The authors tested the defucosylated chimeric anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, KM2760, to develop a novel immunotherapy for this refractory tumor.  In the presence of peripheral blood mononuclear cells (PBMCs) from healthy adult donors, KM2760 induced CCR4-specific antibody-dependent cellular cytotoxicity (ADCC) against CCR4-pos. ATLL cell lines and primary tumor cells obtained from ATLL patients.  The authors next examd. the KM2760-induced ADCC against primary ATLL cells in an autologous setting.  Antibody-dependent cellular cytotoxicity mediated by autologous effector cells was generally lower than that mediated by allogeneic control effector cells.  However, a robust ADCC activity was induced in some cases, which was comparable with that mediated by allogeneic effector cells.  This suggests that the ATLL patients' PBMCs retain substantial ADCC-effector function, although the optimal conditions for maximal effect have not yet been detd.  In addn., the authors also found a high expression of FoxP3 mRNA and protein, a hallmark of regulatory T cells, in ATLL cells, indicating the possibility that ATLL cells originated from regulatory T cells.  KM2760 reduced FoxP3 mRNA expression in normal PBMCs along with CCR4 mRNA by lysis of CCR4+ T cells in vitro.  Thus, not only the CCR4 mol. could be a suitable target for the novel antibody-based therapy for patients with ATLL but also KM2760 may induce effective tumor immunity by reducing the no. of regulatory T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFKhZ41A4cTrVg90H21EOLACvtfcHk0ljUZgNlhQ-4aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVanur%252FP&md5=a3a4c4bbd792aa62dbbbb11771190a7f</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-0983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-0983%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DAkatsuka%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DOkada%26aufirst%3DN.%26aulast%3DFujita%26aufirst%3DT.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DUtsunomiya%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DThe%2520CC%2520chemokine%2520receptor%25204%2520as%2520a%2520novel%2520specific%2520molecular%2520target%2520for%2520immunotherapy%2520in%2520adult%2520T-cell%2520leukemia%252Flymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7529%26epage%3D7539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Pease, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span> </span><span class="NLM_article-title">Chemokine receptor antagonists:Part 1</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1517%2F13543770802641346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19441897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=39-58&author=J.+E.+Peaseauthor=R.+Horuk&title=Chemokine+receptor+antagonists%3APart+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor antagonists: Part 1</span></div><div class="casAuthors">Pease, James E.; Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-58</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Chemokines were originally defined as host defense proteins, however, their biol. role goes well beyond this simple description of their function as immune cell chemoattractants, and they have since been shown to be involved in a no. of other biol. processes, including growth regulation, hematopoiesis, embryol. development, angiogenesis, and HIV-1 infection.  Because of their diverse role in autoimmune diseases and AIDS, chemokines and their receptors, which belong to the G-protein-coupled receptor superfamily, have been considered good drug targets by the pharmaceutical industry.  In the first part of this two-part review, we highlight recent developments in the chemokine receptor antagonist field both in the peer reviewed and in the patent literature for the CC chemokine receptors CCR1, CCR2, CCR3, and CCR4.  A no. of chemokine receptor antagonists have made the transition from lead compds. to clin. candidates, some of which are described here.  Although there has been no clin. success yet for antagonists targeting the group of receptors discussed here, the compds. have been invaluable in generating information that should pave the way for producing successful therapeutics in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp97IrxM1COU7Vg90H21EOLACvtfcHk0ljUZgNlhQ-4aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyrtw%253D%253D&md5=4452f7ab2618212991c97c9f5243483c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1517%2F13543770802641346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770802641346%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DChemokine%2520receptor%2520antagonists%253APart%25201%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D39%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utsunomiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobinai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uike, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uozumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomonaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">â</span> <span class="NLM_lpage">1598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1200%2FJCO.2009.25.3575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20177026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFGht7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1591-1598&author=K.+Yamamotoauthor=A.+Utsunomiyaauthor=K.+Tobinaiauthor=K.+Tsukasakiauthor=N.+Uikeauthor=K.+Uozumiauthor=K.+Yamaguchiauthor=Y.+Yamadaauthor=S.+Hanadaauthor=K.+Tamuraauthor=S.+Nakamuraauthor=H.+Inagakiauthor=K.+Ohshimaauthor=H.+Kiyoiauthor=T.+Ishidaauthor=K.+Matsushimaauthor=S.+Akinagaauthor=M.+Oguraauthor=M.+Tomonagaauthor=R.+Ueda&title=Phase+I+study+of+KW-0761%2C+a+defucosylated+humanized+anti-CCR4+antibody%2C+in+relapsed+patients+with+adult+T-cell+leukemia-lymphoma+and+peripheral+T-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma</span></div><div class="casAuthors">Yamamoto, Kazuhito; Utsunomiya, Atae; Tobinai, Kensei; Tsukasaki, Kunihiro; Uike, Naokuni; Uozumi, Kimiharu; Yamaguchi, Kazunari; Yamada, Yasuaki; Hanada, Shuichi; Tamura, Kazuo; Nakamura, Shigeo; Inagaki, Hiroshi; Ohshima, Koichi; Kiyoi, Hitoshi; Ishida, Takashi; Matsushima, Kouji; Akinaga, Shiro; Ogura, Michinori; Tomonaga, Masao; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1591-1598</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose KW-0761, a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody, exerts a strong antibody-dependent cellular cytotoxic effect.  This phase I study assessed the safety, pharmacokinetics, recommended phase II dose and efficacy of KW-0761 in patients with relapsed CCR4-pos. adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL).  Patients and Methods Sixteen patients received KW-0761 once a week for 4 wk by i.v. infusion.  Doses were escalated, starting at 0.01, 0.1, 0.5, and finally 1.0 mg/kg by a 3 + 3 design.  Results Fifteen patients completed the protocol treatment.  Only one patient, at the 1.0 mg/kg dose, developed grade 3 dose-limiting toxicities, skin rash, and febrile neutropenia, and grade 4 neutropenia.  Other treatment-related grade 3 to 4 toxicities were lymphopenia (n = 10), neutropenia (n = 3), leukopenia (n = 2), herpes zoster (n = 1), and acute infusion reaction/cytokine release syndrome (n = 1).  Neither the frequency nor severity of toxicities increased with dose escalation.  The max. tolerated dose was not reached.  Therefore, the recommended phase II dose was detd. to be 1.0 mg/kg.  No patients had detectable levels of anti-KW-0761 antibody.  The plasma max. and trough, and the area under the curve of 0 to 7 days of KW-0761, tended to increase dose and frequency dependently.  Five patients (31%; 95% CI, 11% to 59%) achieved objective responses: two complete (0.1; 1.0 mg/kg) and three partial (0.01; 2 at 1.0 mg/kg) responses.  Conclusion KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-pos. ATL or PTCL.  Subsequent phase II studies at the 1.0 mg/kg dose are thus warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzVwF97DSVUbVg90H21EOLACvtfcHk0ljUZgNlhQ-4aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFGht7w%253D&md5=8717c3ccf58f4b3484ec94eced9c1da3</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.3575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.3575%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DUtsunomiya%26aufirst%3DA.%26aulast%3DTobinai%26aufirst%3DK.%26aulast%3DTsukasaki%26aufirst%3DK.%26aulast%3DUike%26aufirst%3DN.%26aulast%3DUozumi%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DHanada%26aufirst%3DS.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DOhshima%26aufirst%3DK.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DOgura%26aufirst%3DM.%26aulast%3DTomonaga%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DPhase%2520I%2520study%2520of%2520KW-0761%252C%2520a%2520defucosylated%2520humanized%2520anti-CCR4%2520antibody%252C%2520in%2520relapsed%2520patients%2520with%2520adult%2520T-cell%2520leukemia-lymphoma%2520and%2520peripheral%2520T-cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1591%26epage%3D1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Ishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uike, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utsunomiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saburi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzushima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishitsuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomonaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobinai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, R.</span><span> </span><span class="NLM_article-title">Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">â</span> <span class="NLM_lpage">842</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1200%2FJCO.2011.37.3472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=22312108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC38XntV2lsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=837-842&author=T.+Ishidaauthor=T.+Johauthor=N.+Uikeauthor=K.+Yamamotoauthor=A.+Utsunomiyaauthor=S.+Yoshidaauthor=Y.+Saburiauthor=T.+Miyamotoauthor=S.+Takemotoauthor=H.+Suzushimaauthor=K.+Tsukasakiauthor=K.+Nosakaauthor=H.+Fujiwaraauthor=K.+Ishitsukaauthor=H.+Inagakiauthor=M.+Oguraauthor=S.+Akinagaauthor=M.+Tomonagaauthor=K.+Tobinaiauthor=R.+Ueda&title=Defucosylated+anti-CCR4+monoclonal+antibody+%28KW-0761%29+for+relapsed+adult+T-cell+leukemia-lymphoma%3A+a+multicenter+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study</span></div><div class="casAuthors">Ishida, Takashi; Joh, Tatsuro; Uike, Naokuni; Yamamoto, Kazuhito; Utsunomiya, Atae; Yoshida, Shinichiro; Saburi, Yoshio; Miyamoto, Toshihiro; Takemoto, Shigeki; Suzushima, Hitoshi; Tsukasaki, Kunihiro; Nosaka, Kisato; Fujiwara, Hiroshi; Ishitsuka, Kenji; Inagaki, Hiroshi; Ogura, Michinori; Akinaga, Shiro; Tomonaga, Masao; Tobinai, Kensei; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">837-842</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Adult T-cell leukemia-lymphoma (ATL) is usually resistant to conventional chemotherapies, and there are few other treatment options.  Because CC chemokine receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL.  Patients and Methods A multicenter phase II study of KW-0761 for patients with relapsed, aggressive CCR4-pos. ATL was conducted to evaluate efficacy, pharmacokinetic profile, and safety.  The primary end point was overall response rate, and secondary end points included progression-free and overall survival from the first dose of KW-0761.  Patients received i.v. infusions of KW-0761 once per wk for 8 wk at a dose of 1.0 mg/kg.  Results Of 28 patients enrolled onto the study, 27 received at least one infusion of KW-0761.  Objective responses were noted in 13 of 26 evaluable patients, including eight complete responses, with an overall response rate of 50% (95% CI, 30% to 70%).  Median progression-free and overall survival were 5.2 and 13.7 mo, resp.  The mean half-life period after the eighth infusion was 422 Â± 147 h (Â± std. deviation).  The most common adverse events were infusion reactions (89%) and skin rashes (63%), which were manageable and reversible in all cases.  Conclusion KW-0761 demonstrated clin. meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile.  Further investigation of KW-0761 for treatment of ATL and other T-cell neoplasms is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-wLRDV_T-BbVg90H21EOLACvtfcHk0ljpVeCYGDfEAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntV2lsbo%253D&md5=ae7f200acf6076c2e41c0346c13df859</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.37.3472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.37.3472%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DT.%26aulast%3DUike%26aufirst%3DN.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DUtsunomiya%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DSaburi%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DTakemoto%26aufirst%3DS.%26aulast%3DSuzushima%26aufirst%3DH.%26aulast%3DTsukasaki%26aufirst%3DK.%26aulast%3DNosaka%26aufirst%3DK.%26aulast%3DFujiwara%26aufirst%3DH.%26aulast%3DIshitsuka%26aufirst%3DK.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DOgura%26aufirst%3DM.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DTomonaga%26aufirst%3DM.%26aulast%3DTobinai%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DDefucosylated%2520anti-CCR4%2520monoclonal%2520antibody%2520%2528KW-0761%2529%2520for%2520relapsed%2520adult%2520T-cell%2520leukemia-lymphoma%253A%2520a%2520multicenter%2520phase%2520II%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D837%26epage%3D842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Procopiou, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Needham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slack, R. J.</span><span> </span><span class="NLM_article-title">Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2730</span><span class="NLM_x">â</span> <span class="NLM_lpage">2733</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2730-2733&author=P.+A.+Procopiouauthor=A.+J.+Fordauthor=R.+H.+Gravesauthor=D.+A.+Hallauthor=S.+T.+Hodgsonauthor=Y.+M.+Lacroixauthor=D.+Needhamauthor=R.+J.+Slack&title=Lead+optimisation+of+the+N1+substituent+of+a+novel+series+of+indazole+arylsulfonamides+as+CCR4+antagonists+and+identification+of+a+candidate+for+clinical+investigation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DLacroix%26aufirst%3DY.%2BM.%26aulast%3DNeedham%26aufirst%3DD.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26atitle%3DLead%2520optimisation%2520of%2520the%2520N1%2520substituent%2520of%2520a%2520novel%2520series%2520of%2520indazole%2520arylsulfonamides%2520as%2520CCR4%2520antagonists%2520and%2520identification%2520of%2520a%2520candidate%2520for%2520clinical%2520investigation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2730%26epage%3D2733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span>Intravenous Microdose Pharmacokinetic (PK) Study with [14C]-GSK2239633. <a href="http://clinicaltrials.gov/show/NCT01086462" class="extLink">http://clinicaltrials.gov/show/NCT01086462</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Intravenous+Microdose+Pharmacokinetic+%28PK%29+Study+with+%5B14C%5D-GSK2239633.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01086462."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Moore, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trkola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragic, T.</span><span> </span><span class="NLM_article-title">Co-receptors for HIV-1 entry</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0952-7915%2897%2980110-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9287172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK2sXlvVyqur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=551-562&author=J.+P.+Mooreauthor=A.+Trkolaauthor=T.+Dragic&title=Co-receptors+for+HIV-1+entry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Co-receptors for HIV-1 entry</span></div><div class="casAuthors">Moore, John P.; Trkola, Alexandra; Dragic, Tatjana</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">551-562</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review and discussion with 93 refs.  HIV-1 enters its target cells by fusion at the plasma membrane.  The primary cellular receptor for HIV is CD4, but this mol. is insufficient to permit viral fusion.  During 1996, the necessary entry co-factors (co-receptors or second receptors) were identified as being members of the seven-transmembrane-spanning receptor family fusin: CXCR4 for T-tropic strains and CCR5, principally, for M-tropic strains.  The co-receptor functions of these proteins are inhibited by their natural Î±- and Î²-chemokine ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNiow88ydm7Vg90H21EOLACvtfcHk0ljpVeCYGDfEAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvVyqur0%253D&md5=d8805ccf35f191ea797470f08effd7a1</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2897%2980110-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252897%252980110-0%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DJ.%2BP.%26aulast%3DTrkola%26aufirst%3DA.%26aulast%3DDragic%26aufirst%3DT.%26atitle%3DCo-receptors%2520for%2520HIV-1%2520entry%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1997%26volume%3D9%26spage%3D551%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, D.</span><span> </span><span class="NLM_article-title">The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">â</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0079-6468%2805%2943007-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15850827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXps1Citbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=239-271&author=A.+Woodauthor=D.+Armour&title=The+discovery+of+the+CCR5+receptor+antagonist%2C+UK-427%2C857%2C+a+new+agent+for+the+treatment+of+HIV+infection+and+AIDS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS</span></div><div class="casAuthors">Wood, Anthony; Armour, Duncan</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-271</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The drug discovery program that led to the identification of UK-427,857, a prototype CCR5 antagonist with excellent potency against lab-adapted and primary HIV-1 isolates, as a clin. candidate for the treatment of HIV is described.  In particular, strategies for minimizing cardiac toxicity while maintaining ADME properties commensurate with low dose are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIJQwMygW-grVg90H21EOLACvtfcHk0ljpVeCYGDfEAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXps1Citbg%253D&md5=8c4bb50b02b7e6d8cfa13d844e39017c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0079-6468%2805%2943007-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6468%252805%252943007-6%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DA.%26aulast%3DArmour%26aufirst%3DD.%26atitle%3DThe%2520discovery%2520of%2520the%2520CCR5%2520receptor%2520antagonist%252C%2520UK-427%252C857%252C%2520a%2520new%2520agent%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%2520and%2520AIDS%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D43%26spage%3D239%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Armour, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groot, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span> </span><span class="NLM_article-title">The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">706</span><span class="NLM_x">â</span> <span class="NLM_lpage">709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=706-709&author=D.+Armourauthor=M.+J.+de+Grootauthor=M.+Edwardsauthor=M.+Perrosauthor=D.+A.+Priceauthor=B.+L.+Stammenauthor=A.+Wood&title=The+discovery+of+CCR5+receptor+antagonists+for+the+treatment+of+HIV+infection%3A+hit-to-lead+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArmour%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DM.%2BJ.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DPerros%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DStammen%26aufirst%3DB.%2BL.%26aulast%3DWood%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520CCR5%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%253A%2520hit-to-lead%2520studies%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D706%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Dorr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macartney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Burchnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros, M.</span><span> </span><span class="NLM_article-title">Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4721</span><span class="NLM_x">â</span> <span class="NLM_lpage">4732</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=4721-4732&author=P.+Dorrauthor=M.+Westbyauthor=S.+Dobbsauthor=P.+Griffinauthor=B.+Irvineauthor=M.+Macartneyauthor=J.+Moriauthor=G.+Rickettauthor=C.+Smith-Burchnellauthor=C.+Napierauthor=R.+Websterauthor=D.+Armourauthor=D.+Priceauthor=B.+Stammenauthor=A.+Woodauthor=M.+Perros&title=Maraviroc+%28UK-427%2C857%29%2C+a+potent%2C+orally+bioavailable%2C+and+selective+small-molecule+inhibitor+of+chemokine+receptor+CCR5+with+broad-spectrum+anti-human+immunodeficiency+virus+type+1+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorr%26aufirst%3DP.%26aulast%3DWestby%26aufirst%3DM.%26aulast%3DDobbs%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DIrvine%26aufirst%3DB.%26aulast%3DMacartney%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DRickett%26aufirst%3DG.%26aulast%3DSmith-Burchnell%26aufirst%3DC.%26aulast%3DNapier%26aufirst%3DC.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DArmour%26aufirst%3DD.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DPerros%26aufirst%3DM.%26atitle%3DMaraviroc%2520%2528UK-427%252C857%2529%252C%2520a%2520potent%252C%2520orally%2520bioavailable%252C%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520chemokine%2520receptor%2520CCR5%2520with%2520broad-spectrum%2520anti-human%2520immunodeficiency%2520virus%2520type%25201%2520activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D4721%26epage%3D4732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Fatkenheuer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pozniak, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plettenberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staszewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoepelman, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goebel, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockstroh, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Ryst, E.</span><span> </span><span class="NLM_article-title">Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">â</span> <span class="NLM_lpage">1172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1170-1172&author=G.+Fatkenheuerauthor=A.+L.+Pozniakauthor=M.+A.+Johnsonauthor=A.+Plettenbergauthor=S.+Staszewskiauthor=A.+I.+Hoepelmanauthor=M.+S.+Saagauthor=F.+D.+Goebelauthor=J.+K.+Rockstrohauthor=B.+J.+Dezubeauthor=T.+M.+Jenkinsauthor=C.+Medhurstauthor=J.+F.+Sullivanauthor=C.+Ridgwayauthor=S.+Abelauthor=I.+T.+Jamesauthor=M.+Youleauthor=E.+van+der+Ryst&title=Efficacy+of+short-term+monotherapy+with+maraviroc%2C+a+new+CCR5+antagonist%2C+in+patients+infected+with+HIV-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFatkenheuer%26aufirst%3DG.%26aulast%3DPozniak%26aufirst%3DA.%2BL.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DPlettenberg%26aufirst%3DA.%26aulast%3DStaszewski%26aufirst%3DS.%26aulast%3DHoepelman%26aufirst%3DA.%2BI.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DGoebel%26aufirst%3DF.%2BD.%26aulast%3DRockstroh%26aufirst%3DJ.%2BK.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJenkins%26aufirst%3DT.%2BM.%26aulast%3DMedhurst%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DJ.%2BF.%26aulast%3DRidgway%26aufirst%3DC.%26aulast%3DAbel%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DI.%2BT.%26aulast%3DYoule%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BRyst%26aufirst%3DE.%26atitle%3DEfficacy%2520of%2520short-term%2520monotherapy%2520with%2520maraviroc%252C%2520a%2520new%2520CCR5%2520antagonist%252C%2520in%2520patients%2520infected%2520with%2520HIV-1%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D1170%26epage%3D1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Lieberman-Blum, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandres, J. C.</span><span> </span><span class="NLM_article-title">Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">â</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0149-2918%2808%2980048-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18691983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVyitL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=1228-1250&author=S.+S.+Lieberman-Blumauthor=H.+B.+Fungauthor=J.+C.+Bandres&title=Maraviroc%3A+a+CCR5-receptor+antagonist+for+the+treatment+of+HIV-1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection</span></div><div class="casAuthors">Lieberman-Blum, Sharon S.; Fung, Horatio B.; Bandres, Juan C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1228-1250</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The emergence of viral resistance is one of the greatest challenges in the treatment of HIV infection.  Maraviroc is the first member of a new class of antiretroviral medications, the CCR5-receptor antagonists.  It is approved by the US Food and Drug Administration (FDA) for use in combination with other antiretroviral agents in treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1.  Objective: This article provides an overview of the pharmacol., efficacy, and tolerability of maraviroc in the treatment of HIV-1 infection.  Methods: Relevant information was identified through a search of MEDLINE (Jan. 2000-May 2008) using the terms maraviroc, UK-427,857, and CCR5-receptor antagonist.  Also consulted were abstrs. from the International AIDS Society Conference, the Conference on Retroviruses and Opportunistic Infections, and other relevant scientific meetings.  Addnl. publications were found by searching the ref. lists of the identified articles and the FDA Web site.  Results: Maraviroc is a selective, reversible, small-mol. CCR5-receptor antagonist.  In vitro, it has potent anti-HIV-1 activity, with a mean 90% inhibitory concn. of 2.0 nmol/L.  It is widely distributed, with a Vd of â¼194 L.  Maraviroc is moderately metabolized in the liver (65.3%), primarily via the cytochrome P 450 3A4 isoenzyme.  It has an elimination t1/2 of 15.9 to 22.9 h.  Until more data are available, maraviroc should be avoided in patients with severe hepatic insufficiency; dose adjustment does not appear to be necessary on the basis of age, sex, or renal function.  In 2 Phase IIb/III studies, maraviroc 300 mg PO QD or BID was found to be more efficacious than placebo in reducing the viral load at 48 wk in treatment-experienced, CCR5-tropic HIV-1-infected patients receiving an optimized background regimen (difference vs placebo-QD arm: -0.89 log10 copies/mL [97.5% CI, -1.17 to -0.62]; BID arm: -1.05 log10 copies/mL [97.5% CI, -1.33 to -0.78]).  The proportion of patients with a viral load <50 copies/mL was 43.2% in the QD arm and 45.5% in the BID arm, compared with 16.7% in the placebo arm (P < 0.001, both treatment arms vs placebo).  In treatment-naive patients infected with CCR5-tropic virus only, maraviroc 300 mg PO BID was not noninferior to oral efavirenz 600 mg QD (difference = -4.2%; lower bound of the 1-sided 97.5% CI, -10.9 [predefined statistical cutoff for noninferiority, -10]).  Maraviroc was generally well tolerated in clin. trials.  The most frequently reported (â¥5%) adverse events were upper respiratory tract infection (20.0%), cough (12.7%), pyrexia (12.0%), rash (9.6%), musculoskeletal complaints (8.7%), gastrointestinal and abdominal pain (8.2%), dizziness (8.2%), appetite disorders (7.3%), insomnia (7.0%), herpes infection (6.8%), sinusitis (6.3%), joint complaints (6.1%), bronchitis (5.9%), and constipation (5.4%).  The recommended dose of maraviroc differs based on concomitant medications, ranging from 150 to 600 mg BID.  Conclusion: When used in combination with other antiretroviral agents, maraviroc appears to be a promising agent for treatment-experienced patients infected with multidrug-resistant, CCR5-tropic HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo73dWGTL6Me7Vg90H21EOLACvtfcHk0lhtgVwfx3ERwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVyitL0%253D&md5=f0923816dd986856a3dd6c3e11a3c45d</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2FS0149-2918%2808%2980048-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-2918%252808%252980048-3%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman-Blum%26aufirst%3DS.%2BS.%26aulast%3DFung%26aufirst%3DH.%2BB.%26aulast%3DBandres%26aufirst%3DJ.%2BC.%26atitle%3DMaraviroc%253A%2520a%2520CCR5-receptor%2520antagonist%2520for%2520the%2520treatment%2520of%2520HIV-1%2520infection%26jtitle%3DClin.%2520Ther.%26date%3D2008%26volume%3D30%26spage%3D1228%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Palani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clader, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B. M.</span><span> </span><span class="NLM_article-title">Discovery of 4-[(<i>Z</i>)-(4-bromophenyl)- (ethoxyimino)methyl]-1â²-[(2,4- dimethyl-3- pyridinyl)carbonyl]-4â²-methyl-1,4â²- bipiperidine <i>N</i>-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3339</span><span class="NLM_x">â</span> <span class="NLM_lpage">3342</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm015526o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3339-3342&author=A.+Palaniauthor=S.+Shapiroauthor=J.+W.+Claderauthor=W.+J.+Greenleeauthor=K.+Coxauthor=J.+Strizkiauthor=M.+Endresauthor=B.+M.+Baroudy&title=Discovery+of+4-%5B%28Z%29-%284-bromophenyl%29-+%28ethoxyimino%29methyl%5D-1%E2%80%B2-%5B%282%2C4-+dimethyl-3-+pyridinyl%29carbonyl%5D-4%E2%80%B2-methyl-1%2C4%E2%80%B2-+bipiperidine+N-oxide+%28SCH+351125%29%3A+an+orally+bioavailable+human+CCR5+antagonist+for+the+treatment+of+HIV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fjm015526o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm015526o%26sid%3Dliteratum%253Aachs%26aulast%3DPalani%26aufirst%3DA.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DStrizki%26aufirst%3DJ.%26aulast%3DEndres%26aufirst%3DM.%26aulast%3DBaroudy%26aufirst%3DB.%2BM.%26atitle%3DDiscovery%2520of%25204-%255B%2528Z%2529-%25284-bromophenyl%2529-%2520%2528ethoxyimino%2529methyl%255D-1%25E2%2580%25B2-%255B%25282%252C4-%2520dimethyl-3-%2520pyridinyl%2529carbonyl%255D-4%25E2%2580%25B2-methyl-1%252C4%25E2%2580%25B2-%2520bipiperidine%2520N-oxide%2520%2528SCH%2520351125%2529%253A%2520an%2520orally%2520bioavailable%2520human%2520CCR5%2520antagonist%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3339%26epage%3D3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">McCombie, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagat, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vice, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. C.</span><span> </span><span class="NLM_article-title">Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=567-571&author=S.+W.+McCombieauthor=J.+R.+Tagatauthor=S.+F.+Viceauthor=S.+I.+Linauthor=R.+Steensmaauthor=A.+Palaniauthor=B.+R.+Neustadtauthor=B.+M.+Baroudyauthor=J.+M.+Strizkiauthor=M.+Endresauthor=K.+Coxauthor=N.+Danauthor=C.+C.+Chou&title=Piperazine-based+CCR5+antagonists+as+HIV-1+inhibitors.+III%3A+Synthesis%2C+antiviral+and+pharmacokinetic+profiles+of+symmetrical+heteroaryl+carboxamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCombie%26aufirst%3DS.%2BW.%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DVice%26aufirst%3DS.%2BF.%26aulast%3DLin%26aufirst%3DS.%2BI.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DPalani%26aufirst%3DA.%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DBaroudy%26aufirst%3DB.%2BM.%26aulast%3DStrizki%26aufirst%3DJ.%2BM.%26aulast%3DEndres%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DDan%26aufirst%3DN.%26aulast%3DChou%26aufirst%3DC.%2BC.%26atitle%3DPiperazine-based%2520CCR5%2520antagonists%2520as%2520HIV-1%2520inhibitors.%2520III%253A%2520Synthesis%252C%2520antiviral%2520and%2520pharmacokinetic%2520profiles%2520of%2520symmetrical%2520heteroaryl%2520carboxamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D567%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Este, J. A.</span><span> </span><span class="NLM_article-title">SCH-351125 and SCH-350634. Schering-Plough</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=379-383&author=J.+A.+Este&title=SCH-351125+and+SCH-350634.+Schering-Plough"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEste%26aufirst%3DJ.%2BA.%26atitle%3DSCH-351125%2520and%2520SCH-350634.%2520Schering-Plough%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D379%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Tagat, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCombie, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazareno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labroli, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, R.</span><span> </span><span class="NLM_article-title">Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(<i>R</i>)-4-(trifluoromethyl)phenyl]ethyl-3(<i>S</i>)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">â</span> <span class="NLM_lpage">2408</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0304515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2405-2408&author=J.+R.+Tagatauthor=S.+W.+McCombieauthor=D.+Nazarenoauthor=M.+A.+Labroliauthor=Y.+Xiaoauthor=R.+W.+Steensmaauthor=J.+M.+Strizkiauthor=B.+M.+Baroudyauthor=K.+Coxauthor=J.+Lachowiczauthor=G.+Vartyauthor=R.+Watkins&title=Piperazine-based+CCR5+antagonists+as+HIV-1+inhibitors.+IV.+Discovery+of+1-%5B%284%2C6-dimethyl-5-pyrimidinyl%29carbonyl%5D-4-%5B4-%5B2-methoxy-1%28R%29-4-%28trifluoromethyl%29phenyl%5Dethyl-3%28S%29-methyl-1-piperazinyl%5D-4-methylpiperidine+%28Sch-417690%2FSch-D%29%2C+a+potent%2C+highly+selective%2C+and+orally+bioavailable+CCR5+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjm0304515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0304515%26sid%3Dliteratum%253Aachs%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DMcCombie%26aufirst%3DS.%2BW.%26aulast%3DNazareno%26aufirst%3DD.%26aulast%3DLabroli%26aufirst%3DM.%2BA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DSteensma%26aufirst%3DR.%2BW.%26aulast%3DStrizki%26aufirst%3DJ.%2BM.%26aulast%3DBaroudy%26aufirst%3DB.%2BM.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DVarty%26aufirst%3DG.%26aulast%3DWatkins%26aufirst%3DR.%26atitle%3DPiperazine-based%2520CCR5%2520antagonists%2520as%2520HIV-1%2520inhibitors.%2520IV.%2520Discovery%2520of%25201-%255B%25284%252C6-dimethyl-5-pyrimidinyl%2529carbonyl%255D-4-%255B4-%255B2-methoxy-1%2528R%2529-4-%2528trifluoromethyl%2529phenyl%255Dethyl-3%2528S%2529-methyl-1-piperazinyl%255D-4-methylpiperidine%2520%2528Sch-417690%252FSch-D%2529%252C%2520a%2520potent%252C%2520highly%2520selective%252C%2520and%2520orally%2520bioavailable%2520CCR5%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2405%26epage%3D2408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span>Aidsmap. Second Company Halts CCR5 Inhibitor Study in Another Blow to New Drug Class. <a href="http://www.aidsmap.com/Second-company-halts-CCR5-inhibitor-study-in-another-blow-to-new-drug-class/page/1422234/" class="extLink">http://www.aidsmap.com/Second-company-halts-CCR5-inhibitor-study-in-another-blow-to-new-drug-class/page/1422234/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Aidsmap.+Second+Company+Halts+CCR5+Inhibitor+Study+in+Another+Blow+to+New+Drug+Class.+http%3A%2F%2Fwww.aidsmap.com%2FSecond-company-halts-CCR5-inhibitor-study-in-another-blow-to-new-drug-class%2Fpage%2F1422234%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Gulick, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flexner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skolnik, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krambrink, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greaves, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zolopa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuritzkes, D. R.</span><span> </span><span class="NLM_article-title">Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">196</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">â</span> <span class="NLM_lpage">312</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1086%2F518797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17570119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVygs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2007&pages=304-312&author=R.+M.+Gulickauthor=Z.+Suauthor=C.+Flexnerauthor=M.+D.+Hughesauthor=P.+R.+Skolnikauthor=T.+J.+Wilkinauthor=R.+Grossauthor=A.+Krambrinkauthor=E.+Coakleyauthor=W.+L.+Greavesauthor=A.+Zolopaauthor=R.+Reichmanauthor=C.+Godfreyauthor=M.+Hirschauthor=D.+R.+Kuritzkes&title=Phase+2+study+of+the+safety+and+efficacy+of+vicriviroc%2C+a+CCR5+inhibitor%2C+in+HIV-1-infected%2C+treatment-experienced+patients%3A+AIDS+clinical+trials+group+5211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211</span></div><div class="casAuthors">Gulick, Roy M.; Su, Zhaohui; Flexner, Charles; Hughes, Michael D.; Skolnik, Paul R.; Wilkin, Timothy J.; Gross, Robert; Krambrink, Amy; Coakley, Eoin; Greaves, Wayne L.; Zolopa, Andrew; Reichman, Richard; Godfrey, Catherine; Hirsch, Martin; Kuritzkes, Daniel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-312</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study.  Methods: The present study was a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficiency virus (HIV)-infected subjects experiencing virol. failure while receiving a ritonavir-contg. regimen with an HIV-1 RNA level â¥5000 copies/mL and CCR5-using virus.  Vicriviroc at 5, 10, or 15 mg or placebo was added to the failing regimen for 14 days, after which the antiretroviral regimen was optimized.  The primary end point was the change in plasma HIV-1 RNA levels at day 14; secondary end points included safety/tolerability and HIV-1 RNA changes at week 24.  Results: One hundred eighteen subjects were randomized with a median HIV-1 RNA level of 36,380 (4.56 log10) copies/mL and a median CD4 cell count of 146 cells/mm3.  At 14 days and 24 wk, mean changes in HIV-1 RNA level (log10 copies/mL) were greater in the vicriviroc groups (-0.87 and -1.51 [5 mg], -1.15 and -1.86 [10 mg], and -0.92 and -1.68 [15 mg]) than in the placebo group (+0.06 and -0.29) (P<.01).  Grade 3/4 adverse events were similar across groups.  Malignancies occurred in 6 subjects randomized to vicriviroc and in 2 to placebo.  Conclusions: In HIV-1-infected, treatment-experienced patients, vicriviroc demonstrated potent virol. suppression through 24 wk.  The relationship of vicriviroc to malignancy is uncertain.  Further development of vicriviroc in treatment-experienced patients is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpo9-4RFsxrVg90H21EOLACvtfcHk0lj418H-NdNeaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVygs7w%253D&md5=9a36e6a182f0a590c5c2d38572062ffa</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1086%2F518797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F518797%26sid%3Dliteratum%253Aachs%26aulast%3DGulick%26aufirst%3DR.%2BM.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DFlexner%26aufirst%3DC.%26aulast%3DHughes%26aufirst%3DM.%2BD.%26aulast%3DSkolnik%26aufirst%3DP.%2BR.%26aulast%3DWilkin%26aufirst%3DT.%2BJ.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DKrambrink%26aufirst%3DA.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DGreaves%26aufirst%3DW.%2BL.%26aulast%3DZolopa%26aufirst%3DA.%26aulast%3DReichman%26aufirst%3DR.%26aulast%3DGodfrey%26aufirst%3DC.%26aulast%3DHirsch%26aufirst%3DM.%26aulast%3DKuritzkes%26aufirst%3DD.%2BR.%26atitle%3DPhase%25202%2520study%2520of%2520the%2520safety%2520and%2520efficacy%2520of%2520vicriviroc%252C%2520a%2520CCR5%2520inhibitor%252C%2520in%2520HIV-1-infected%252C%2520treatment-experienced%2520patients%253A%2520AIDS%2520clinical%2520trials%2520group%25205211%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2007%26volume%3D196%26spage%3D304%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span>AIDSMEDS. Merck Terminates Development of Its HIV Entry Inhibitor, Vicriviroc. <a href="http://www.aidsmeds.com/articles/hiv_vicriviroc_merck_1667_18742.shtml" class="extLink">http://www.aidsmeds.com/articles/hiv_vicriviroc_merck_1667_18742.shtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AIDSMEDS.+Merck+Terminates+Development+of+Its+HIV+Entry+Inhibitor%2C+Vicriviroc.+http%3A%2F%2Fwww.aidsmeds.com%2Farticles%2Fhiv_vicriviroc_merck_1667_18742.shtml."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaoka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moravek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyanagi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">8654</span><span class="NLM_x">â</span> <span class="NLM_lpage">8662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1128%2FJVI.78.16.8654-8662.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15280474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslSmtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=8654-8662&author=K.+Maedaauthor=H.+Nakataauthor=Y.+Kohauthor=T.+Miyakawaauthor=H.+Ogataauthor=Y.+Takaokaauthor=S.+Shibayamaauthor=K.+Sagawaauthor=D.+Fukushimaauthor=J.+Moravekauthor=Y.+Koyanagiauthor=H.+Mitsuya&title=Spirodiketopiperazine-based+CCR5+inhibitor+which+preserves+CC-chemokine%2FCCR5+interactions+and+exerts+potent+activity+against+R5+human+immunodeficiency+virus+type+1+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro</span></div><div class="casAuthors">Maeda, Kenji; Nakata, Hirotomo; Koh, Yasuhiro; Miyakawa, Toshikazu; Ogata, Hiromi; Takaoka, Yoshikazu; Shibayama, Shiro; Sagawa, Kenji; Fukushima, Daikichi; Moravek, Joseph; Koyanangi, Yoshio; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8654-8662</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We identified a novel spirodiketopiperazine (SDP) deriv., AK602/ONO4128/GW873140, which specifically blocked the binding of macrophage inflammatory protein 1Î± (MIP-1Î±) to CCR5 with a high affinity (Kd of â3 nM), potently blocked human immunodeficiency virus type 1 (HIV-1) gp120/CCR5 binding and exerted potent activity against a wide spectrum of lab. and primary R5 HIV-1 isolates, including multidrug-resistant HIV-1 (HIV-1MDR) (50% inhibitory concn. values of 0.1 to 0.6 nM) in vitro.  AK602 competitively blocked the binding to CCR5 expressed on Chinese hamster ovary cells of two monoclonal antibodies, 45523, directed against multidomain epitopes of CCR5, and 45531, specific against the C-terminal half of the second extracellular loop (ECL2B) of CCR5.  AK602, despite its much greater anti-HIV-1 activity than other previously published CCR5 inhibitors, including TAK-779 and SCH-C, preserved RANTES (regulated on activation normal T-cell expressed and secreted) and MIP-1Î² binding to CCR5+ cells and their functions, including CC-chemokine-induced chemotaxis and CCR5 internalization, while TAK-779 and SCH-C fully blocked the CC-chemokine/CCR5 interactions.  Pharmacokinetic studies revealed favorable oral bioavailability in rodents.  These data warrant further development of AK602 as a potential therapeutic for HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6GrcsfDbiybVg90H21EOLACvtfcHk0ljxPfUBhIIITQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslSmtbg%253D&md5=c89226433dd565f24f37b51b3504d780</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.16.8654-8662.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.16.8654-8662.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DMiyakawa%26aufirst%3DT.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DTakaoka%26aufirst%3DY.%26aulast%3DShibayama%26aufirst%3DS.%26aulast%3DSagawa%26aufirst%3DK.%26aulast%3DFukushima%26aufirst%3DD.%26aulast%3DMoravek%26aufirst%3DJ.%26aulast%3DKoyanagi%26aufirst%3DY.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DSpirodiketopiperazine-based%2520CCR5%2520inhibitor%2520which%2520preserves%2520CC-chemokine%252FCCR5%2520interactions%2520and%2520exerts%2520potent%2520activity%2520against%2520R5%2520human%2520immunodeficiency%2520virus%2520type%25201%2520in%2520vitro%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D8654%26epage%3D8662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shachoy-Clark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâMara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piscitelli, S. C.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2802</span><span class="NLM_x">â</span> <span class="NLM_lpage">2806</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=2802-2806&author=K.+K.+Adkisonauthor=A.+Shachoy-Clarkauthor=L.+Fangauthor=Y.+Louauthor=K.+O%E2%80%99Maraauthor=M.+M.+Berreyauthor=S.+C.+Piscitelli&title=Pharmacokinetics+and+short-term+safety+of+873140%2C+a+novel+CCR5+antagonist%2C+in+healthy+adult+subjects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DShachoy-Clark%26aufirst%3DA.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Mara%26aufirst%3DK.%26aulast%3DBerrey%26aufirst%3DM.%2BM.%26aulast%3DPiscitelli%26aufirst%3DS.%2BC.%26atitle%3DPharmacokinetics%2520and%2520short-term%2520safety%2520of%2520873140%252C%2520a%2520novel%2520CCR5%2520antagonist%252C%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2802%26epage%3D2806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Nichols, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonny, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabeya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clumeck, N.</span><span> </span><span class="NLM_article-title">Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">â</span> <span class="NLM_lpage">865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1128%2FAAC.00821-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18070967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFalsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=858-865&author=W.+G.+Nicholsauthor=H.+M.+Steelauthor=T.+Bonnyauthor=K.+Adkisonauthor=L.+Curtisauthor=J.+Millardauthor=K.+Kabeyaauthor=N.+Clumeck&title=Hepatotoxicity+observed+in+clinical+trials+of+aplaviroc+%28GW873140%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)</span></div><div class="casAuthors">Nichols, W. G.; Steel, H. M.; Bonny, T.; Adkison, K.; Curtis, L.; Millard, J.; Kabeya, K.; Clumeck, N.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">858-865</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Aplaviroc (APL) was a new CCR5 antagonist that was investigated in two dose-ranging studies with antiretroviral therapy-naive, human immunodeficiency virus-infected adults: ASCENT, in which 147 subjects were randomized 2:2:1 to receive zidovudine-lamivudine (ZDV-3TC) plus APL 600 mg twice a day (BID), APL 800 mg BID, or efavirenz (EFV), resp., and EPIC, in which 195 subjects were randomized 2:2:2:1 to receive lopinavir-ritonavir (LPV-RTV) plus APL 200 mg BID, APL 400 mg BID, APL 800 mg once a day, or ZDV-3TC BID, resp.  Both studies (and, ultimately, the clin. development of APL) were discontinued after a mean of 14 wk of therapy because of higher than anticipated severe liver toxicity; grade 2 or higher treatment-emergent elevations in alanine aminotransferase (ALT) levels were obsd. in 17/281 (6.0%) APL recipients but only 2/55 (3.6%) control recipients, while grade 2 or higher elevations in total bilirubin levels occurred in 29/281 (10.3%) APL recipients but only 4/55 (7.3%) controls.  Two APL recipients developed grade 3 or higher treatment-emergent elevations in both ALT and total bilirubin levels, and one of these individuals had a severe case of hepatic cytolysis that was attributed to APL.  Despite the high intersubject variability in APL plasma exposures, a Pearson correlation anal. of the combined study data did not reveal any significant assocns. between plasma concns. and the liver enzyme elevations obsd. during the study.  The mechanism for the idiosyncratic hepatotoxicity obsd. in the clin. trials of APL is unknown but is likely intrinsic to the mol. rather than its novel mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_qgm3ocb7DLVg90H21EOLACvtfcHk0ljxPfUBhIIITQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFalsL8%253D&md5=e8ed6796bd0c8673fcd8e3e10a61de90</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1128%2FAAC.00821-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00821-07%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DW.%2BG.%26aulast%3DSteel%26aufirst%3DH.%2BM.%26aulast%3DBonny%26aufirst%3DT.%26aulast%3DAdkison%26aufirst%3DK.%26aulast%3DCurtis%26aufirst%3DL.%26aulast%3DMillard%26aufirst%3DJ.%26aulast%3DKabeya%26aufirst%3DK.%26aulast%3DClumeck%26aufirst%3DN.%26atitle%3DHepatotoxicity%2520observed%2520in%2520clinical%2520trials%2520of%2520aplaviroc%2520%2528GW873140%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D858%26epage%3D865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Moyle, G.</span><span> </span><span class="NLM_article-title">The Last Word on Aplaviroc: A CCR5 Antagonist with Poor Efficacy</span>.  <span class="citation_source-book">The Body</span>; <span class="NLM_publisher-name">Remedy Health Media, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span><a href="http://www.thebody.com/content/confs/hiv8/art39205.html" class="extLink">http://www.thebody.com/content/confs/hiv8/art39205.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=G.+Moyle&title=The+Body"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMoyle%26aufirst%3DG.%26atitle%3DThe%2520Last%2520Word%2520on%2520Aplaviroc%253A%2520A%2520CCR5%2520Antagonist%2520with%2520Poor%2520Efficacy%26btitle%3DThe%2520Body%26pub%3DRemedy%2520Health%2520Media%252C%2520LLC%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okonogi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meguro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">5698</span><span class="NLM_x">â</span> <span class="NLM_lpage">5703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=5698-5703&author=M.+Babaauthor=O.+Nishimuraauthor=N.+Kanzakiauthor=M.+Okamotoauthor=H.+Sawadaauthor=Y.+Iizawaauthor=M.+Shiraishiauthor=Y.+Aramakiauthor=K.+Okonogiauthor=Y.+Ogawaauthor=K.+Meguroauthor=M.+Fujino&title=A+small-molecule%2C+nonpeptide+CCR5+antagonist+with+highly+potent+and+selective+anti-HIV-1+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DO.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DShiraishi%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DOkonogi%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DMeguro%26aufirst%3DK.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DA%2520small-molecule%252C%2520nonpeptide%2520CCR5%2520antagonist%2520with%2520highly%2520potent%2520and%2520selective%2520anti-HIV-1%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D5698%26epage%3D5703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Shiraishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">â</span> <span class="NLM_lpage">2063</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9906264" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGhsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2049-2063&author=M.+Shiraishiauthor=Y.+Aramakiauthor=M.+Setoauthor=H.+Imotoauthor=Y.+Nishikawaauthor=N.+Kanzakiauthor=M.+Okamotoauthor=H.+Sawadaauthor=O.+Nishimuraauthor=M.+Babaauthor=M.+Fujino&title=Discovery+of+novel%2C+potent%2C+and+selective+small-molecule+CCR5+antagonists+as+anti-HIV-1+agents%3A+synthesis+and+biological+evaluation+of+anilide+derivatives+with+a+quaternary+ammonium+moiety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety</span></div><div class="casAuthors">Shiraishi, Mitsuru; Aramaki, Yoshio; Seto, Masaki; Imoto, Hiroshi; Nishikawa, Youichi; Kanzaki, Naoyuki; Okamoto, Mika; Sawada, Hidekazu; Nishimura, Osamu; Baba, Masanori; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2049-2063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The search for new small-mol. CCR5 antagonists by high-throughput screening (HTS) of the Takeda chem. library using [125I]RANTES and CHO/CCR5 cells led to the discovery of lead compds. with a quaternary ammonium or phosphonium moiety, which were synthesized to investigate new MCP-1 receptor antagonists.  A series of novel anilide derivs. with a quaternary ammonium moiety were designed, synthesized, and tested for their CCR5 antagonistic activity.  Through the optimization of lead compds., we have found N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium chloride as a highly potent and selective nonpeptide CCR5 antagonist with a IC50 value of 1.4 nM in the binding assay.  The synthesis and structure-activity relationships of the title compds. and their related compds. are detailed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuJ_2cLr9HB7Vg90H21EOLACvtfcHk0lgytNNhmzV3sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGhsrc%253D&md5=fa4bc03a80d858423cfe7c4f73a53523</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm9906264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9906264%26sid%3Dliteratum%253Aachs%26aulast%3DShiraishi%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DImoto%26aufirst%3DH.%26aulast%3DNishikawa%26aufirst%3DY.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DOkamoto%26aufirst%3DM.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DNishimura%26aufirst%3DO.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%252C%2520potent%252C%2520and%2520selective%2520small-molecule%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520anilide%2520derivatives%2520with%2520a%2520quaternary%2520ammonium%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2049%26epage%3D2063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span> </span><span class="NLM_article-title">TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4584</span><span class="NLM_x">â</span> <span class="NLM_lpage">4591</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=4584-4591&author=M.+Babaauthor=K.+Takashimaauthor=H.+Miyakeauthor=N.+Kanzakiauthor=K.+Teshimaauthor=X.+Wangauthor=M.+Shiraishiauthor=Y.+Iizawa&title=TAK-652+inhibits+CCR5-mediated+human+immunodeficiency+virus+type+1+infection+in+vitro+and+has+favorable+pharmacokinetics+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTeshima%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShiraishi%26aufirst%3DM.%26aulast%3DIizawa%26aufirst%3DY.%26atitle%3DTAK-652%2520inhibits%2520CCR5-mediated%2520human%2520immunodeficiency%2520virus%2520type%25201%2520infection%2520in%2520vitro%2520and%2520has%2520favorable%2520pharmacokinetics%2520in%2520humans%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D4584%26epage%3D4591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span> </span><span class="NLM_article-title">Orally active CCR5 antagonists as anti-HIV-1 agents 2: synthesis and biological activities of anilide derivatives containing a pyridine <i>N</i>-oxide moiety</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">â</span> <span class="NLM_lpage">829</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=818-829&author=M.+Setoauthor=Y.+Aramakiauthor=H.+Imotoauthor=K.+Aikawaauthor=T.+Odaauthor=N.+Kanzakiauthor=Y.+Iizawaauthor=M.+Babaauthor=M.+Shiraishi&title=Orally+active+CCR5+antagonists+as+anti-HIV-1+agents+2%3A+synthesis+and+biological+activities+of+anilide+derivatives+containing+a+pyridine+N-oxide+moiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DImoto%26aufirst%3DH.%26aulast%3DAikawa%26aufirst%3DK.%26aulast%3DOda%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShiraishi%26aufirst%3DM.%26atitle%3DOrally%2520active%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%25202%253A%2520synthesis%2520and%2520biological%2520activities%2520of%2520anilide%2520derivatives%2520containing%2520a%2520pyridine%2520N-oxide%2520moiety%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2004%26volume%3D52%26spage%3D818%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span> </span><span class="NLM_article-title">Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">â</span> <span class="NLM_lpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=577-590&author=M.+Setoauthor=Y.+Aramakiauthor=T.+Okawaauthor=N.+Miyamotoauthor=K.+Aikawaauthor=N.+Kanzakiauthor=S.+Niwaauthor=Y.+Iizawaauthor=M.+Babaauthor=M.+Shiraishi&title=Orally+active+CCR5+antagonists+as+anti-HIV-1+agents%3A+synthesis+and+biological+activity+of+1-benzothiepine+1%2C1-dioxide+and+1-benzazepine+derivatives+containing+a+tertiary+amine+moiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DOkawa%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DAikawa%26aufirst%3DK.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DNiwa%26aufirst%3DS.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShiraishi%26aufirst%3DM.%26atitle%3DOrally%2520active%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%253A%2520synthesis%2520and%2520biological%2520activity%2520of%25201-benzothiepine%25201%252C1-dioxide%2520and%25201-benzazepine%2520derivatives%2520containing%2520a%2520tertiary%2520amine%2520moiety%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2004%26volume%3D52%26spage%3D577%26epage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span>Takeda To License CCR5 Antagonists for Treatment of HIV Infection to Tobira Therapeutics, Inc. <a href="http://www.takeda.com/press/article_27377.html" class="extLink">http://www.takeda.com/press/article_27377.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Takeda+To+License+CCR5+Antagonists+for+Treatment+of+HIV+Infection+to+Tobira+Therapeutics%2C+Inc.+http%3A%2F%2Fwww.takeda.com%2Fpress%2Farticle_27377.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dejesus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galindez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palleja, S. M.</span><span> </span><span class="NLM_article-title">Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects</span> <span class="citation_source-journal">J. Acquired Immune Defic. Syndr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1097%2FQAI.0b013e318213c2c0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21317794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFyhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2011&pages=118-125&author=J.+Lalezariauthor=J.+Gatheauthor=C.+Brinsonauthor=M.+Thompsonauthor=C.+Cohenauthor=E.+Dejesusauthor=J.+Galindezauthor=J.+A.+Ernstauthor=D.+E.+Martinauthor=S.+M.+Palleja&title=Safety%2C+efficacy%2C+and+pharmacokinetics+of+TBR-652%2C+a+CCR5%2FCCR2+antagonist%2C+in+HIV-1-infected%2C+treatment-experienced%2C+CCR5+antagonist-naive+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1-Infected, Treatment-Experienced, CCR5 Antagonist-Naive Subjects</span></div><div class="casAuthors">Lalezari, Jacob; Gathe, Joseph; Brinson, Cynthia; Thompson, Melanie; Cohen, Calvin; Dejesus, Edwin; Galindez, Jorge; Ernst, Jerome A.; Martin, David E.; Palleja, Sandra M.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-125</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: To det. the antiviral activity, pharmacokinetics, pharmacodynamics, safety, and tolerability of several dose levels of oral TBR-652 monotherapy in HIV-1-infected, antiretroviral experienced, CCR5 antagonist-naive subjects.  Design: Double-blind placebo-controlled study in the United States and Argentina.  Methods: Subjects were randomized in a ratio of 4:1 per dose level to TBR-652 (25, 50, 75, 100, or 150 mg) or placebo, taken once daily for 10 days.  Changes from baseline in HIV-1 RNA and CD4 cell counts were measured through day 40 and for monocyte chemotactic protein-1 (MCP-1), high-sensitivity C-reactive protein (hs-CRP), and IL-6 at day 10.  Pharmacokinetic data were analyzed using noncompartmental statistics.  Lab. and clin. adverse events (AEs) and ECG changes were recorded.  Results: Maximum median redns. in HIV-1 RNA values for the 25, 50, 75, and 150 mg doses were -0.7, -1.6, -1.8, and -1.7 log10 copies per mL, resp.  All changes were significant.  Median time to nadir was 10-11 days.  Suppression persisted well into the posttreatment period.  Mean MCP-1 increased significantly by day 10 in the 50-mg and 150-mg dose groups.  Effects on CD4 cell counts, hs-CRP, and IL-6 levels were negligible.  TBR-652 was generally safe and well tolerated, with no withdrawals due to AEs.  Conclusions: TBR-652 caused significant redns. in HIV-1 RNA at all doses.  Significant increases in MCP-1 levels suggested a strong CCR2 blockade.  TBR-652 was generally well tolerated with no dose-limiting AEs.  Pharmacodynamics indicate that TBR-652 warrants further investigation as an unboosted once-daily oral CCR5 antagonist with potentially important CCR2-mediated anti-inflammatory effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhtZ1heEtEJrVg90H21EOLACvtfcHk0lgLkxPbMfQBZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFyhsL4%253D&md5=9314a830e5558eacc49cff18904b13d7</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e318213c2c0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e318213c2c0%26sid%3Dliteratum%253Aachs%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DGathe%26aufirst%3DJ.%26aulast%3DBrinson%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DC.%26aulast%3DDejesus%26aufirst%3DE.%26aulast%3DGalindez%26aufirst%3DJ.%26aulast%3DErnst%26aufirst%3DJ.%2BA.%26aulast%3DMartin%26aufirst%3DD.%2BE.%26aulast%3DPalleja%26aufirst%3DS.%2BM.%26atitle%3DSafety%252C%2520efficacy%252C%2520and%2520pharmacokinetics%2520of%2520TBR-652%252C%2520a%2520CCR5%252FCCR2%2520antagonist%252C%2520in%2520HIV-1-infected%252C%2520treatment-experienced%252C%2520CCR5%2520antagonist-naive%2520subjects%26jtitle%3DJ.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2011%26volume%3D57%26spage%3D118%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Xue, C.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span> </span><span class="NLM_article-title">Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">â</span> <span class="NLM_lpage">487</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml1001536" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=483-487&author=C.-B.+Xueauthor=L.+Chenauthor=G.+Caoauthor=K.+Zhangauthor=A.+Wangauthor=D.+Meloniauthor=J.+Glennauthor=R.+Anandauthor=M.+Xiaauthor=L.+Kongauthor=T.+Huangauthor=H.+Fengauthor=C.+Zhengauthor=M.+Liauthor=L.+Galyaauthor=J.+Zhouauthor=N.+Shinauthor=F.+Baribaudauthor=K.+Solomonauthor=P.+Scherleauthor=B.+Zhaoauthor=S.+Diamondauthor=T.+Emmauthor=D.+Kellerauthor=N.+Contelauthor=S.+Yeleswaramauthor=K.+Vaddiauthor=G.+Hollisauthor=R.+Newtonauthor=S.+Friedmanauthor=B.+Metcalf&title=Discovery+of+INCB9471%2C+a+potent%2C+selective%2C+and+orally+bioavailable+CCR5+antagonist+with+potent+anti-HIV-1+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Fml1001536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001536%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DC.-B.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DAnand%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DN.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DKeller%26aufirst%3DD.%26aulast%3DContel%26aufirst%3DN.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DMetcalf%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520INCB9471%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520CCR5%2520antagonist%2520with%2520potent%2520anti-HIV-1%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D483%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Shin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlapati, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baribaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerniak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span> </span><span class="NLM_article-title">Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">â</span> <span class="NLM_lpage">239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.111.179531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21459966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFChsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=228-239&author=N.+Shinauthor=K.+Solomonauthor=N.+Zhouauthor=K.+H.+Wangauthor=V.+Garlapatiauthor=B.+Thomasauthor=Y.+Liauthor=M.+Covingtonauthor=F.+Baribaudauthor=S.+Erickson-Viitanenauthor=P.+Czerniakauthor=N.+Contelauthor=P.+Liuauthor=T.+Burnauthor=G.+Hollisauthor=S.+Yeleswaramauthor=K.+Vaddiauthor=C.+B.+Xueauthor=B.+Metcalfauthor=S.+Friedmanauthor=P.+Scherleauthor=R.+Newton&title=Identification+and+characterization+of+INCB9471%2C+an+allosteric+noncompetitive+small-molecule+antagonist+of+C-C+chemokine+receptor+5+with+potent+inhibitory+activity+against+monocyte+migration+and+HIV-1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection</span></div><div class="casAuthors">Shin, Niu; Solomon, Kim; Zhou, Naiming; Wang, Kathy He; Garlapati, Vasudha; Thomas, Beth; Li, Yanlong; Covington, Maryanne; Baribaud, Frederic; Erickson-Viitanen, Susan; Czerniak, Phil; Contel, Nancy; Liu, Phillip; Burn, Timothy; Hollis, Gregory; Yeleswaram, Swamy; Vaddi, Kris; Xue, Chu-Biao; Metcalf, Brian; Friedman, Steve; Scherle, Peggy; Newton, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-239</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">C-C chemokine receptor 5 (CCR5) is a clin. proven target for inhibition of HIV-1 infection and a potential target for various inflammatory diseases.  In this article, we describe 5-[(4-{(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-4,6-dimethylpyrimidine dihydrochloride (INCB9471), a potent and specific inhibitor of human CCR5 that has been proven to be safe and efficacious in viral load redn. in phase I and II human clin. trails.  INCB9471 was identified using a primary human monocyte-based radioligand competition binding assay.  It potently inhibited macrophage inflammatory protein-1Î²-induced monocyte migration and infection of peripheral blood mononuclear cells by a panel of R5-HIV-1 strains.  The results from binding and signaling studies using incremental amts. of INCB9471 demonstrated INCB9471 as a noncompetitive CCR5 inhibitor.  The CCR5 residues that are essential for interaction with INCB9471 were identified by site-specific mutagenesis studies.  INCB9471 rapidly assocs. with but slowly dissocs. from CCR5.  When INCB9471 was compared with three CCR5 antagonists that had been tested in clin. trials, the potency of INCB9471 in blocking CCR5 ligand binding was similar to those of 4,6-dimethyl-5-{[4-methyl-4-((3S)-3-methyl-4-{(1R0-2-(methyloxy)-1-[4-(trifluoromethyl) phenyl]ethyl}-1-piperazingyl)-1-piperidinyl]carbonyl}pyrimidine (SCH-D; vicriviroc), 4-{[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxyl)methyl]-2, 5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenyl]oxy}benzoic acid hydrochloride (873140; aplaviroc), and 4,4-difluoro-N-((1S)-3-{(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenylpropyl)cyclohexanecarboxamide (UK427857; maraviroc).  Its inhibitory activity against CCR5-mediated Ca2+ mobilization was also similar to those of SCH-D and 873140.  Further anal. suggested that INCB9471 and UK427857 may have different binding sites on CCR5.  The significance of two CCR5 antagonists with different binding sites is discussed in the context of potentially overcoming drug-resistant HIV-1 strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZXJIXoWpxVbVg90H21EOLACvtfcHk0lgLkxPbMfQBZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFChsr8%253D&md5=cd5e8e0e33c10197981439fa3ff8db0d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.179531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.179531%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DN.%26aulast%3DSolomon%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DK.%2BH.%26aulast%3DGarlapati%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DBaribaud%26aufirst%3DF.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DCzerniak%26aufirst%3DP.%26aulast%3DContel%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DXue%26aufirst%3DC.%2BB.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DNewton%26aufirst%3DR.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520INCB9471%252C%2520an%2520allosteric%2520noncompetitive%2520small-molecule%2520antagonist%2520of%2520C-C%2520chemokine%2520receptor%25205%2520with%2520potent%2520inhibitory%2520activity%2520against%2520monocyte%2520migration%2520and%2520HIV-1%2520infection%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D228%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Cohen, C.; DeJesus, E.; Mills, A.; Pierone, G.; Kumar, P.; Ruane, P.; Elion, R.; Fusco, G.; Levy, R.; Solomon, K.</span><span> </span><span class="NLM_article-title">Potent Antiretroviral Activity of the Once Daily Antagonist INCB009471 over 14 Days of Monotherapy</span>. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, Australia,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Cohen&author=E.+DeJesus&author=A.+Mills&author=G.+Pierone&author=P.+Kumar&author=P.+Ruane&author=R.+Elion&author=G.+Fusco&author=R.+Levy&author=K.+Solomon&title=Potent+Antiretroviral+Activity+of+the+Once+Daily+Antagonist+INCB009471+over+14+Days+of+Monotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DC.%26atitle%3DPotent%2520Antiretroviral%2520Activity%2520of%2520the%2520Once%2520Daily%2520Antagonist%2520INCB009471%2520over%252014%2520Days%2520of%2520Monotherapy%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Dalton, P.</span><span> </span><span class="NLM_article-title">Incyte Halts Development of Promising New CCR5 Drug</span>.  <span class="citation_source-book">The Body</span>; <span class="NLM_publisher-name">Remedy Health Media, LLC</span>: <span class="NLM_publisher-loc">New York</span>; <a href="http://www.thebody.com/content/art46326.html" class="extLink">http://www.thebody.com/content/art46326.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dalton%2C+P.+Incyte+Halts+Development+of+Promising+New+CCR5+Drug.+The+Body%3B+Remedy+Health+Media%2C+LLC%3A+New+York%3B+http%3A%2F%2Fwww.thebody.com%2Fcontent%2Fart46326.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDalton%26aufirst%3DP.%26atitle%3DIncyte%2520Halts%2520Development%2520of%2520Promising%2520New%2520CCR5%2520Drug%26btitle%3DThe%2520Body%26pub%3DRemedy%2520Health%2520Media%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Burrows, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillery, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamlin, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span> </span><span class="NLM_article-title">Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=25-28&author=J.+N.+Burrowsauthor=J.+G.+Cummingauthor=S.+M.+Filleryauthor=G.+A.+Hamlinauthor=J.+A.+Hudsonauthor=R.+J.+Jacksonauthor=S.+McLaughlinauthor=J.+S.+Shaw&title=Modulators+of+the+human+CCR5+receptor.+Part+1%3A+Discovery+and+initial+SAR+of+1-%283%2C3-diphenylpropyl%29-piperidinyl+amides+and+ureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DFillery%26aufirst%3DS.%2BM.%26aulast%3DHamlin%26aufirst%3DG.%2BA.%26aulast%3DHudson%26aufirst%3DJ.%2BA.%26aulast%3DJackson%26aufirst%3DR.%2BJ.%26aulast%3DMcLaughlin%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26atitle%3DModulators%2520of%2520the%2520human%2520CCR5%2520receptor.%2520Part%25201%253A%2520Discovery%2520and%2520initial%2520SAR%2520of%25201-%25283%252C3-diphenylpropyl%2529-piperidinyl%2520amides%2520and%2520ureas%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D25%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grime, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span> </span><span class="NLM_article-title">Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5012</span><span class="NLM_x">â</span> <span class="NLM_lpage">5015</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=5012-5015&author=J.+G.+Cummingauthor=A.+E.+Cooperauthor=K.+Grimeauthor=C.+J.+Loganauthor=S.+McLaughlinauthor=J.+Oldfieldauthor=J.+S.+Shawauthor=H.+Tuckerauthor=J.+Winterauthor=D.+Whittaker&title=Modulators+of+the+human+CCR5+receptor.+Part+2%3A+SAR+of+substituted+1-%283%2C3-diphenylpropyl%29-piperidinyl+phenylacetamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DLogan%26aufirst%3DC.%2BJ.%26aulast%3DMcLaughlin%26aufirst%3DS.%26aulast%3DOldfield%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26aulast%3DTucker%26aufirst%3DH.%26aulast%3DWinter%26aufirst%3DJ.%26aulast%3DWhittaker%26aufirst%3DD.%26atitle%3DModulators%2520of%2520the%2520human%2520CCR5%2520receptor.%2520Part%25202%253A%2520SAR%2520of%2520substituted%25201-%25283%252C3-diphenylpropyl%2529-piperidinyl%2520phenylacetamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D5012%26epage%3D5015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faull, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grime, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span> </span><span class="NLM_article-title">Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3533</span><span class="NLM_x">â</span> <span class="NLM_lpage">3536</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3533-3536&author=J.+G.+Cummingauthor=S.+J.+Brownauthor=A.+E.+Cooperauthor=A.+W.+Faullauthor=A.+P.+Flynnauthor=K.+Grimeauthor=J.+Oldfieldauthor=J.+S.+Shawauthor=E.+Shepherdauthor=H.+Tuckerauthor=D.+Whittaker&title=Modulators+of+the+human+CCR5+receptor.+Part+3%3A+SAR+of+substituted+1-%5B3-%284-methanesulfonylphenyl%29-3-phenylpropyl%5D-piperidinyl+phenylacetamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFaull%26aufirst%3DA.%2BW.%26aulast%3DFlynn%26aufirst%3DA.%2BP.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DOldfield%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DJ.%2BS.%26aulast%3DShepherd%26aufirst%3DE.%26aulast%3DTucker%26aufirst%3DH.%26aulast%3DWhittaker%26aufirst%3DD.%26atitle%3DModulators%2520of%2520the%2520human%2520CCR5%2520receptor.%2520Part%25203%253A%2520SAR%2520of%2520substituted%25201-%255B3-%25284-methanesulfonylphenyl%2529-3-phenylpropyl%255D-piperidinyl%2520phenylacetamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3533%26epage%3D3536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Highton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faull, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J.</span><span> </span><span class="NLM_article-title">Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">â</span> <span class="NLM_lpage">1659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1655-1659&author=J.+G.+Cummingauthor=H.+Tuckerauthor=J.+Oldfieldauthor=C.+Fieldingauthor=A.+Hightonauthor=A.+Faullauthor=M.+Wildauthor=D.+Brownauthor=S.+Wellsauthor=J.+Shaw&title=Balancing+hERG+affinity+and+absorption+in+the+discovery+of+AZD5672%2C+an+orally+active+CCR5+antagonist+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DTucker%26aufirst%3DH.%26aulast%3DOldfield%26aufirst%3DJ.%26aulast%3DFielding%26aufirst%3DC.%26aulast%3DHighton%26aufirst%3DA.%26aulast%3DFaull%26aufirst%3DA.%26aulast%3DWild%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DJ.%26atitle%3DBalancing%2520hERG%2520affinity%2520and%2520absorption%2520in%2520the%2520discovery%2520of%2520AZD5672%252C%2520an%2520orally%2520active%2520CCR5%2520antagonist%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1655%26epage%3D1659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vencovsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekanecz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braddock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">3154</span><span class="NLM_x">â</span> <span class="NLM_lpage">3160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.27652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20662070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=3154-3160&author=D.+M.+Gerlagauthor=S.+Hollisauthor=M.+Laytonauthor=J.+Vencovskyauthor=Z.+Szekaneczauthor=M.+Braddockauthor=P.+P.+Tak&title=Preclinical+and+clinical+investigation+of+a+CCR5+antagonist%2C+AZD5672%2C+in+patients+with+rheumatoid+arthritis+receiving+methotrexate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate</span></div><div class="casAuthors">Gerlag, Danielle M.; Hollis, Sally; Layton, Mark; Vencovsky, Jiri; Szekanecz, Zoltan; Braddock, Martin; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3154-3160</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. To investigate both the preclin. effects of blocking the chemokine receptor CCR5 and the clin. effects of this approach on the signs and symptoms of rheumatoid arthritis (RA) in patients with active disease.  Methods. Preclin. evaluations of AZD5672, a small-mol. antagonist of CCR5, were performed, including studies of ligand binding and chemotaxis.  The pharmacokinetics of AZD5672 were assessed in both single- and multiple-dose studies in healthy volunteers.  A randomized, placebo-controlled, phase IIb study was conducted in patients with active RA receiving methotrexate.  Treatment arms were AZD5672 (20, 50, 100, or 150 mg orally, once daily), matched placebo, or open-label etanercept (50 mg s.c., once weekly).  The primary end point was the proportion of patients achieving a 20% improvement response on the American College of Rheumatol. improvement criteria (ACR20) at week 12.  Secondary end points included the ACR20 over time, as well as 50% (ACR50) and 70% (ACR70) improvement responses, changes in individual components of the ACR improvement criteria, and disease activity measured with the Disease Activity Score based on the 28-joint count.  Results. AZD5672 was a highly potent and selective antagonist of CCR5, displaying nonproportional steady-state pharmacokinetics while inhibiting internalization of CCR5 in an ex vivo macrophage inflammatory protein 1Î² stimulation assay in which AZD5672 was evaluated over the 20-150-mg dose range.  In the phase IIb study testing this dose range in patients with RA (n = 371 patients randomized to received treatment), AZD5672 was generally well tolerated, with no unexpected adverse events.  There was no statistically significant difference in the proportion of patients achieving an ACR20 response at week 12 between those receiving any dose of AZD5672 and those receiving placebo; etanercept was significantly more efficacious than AZD5672 and placebo.  Conclusion. Despite a clear rationale for targeting CCR5, this clin. study showed that AZD5672, administered orally, did not have any clin. benefit, suggesting that CCR5 antagonism alone is unlikely to be a viable therapeutic strategy in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNMtJlWPEReLVg90H21EOLACvtfcHk0liPuvccPW9EpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrP&md5=78b9ccb1c6e3fd325a5abe24c703751b</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1002%2Fart.27652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27652%26sid%3Dliteratum%253Aachs%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DLayton%26aufirst%3DM.%26aulast%3DVencovsky%26aufirst%3DJ.%26aulast%3DSzekanecz%26aufirst%3DZ.%26aulast%3DBraddock%26aufirst%3DM.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DPreclinical%2520and%2520clinical%2520investigation%2520of%2520a%2520CCR5%2520antagonist%252C%2520AZD5672%252C%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520receiving%2520methotrexate%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D3154%26epage%3D3160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Jacobson, J.; Thompson, M.; Fischl, M.</span><span> </span><span class="NLM_article-title">Phase 2a Study of PRO 140 in HIV-Infected Adults</span>. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009), San Francisco, CA 2009; Abstract H-1229.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Jacobson%2C+J.%3B+Thompson%2C+M.%3B+Fischl%2C+M.+Phase+2a+Study+of+PRO+140+in+HIV-Infected+Adults.+Presented+at+the+49th+Interscience+Conference+on+Antimicrobial+Agents+and+Chemotherapy+%28ICAAC+2009%29%2C+San+Francisco%2C+CA+2009%3B+Abstract+H-1229."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DJ.%26atitle%3DPhase%25202a%2520Study%2520of%2520PRO%2520140%2520in%2520HIV-Infected%2520Adults" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadavalli, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Para, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dejesus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novello, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">â</span> <span class="NLM_lpage">727</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1086%2F527327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18266604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFSmsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2008&pages=721-727&author=J.+Lalezariauthor=G.+K.+Yadavalliauthor=M.+Paraauthor=G.+Richmondauthor=E.+Dejesusauthor=S.+J.+Brownauthor=W.+Caiauthor=C.+Chenauthor=J.+Zhongauthor=L.+A.+Novelloauthor=M.+M.+Ledermanauthor=G.+M.+Subramanian&title=Safety%2C+pharmacokinetics%2C+and+antiviral+activity+of+HGS004%2C+a+novel+fully+human+IgG4+monoclonal+antibody+against+CCR5%2C+in+HIV-1-infected+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV1-1-infected patients</span></div><div class="casAuthors">Lalezari, Jacob; Yadavalli, Gopal K.; Para, Michael; Richmond, Gary; DeJesus, Edwin; Brown, Stephen J.; Cai, Wendy; Chen, Cecil; Zhong, John; Novello, Lu Anne; Lederman, Michael M.; Subramanian, G. Mani</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-727</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">HGS004 is a fully human Ig (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5) with robust in vitro activity against a diverse panel of CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates.  A single-blind, randomized, placebo-controlled study was conducted in patients infected with CCR5-tropic HIV-1 to evaluate the safety, pharmacokinetics, and antiviral activity of HGS004.  Sixty-three subjects were randomized into 5 dose cohorts (0.4, 2, 8, 20, and 40 mg/kg) and received a single i.v. dose of HGS004 or placebo.  HGS004 was well tolerated, and no dose-limiting toxicities were obsd.  Pharmacokinetics were nonlinear across the 0.4-40-mg/kg dose range, with dose-proportional increases in max. concn., although the area under the curve increased more than proportionally to dose.  High levels of receptor occupancy were obsd. for up to 28 days in the higher-dose cohorts.  Plasma HIV-1 RNA redns. of > 1 log10 at day 14 were obsd. in 14 (54%) of 26 subjects in the 8-, 20-, and 40-mg/kg cohorts.  In the 40-mg/kg cohort, 4 of 10 subjects had a >1 log10, HIV-1 RNA redn. at day 28.  Drug concns. relative to isolate sensitivity (the ratio of the concn. at day 14 to IC90) predicted antiviral response on day 14.  HGS004 is safe and well tolerated and demonstrates meaningful antiviral activity when administered to patients infected with CCRS-tropic HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF9geFO64f_LVg90H21EOLACvtfcHk0licqEcLttYUlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFSmsL8%253D&md5=9618f150676a1871bf17bb54269a29f8</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1086%2F527327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F527327%26sid%3Dliteratum%253Aachs%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DYadavalli%26aufirst%3DG.%2BK.%26aulast%3DPara%26aufirst%3DM.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DDejesus%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DCai%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DNovello%26aufirst%3DL.%2BA.%26aulast%3DLederman%26aufirst%3DM.%2BM.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520antiviral%2520activity%2520of%2520HGS004%252C%2520a%2520novel%2520fully%2520human%2520IgG4%2520monoclonal%2520antibody%2520against%2520CCR5%252C%2520in%2520HIV-1-infected%2520patients%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D197%26spage%3D721%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Miltz, W.</span><span> </span><span class="NLM_article-title">Dual CCR2/ CCR5Antagonists: A New Approach for the Treatment of Autoimmune Diseases</span>. Presented at the 235th National Meeting of the American Chemical Society, New Orleans, LA,  Apr 6â10,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span><a href="http://oasys2.confex.com/acs/235nm/techprogram/S26267.HTM" class="extLink">http://oasys2.confex.com/acs/235nm/techprogram/S26267.HTM</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=W.+Miltz&title=Dual+CCR2%2F+CCR5Antagonists%3A+A+New+Approach+for+the+Treatment+of+Autoimmune+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DMiltz%26aufirst%3DW.%26atitle%3DDual%2520CCR2%252F%2520CCR5Antagonists%253A%2520A%2520New%2520Approach%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Urnov, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebar, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, P. D.</span><span> </span><span class="NLM_article-title">Genome editing with engineered zinc finger nucleases</span> <span class="citation_source-journal">Nat. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">â</span> <span class="NLM_lpage">646</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnrg2842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20717154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCnurzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=636-646&author=F.+D.+Urnovauthor=E.+J.+Rebarauthor=M.+C.+Holmesauthor=H.+S.+Zhangauthor=P.+D.+Gregory&title=Genome+editing+with+engineered+zinc+finger+nucleases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Genome editing with engineered zinc finger nucleases</span></div><div class="casAuthors">Urnov, Fyodor D.; Rebar, Edward J.; Holmes, Michael C.; Zhang, H. Steve; Gregory, Philip D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-646</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Zinc finger nucleases (ZFNs) are versatile tools for making precise modifications to genomes, and their use is now established in a range of model systems.  ZFNs are also showing potential in human gene therapy, and several clin. trials are underway.  Reverse genetics in model organisms such as Drosophila melanogaster, Arabidopsis thaliana, zebrafish and rats, efficient genome engineering in human embryonic stem and induced pluripotent stem cells, targeted integration in crop plants, and HIV resistance in immune cells - this broad range of outcomes has resulted from the application of the same core technol.: targeted genome cleavage by engineered, sequence-specific zinc finger nucleases followed by gene modification during subsequent repair.  Such 'genome editing' is now established in human cells and a no. of model organisms, thus opening the door to a range of new exptl. and therapeutic possibilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLqJej0w25drVg90H21EOLACvtfcHk0licqEcLttYUlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCnurzE&md5=23222b7a08e0ddddd083f69e6f53af5f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fnrg2842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2842%26sid%3Dliteratum%253Aachs%26aulast%3DUrnov%26aufirst%3DF.%2BD.%26aulast%3DRebar%26aufirst%3DE.%2BJ.%26aulast%3DHolmes%26aufirst%3DM.%2BC.%26aulast%3DZhang%26aufirst%3DH.%2BS.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26atitle%3DGenome%2520editing%2520with%2520engineered%2520zinc%2520finger%2520nucleases%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2010%26volume%3D11%26spage%3D636%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paxton, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceradini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuhlmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landau, N. R.</span><span> </span><span class="NLM_article-title">Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">â</span> <span class="NLM_lpage">377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1996&pages=367-377&author=R.+Liuauthor=W.+A.+Paxtonauthor=S.+Choeauthor=D.+Ceradiniauthor=S.+R.+Martinauthor=R.+Horukauthor=M.+E.+MacDonaldauthor=H.+Stuhlmannauthor=R.+A.+Koupauthor=N.+R.+Landau&title=Homozygous+defect+in+HIV-1+coreceptor+accounts+for+resistance+of+some+multiply-exposed+individuals+to+HIV-1+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPaxton%26aufirst%3DW.%2BA.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DCeradini%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DS.%2BR.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DMacDonald%26aufirst%3DM.%2BE.%26aulast%3DStuhlmann%26aufirst%3DH.%26aulast%3DKoup%26aufirst%3DR.%2BA.%26aulast%3DLandau%26aufirst%3DN.%2BR.%26atitle%3DHomozygous%2520defect%2520in%2520HIV-1%2520coreceptor%2520accounts%2520for%2520resistance%2520of%2520some%2520multiply-exposed%2520individuals%2520to%2520HIV-1%2520infection%26jtitle%3DCell%26date%3D1996%26volume%3D86%26spage%3D367%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Saruta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Q. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanesyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleshner, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadakis, K. A.</span><span> </span><span class="NLM_article-title">Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohnâs disease</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">3293</span><span class="NLM_x">â</span> <span class="NLM_lpage">3300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2007&pages=3293-3300&author=M.+Sarutaauthor=Q.+T.+Yuauthor=A.+Avanesyanauthor=P.+R.+Fleshnerauthor=S.+R.+Targanauthor=K.+A.+Papadakis&title=Phenotype+and+effector+function+of+CC+chemokine+receptor+9-expressing+lymphocytes+in+small+intestinal+Crohn%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaruta%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DQ.%2BT.%26aulast%3DAvanesyan%26aufirst%3DA.%26aulast%3DFleshner%26aufirst%3DP.%2BR.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DPapadakis%26aufirst%3DK.%2BA.%26atitle%3DPhenotype%2520and%2520effector%2520function%2520of%2520CC%2520chemokine%2520receptor%25209-expressing%2520lymphocytes%2520in%2520small%2520intestinal%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Immunol.%26date%3D2007%26volume%3D178%26spage%3D3293%26epage%3D3300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Ungashe, S.; Wright, J. J.; Pennell, A.</span><span> </span><span class="NLM_article-title">Aryl Sulfonamides</span>. US 7,932,252,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Ungashe&author=J.+J.+Wright&author=A.+Pennell&title=Aryl+Sulfonamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUngashe%26aufirst%3DS.%26atitle%3DAryl%2520Sulfonamides%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span>Vercirnon. <a href="http://www.chemspider.com/Chemical-Structure.8518913.html" class="extLink">http://www.chemspider.com/Chemical-Structure.8518913.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vercirnon.+http%3A%2F%2Fwww.chemspider.com%2FChemical-Structure.8518913.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Walters, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgart, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairaghi, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penfold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ungashe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T. J.</span><span> </span><span class="NLM_article-title">Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">â</span> <span class="NLM_lpage">69</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.110.169714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20660125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=61-69&author=M.+J.+Waltersauthor=Y.+Wangauthor=N.+Laiauthor=T.+Baumgartauthor=B.+N.+Zhaoauthor=D.+J.+Dairaghiauthor=P.+Bekkerauthor=L.+S.+Ertlauthor=M.+E.+Penfoldauthor=J.+C.+Jaenauthor=S.+Keshavauthor=E.+Wendtauthor=A.+Pennellauthor=S.+Ungasheauthor=Z.+Weiauthor=J.+J.+Wrightauthor=T.+J.+Schall&title=Characterization+of+CCX282-B%2C+an+orally+bioavailable+antagonist+of+the+CCR9+chemokine+receptor%2C+for+treatment+of+inflammatory+bowel+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease</span></div><div class="casAuthors">Walters, Matthew J.; Wang, Yu; Lai, Nu; Baumgart, Trageen; Zhao, Bin N.; Dairaghi, Daniel J.; Bekker, Pirow; Ertl, Linda S.; Penfold, Mark E. T.; Jaen, Juan C.; Keshav, Satish; Wendt, Emily; Pennell, Andrew; Ungashe, Solomon; Wei, Zheng; Wright, J. J. Kim; Schall, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chemokine system represents a diverse group of G protein-coupled receptors responsible for orchestrating cell recruitment under both homeostatic and inflammatory conditions.  Chemokine receptor 9 (CCR9) is a chemokine receptor known to be central for migration of immune cells into the intestine.  Its only ligand, CCL25, is expressed at the mucosal surface of the intestine and is known to be elevated in intestinal inflammation.  To date, there are no reports of small-mol. antagonists targeting CCR9.  We report, for the first time, the discovery of a small mol., CCX282-B, which is an orally bioavailable, selective, and potent antagonist of human CCR9.  CCX282-B inhibited CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, resp.  In the presence of 100% human serum, CCX282-B inhibited CCR9-mediated chemotaxis with an IC50 of 33 nM, and the addn. of Î±1-acid glycoprotein did not affect its potency.  CCX282-B inhibited chemotaxis of primary CCR9-expressing cells to CCL25 with an IC50 of 6.8 nM.  CCX282-B was an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, resp.  CCX282-B also inhibited mouse and rat CCR9-mediated chemotaxis.  Inhibition of CCR9 with CCX282-B results in normalization of Crohn's disease such as histopathol. assocd. with the TNFÎARE mice.  Anal. of the plasma level of drug assocd. with this improvement provides an understanding of the pharmacokinetic/pharmacodynamic relationship for CCR9 antagonists in the treatment of intestinal inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvKRxhmslqLVg90H21EOLACvtfcHk0lhXFUzBlf6cuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3I&md5=0d7903a7e25721ede33196f8e32f0e87</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.169714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.169714%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DN.%26aulast%3DBaumgart%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DB.%2BN.%26aulast%3DDairaghi%26aufirst%3DD.%2BJ.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DErtl%26aufirst%3DL.%2BS.%26aulast%3DPenfold%26aufirst%3DM.%2BE.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DKeshav%26aufirst%3DS.%26aulast%3DWendt%26aufirst%3DE.%26aulast%3DPennell%26aufirst%3DA.%26aulast%3DUngashe%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26atitle%3DCharacterization%2520of%2520CCX282-B%252C%2520an%2520orally%2520bioavailable%2520antagonist%2520of%2520the%2520CCR9%2520chemokine%2520receptor%252C%2520for%2520treatment%2520of%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D61%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Keshav, S.</span><span> </span><span class="NLM_article-title">CCX282-B, an Orally Active Inhibitor of Chemokine Receptor CCR9, in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Moderate to Severe Crohnâs Disease</span>. Presented at the 14th United European Gastroenterology Week (UEGW 2006), Berlin,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+Keshav&title=CCX282-B%2C+an+Orally+Active+Inhibitor+of+Chemokine+Receptor+CCR9%2C+in+a+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Phase+2+Study+in+Moderate+to+Severe+Crohn%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKeshav%26aufirst%3DS.%26atitle%3DCCX282-B%252C%2520an%2520Orally%2520Active%2520Inhibitor%2520of%2520Chemokine%2520Receptor%2520CCR9%252C%2520in%2520a%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25202%2520Study%2520in%2520Moderate%2520to%2520Severe%2520Crohn%25E2%2580%2599s%2520Disease%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurewicz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">10095</span><span class="NLM_x">â</span> <span class="NLM_lpage">10098</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1074%2Fjbc.273.17.10095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9553055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=10095-10098&author=J.+R.+Whiteauthor=J.+M.+Leeauthor=P.+R.+Youngauthor=R.+P.+Hertzbergauthor=A.+J.+Jurewiczauthor=M.+A.+Chaikinauthor=K.+Widdowsonauthor=J.+J.+Foleyauthor=L.+D.+Martinauthor=D.+E.+Griswoldauthor=H.+M.+Sarau&title=Identification+of+a+potent%2C+selective+non-peptide+CXCR2+antagonist+that+inhibits+interleukin-8-induced+neutrophil+migration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span></div><div class="casAuthors">White, John R.; Lee, Judithann M.; Young, Peter R.; Hertzberg, Robert P.; Jurewicz, Anthony J.; Chaikin, Margery A.; Widdowson, Katherine; Foley, James J.; Martin, Lenox D.; Griswold, Don E.; Sarau, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">10095-10098</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Interleukin-8 (IL-8) and closely related Glu-Leu-Arg (ELR) contg. CXC chemokines, including growth-related oncogene (GRO)Î±, GROÎ², GROÎ³, and epithelial cell-derived neutrophil-activating peptide-78 (ENA-78), are potent neutrophil chemotactic and activating peptides, which are proposed to be major mediators of inflammation.  IL-8 activates neutrophils by binding to two distinct seven-transmembrane (7-TMR) G-protein coupled receptors CXCR1 (IL-8RA) and CXCR2 (IL-8RB), while GROÎ±, GROÎ², GROÎ³, and ENA-78 bind to and activate only CXCR2.  A chem. lead, which selectively inhibited CXCR2 was discovered by high throughput screening and chem. optimized.  SB 225002 (N-(2-hydroxy-4-nitrophenyl)-N'-(2-bromophenyl)urea) is the first reported potent and selective non-peptide inhibitor of a chemokine receptor.  It is an antagonist of 125I-IL-8 binding to CXCR2 with an IC50 = 22 nM.  SB 225002 showed > 150-fold selectivity over CXCR1 and four other 7-TMRs tested.  In vitro, SB 225002 potently inhibited human and rabbit neutrophil chemotaxis induced by both IL-8 and GROÎ±.  In vivo, SB 225002 selectively blocked IL-8-induced neutrophil margination in rabbits.  The present findings suggest that CXCR2 is responsible for neutrophil chemotaxis and margination induced by IL-8.  This selective antagonist will be a useful tool compd. to define the role of CXCR2 in inflammatory diseases where neutrophils play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO6PNyFAVGW7Vg90H21EOLACvtfcHk0lhXFUzBlf6cuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivFKnsL8%253D&md5=28b894f2ff3672653a92f3ff5230d1ac</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.17.10095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.17.10095%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DWiddowson%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%2520non-peptide%2520CXCR2%2520antagonist%2520that%2520inhibits%2520interleukin-8-induced%2520neutrophil%2520migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D10095%26epage%3D10098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutledge, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleland, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurewicz, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span> </span><span class="NLM_article-title">Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1319</span><span class="NLM_x">â</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm034248l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1319-1321&author=K.+L.+Widdowsonauthor=J.+D.+Elliottauthor=D.+F.+Veberauthor=H.+Nieauthor=M.+C.+Rutledgeauthor=B.+W.+McClelandauthor=J.+N.+Xiangauthor=A.+J.+Jurewiczauthor=R.+P.+Hertzbergauthor=J.+J.+Foleyauthor=D.+E.+Griswoldauthor=L.+Martinauthor=J.+M.+Leeauthor=J.+R.+Whiteauthor=H.+M.+Sarau&title=Evaluation+of+potent+and+selective+small-molecule+antagonists+for+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm034248l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034248l%26sid%3Dliteratum%253Aachs%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DNie%26aufirst%3DH.%26aulast%3DRutledge%26aufirst%3DM.%2BC.%26aulast%3DMcCleland%26aufirst%3DB.%2BW.%26aulast%3DXiang%26aufirst%3DJ.%2BN.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DMartin%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DEvaluation%2520of%2520potent%2520and%2520selective%2520small-molecule%2520antagonists%2520for%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1319%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleland, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nord, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorycki, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Discovery of potent and orally bioavailable <i>N</i>,<i>N</i>â²-diarylurea antagonists for the CXCR2 chemokine receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4375</span><span class="NLM_x">â</span> <span class="NLM_lpage">4378</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4375-4378&author=Q.+Jinauthor=H.+Nieauthor=B.+W.+McClelandauthor=K.+L.+Widdowsonauthor=M.+R.+Palovichauthor=J.+D.+Elliottauthor=R.+M.+Goodmanauthor=M.+Burmanauthor=H.+M.+Sarauauthor=K.+W.+Wardauthor=M.+Nordauthor=B.+M.+Orrauthor=P.+D.+Goryckiauthor=J.+Busch-Petersen&title=Discovery+of+potent+and+orally+bioavailable+N%2CN%E2%80%B2-diarylurea+antagonists+for+the+CXCR2+chemokine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DNie%26aufirst%3DH.%26aulast%3DMcCleland%26aufirst%3DB.%2BW.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DGoodman%26aufirst%3DR.%2BM.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DNord%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DB.%2BM.%26aulast%3DGorycki%26aufirst%3DP.%2BD.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520bioavailable%2520N%252CN%25E2%2580%25B2-diarylurea%2520antagonists%2520for%2520the%2520CXCR2%2520chemokine%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4375%26epage%3D4378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">Lazaar, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexis, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tal-Singer, R.</span><span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">282</span><span class="NLM_x">â</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&author=A.+L.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0lhqVhMsbBxL5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D282%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Allegretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesta, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bizzarri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bitondo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cioccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliera, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zampella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bello, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantucci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span> </span><span class="NLM_article-title">2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4312</span><span class="NLM_x">â</span> <span class="NLM_lpage">4331</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049082i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4312-4331&author=M.+Allegrettiauthor=R.+Bertiniauthor=M.+C.+Cestaauthor=C.+Bizzarriauthor=R.+Di+Bitondoauthor=V.+Di+Cioccioauthor=E.+Gallieraauthor=V.+Berdiniauthor=A.+Topaiauthor=G.+Zampellaauthor=V.+Russoauthor=N.+Di+Belloauthor=G.+Nanoauthor=L.+Nicoliniauthor=M.+Locatiauthor=P.+Fantucciauthor=S.+Florioauthor=F.+Colotta&title=2-Arylpropionic+CXC+chemokine+receptor+1+%28CXCR1%29+ligands+as+novel+noncompetitive+CXCL8+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Fjm049082i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049082i%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DDi%2BCioccio%26aufirst%3DV.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DTopai%26aufirst%3DA.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DRusso%26aufirst%3DV.%26aulast%3DDi%2BBello%26aufirst%3DN.%26aulast%3DNano%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DL.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DFantucci%26aufirst%3DP.%26aulast%3DFlorio%26aufirst%3DS.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3D2-Arylpropionic%2520CXC%2520chemokine%2520receptor%25201%2520%2528CXCR1%2529%2520ligands%2520as%2520novel%2520noncompetitive%2520CXCL8%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4312%26epage%3D4331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Ginestier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diebel, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korkaya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabaud, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charafe-Jauffret, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dontu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicha, M. S.</span><span> </span><span class="NLM_article-title">CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=485-497&author=C.+Ginestierauthor=S.+Liuauthor=M.+E.+Diebelauthor=H.+Korkayaauthor=M.+Luoauthor=M.+Brownauthor=J.+Wicinskiauthor=O.+Cabaudauthor=E.+Charafe-Jauffretauthor=D.+Birnbaumauthor=J.+L.+Guanauthor=G.+Dontuauthor=M.+S.+Wicha&title=CXCR1+blockade+selectively+targets+human+breast+cancer+stem+cells+in+vitro+and+in+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDiebel%26aufirst%3DM.%2BE.%26aulast%3DKorkaya%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DWicinski%26aufirst%3DJ.%26aulast%3DCabaud%26aufirst%3DO.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DBirnbaum%26aufirst%3DD.%26aulast%3DGuan%26aufirst%3DJ.%2BL.%26aulast%3DDontu%26aufirst%3DG.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26atitle%3DCXCR1%2520blockade%2520selectively%2520targets%2520human%2520breast%2520cancer%2520stem%2520cells%2520in%2520vitro%2520and%2520in%2520xenografts%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D485%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">Suling, L.; Korkaya, H.; Wicha, M. S.</span><span> </span><span class="NLM_article-title">Are Cancer Stem Cells Ready for Prime Time?</span> <span class="citation_source-book">The Scientist</span>; LabX Media Group: New York; <a href="http://the-scientist.com/2012/04/01/are-cancer-stem-cells-ready-for-prime-time/" class="extLink">http://the-scientist.com/2012/04/01/are-cancer-stem-cells-ready-for-prime-time/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Suling%2C+L.%3B+Korkaya%2C+H.%3B+Wicha%2C+M.+S.+Are+Cancer+Stem+Cells+Ready+for+Prime+Time%3FThe+Scientist%3B+LabX+Media+Group%3A+New+York%3B+http%3A%2F%2Fthe-scientist.com%2F2012%2F04%2F01%2Fare-cancer-stem-cells-ready-for-prime-time%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSuling%26aufirst%3DL.%26atitle%3DAre%2520Cancer%2520Stem%2520Cells%2520Ready%2520for%2520Prime%2520Time%253F%26btitle%3DThe%2520Scientist" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biju, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rindgen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Ezel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terminelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merritt, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozgur, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span> </span><span class="NLM_article-title">Discovery of 2-hydroxy-<i>N</i>,<i>N</i>-dimethyl-3-{2-[[(<i>R</i>)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7603</span><span class="NLM_x">â</span> <span class="NLM_lpage">7606</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0609622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7603-7606&author=M.+P.+Dwyerauthor=Y.+Yuauthor=J.+Chaoauthor=C.+Akiauthor=P.+Bijuauthor=V.+Girijavallabhanauthor=D.+Rindgenauthor=R.+Bondauthor=R.+Mayer-Ezelauthor=J.+Jakwayauthor=R.+W.+Hipkinauthor=J.+Fossettaauthor=W.+Gonsiorekauthor=H.+Bianauthor=X.+Fanauthor=C.+Terminelliauthor=J.+Fineauthor=D.+Lundellauthor=J.+R.+Merrittauthor=L.+L.+Rokoszauthor=B.+Kaiserauthor=G.+Liauthor=W.+Wangauthor=T.+Staufferauthor=L.+Ozgurauthor=J.+Baldwinauthor=A.+G.+Taveras&title=Discovery+of+2-hydroxy-N%2CN-dimethyl-3-%7B2-%5B%5B%28R%29-1-%285-+methylfuran-2-yl%29propyl%5Damino%5D-3%2C4-dioxocyclobut-1-enylamino%7Dbenzamide+%28SCH+527123%29%3A+a+potent%2C+orally+bioavailable+CXCR2%2FCXCR1+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm0609622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0609622%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DAki%26aufirst%3DC.%26aulast%3DBiju%26aufirst%3DP.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DRindgen%26aufirst%3DD.%26aulast%3DBond%26aufirst%3DR.%26aulast%3DMayer-Ezel%26aufirst%3DR.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DTerminelli%26aufirst%3DC.%26aulast%3DFine%26aufirst%3DJ.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DJ.%2BR.%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DKaiser%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DStauffer%26aufirst%3DT.%26aulast%3DOzgur%26aufirst%3DL.%26aulast%3DBaldwin%26aufirst%3DJ.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26atitle%3DDiscovery%2520of%25202-hydroxy-N%252CN-dimethyl-3-%257B2-%255B%255B%2528R%2529-1-%25285-%2520methylfuran-2-yl%2529propyl%255Damino%255D-3%252C4-dioxocyclobut-1-enylamino%257Dbenzamide%2520%2528SCH%2520527123%2529%253A%2520a%2520potent%252C%2520orally%2520bioavailable%2520CXCR2%252FCXCR1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7603%26epage%3D7606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakway, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.106.118927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17496166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=477-485&author=W.+Gonsiorekauthor=X.+Fanauthor=D.+Heskauthor=J.+Fossettaauthor=H.+Qiuauthor=J.+Jakwayauthor=M.+Billahauthor=M.+Dwyerauthor=J.+Chaoauthor=G.+Denoauthor=A.+Taverasauthor=D.+J.+Lundellauthor=R.+W.+Hipkin&title=Pharmacological+characterization+of+Sch527123%2C+a+potent+allosteric+CXCR1%2FCXCR2+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span></div><div class="casAuthors">Gonsiorek, Waldemar; Fan, Xuedong; Hesk, David; Fossetta, James; Qiu, Hongchen; Jakway, James; Billah, Motasim; Dwyer, Michael; Chao, Jianhua; Deno, Gregory; Taveras, Art; Lundell, Daniel J.; Hipkin, R. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In neutrophils, growth-related protein-Î± (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2.  The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small mol. antagonists for these receptors.  The data presented herein describe the pharmacol. of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2.  Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist.  Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine.  The pharmacol. specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors.  To measure compd. affinity, we characterized [3H]Sch527123 in both equil. and nonequil. binding analyses.  Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible.  Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9Â±0.3 nM), the compd. is CXCR2-selective (Kd = 0.049Â±0.004 nM).  Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb79iH3wA1yrVg90H21EOLACvtfcHk0ljRK9xhYaZ7qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D&md5=37691994ca29fa4dfe33d094d0cd9b93</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.118927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.118927%26sid%3Dliteratum%253Aachs%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DPharmacological%2520characterization%2520of%2520Sch527123%252C%2520a%2520potent%2520allosteric%2520CXCR1%252FCXCR2%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnicozzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celly, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipkin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rindgen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonsiorek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billah, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey, J. A.</span><span> </span><span class="NLM_article-title">A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">â</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1124%2Fjpet.106.119040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17496165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=486-493&author=R.+W.+Chapmanauthor=M.+Minnicozziauthor=C.+S.+Cellyauthor=J.+E.+Phillipsauthor=T.+T.+Kungauthor=R.+W.+Hipkinauthor=X.+Fanauthor=D.+Rindgenauthor=G.+Denoauthor=R.+Bondauthor=W.+Gonsiorekauthor=M.+M.+Billahauthor=J.+S.+Fineauthor=J.+A.+Hey&title=A+novel%2C+orally+active+CXCR1%2F2+receptor+antagonist%2C+Sch527123%2C+inhibits+neutrophil+recruitment%2C+mucus+production%2C+and+goblet+cell+hyperplasia+in+animal+models+of+pulmonary+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation</span></div><div class="casAuthors">Chapman, Richard W.; Minnicozzi, Michael; Celly, Chander S.; Phillips, Jonathan E.; Kung, Ted T.; Hipkin, R. William; Fan, Xuedong; Rindgen, Diane; Deno, Gregory; Bond, Richard; Gonsiorek, Waldemar; Billah, Motasim M.; Fine, Jay S.; Hey, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">486-493</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sch527123 [2-hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide] is a potent, selective antagonist of the human CXCR1 and CXCR2 receptors.  Here we describe its pharmacol. properties at rodent CXCR2 and at the CXCR1 and CXCR2 receptors in the cynomolgus monkey, as well as its in vivo activity in models demonstrating prominent pulmonary neutrophilia, goblet cell hyperplasia, and mucus prodn.  Sch527123 bound with high affinity to the CXCR2 receptors of mouse (Kd = 0.20 nM), rat (Kd = 0.20 nM), and cynomolgus monkey (Kd = 0.08 nM) and was a potent antagonist of CXCR2-mediated chemotaxis (IC50 â¼3-6 nM).  In contrast, Sch527123 bound to cynomolgus CXCR1 with lesser affinity (Kd = 41 nM) and weakly inhibited cynomolgus CXCR1-mediated chemotaxis (IC50 â¼1000 nM).  Oral treatment with Sch527123 blocked pulmonary neutrophilia (ED50 = 1.2 mg/kg) and goblet cell hyperplasia (32-38% inhibition at 1-3 mg/kg) in mice following the intranasal lipopolysaccharide (LPS) administration.  In rats, Sch527123 suppressed the pulmonary neutrophilia (ED50 = 1.8 mg/kg) and increase in bronchoalveolar lavage (BAL) mucin content (ED50 = <0.1 mg/kg) induced by intratracheal (i.t.) LPS.  Sch527123 also suppressed the pulmonary neutrophilia (ED50 = 1.3 mg/kg), goblet cell hyperplasia (ED50 = 0.7 mg/kg), and increase in BAL mucin content (ED50 = <1 mg/kg) in rats after i.t. administration of vanadium pentoxide.  In cynomolgus monkeys, Sch527123 reduced the pulmonary neutrophilia induced by repeat bronchoscopy and lavage (ED50 = 0.3 mg/kg).  Therefore, Sch527123 may offer benefit for the treatment of inflammatory lung disorders in which pulmonary neutrophilia and mucus hypersecretion are important components of the underlying disease pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9jt7WBXMZ5bVg90H21EOLACvtfcHk0lgLHAkDM297qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7g%253D&md5=825742c8a19cd163e9275658974cfcbf</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.119040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.119040%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DMinnicozzi%26aufirst%3DM.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DKung%26aufirst%3DT.%2BT.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DRindgen%26aufirst%3DD.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DBond%26aufirst%3DR.%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DBillah%26aufirst%3DM.%2BM.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26aulast%3DHey%26aufirst%3DJ.%2BA.%26atitle%3DA%2520novel%252C%2520orally%2520active%2520CXCR1%252F2%2520receptor%2520antagonist%252C%2520Sch527123%252C%2520inhibits%2520neutrophil%2520recruitment%252C%2520mucus%2520production%252C%2520and%2520goblet%2520cell%2520hyperplasia%2520in%2520animal%2520models%2520of%2520pulmonary%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D486%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group">Holz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalilieh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig-Sengpiel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stryszak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span> </span><span class="NLM_article-title">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">564</span><span class="NLM_x">â</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1183%2F09031936.00048509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19643947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=564-570&author=O.+Holzauthor=S.+Khaliliehauthor=A.+Ludwig-Sengpielauthor=H.+Watzauthor=P.+Stryszakauthor=P.+Soniauthor=M.+Tsaiauthor=J.+Sadehauthor=H.+Magnussen&title=SCH527123%2C+a+novel+CXCR2+antagonist%2C+inhibits+ozone-induced+neutrophilia+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span></div><div class="casAuthors">Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-570</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease.  The purpose of this proof-of-principle study was to det. whether SCH527123 inhibits ozone-induced neutrophil recruitment in healthy humans.  In a randomized, double-blind, placebo-controlled, three-way crossover study, oral SCH527123 (50 mg once daily, 4 days), prednisolone (50 mg once), or placebo was alternated with 2-wk washouts.  18 Healthy ozone responders (>20% increase in sputum neutrophils) underwent ozone challenge tests (250 ppb, 3 h intermittent exercise) 1 h after the last treatment dose.  Sputum was induced at 3 h post-challenge.  After SCH527123 treatment, the ozone challenge resulted in significantly lower sputum neutrophil counts (0.13 Ã 106 mL-1) compared with prednisolone (0.84 Ã 106/mL-1; p < 0.001) or placebo (2.98 Ã 106 mL-1; p < 0.001).  Comparable results were obtained for total cell count, percentage of sputum neutrophils, and for interleukin-8 and myeloperoxidase in sputum supernatant.  Post-challenge, SCH527123 inhibited neutrophilia in peripheral blood but significantly less than in sputum.  All treatments were safe and well tolerated.  SCH527123 causes significant attenuation of ozone-induced airway neutrophilia in healthy subjects.  Further evaluation in a large trial of patients with pulmonary disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwysQ82AncbVg90H21EOLACvtfcHk0lgLHAkDM297qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D&md5=ae0702b5eb1122d2c919a4130b3f471e</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1183%2F09031936.00048509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00048509%26sid%3Dliteratum%253Aachs%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DKhalilieh%26aufirst%3DS.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSoni%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DSadeh%26aufirst%3DJ.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DSCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520inhibits%2520ozone-induced%2520neutrophilia%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D564%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group">Jenh, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinsley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodny, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span> </span><span class="NLM_article-title">A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection</span> <span class="citation_source-journal">BMC Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1186%2F1471-2172-13-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=22435930" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=13-22&author=C.+H.+Jenhauthor=M.+A.+Coxauthor=L.+Cuiauthor=E.+P.+Reichauthor=L.+Sullivanauthor=S.+C.+Chenauthor=D.+Kinsleyauthor=S.+Qianauthor=S.+H.+Kimauthor=S.+Rosenblumauthor=J.+Kozlowskiauthor=J.+S.+Fineauthor=P.+J.+Zavodnyauthor=D.+Lundell&title=A+selective+and+potent+CXCR3+antagonist+SCH+546738+attenuates+the+development+of+autoimmune+diseases+and+delays+graft+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1186%2F1471-2172-13-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2172-13-2%26sid%3Dliteratum%253Aachs%26aulast%3DJenh%26aufirst%3DC.%2BH.%26aulast%3DCox%26aufirst%3DM.%2BA.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DReich%26aufirst%3DE.%2BP.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DKinsley%26aufirst%3DD.%26aulast%3DQian%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DRosenblum%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26aulast%3DZavodny%26aufirst%3DP.%2BJ.%26aulast%3DLundell%26aufirst%3DD.%26atitle%3DA%2520selective%2520and%2520potent%2520CXCR3%2520antagonist%2520SCH%2520546738%2520attenuates%2520the%2520development%2520of%2520autoimmune%2520diseases%2520and%2520delays%2520graft%2520rejection%26jtitle%3DBMC%2520Immunol.%26date%3D2012%26volume%3D13%26spage%3D13%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebsworth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sablan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairaghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J.</span><span> </span><span class="NLM_article-title">Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3339</span><span class="NLM_x">â</span> <span class="NLM_lpage">3343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3339-3343&author=M.+Johnsonauthor=A.+R.+Liauthor=J.+Liuauthor=Z.+Fuauthor=L.+Zhuauthor=S.+Miaoauthor=X.+Wangauthor=Q.+Xuauthor=A.+Huangauthor=A.+Marcusauthor=F.+Xuauthor=K.+Ebsworthauthor=E.+Sablanauthor=J.+Danaoauthor=J.+Kumerauthor=D.+Dairaghiauthor=C.+Lawrenceauthor=T.+Sullivanauthor=G.+Tonnauthor=T.+Schallauthor=T.+Collinsauthor=J.+Medina&title=Discovery+and+optimization+of+a+series+of+quinazolinone-derived+antagonists+of+CXCR3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DMarcus%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DEbsworth%26aufirst%3DK.%26aulast%3DSablan%26aufirst%3DE.%26aulast%3DDanao%26aufirst%3DJ.%26aulast%3DKumer%26aufirst%3DJ.%26aulast%3DDairaghi%26aufirst%3DD.%26aulast%3DLawrence%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DT.%26aulast%3DTonn%26aufirst%3DG.%26aulast%3DSchall%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DT.%26aulast%3DMedina%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520series%2520of%2520quinazolinone-derived%2520antagonists%2520of%2520CXCR3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3339%26epage%3D3343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group">Tonn, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kersey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Lengerich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. K.</span><span> </span><span class="NLM_article-title">An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (<i>R</i>)-<i>N</i>-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-<i>d</i>]pyrimidin-2-yl]-ethy l}-<i>N</i>-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=502-513&author=G.+R.+Tonnauthor=S.+G.+Wongauthor=S.+C.+Wongauthor=M.+G.+Johnsonauthor=J.+Maauthor=R.+Choauthor=L.+C.+Florenauthor=K.+Kerseyauthor=K.+Berryauthor=A.+P.+Marcusauthor=X.+Wangauthor=B.+Van+Lengerichauthor=J.+C.+Medinaauthor=P.+G.+Pearsonauthor=B.+K.+Wong&title=An+inhibitory+metabolite+leads+to+dose-+and+time-dependent+pharmacokinetics+of+%28R%29-N-%7B1-%5B3-%284-ethoxy-phenyl%29-4-oxo-3%2C4-dihydro-pyrido%5B2%2C3-d%5Dpyrimidin-2-yl%5D-ethy+l%7D-N-pyridin-3-yl-methyl-2-%284-trifluoromethoxy-phenyl%29-acetamide+%28AMG+487%29+in+human+subjects+after+multiple+dosing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DWong%26aufirst%3DS.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DFloren%26aufirst%3DL.%2BC.%26aulast%3DKersey%26aufirst%3DK.%26aulast%3DBerry%26aufirst%3DK.%26aulast%3DMarcus%26aufirst%3DA.%2BP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DVan%2BLengerich%26aufirst%3DB.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DWong%26aufirst%3DB.%2BK.%26atitle%3DAn%2520inhibitory%2520metabolite%2520leads%2520to%2520dose-%2520and%2520time-dependent%2520pharmacokinetics%2520of%2520%2528R%2529-N-%257B1-%255B3-%25284-ethoxy-phenyl%2529-4-oxo-3%252C4-dihydro-pyrido%255B2%252C3-d%255Dpyrimidin-2-yl%255D-ethy%2520l%257D-N-pyridin-3-yl-methyl-2-%25284-trifluoromethoxy-phenyl%2529-acetamide%2520%2528AMG%2520487%2529%2520in%2520human%2520subjects%2520after%2520multiple%2520dosing%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D502%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group">Peled, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabovsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandbank, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenzana-Seisdedos, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petit, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Hur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alon, R.</span><span> </span><span class="NLM_article-title">The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">â</span> <span class="NLM_lpage">1211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=1199-1211&author=A.+Peledauthor=V.+Grabovskyauthor=L.+Hablerauthor=J.+Sandbankauthor=F.+Arenzana-Seisdedosauthor=I.+Petitauthor=H.+Ben-Hurauthor=T.+Lapidotauthor=R.+Alon&title=The+chemokine+SDF-1+stimulates+integrin-mediated+arrest+of+CD34%28%2B%29+cells+on+vascular+endothelium+under+shear+flow"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeled%26aufirst%3DA.%26aulast%3DGrabovsky%26aufirst%3DV.%26aulast%3DHabler%26aufirst%3DL.%26aulast%3DSandbank%26aufirst%3DJ.%26aulast%3DArenzana-Seisdedos%26aufirst%3DF.%26aulast%3DPetit%26aufirst%3DI.%26aulast%3DBen-Hur%26aufirst%3DH.%26aulast%3DLapidot%26aufirst%3DT.%26aulast%3DAlon%26aufirst%3DR.%26atitle%3DThe%2520chemokine%2520SDF-1%2520stimulates%2520integrin-mediated%2520arrest%2520of%2520CD34%2528%252B%2529%2520cells%2520on%2520vascular%2520endothelium%2520under%2520shear%2520flow%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3D1199%26epage%3D1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group">Broxmeyer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orschell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapp, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hangoc, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plett, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liles, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham-Evans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srour, E. F.</span><span> </span><span class="NLM_article-title">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">201</span><span class="NLM_x">, </span> <span class="NLM_fpage">1307</span><span class="NLM_x">â</span> <span class="NLM_lpage">1318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1084%2Fjem.20041385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15837815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=1307-1318&author=H.+E.+Broxmeyerauthor=C.+M.+Orschellauthor=D.+W.+Clappauthor=G.+Hangocauthor=S.+Cooperauthor=P.+A.+Plettauthor=W.+C.+Lilesauthor=X.+Liauthor=B.+Graham-Evansauthor=T.+B.+Campbellauthor=G.+Calandraauthor=G.+Bridgerauthor=D.+C.+Daleauthor=E.+F.+Srour&title=Rapid+mobilization+of+murine+and+human+hematopoietic+stem+and+progenitor+cells+with+AMD3100%2C+a+CXCR4+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span></div><div class="casAuthors">Broxmeyer, Hal E.; Orschell, Christie M.; Clapp, D. Wade; Hangoc, Giao; Cooper, Scott; Plett, P. Artur; Liles, W. Conrad; Li, Xiaxin; Graham-Evans, Barbara; Campbell, Timothy B.; Calandra, Gary; Bridger, Gary; Dale, David C.; Srour, Edward F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1307-1318</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Improving approaches for hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization is clin. important because increased nos. of these cells are needed for enhanced transplantation.  Chemokine stromal cell derived factor-1 (also known as CXCL12) is believed to be involved in retention of HSCs and HPCs in bone marrow.  AMD3100, a selective antagonist of CXCL12 that binds to its receptor, CXCR4, was evaluated in murine and human systems for mobilizing capacity, alone and in combination with granulocyte colony-stimulating factor (G-CSF).  AMD3100 induced rapid mobilization of mouse and human HPCs and synergistically augmented G-CSF-induced mobilization of HPCs.  AMD3100 also mobilized murine long-term repopulating (LTR) cells that engrafted primary and secondary lethally-irradiated mice, and human CD34+ cells that can repopulate nonobese diabetic-severe combined immunodeficiency (SCID) mice.  AMD3100 synergized with G-CSF to mobilize murine LTR cells and human SCID repopulating cells (SRCs).  Human CD34+ cells isolated after treatment with G-CSF plus AMD3100 expressed a phenotype that was characteristic of highly engrafting mouse HSCs.  Synergy of AMD3100 and G-CSF in mobilization was due to enhanced nos. and perhaps other characteristics of the mobilized cells.  These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clin. potential of AMD3100 for HSC mobilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDUgOByTJX07Vg90H21EOLACvtfcHk0lgmadVHYYdnEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D&md5=e5942dc81a7687a8b7c10f9542cbf29d</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041385%26sid%3Dliteratum%253Aachs%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DOrschell%26aufirst%3DC.%2BM.%26aulast%3DClapp%26aufirst%3DD.%2BW.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DPlett%26aufirst%3DP.%2BA.%26aulast%3DLiles%26aufirst%3DW.%2BC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGraham-Evans%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DT.%2BB.%26aulast%3DCalandra%26aufirst%3DG.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DSrour%26aufirst%3DE.%2BF.%26atitle%3DRapid%2520mobilization%2520of%2520murine%2520and%2520human%2520hematopoietic%2520stem%2520and%2520progenitor%2520cells%2520with%2520AMD3100%252C%2520a%2520CXCR4%2520antagonist%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D1307%26epage%3D1318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group">DiPersio, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micallef, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stiff, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolwell, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maziarz, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nademanee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, G.</span><span> </span><span class="NLM_article-title">Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkinâs lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4767</span><span class="NLM_x">â</span> <span class="NLM_lpage">4773</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1200%2FJCO.2008.20.7209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=19720922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4767-4773&author=J.+F.+DiPersioauthor=I.+N.+Micallefauthor=P.+J.+Stiffauthor=B.+J.+Bolwellauthor=R.+T.+Maziarzauthor=E.+Jacobsenauthor=A.+Nademaneeauthor=J.+McCartyauthor=G.+Bridgerauthor=G.+Calandra&title=Phase+III+prospective+randomized+double-blind+placebo-controlled+trial+of+plerixafor+plus+granulocyte+colony-stimulating+factor+compared+with+placebo+plus+granulocyte+colony-stimulating+factor+for+autologous+stem-cell+mobilization+and+transplantation+for+patients+with+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma</span></div><div class="casAuthors">DiPersio, John F.; Micallef, Ivana N.; Stiff, Patrick J.; Bolwell, Brian J.; Maziarz, Richard T.; Jacobsen, Eric; Nademanee, Auayporn; McCarty, John; Bridger, Gary; Calandra, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">4767-4773</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients.  Patients and Methods: This is a phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study.  Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible.  Patients received granulocyte colony-stimulating factor (G-CSF; 10 Î¼g/kg) s.c. daily for up to 8 days.  Beginning on evening of day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 Î¼g/kg) or placebo s.c.  Starting on day 5, patients began daily apheresis for up to 4 days or until â¥ 5 Ã 106 CD34+ cells/kg were collected.  The primary end point was the percentage of patients who collected â¥ 5 Ã 106 CD34+ cells/kg in 4 or fewer apheresis days.  Results: This report presents all data for all patients (n = 298) through 12 mo follow-up.  Eighty-nine (59%) of 150 patients in the plerixafor group and 29 (20%) of 148 patients in the placebo group met the primary end point (P < .001).  One hundred thirty-five patients (90%) in plerixafor group and 82 patients (55%) in placebo group underwent transplantation after initial mobilization.  Median time to engraftment was similar in both groups.  The most common plerixafor-assocd. adverse events were GI disorders and injection site reactions.  Conclusion: Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYjfnL3AIfbbVg90H21EOLACvtfcHk0lhwbUII-rq9rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbI&md5=b2e30e8f1372875267ca61af49ee96cd</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.7209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.7209%26sid%3Dliteratum%253Aachs%26aulast%3DDiPersio%26aufirst%3DJ.%2BF.%26aulast%3DMicallef%26aufirst%3DI.%2BN.%26aulast%3DStiff%26aufirst%3DP.%2BJ.%26aulast%3DBolwell%26aufirst%3DB.%2BJ.%26aulast%3DMaziarz%26aufirst%3DR.%2BT.%26aulast%3DJacobsen%26aufirst%3DE.%26aulast%3DNademanee%26aufirst%3DA.%26aulast%3DMcCarty%26aufirst%3DJ.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DCalandra%26aufirst%3DG.%26atitle%3DPhase%2520III%2520prospective%2520randomized%2520double-blind%2520placebo-controlled%2520trial%2520of%2520plerixafor%2520plus%2520granulocyte%2520colony-stimulating%2520factor%2520compared%2520with%2520placebo%2520plus%2520granulocyte%2520colony-stimulating%2520factor%2520for%2520autologous%2520stem-cell%2520mobilization%2520and%2520transplantation%2520for%2520patients%2520with%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4767%26epage%3D4773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group">Shia, K. S.; Hakimelahi, G. H.; Zhu, J. L.; Yen, C. F.; Huang, Y. H.; Xiang, Y.; Chen, H. C.; Changhua, C. W.</span><span> </span><span class="NLM_article-title">Polyamine Compounds for Treating Chemokine Receptor Mediated Diseases</span>. US 7,399,776,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+S.+Shia&author=G.+H.+Hakimelahi&author=J.+L.+Zhu&author=C.+F.+Yen&author=Y.+H.+Huang&author=Y.+Xiang&author=H.+C.+Chen&author=C.+W.+Changhua&title=Polyamine+Compounds+for+Treating+Chemokine+Receptor+Mediated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShia%26aufirst%3DK.%2BS.%26atitle%3DPolyamine%2520Compounds%2520for%2520Treating%2520Chemokine%2520Receptor%2520Mediated%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group">Chung, D. T.; Chang, L.; Huang, Y.; Tsai, C.; Hsu, C.; King, C. R.; Yuan, J. H.; Yen, C.; Chen, Y.; Lu, Y. C.; Hsu, M.</span><span> </span><span class="NLM_article-title">TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial</span>. Presented at the 51st ASH Meeting, New Orleans, LA,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=D.+T.+Chung&author=L.+Chang&author=Y.+Huang&author=C.+Tsai&author=C.+Hsu&author=C.+R.+King&author=J.+H.+Yuan&author=C.+Yen&author=Y.+Chen&author=Y.+C.+Lu&author=M.+Hsu&title=TG-0054%2C+a+Novel+and+Potent+Stem+Cell+Mobilizer%2C+Displays+Excellent+PK%2FPD+and+Safety+Profile+in+Phase+I+Trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DD.%2BT.%26atitle%3DTG-0054%252C%2520a%2520Novel%2520and%2520Potent%2520Stem%2520Cell%2520Mobilizer%252C%2520Displays%2520Excellent%2520PK%252FPD%2520and%2520Safety%2520Profile%2520in%2520Phase%2520I%2520Trial%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group">Zumbrunn, J.; Demarco, S. J.; Lociuro, S.; Vrijbloed, J. W.; Gombert, F.; Mukherjee, R.; Moehle, K.; Obrecht, D.; Robinson, J. A.; Henze, H.; Romagnoli, B.; Ludin, C.</span><span> </span><span class="NLM_article-title">Template Fixed 8 Hairpin Peptidomimetics with CXCR4 Antagonizing Activity</span>. US 7,786,078,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Zumbrunn&author=S.+J.+Demarco&author=S.+Lociuro&author=J.+W.+Vrijbloed&author=F.+Gombert&author=R.+Mukherjee&author=K.+Moehle&author=D.+Obrecht&author=J.+A.+Robinson&author=H.+Henze&author=B.+Romagnoli&author=C.+Ludin&title=Template+Fixed+8+Hairpin+Peptidomimetics+with+CXCR4+Antagonizing+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZumbrunn%26aufirst%3DJ.%26atitle%3DTemplate%2520Fixed%25208%2520Hairpin%2520Peptidomimetics%2520with%2520CXCR4%2520Antagonizing%2520Activity%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group">Roccaro, A. M.; Sacco, A.; Kuhne, M.; Azab, A. K.; Maiso, P.; Zhang, Y.; Liu, Y.; Azab, F.; Issa, G. C.; Quang, P.; Ngo, H. T.; Pan, C.; Choen, L.; Cardarelli, P. M.; Ghobrial, I. M.</span><span> </span><span class="NLM_article-title">The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma</span>. Presented at 53rd ASH Meeting, San Diego CA,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Abstract 1844.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+M.+Roccaro&author=A.+Sacco&author=M.+Kuhne&author=A.+K.+Azab&author=P.+Maiso&author=Y.+Zhang&author=Y.+Liu&author=F.+Azab&author=G.+C.+Issa&author=P.+Quang&author=H.+T.+Ngo&author=C.+Pan&author=L.+Choen&author=P.+M.+Cardarelli&author=I.+M.+Ghobrial&title=The+New+CXCR4+Inhibitor+MDX-1338+Exerts+Anti-Tumor+Activity+in+Multiple+Myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26atitle%3DThe%2520New%2520CXCR4%2520Inhibitor%2520MDX-1338%2520Exerts%2520Anti-Tumor%2520Activity%2520in%2520Multiple%2520Myeloma%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group">Fujii, N.; Tamamura, H.; Hori, A.</span><span> </span><span class="NLM_article-title">CXCR4 Antagonist and Use Thereof</span>. US 8,017,585,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Fujii&author=H.+Tamamura&author=A.+Hori&title=CXCR4+Antagonist+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DN.%26atitle%3DCXCR4%2520Antagonist%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span> </span><span class="NLM_article-title">Is CCR2 the right chemokine receptor to target in rheumatoid arthritis?</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">â</span> <span class="NLM_lpage">1891</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.23590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18576326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=1889-1891&author=A.+E.+Proudfoot&title=Is+CCR2+the+right+chemokine+receptor+to+target+in+rheumatoid+arthritis%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Is CCR2 the right chemokine receptor to target in rheumatoid arthritis?</span></div><div class="casAuthors">Proudfoot, Amanda E. I.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1889-1891</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A polemic in response to Vergunst et al. (Arthritis Rheum. 2008, 58, 1931-9) is given.  In their study, Vergunst et al. describes the lack of efficacy of a neutralizing antibody against CCR2, MLN12O2, in a relatively small phase IIa clin. trial in patients with rheumatoid arthritis (RA).  The authors argued on the drawn statistical conclusion about clin. effectiveness due to the very small no. of patients analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoInK80K2hJVbVg90H21EOLACvtfcHk0ligLy8dIJk2LA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wkur8%253D&md5=be0bb74e09ddc1e88fbfc3ff23cbe2d0</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1002%2Fart.23590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.23590%26sid%3Dliteratum%253Aachs%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26atitle%3DIs%2520CCR2%2520the%2520right%2520chemokine%2520receptor%2520to%2520target%2520in%2520rheumatoid%2520arthritis%253F%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D1889%26epage%3D1891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group">Karpus, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRae, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strieter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S. D.</span><span> </span><span class="NLM_article-title">An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">â</span> <span class="NLM_lpage">5010</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=5003-5010&author=W.+J.+Karpusauthor=N.+W.+Lukacsauthor=B.+L.+McRaeauthor=R.+M.+Strieterauthor=S.+L.+Kunkelauthor=S.+D.+Miller&title=An+important+role+for+the+chemokine+macrophage+inflammatory+protein-1+alpha+in+the+pathogenesis+of+the+T+cell-mediated+autoimmune+disease%2C+experimental+autoimmune+encephalomyelitis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarpus%26aufirst%3DW.%2BJ.%26aulast%3DLukacs%26aufirst%3DN.%2BW.%26aulast%3DMcRae%26aufirst%3DB.%2BL.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DMiller%26aufirst%3DS.%2BD.%26atitle%3DAn%2520important%2520role%2520for%2520the%2520chemokine%2520macrophage%2520inflammatory%2520protein-1%2520alpha%2520in%2520the%2520pathogenesis%2520of%2520the%2520T%2520cell-mediated%2520autoimmune%2520disease%252C%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26spage%3D5003%26epage%3D5010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group">Liang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghannam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oanh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergona, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taub, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunning, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselgesser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, H. D.</span><span> </span><span class="NLM_article-title">Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">19000</span><span class="NLM_x">â</span> <span class="NLM_lpage">19008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=19000-19008&author=M.+Liangauthor=C.+Mallariauthor=M.+Rosserauthor=H.+P.+Ngauthor=K.+Mayauthor=S.+Monahanauthor=J.+G.+Baumanauthor=I.+Islamauthor=A.+Ghannamauthor=B.+Buckmanauthor=K.+Shawauthor=G.+P.+Weiauthor=W.+Xuauthor=Z.+Zhaoauthor=E.+Hoauthor=J.+Shenauthor=H.+Oanhauthor=B.+Subramanyamauthor=R.+Vergonaauthor=D.+Taubauthor=L.+Dunningauthor=S.+Harveyauthor=R.+M.+Sniderauthor=J.+Hesselgesserauthor=M.+M.+Morrisseyauthor=H.+D.+Perez&title=Identification+and+characterization+of+a+potent%2C+selective%2C+and+orally+active+antagonist+of+the+CC+chemokine+receptor-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DM.%26aulast%3DMallari%26aufirst%3DC.%26aulast%3DRosser%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DH.%2BP.%26aulast%3DMay%26aufirst%3DK.%26aulast%3DMonahan%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DJ.%2BG.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DGhannam%26aufirst%3DA.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DShaw%26aufirst%3DK.%26aulast%3DWei%26aufirst%3DG.%2BP.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DE.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DOanh%26aufirst%3DH.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DTaub%26aufirst%3DD.%26aulast%3DDunning%26aufirst%3DL.%26aulast%3DHarvey%26aufirst%3DS.%26aulast%3DSnider%26aufirst%3DR.%2BM.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26aulast%3DPerez%26aufirst%3DH.%2BD.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520antagonist%2520of%2520the%2520CC%2520chemokine%2520receptor-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D19000%26epage%3D19008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group">Aktas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kury, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieseier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, H. P.</span><span> </span><span class="NLM_article-title">Fingolimod is a potential novel therapy for multiple sclerosis</span> <span class="citation_source-journal">Nat. Rev. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnrneurol.2010.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20551946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFKgt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=373-382&author=O.+Aktasauthor=P.+Kuryauthor=B.+Kieseierauthor=H.+P.+Hartung&title=Fingolimod+is+a+potential+novel+therapy+for+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod is a potential novel therapy for multiple sclerosis</span></div><div class="casAuthors">Aktas, Orhan; Kuery, Patrick; Kieseier, Bernd; Hartung, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">373-382</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Only moderately effective therapies are currently available for the treatment of multiple sclerosis (MS).  New treatments for MS that have neuroprotective properties as well as anti-inflammatory effects are needed.  Fingolimod could be one such potential treatment.  In this article, Aktas et al. examine the underlying biol. actions of this prospective new therapy, review the data from phase II and phase III oral fingolimod clin. trials and provide an update on the emerging field of sphingosine-1-phosphate receptor-mediated therapies for MS.  Fingolimod (also known as FTY720) is an orally available sphingosine-1-phosphate (S1P) receptor modulator that has unique and potent immunoregulatory properties.  Mechanistic studies indicate that on phosphorylation fingolimod can bind with high affinity to S1P1 receptors.  Persistent modulation of lymphocyte S1P1 receptors by fingolimod and the subsequent internalization of these receptors inhibits lymphocyte egress from the lymph nodes, and prevents these cells from infiltrating inflammatory lesions in the CNS.  Results of two phase III studies-FREEDOMS and TRANSFORMS-support previous phase II trial observations indicating that fingolimod exerts powerful anti-inflammatory effects in relapsing-remitting multiple sclerosis (MS).  Fingolimod might, therefore, be one of the first orally active drug therapies available for the treatment of relapsing-remitting MS.  Moreover, results from preclin. studies suggest that fingolimod might promote neural repair in vivo.  In this article, we review the background to these findings, present the proposed immunol. and neurobiol. profile of fingolimod, discuss the data from the FREEDOMS and TRANSFORMS trials, and provide an expert opinion regarding the future of next-generation S1P receptor modulators for MS therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbGeDeonkrpLVg90H21EOLACvtfcHk0lgUmnMvTckMPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFKgt7s%253D&md5=11690f6c74fe1fcb1fee8325d1f7b066</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fnrneurol.2010.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneurol.2010.76%26sid%3Dliteratum%253Aachs%26aulast%3DAktas%26aufirst%3DO.%26aulast%3DKury%26aufirst%3DP.%26aulast%3DKieseier%26aufirst%3DB.%26aulast%3DHartung%26aufirst%3DH.%2BP.%26atitle%3DFingolimod%2520is%2520a%2520potential%2520novel%2520therapy%2520for%2520multiple%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2010%26volume%3D6%26spage%3D373%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group">Fleishaker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Meijide, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohen, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeiher, B. G.</span><span> </span><span class="NLM_article-title">Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">R11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=R11&author=D.+L.+Fleishakerauthor=J.+A.+Garcia+Meijideauthor=A.+Petrovauthor=M.+D.+Kohenauthor=X.+Wangauthor=S.+Menonauthor=T.+C.+Stockauthor=C.+A.+Mebusauthor=J.+M.+Goodrichauthor=H.+B.+Mayerauthor=B.+G.+Zeiher&title=Maraviroc%2C+a+chemokine+receptor-5+antagonist%2C+fails+to+demonstrate+efficacy+in+the+treatment+of+patients+with+rheumatoid+arthritis+in+a+randomized%2C+double-blind+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleishaker%26aufirst%3DD.%2BL.%26aulast%3DGarcia%2BMeijide%26aufirst%3DJ.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DKohen%26aufirst%3DM.%2BD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DMebus%26aufirst%3DC.%2BA.%26aulast%3DGoodrich%26aufirst%3DJ.%2BM.%26aulast%3DMayer%26aufirst%3DH.%2BB.%26aulast%3DZeiher%26aufirst%3DB.%2BG.%26atitle%3DMaraviroc%252C%2520a%2520chemokine%2520receptor-5%2520antagonist%252C%2520fails%2520to%2520demonstrate%2520efficacy%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520rheumatoid%2520arthritis%2520in%2520a%2520randomized%252C%2520double-blind%2520placebo-controlled%2520trial%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2012%26volume%3D14%26spage%3DR11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group">Plater-Zyberk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogewerf, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Power, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, T. N.</span><span> </span><span class="NLM_article-title">Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice</span> <span class="citation_source-journal">Immunol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS0165-2478%2897%2900075-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=9232436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADyaK2sXksl2ns7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=117-120&author=C.+Plater-Zyberkauthor=A.+J.+Hoogewerfauthor=A.+E.+Proudfootauthor=C.+A.+Powerauthor=T.+N.+Wells&title=Effect+of+a+CC+chemokine+receptor+antagonist+on+collagen+induced+arthritis+in+DBA%2F1+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice</span></div><div class="casAuthors">Plater-Zyberk, Christine; Hoogewerf, Arlene J.; Proudfoot, Amanda E. I.; Power, Christine A.; Wells, Timothy N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">117-120</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Chemokines are small proteins that selectively activate and recruit leukocytes to sites of inflammation.  Several of them, including the CC chemokines, MIP-1Î±, MIP-1Î², MCP-1, and the CXC chemokines IL-8, GRO-Î±, ENA-78 have been identified in rheumatoid synovium, implicating a potential role for these mols. in rheumatoid arthritis.  We have investigated the expression patterns of CC chemokine receptors in the joints of mice with collagen-induced arthritis, a model for human rheumatoid arthritis.  In addn., we have investigated the incidence and severity of arthritis in mice receiving administration of MetRANTES, a modified chemokine which is a nanomolar antagonist of certain CC chemokine receptors.  The mRNA expression pattern of the chemokines and their receptors in the joints of arthritic mice was investigated using reverse transcriptase-PCR and in situ hybridization.  An upregulation of the CC chemokine receptors mCCR1, mCCR2, mCCR3 and mCCR5 was found in the joints from arthritic mice, compared to control animals.  In addn., injections of MetRANTES reduced the incidence of disease in a dose dependent manner.  Furthermore, in MetRANTES-treated mice that did develop arthritis a significantly lower severity of disease was obsd. compared with control animals.  Our data clearly demonstrate a role for CC chemokines and their receptors in inflammatory joint destruction and support the use of chemokine receptor antagonists as potential tools to control inflammatory diseases such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohSfRz-zJvBrVg90H21EOLACvtfcHk0lgUmnMvTckMPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksl2ns7k%253D&md5=1eb75a63bd534805d058f34eec462078</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2FS0165-2478%2897%2900075-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-2478%252897%252900075-8%26sid%3Dliteratum%253Aachs%26aulast%3DPlater-Zyberk%26aufirst%3DC.%26aulast%3DHoogewerf%26aufirst%3DA.%2BJ.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26aulast%3DPower%26aufirst%3DC.%2BA.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DEffect%2520of%2520a%2520CC%2520chemokine%2520receptor%2520antagonist%2520on%2520collagen%2520induced%2520arthritis%2520in%2520DBA%252F1%2520mice%26jtitle%3DImmunol.%2520Lett.%26date%3D1997%26volume%3D57%26spage%3D117%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group">Vierboom, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodny, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagat, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliese-Sivo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCombie, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celebi-Paul, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remarque, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, B.</span><span> </span><span class="NLM_article-title">Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">â</span> <span class="NLM_lpage">636</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2Fart.20850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15693002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Gjtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2005&pages=627-636&author=M.+P.+Vierboomauthor=P.+J.+Zavodnyauthor=C.+C.+Chouauthor=J.+R.+Tagatauthor=C.+Pugliese-Sivoauthor=J.+Strizkiauthor=R.+W.+Steensmaauthor=S.+W.+McCombieauthor=L.+Celebi-Paulauthor=E.+Remarqueauthor=M.+Jonkerauthor=S.+K.+Narulaauthor=B.+Hart&title=Inhibition+of+the+development+of+collagen-induced+arthritis+in+rhesus+monkeys+by+a+small+molecular+weight+antagonist+of+CCR5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5</span></div><div class="casAuthors">Vierboom, Michel P. M.; Zavodny, Paul J.; Chou, Chuan-Chu; Tagat, Jayaram R.; Pugliese-Sivo, Catherine; Strizki, Julie; Steensma, Ruo W.; McCombie, Stuart W.; Celebi-Paul, Liesbeth; Remarque, Ed; Jonker, Margreet; Narula, Satwant K.; 't Hart, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-636</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: Collagen-induced arthritis (CIA) in the rhesus monkey is a nonhuman primate model of rheumatoid arthritis (RA).  The close phylogenetic relationship between humans and the rhesus monkey makes this model useful for the preclin. safety and efficacy testing of new therapies that are inactive in animals more distinctly related to humans.  In this study, we tested the therapeutic potential of a novel, small mol. wt. antagonist of CCR5, SCH-X, in this model.  Methods: CIA was induced in 10 rhesus monkeys.  The animals were allocated to receive SCH-X or saline as the control (n = 5 in each group).  Treatment was initiated on the day of CIA induction and continued for 45 days.  Monkeys were monitored before and 63 days after CIA induction for macroscopic signs of clin. arthritis, such as soft-tissue swelling and body wt.  Furthermore, markers of inflammation and joint degrdn. were monitored to follow the disease course.  Results: Only 2 of 5 animals in the SCH-X-treated group displayed prominent soft-tissue swelling, compared with all 5 saline-treated monkeys.  In addn. to the suppression of joint inflammation, treatment with SCH-X resulted in a redn. in joint destruction, as demonstrated by lower rates of urinary excretion of collagen crosslinks, with confirmation by histol.  Whereas in all saline-treated monkeys, marked erosion of joint cartilage was obsd., this was absent in 4 of the 5 SCH-X-treated monkeys.  Conclusion: The systemic effects of treatment with SCH-X were a suppressed acute-phase reaction (redn. in C-reactive protein level) in the 3 treated monkeys with CIA that remained asymptomatic, and an altered antibody response toward type II collagen.  The results suggest that the CCR5 antagonist SCH-X might have a strong clin. potential for treatment during periods of active inflammation, as seen in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAV6q5T21UrLVg90H21EOLACvtfcHk0lgUmnMvTckMPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Gjtbg%253D&md5=ceb5108f15ff73ddfc114cd24880be91</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1002%2Fart.20850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.20850%26sid%3Dliteratum%253Aachs%26aulast%3DVierboom%26aufirst%3DM.%2BP.%26aulast%3DZavodny%26aufirst%3DP.%2BJ.%26aulast%3DChou%26aufirst%3DC.%2BC.%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DPugliese-Sivo%26aufirst%3DC.%26aulast%3DStrizki%26aufirst%3DJ.%26aulast%3DSteensma%26aufirst%3DR.%2BW.%26aulast%3DMcCombie%26aufirst%3DS.%2BW.%26aulast%3DCelebi-Paul%26aufirst%3DL.%26aulast%3DRemarque%26aufirst%3DE.%26aulast%3DJonker%26aufirst%3DM.%26aulast%3DNarula%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520the%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520rhesus%2520monkeys%2520by%2520a%2520small%2520molecular%2520weight%2520antagonist%2520of%2520CCR5%26jtitle%3DArthritis%2520Rheum.%26date%3D2005%26volume%3D52%26spage%3D627%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group">Yang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obika, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaoka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, H.</span><span> </span><span class="NLM_article-title">A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2124</span><span class="NLM_x">â</span> <span class="NLM_lpage">2132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=2124-2132&author=Y.+F.+Yangauthor=T.+Mukaiauthor=P.+Gaoauthor=N.+Yamaguchiauthor=S.+Onoauthor=H.+Iwakiauthor=S.+Obikaauthor=T.+Imanishiauthor=T.+Tsujimuraauthor=T.+Hamaokaauthor=H.+Fujiwara&title=A+non-peptide+CCR5+antagonist+inhibits+collagen-induced+arthritis+by+modulating+T+cell+migration+without+affecting+anti-collagen+T+cell+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DMukai%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DYamaguchi%26aufirst%3DN.%26aulast%3DOno%26aufirst%3DS.%26aulast%3DIwaki%26aufirst%3DH.%26aulast%3DObika%26aufirst%3DS.%26aulast%3DImanishi%26aufirst%3DT.%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DHamaoka%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DH.%26atitle%3DA%2520non-peptide%2520CCR5%2520antagonist%2520inhibits%2520collagen-induced%2520arthritis%2520by%2520modulating%2520T%2520cell%2520migration%2520without%2520affecting%2520anti-collagen%2520T%2520cell%2520responses%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26spage%3D2124%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group">Pokorny, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeoman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Highton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, L.</span><span> </span><span class="NLM_article-title">Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">4897</span><span class="NLM_x">â</span> <span class="NLM_lpage">490</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1136%2Fard.2004.023333" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4897-490&author=V.+Pokornyauthor=F.+McQueenauthor=S.+Yeomanauthor=M.+Merrimanauthor=T.+Merrimanauthor=A.+Harrisonauthor=J.+Hightonauthor=L.+McLean&title=Evidence+for+negative+association+of+the+chemokine+receptor+CCR5+d32+polymorphism+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.023333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.023333%26sid%3Dliteratum%253Aachs%26aulast%3DPokorny%26aufirst%3DV.%26aulast%3DMcQueen%26aufirst%3DF.%26aulast%3DYeoman%26aufirst%3DS.%26aulast%3DMerriman%26aufirst%3DM.%26aulast%3DMerriman%26aufirst%3DT.%26aulast%3DHarrison%26aufirst%3DA.%26aulast%3DHighton%26aufirst%3DJ.%26aulast%3DMcLean%26aufirst%3DL.%26atitle%3DEvidence%2520for%2520negative%2520association%2520of%2520the%2520chemokine%2520receptor%2520CCR5%2520d32%2520polymorphism%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2004%26volume%3D64%26spage%3D4897%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group">Bruhl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cihak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plachy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupp, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenzel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakarami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwart, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stangassinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlondorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, M.</span><span> </span><span class="NLM_article-title">Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">890</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2004&pages=890-898&author=H.+Bruhlauthor=J.+Cihakauthor=M.+A.+Schneiderauthor=J.+Plachyauthor=T.+Ruppauthor=I.+Wenzelauthor=M.+Shakaramiauthor=S.+Milzauthor=J.+W.+Ellwartauthor=M.+Stangassingerauthor=D.+Schlondorffauthor=M.+Mack&title=Dual+role+of+CCR2+during+initiation+and+progression+of+collagen-induced+arthritis%3A+evidence+for+regulatory+activity+of+CCR2%2B+T+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruhl%26aufirst%3DH.%26aulast%3DCihak%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%2BA.%26aulast%3DPlachy%26aufirst%3DJ.%26aulast%3DRupp%26aufirst%3DT.%26aulast%3DWenzel%26aufirst%3DI.%26aulast%3DShakarami%26aufirst%3DM.%26aulast%3DMilz%26aufirst%3DS.%26aulast%3DEllwart%26aufirst%3DJ.%2BW.%26aulast%3DStangassinger%26aufirst%3DM.%26aulast%3DSchlondorff%26aufirst%3DD.%26aulast%3DMack%26aufirst%3DM.%26atitle%3DDual%2520role%2520of%2520CCR2%2520during%2520initiation%2520and%2520progression%2520of%2520collagen-induced%2520arthritis%253A%2520evidence%2520for%2520regulatory%2520activity%2520of%2520CCR2%252B%2520T%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2004%26volume%3D172%26spage%3D890%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group">Lebre, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergunst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aarrass, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyant, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horuk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedquist, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21772&author=M.+C.+Lebreauthor=C.+E.+Vergunstauthor=I.+Y.+Choiauthor=S.+Aarrassauthor=A.+S.+Oliveiraauthor=T.+Wyantauthor=R.+Horukauthor=K.+A.+Reedquistauthor=P.+P.+Tak&title=Why+CCR2+and+CCR5+blockade+failed+and+why+CCR1+blockade+might+still+be+effective+in+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLebre%26aufirst%3DM.%2BC.%26aulast%3DVergunst%26aufirst%3DC.%2BE.%26aulast%3DChoi%26aufirst%3DI.%2BY.%26aulast%3DAarrass%26aufirst%3DS.%26aulast%3DOliveira%26aufirst%3DA.%2BS.%26aulast%3DWyant%26aufirst%3DT.%26aulast%3DHoruk%26aufirst%3DR.%26aulast%3DReedquist%26aufirst%3DK.%2BA.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DWhy%2520CCR2%2520and%2520CCR5%2520blockade%2520failed%2520and%2520why%2520CCR1%2520blockade%2520might%2520still%2520be%2520effective%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group">Flier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boorsma, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Beek, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieboer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoof, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tensen, C. P.</span><span> </span><span class="NLM_article-title">Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">â</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1002%2F1096-9896%28200108%29194%3A4%3C397%3A%3AAID-PATH899%3E3.0.CO%3B2-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=11523046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslWku70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2001&pages=398-405&author=J.+Flierauthor=D.+M.+Boorsmaauthor=P.+J.+van+Beekauthor=C.+Nieboerauthor=T.+J.+Stoofauthor=R.+Willemzeauthor=C.+P.+Tensen&title=Differential+expression+of+CXCR3+targeting+chemokines+CXCL10%2C+CXCL9%2C+and+CXCL11+in+different+types+of+skin+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation</span></div><div class="casAuthors">Flier, Jacoba; Boorsma, Dick M.; van Beek, Peter J.; Nieboer, Cees; Stoof, Tom J.; Willemze, Rein; Tensen, Comelis P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-405</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Recruitment of activated T-cells to the skin is a common feature in a wide variety of inflammatory skin diseases.  As CXCR3 activating chemokines CXCL10 (IP-10), CXCL9 (Mig), and CXCL11 (IP-9/I-TAC) specifically attract activated T-cells, this study addressed the question of whether differences in the expression of these chemokines correlate with the site and cellular compn. of the skin infiltrates in different types of inflammatory skin disease.  Skin biopsies from lichen planus, chronic discoid lupus erythematosus, allergic patch test reactions, psoriasis, and Jessner's lymphocytic infiltration of the skin were investigated for chemokine expression using RNA in situ hybridization, and for the expression of CXCR3 using immunohistochem.  The results showed differential expression of CXCL10, CXCL9, and CXCL11, which correlated with differences in the localization and cellular compn. of the infiltrates.  Whereas CXCL10 and CXCL11 were mainly expressed by basal keratinocytes, CXCL9 mRNA expression was located predominantly in the dermal infiltrates.  Correlation with immunohistochem. data suggested that macrophages and activated keratinocytes were the main producers of these chemokines.  CXCR3 was expressed by a majority of both CD4+ and CD8+ infiltrating T-cells, suggesting a functional interaction between locally produced chemokines and CXCR3-expressing T-cells.  In conclusion, these findings indicate that these CXCR3 activating chemokines play a significant role in the recruitment and maintenance of T-cell infiltrates in the inflammatory skin diseases studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo4eW7-3RwxLVg90H21EOLACvtfcHk0liRWwfu6N9KRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslWku70%253D&md5=796edd18e109b4ff5d8d2ebed5bcb8fc</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1002%2F1096-9896%28200108%29194%3A4%3C397%3A%3AAID-PATH899%3E3.0.CO%3B2-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1096-9896%2528200108%2529194%253A4%253C397%253A%253AAID-PATH899%253E3.0.CO%253B2-S%26sid%3Dliteratum%253Aachs%26aulast%3DFlier%26aufirst%3DJ.%26aulast%3DBoorsma%26aufirst%3DD.%2BM.%26aulast%3Dvan%2BBeek%26aufirst%3DP.%2BJ.%26aulast%3DNieboer%26aufirst%3DC.%26aulast%3DStoof%26aufirst%3DT.%2BJ.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DTensen%26aufirst%3DC.%2BP.%26atitle%3DDifferential%2520expression%2520of%2520CXCR3%2520targeting%2520chemokines%2520CXCL10%252C%2520CXCL9%252C%2520and%2520CXCL11%2520in%2520different%2520types%2520of%2520skin%2520inflammation%26jtitle%3DJ.%2520Pathol.%26date%3D2001%26volume%3D194%26spage%3D398%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group">Xie, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudgett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicker, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span> </span><span class="NLM_article-title">Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1189%2Fjlb.1102573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=12773510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFegtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2003&pages=771-780&author=J.+H.+Xieauthor=N.+Nomuraauthor=M.+Luauthor=S.+L.+Chenauthor=G.+E.+Kochauthor=Y.+Wengauthor=R.+Rosaauthor=J.+Di+Salvoauthor=J.+Mudgettauthor=L.+B.+Petersonauthor=L.+S.+Wickerauthor=J.+A.+DeMartino&title=Antibody-mediated+blockade+of+the+CXCR3+chemokine+receptor+results+in+diminished+recruitment+of+T+helper+1+cells+into+sites+of+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation</span></div><div class="casAuthors">Xie, Jenny H.; Nomura, Naomi; Lu, Min; Chen, Shiow-Ling; Koch, Greg E.; Weng, Youmin; Rosa, Raymond; Di Salvo, Jerry; Mudgett, John; Peterson, Laurence B.; Wicker, Linda S.; DeMartino, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">771-780</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Naive T cells, when activated by specific antigen and cytokines, up-regulate adhesion mols. as well as chemokine receptors on their surface, which allows them to migrate to inflamed tissues.  Human studies have shown that CXCR3 is one of the chemokine receptors that is induced during T cell activation.  Moreover, CXCR3-pos. T cells are enriched at inflammatory sites in patients with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.  In this study, we use a mouse model of inflammation to demonstrate that CXCR3 is required for activated T cell transmigration to inflamed tissue.  Using an anti- mCXCR3 antibody, we have shown that in vitro-differentiated Th1 and Th2 cells up-regulated CXCR3 upon stimulation with specific antigen/major histocompatibility complex.  However, only Th1 cells, when adoptively transferred to syngeneic recipients, are efficiently recruited to the peritoneum in an adjuvant-induced peritonitis model.  Furthermore, the neutralizing anti-mCXCR3 antibody profoundly inhibits the recruitment of Th1 cells to the inflamed peritoneum.  Real-time, quant. reverse transcriptase-polymerase chain reaction anal. demonstrates that the CXCR3 ligands, interferon (IFN)-inducible protein 10 (CXCL10) and IFN-inducible T cell Î± chemoattractant (CXCL11), are among the many chemokines induced in the adjuvant-treated peritoneum.  The anti-mCXCR3 antibody is also effective in inhibiting a delayed-type hypersensitivity response, which is largely mediated by enhanced trafficking of activated T cells to peripheral inflammatory sites.  Collectively, our results suggest that CXCR3 has a crit. role in T cell transmigration to sites of inflammation and thus, may serve as a mol. target for anti-inflammatory therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr3rVCjsbnBbVg90H21EOLACvtfcHk0lhy-fU7zmHeOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFegtro%253D&md5=8aece82b771041b3cf858f943ce7d3c6</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1102573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1102573%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%2BL.%26aulast%3DKoch%26aufirst%3DG.%2BE.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DRosa%26aufirst%3DR.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DMudgett%26aufirst%3DJ.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DWicker%26aufirst%3DL.%2BS.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26atitle%3DAntibody-mediated%2520blockade%2520of%2520the%2520CXCR3%2520chemokine%2520receptor%2520results%2520in%2520diminished%2520recruitment%2520of%2520T%2520helper%25201%2520cells%2520into%2520sites%2520of%2520inflammation%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2003%26volume%3D73%26spage%3D771%26epage%3D780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group">Hancock, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csizmadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C.</span><span> </span><span class="NLM_article-title">Requirement of the chemokine receptor CXCR3 for acute allograft rejection</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">1515</span><span class="NLM_x">â</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1515-1520&author=W.+W.+Hancockauthor=B.+Luauthor=W.+Gaoauthor=V.+Csizmadiaauthor=K.+Faiaauthor=J.+A.+Kingauthor=S.+T.+Smileyauthor=M.+Lingauthor=N.+P.+Gerardauthor=C.+Gerard&title=Requirement+of+the+chemokine+receptor+CXCR3+for+acute+allograft+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DFaia%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DJ.%2BA.%26aulast%3DSmiley%26aufirst%3DS.%2BT.%26aulast%3DLing%26aufirst%3DM.%26aulast%3DGerard%26aufirst%3DN.%2BP.%26aulast%3DGerard%26aufirst%3DC.%26atitle%3DRequirement%2520of%2520the%2520chemokine%2520receptor%2520CXCR3%2520for%2520acute%2520allograft%2520rejection%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1515%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group">Clark, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupper, T. S.</span><span> </span><span class="NLM_article-title">Misbehaving macrophages in the pathogenesis of psoriasis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2084</span><span class="NLM_x">â</span> <span class="NLM_lpage">2087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2084-2087&author=R.+A.+Clarkauthor=T.+S.+Kupper&title=Misbehaving+macrophages+in+the+pathogenesis+of+psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DR.%2BA.%26aulast%3DKupper%26aufirst%3DT.%2BS.%26atitle%3DMisbehaving%2520macrophages%2520in%2520the%2520pathogenesis%2520of%2520psoriasis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2084%26epage%3D2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lhy-fU7zmHeOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">â</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lj5ZjUD7Y-z4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group">Bymaster, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calligaro, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tye, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D. T.</span><span> </span><span class="NLM_article-title">Radioreceptor binding profile of the atypical antipsychotic olanzapine</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">â</span> <span class="NLM_lpage">96</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=87-96&author=F.+P.+Bymasterauthor=D.+O.+Calligaroauthor=J.+F.+Falconeauthor=R.+D.+Marshauthor=N.+A.+Mooreauthor=N.+C.+Tyeauthor=P.+Seemanauthor=D.+T.+Wong&title=Radioreceptor+binding+profile+of+the+atypical+antipsychotic+olanzapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DR.%2BD.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DTye%26aufirst%3DN.%2BC.%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DD.%2BT.%26atitle%3DRadioreceptor%2520binding%2520profile%2520of%2520the%2520atypical%2520antipsychotic%2520olanzapine%26jtitle%3DNeuropsychopharmacology%26date%3D1996%26volume%3D14%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group">Naya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, N.</span><span> </span><span class="NLM_article-title">Structureâactivity relationships of 2-(benzothiazolylthio)acetamide class of CCR3 selective antagonist</span> <span class="citation_source-journal">Chem. Pharm. Bull. (Tokyo)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">â</span> <span class="NLM_lpage">701</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=697-701&author=A.+Nayaauthor=K.+Kobayashiauthor=M.+Ishikawaauthor=K.+Ohwakiauthor=T.+Saekiauthor=K.+Noguchiauthor=N.+Ohtake&title=Structure%E2%80%93activity+relationships+of+2-%28benzothiazolylthio%29acetamide+class+of+CCR3+selective+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaya%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DOhwaki%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DOhtake%26aufirst%3DN.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%25202-%2528benzothiazolylthio%2529acetamide%2520class%2520of%2520CCR3%2520selective%2520antagonist%26jtitle%3DChem.%2520Pharm.%2520Bull.%2520%2528Tokyo%2529%26date%3D2003%26volume%3D51%26spage%3D697%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group">Sabroe, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Keulen, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorritsma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapham, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, J. E.</span><span> </span><span class="NLM_article-title">A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">25985</span><span class="NLM_x">â</span> <span class="NLM_lpage">25992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=25985-25992&author=I.+Sabroeauthor=M.+J.+Peckauthor=B.+J.+Van+Keulenauthor=A.+Jorritsmaauthor=G.+Simmonsauthor=P.+R.+Claphamauthor=T.+J.+Williamsauthor=J.+E.+Pease&title=A+small+molecule+antagonist+of+chemokine+receptors+CCR1+and+CCR3.+Potent+inhibition+of+eosinophil+function+and+CCR3-mediated+HIV-1+entry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSabroe%26aufirst%3DI.%26aulast%3DPeck%26aufirst%3DM.%2BJ.%26aulast%3DVan%2BKeulen%26aufirst%3DB.%2BJ.%26aulast%3DJorritsma%26aufirst%3DA.%26aulast%3DSimmons%26aufirst%3DG.%26aulast%3DClapham%26aufirst%3DP.%2BR.%26aulast%3DWilliams%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DJ.%2BE.%26atitle%3DA%2520small%2520molecule%2520antagonist%2520of%2520chemokine%2520receptors%2520CCR1%2520and%2520CCR3.%2520Potent%2520inhibition%2520of%2520eosinophil%2520function%2520and%2520CCR3-mediated%2520HIV-1%2520entry%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D25985%26epage%3D25992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group">Naya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, N.</span><span> </span><span class="NLM_article-title">Discovery of a novel CCR3 selective antagonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">â</span> <span class="NLM_lpage">1223</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1219-1223&author=A.+Nayaauthor=K.+Kobayashiauthor=M.+Ishikawaauthor=K.+Ohwakiauthor=T.+Saekiauthor=K.+Noguchiauthor=N.+Ohtake&title=Discovery+of+a+novel+CCR3+selective+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaya%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DOhwaki%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DOhtake%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520CCR3%2520selective%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1219%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group">Seto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aramaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuze, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iizawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraishi, M.</span><span> </span><span class="NLM_article-title">Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2037</span><span class="NLM_x">â</span> <span class="NLM_lpage">2048</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0509703" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVCjsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2037-2048&author=M.+Setoauthor=K.+Aikawaauthor=N.+Miyamotoauthor=Y.+Aramakiauthor=N.+Kanzakiauthor=K.+Takashimaauthor=Y.+Kuzeauthor=Y.+Iizawaauthor=M.+Babaauthor=M.+Shiraishi&title=Highly+potent+and+orally+active+CCR5+antagonists+as+anti-HIV-1+agents%3A+synthesis+and+biological+activities+of+1-benzazocine+derivatives+containing+a+sulfoxide+moiety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent and Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activities of 1-Benzazocine Derivatives Containing a Sulfoxide Moiety</span></div><div class="casAuthors">Seto, Masaki; Aikawa, Katsuji; Miyamoto, Naoki; Aramaki, Yoshio; Kanzaki, Naoyuki; Takashima, Katsunori; Kuze, Yoji; Iizawa, Yuji; Baba, Masanori; Shiraishi, Mitsuru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2037-2048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. modification was performed on the orally bioavailable and potent CCR5 antagonist sulfoxide compd. I, mainly focusing on replacement of the [6,7]-fused 1-benzazepine nucleus.  Ring-expanded [6,8]-, [6,9]-, and [6,10]-fused compds. contg. S-sulfoxide moieties were prepd. and evaluated for biol. activities which led to 1-benzazocine and 1-benzazonine compds. that exhibited potent inhibitory activities.  1-Benzazocine compds. possessing the S-sulfoxide moiety showed greater potency than I in a fusion assay.  Further investigation in a multi-round infection assay showed that the 1-isobutyl-1-benzazocine compd. II, contg. the S-[[(1-propyl-1H-imidazol)-5-yl]methyl]sulfinyl group, showed the most potent anti-HIV-1 activity.  II (TAK-652) also inhibited the replication of six macrophage-tropic HIV-1 clin. isolates in peripheral blood mononuclear cells.  It was also absorbed after oral administration in rats, dogs, and monkeys and was thus selected as a clin. candidate.  The synthesis and biol. activity of II and derivs. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6VVfNAhytC7Vg90H21EOLACvtfcHk0lj5ZjUD7Y-z4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVCjsrY%253D&md5=e579dea40031ca3ac3d7b2d96875ab4c</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1021%2Fjm0509703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0509703%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DAikawa%26aufirst%3DK.%26aulast%3DMiyamoto%26aufirst%3DN.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTakashima%26aufirst%3DK.%26aulast%3DKuze%26aufirst%3DY.%26aulast%3DIizawa%26aufirst%3DY.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShiraishi%26aufirst%3DM.%26atitle%3DHighly%2520potent%2520and%2520orally%2520active%2520CCR5%2520antagonists%2520as%2520anti-HIV-1%2520agents%253A%2520synthesis%2520and%2520biological%2520activities%2520of%25201-benzazocine%2520derivatives%2520containing%2520a%2520sulfoxide%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2037%26epage%3D2048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group">Hersperger, R.; Janser, P.; Pfenninger, E.; Wuethrich, H. J.; Miltz, W.</span><span> </span><span class="NLM_article-title">Chemokine Receptor Antagonists</span>. US 20070155721,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=R.+Hersperger&author=P.+Janser&author=E.+Pfenninger&author=H.+J.+Wuethrich&author=W.+Miltz&title=Chemokine+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHersperger%26aufirst%3DR.%26atitle%3DChemokine%2520Receptor%2520Antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group">Cole, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasiliou, S.</span><span> </span><span class="NLM_article-title">Highlights from the 50th interscience conference on anti-microbial agents and chemotherapy (ICAAC)</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">â</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1358%2Fdof.2010.035.012.1583180" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=1045-1067&author=P.+Coleauthor=S.+Vasiliou&title=Highlights+from+the+50th+interscience+conference+on+anti-microbial+agents+and+chemotherapy+%28ICAAC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1358%2Fdof.2010.035.012.1583180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2010.035.012.1583180%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DP.%26aulast%3DVasiliou%26aufirst%3DS.%26atitle%3DHighlights%2520from%2520the%252050th%2520interscience%2520conference%2520on%2520anti-microbial%2520agents%2520and%2520chemotherapy%2520%2528ICAAC%2529%26jtitle%3DDrugs%2520Future%26date%3D2010%26volume%3D35%26spage%3D1045%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group">Walters, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cage, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grahames, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, R.</span><span> </span><span class="NLM_article-title">Evaluation of a series of bicyclic CXCR2 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">798</span><span class="NLM_x">â</span> <span class="NLM_lpage">803</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=798-803&author=I.+Waltersauthor=C.+Austinauthor=R.+Austinauthor=R.+Bonnertauthor=P.+Cageauthor=M.+Christieauthor=M.+Ebdenauthor=S.+Gardinerauthor=C.+Grahamesauthor=S.+Hillauthor=F.+Huntauthor=R.+Jewellauthor=S.+Lewisauthor=I.+Martinauthor=N.+Davidauthor=R.+David&title=Evaluation+of+a+series+of+bicyclic+CXCR2+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DAustin%26aufirst%3DR.%26aulast%3DBonnert%26aufirst%3DR.%26aulast%3DCage%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DEbden%26aufirst%3DM.%26aulast%3DGardiner%26aufirst%3DS.%26aulast%3DGrahames%26aufirst%3DC.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DI.%26aulast%3DDavid%26aufirst%3DN.%26aulast%3DDavid%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520a%2520series%2520of%2520bicyclic%2520CXCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D798%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group">Suzuki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morokata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morihira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takizawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, Y.</span><span> </span><span class="NLM_article-title">A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">563</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1016%2Fj.ejphar.2007.01.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=17336292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksV2ktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=563&publication_year=2007&pages=224-232&author=K.+Suzukiauthor=T.+Morokataauthor=K.+Morihiraauthor=I.+Satoauthor=S.+Takizawaauthor=M.+Kanekoauthor=K.+Takahashiauthor=Y.+Shimizu&title=A+dual+antagonist+for+chemokine+CCR3+receptor+and+histamine+H1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor</span></div><div class="casAuthors">Suzuki, Keiko; Morokata, Tatsuaki; Morihira, Koichiro; Sato, Ippei; Takizawa, Satoko; Kaneko, Masayuki; Takahashi, Koichiro; Shimizu, Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">563</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">224-232</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Eosinophilic chemokines and histamine play distinct but important roles in allergic diseases.  Inhibition of both eosinophilic chemokines and histamine, therefore, is an ideal strategy for the treatment of allergic inflammation, such as asthma, allergic rhinitis, and atopic dermatitis.  YM-344484 was found to potently inhibit both the CCL11-induced Ca2+ influx in human CCR3-expressing cells (Kb = 1.8 nM) and histamine-induced Ca2+ influx in histamine H1 receptor-expressing PC3 cells (Kb = 47 nM).  YM-344484 also inhibited the CCL11-induced chemotaxis of human CCR3-expressing cells (IC50 = 6.2 nM) and CCL11-induced eosinophil-derived neurotoxin release from human eosinophils (IC50 = 19 nM).  Orally administered YM-344484 inhibited the increase in histamine-induced vascular permeability in mice (82% inhibition at a dose of 10 mg/kg) and the accumulation of eosinophils in a mouse asthma model (74% at a dose of 300 mg/kg).  These results indicate that YM-344484, a novel and functional dual antagonist for chemokine CCR3 receptor and histamine H1 receptor, is an attractive candidate for development as a novel anti-allergic inflammation drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRXmYzSP8LcbVg90H21EOLACvtfcHk0lgki8ACWChg1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksV2ktLw%253D&md5=9ee198a3dfca217f9a738d392a6d8ab4</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2007.01.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2007.01.074%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMorokata%26aufirst%3DT.%26aulast%3DMorihira%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DI.%26aulast%3DTakizawa%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DY.%26atitle%3DA%2520dual%2520antagonist%2520for%2520chemokine%2520CCR3%2520receptor%2520and%2520histamine%2520H1%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D563%26spage%3D224%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group">Melancon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmitte, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niswender, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">â</span> <span class="NLM_lpage">1464</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201139r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SmurnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1445-1464&author=B.+J.+Melanconauthor=C.+R.+Hopkinsauthor=M.+R.+Woodauthor=K.+A.+Emmitteauthor=C.+M.+Niswenderauthor=A.+Christopoulosauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Allosteric+modulation+of+seven+transmembrane+spanning+receptors%3A+theory%2C+practice%2C+and+opportunities+for+central+nervous+system+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery</span></div><div class="casAuthors">Melancon, Bruce J.; Hopkins, Corey R.; Wood, Michael R.; Emmitte, Kyle A.; Niswender, Colleen M.; Christopoulos, Arthur; Conn, P. Jeffrey; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1445-1464</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of Seven transmembrane spanning receptors and the opportunities for CNS drug discovery is reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlr4lj_Wp-O7Vg90H21EOLACvtfcHk0lgki8ACWChg1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SmurnJ&md5=7c70f066f1581f1ff327c0dce37bb0e1</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1021%2Fjm201139r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201139r%26sid%3Dliteratum%253Aachs%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DAllosteric%2520modulation%2520of%2520seven%2520transmembrane%2520spanning%2520receptors%253A%2520theory%252C%2520practice%252C%2520and%2520opportunities%2520for%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1445%26epage%3D1464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group">Schnickel, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shefizadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishbein, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belperio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardehali, A.</span><span> </span><span class="NLM_article-title">Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">4714</span><span class="NLM_x">â</span> <span class="NLM_lpage">4721</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=4714-4721&author=G.+T.+Schnickelauthor=S.+Bastaniauthor=G.+R.+Hsiehauthor=A.+Shefizadehauthor=R.+Bhatiaauthor=M.+C.+Fishbeinauthor=J.+Belperioauthor=A.+Ardehali&title=Combined+CXCR3%2FCCR5+blockade+attenuates+acute+and+chronic+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchnickel%26aufirst%3DG.%2BT.%26aulast%3DBastani%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DG.%2BR.%26aulast%3DShefizadeh%26aufirst%3DA.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DFishbein%26aufirst%3DM.%2BC.%26aulast%3DBelperio%26aufirst%3DJ.%26aulast%3DArdehali%26aufirst%3DA.%26atitle%3DCombined%2520CXCR3%252FCCR5%2520blockade%2520attenuates%2520acute%2520and%2520chronic%2520rejection%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D4714%26epage%3D4721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faia, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csizmadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danoff, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span> </span><span class="NLM_article-title">Beneficial effects of targeting CCR5 in allograft recipients</span> <span class="citation_source-journal">Transplantation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1199</span><span class="NLM_x">â</span> <span class="NLM_lpage">1205</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2001&pages=1199-1205&author=W.+Gaoauthor=K.+L.+Faiaauthor=V.+Csizmadiaauthor=S.+T.+Smileyauthor=D.+Solerauthor=J.+A.+Kingauthor=T.+M.+Danoffauthor=W.+W.+Hancock&title=Beneficial+effects+of+targeting+CCR5+in+allograft+recipients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26aulast%3DFaia%26aufirst%3DK.%2BL.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DS.%2BT.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DJ.%2BA.%26aulast%3DDanoff%26aufirst%3DT.%2BM.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26atitle%3DBeneficial%2520effects%2520of%2520targeting%2520CCR5%2520in%2520allograft%2520recipients%26jtitle%3DTransplantation%26date%3D2001%26volume%3D72%26spage%3D1199%26epage%3D1205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vergis, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosin, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, C. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusa, M. D.</span><span> </span><span class="NLM_article-title">The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemiaâreperfusion injury</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1526</span><span class="NLM_x">â</span> <span class="NLM_lpage">1537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fki.2008.500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=18843253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVajtrbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1526-1537&author=L.+Liauthor=L.+Huangauthor=S.+S.+Sungauthor=A.+L.+Vergisauthor=D.+L.+Rosinauthor=C.+E.+Roseauthor=P.+I.+Loboauthor=M.+D.+Okusa&title=The+chemokine+receptors+CCR2+and+CX3CR1+mediate+monocyte%2Fmacrophage+trafficking+in+kidney+ischemia%E2%80%93reperfusion+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury</span></div><div class="casAuthors">Li, Li; Huang, Liping; Sung, Sun-Sang J.; Vergis, Amy L.; Rosin, Diane L.; Rose, C. Edward, Jr.; Lobo, Peter I.; Okusa, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1526-1537</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chemokines and their receptors such as CCR2 and CX3CR1 mediate leukocyte adhesion and migration into injured tissue.  To further define mechanisms of monocyte trafficking during kidney injury we identified two groups of F4/80-pos. cells (F4/80low and F4/80high) in the normal mouse kidney that phenotypically correspond to macrophages and dendritic cells, resp.  Following ischemia and 3 h of reperfusion, there was a large influx of F4/80low inflamed monocytes, but not dendritic cells, into the kidney.  These monocytes produced TNF-Î±, IL-6, IL-1Î± and IL-12.  Ischemic injury induced in CCR2-/- mice or in CCR2+/+ mice, made chimeric with CCR2-/- bone marrow, resulted in lower plasma creatinine levels and their kidneys had fewer infiltrated F4/80low macrophages compared to control mice.  CX3CR1 expression contributed to monocyte recruitment into inflamed kidneys, as ischemic injury in CX3CR1-/- mice was reduced, with fewer F4/80low macrophages than controls.  Monocytes transferred from CCR2+/+ or CX3CR1+/- mice migrated into reperfused kidneys better than monocytes from either CCR2-/- or CX3CR1-/- mice.  Adoptive transfer of monocytes from CCR2+/+ mice, but not CCR2-/- mice, reversed the protective effect in CCR2-/- mice following ischemia-reperfusion.  Egress of CD11b+Ly6Chigh monocytes from blood into inflamed kidneys was CCR2- and CX3CR1-dependent.  Our study shows that inflamed monocyte migration, through CCR2- and CX3CR1-dependent mechanisms, plays a crit. role in kidney injury following ischemia reperfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcUXO2HFE4q7Vg90H21EOLACvtfcHk0lhZ87sp3r14lA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVajtrbF&md5=1316985a3b7692ee0efbef19ecf2834d</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1038%2Fki.2008.500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2008.500%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DSung%26aufirst%3DS.%2BS.%26aulast%3DVergis%26aufirst%3DA.%2BL.%26aulast%3DRosin%26aufirst%3DD.%2BL.%26aulast%3DRose%26aufirst%3DC.%2BE.%26aulast%3DLobo%26aufirst%3DP.%2BI.%26aulast%3DOkusa%26aufirst%3DM.%2BD.%26atitle%3DThe%2520chemokine%2520receptors%2520CCR2%2520and%2520CX3CR1%2520mediate%2520monocyte%252Fmacrophage%2520trafficking%2520in%2520kidney%2520ischemia%25E2%2580%2593reperfusion%2520injury%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D74%26spage%3D1526%26epage%3D1537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group">Jerath, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, A. M.</span><span> </span><span class="NLM_article-title">Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation</span> <span class="citation_source-journal">Thromb. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1186%2F1477-9560-8-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=20836883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A280%3ADC%252BC3cfkvFGisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=14&author=M.+R.+Jerathauthor=P.+Liuauthor=M.+Struthersauthor=J.+A.+Demartinoauthor=R.+Pengauthor=L.+B.+Petersonauthor=A.+M.+Cumiskeyauthor=L.+Yangauthor=M.+Rojasauthor=D.+D.+Patelauthor=A.+M.+Fong&title=Dual+targeting+of+CCR2+and+CX3CR1+in+an+arterial+injury+model+of+vascular+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation</span></div><div class="casAuthors">Jerath Maya R; Liu Peng; Struthers Mary; Demartino Julie A; Peng Roche; Peterson Laurence B; Cumiskey Anne-Marie; Yang Lihu; Rojas Mauricio; Patel Dhavalkumar D; Fong Alan M</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The chemokine receptors CCR2 and CX3CR1 are important in the development of coronary artery disease.  The purpose of this study is to analyze the effect of a novel CCR2 inhibitor in conjunction with CX3CR1 deletion on vascular inflammation.  METHODS:  The novel CCR2 antagonist MRL-677 was characterized using an in vivo model of monocyte migration.  To determine the relative roles of CCR2 and CX3CR1 in vascular remodeling, normal or CX3CR1 deficient mice were treated with MRL-677.  After 14 days, the level of intimal hyperplasia in the artery was visualized by paraffin sectioning and histology of the hind limbs.  RESULTS:  MRL-677 is a CCR2 antagonist that is effective in blocking macrophage trafficking in a peritoneal thioglycollate model.  Intimal hyperplasia resulting from vascular injury was also assessed in mice.  Based on the whole-blood potency of MRL-677, sufficient drug levels were maintained for the entire 14 day experimental period to afford good coverage of mCCR2 with MRL-677.  Blocking CCR2 with MRL-677 resulted in a 56% decrease in the vascular injury response (n = 9, p < 0.05) in normal animals.  Mice in which both CCR2 and CX3CR1 pathways were targeted (CX3CR1 KO mice given MRL-677) had an 88% decrease in the injury response (n = 6, p = 0.009).  CONCLUSION:  In this study we have shown that blocking CCR2 with a low molecular weight antagonist ameliorates the inflammatory response to vascular injury.  The protective effect of CCR2 blockade is increased in the presence of CX3CR1 deficiency suggesting that CX3CR1 and CCR2 have non-redundant functions in the progression of vascular inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC23SCD_Mi61MGsG_HTXYFfW6udTcc2eYokRf6kDnan7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cfkvFGisg%253D%253D&md5=0c48415369f27e5edbaa099293da04fb</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1186%2F1477-9560-8-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1477-9560-8-14%26sid%3Dliteratum%253Aachs%26aulast%3DJerath%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DDemartino%26aufirst%3DJ.%2BA.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DRojas%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DD.%2BD.%26aulast%3DFong%26aufirst%3DA.%2BM.%26atitle%3DDual%2520targeting%2520of%2520CCR2%2520and%2520CX3CR1%2520in%2520an%2520arterial%2520injury%2520model%2520of%2520vascular%2520inflammation%26jtitle%3DThromb.%2520J.%26date%3D2010%26volume%3D8%26spage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span>BusinessWire. Ligand Licenses DARA Program to Retrophin. <a href="http://www.businesswire.com/news/home/20120221005513/en/Ligand-Licenses-DARA-Program-Retrophin" class="extLink">http://www.businesswire.com/news/home/20120221005513/en/Ligand-Licenses-DARA-Program-Retrophin</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BusinessWire.+Ligand+Licenses+DARA+Program+to+Retrophin.+http%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20120221005513%2Fen%2FLigand-Licenses-DARA-Program-Retrophin."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group">Ohshima, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harakawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span> </span><span class="NLM_article-title">Dibenz[<i>b</i>,<i>e</i>]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">â</span> <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00055a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=417-420&author=E.+Ohshimaauthor=H.+Takamiauthor=H.+Harakawaauthor=H.+Satoauthor=H.+Obaseauthor=I.+Mikiauthor=A.+Ishiiauthor=H.+Ishiiauthor=Y.+Sasakiauthor=K.+Ohmoriauthor=A.+Karasawaauthor=K.+Kubo&title=Dibenz%5Bb%2Ce%5Doxepin+derivatives%3A+novel+antiallergic+agents+possessing+thromboxane+A2+and+histamine+H1+dual+antagonizing+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1021%2Fjm00055a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00055a013%26sid%3Dliteratum%253Aachs%26aulast%3DOhshima%26aufirst%3DE.%26aulast%3DTakami%26aufirst%3DH.%26aulast%3DHarakawa%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DObase%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DI.%26aulast%3DIshii%26aufirst%3DA.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DOhmori%26aufirst%3DK.%26aulast%3DKarasawa%26aufirst%3DA.%26aulast%3DKubo%26aufirst%3DK.%26atitle%3DDibenz%255Bb%252Ce%255Doxepin%2520derivatives%253A%2520novel%2520antiallergic%2520agents%2520possessing%2520thromboxane%2520A2%2520and%2520histamine%2520H1%2520dual%2520antagonizing%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D417%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group">Schall, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, A. E.</span><span> </span><span class="NLM_article-title">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">â</span> <span class="NLM_lpage">363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fnri2972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=21494268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=355-363&author=T.+J.+Schallauthor=A.+E.+Proudfoot&title=Overcoming+hurdles+in+developing+successful+drugs+targeting+chemokine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming hurdles in developing successful drugs targeting chemokine receptors</span></div><div class="casAuthors">Schall, Thomas J.; Proudfoot, Amanda E. I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-363</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokines and their receptors are central to the inflammatory process and are attractive therapeutic targets.  Drugs that inhibit chemokine receptors are approved for the treatment of HIV infection and for stem cell mobilization, but none have been approved yet for the treatment of inflammatory and/or autoimmune diseases.  We analyze the challenges of developing chemokine receptor antagonists, and propose that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies.  We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJxZhyoAteTLVg90H21EOLACvtfcHk0lgk-UrzB7CjGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCmtb0%253D&md5=3173fc889bd22b7d7e19bd138a599897</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1038%2Fnri2972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2972%26sid%3Dliteratum%253Aachs%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26aulast%3DProudfoot%26aufirst%3DA.%2BE.%26atitle%3DOvercoming%2520hurdles%2520in%2520developing%2520successful%2520drugs%2520targeting%2520chemokine%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2011%26volume%3D11%26spage%3D355%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group">OâBoyle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willet, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavin, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hine, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, J. A.</span><span> </span><span class="NLM_article-title">Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4598</span><span class="NLM_x">â</span> <span class="NLM_lpage">4603</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=4598-4603&author=G.+O%E2%80%99Boyleauthor=C.+R.+Foxauthor=H.+R.+Waldenauthor=J.+D.+Willetauthor=E.+R.+Mavinauthor=D.+W.+Hineauthor=J.+M.+Palmerauthor=C.+E.+Barkerauthor=C.+A.+Lambauthor=S.+Aliauthor=J.+A.+Kirby&title=Chemokine+receptor+CXCR3+agonist+prevents+human+T-cell+migration+in+a+humanized+model+of+arthritic+inflammation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DG.%26aulast%3DFox%26aufirst%3DC.%2BR.%26aulast%3DWalden%26aufirst%3DH.%2BR.%26aulast%3DWillet%26aufirst%3DJ.%2BD.%26aulast%3DMavin%26aufirst%3DE.%2BR.%26aulast%3DHine%26aufirst%3DD.%2BW.%26aulast%3DPalmer%26aufirst%3DJ.%2BM.%26aulast%3DBarker%26aufirst%3DC.%2BE.%26aulast%3DLamb%26aufirst%3DC.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DKirby%26aufirst%3DJ.%2BA.%26atitle%3DChemokine%2520receptor%2520CXCR3%2520agonist%2520prevents%2520human%2520T-cell%2520migration%2520in%2520a%2520humanized%2520model%2520of%2520arthritic%2520inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D4598%26epage%3D4603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group">Takeda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffi, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nozaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albuquerque, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dridi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisler, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geisen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munitz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambati, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishibashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbles, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grisanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartnett, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambati, J.</span><span> </span><span class="NLM_article-title">CCR3 is a target for age-related macular degeneration diagnosis and therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">460</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">â</span> <span class="NLM_lpage">230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=460&publication_year=2009&pages=225-230&author=A.+Takedaauthor=J.+Z.+Baffiauthor=M.+E.+Kleinmanauthor=W.+G.+Choauthor=M.+Nozakiauthor=K.+Yamadaauthor=H.+Kanekoauthor=R.+J.+Albuquerqueauthor=S.+Dridiauthor=K.+Saitoauthor=B.+J.+Raislerauthor=S.+J.+Buddauthor=P.+Geisenauthor=A.+Munitzauthor=B.+K.+Ambatiauthor=M.+G.+Greenauthor=T.+Ishibashiauthor=J.+D.+Wrightauthor=A.+A.+Humblesauthor=C.+J.+Gerardauthor=Y.+Oguraauthor=Y.+Panauthor=J.+R.+Smithauthor=S.+Grisantiauthor=M.+E.+Hartnettauthor=M.+E.+Rothenbergauthor=J.+Ambati&title=CCR3+is+a+target+for+age-related+macular+degeneration+diagnosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DA.%26aulast%3DBaffi%26aufirst%3DJ.%2BZ.%26aulast%3DKleinman%26aufirst%3DM.%2BE.%26aulast%3DCho%26aufirst%3DW.%2BG.%26aulast%3DNozaki%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DAlbuquerque%26aufirst%3DR.%2BJ.%26aulast%3DDridi%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DRaisler%26aufirst%3DB.%2BJ.%26aulast%3DBudd%26aufirst%3DS.%2BJ.%26aulast%3DGeisen%26aufirst%3DP.%26aulast%3DMunitz%26aufirst%3DA.%26aulast%3DAmbati%26aufirst%3DB.%2BK.%26aulast%3DGreen%26aufirst%3DM.%2BG.%26aulast%3DIshibashi%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DJ.%2BD.%26aulast%3DHumbles%26aufirst%3DA.%2BA.%26aulast%3DGerard%26aufirst%3DC.%2BJ.%26aulast%3DOgura%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DGrisanti%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DM.%2BE.%26aulast%3DRothenberg%26aufirst%3DM.%2BE.%26aulast%3DAmbati%26aufirst%3DJ.%26atitle%3DCCR3%2520is%2520a%2520target%2520for%2520age-related%2520macular%2520degeneration%2520diagnosis%2520and%2520therapy%26jtitle%3DNature%26date%3D2009%26volume%3D460%26spage%3D225%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group">Villeda, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosher, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britschgi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fainberg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucin, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czirr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couillard-Despres, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aigner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peskind, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasko, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rando, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss-Coray, T.</span><span> </span><span class="NLM_article-title">The ageing systemic milieu negatively regulates neurogenesis and cognitive function</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">477</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">â</span> <span class="NLM_lpage">94</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=90-94&author=S.+A.+Villedaauthor=J.+Luoauthor=K.+I.+Mosherauthor=B.+Zouauthor=M.+Britschgiauthor=G.+Bieriauthor=T.+M.+Stanauthor=N.+Fainbergauthor=Z.+Dingauthor=A.+Eggelauthor=K.+M.+Lucinauthor=E.+Czirrauthor=J.+S.+Parkauthor=S.+Couillard-Despresauthor=L.+Aignerauthor=G.+Liauthor=E.+R.+Peskindauthor=J.+A.+Kayeauthor=J.+F.+Quinnauthor=D.+R.+Galaskoauthor=X.+S.+Xieauthor=T.+A.+Randoauthor=T.+Wyss-Coray&title=The+ageing+systemic+milieu+negatively+regulates+neurogenesis+and+cognitive+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilleda%26aufirst%3DS.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMosher%26aufirst%3DK.%2BI.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DBritschgi%26aufirst%3DM.%26aulast%3DBieri%26aufirst%3DG.%26aulast%3DStan%26aufirst%3DT.%2BM.%26aulast%3DFainberg%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DEggel%26aufirst%3DA.%26aulast%3DLucin%26aufirst%3DK.%2BM.%26aulast%3DCzirr%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DCouillard-Despres%26aufirst%3DS.%26aulast%3DAigner%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPeskind%26aufirst%3DE.%2BR.%26aulast%3DKaye%26aufirst%3DJ.%2BA.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DGalasko%26aufirst%3DD.%2BR.%26aulast%3DXie%26aufirst%3DX.%2BS.%26aulast%3DRando%26aufirst%3DT.%2BA.%26aulast%3DWyss-Coray%26aufirst%3DT.%26atitle%3DThe%2520ageing%2520systemic%2520milieu%2520negatively%2520regulates%2520neurogenesis%2520and%2520cognitive%2520function%26jtitle%3DNature%26date%3D2011%26volume%3D477%26spage%3D90%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group">Shimaoka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kume, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohsumi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshie, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonehara, S.</span><span> </span><span class="NLM_article-title">Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">â</span> <span class="NLM_lpage">274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1189%2Fjlb.1003465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=14634054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFKnt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=267-274&author=T.+Shimaokaauthor=T.+Nakayamaauthor=N.+Fukumotoauthor=N.+Kumeauthor=S.+Takahashiauthor=J.+Yamaguchiauthor=M.+Minamiauthor=K.+Hayashidaauthor=T.+Kitaauthor=J.+Ohsumiauthor=O.+Yoshieauthor=S.+Yonehara&title=Cell+surface-anchored+SR-PSOX%2FCXC+chemokine+ligand+16+mediates+firm+adhesion+of+CXC+chemokine+receptor+6-expressing+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells</span></div><div class="casAuthors">Shimaoka, Takeshi; Nakayama, Takashi; Fukumoto, Noriko; Kume, Noriaki; Takahashi, Shu; Yamaguchi, Junko; Minami, Manabu; Hayashida, Kazutaka; Kita, Toru; Ohsumi, Jun; Yoshie, Osamu; Yonehara, Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-274</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Direct contacts between dendritic cells (DCs) and T cells or natural killer T (NKT) cells play important roles in primary and secondary immune responses.  SR-PSOX/CXC chemokine ligand 16 (CXCL16), which is selectively expressed on DCs and macrophages, is a scavenger receptor for oxidized low-d. lipoprotein and also the chemokine ligand for a G protein-coupled receptor CXC chemokine receptor 6 (CXCR6), expressed on activated T cells and NKT cells.  SR-PSOX/CXCL16 is the second transmembrane-type chemokine with a chemokine domain fused to a mucin-like stalk, a structure very similar to that of fractalkine (FNK).  Here, we demonstrate that SR-PSOX/CXCL16 functions as a cell adhesion mol. for cells expressing CXCR6 in the same manner that FNK functions as a cell adhesion mol. for cells expressing CX3C chemokine receptor 1 (CX3CR1) without requiring CX3CR1-mediated signal transduction or integrin activation.  The chemokine domain of SR-PSOX/CXCL16 mediated the adhesion of CXCR6-expressing cells, which was not impaired by treatment with pertussis toxin, a GÎ±i protein blocker, which inhibited chemotaxis of CXCR6-expressing cells induced by SR-PSOX/CXCL16.  Furthermore, the adhesion activity was up-regulated by treatment of SR-PSOX/CXCL16-expressing cells with a metalloprotease inhibitor, which increased surface expression levels of SR-PSOX/CXCL16.  Thus, SR-PSOX/CXCL16 is a unique mol. that not only attracts T cells and NKT cells toward DCs but also supports their firm adhesion to DCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbzkIQb5hFbVg90H21EOLACvtfcHk0li1RnS7H-tfiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFKnt7Y%253D&md5=696a00c998088299d30e90a4b07f721d</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1003465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1003465%26sid%3Dliteratum%253Aachs%26aulast%3DShimaoka%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DFukumoto%26aufirst%3DN.%26aulast%3DKume%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DMinami%26aufirst%3DM.%26aulast%3DHayashida%26aufirst%3DK.%26aulast%3DKita%26aufirst%3DT.%26aulast%3DOhsumi%26aufirst%3DJ.%26aulast%3DYoshie%26aufirst%3DO.%26aulast%3DYonehara%26aufirst%3DS.%26atitle%3DCell%2520surface-anchored%2520SR-PSOX%252FCXC%2520chemokine%2520ligand%252016%2520mediates%2520firm%2520adhesion%2520of%2520CXC%2520chemokine%2520receptor%25206-expressing%2520cells%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2004%26volume%3D75%26spage%3D267%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group">Sheikine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirsjo, A.</span><span> </span><span class="NLM_article-title">CXCL16/SR-PSOXâa friend or a foe in atherosclerosis?</span> <span class="citation_source-journal">Atherosclerosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">â</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2008&pages=487-495&author=Y.+Sheikineauthor=A.+Sirsjo&title=CXCL16%2FSR-PSOX%E2%80%94a+friend+or+a+foe+in+atherosclerosis%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSheikine%26aufirst%3DY.%26aulast%3DSirsjo%26aufirst%3DA.%26atitle%3DCXCL16%252FSR-PSOX%25E2%2580%2594a%2520friend%2520or%2520a%2520foe%2520in%2520atherosclerosis%253F%26jtitle%3DAtherosclerosis%26date%3D2008%26volume%3D197%26spage%3D487%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group">Terashima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poonpiriya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motomura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanegasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span> </span><span class="NLM_article-title">Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">â</span> <span class="NLM_lpage">835</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Fjm300682j&amp;key=10.1038%2Fni1222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Fjm300682j&amp;key=15995708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Fjm300682j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlSisLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=827-835&author=Y.+Terashimaauthor=N.+Onaiauthor=M.+Muraiauthor=M.+Enomotoauthor=V.+Poonpiriyaauthor=T.+Hamadaauthor=K.+Motomuraauthor=M.+Suwaauthor=T.+Ezakiauthor=T.+Hagaauthor=S.+Kanegasakiauthor=K.+Matsushima&title=Pivotal+function+for+cytoplasmic+protein+FROUNT+in+CCR2-mediated+monocyte+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis</span></div><div class="casAuthors">Terashima, Yuya; Onai, Nobuyuki; Murai, Masako; Enomoto, Masahiko; Poonpiriya, Vongsakorn; Hamada, Tsuyoshi; Motomura, Kazushi; Suwa, Makiko; Ezaki, Taichi; Haga, Tatsuya; Kanegasaki, Shiro; Matsushima, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-835</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ligation of the chemokine receptor CCR2 on monocytes and macrophages with its ligand CCL2 results in activation of the cascade consisting of phosphatidylinositol-3-OH kinase (PI(3)K), the small G protein Rac and lamellipodium protrusion.  The authors show here that a unique clathrin heavy-chain repeat homol. protein, FROUNT, directly bound activated CCR2 and formed clusters at the cell front during chemotaxis.  Overexpression of FROUNT amplified the chemokine-elicited PI(3)K-Rac-lamellipodium protrusion cascade and subsequent chemotaxis.  Blocking FROUNT function by using a truncated mutant or antisense strategy substantially diminished signaling via CCR2.  In a mouse peritonitis model, suppression of endogenous FROUNT markedly prevented macrophage infiltration.  Thus, FROUNT links activated CCR2 to the PI(3)K-Rac-lamellipodium protrusion cascade and could be a therapeutic target in chronic inflammatory immune diseases assocd. with macrophage infiltration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfaqLVEW9Cp7Vg90H21EOLACvtfcHk0li1RnS7H-tfiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlSisLo%253D&md5=5067ce5c5705892030b2567e815222c3</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1038%2Fni1222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1222%26sid%3Dliteratum%253Aachs%26aulast%3DTerashima%26aufirst%3DY.%26aulast%3DOnai%26aufirst%3DN.%26aulast%3DMurai%26aufirst%3DM.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DPoonpiriya%26aufirst%3DV.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DMotomura%26aufirst%3DK.%26aulast%3DSuwa%26aufirst%3DM.%26aulast%3DEzaki%26aufirst%3DT.%26aulast%3DHaga%26aufirst%3DT.%26aulast%3DKanegasaki%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DK.%26atitle%3DPivotal%2520function%2520for%2520cytoplasmic%2520protein%2520FROUNT%2520in%2520CCR2-mediated%2520monocyte%2520chemotaxis%26jtitle%3DNat.%2520Immunol.%26date%3D2005%26volume%3D6%26spage%3D827%26epage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group">Toda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanegasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, K.</span><span> </span><span class="NLM_article-title">FROUNT is a common regulator of CCR2 and CCR5 signaling to control directional migration</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">6387</span><span class="NLM_x">â</span> <span class="NLM_lpage">6394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=6387-6394&author=E.+Todaauthor=Y.+Terashimaauthor=T.+Satoauthor=K.+Hiroseauthor=S.+Kanegasakiauthor=K.+Matsushima&title=FROUNT+is+a+common+regulator+of+CCR2+and+CCR5+signaling+to+control+directional+migration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DE.%26aulast%3DTerashima%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DHirose%26aufirst%3DK.%26aulast%3DKanegasaki%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DK.%26atitle%3DFROUNT%2520is%2520a%2520common%2520regulator%2520of%2520CCR2%2520and%2520CCR5%2520signaling%2520to%2520control%2520directional%2520migration%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D6387%26epage%3D6394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ODU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ODU','PDB','3ODU'); return false;">PDB: 3ODU</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300682j&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm300682j%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-22%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300682j" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667989a2082924d3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
